<SEC-DOCUMENT>0001144204-18-013053.txt : 20180306
<SEC-HEADER>0001144204-18-013053.hdr.sgml : 20180306
<ACCEPTANCE-DATETIME>20180306160823
ACCESSION NUMBER:		0001144204-18-013053
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180306
DATE AS OF CHANGE:		20180306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		18669944

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tv486893_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR ANNUAL AND TRANSITION REPORTS PURSUANT
TO SECTIONS 13 OR 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>x</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>ANNUAL
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><B>For the fiscal year ended December&nbsp;31, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>TRANSITION
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none; width: 49%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none; width: 49%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>65-0643773</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State or other
    jurisdiction</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S. Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of incorporation
    or organization</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
    No.)</B></FONT></TD></TR>
<TR STYLE="text-decoration: none">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2 Snunit Street</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Science Park</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>POB 455</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carmiel, Israel</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>20100</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address of principal
    executive offices)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Common stock, par value $0.001 per share</B></TD>
    <TD STYLE="text-align: center"><B>NYSE AMERICAN</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(g)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). &nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if disclosure of
delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best of
registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 40%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-indent: 0in">(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Emerging growth company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><FONT STYLE="font-size: 10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">The aggregate market value of the voting
common equity held by non-affiliates of the Registrant, as of June 30, 2017 was approximately $105.4 million, based upon a per
share price equal to $0.84, the closing price for shares of the Registrant&rsquo;s common stock reported by the NYSE American for
such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">On March 1, 2018, approximately
145,569,955 shares of the Registrant&rsquo;s common stock, par value $0.001 per share, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
</FONT>of <FONT STYLE="font-family: Times New Roman, Times, Serif">the registrant&rsquo;s definitive Proxy Statement for its 2018
Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission no later than May&nbsp;1, 2018 and to be
delivered to shareholders in connection with the 2018 Annual Meeting of Stockholders, are herein incorporated by reference in Part&nbsp;III
of this Form&nbsp;10-K.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: right"><B>&nbsp;</B></TD>
    <TD STYLE="width: 80%; text-align: right"><B>&nbsp;</B></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_001"><B>PART I</B></A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_002">Cautionary Statement Regarding Forward-Looking Statements</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">1</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_003">Item 1.</A></TD>
    <TD><A HREF="#a_003">Business</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">3</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004">Item 1A.</A></TD>
    <TD><A HREF="#a_004">Risk Factors</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">30</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_005">Item 1B.</A></TD>
    <TD><A HREF="#a_005">Unresolved Staff Comments</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">55</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006">Item 2.</A></TD>
    <TD><A HREF="#a_006">Properties</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">55</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_007">Item 3.</A></TD>
    <TD><A HREF="#a_007">Legal Proceedings</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">55</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008">Item 4.</A></TD>
    <TD><A HREF="#a_008">Mine Safety Disclosures</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">55</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_009"><B>PART II</B></A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010">Item 5.</A></TD>
    <TD><A HREF="#a_010">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">56</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_011">Item 6.</A></TD>
    <TD><A HREF="#a_011">Selected Financial Data</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">58</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012">Item 7.</A></TD>
    <TD><A HREF="#a_012">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">59</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_013">Item 7A.</A></TD>
    <TD><A HREF="#a_013">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">68</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014">Item 8.</A></TD>
    <TD><A HREF="#a_014">Financial Statements and Supplementary Data</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014">68</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_015">Item 9.</A></TD>
    <TD><A HREF="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015">68</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_016">Item 9A.</A></TD>
    <TD><A HREF="#a_016">Controls and Procedures</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_016">68</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_017">Item 9B.</A></TD>
    <TD><A HREF="#a_017">Other Information</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017">70</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_018"><B>PART III</B></A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_019">Item 10.</A></TD>
    <TD><A HREF="#a_019">Directors, Executive Officers and Corporate Governance</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_020">Item 11.</A></TD>
    <TD><A HREF="#a_020">Executive Compensation</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_020">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_021">Item 12.</A></TD>
    <TD><A HREF="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_021">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_022">Item 13.</A></TD>
    <TD><A HREF="#a_022">Certain Relationships and Related Transactions, and Director Independence</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_022">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_023">Item 14.</A></TD>
    <TD><A HREF="#a_023">Principal Accountant Fees and Services</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_023">71</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_024"><B>PART IV</B></A></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_025">Item 15.</A></TD>
    <TD><A HREF="#a_025">Exhibits and Financial Statement Schedules</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_025">72</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_026">Item 16.</A></TD>
    <TD><A HREF="#a_026">Form 10-K Summary</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_026">75</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_027">Signatures</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_027">76</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Risk Factors,&rdquo;
and other statements included elsewhere in this Annual Report on Form 10-K, which are not historical, constitute &ldquo;forward-looking
statements&rdquo; within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section
21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs,
intentions or strategies for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo;
&ldquo;would&rdquo; and other words or phrases of similar import, as they relate to our company or our subsidiaries or our management,
are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect
our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation
to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under
applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several
factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues;
lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards
to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient
funding to finance our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the results of our clinical trials will not support the applicable claims of superiority, safety or efficacy
and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to manage our relationship with Chiesi Farmaceutici S.p.A., or Chiesi, and any other
collaborator, distributor or partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance or satisfy
conversions of our outstanding convertible notes or any other indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to defease the remaining outstanding 4.5% convertible notes on or prior to June 16, 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health,
or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material
adverse effect on our company and may also result in the termination of such agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial
services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our research programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in preparing and filing applications for regulatory approval of our product candidates in the United States, the European
Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, one or more of our product candidate may become be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our supply of drug product to Pfizer Inc., or Pfizer, pursuant to our amended and restated exclusive license
and supply agreement with Pfizer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in Brazil;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading
<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Risk Factors&rdquo; in this Annual Report and are described from time to
time in the reports we file with the U.S. Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B><A NAME="a_003"></A>Item&nbsp;1.</B></TD><TD><B>Business </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system. We developed our first commercial drug product, Elelyso<SUP>&reg;</SUP>, using our ProCellEx system and we are now focused
on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins
that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of
action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins
that are therapeutically superior to existing recombinant proteins currently marketed for the same indications, including applying
the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our current product candidates
and their respective stages of clinical development:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><IMG SRC="tv486893_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 19, 2017, Protalix Ltd., our wholly-owned subsidiary, and Chiesi entered into an Ex-US license and collaboration agreement,
which we refer to as the Chiesi Agreement, pursuant to which Chiesi was granted an exclusive, license for all markets outside of
the United States to develop and commercialize pegunigalsidase alfa. </FONT>Pegunigalsidase alfa, or PRX-102, is our chemically
modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical
trials for the treatment of Fabry disease<FONT STYLE="font-family: Times New Roman, Times, Serif">. Under the terms and conditions
of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase alfa in the United States. Under the
Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the agreement
and Protalix Ltd. is entitled to additional payments of up to $25 million in development costs, capped at $10 million per year.
Protalix Ltd. is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone
payments. Protalix Ltd. and Chiesi have agreed to a specific allocation of the responsibilities for the continued development efforts
for pegunigalsidase alfa. Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject
to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi
will make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply
of pegunigalsidase alfa. The Chiesi Agreement also provides for reimbursement by Chiesi of certain costs to be incurred by Protalix
Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the European Commission granted Orphan Drug
Designation for pegunigalsidase alfa for the treatment of Fabry disease. The designation was granted after the EMA&rsquo;s Committee
for Orphan Medicinal Products, or the COMP, issued a positive opinion supporting the designation noting that we had established
that there was medically plausible evidence that pegunigalsidase alfa will provide a significant benefit over existing approved
therapies in the European Union for the treatment of Fabry disease. The COMP cited clinical and non-clinical justifications we
provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications to constitute
a clinically relevant advantage. Orphan Drug Designation for pegunigalsidase alfa qualifies Protalix Ltd. for access to a centralized
marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation
is maintained at the time pegunigalsidase alfa is approved for marketing in the European Union, if at all, we expect that PRX-102
will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on
Fabry disease treatments already approved at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, FDA granted Fast Track designation to PRX-102.
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious
conditions that fill an unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the FDA approved for sale our first commercial
product, taliglucerase alfa for injection, an enzyme replacement therapy, or ERT, for the long-term treatment of adult patients
with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory
authorities of other countries. Taliglucerase alfa is called alfataliglicerase in Brazil and certain other Latin American countries,
where it is marketed under the name alfataliglicerase. Taliglucerase alfa is marketed under the name Elelyso in other territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the exclusive license and supply agreement
by and between Protalix Ltd. and Pfizer, which we refer to as the Pfizer Agreement. In </FONT>October 2015, we entered into an
Amended and Restated Exclusive License and Supply Agreement, or the Amended Pfizer Agreement, which amends and restates the Pfizer
Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under
the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0 million. As part
of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer, while gaining full rights to Elelyso in Brazil. We
will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions. Under the Amended Pfizer Agreement,
Pfizer is responsible for 100% of expenses, and entitled to all revenues, globally for Elelyso, excluding Brazil, where we are
responsible for all expenses and retain all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of the Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. Any failure to comply
with our supply commitments may subject us to substantial financial penalties, which will have a material adverse effect on our
business, results of operations and financial condition. The Amended Pfizer Agreement also includes customary provisions regarding
cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 18, 2013, we entered into a Supply and Technology Transfer Agreement, or the Brazil Agreement, with </FONT>Fiocruz, an arm
of the Brazilian MoH, <FONT STYLE="font-family: Times New Roman, Times, Serif">for taliglucerase alfa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, we received a purchase order from the Brazilian MoH
for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil. The purchase
order consists of a number of shipments in increasing volumes. Shipments started in June 2017. Fiocruz&rsquo;s purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate
the Brazil Agreement. Notwithstanding, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and,
based on such discussions, we will determine what we believe to be the course of action that is in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our strategy centers around prioritizing existing and new pipeline
candidates to focus on products that we believe offer a clear competitive advantage over existing treatments. The strategy was
the culmination of an intensive review by our management of our internal resources and of the markets in which we expect we can
operate. The following highlights the details of the strategic plan as it relates to our development of an innovative product pipeline
using our ProCellEx protein expression system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Pegunigalsidase alfa (PRX-102) for
the Treatment of Fabry Disease</B>. pegunigalsidase alfa, or PRX-102<FONT STYLE="font-family: Times New Roman, Times, Serif">,
</FONT>is designed to be an improved enzyme replacement therapy product for the treatment of Fabry disease given its potential
for clinically superior outcomes and enhanced safety when compared to currently marketed enzyme replacement therapies. The product
candidate is a key focus for us. We are continuing to enroll patients and recruit clinical sites for our phase III clinical trials
of PRX-102, and our <FONT STYLE="font-family: Times New Roman, Times, Serif">phase I/II clinical trial remains ongoing in an extension
period</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>alidornase alfa (PRX-110) for the Treatment
of Cystic Fibrosis</B>. alidornase alfa, our <FONT STYLE="font-family: Times New Roman, Times, Serif">proprietary plant cell recombinant
human Deoxyribonuclease 1, is under development for the treatment of cystic fibrosis (CF), to be administered by inhalation. </FONT>alidornase
alfa has an actin inhibition resistance that is designed to improve lung function and lower the incidence of recurrent infections
by enhancing the enzyme&rsquo;s efficacy in patients&rsquo; sputa. We released the final results of our phase II clinical trial
of alidornase alfa for the treatment of CF in April 2017. We are currently studying the final results of the trial and are considering
different collaboration alternatives as part of our further development plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Oral Anti-TNF (OPRX-106) Anti Inflammatory</B>.
Oral anti-TNF represents a novel mode of administering a recombinant anti-TNF protein. It <FONT STYLE="font-family: Times New Roman, Times, Serif">is
under development as </FONT>an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed
protein. <FONT STYLE="font-family: Times New Roman, Times, Serif">Currently, the first 14 patients have completed </FONT>our phase
II <FONT STYLE="font-family: Times New Roman, Times, Serif">proof of concept efficacy study</FONT> of OPRX-106 for the treatment
of ulcerative colitis<FONT STYLE="font-family: Times New Roman, Times, Serif">, and four patients are currently in treatment and
follow-up. The trial is evaluating key efficacy endpoints including clinical response and remission utilizing the Mayo score, as
well as safety and pharmacokinetics. Interim data generated from the first 14 patients that completed the trial was released in
January 2018. We expect to release complete results by the end of March, 2018. </FONT>Upon review of the final proof of concept
data, we intend to identify and collaborate with a well-suited partner for further development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><B>Potential Pipeline Candidates</B>.
We aim to expand our pipeline by leveraging the advantages of our proprietary ProCellEx protein expression technology. The focus
is expected to be on biologics with significantly improved clinical profiles than the currently marketed proteins for these indications.
Biosimilars will not be a market on which we focus, and will only be considered in the case of proteins that are highly difficult
to express or that represent opportunities for early market entry arising from the intellectual property advantages arising from
ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Brazil), which we licensed to Pfizer, and the rights to PRX-102 which we licensed to Chiesi for territories outside
the United States, we hold the worldwide commercialization rights to all of our proprietary development candidates. We continuously
evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies
and academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ProCellEx: Our Proprietary Protein Expression System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx is our proprietary production system. We have developed
our ProCellEx system based on our plant cell culture technology for the development, expression and manufacture of recombinant
proteins. Our protein expression system does not involve mammalian or animal components or transgenic field-grown, whole plants
at any point in the production process. Our ProCellEx system consists of a comprehensive set of capabilities and proprietary technologies,
including advanced genetic engineering and plant cell culture technology, which enables us to produce complex, proprietary and
biologically equivalent proteins for a variety of human diseases. This protein expression system facilitates the creation and selection
of high expressing, genetically stable cell lines capable of expressing recombinant proteins. The entire protein expression process,
from initial nucleotide cloning to large-scale production of the protein product, occurs under cGMP-compliant, controlled processes.
Our plant cell culture technology uses plant cells, such as carrot and tobacco cells, which undergo advanced genetic engineering
and are grown on an industrial scale in a flexible bioreactor system. Cell growth, from scale up through large-scale production,
takes place in flexible, sterile, polyethylene bioreactors which are confined to a clean-room environment. Our bioreactors are
well-suited for plant cell growth using a simple, inexpensive, chemically-defined growth medium as a catalyst for growth. The reactors
are custom-designed and optimized for plant cell cultures, easy to use, entail low initial capital investment, are rapidly scalable
at a low cost and require less hands-on maintenance between cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx system is capable of producing proteins with an
amino acid sequence and three dimensional structure practically equivalent to that of the desired human protein, and with a very
similar, although not identical, glycan, or sugar, structure, as demonstrated in our internal research and external laboratory
studies. In collaboration with the Weizmann Institute of Science, we have demonstrated that the three-dimensional structure of
a protein expressed in our proprietary plant cell-based expression system retains the same three-dimensional structure as exhibited
by the mammalian cell-based expressed version of the same protein. In addition, proteins produced by our ProCellEx system maintain
the biological activity that characterize that of the naturally-produced proteins. Based on these results, we believe that proteins
developed using our ProCellEx protein expression system have the intended composition and correct biological activity of their
human equivalent proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our ProCellEx system will enable us to develop
recombinant therapeutic proteins yielding substantial cost advantages, accelerated development and other competitive benefits when
compared to mammalian cell-based protein expression systems. In addition, our ProCellEx system may enable us, in certain cases,
to develop and commercialize recombinant proteins without infringing upon the method-based patents or other intellectual property
rights of third parties. The major elements of our ProCellEx system are patent protected in most major countries. Moreover, we
expect to enjoy method-based patent protection for the proteins we develop using our proprietary ProCellEx protein expression technology,
although there can be no assurance that any such patents will be granted. In some cases, we may be able to obtain patent protection
for the compositions of the proteins themselves. We have filed for United States and international composition of matter patents
for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have successfully demonstrated the feasibility of our ProCellEx
system through: (i) the FDA&rsquo;s approval of taliglucerase alfa, and its subsequent approval by other regulatory authorities;
(ii) the clinical and preclinical studies we have performed to date, including the positive efficacy and safety data in our clinical
trials for taliglucerase alfa, pegunigalsidase alfa, alidornase alfa and OPRX-106 for the treatment of ulcerative colitis; (iii)
preclinical results in well-known models in our enzyme for each of Fabry disease, DNase and antiTNF; and (iv) by expressing, on
an exploratory, research scale, many additional complex therapeutic proteins belonging to different drug classes, such as enzymes,
hormones, monoclonal antibodies, cytokines and vaccines. The therapeutic proteins we have expressed to date in research models
have produced the intended composition and similar or superior biological activity compared to their respective human-equivalent
proteins. Moreover, several of such proteins demonstrated advantageous biological activity when compared to the biotherapeutics
currently available in the market to treat the applicable disease or disorder. We believe that the FDA&rsquo;s approval of taliglucerase
alfa represents a strong proof-of-concept of our ProCellEx system and plant cell-based protein expression technology. We also believe
that the significant benefits of our ProCellEx system, if further substantiated in clinical trials and in the successful commercialization
of taliglucerase alfa and our other product candidates, have the potential to transform the industry standard for the development
of complex therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mammalian cell-based expression technology is based on the introduction
of a human gene encoding for a specific therapeutic protein into the genome of a mammalian cell, and such systems have become the
dominant system for the expression of recombinant proteins due to their capacity for sophisticated, proper protein folding (which
is necessary for proteins to carry out their intended biological activity), assembly and post-expression modification, such as
glycosilation (the addition of sugar residues to a protein which is necessary to enable specific biological activity by the protein).
Many of the biotechnology industry&rsquo;s largest and most successful therapeutic proteins, including Epogen<SUP>&reg;</SUP>,
Neupogen<SUP>&reg;</SUP>, Cerezyme<SUP>&reg;</SUP>, Rituxan<SUP>&reg;</SUP>, Humira<SUP>&reg;</SUP>, Enbrel<SUP>&reg;</SUP>, Neulasta<SUP>&reg;</SUP>,
Remicade<SUP>&reg;</SUP> and Herceptin<SUP>&reg; </SUP>are produced through mammalian cell-based expression systems. Mammalian
cell-based expression systems can produce proteins with superior quality and efficacy compared to proteins expressed in bacteria
and yeast cell-based systems. As a result, the majority of currently approved therapeutic proteins, as well as those under development,
are produced in mammalian cell-based systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While bacterial and yeast cell-based expression systems were
the first protein expression systems developed by the biotechnology industry and remain cost-effective compared to mammalian cell-based
production methodologies, proteins expressed in bacterial and yeast cell-based systems lack the capacity for sophisticated protein
folding, assembly and post-expression modifications, which are key factors of mammalian cell-based systems. Accordingly, such systems
cannot be used to produce glycoproteins or other complex proteins and, therefore, bacterial and yeast cell-based systems are limited
to the expression of the most basic, simple proteins, such as insulin and growth hormones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several companies and research institutions have been exploring
the expression of human proteins in genetically-modified organisms, or GMOs, such as transgenic field-grown, whole plants and transgenic
animals. However, these alternate techniques may be restricted by regulatory and environmental risks regarding contamination of
agricultural crops and by the difficulty in applying cGMP standards of the pharmaceutical industry to these expression technologies
and none of these technologies have been approved by the regulatory agencies with jurisdiction over any substantial market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our manufacturing facility, in which we utilize our
ProCellEx system, was determined to be acceptable by each of the FDA, the European Medicines Agency, or the EMA, ANVISA, the Israeli
MOH, the Australian Therapeutic Goods Administration, or the TGA, and Health Canada, after GMP inspections were performed as part
of their respective reviews for marketing approval of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Advantages of Our ProCellEx Protein Expression
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to continue to leverage the multiple unique advantages
of our proprietary ProCellEx protein expression system, including our advanced genetic engineering technology and plant cell-based
protein expression methods, to develop our pipeline. Significant advantages of our ProCellEx system over mammalian, bacterial,
yeast and transgenic cell-based expression technologies, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Biologic Optimization.</I></B> ProCellEx
has internal capabilities developed to improve the biologic dynamics of an expressed protein. For example, the proteins produced
through our system have uniform glycosilation patterns and therefore do not require the lengthy and expensive post-expression modifications
that are required for certain proteins produced by mammalian cell-based systems. Such post-expression modifications in mammalian
cell-produced proteins are made in order to expose the terminal mannose sugar residues, which are structures on a protein that
are key elements in allowing the expressed protein to bind to a target cell and subsequently be taken into the target cell for
therapeutic benefit. In addition, these steps do not guarantee the exposure of all of the required terminal mannose sugar residues,
resulting in potentially lower effective yields and inconsistency in potency from batch to batch. We believe this quality increases
the potency and consistency of the expressed proteins, and thus, the effectiveness of the protein which presents an additional
cost advantage of ProCellEx over competing protein expression methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Ability to Penetrate Certain Patent-Protected
Markets.</I></B> ProCellEx has the potential to provide workaround manufacturing that does not infringe the method-based patents
or other intellectual property rights of third parties. Certain biotherapeutic proteins available for commercial sale are not protected
by patents that cover the compound and are available for use in the public domain. Rather, the process of expressing the protein
product in mammalian or bacterial cell systems is protected by method-based patents. Using our plant cell-based protein expression
technology, we are able to express an equivalent protein without infringing upon these method-based patents. Moreover, we expect
to enjoy method-based patent protection for the proteins we develop using our ProCellEx system, although there can be no assurance
that any such patents will be granted. In some cases, we may be able to obtain patent protection for the compositions of the proteins
themselves. We have filed for U.S. and international composition of matter patents for PRX-102 and certain of our other product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Broad Range of Expression Capabilities.</I></B>
ProCellEx is able to produce a broad array of complex glycosilated proteins, which are difficult to produce in other systems, such
as bacterial and yeast cell-based systems, as well as CHO systems. We have successfully demonstrated the feasibility of our ProCellEx
system by producing, on an exploratory, research scale, a variety of therapeutic proteins belonging to different classes of recombinant
drugs, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. We have demonstrated that the recombinant proteins
we have expressed to date have the intended composition and correct biological activity of their human-equivalent protein, with
several of such proteins demonstrating advantageous biological activity compared to the currently available biotherapeutics. In
specific cases, we have been successful in expressing proteins that have not been successfully expressed in other production systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Significantly Lower Capital and Production
Costs.</I></B> ProCellEx entails a lower cost of scale-up and of production. Plant cells grow rapidly under a variety of conditions
and are not as sensitive as mammalian cells are to temperature, pH and oxygen levels which generally can only be grown under near
perfect conditions. Our system, therefore, does not require the highly complex, expensive, stainless steel bioreactors typically
used in mammalian cell-based production systems to maintain very specific temperature, pH and oxygen levels. Instead, we use simple
polyethylene bioreactors that can be maintained at the room temperature of the clean-room in which they are placed. This system
also reduces ongoing production and monitoring costs typically associated with mammalian cell-based expression technologies. Furthermore,
while mammalian cell-based systems require very costly growth media at various stages of the production process to achieve target
yields of proteins, plant cells require only simple and much less expensive solutions based on sugar, water and microelements at
infrequent intervals to achieve target yields. Mammalian cell-based expression systems require large quantities of sophisticated
and expensive growth medium to accelerate the expression process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Elimination of the Risk of Viral Transmission
or Infection by Mammalian Components.</I></B> By nature, plant cells do not carry the risk of infection by human or other animal
viruses. Mammalian cells, to the contrary, are susceptible to viral infections, including human viruses, and several cases of viral
contamination have occurred. As a result, the risk of contamination of our products under development and the potential risk of
viral transmission from our product and product candidates to future patients, whether from known or unknown mammalian viruses,
is eliminated. Because our products and product candidates do not bear the risk of mammalian viral transmission, we are not required
by the FDA or other regulatory authorities to perform the constant monitoring procedures for mammalian viruses during the protein
expression process that are required in mammalian cell-based production. In addition, the production process of our ProCellEx system
is void of any mammalian components which are susceptible to the transmission of prions, such as those related to bovine spongiform
encephalopathy (commonly known as &ldquo;mad-cow disease&rdquo;). These factors further reduce the risks and operating costs of
ProCellEx compared to mammalian cell-based expression systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and other regulatory authorities require viral inactivation
and other rigorous and detailed procedures for mammalian cell-based manufacturing processes in order to address these potential
hazards, thereby increasing the cost and time demands of such expression systems. Furthermore, the current FDA and other procedures
only ensure screening for scientifically identified, known viruses. Accordingly, compliance with current FDA and other procedures
does not fully guarantee that patients are protected against transmission of unknown or new potentially fatal viruses that may
infect mammalian cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"><B><I>Potential ability to administer
active therapeutic proteins orally. </I></B>We are using ProCellEx to produce active recombinant proteins through oral administration
of plant cells expressing biotherapeutic proteins. In such method, an enzyme is naturally encapsulated within plant cells genetically
engineered to express the targeted enzyme. Plant cells have the unique attribute of a cellulose cell wall which makes them resistant
to enzyme degradation when passing through the digestive tract. The plant cell itself serves as a delivery vehicle, once released
and absorbed, to transport an enzyme in active form to the bloodstream. If proven effective, this would be the first time an enzyme
will be administered orally rather than through intravenous therapy. To date we have completed successful preclinical animal studies
for oral GCD and oral antiTNF, and early clinical trials of oral GCD in Gaucher patients. In addition, we have completed a phase
IIa proof of concept trial of oral antiTNF as well as a phase I clinical trial of oral antiTNF in healthy volunteers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our First Commercial Product &ndash; Elelyso for the Treatment
of Gaucher Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elelyso (taliglucerase alfa), our first commercial product,
is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. On May 1, 2012, the
FDA approved Elelyso for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a
confirmed diagnosis of type 1 Gaucher disease. It was subsequently approved by the Israeli MOH, ANVISA and the regulatory authorities
of other countries<FONT STYLE="font-family: Times New Roman, Times, Serif">. In August 2014, the FDA approved Elelyso for injection
for pediatric patients, and other jurisdictions, including Brazil, approved pediatric indications thereafter. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gaucher disease, a hereditary, genetic disorder with severe
and debilitating symptoms, is the most prevalent lysosomal storage disorder in humans. Lysosomal storage disorders are metabolic
disorders in which a lysosomal enzyme, a protein that degrades cellular substrates in the lysosomes of cells, is mutated or deficient.
Lysosomes are small membrane-bound cellular structures within cells that contain enzymes necessary for intracellular digestion.
Gaucher disease is caused by mutations or deficiencies in the gene encoding GCD, a lysosomal enzyme that catalyzes the degradation
of the fatty substrate, glucosylceramide (GlcCer). Patients with Gaucher disease lack or otherwise have dysfunctional GCD and,
accordingly, are not able to break down GlcCer. The GlcCer accumulates in lysosomes of certain white blood cells called macrophages
which consequently become highly enlarged. The enlarged cells accumulate in the spleen, liver, lungs, bone marrow and brain. Signs
and symptoms of Gaucher disease may include enlarged liver and spleen, abnormally low levels of red blood cells and platelets and
skeletal complications. In some cases, the patient may suffer an impairment of the central nervous system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The standard of care for Gaucher disease is enzyme replacement
therapy using recombinant GCD to replace the mutated or deficient natural GCD enzyme. Enzyme replacement therapy is a medical treatment
in which recombinant enzymes are injected into patients in whom the enzyme is lacking or dysfunctional. Cerezyme<SUP>&reg;</SUP>
and VPRIV<SUP>&reg; </SUP>are the only other ERTs currently available for the treatment of Gaucher disease. In addition, Cerdelga<SUP>&reg;</SUP>
(eliglustat) is a substrate reduction therapy for Gaucher disease that was approved for marketing by the FDA in August 2014 and
by the European Commission in January 2015. Finally, Zavesca (miglustat) is a small molecule drug for the treatment of Gaucher
disease. Zavesca has been approved by the FDA for use in the United States as an oral treatment. However, it has many side effects
and the FDA has approved it only for administration to those patients who cannot be treated through ERT, and, accordingly, have
no other treatment alternative. As a result, the use of Zavesca has been limited with respect to the treatment of Gaucher disease.
However, Zavesca is also used to treat other rare disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have licensed to Pfizer the worldwide rights to Elelyso with
the exception of Brazil, a market where we have retained own full rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Pipeline Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 for the Treatment of Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing PRX-102, our proprietary plant cell expressed
chemically modified version of the recombinant alpha-GAL-A protein, a therapeutic enzyme, for the treatment of Fabry disease, a
rare genetic lysosomal storage disorder. We believe that PRX-102 has the potential to be a significantly improved version of the
currently marketed Fabry disease enzymes, Fabrazyme<SUP>&reg;</SUP> and Replagal<SUP>&reg;</SUP>, with improved activity in the
Fabry disease target organs and significantly longer half-life due to higher stability, which together can potentially lead to
improved substrate clearance and significantly lower formation of antibodies, as observed in our phase I/II clinical trial in Fabry
patients. We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there
is a significant unmet medical need for Fabry disease treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Fabry Disease Background</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fabry disease is a serious, life-threatening condition. It is
a disease or condition associated with morbidity that has a substantial impact on survival, day-to-day function, and the likelihood
that the disease, if left untreated, will progress from a less severe condition to a more serious one. Fabry disease is an X-linked
multisystem lysosomal storage disorder caused by the absence or reduction of &alpha;-galactosidase-A (&alpha;-Gal-A) activity,
which is a lysosomal enzyme that catalyzes the hydrolysis of globotriaosylceramide (Gb3) from oligosaccharides, glycoproteins and
glycolipids. The absence or reduction of this enzymatic activity leads to the progressive accumulation of glycolipids, especially
Gb3, in capillary endothelial cells, podocytes, tubular cells, glomerular endothelial cells, mesangial cells, interstitial cells,
cardiomyocytes, fibroblasts, and neurons. The accumulation of glycosphingolipids (e.g., Gb3) leads to chronic pain, skin lesions,
cardiac, deficiencies, and, in particular, renal involvement. End-stage renal failure and cardiomyopathy often lead to early death
in Fabry patients. Fabry disease causes substantial reduction in life-expectancy, by an average of 15 years in female patients
and 20 years in male patients, compared to the general population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Current Treatments of Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently there are two enzyme replacement therapies drugs available
on the market to treat Fabry disease. Fabrazyme, marketed by Genzyme Corporation (acquired by Sanofi), is approved for the treatment
of Fabry disease in the United States and the European Union. Sanofi reported &euro;722&nbsp;million (approximately $865&nbsp;million)
in worldwide sales of Fabrazyme in 2017. The other approved enzyme replacement therapy for the treatment of Fabry disease in the
European Union is Replagal, which is marketed by Shire. Shire reported $472&nbsp;million in sales of Replagal in 2017. In April
2016, Galafold<SUP>TM</SUP>, a chaperone therapy manufactured by Amicus Therapeutics, Inc., or Amicus, was approved in the European
Union as a monotherapy for Fabry disease in patients with amenable mutations. Galafold has also been accepted for marketing in
a number of other countries. Amicus reported revenues of approximately $36&nbsp;million in sales of Galafold in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2016, the first patient was dosed in our global phase
III clinical trial of PRX-102 for the treatment of Fabry disease. Over 40 sites are currently participating in this trial. The
phase III efficacy and safety clinical trial, which we refer to as the BALANCE Study, is a multi-center, randomized, double-blind,
active control study of PRX-102 in Fabry patients with impaired renal function. The trial is designed to enroll 78 patients previously
treated with Fabrazyme (agalsidase beta) with a stable dose for at least six months. Enrolled patients are randomized to continue
treatment with 1 mg/kg of either Fabrazyme or PRX-102, at a 2:1 ratio of PRX-102 to Fabrazyme, respectively. Patients are to be
treated via intravenous (IV) infusions every two weeks. The sites are recruiting adult symptomatic Fabry patients with plasma and/or
leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels. All patients must have had treatment
with a dose of 1 mg/kg agalsidase beta per infusion every two weeks for at least one year. In addition, to be included in the trial,
patients need to have certain eGFR values and a meaningful decline in annualize eGFR slope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint for the BALANCE study, which was agreed
with both the FDA and the EMA, is the comparison in the rate of decline of eGFR slope between Fabrazyme and PRX-102. At 12 months,
we intend to conduct an interim analysis to test for non-inferiority to support an anticipated regulatory filing with the EMA.
At the same time, we intend to approach the FDA to request its review of the then totality of data. Notwithstanding, patients enrolled
in the study will continue to be treated for a total of 24 months, at which point the data will be analyzed to test for superiority,
which is the original guidance we received from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrently with the BALANCE study, we are also performing
a supportive phase III clinical trial of PRX-102, which we refer to as the BRIDGE Study. The BRIDGE study is an open-label, single-arm,
switchover study to assess the efficacy and safety of PRX-102 in Fabry patients currently treated with Replagal. The trial is designed
to enroll 22 patients. The objective of the study is to generate safety and efficacy data of patients switched from Replagal to
PRX-102 over a 12-month period. The endpoints of the study are safety, mean annualized change (slope) in eGFR, pain, plasma lyso
GB3, immunogenicity and Quality of Life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the BALANCE and BRIDGE studies, we are performing
a third clinical trial to evaluate the safety and efficacy of administering 2 mg/kg of PRX-102 once monthly in Fabry patients.
PRX-102 with a 2 mg/kg dose was found to be safe and well tolerated with no formation of antibodies in our phase I/II clinical
trial of PRX-102 for the treatment of Fabry disease. Additionally, in our phase I/II clinical trial, 2 mg/kg of PRX-102 demonstrated
approximately a 40 times higher circulatory half-life compared with other enzyme replacement therapies, and, as demonstrated in
a Fabry mice model, with materially higher active enzyme reaching target organs affected by Fabry disease. Pharmacokinetic (PK)
analysis and modeling from the phase I/II clinical trial indicate that PRX-102 levels at the second week after infusion remain
10 times higher than published Fabrazyme levels at the day of infusion. Moreover, the amount of PRX-102 in the circulation at weeks
three and four, are higher than those of Fabrazyme during the two-week treatments. These results provide strong rationale for the
clinical evaluation of a once-monthly dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We plan to enroll up to 30 Fabry patients currently treated
with an approved enzyme replacement therapy in this study. A safety and efficacy evaluation will occur at 12 months with additional
long term follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Phase I/II Clinical Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our phase I/II clinical trial of PRX-102, which we completed
in 2015, was a worldwide, multi-center, open label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics,
immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult naive Fabry patients (9 male and 7 female)
completed the trial, each in one of three dosing groups, 0.2 mg/kg, 1mg/kg and 2mg/kg. Each patient received intravenous infusions
of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. All patients that completed
the trial opted to continue to receive 1 mg/kg of PRX-102 in an open-label, 60-month extension study under which all patients have
been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The data set forth below was recorded at 24 months from 11 patients
enrolled and treated in the long-term open-label extension trial. Patients who did not continue in the extension trial included
female patients who became or planned to become pregnant, and therefore were unable to continue in accordance with the study protocol,
and patients that relocated to a location where treatment was not available under the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Efficacy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Lyso Gb3 levels decreased approximately 90% from baseline
(see Figure 1);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Renal function remained stable with mean eGRF levels of
108.02 and 107.20 at baseline and 24 months, respectively with a modest annual eGFR slope of -2.1; (see Figure 2)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">An improvement across all the gastrointestinal symptoms
evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, were noted (see Figure 1);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cardiac parameters, including LVM, LVMI and EF, remained
stable with no cardiac fibrosis development detected;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In conclusion, an improvement of over 40% in disease severity
was shown as measured by the Mainz Severity Score Index (MSSI), a score compiling the different elements of the disease severity
including neurological, renal and cardiovascular parameters; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">An improvement was noted in each of the individual parameters
of the MSSI.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 1. Continuous reductions observed over 24 months</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in"><IMG SRC="tv486893_img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 2. Continuous clinical stability observed over 24
months</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in"><IMG SRC="tv486893_img3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Safety</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The majority of adverse events were mild to moderate in severity, and transient in nature;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which
two of these patients (less than 13%) had neutralizing antibodies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Importantly, however, the ADAs turned negative for all three of these patients following 12 months of treatment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B><I>alidornase Alfa (PRX-110) for the Treatment
of Cystic Fibrosis </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alidornase alfa is our proprietary plant cell recombinant form
of human deoxyribonuclease I (DNase I) that we are developing for the treatment of CF, to be administered by inhalation. DNase
I cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of CF patients. Currently, Pulmozyme<SUP>&reg;</SUP>
is the only DNase I commercially available, with annual sales of approximately CHF 730 million (approximately $748 million) in
sales for 2017 according to public reports by F. Hoffman-La Roche Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In vitro studies with PRX-110 demonstrated improved enzyme kinetics,
significantly reduced sensitivity to inhibition by actin and improved ex vivo efficacy when compared to Pulmozyme. Preclinical
studies of alidornase alfa administered by inhalation showed substantial enzymatic activity in lungs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We designed alidornase alfa, through chemical modification,
to be resistant to inhibition by actin so as to improve lung function and lower the incidence of recurrent infections by enhancing
the enzyme&rsquo;s efficacy in patients&rsquo; sputa. Actin, a potent inhibitor of DNase, is found in high concentration in CF
patients&rsquo; sputum. As demonstrated in Figure 3, the activity of alidornase alfa, as demonstrated in in vitro studies, remains
almost with no change in the relevant actin concentration found in CF patients while Pulmozyme is degraded significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 3. Actin and DNase concentrations in human sputum
tested in <I>in vitro </I>assays; Rheology Data Analysis in in human sputum samples</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in"><IMG SRC="tv486893_img4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, alidornase alfa has demonstrated improved disease
parameters in human models sputum testing when compared to the currently marketed product. In particular, alidornase alfa has demonstrated
a reduction in mucus viscosity in human sputum samples when compared to the currently marketed product. See Figure 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>alidornase alfa Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We completed a phase I clinical trial of alidornase alfa with
18 healthy volunteers in which alidornase alfa was found to be safe and tolerable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016 we commenced a phase IIa clinical trial of alidornase
alfa for the treatment of CF, and we released the final results of the study in April 2017. Sixteen patients were enrolled in the
study, all of whom completed the study. The phase II trial was a 28-day switchover study to evaluate the safety and efficacy of
alidornase alfa in CF patients previously treated with Pulmozyme (currently the only commercially available DNase therapy). Participation
in the trial was preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary efficacy results show that treatment with alidornase
alfa resulted in clinically meaningful lung function improvement, as demonstrated by a mean absolute increase in the percent predicted
forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline. Moreover, a mean absolute increase in ppFEV1 of 2.8
points was also observed in patients participating in the trial when compared to measurements taken from patients at initiation
before the switch from Pulmozyme to alidornase alfa. See Figure 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 4. Phase II trial demonstrates clinically meaningful
lung function improvement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in"><IMG SRC="tv486893_img5.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A commercially available small molecule CFTR modulator for the
treatment of CF has reported a mean absolute increase in ppFEV1 of 2.5 from baseline in its registration clinical study. This score
was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with the modulator on
top of Pulmozyme. While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, alidornase
alfa is being developed to treat all CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sputa available DNA samples were analyzed for approximately
half of the patients. A mean reduction of over 70% in DNA content from baseline was observed, and a mean reduction of over 90%
from baseline was observed for sputa visco-elasticity. Correlation between improvement in sputa parameters and pulmonary function
was observed. See Figure 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 5. Decrease in sputum DNA content and sputum viscosity
upon alidornase alfa treatment initiation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in"><IMG SRC="tv486893_img6.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, an in vitro study of alidornase alfa demonstrated
a significant inhibition of Pseudomonas Aeruginosa, with alidornase alfa treated colonies reduced by over 50%, compared to baseline.
Pseudomonas, strains of bacteria that are widely found in the environment, are a major cause of lung infections in CF patients.
Chronic pulmonary infection is a leading cause of morbidity and mortality in CF patients, despite the aggressive use of antibiotics,
and Pseudomonas is the most prevalent organism in the airway colonization of CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PK analysis performed indicated alidornase alfa is not absorbed
into a patient&rsquo;s circulatory system, suggesting higher levels of alidornase alfa remains available in the patient&rsquo;s
lungs. This provides further support for the potential that alidornase alfa may offer additional efficacy to CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above-mentioned material decrease in visco-elasticity and
DNA presence in CF patients&rsquo; sputa, coupled with the significant inhibition of Pseudomonas and higher levels of alidornase
alfa available in the patients&rsquo; lungs, provides further supportive evidence of improved lung function after treatment with
alidornase alfa, as demonstrated by the increase in FEV1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alidornase alfa was well tolerated with no serious adverse events
reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><B>OPRX-106; Oral antiTNF for the treatment of inflammatory
diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX-106, our oral antiTNF product candidate, is a recombinant
antiTNF (Tumor, Necrosis Factor) protein that we are expressing through ProCellEx. Auto-immune-mediated inflammatory disorders
are conditions that are characterized by common pathways that lead to inflammation and are caused or triggered by a compromised
or dysregulation of the normal immune response. Immune-mediated inflammatory disorders can cause organ damage, and are associated
with increased morbidity. Common auto-immune diseases include rheumatoid arthritis, inflammatory bowel disease (IBD) such as ulcerative
colitis and crohn&rsquo;s disease, psoriasis, and others. Some of the major treatments are antiTNF drugs, administered as subcutaneous
injections or as intravenous infusions. Sales of anti-TNF drugs exceeded $30 billion annually. Well-known antiTNF drugs include
Humira, Remicade and Enbrel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX-106 is a plant cell-expressed form of the fused protein
that is naturally encapsulated within BY-2 cells genetically engineered to express the enzyme. Plant cells have the unique attribute
of a cellulose cell wall which makes them resistant to enzyme degradation when passing through the digestive tract. The plant cell
itself serves as a delivery vehicle, once released and absorbed, to transport the enzyme in active form to the bloodstream. If
proven effective, our experimental oral antiTNF would be the first protein to be administered orally rather than through injection.
We believe that our oral delivery mechanism could be applied to additional proteins and has the potential to change the method
of protein administration in certain indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>OPRX-106 Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX-102 for the treatment of ulcerative colitis is currently
the subject of a phase IIa clinical trial. The first patient was enrolled in the trial in November 2016. The phase II clinical
trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis. A total
of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks.
Currently, the first 14 patients have completed the study, and four patients are currently in treatment and follow-up.&nbsp; The
trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and
pharmacokinetics. Interim data generated from the first 14 patients that completed the trial was released in January 2018. The
interim data demonstrates that 57% of the patients achieved clinical response and 36% achieved clinical remission at week 8. In
the rectal bleeding analysis, a sub category of the Mayo score, 79% of those patients show an improvement. In addition, the majority
of those patients show improvement in the study&rsquo;s additional efficacy endpoints, with 86% of the patients achieved an improvement
in calprotectin, a protein biomarker present in the feces indicating intestinal inflammation, and 64% have an improved Geboes score,
a histopathological scoring for the assessment of disease activity in ulcerative colitis. We except to release complete results
by the end of March, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of the study, clinical response at week 8 is defined
as a decrease in the Mayo score of at least 3 points and either a decrease in the sub-score for rectal bleeding of at least 1 point
from baseline, or rectal bleeding sub-score of 0 or 1. Clinical remission at week 8 is defined as clinically symptom free, a Mayo
score &le; 2, with no individual sub-score&nbsp;exceeding 1 point after treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Treatment was well tolerated and the majority of adverse events
have been mild to moderate and transient in nature, with headaches being the most common. No immunosuppression was evident.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results from our phase I clinical trial of OPRX-106 demonstrated
that the drug was safe and well tolerated, and showed biological activity in the gut. The phase I clinical trial was a randomized,
parallel-design, open-label study designed to evaluate the safety and pharmacokinetics of OPRX-106 in healthy volunteers. The trial
enrolled 14 subjects that were randomized to one of three dosing cohorts receiving OPRX-106 doses equivalent to 2mg, 8mg or 16mg
Tumor Necrosis Factor receptor-Fc fusion protein. Subjects received once daily oral administrations for five consecutive days.
The results demonstrated that oral administration of OPRX-106 is safe and well tolerated. No major side effects were noted, and
no suppression of the immune system was observed. Regulatory T cell activation showing biological activity in the gut was observed.
Fluorescence-activated cell sorting analysis (FACS) was performed using various antibodies for surface markers, and it was observed
that all three dosages of OPRX-106 promoted the induction of various subsets of T cells, some of which are correlated with anti-inflammatory
response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Commercialization Agreement with Chiesi Farmaceutici</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 19, 2017, Protalix Ltd. and Chiesi entered into the
Chiesi Agreement pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to develop
and commercialize pegunigalsidase alfa. Protalix Ltd. retained the right to commercialize pegunigalsidase alfa in the United States.
Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the agreement and Protalix
Ltd. is entitled to additional payments of up to $25 million in development costs, capped at $10 million per year. Protalix Ltd.
is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments.
Protalix Ltd. and Chiesi have agreed to a specific allocation of the responsibilities for the continued development efforts for
pegunigalsidase alfa. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject
to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi
is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for
the supply of pegunigalsidase alfa. The Chiesi Agreement also provides for reimbursement by Chiesi of certain costs to be incurred
by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are required to pay a royalty equal to 3% of the PRX-102-related revenues Chiesi records under the Chiesi Agreement to the</FONT>
National Authority for Technological Innovation, or NATI<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology Transfer Agreement with Fiocruz</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Brazil Agreement became effective in January 2014. The technology
transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and skills required for
the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality,
and cost-effective supply of taliglucerase alfa. The initial term of the technology transfer is seven years. The agreement contains
certain purchase commitments by Fiocruz. If Fiocruz fails to comply with the purchase commitments, we may terminate the agreement,
and all of our rights to the technology will be returned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, we received a purchase order from the Brazilian MoH
for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil. The purchase
order consists of a number of shipments in increasing volumes. Shipments started in June 2017. Fiocruz&rsquo;s purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate
the Brazil Agreement. Notwithstanding, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and,
based on such discussions, we will determine what we believe to be the course of action that is in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a proactive intellectual property strategy which
includes patent filings in multiple jurisdictions, including the United States and other commercially significant markets. As of
December 31, 2017, we held, or had license rights to, 69 patents and 58 pending patent applications with respect to various compositions,
methods of production and methods of use relating to our ProCellEx protein expression system and our proprietary product pipeline.
Of the above, one is a joint patent, eight are joint patent applications, and one is a licensed patent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our competitive position and future success depend in part on
our ability, and that of our licensees, to obtain and leverage the intellectual property covering our product candidates, know-how,
methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property
and to operate without infringing the intellectual property of third parties. We seek to protect our competitive position by filing
United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology
and improvements to existing technology. Our patent strategy includes obtaining patents, where possible, on methods of production,
compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership
opportunities to develop and maintain our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We issued a series of 7.5% convertible notes in
December 2016 and July 2017, which are guaranteed by our subsidiaries and secured by perfected liens on all of our material
assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in
favor of the holders of outstanding 7.5% convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017, our patent portfolio consisted of several
patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and
system and product candidates, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0.25in">With respect to our ProCellEx protein expression system, we held nine issued patents and seven
patent applications relating to the large scale production of proteins in cultured plant cells. The issued patents and any patents
to issue in the future based on pending patent applications in this patent family, if at all, are expected to expire in 2028. One
patent relating to a separate family, covering methods for culturing and harvesting plant cells and/or tissues in consecutive cycles
is expected to expire in 2025.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing 24 issued patents and one patent application in India, South Africa, Russian Federation,
Australia, China, the United States, Ukraine, Singapore, Japan, Europe, Hong Kong, Mexico, Korea, Canada, Brazil and Israel relating
to the production of recombinant glycosylated lysosomal proteins in our plant culture platform, including taliglucerase alfa, and
uses of these proteins and cells containing these proteins for the treatment of lysosomal disorders. The issued patents and any
patents to issue in the future based on pending patent applications in this patent family, if at all, are expected to expire in
2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing three granted patents relating to a system and method for production of antibodies in a
plant cell culture, and antibodies produced in such a system. The issued patents in this patent family are expected to expire in
2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing four issued patents in Europe, South Africa, Australia and Israel, and one pending patent
application relating to a new method for delivering active recombinant proteins systemically through oral administration of transgenic
plant cells. The issued patents and any patents to issue in the future based on patent applications in this patent family, if at
all, are expected to expire in 2026.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing five granted patents in the United States, Europe, South Africa, Israel and Australia, relating
to saccharide containing protein conjugates. The issued patents and any patents to issue in the future based on the patent applications
in this patent family, if at all, are expected to expire in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing four granted patents in Japan, United States, Europe and China, and six pending patent
applications relating to Nucleic Acid construct for expression of alpha-galactosidase enzyme in plants and plant cells. The patents
to issue in the future based on the patent applications in this patent family, if at all, are expected to expire in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a patent family containing 16 granted patents in Europe, United States, Australia, Japan, Russian Federation, China,
Hong Kong, Singapore, New Zealand and South Africa, and eight pending patent applications relating to multimeric protein structures
of &alpha;-galactosidase and to uses thereof in treating Fabry disease. The issued patents and any patents to issue in the future
based on the patent applications in this patent family, if at all, are expected to expire in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held three patent families containing two granted patents in the United States and six pending applications relating to
plant recombinant human DNase I and uses in therapy. The patents to issue in the future based on these patent applications, if
at all, are expected to expire in 2033.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held a a patent family containing 11 patent applications relating to chemically modified plant recombinant human DNase I
and uses in therapy. The patents to issue in the future based on this patent application, if at all, are expected to expire in
2036.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We held three families containing 10 patent applications relating to plant recombinant TNF alpha inhibitor polypeptides. The
patents to issue in the future based on these patent applications, if at all, are expected to expire in 2034/2035.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our patent portfolio includes a patent that we co-own that covers human glycoprotein hormone and chain splice variants, including
isolated nucleic acids encoding these variants. More specifically, this patent covers a new splice variant of human FSH. This patent
was issued in the United States and is expected to expire in 2024.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We co-own and have an exclusive license to a patent family, containing eight pending applications, that covers use of plant
cells expressing a TNF alpha polypeptide inhibitor in therapy. The patents to issue in the future based on these patent applications,
if at all, are expected to expire in 2034.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have licensed the rights to a United States patent application covering oral composition comprising a TNF antagonist. The
patents to issue in the future based on this application, if at all, are expected to expire in 2034.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are aware of U.S. patents, and corresponding international
counterparts of such patents, owned by third parties that contain claims covering methods of producing GCD. We do not believe that,
if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to infringe
any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that, if we choose
or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable terms or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2005, Protalix Ltd. entered into a license agreement
with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize
Icon&rsquo;s technology to express certain proteins in our ProCellEx protein expression system. We are also entitled to a non-exclusive
worldwide license to make and have made other proteins expressed by using Icon&rsquo;s technology in our technology. As consideration
for the license, we are obligated to make royalty payments equal to varying low, single-digit percentages of net sales of products
by us, our affiliates, or any sublicensees under the agreement. In addition, we are obligated to make milestone payments equal
to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our license agreement with Icon remains in effect until the
earlier of the expiration of the last patent under the agreement or, if all of the patents under the agreement expire, 20 years
after the first commercial sale of any product under the agreement. Icon may terminate the agreement upon written notice to us
that we are in material breach of our obligations under the agreement and we are unable to remedy such material breach within 30
days after we receive such notice. Further, Icon may terminate the agreement in connection with certain events relating to a wind
up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to conduct operations for a
certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to reach certain milestones
within a designated period of time. Notwithstanding the termination date of the agreement, our obligation to pay royalties to Icon
under the agreement may expire prior to the termination of the agreement, subject to certain conditions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Manufacturing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We use our current facility, which has approximately
20,000 sq/ft of clean rooms built according to industry standards, to develop, process and manufacture pegunigalsidase alfa, taliglucerase
alfa and other recombinant proteins. Pegunigalsidase alfa and our other drug product candidates, as well as taliglucerase alfa,
must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory
authorities. We are currently producing Fabry drug substance for our phase III and other clinical trials, as well as the manufacture
of the taliglucerase alfa we need in the near future, included the taliglucerase alfa to be purchased by Pfizer under the Pfizer
Agreement. In addition, we intend to use our manufacturing space to produce all of the drug substance needed in connection with
the clinical trials for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In 2017, the FDA approved the Supplemental
New Drug Application (sNDA) we submitted to allow us to convert our manufacturing facility from a single dedicated product facility
to a multi-product facility. We expect that the conversion will allow us to realize potentially significant operational savings.
Our facility&rsquo;s current capacity can serve all of our current and expected commercial and clinical needs, and we believe it
will be sufficient to serve our production needs for the anticipated commercialization of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">O</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">ur
manufacturing facilities in Carmiel, Israel, have undergone successful audits by the Israeli MOH, the FDA, ANVISA, and the </FONT>European
Union under the European Union&rsquo;s centralized marketing authorization procedure, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Australian TGA and Health Canada</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our current facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and we have elected to participate in the alternative benefits program. Our facility is located in a
Zone A location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period commencing
with the year in which we first generate taxable income from the relevant Approved Enterprise and after we use our net operating
loss carryforwards, or &ldquo;NOLs.&rdquo; We expect to be entitled to similar tax benefits for a number of years thereafter. To
remain eligible for these tax benefits, we must continue to meet certain conditions, and if we increase our activities outside
of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli
tax benefit programs. In addition, our technology is subject to certain restrictions with respect to the transfer of technology
and manufacturing rights. &ldquo;See Risk Factors&mdash;The manufacture of our products is an exacting and complex process, and
if we or one of our materials suppliers encounter problems manufacturing our products, it will have a material adverse effect on
our business and results of operations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raw Materials and Suppliers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the raw materials that we require throughout
the manufacturing process of Elelyso, PRX-102, alidornase alfa and OPRX-106 and our other current and potential drug product candidates
are widely available from numerous suppliers and are generally considered to be generic industrial biological supplies. We rely
on a single approved supplier for certain materials relating to the current expression of our proprietary biotherapeutic proteins
through ProCellEx. We have identified additional suppliers for most of the materials required for the production of our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Development and regulatory approval of our pharmaceutical products
are dependent upon our ability to procure active ingredients and certain packaging materials from sources approved by the FDA and
other regulatory authorities. Since the FDA and other regulatory approval processes require manufacturers to specify their proposed
suppliers of active ingredients and certain packaging materials in their applications, FDA approval of a supplemental application
to use a new supplier in connection with any drug candidate or approved product, if any, would be required if active ingredients
or such packaging materials were no longer available from the specified supplier, which could result in manufacturing delays. From
time to time, we intend to continue to identify alternative FDA-approved suppliers to ensure the continued supply of necessary
raw materials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The biotechnology and pharmaceutical industries are characterized
by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the
fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and
development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many
specialized biotechnology companies have formed collaborations with large, established companies to support research, development
and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions
of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&rsquo; financial,
marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations
are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies
on their own or through collaborations with pharmaceutical and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are two approved ERTs for the treatment of Fabry disease;
Fabrazyme which is marketed by Genzyme and Replagal, which is marketed by Shire. Fabrazyme is available in the United States and
the European Union. Replagal is available in the European Union and certain other territories outside the United States. In addition,
we are aware of other late clinical stage, early clinical stage and experimental drugs which are being developed for the treatment
of Fabry disease by Amicus Therapeutics, Inc. and other companies. In addition, in May 2016, Galafold&trade; (migalastat), an oral
small molecule pharmacological chaperone marketed by Amicus was approved in the European Union and other countries, but not in
the United States, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed
diagnosis of Fabry disease and who have an amenable mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to alidornase alfa, we face competition from Genentech
Inc., a member of the Roche Group, which markets Pulmozyme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to PRX-106, we face competition from AbbVie Inc.
(Humira), Johnson &amp; Johnson and Merck &amp; Co. (Remicade) and Pfizer and Amgen Inc. (Enbrel). In addition, we are aware of
other clinical stage, early clinical stage and experimental antiTNF drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also face competition from companies that are developing
other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include, among others, iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH, none of which are cell-based.
Rather, such companies base their product development on transgenic plants or whole plants. See &ldquo;Risk Factors&mdash;Developments
by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on
our business, results of operations and financial condition.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scientific Advisory Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have reorganized our scientific advisory board by establishing
a core team of advisors. The scientific advisory board may invite additional experts to attend meetings on a case-by-case basis.
Members of our scientific advisory board consult with our management within their professional areas of expertise; exchange strategic
and business development ideas with our management; attend scientific, medical and business meetings with our management, such
as meetings with the FDA and comparable foreign regulatory authorities, meetings with strategic or potential strategic partners
and other meetings relevant to their areas of expertise; and attend meetings of our scientific advisory board. We expect our scientific
advisory board to convene at least twice annually, and we frequently consult with the individual members of our scientific advisory
board. Our scientific advisory board currently includes the following people:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><B>Name</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><B>Affiliations
        (selected)</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Roger D. Kornberg, Ph.D. (Chairman)</TD>
    <TD>&nbsp;</TD>
    <TD>Laureate of the Nobel Prize in Chemistry</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Member, U.S. National Academy of Sciences</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Winzer Professor of Medicine, Department of Structural Biology at Stanford University</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>2001 Welch Prize (highest award granted in the field of chemistry in the United States)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>2002 Leopold Mayer Prize (the highest award granted in the field of biomedical sciences from the French Academy of Sciences)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Professor Aaron Ciechanover, M.D., D.Sc.</TD>
    <TD>&nbsp;</TD>
    <TD>Laureate of the Nobel Prize in Chemistry</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Distinguished research Professor at the Cancer and Vascular Biology Research Center of the Rappaport Research Institute and Faculty of Medicine at the Technion, Israel&rsquo;s Institute of Technology</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>American Academy of Arts and Sciences, Member</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Alexander Levitzki, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>Wolfson Family Professor of Biochemistry in the Department of Biological Chemistry of The Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>American Association for Cancer Research, 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>1990 Israel Prize in Biochemistry</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>1990 Rothschild Prize in Biology</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%">2002 Hamilton-Fairley Award, European Society of Medical Oncology</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>2005 Wolf Prize for Medicine</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>2012 Nauta Award in Pharmacochemistry, The European Federation of Medicinal Chemistry (EFMC) (the highest award from the European Federation for Medicinal Chemistry)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Charles J. Arntzen, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>Regent&rsquo;s Profession and Florence Ely Nelson Presidential Chair</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Biodesign Institute, CIDV, Arizona State University</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Member, National Academy of Sciences, USA</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>American Society of Plant Biology Leadership in Science Public Service Award (2004)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Botanical Society of America Centennial Award (2006)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Fellow of American Society of Plant Biologists (2007)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Doctor of Science <I>honoris causa.</I>, Hebrew University of Jerusalem</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chair, Section O &ldquo;Agriculture, Food, and Renewable Resources,&rdquo; American Association for the Advancement of Science (AAAS) (2011-2012)</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The testing, manufacture, distribution, advertising and marketing
of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States,
including the FDA, and by similar authorities in other countries. Any product that we develop must receive all relevant regulatory
approvals or clearances, as the case may be, before it may be marketed in a particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory process, which includes overseeing preclinical
studies and clinical trials of each pharmaceutical compound to establish its safety and efficacy and confirmation by the FDA that
good laboratory, clinical and manufacturing practices were maintained during testing and manufacturing, can take many years, requires
the expenditure of substantial resources and gives larger companies with greater financial resources a competitive advantage over
us. Delays or terminations of clinical trials that we undertake would likely impair our development of product candidates. Delays
or terminations could result from a number of factors, including stringent enrollment criteria, slow rate of enrollment, size of
patient population, having to compete with other clinical trials for eligible patients, geographical considerations and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA review process can be lengthy and unpredictable, and
we may encounter delays or rejections of our applications when submitted. Generally, in order to gain FDA approval, we must first
conduct preclinical studies in a laboratory and in animal models to obtain preliminary information on a compound and to identify
any potential safety problems. The results of these studies are submitted as part of an IND application that the FDA must review
before human clinical trials of an investigational drug can commence. Clinical trials may be terminated by the clinical trial site,
sponsor or the FDA if toxicities appear that are either worse than expected or unexpected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trials are normally performed in three sequential phases
and generally take two to five years, or longer, to complete. Phase I consists of testing the drug product in a small number of
humans, normally healthy volunteers, to determine preliminary safety and tolerable dose range. Phase II usually involves studies
in a limited patient population to evaluate the effectiveness of the drug product in humans having the disease or medical condition
for which the product is indicated, determine dosage tolerance and optimal dosage and identify possible common adverse effects
and safety risks. Phase III consists of additional controlled testing at multiple clinical sites to establish clinical safety and
effectiveness in an expanded patient population of geographically dispersed test sites to evaluate the overall benefit-risk relationship
for administering the product and to provide an adequate basis for product labeling. Phase IV clinical trials may be conducted
after approval to gain additional experience from the treatment of patients in the intended therapeutic indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completion of clinical trials of a new drug product, FDA
and foreign regulatory authority marketing approval must be obtained. Assuming that the clinical data support the product&rsquo;s
safety and effectiveness for its intended use, a new drug application, or NDA, or a BLA is submitted to the FDA for review. Generally,
it takes one to three years to obtain approval. If questions arise during the FDA review process, approval may take a significantly
longer period of time. The testing and approval processes require substantial time and effort and approval on a timely basis, if
at all, or the approval that we receive may be for a narrower indication than we had originally sought, potentially undermining
the commercial viability of the product. Even if regulatory approvals are obtained, approved products are subject to continual
review and holders of an approved product are required, for example, to report certain adverse reactions and production problems,
if any, to the FDA, and to comply with certain requirements concerning advertising and promotional labeling for the product. Also,
quality control and manufacturing procedures relating to a product must continue to conform to cGMP after approval, and the FDA
periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend
time, money and effort in the area of production and quality control to comply with cGMP and other aspects of regulatory compliance.
The later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements with respect
to any product may result in restrictions on the marketing of the product or withdrawal of the product from the market as well
as possible civil or criminal sanctions. See also &ldquo;&mdash;International Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Orphan Drug Act of 1983, the FDA may grant orphan
drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or
condition that affects fewer than 200,000 individuals in the United States. The FDA grants orphan drug designation to drugs that
may provide a significant therapeutic advantage over existing treatments and target conditions affecting 200,000 or fewer U.S.
patients per year. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and
approval process. Among the other benefits of orphan drug designation are possible funding and tax savings to support clinical
trials and for other financial incentives and a waiver of the marketing application user fee and most likely priority review. If
a significant therapeutic advantage over existing treatments is shown in the marketing application, the FDA may grant orphan drug
approval and provide a seven-year period of marketing exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA has a fast track program that is is designed to facilitate
the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the purpose being
to make important new drugs available to patients earlier. A drug candidate that receives Fast Track designation from the FDA is
eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug&rsquo;s development plan and
ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such
things as the design of the proposed clinical trials; eligibility for the FDA&rsquo;s Accelerated Approval and Priority Review,
if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its
BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application
can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
We used the Rolling Review option for our taliglucerase alfa NDA, which we completed in April 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The United States federal government regulates healthcare through
various agencies, including but not limited to the following: (i) the FDA, which administers the Federal Food, Drug, and Cosmetic
Act (FDCA), as well as other relevant laws; (ii) the Center for Medicare &amp; Medicaid Services (CMS), which administers the Medicare
and Medicaid programs; (iii) the Office of Inspector General (OIG) which enforces various laws aimed at curtailing fraudulent or
abusive practices, including by way of example, the Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to as
Stark, the Anti-Inducement Law, the Civil Money Penalty Law and the laws that authorize the OIG to exclude healthcare providers
and others from participating in federal healthcare programs; and (iv) the Office of Civil Rights, which administers the privacy
aspects of the Health Insurance Portability and Accountability Act of 1996, or HIPAA. All of the aforementioned are agencies within
the Department of Health and Human Services (HHS). Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs, especially through the Veterans Health Care Act of
1992, the Public Health Service within HHS under Public Health Service Act &sect; 340B (42 U.S.C. &sect; 256b), the Department
of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid and other
state sponsored or funded programs and their internal laws regulating all healthcare activities. Many states also have anti-kickback
and anti-physician referral laws that are similar to the federal laws, but may be applicable in situations where federal laws do
not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Medicare is the federal healthcare program for those who are
(i) over 65 years of age, (ii) disabled, (iii) suffering from end-stage renal disease or (iv) suffering from Lou Gehrig&rsquo;s
disease. Medicare consists of part A, which covers inpatient costs, part B, which covers services by physicians and laboratories,
durable medical equipment and certain drugs, primarily those administered by physicians, and part D, which provides drug coverage
for most prescription drugs other than those covered under part B. Medicare also offers a managed care option under part C. Medicare
is administered by CMS. In contrast, Medicaid is a state-federal healthcare program for the poor and is administered by the states
pursuant to an agreement with the Secretary of Health and Human Services. Most state Medicaid programs cover most outpatient prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2010, the Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, PPACA, became law in the United
States. PPACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly
affects the pharmaceutical industry. Key provisions of PPACA specific to the pharmaceutical industry, among others, include the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents
into the United States, apportioned among these entities according to their market share in certain federal government healthcare
programs (excluding sales of any drug or biologic product marketed for an orphan indication), beginning in 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010,
to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of sale discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for
the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D, beginning in 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Extension of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid
managed care organizations, effective March 23, 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to additional individuals beginning in April 2010 and by adding new mandatory eligibility categories for certain individuals with
income at or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing both the volume of sales
and manufacturers&rsquo; Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program, effective
January 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>New requirements to report certain financial arrangements with physicians and others, including reporting any &ldquo;transfer
of value&rdquo; made or distributed to prescribers and other healthcare providers and reporting any investment interests held by
physicians and their immediate family members during each calendar year beginning in 2012, with reporting starting in 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new requirement to annually report drug samples that manufacturers and distributors provide to physicians, effective April
1, 2012;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A licensure framework for follow-on biologic products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to regulations and product registration requirements
in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements,
labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to
obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements
for licensing a product in a foreign country may differ significantly from FDA requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmaceutical products may not be imported into, or manufactured
or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals
in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli MOH requires pharmaceutical companies to
conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific
advances as well as social and ethical values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relevant legislation of the European Union requires that
medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations,
of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union.
Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order
to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized
procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical,
biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials. All
of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate the
quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal products
intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect not more
than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that treat conditions
for which no current therapy exists or are expected to bring a significant benefit to patients over existing therapies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli Government Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the current principal Israeli
tax laws applicable to us and Protalix Ltd., and of the Israeli Government programs from which Protalix Ltd. benefits. Some parts
of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore,
the views expressed in the discussion may not be accepted by the tax authorities in question. The discussion should not be construed
as legal or professional tax advice and does not cover all possible tax considerations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Corporate Tax Structure in Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income of Protalix Ltd., other than income from &ldquo;Approved
Enterprises,&rdquo; is taxed in Israel at the regular rates which were 26.5% for fiscal year 2015, 25% in 2016 and 24% in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2016, the Law for the Amendment of the Income Tax
Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from 26.5% to 25%.
In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018
Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also
included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate was 24% in 2017
and will be 23% in 2018 and thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capital gains on the sale of assets are subject to capital gains
tax according to the corporate tax rate in effect in the year which the assets are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Law for the Encouragement of Capital Investments, 1959</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Law for the Encouragement of Capital Investments, 1959,
as amended, or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible
assets). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred
to as an &ldquo;Approved Enterprise,&rdquo; is entitled to benefits. These benefits may include cash grants from the Israeli government
and tax benefits, based upon, among other things, the location of the facility in which the investment is made and specific elections
made by the grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd. will continue to enjoy the tax benefits under
the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix Ltd. in the future, Protalix Ltd.
will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion
is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law prior to its amendment, a company that
wished to receive benefits had to receive approval from the Authority for the Investment and Development of the Industry and Economy,
or the Authority. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved
Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the
asset, e.g., the equipment to be purchased and utilized pursuant to the program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An Approved Enterprise may elect to forego any entitlement to
the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under which
the undistributed income from the Approved Enterprise is fully exempt from corporate tax for a defined period of time. Under the
alternative package of benefits, a company&rsquo;s undistributed income derived from an Approved Enterprise will be exempt from
corporate tax for a period of between two and 10 years from the first year of taxable income, depending upon the geographic location
within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible for the
reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits period (up
to an aggregate benefits period of either seven or 10 years, depending on the location of the company or its definition as a foreign
investors&rsquo; company). If a company has more than one Approved Enterprise program or if only a portion of its capital investments
are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits from any
certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise. Income from activity that
is derived from different Approved Enterprises does not enjoy these tax benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has an Approved Enterprise program is eligible
for further tax benefits if it qualifies as a foreign investors&rsquo; company. A foreign investors&rsquo; company eligible for
benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and
appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents.
A company that qualifies as a foreign investors&rsquo; company and has an Approved Enterprise program is eligible for tax benefits
for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 25%, depending on the amount of the company&rsquo;s
shares held by non-Israeli shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a company that has an Approved Enterprise program is a wholly
owned subsidiary of another company, the percentage of foreign investments is determined based on the percentage of foreign investment
in the parent company. The tax rates and related levels of foreign investments are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%; text-align: center"><B>Percent of Foreign </B><BR>
<B>Ownership</B></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center"><B>Rate of Reduced </B><BR>
<B>Tax</B></TD></TR>
<TR>
    <TD STYLE="text-align: center">0-49%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
<TR>
    <TD STYLE="text-align: center">49-74%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20%</TD></TR>
<TR>
    <TD STYLE="text-align: center">74-90%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
<TR>
    <TD STYLE="text-align: center">90-100%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our original facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved
Enterprise program, the facility is located in a top priority location, or &ldquo;Zone A,&rdquo; and, therefore, the income from
that Approved Enterprise will be tax exempt in Israel for a period of 10 years, commencing with the year in which taxable income
is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix
Ltd. may not continue to qualify for its benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has elected to participate in the alternative
benefits program and that subsequently pays a dividend out of the income derived from the Approved Enterprise during the tax exemption
period will be subject to corporate tax in respect of the amount distributed at the rate that would have been applicable had the
company not elected the alternative benefits program (generally 10% to 25%, depending on the extent to which non-Israeli shareholders
hold such company&rsquo;s shares). If the dividend is distributed within 12 years after the commencement of the benefits period
(or, in the case of a foreign investor&rsquo;s company, without time limitation), the dividend recipient is taxed at the reduced
withholding tax rate of 15% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty.
After this period, the withholding tax rate is 25%, or at the lower rate under an applicable tax treaty. In the case of a company
with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding
tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted
into foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Investment Law also provides that an Approved Enterprise
is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This
benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The benefits available to an Approved Enterprise are conditioned
upon terms stipulated in the Investment Law and regulations and the criteria set forth in the applicable certificate of approval.
If Protalix Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix Ltd. may be required
to refund the received benefits, linked to the Israeli consumer price index with the addition of interest or alternatively with
an additional penalty payment. We believe that Protalix Ltd. currently operates in compliance with all applicable conditions and
criteria, but there can be no assurance that Protalix Ltd. will continue to do so. Furthermore, there can be no assurance that
any Approved Enterprise status granted to Protalix Ltd.&rsquo;s facilities will entitle Protalix Ltd. to the same benefits to which
it is currently entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law, the approval of the Authority is required
only for Approved Enterprises that receive cash grants. Approved Enterprises that do not receive benefits in the form of governmental
cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Approved Enterprises are required
to make certain investments as specified in the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amended Investment Law specifies certain conditions for
an Approved Enterprise to be entitled to benefits. These conditions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the Approved Enterprise&rsquo;s revenues from any single country or a separate customs territory may not exceed 75% of the
Approved Enterprise&rsquo;s total revenues; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at least 25% of the Approved Enterprise&rsquo;s revenues during the benefits period must be derived from sales into a single
country or a separate customs territory with a population of at least 14 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that Protalix Ltd. will comply with
the above conditions in the future or that Protalix Ltd. will be entitled to any additional benefits under the Investment Law.
In addition, it is possible that Protalix Ltd. may not be able to operate in a manner that maximizes utilization of the potential
benefits available under the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, the Israeli Government has considered reducing
the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available
under the Investment Law could materially impact the cost of our future investments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Encouragement of Industrial Research, Development and Technology
Innovation Law, 1984</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, Protalix Ltd. has received grants from the OCS
under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related
regulations, or the Research Law. On January 1, 2016, the Israeli government established NATI which replaced many of the
functions of the Office of the Chief Scientist of the Israeli Department of Labor, or the OCS. For purposes of clarity,
references to NATI will include the OCS. NATI grants are made available to finance of a portion of Protalix Ltd.&rsquo;s
research and development expenditures in Israel. As of December 31, 2017, NATI approved grants in respect of Protalix
Ltd.&rsquo;s continuing operations totaling approximately $50.9 million, measured from inception. Protalix Ltd. is required
to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after
January 1, 1999) to NATI through payments of royalties at a rate of 3% to 6% of the revenues generated from NATI-funded
project, depending on the period in which revenues were generated. As of December 31, 2017, Protalix Ltd. either paid or
accrued royalties payable of $8.7 million and Protalix Ltd.&rsquo;s contingent liability to NATI with respect to grants
received was approximately $42.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law, recipients of grants from NATI are prohibited
from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the
Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being
subject to increased royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants
outside of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts
plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty
rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, Protalix Ltd. is prohibited
from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under
limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix Ltd. may not receive the required
approvals for any proposed transfer and, if received, Protalix Ltd. may be required to pay NATI a portion of the consideration
that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that
Protalix Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred
and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order
to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required,
and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions
on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if
requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law and the regulations promulgated thereunder,
NATI Council may allow the transfer outside of Israel of know-how derived from an approved program and the related manufacturing
rights in limited circumstances which are currently as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event of a sale of know-how itself to a non-affiliated third party, provided that upon such sale the owner of the know-how
pays to NATI an amount, in cash, as set forth in the Research Law (and the regulations promulgated thereunder). In addition, the
amendment provides that if the purchaser of the know-how gives the selling Israeli company the right to exploit the know-how by
way of an exclusive, irrevocable and unlimited license, the research committee may approve such transfer in special cases without
requiring a cash payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event of a sale of a company which is the owner of know-how, pursuant to which the company ceases to be an Israeli company,
provided that upon such sale, the owner of the know-how makes a cash payment to NATI as set forth in the Research Law (and the
regulations promulgated thereunder).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event of an exchange of know-how such that in exchange for the transfer of know-how outside of Israel, the recipient
of the know-how transfers other know-how to the company in Israel in a manner in which NATI is convinced that the Israeli economy
realizes a greater, overall benefit from the exchange of know-how.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Research Committee may, in special cases, approve the transfer
of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results
therefrom, outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The State of Israel does not own intellectual property rights
in technology developed with NATI funding and there is no restriction on the export of products manufactured using technology developed
with NATI funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described
above. For a description of such restrictions, please see &ldquo;Risk Factors&mdash;Risks Relating to Our Operations in Israel.&rdquo;
NATI approval is not required for the export of any products resulting from the research or development or for the licensing of
any technology in the ordinary course of business.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Law for the Encouragement of Industry (Taxes), 1969</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that Protalix Ltd. currently qualifies as an &ldquo;Industrial
Company&rdquo; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.
The Industry Encouragement Law defines &ldquo;Industrial Company&rdquo; as a company resident in Israel and incorporated in Israel,
that derives 90% or more of its income in any tax year (other than specified kinds of passive income such as capital gains, interest
and dividends) from an &ldquo;Industrial Enterprise&rdquo; operating in Israel (including Judea &amp; Samaria territories and the
Gaza strip), that it owns. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise whose major activity in a given tax
year is industrial production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following corporate tax benefits, among others, are available
to Industrial Companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>accelerated depreciation rates on equipment and buildings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>under specified conditions, an election to file consolidated tax returns with other related Israeli Industrial Companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 27.9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expenses related to a public offering are deductible in equal amounts over three years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eligibility for the benefits under the Industry Encouragement
Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix Ltd. may fail to
qualify or may not continue to qualify as an &ldquo;Industrial Company&rdquo; or that the benefits described above will not be
available in the future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax Benefits for Research and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under specified conditions, Israeli tax laws allow a tax deduction
by a company for research and development expenditures, including capital expenditures, for the year in which such expenditures
are incurred. These expenditures must relate to scientific research and development projects and must be approved by NATI. Furthermore,
the research and development projects must be for the promotion of the company and carried out by or on behalf of the company seeking
such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds received through government
grants for the finance of such scientific research and development projects. Expenditures not so approved are deductible over a
three-year period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017, we had 190 employees, of whom 21 have
a Ph.D. or an M.D.in their respective scientific fields. We believe that our relations with these employees are good. We believe
that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of
Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply
to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries,
length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented
by a labor union or represented under a collective bargaining agreement. See &ldquo;Risk Factors&mdash;We depend upon key employees
and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely
affect our ability to develop and market our products.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal business address is set forth below. Our executive
offices and our main research manufacturing facility are located at that address. Our telephone number is +972-4-988-9488. We were
originally incorporated in the State of Florida in April 1992, and reincorporated in the State of Delaware in March 2016. Protalix
Ltd., our wholly-owned subsidiary and sole operating unit, is an Israeli company and was originally incorporated in Israel on December
27, 1993. During 1999, Protalix Ltd. changed its focus from plant secondary metabolites to the expression of recombinant therapeutic
proteins in plant cells, and in April 2004 changed its name to Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx<SUP>&reg;</SUP> is our registered trademark. Each
of the other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K belongs to its respective holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Available Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate website is www.protalix.com. We make available
on our website, free of charge, our Commission filings, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file
these documents with, or furnish them to, the Commission. Additionally, from time to time, we provide notifications of material
news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences
may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is
not intended to be incorporated by reference into this report or in any other report or document we file and any references to
these websites are intended to be inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also listed on the Tel Aviv Stock Exchange, or the TASE,
and, accordingly, we submit copies of all our filings with the Commission to the Israeli Securities Authority and the TASE. Such
copies can be retrieved electronically through the TASE&rsquo;s internet messaging system (www.maya.tase.co.il) and through the
MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our website also includes printable versions of our Code of
Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors.
Each of these documents is also available in print, free of charge, to any shareholder who requests a copy by addressing a request
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2 Snunit Street, Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">P.O. Box 455</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carmiel 20100, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Mr. Yossi Maimon, Chief Financial
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 45pt"><A NAME="a_004"></A>Item&nbsp;1A.</TD><TD>Risk Factors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>You should carefully consider the risks described below together
with the other information included in this Annual Report on Form 10-K. Our business, financial condition or results of operations
could be adversely affected by any of these risks. If any of these risks occur, the value of our common stock could decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Clinical Trials and Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Clinical
trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs which may have
a material adverse effect on our business, results of operations and financial condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Human
clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory
requirements. The clinical trial process is also time-consuming. Other than taliglucerase alfa, all of our other drug candidates,
including pegunigalsidase alfa, are in the clinical, preclinical or research stages and will take at least several years to complete.
Preliminary and initial results from a clinical trial do not necessarily predict final results, and failure can occur at any stage
of the trial. We may encounter problems that cause us to abandon or repeat preclinical studies or clinical trials. Failure or delay
in the commencement or completion of our clinical trials may be caused by several factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>slower than expected rates of patient recruitment, particularly with respect to trials of rare diseases such as Fabry disease;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>determination of dosing issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen safety issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of effectiveness during clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>disagreement by applicable regulatory bodies over our trial protocols, our the interpretation of data from preclinical studies
or clinical trials or conduct and control of clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>determination that the patient population participating in a clinical trial may not be sufficiently broad or representative
to assess efficacy and safety for our target population;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability to monitor patients adequately during or after treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of sufficient funding to finance the clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure or delay in commencement or completion of any clinical
trials of <FONT STYLE="background-color: white">pegunigalsidase alfa</FONT> or our other product candidates will have a material
adverse effect on our business, results of operations and financial condition. In addition, we or the FDA or other regulatory authorities
may suspend any clinical trial at any time if it appears that we are exposing participants in the trial to unacceptable safety
or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies in our IND submissions or
the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
may find it difficult to enroll patients in our clinical trials, which could cause significant delays in the completion of such
trials or may cause us to abandon one or more clinical trials.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Some
of the diseases or disorders that our drug candidates are intended to treat, such as Fabry disease, are relatively rare and we
expect only a subset of the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally
mandate that a patient cannot be involved in another clinical trial for the same indication. Therefore, subjects that participate
in ongoing clinical trials for products that are competitive with our drug candidates are not available for our clinical trials.
An inability to enroll a sufficient number of patients for our ongoing phase III clinical trials of pegunigalsidase alfa, or for
any of our other current or future clinical trials, would result in significant delays or may require us to abandon one or more
clinical trials altogether, which will have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>If
the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified,
the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether,
which will significantly impair our ability to generate product revenues.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The results of our clinical
trials with respect to any drug candidate might not support our claims of superiority, safety or efficacy, the effects of our drug
candidates may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected
characteristics.&nbsp;&nbsp;Further, success in preclinical testing and early clinical trials does not ensure that later clinical
trials will be successful, and the results of later clinical trials may not replicate the results of prior clinical trials and
preclinical testing. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory
approval. The clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated
uses. In addition, our clinical trials, particularly with respect to pegunigalsidase alfa, may involve specific and small patient
populations. Results of early clinical trials conducted on a small patient population may not be indicative of future results.
Adverse or inconclusive results may cause us to abandon a drug candidate and may delay development of other drug candidates. Any
delay in, or termination of, our clinical trials will delay the filing of NDAs and BLAs with the FDA, or other filings with other
foreign regulatory authorities, and, ultimately, significantly impair our ability to commercialize our drug candidates and generate
product revenues which would have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Patients
may discontinue their participation in our clinical trials which may negatively impact the results of these studies and extend
the timeline for completion of our development programs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Patients enrolled in our
clinical trials may discontinue their participation at any time during the study as a result of a number of factors, including
withdrawing their consent, experiencing adverse clinical events, which may or may not be judged related to our drug candidates
under evaluation, or due to planned or actual pregnancies. The discontinuation of patients in any one of our studies may delay
the completion of the study or cause the results from the study not to be positive or to not support a filing for regulatory approval
of the applicable drug candidate, which would have a material adverse effect on our business, results of operations and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because our clinical trials depend upon third-party researchers,
the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent,
beyond our control, which could impair our clinical development programs and our competitive position. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend upon independent investigators and collaborators,
such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our
employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators
may not assign as great a priority to our clinical development programs or pursue them as diligently as we would if we were undertaking
such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs,
or if their performance is substandard, the approval of anticipated NDAs, BLAs and other marketing applications, and our introduction
of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material adverse effect
on our business and results of operations. The collaborators may also have relationships with other commercial entities, some of
whom may compete with us. If our collaborators also assist our competitors, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities
before our drug candidates may be marketed.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Both
before and after marketing approval of our drug candidates, if at all, we, our drug candidates, our suppliers, our contract manufacturers
and our contract testing laboratories are subject to extensive regulation by the FDA and comparable foreign regulatory authorities.
Failure to comply with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other
things, any of the following actions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warning letters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines and other monetary penalties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unanticipated expenditures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the FDA&rsquo;s or other foreign regulatory authorities&rsquo; approving, or the refusal of any regulatory authority
to approve, any drug candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product recall or seizure;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interruption of manufacturing or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>operating restrictions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>criminal prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">In
addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval,
to us, our drug candidates, and our suppliers, contract manufacturers, and contract laboratories. These include requirements related
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>testing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>quality control;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>advertising;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>promotion;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>export;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">We
also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory
requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that
the FDA or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or
distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations
in response to these inspections which may require significant resources and may have a material adverse effect upon our business,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative
action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory
reviews of such drug candidate. Delays in obtaining regulatory approva</FONT>ls with respect to any drug candidate may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay commercialization of, and our ability to derive product revenues from, such drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require us to perform costly procedures with respect to such drug candidate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Delays
in the approval process for any drug candidate may have a material adverse effect upon our business, results of operations and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely
manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">We
need FDA approval to commercialize our drug candidates in the United States, EMA approval to commercialize our drug candidates
in the European Union and approvals from other foreign regulators to commercialize our drug candidates elsewhere. In order to obtain
FDA approval of any of our drug candidates, we must submit to the FDA an NDA or a BLA demonstrating that the drug candidate is
safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are
referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. In the European Union, we
must submit an MAA to the EMA. Satisfaction of the regulatory requirements of the FDA, EMA and other foreign regulatory authorities
typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources
for research, development and testing. Even if we comply with all the requests of regulatory authorities, the authorities may ultimately
reject any marketing application that we file for a product candidate in the future, if any, or we might not obtain regulatory
clearance in a timely manner. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in
advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other
comparable authorities for such clinical trials. Further, even if favorable testing data is generated by the clinical trials of
a drug candidate, the applicable regulatory authority may not accept or approve the marketing application filed by a pharmaceutical
or biotechnology company for the drug candidate. Failure to obtain approval of the FDA, EMA or comparable foreign authorities of
any of our drug candidates in a timely manner, if at all, will severely undermine our business, financial condition and results
of operation by reducing our potential marketable products and our ability to generate corresponding product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Our
research and clinical efforts may not result in drugs that the FDA, EMA or foreign regulatory authorities consider safe for humans
and effective for indicated uses, which would have a material adverse effect on our business, results of operations and financial
condition. After clinical trials are completed for any drug candidate, if at all, the FDA, EMA and foreign regulatory authorities
have substantial discretion in the drug approval process of the drug candidate in their respective jurisdictions and may require
us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional costs. Incurring
such costs may have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors
may affect our ability or the time we require to obtain necessary regulatory approvals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We have only limited experience
in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover,
some of the drug candidates that are likely to result from our development programs may be based on new technologies that have
not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may be less well defined
or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in connection with
obtaining regulatory approvals of any products that we develop</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Orphan
drug designation may not ensure that we will enjoy market exclusivity in any jurisdiction. If any of our other competitors are
able to obtain orphan drug exclusivity for any products that are competitive with our products, we may be precluded from selling
or obtaining approval of our competing products by the applicable regulatory authorities for a significant period of time.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">In
the United States, the European Union and other countries, a drug may be designated as having orphan drug status, subject to certain
conditions. There can be no assurance that a drug candidate that receives orphan drug designation will receive orphan drug marketing
exclusivity and more than one drug can have orphan designation for the same indication. In addition, the orphan drug designation
granted to pegunigalsidase alfa by the EMA does not affect Fabry disease treatments that preexist the approval of pegunigalsidase
alfa, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Foreign
regulations regarding orphan drugs are similar to those in the United States but there are several differences. For example, the
exclusivity period in the European Union is generally 10 years. From time to time, we may apply to the FDA or any comparable foreign
regulatory authority for orphan drug designation for any one or more of our drug candidates. Other than pegunigalsidase alfa which
was granted orphan drug designation by the EMA, none of our drug candidates have been designated as an orphan drug and there is
no guarantee that the FDA or any other regulatory authority will grant such designation in the future. In addition, neither orphan
drug designation nor orphan drug exclusivity prevents competitors from developing or marketing different drugs for the relevant
indication. Even if we obtain orphan drug exclusivity for one or more indications for one of our drug candidates, we may not be
able to maintain the exclusivity. For example, if a competitive product that is the same drug or biologic as one of our drug candidates
is shown to be clinically superior to the drug candidate, any orphan drug exclusivity granted to the drug candidate will not block
the approval of the competitive product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">If any drug receives orphan
drug exclusivity in any jurisdiction for the same indication of any of our drug candidates, we may be prevented from attaining
a similar designation with respect to our drug candidate or from marketing the drug candidate in the jurisdiction during the applicable
exclusivity period, which will have a material adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The fast track designation for pegunigalsidase alfa for the
treatment of Fabry disease may not lead to a faster development or regulatory review or approval process or increase the likelihood
that pegunigalsidase alfa will receive regulatory approval for the treatment of Fabry disease. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In January 2018, the FDA
granted Fast Track designation to pegunigalsidase alfa for the treatment of Fabry disease. A drug that receives Fast Track designation
from the FDA is eligible for certain benefits. However, fast track designation does not increase the likelihood that pegunigalsidase
alfa will receive regulatory approval for the treatment of Fabry disease. Further, despite the designation, we may not experience
a faster development process, review or approval compared to applications considered for approval under conventional FDA procedures.
In addition, the FDA is entitled to withdraw the Fast Track designation of a drug candidate at any time. Any failure to realize
the benefits of fast track designation may have a material adverse effect </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">on
our business, results of operations and financial condition</FONT><FONT STYLE="background-color: white">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have a limited operating history which may limit the ability
of investors to make an informed investment decision. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Taliglucerase alfa is our only product with commercial approvals.
The successful commercialization of our other drug candidates will require us to perform a variety of functions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continuing to perform preclinical development and clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>participating in regulatory approval processes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating and manufacturing products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>conducting sales and marketing activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our operations have been limited to organizing and staffing
our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical
trials and clinical trials of our principal drug candidates. To date, our phase III clinical trial of taliglucerase alfa is the
only phase III study we have completed. These operations provide a limited basis for investors to assess our ability to commercialize
our drug candidates and whether to invest in our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently depend heavily on the success of pegunigalsidase
alfa. Any failure to commercialize pegunigalsidase alfa, or the experience of significant delays in doing so, will have a material
adverse effect on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are investing a significant portion of our efforts and financial
resources in the development of pegunigalsidase alfa and our ability to generate significant product revenues in the future, will
depend heavily on the successful development and commercialization of pegunigalsidase alfa. The successful commercialization of
pegunigalsidase alfa will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successful completion of our ongoing studies of pegunigalsidase alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Chiesi&rsquo;s efforts under the Chiesi Agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining marketing approvals from the FDA, the EMA and other foreign regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful audit of our facilities by the FDA and other foreign regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our development of a successful sales and marketing organization for pegunigalsidase in the United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the availability of reimbursement to patients from healthcare payors for pegunigalsidase alfa, if approved;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued acceptable safety and efficacy profile of pegunigalsidase alfa following approval; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other risks described in these Risk Factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to commercialize pegunigalsidase alfa or the experience
of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Any failure by us to supply drug substance to Pfizer may
have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the </FONT>Amended Pfizer Agreement, we have agreed, for the first 10-year period after the execution of the agreement, to sell
drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two
additional 30-month periods subject to certain terms and conditions. As part of that obligation, we agreed to substantial financial
penalties in case we fail to comply with the supply commitments, or are delayed in doing so. The amounts of the penalties depend
on when any such failure occurs and for how long it persists, if at all, and other considerations. Any failure to comply with the
supply commitments under the Amended Pfizer Agreement may have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our strategy, in certain cases, is to enter into collaboration
agreements with third parties to leverage our ProCellEx system to develop product candidates. If we fail to enter into these agreements
or if we or the third parties do not perform under such agreements or terminate or elect to discontinue the collaboration, it could
have a material adverse effect on our revenues.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our strategy, in certain cases, is to enter into arrangements
with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Under these arrangements,
we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements,
as we have done with pegunigalsidase alfa. Our partners may control key decisions relating to the development of the products and
we may depend on our partners&rsquo; expertise and dedication of sufficient resources to develop and commercialize our product
candidates. The rights of our partners limit our flexibility in considering alternatives for the commercialization of our product
candidates. If we or any of our current or future partners breach or terminate the agreements that make up such arrangements, our
partners otherwise fail to conduct their obligations under such arrangements in a timely manner, there is a dispute about their
obligations or if either party terminates the applicable agreement or elects not to continue the arrangement, we may not enjoy
the benefits of the agreements or receive a sufficient amount of royalty or milestone payments from them, if any, which may have
a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to develop and commercialize our product
candidates, our business will be adversely affected. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A key element of our strategy is to develop and commercialize
a portfolio of new products in addition to taliglucerase alfa. We seek to do so through our internal research programs and strategic
collaborations for the development of new products. Research programs to identify new product candidates require substantial technical,
financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially
show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many
reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate may not be accepted by patients, the medical community or third-party payors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competitors may develop alternatives that render our product candidates obsolete;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the research methodology used may not be successful in identifying potential product candidates; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to develop or commercialize any of our other product
candidates may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology which has a limited history and any material problems with the system, which may be unforeseen,
may have a material adverse effect on our business, results of operations and financial condition.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology. The success of our business is dependent upon the successful development and approval of
our product and product candidates produced through this technology. Although taliglucerase alfa and all of our product candidates
are produced through ProCellEx, the technology remains novel. Accordingly, the technology remains subject to certain risks. Mammalian
cell-based protein expression systems have been used in connection with recombinant therapeutic protein expression for more than
30 years and are the subject of a wealth of data; in contrast, there is not a significant amount of data generated regarding plant
cell-based protein expression and, accordingly, plant cell-based protein expression systems may be subject to unknown risks. In
addition, the protein glycosilation pattern created by our protein expression system is not identical to the natural human glycosilation
pattern and, although to date clinical data for up to five years, and commercial data for an additional five years, on taliglucerase
alfa has not demonstrated any sign of any effect, the longer term effect of the protein glycosilation pattern created by our protein
expression system on human patients, if any, is still unknown. Lastly, as our protein expression system is a new technology, we
cannot always rely on existing equipment; rather, there is a need to design custom-made equipment and to generate specific growth
media for the plant cells which may not be available at favorable prices, if at all. Any material problems with the technology
underlying our plant cell-based protein expression system may have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The manufacture of our products is an exacting and complex
process, and if we or one of our materials suppliers encounter problems manufacturing our products, it will have a material adverse
effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and foreign regulators require manufacturers to register
manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar
requirements that the FDA or foreign regulators establish. We or our materials suppliers may face manufacturing or quality control
problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance
with the FDA&rsquo;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing our drug candidates.
Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely affect our clinical
research activities and our ability to market and develop our products. To date, our current facility has passed audits by the
FDA and a number of other regulatory authorities but remains subject to audit by other foreign regulatory authorities. There can
be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements for our current facility
or any facility we may establish in the future, and the failure to so comply will have a material adverse effect on our business,
<FONT STYLE="background-color: white">results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on third parties for final processing of taliglucerase
alfa, pegunigalsidase alfa and our product candidates, which exposes us to a number of risks that may delay development, regulatory
approval and commercialization of taliglucerase alfa and our other product candidates or result in higher product costs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no experience in the final filling and freeze drying
steps of the drug manufacturing process. We have engaged a European contract manufacturer to act as an additional source of fill
and finish activities for taliglucerase alfa and pegunigalsidase alfa, and have engaged other parties for our product candidates.
We currently rely primarily on other third-party contractors to perform the final manufacturing steps for taliglucerase alfa on
a commercial scale. We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all because
the number of potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve any
manufacturer and/or replacement manufacturer, including us, and we or any such third party manufacturer might be unable to formulate
and manufacture our drug products in the volume and of the quality required to meet our clinical and commercial needs. If we engage
any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business
for the time required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the rules
and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find
that they are not in compliance with applicable regulations. Each of these risks, if realized, could delay our clinical trials,
the approval, if any, of taliglucerase alfa and our other potential drug candidates by the FDA and other regulatory authorities,
or the commercialization of taliglucerase alfa and our other drug candidates or could result in higher product costs or otherwise
deprive us of potential product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Developments by competitors may render our products or technologies
obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compete against fully integrated pharmaceutical companies
and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and
other public and private research organizations. Our drug candidates will have to compete with existing therapies and therapies
under development by our competitors. In addition, our commercial opportunities may be reduced or eliminated if our competitors
develop and market products that are less expensive, more effective or safer than our drug products. Other companies have drug
candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop
drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be
commercialized earlier. Even if we are successful in developing effective drugs, our products may not compete successfully with
products produced by our competitors. See Business &ndash; Competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most of our competitors, either alone or together with their
collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial
resources than we do, as well as significantly greater experience in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developing drugs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>undertaking preclinical testing and human clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining marketing approvals from the FDA and other regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating and manufacturing drugs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>launching, marketing and selling drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These organizations also compete with us to attract qualified
personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated
costs on our business which would have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we in-license drug candidates, we may delay or otherwise
adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations
and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to our own internally developed drug candidates,
we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential
to take advantage of our development know-how and technology. If we in-license any additional drug candidate, our capital requirements
may increase significantly. In addition, in-licensing additional drug candidates may place a strain on the time of our existing
personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize
our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may delay the
development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to manage future growth successfully, there
could be a material adverse impact on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To manage our anticipated future growth, we must continue to
implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train
additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert
our management and business development resources. Any inability on the part of our management to manage growth could delay the
execution of our business plans or disrupt our operations. If we are unable to manage our growth effectively, we may not use our
resources in an efficient manner, which may delay the development of our drug candidates and materially and adversely impact our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we acquire companies, products or technologies, we may
face integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are presented with appropriate opportunities, we may acquire
or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of any acquisition
or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration
process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology
with our products, diversion of our management&rsquo;s attention from other business concerns, the potential loss of key employees
or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate.
In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating
to acquired intangible assets. Any failure to successfully integrate other companies, products or technologies that we may acquire
may have a material adverse effect on our business and results of operations. Furthermore, we may have to incur debt or issue equity
securities to pay for any additional future acquisitions or investments, the issuance of which could be dilutive to our existing
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We depend upon key employees and consultants in a competitive
market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop
and market our products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are highly dependent upon the principal members of our management
team, especially our President and Chief Executive Officer, Moshe Manor, as well as the Chairman of our Board of Directors, Shlomo
Yanai, our other directors, our scientific advisory board members, consultants and collaborating scientists. Many of these people
have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue
to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical
development and regulatory programs. We have employment agreements with Moshe Manor and our other executive officers that may be
terminated by us or the applicable officer at any time with varying notice periods of 60 to 90 days. Although these employment
agreements generally include non-competition covenants, the applicable noncompetition provisions can be difficult and costly to
monitor and enforce. The loss of any of these persons&rsquo; services may adversely affect our ability to develop and market our
products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also depend in part on the continued service of our key scientific
personnel and our ability to identify, hire and retain additional personnel, including marketing and sales staff. We experience
intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and
their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we
attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to
have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our collaborations with outside scientists and consultants
may be subject to restriction and change.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We work with medical experts, biologists, chemists and other
scientists at academic and other institutions, and consultants who assist us in our research, development, regulatory and commercial
efforts, including the members of our scientific advisory board. These scientists and consultants have provided, and we expect
that they will continue to provide, valuable advice regarding our programs. These scientists and consultants are not our employees,
may have other commitments that would limit their future availability to us and typically will not enter into non-compete agreements
with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services.
In addition, we will be unable to prevent them from establishing competing businesses or developing competing products. For example,
if a key scientist acting as a principal investigator in any of our clinical trials identifies a potential product or compound
that is more scientifically interesting to his or her professional or academic interests, his or her availability to remain involved
in our clinical trials could be restricted or eliminated, which may have a material adverse effect on our business, results of
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Under current U.S. and Israeli law, we may not be able to
enforce employees&rsquo; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the
expertise of some of our former employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into non-competition agreements with substantially
all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or
working for our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements
against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former
employees gained while working for us. If we cannot enforce our employees&rsquo; non-compete agreements, we may be unable to prevent
our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect on our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our internal computer systems, or those used by our third-party
contractors or consultants, may fail or suffer security breaches.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Despite the implementation of security
measures, our internal computer systems and those of our present and future contractors and consultants are vulnerable to damage
from computer viruses and unauthorized access. Although to our knowledge we have not experienced any material system failure or
security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material
disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of
our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and
similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that
any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure
of confidential or proprietary information, we could incur liability and the further development and commercialization of our product
candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If product liability claims are brought against us, it may
result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clinical testing, marketing and use of our products and
product candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury
or disease, or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval,
could result in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0 million
per occurrence and $10.0 million in the aggregate, an amount we consider reasonable and customary. However, this insurance coverage
includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims.
We may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We expect to
obtain product liability insurance coverage before commercialization of our product candidates; however, such insurance is expensive
and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in
the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one
that is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and development,
which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims,
even if without merit, may result in reduced demand for our products, if approved, which would have a material adverse effect on
our business, results of operations and financial condition. In addition, the existence of a product liability claim could affect
the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reforms in the healthcare industry and the uncertainty associated
with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our
products, if approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Increasing healthcare expenditures have been the subject of
considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain
healthcare costs. Numerous proposals that would result in changes in the U.S. healthcare system have been introduced or proposed
in the U.S. Congress and in some state legislatures within the United States, including reductions in the pricing of prescription
products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.
Legislation passed in recent years has imposed certain changes to the way in which drugs, including our product candidates, are
covered and reimbursed in the United States. For example, federal legislation and regulations have implemented new reimbursement
methodologies for certain drugs, created a voluntary prescription drug benefit, Medicare Part D, and have imposed significant revisions
to the Medicaid Drug Rebate Program. The PPACA imposes yet additional changes to these programs. We believe that legislation that
reduces reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers
will prescribe or administer our product candidates, if approved. This could materially and adversely impact our business by reducing
our ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition,
we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and
usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governments outside the United States tend to impose strict
price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In some countries, particularly European Union member states,
the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time (six to 12&nbsp;months or longer) after the receipt of marketing approval for a product.
To obtain reimbursement or pricing approval in some countries with respect to any product candidate that achieves regulatory approval,
we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available
therapies. If reimbursement of our products upon approval, if at all, is unavailable or limited in scope or amount, or if pricing
is set at unsatisfactory levels, our prospects for generating revenue, if any, could be adversely affected which would have a material
adverse effect on our business, results of operations and financial condition. Further, if we achieve regulatory approval of any
product, we must successfully negotiate product pricing for such product in individual countries. As a result, the pricing of our
product candidates, if approved, in different countries may vary widely, thus creating the potential for third-party trade in our
products in an attempt to exploit price differences between countries. This third-party trade of our products could undermine our
sales in markets with higher prices <FONT STYLE="font-family: Times New Roman, Times, Serif">which could have a material adverse
effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ability to utilize net operating loss carryforwards may
be limited.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our NOLs, as of December 31, 2017, are equal to
approximately $207 million, of which approximately $23 million may be restricted under Section 382 of the Internal Revenue
Code of 1986, as amended, or the &ldquo;Code.&rdquo; Section 382 of the Code imposes limitations on a corporation&rsquo;s
ability to utilize NOLs to offset taxable income if the corporation experiences an &ldquo;ownership change.&rdquo; In general
terms, an &ldquo;ownership change&rdquo; may result from transactions increasing the ownership of certain stockholders in the
stock of a corporation by more than 50% over a three-year period. In the event that an ownership change has occurred
(including as a result of conversion of our outstanding convertible notes into shares of our common stock), or were to occur,
utilization of our NOLs would be subject to an annual limitation under Section 382, which is generally the fair market value
of the pre-change entity multiplied by the long-term tax exempt rate, which is published monthly by the U.S. Internal Revenue
Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our corporate structure may create U.S. federal income tax
inefficiencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd. is our wholly-owned subsidiary and thus a controlled
foreign corporation of our company for U.S. federal income tax purposes. This organizational structure may create inefficiencies,
as certain types of income and investments of Protalix Ltd. that otherwise would not be currently taxable under general U.S. federal
income tax principles may become taxable. These inefficiencies may require us to use more of our NOLs than we otherwise might and
may result in a tax liability without a corresponding distribution from our subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are a holding company with no operations of our own. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a holding company with no operations of our own. Accordingly,
our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent
upon the earnings from the business conducted by Protalix Ltd. The distribution of those earnings or advances or other distributions
of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of Protalix Ltd. and are
subject to various business considerations and U.S. and Israeli law. If Protalix Ltd. is unable to make sufficient distributions
or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash
resources necessary to conduct our corporate operations or service our debt which would have a material adverse effect on our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Financial Condition and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Servicing our debt and settling conversion requests may require
a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt. Furthermore, restrictive
covenants governing our indebtedness may restrict our ability to raise additional capital.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to pay interest on, or to make any scheduled or otherwise required payment of the principal of, and settle conversion requests
on our outstanding convertible notes depends on our future performance, which is subject to economic, financial, competitive and
other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our
debt and make necessary expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives,
such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive.
Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. If we raise
additional debt, it would increase our interest expense, leverage and operating and financial costs. In addition, the terms of
the indentures governing our outstanding convertible notes</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">which
are secured by certain of our material assets, including all of our intellectual property, and the agreements governing future
indebtedness may restrict us from adopting any of these alternatives. </FONT>We may be able to obtain amendments and waivers of
such restrictions, subject to such restrictions under the terms of the applicable indenture or any subsequent indebtedness. In
the event of any such default, the holders of the indebtedness could, among other things, elect to declare all amounts owed immediately
due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby
reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, with respect to
our indebtedness that is secured, result in the foreclosure on the assets that secure the debt, which would force us to relinquish
rights to assets that we may believe are critical to our business. <FONT STYLE="font-family: Times New Roman, Times, Serif">We
may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a
default on our debt obligations. Any default on our debt will have a material adverse effect </FONT>on our business, results of
operations and financial condition<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A substantial majority of our authorized shares of common
stock under our certificate of incorporation are either outstanding or reserved for issuance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation currently authorizes the issuance
of 250,000,000 shares of common stock and 100,000,000 shares of preferred stock, par value $0.0001 per share, for a total of 350,000,000
shares of capital stock. As of December 31, 2017, a total of approximately 4.9 million shares of common stock are reserved for
issuance upon the exercise of outstanding stock options under our 2006 Stock Incentive Plan, as amended, and a total of 2,554,075
shares of common stock are reserved for issuance in connection with future grants of stock options and/or future issuances of shares
under the plan. In addition, approximately 81.6 million shares of common stock are reserved for issuance upon the conversion of
our outstanding convertible notes. After taking into account the total number of shares of common stock issued and outstanding,
in addition to the aggregate number of shares of common stock reserved for future issuance as described above, approximately 6.9%
of our authorized shares of common stock remain available to be issued or reserved for issuance as of the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to solicit the approval of our stockholders
at our upcoming 2018 annual meeting of stockholders to increase the number of authorized shares. Absent the approval, we are left
without sufficient, authorized shares of common stock to pursue a variety of other business and financial objectives without further
action of the stockholders (except when required by applicable law or regulation). As a result, a delay in securing, or a failure
to secure, stockholder approval to amend our certificate of incorporation would seriously jeopardize the financial viability of
the Company. Unless and until we attain the approval of our stockholders to increase the number of authorized shares, our ability
to manage our capital needs is restricted which may have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our significant level of indebtedness could adversely affect
our business, results of operations and financial condition and prevent us from fulfilling our obligations under our convertible
notes and our other indebtedness.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our outstanding convertible notes represent a significant amount
of indebtedness with substantial debt service requirements. We may also incur additional indebtedness to meet future financing
needs. Our substantial indebtedness could have material adverse effects on our business, results of operations and financial condition.
For example, it could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>make it more difficult for us to satisfy our financial obligations, including with respect to the <FONT STYLE="font-family: Times New Roman, Times, Serif">convertible
notes</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>result in an event of default under our outstanding convertible notes if we fail to comply with the financial and other restrictive
covenants contained in agreements governing any future indebtedness, which event of default could result in all of our debt becoming
immediately due and payable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase our vulnerability to general adverse economic, industry and competitive conditions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduce the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate
purposes because we will be required to dedicate a substantial portion of our cash flow from operations to the payment of principal
and interest on our indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit our flexibility in planning for, or reacting to, and increasing our vulnerability to changes in our business, the industry
in which we operate and the general economy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prevent us from raising funds necessary to purchase <FONT STYLE="font-family: Times New Roman, Times, Serif">convertible notes</FONT>
surrendered to us by holders upon a fundamental change (as described in the indentures governing the two series of <FONT STYLE="font-family: Times New Roman, Times, Serif">convertible
notes</FONT>), which failure would result in an event of default with respect to the convertible notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>place us at a competitive disadvantage compared to our competitors that have less indebtedness or are less highly leveraged
and that, therefore, may be able to take advantage of opportunities that our debt levels or leverage prevent us from exploiting;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit our ability to obtain additional financing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of these factors may have a material and adverse effect
on our business, results of operations and financial condition and our ability to meet our payment obligations under the convertible
notes and our other indebtedness. Our ability to make payments with respect to the convertible notes and to satisfy any other debt
obligations depends on our future operating performance and our ability to generate significant cash flow in the future, which
will be affected by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as
well as other factors affecting our company and industry, many of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to refinance or otherwise defease the remaining
outstanding 4.5% convertible notes on or prior to June 16, 2018, we may face liquidity constraints.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are not able to refinance or otherwise defease all of
our outstanding 4.5% convertible notes by June 16, 2018, the maturity date of the 7.5% convertible notes will be accelerated to
June 15, 2018. Our ability to refinance or retire our outstanding 4.5% convertible notes will depend on our cash balance, the capital
markets environment and our financial condition as well as the terms of the indenture governing the 7.5% convertible notes. The
indenture governing the 7.5% convertible notes includes certain payment restrictions that may limit our ability to defease the
4.5% convertible notes. If the maturity of the 7.5% convertible notes is accelerated, we may be unable to obtain financing to pay
the principal amount thereof, which will have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are required to comply with a number of covenants under
the indenture governing our outstanding 7.5% convertible notes that could hinder our growth. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
indenture governing our 7.5% convertible notes contains a number of restrictive affirmative and negative covenants, which limit
our ability to incur additional debt; exceed certain limits; pay dividends or distributions; or merge, consolidate or dispose of
substantially all of our assets, including all of our intellectual property assets and other material assets securing such convertible
notes. A breach of these covenants could result in default, and if such default is not cured or waived, </FONT>the holders of the
indebtedness could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or
a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue
our business plans or force us into bankruptcy or liquidation, or, result in the foreclosure on the assets that secure the debt,
including all of our intellectual property assets, which would force us to relinquish rights to such assets that we may believe
are critical to our business. <FONT STYLE="font-family: Times New Roman, Times, Serif">We may not be able to engage in any of these
activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. Any default
on our debt will have a material adverse effect </FONT>on our business, results of operations and financial condition<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Any conversion of our outstanding convertible notes into
common stock will dilute the ownership interest of our existing stockholders, including holders who had previously converted their
notes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
conversion of some or all of our convertible notes into shares of our common stock will dilute the ownership interests of our existing
stockholders. Any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing
market prices of our common stock. In addition, the existence of </FONT>our outstanding convertible notes <FONT STYLE="font-family: Times New Roman, Times, Serif">may
encourage short selling by market participants because the conversion of convertible notes could depress the market price of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The fundamental change purchase feature of our outstanding
convertible notes may delay or prevent an otherwise beneficial attempt to take over our company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of our outstanding convertible notes require us to
offer to purchase the notes for cash in the event of a fundamental change. A non-stock takeover of our company may trigger the
requirement that we purchase the notes. This feature may have the effect of delaying or preventing a takeover of our company that
would otherwise be beneficial to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may fail to meet the continued market capitalization-based
listing requirement or other continued listing requirements of The NYSE American.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stock market in general, and the market for life sciences
companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate
to the operating performance of the listed companies. There have been dramatic fluctuations in the market prices of securities
of biotechnology companies. These price fluctuations may be rapid and severe and may leave investors little time to react. Broad
market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Sharp
drops in the market price of our common stock expose us to securities class-action litigation. The trading price of our common
stock has been volatile and has been subject to wide price fluctuations in response to various factors, many of which are beyond
our control. The volatility of our stock price has from time to time in recent periods affected our market capitalization. Stock
price fluctuations that adversely affect our market capitalization may result in a failure to meet the continued market capitalization-based
listing requirement for The NYSE American, which would require us to take steps to gain compliance with alternate listing standards
or take remedial steps to bring us into compliance. A failure to maintain or regain compliance with applicable listing standards
could adversely affect the liquidity of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently have no significant product revenues and may
need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will
have a dilutive effect on our stockholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not generated significant revenues from product
sales and only minimal revenues from research and development services and other fees, other than the milestone and other payments
we have received in connection with our agreements with Pfizer and Chiesi. For the years ended December 31, 2017, 2016 and 2015,
we had net losses from continuing operations of $47.3 million, excluding a one-time, non-cash net charge of $38 million in connection
with the remeasurement of a derivative, $29.2 million and $27.3 million, respectively, primarily as a result of expenses incurred
through a combination of research and development activities and expenses supporting those activities, which includes share-based
compensation expense. Drug development and commercialization is very capital intensive. We fund all of our operations and capital
expenditures from the revenues we generate from licensing fees and grants, the net proceeds of equity and debt offerings and other
sources. Based on our current plans, expectations and capital resources, we believe that our cash and cash equivalents will be
sufficient to enable us to meet our planned operating needs for at least 12 months. However, changes may occur that could consume
our existing capital at a faster rate than projected, including, among others, the cost and timing of regulatory approvals, changes
in the progress of our research and development efforts and the costs of protecting our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to finance our future cash needs through corporat<FONT STYLE="font-family: Times New Roman, Times, Serif">e</FONT>
collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. If we are unable to secure
additional financing in the future on acceptable terms, or at all, we may be unable to commence or complete planned preclinical
and clinical trials or obtain approval of our drug candidates from the FDA and other regulatory authorities. In addition, we may
be forced to reduce or discontinue product development or product licensing, reduce or forego sales and marketing efforts and other
commercialization activities or forego attractive business opportunities in order to improve our liquidity and to enable us to
continue operations which would have a material adverse effect on our business and results of operations. Furthermore, any additional
source of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.
See also &ldquo;&mdash;A substantial majority of our authorized shares of common stock under our certificate of incorporation are
either outstanding or reserved for issuance.<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are not currently profitable and delays in achieving profitability,
if at all, will have a material adverse effect on our business and results of operations and could negatively impact the value
of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may incur losses for the foreseeable future. We expect to
continue to incur significant operating expenditures, and we anticipate that our expenses will increase in the foreseeable future
as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continue to undertake preclinical development and clinical trials for our current and new drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>seek regulatory approvals for our drug candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>seek to license-in additional technologies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also may continue to experience negative cash flow for the
foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate significant
revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability
in the foreseeable future, if at all. Delays in achieving profitability, or subsequent failures to maintain profitability, will
have a material adverse effect on our business and results of operations and could negatively impact the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Investing in our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The market price of our common stock may fluctuate significantly.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock may fluctuate significantly
in response to numerous factors, some of which are beyond our control, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the progress and results of our ongoing studies regarding pegunigalsidase alfa and our other product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>announcements regarding partnerships or collaborations by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> in Brazil;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments concerning intellectual property rights and regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the announcement of new products or product enhancements by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations in our and our competitors&rsquo; results of operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in earnings estimates or recommendations by securities analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments in the biotechnology industry; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general market conditions and other factors, including factors unrelated to our operating performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, stock markets in general, and the market for biotechnology
companies in particular, have recently experienced price and volume fluctuations. Continued market fluctuations could result in
extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility
of our common stock may be worse if the trading volume of our common stock is low. We have not paid, and do not expect to pay,
any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations.
As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold
at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future sales of our common stock could
reduce our stock price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our existing stockholders or their distributees sell substantial
amounts of our common stock in the public market, including shares of our common stock issuable upon conversion of our outstanding
convertible notes, the market price of our common stock could decrease significantly. The perception in the public market that
our existing stockholders might sell shares of common stock could also depress the trading price of our common stock. Any such
sales of our common stock in the public market may affect the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A substantial majority of our outstanding shares of our common
stock are freely tradable without restriction or further registration under the federal securities laws, unless owned by our affiliates.
In addition, we may sell additional shares of our common stock in the future to raise capital and a substantial number of shares
of our common stock are reserved for issuance upon the exercise of stock options and upon conversion of our outstanding convertible
notes. We cannot predict the size of future issuances, if any. At December&nbsp;31, 2017, there were outstanding options to purchase
common stock issued covering approximately 4.9 million shares of our common stock with a weighted average exercise price of $3.59
per share. Also at December&nbsp;31, 2017, there were approximately 2.6 million shares of common stock available for future for
issuance in connection with future grants of incentives under our amended 2006 stock incentive plan and approximately 81.1 million
shares of common stock reserved for issuance upon conversion of our outstanding convertible notes. The issuance and sale of substantial
amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of
our common stock and impair our ability to raise capital through the sale of additional equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If securities analysts stop publishing research or reports
about us or our business or if they downgrade our common stock, the market price of our common stock could decline.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market for our common stock relies in part on the research
and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If any analyst
who covers us downgrades our stock or lowers its future stock price targets or estimates of our operating results, the market price
for our common stock could decline rapidly. Furthermore, if any analyst ceases to cover us, we could lose visibility in the market,
which in turn could cause the market price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our common stock is listed to trade on more than one stock
exchange, and this may result in price variations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed for trade on both the NYSE American
and the TASE. Dual-listing may result in price variations between the exchanges due to a number of factors. First, our common stock
is traded in U.S. dollars on the NYSE American and in NIS on the TASE. In addition, the exchanges are open for trade at different
times of the day and on different days. For example, the TASE opens generally during Israeli business hours, Sunday through Thursday,
while the NYSE American opens generally during U.S. business hours, Monday through Friday. The two exchanges also have differing
vacation schedules. Differences in the trading schedules, as well as volatility in the exchange rate of the two currencies, among
other factors, may result different trading prices for our common stock on the two exchanges. Other external influences may have
different effects on the trading price of our common stock on the two exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors and executive officers own a significant percentage
of our capital stock, and they may make decisions that an investor may not consider to be in the best interests of our stockholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our directors and executive officers, principal stockholders
and affiliated entities beneficially own, in the aggregate, approximately 4.0% of our common stock, as of February 15, 2018, giving
effect to stock options that are held by such persons that are exercisable within such 60 days from such date. As a result, if
some or all of them acted together, they would have the ability to exert substantial influence over the election of our Board of
Directors and the outcome of issues requiring approval by our stockholders. This concentration of ownership may have the effect
of delaying or preventing a change in control of our company that may be favored by other stockholders. This could prevent the
consummation of transactions favorable to other stockholders, such as a transaction in which stockholders might otherwise receive
a premium for their shares over current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Failure to maintain effective internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and operating results. In addition,
current and potential stockholders could lose confidence in our financial reporting, which could have a material adverse effect
on the price of our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective internal controls are necessary for us to provide
reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our
results of operation could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 404 of the Sarbanes-Oxley Act of 2002 requires annual
management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent registered
public accounting firm addressing these assessments. We continuously monitor our existing internal controls over financial reporting
systems to confirm that they are compliant with Section 404, and we may identify deficiencies that we may not be able to remediate
in time to meet the deadlines imposed by the Sarbanes-Oxley Act. This process may divert internal resources and will take a significant
amount of time and effort to complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If, at any time, it is determined that we are not in compliance
with Section 404, we may be required to implement new internal control procedures and reevaluate our financial reporting. We may
experience higher than anticipated operating expenses as well as increased independent auditor fees during the implementation of
these changes and thereafter. Further, we may need to hire additional qualified personnel. If we fail to maintain the adequacy
of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to conclude
on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act, which could result in our being unable to obtain an unqualified report on internal controls from our independent auditors.
Failure to maintain an effective internal control environment could also cause investors to lose confidence in our reported financial
information, which could have a material adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with changing regulation of corporate governance
and public disclosure may result in additional expenses, divert management&rsquo;s attention from operating our business which
could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been other changing laws, regulations and standards
relating to corporate governance and public disclosure in addition to the Sarbanes-Oxley Act, as well as new regulations promulgated
by the Commission and rules promulgated by the national securities exchanges, including the NYSE American and the NASDAQ. These
new or changed laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity,
and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies,
which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards are likely
to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating
activities to compliance activities. Our board members, Chief Executive Officer and Chief Financial Officer could face an increased
risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and
retaining qualified board members and executive officers, which could have a material adverse effect on our business. If our efforts
to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies,
we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which would have a
material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The issuance of preferred stock or additional shares of common
stock could adversely affect the rights of the holders of shares of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors is authorized to issue up to 100,000,000
shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority
to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we
have no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may, at any time, authorize the issuance
of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive
dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares,
together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the
holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue
large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without
any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable
to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the rules of the TASE, other than incentives under our
amended 2006 stock incentive plan, we were prohibited from issuing any securities of any class or series different than the common
stock that is listed on the TASE for the 12-month period immediately succeeding our initial listing, which occurred on September&nbsp;6,
2010. As of the date hereof, the rules of the TASE allow us to issue securities with preferential rights with respect to dividends
but such other securities may not include voting rights. The foregoing does not limit our liability to issue and grant options
and warrants for the purchase of shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Commercialization of Drug Products </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fiocruz may not comply with the terms and conditions of the
Supply and Technology Transfer Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not control and may not be able to effectively influence
Fiocruz&rsquo;s ability to distribute <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> in Brazil.
If Fiocruz fails to comply with the purchase requirements of the Supply and Technology Transfer Agreement, we may terminate the
agreement and market <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> in Brazil on our own. Any
failure by Fiocruz to comply with the purchase requirements of the Supply and Technology Transfer Agreement, or any other material
breach by Fiocruz of the agreement, may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, we received a purchase order from the Brazilian MoH
for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil. The purchase
order consists of a number of shipments in increasing volumes. Shipments started in June 2017. Fiocruz&rsquo;s purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate
the Brazil Agreement. Notwithstanding, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and,
based on such discussions, we will determine what we believe to be the course of action that is in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
face the risk that the Brazilian MoH may ultimately fail to purchase the amounts of alfataliglicerase for which it has already
stated its intentions. In addition, we may fail to supply the intended amounts on time, if at all. We also cannot accurately predict
the amount of revenues we will generate under our Supply and Technology Transfer with Fiocruz in future periods, if any. </FONT>Any
failure by the Brazilian MoH to purchase <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>, by
us, to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> for purchase or by Fiocruz to distribute
<FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> in Brazil, or the experience of significant delays
in any of the foregoing, may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have limited experience in selling, marketing or distributing
products and limited internal capability to do so. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently have very limited sales, marketing or distribution
capabilities and no experience in building a sales force and distribution capabilities. We retained the marketing rights to <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil and, under the Chiesi Agreement, we retained the rights to market pegunigalsidase alfa in the United States, if approved.
We have not licensed the marketing or commercialization rights to any of our other product candidates to any party. The commercialization
of a drug product requires that we commit significant financial and managerial resources to develop a marketing and sales force
with technical expertise and with supporting distribution capabilities. Factors that may inhibit our efforts to commercialize our
products directly and without strategic partners include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability to recruit and retain adequate numbers of effective sales and marketing personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability of sales personnel to obtain access to an adequate numbers of physicians or to pursuance them to prescribe our
products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative
to companies with more extensive product lines;&nbsp;and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be successful in recruiting or retaining the sales
and marketing personnel necessary to sell <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> or
any of our products upon approval, if at all, which would have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may enter into distribution arrangements and marketing
alliances for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if
at all, may impair our ability to commercialize our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to establish a sales force to market <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
or our our product candidates, if approved. We do not anticipate having the resources in the foreseeable future to develop global
sales and marketing capabilities for all of the products we are developing. We may elect to pursue arrangements regarding the sales
and marketing and distribution of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> or one or more
of our product candidates, and our future revenues may depend, in part, on our ability to enter into and maintain arrangements
with other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market
and sell any such products. Any failure to enter into such arrangements and marketing alliances on favorable terms, if at all,
could delay or impair our ability to commercialize our product candidates and could increase our costs of commercialization. Any
use of distribution arrangements and marketing alliances to commercialize our product candidates will subject us to a number of
risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be required to relinquish important rights to our products or product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may not be able to control the amount and timing of resources that our distributors or collaborators may devote to the commercialization
of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors or collaborators may experience financial difficulties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors or collaborators may not devote sufficient time to the marketing and sales of our products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>business combinations or significant changes in a collaborator&rsquo;s business strategy may adversely affect a collaborator&rsquo;s
willingness or ability to complete its obligations under any arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to enter into additional co-promotion arrangements
with third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market.
We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter
into may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If physicians, patients, third party payors and others in
the medical community do not accept and use taliglucerase alfa, or any of our other product candidates, if approved, our ability
to generate revenue from product sales will be materially impaired. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Physicians and patients, and other healthcare providers, may
not accept and use any of our products or any product candidates, if approved, for marketing. Future acceptance and use of any
of our products or any product candidates, if approved, will depend upon a number of factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness
of taliglucerase alfa or our other drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence and severity of any side effects, including any limitations or warnings contained in our products&rsquo; approved
labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pharmacological benefits of taliglucerase alfa or our other drug candidates relative to competing products and products under
development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the efficacy and potential advantages relative to competing products and products under development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>relative convenience and ease of administration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>effectiveness of education, marketing and distribution efforts by us and our licensees and distributors, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publicity concerning taliglucerase alfa or our other drug candidates or competing products and treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>coverage and reimbursement of our products by third party payors; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.1pt"></TD><TD STYLE="width: 28.1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price for our products and competing products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A lack of market acceptance of taliglucerase alfa in Brazil,
or globally for any of our other products candidates, if approved, would have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If the market opportunities for other product candidates,
and for taliglucerase alfa in Brazil, are smaller than we believe they are, our revenues may be adversely affected and our business
may suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our development efforts have focused mainly on relatively
rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates
of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which
are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed,
the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry
disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the
broader world population. If the market opportunities for our current product candidates are smaller than we believe they are,
our revenues may be adversely affected and our business may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Coverage
and reimbursement may not be available for alfataliglicerase</B></FONT><B> or any of our other product candidates, if approved<FONT STYLE="font-family: Times New Roman, Times, Serif">,
in all territories which could diminish our sales or affect our ability to sell alfataliglicerase or any other products profitably.
</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Market acceptance and sales of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil, or for any of our other product candidates globally, if approved, will depend on coverage and reimbursement policies
in the countries in which they are approved for sale. Government authorities and third-party payors, such as private health insurers
and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Obtaining reimbursement
approval for an approved product from governments and other third party payors is a time consuming and costly process that requires
our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use
of our products, if and when approved, to every payor. We may not be able to provide data sufficient to gain acceptance with respect
to coverage and reimbursement or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness
of approved products, if any, to such payors&rsquo; satisfaction. Such studies might require our collaborators or us to commit
a significant amount of management time and financial and other resources. Even if a payor determines that an approved product
is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved
by the FDA or other regulatory authorities. In addition, full reimbursement may not be available for high priced products. Moreover,
eligibility for coverage does not imply that any approved product will be reimbursed in all cases or at a rate that allows us to
make a profit or even cover our costs. Also, limited reimbursement amounts may reduce the demand for, or the price of, our product
candidates. Except with respect to taliglucerase alfa, we have not commenced efforts to have our product candidates covered and
reimbursed by government or third-party payors. If coverage and reimbursement are not available or are available only to limited
levels, the sales of our products, if approved may be diminished or we may not be able to sell such products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We and our collaborating partners may be subject, directly
or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating
partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All marketing activities associated with drug products that
are approved for sale in the United States, if any, will be<FONT STYLE="font-family: Times New Roman, Times, Serif">, directly
or indirectly through our customers,</FONT> subject to numerous federal and state laws governing the marketing and promotion of
pharmaceutical products in the United States<FONT STYLE="font-family: Times New Roman, Times, Serif">, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act and HIPAA. These laws may adversely impact, among other things,
our proposed sales, marketing and education programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration,
directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good
or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The term
&ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value, including for example, gifts, discounts,
the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership
interests and providing anything at less than its fair market value. The reach of the Anti-Kickback Statute was also broadened
by the </FONT>PPACA <FONT STYLE="font-family: Times New Roman, Times, Serif">which, among other things, amends the intent requirement
of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &sect; 1320a-7b,
effective March 23, 2010. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this
statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute,
which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health
program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
The federal Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices
that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Statute
include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other
state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of
which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid
programs, and do not contain identical safe harbors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal False Claims Act imposes liability on any person
who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare
program. The &ldquo;qui tam&rdquo; provisions of the False Claims Act allow a private individual to bring civil actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these
state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. When an entity
is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by
the government, plus civil penalties of $5,500 to $11,000 for each separate false claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HIPAA created several new federal crimes, including health care
fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing
a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for health care benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are unable to predict whether we could be subject to actions
under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that taliglucerase alfa,
or any of our products, if approved for marketing, will be sold in a foreign country, we and our future collaborators, may be subject
to similar foreign laws and regulations. If we or any of our future collaborators are found to be in violation of any of the laws
described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and
criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring
or our operations, any of which could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Intellectual Property Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The intellectual property and assets owned by our subsidiaries
are subject to security agreements that secure our payment and other obligations under our 7.5% convertible notes, and our subsidiaries
have guaranteed all of those obligations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In connection with the issuance of
our 7.5% convertible notes, we entered into security agreements pursuant to which our subsidiaries provided first priority security
interests in all of their assets, which consist of all of our intellectual property and other material assets. The security agreements
secure certain payment, indemnification and other obligations under the 7.5% convertible notes. If we were to default on certain
of ours obligations, or in certain other circumstances generally related to a bankruptcy or insolvency, holders of our outstanding
7.5% convertible notes could seek to foreclose on the collateral under the security agreements to obtain satisfaction our obligations,
and our business could be materially and adversely impacted, which would in turn materially and adversely impact our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Furthermore, in connection with the
issuance of the 7.5% convertible notes, our subsidiaries guaranteed all of our obligations under the indenture governing such convertible
notes. If we were to default on our obligations under the indenture, the holders could require our subsidiaries to satisfy all
of those obligations under the guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we fail to adequately protect or enforce our intellectual
property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business,
competitive position and results of operations would suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017, we had 58 pending patent applications
of which eight are joint pending patent applications with a third party and one is an-in licensed application. However, the filing
of a patent application does not mean that we will be issued a patent, or that any patent eventually issued will be as broad as
requested in the patent application or sufficient to protect our technology. Any modification required to a current patent application
may delay the approval of such patent application which would have a material adverse effect on our business, results of operations
and financial condition. In addition, there are a number of factors that could cause our patents, if granted, to become invalid
or unenforceable or that could cause our patent applications to not be granted, including known or unknown prior art, deficiencies
in the patent application or the lack of originality of the technology. Our competitive position and future revenues will depend
in part on our ability and the ability of our licensors and collaborators to obtain and maintain patent protection for our products,
methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary
rights and to operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications
for process patents, as well as composition of matter patents, for taliglucerase alfa and other product candidates. However, we
cannot predict:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents,
including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if and when patents will issue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications;
or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether we will need to initiate litigation or administrative proceedings, which may be costly, and whether we win or lose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017, we held, or had license rights to,
69 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient
proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the
U.S. Patent and Trademark Office or foreign patent offices issue patents to us or our licensors, others may challenge the patents
or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from
or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furthermore, the life of our patents is limited. The patents
we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our
ProCellEx protein expression system are expected to expire between 2017 and 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on confidentiality agreements that could be breached
and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to enter agreements relating to the non-disclosure
of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as
well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries
and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to
enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently
develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual
property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can
be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by
confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures we
employ, we still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may be breached;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may not provide adequate remedies for the applicable type of breach; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our trade secrets or proprietary know-how will otherwise become known.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any breach of our confidentiality agreements or our failure
to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we infringe the rights of third parties we could be prevented
from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs
and may have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not received to date any claims of infringement by any
third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile
and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment
adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position.
If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial
costs and we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain licenses, which may not be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>redesign our products or processes to avoid infringement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of
our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial
diversion of management resources; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any costs incurred in connection with such events or the inability
to sell our products may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we cannot meet requirements under our license agreements,
we could lose the rights to our products, which could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend on licensing agreements with third parties to maintain
the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and satisfy
performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout
the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of years
after the first commercial sale of the relevant product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we are responsible for the cost of filing and prosecuting
certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our
license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse
effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Operations in Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential political, economic and military instability in
the State of Israel, where the majority of our senior management and our research and development facilities are located, may adversely
affect our results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive office and operations are located in the State
of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business. Since the State of
Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. Any hostilities
involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant
downturn in the economic or financial condition of Israel, could affect adversely our operations and product development. Although
Israel has entered into various agreements with Egypt, Jordan and the Palestinian Authority, there have been times since October
2000 when Israel has experienced an increase in unrest and terrorist activity. The establishment in 2006 of a government in the
Gaza Strip by representatives of the Hamas militant group has created additional unrest and uncertainty in the region. Starting
in December 2008, for approximately three weeks, Israel engaged in an armed conflict with Hamas in the Gaza Strip. Armed conflicts
have taken place between Israel and Hamas in the Gaza Strip in 2008, 2012 and 2014. Our facilities in northern Israel are in range
of rockets that were fired from Lebanon into Israel during a 2006 war with the Hizbollah in Lebanon, and suffered minimal damages
during one of the rocket attacks. Our insurance policies do not cover us for the damages incurred in connection with these conflicts
or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement
value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage
or the coverage might not be enough to cover potential damages. If our facilities are damaged as a result of hostile action, our
operations may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, since the end of 2010, numerous
acts of protest and civil unrest have taken place in several countries in the Middle East and North Africa, many of which involved
significant violence. Civil unrest in Egypt, which borders Israel, has resulted in significant changes to the country&rsquo;s government.
There is currently a civil war in Syria, also bordering Israel, and Israel has been hit by rockets and mortars originating from
Syria. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel&rsquo;s
position within the region is not clear at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our operations may be disrupted by the obligations of our
personnel to perform military service which could have a material adverse effect on our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many of our male employees in Israel, including members of senior
management, are obligated to perform up to one month (in some cases more) of annual military reserve duty until they reach the
age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the absence
of a significant number of our employees related to military service or the absence for extended periods of military service of
one or more of our key employees. A disruption could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because a certain portion of our expenses is incurred in
New Israeli Shekels, our results of operations may be seriously harmed by currency fluctuations and inflation. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We report our financial statements in U.S. dollars, our functional
currency. Although most of our expenses are incurred in U.S. dollars, we pay a portion of our expenses in New Israeli Shekels,
or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation
of the NIS in relation to the U.S. dollar or if the timing of these devaluations lags behind inflation in Israel. In that event,
the U.S. dollar cost of our operations in Israel will increase and our U.S. dollar-measured results of operations will be adversely
affected. To the extent that the value of the NIS increases against the dollar, our expenses on a dollar cost basis increase. Our
operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we
have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of
financial exposure from fluctuations in the exchange rate of the U.S. dollar against the NIS. These measures, however, may not
adequately protect us from material adverse effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The tax benefits available to us require that we meet several
conditions and may be terminated or reduced in the future, which would increase our taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are able to take advantage of tax exemptions and reductions
resulting from the &ldquo;Approved Enterprise&rdquo; status of our facilities in Israel. To remain eligible for these tax benefits,
we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at
least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be
canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment
policy by the Investment Center and may not be continued in the future at their current levels or at any level. In recent years
the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these
benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &ldquo;Approved
Enterprise&rdquo; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely
affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by future
acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Israeli government grants we have received for certain
research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel
and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously
received together with interest and penalties which could have a material adverse effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development efforts have been financed, in
part, through grants that we have received from NATI. We, therefore, must comply with the requirements of the Research Law. Under
the Research Law we are prohibited from manufacturing products developed using these grants outside of the State of Israel without
special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities
outside of Israel without being subject to increased royalties. We may not receive the required approvals for any proposed transfer
of manufacturing activities. Even if we do receive approval to manufacture products developed with government grants outside of
Israel, we may be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest),
depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate. This
restriction may impair our ability to outsource manufacturing or engage in similar arrangements for those products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, Protalix Ltd. is prohibited
from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under
limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix Ltd. may not receive the required
approvals for any proposed transfer and, if received, Protalix Ltd. may be required to pay NATI a portion of the consideration
that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that
Protalix Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred
and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order
to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required,
and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions
on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if
requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These restrictions may impair our ability to sell our technology
assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even
after we have repaid the full amount of royalties payable for the grants. For the years ended December 31, 2015, 2016 and 2017,
we recorded grants totaling $4.9 million, $5.8 million and $3.3 million from NATI, respectively. The grants represent 19.5%, 19.1%
and 10.4%, respectively, of our gross research and development expenditures for the years ended December 31, 2015, 2016 and 2017.
If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together
with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors may have difficulties enforcing a U.S. judgment,
including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers
and most of our directors or asserting U.S. securities laws claims in Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of our directors and executive officers are residents of
Israel, and accordingly, most of their assets and our assets are located outside the United States. Service of process upon our
non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us, some of our directors
and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel
that investors may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain
a judgment based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors.
Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors
because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli courts might not enforce judgments rendered outside
Israel which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli
court may declare a foreign civil judgment enforceable only if it finds that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment may no longer be appealed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in
Israel and the substance of the judgment is not contrary to public policy; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is executory in the state in which it was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if these conditions are satisfied, an Israeli court will
not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of
Israel. An Israeli court also will not declare a foreign judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was obtained by fraud;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is a finding of lack of due process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is at variance with another judgment that was given in the same matter between the same parties and that is still
valid; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at the time the action was brought in the foreign court, a suit in the same matter and between the same parties was pending
before a court or tribunal in Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_005"></A>Item 1B.</TD><TD>Unresolved Staff Comments</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_006"></A>Item 2.</TD><TD>Properties</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our manufacturing facility and executive offices are located
in Carmiel, Israel. The facilities currently contain approximately 20,000 sq/ft of manufacturing space and additional 48,000 sq/ft
of laboratory, warehouse and office space and are leased at a rate of approximately $65,000 per month. In addition, we are entitled
to use an additional 13,000 sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion
of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business,
and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. Our original lease for the
facility was in effect until 2016, at which time we extended the term until 2021. We retain two addition options to extend the
term for a five-year period, for an aggregate of 10 additional years. Upon the exercise of each remaining option to extend the
term of the lease, if any, the then current base rent shall be increased by 10%.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_007"></A>Item 3.</TD><TD>Legal Proceedings</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_008"></A>Item 4.</TD><TD><B>Mine Safety Disclosures</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_010"></A>Item 5.</TD><TD>Market for Registrant&rsquo;s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our common stock is traded on the NYSE American
under the symbol &ldquo;PLX.&rdquo; Our common stock is also listed on the TASE under the symbol &ldquo;PLX.&rdquo; The following
table sets forth the quarterly high and low closing prices for our common stock on the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price Range</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 11pt">Fourth Quarter 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11pt">Third Quarter 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11pt">Second Quarter 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11pt">First Quarter 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11pt">Fourth Quarter 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11pt">Third Quarter 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11pt">Second Quarter 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11pt">First Quarter 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">These quotations reflect prices between
dealers and do not include retained mark-ups, mark-downs and commissions and may not necessarily represent actual
transactions. There were approximately 80 holders of record of our common stock at March 1, 2018. A substantially greater
number of holders of our common stock are &ldquo;street name&rdquo; or beneficial holders, whose shares are held of record by
banks, brokers and other financial institutions. To date, we have not declared or paid any cash dividends on our common
stock. We do not anticipate paying any dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>STOCK PERFORMANCE GRAPH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following graph compares the cumulative
total shareholder return data for our common stock from December 31, 2012 through December 31, 2017 to the cumulative return over
such time period of (i) The NYSE American Index and (ii) The Nasdaq Biotechnology Index. The graph assumes an investment of $100
on December 31, 2012 in each of our common stock, the stocks comprising the NYSE American Index and the stocks comprising the Nasdaq
Biotechnology Index, including dividend reinvestment, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>The stock price performance shown on
the graph below represents historical price performance and is not necessarily indicative of any future stock price performance.
Notwithstanding anything to the contrary set forth in any of our previous filings under the Securities Act or the Exchange Act,
which might incorporate future filings made by us under those statutes, this Stock Performance Graph will not be incorporated by
reference into any of those prior filings, nor will such report or graph be incorporated by reference into any future filings made
by us under those Acts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tv486893_img7.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_011"></A>Item 6.</TD><TD>Selected Financial Data</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The selected consolidated financial data below
should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The selected
consolidated statements of operations data for the years ended December&nbsp;31, 2017, 2016 and 2015 and the selected consolidated
balance sheet data as of December&nbsp;31, 2017 and 2016, are derived from the audited consolidated financial statements included
elsewhere in this Annual Report. The statement of operations data for the years ended December 31, 2014 and 2013 and the balance
sheet data as of December 31, 2015, 2014 and 2013 are derived from audited financial statements not included in this Annual Report.
We adopted, retrospectively, ASU 2014-08 during 2015 regarding discontinued operations which resulted in the reclassification of
prior year amounts. The historical results presented below are not necessarily indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="18" STYLE="font-weight: bold; text-align: center">Year Ended December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD NOWRAP COLSPAN="18" STYLE="font-weight: bold; font-style: italic; text-align: center">(in thousands, except share and per share amounts)</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.5pt">Consolidated Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,523</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,364</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9,199</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,242</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,398</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,231</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">801</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,011</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development expenses, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling, general and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,530</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financial income (expenses), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,987</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(48,923</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,737</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,298</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,176</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,276</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">(Loss) income from discontinued operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,947</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,355</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">85,319</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 0.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net income (loss) for the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(27,790</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,943</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,037</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,365</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,276</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net income (loss) per share of common stock, basic and diluted:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.65</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(Loss) income from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net (loss) income per share of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.61</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Weighted average number of shares of common stock used in computing net loss per share of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,368,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,891,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,922,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,387,704</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,085,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.5pt">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">86,398</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">76,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">63,281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,214</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long term convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity (capital deficiency)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,946</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,601</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,957</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,293</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_012"></A>Item 7.</B></TD><TD><B>Management&rsquo;s Discussion and Analysis
                                         of Financial Condition and Results of Operations</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our consolidated financial statements and the related
notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis,
particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements
that involve risks and uncertainties. You should read &ldquo;Risk Factors&rdquo; in Item 1A of this Annual Report on Form 10-K
for a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system. We developed our first commercial drug product, Elelyso<SUP>&reg;</SUP>, using our ProCellEx system and we are now focused
on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins
that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of
action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins
that are therapeutically superior to existing recombinant proteins currently marketed for the same indications including applying
the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 19, 2017, Protalix Ltd., our wholly-owned subsidiary, and Chiesi entered into the Chiesi Agreement pursuant to which Chiesi
was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase alfa.
</FONT>Pegunigalsidase alfa is our chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is
currently being evaluated in phase III clinical trials for the treatment of Fabry disease<FONT STYLE="font-family: Times New Roman, Times, Serif">.
Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase alfa
in the United States. Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection
with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $25 million in development costs,
capped at $10 million per year. Protalix Ltd. is also eligible to receive an additional up to $320 million, in the aggregate, in
regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for
all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject
to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount
of annual sales, as consideration for the supply of pegunigalsidase alfa. The Chiesi Agreement also provides for reimbursement
by Chiesi of certain costs to be incurred by Protalix Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the European Commission granted Orphan Drug
Designation for pegunigalsidase alfa for the treatment of Fabry disease. The designation was granted after the COMP issued a positive
opinion supporting the designation noting that we had established that there was medically plausible evidence that pegunigalsidase
alfa will provide a significant benefit over existing approved therapies in the European Union for the treatment of Fabry disease.
The COMP cited clinical and non-clinical justifications we provided to establish the significant benefit of pegunigalsidase alfa,
noting that the COMP considered the justifications to constitute a clinically relevant advantage. Orphan Drug Designation for pegunigalsidase
alfa qualifies Protalix Ltd. for access to a centralized marketing authorization procedure, including applications for inspections
and for protocol assistance. If the orphan drug designation is maintained at the time pegunigalsidase alfa is approved for marketing
in the European Union, if at all, we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union.
The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, the FDA granted Fast Track designation to PRX-102.
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious
conditions that fill an unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the FDA approved for sale our first commercial
product, taliglucerase alfa for injection, an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type
1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries.
Taliglucerase alfa is called alfataliglicerase in Brazil and certain other Latin American countries, where it is marketed under
the name alfataliglicerase. Taliglucerase alfa is marketed under the name Elelyso in other territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the Pfizer Agreement. In </FONT>October
2015, we entered into the Amended Pfizer Agreement which amends and restates the Pfizer Agreement in its entirety. Pursuant to
the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement for the
commercialization of Elelyso in exchange for a cash payment equal to $36.0 million. As part of the sale, we agreed to transfer
our rights to Elelyso in Israel to Pfizer, while gaining full rights to Elelyso in Brazil. We will continue to manufacture drug
substance for Pfizer, subject to certain terms and conditions. Under the Amended Pfizer Agreement, Pfizer is responsible for 100%
of expenses, and entitled to all revenues globally for Elelyso, excluding Brazil, where we are responsible for all expenses and
retain all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of the Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. Any failure to comply
with our supply commitments may subject us to substantial financial penalties, which will have a material adverse effect on our
business, results of operations and financial condition. The Amended Pfizer Agreement also includes customary provisions regarding
cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 18, 2013, we entered into the Brazil Agreement with </FONT>Fiocruz, an arm of the Brazilian MoH, <FONT STYLE="font-family: Times New Roman, Times, Serif">for
taliglucerase alfa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, we received a purchase order from the Brazilian MoH
for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil. The purchase
order consists of a number of shipments in increasing volumes. Shipments started in June 2017. Fiocruz&rsquo;s purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate
the Brazil Agreement. Notwithstanding, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and,
based on such discussions, we will determine what we believe to be the course of action that is in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing an innovative product pipeline using our ProCellEx
protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein
candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase III clinical
trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant
human Deoxyribonuclease 1 under development for the treatment of CF, to be administered by inhalation. We recently completed a
phase IIa efficacy and safety study of alidornase alfa for the treatment of CF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
OPRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein. We
expect to release final data generated in our phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis by the
end of March, 2018<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Brazil), which we licensed to Pfizer, and the rights to pegunigalsidase alfa Chiesi outside the United States, which
we licensed to Chiesi, we hold the worldwide commercialization rights to all of our proprietary development candidates. In addition,
we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K. We believe that
the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Functional Currency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The currency of the primary economic environment in which our
operations are conducted is the U.S. dollar. All of our revenues are derived in dollars. In addition, most of our expenses and
capital expenditures are incurred in dollars, and the major source of our financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our primary sources of revenues include our
sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under our Amended Pfizer Agreement. We recognize revenue
when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence
a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability
is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We also generate revenues from the Chiesi
Agreement. As Chiesi is obligated to acquire pegunigalsidase alfa from us, and has limited, immaterial rights until then, the development
services performed under the agreement are not considered to have a stand-alone value, and will be viewed as one unit of account
- manufacturing and supply of the drug. Therefore payments received from Chiesi prior to the fulfillment of the one unit of account
will be deferred until the commencement of the commercial manufacturing. We will recognize revenues after the commencement of drug
supply over the period of the product&rsquo;s sales according to our best estimate of sale price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Discontinued Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pursuant to the Amended Pfizer Agreement,
we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso.
As part of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer while gaining full rights to Elelyso in Brazil.
Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all of the revenues, globally,
for Elelyso, excluding Brazil where we are responsible for all expenses and retain all revenues. The Amended Pfizer Agreement eliminated
Pfizer&rsquo;s entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso in Brazil. For
further details please see notes 2 and 12 to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We accounted for the sale of our share in
the collaboration created under the initial Pfizer Agreement, including the transfer of our rights to Elelyso in Israel, in accordance
with ASU No.&nbsp;2014-08.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of our assets and liabilities associated with our share
in the former collaboration, including our rights to Elelyso in Israel, have been segregated and classified as assets and liabilities
of discontinued operations, as appropriate, in our consolidated balance sheets as of December&nbsp;31, 2016 and 2017. In addition,
certain financial information related to our share in the former collaboration, including our rights to Elelyso in Israel, have
been segregated from continuing operations and have been reported as discontinued operations in our consolidated statements of
operations. See note 12 to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expense to remain our
primary expense in the near future as we continue to develop our product candidates. Research and development expense consists
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>internal costs associated with research and development activities;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>payments made to third party contract research organizations, investigative/clinical sites and consultants;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing development costs;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in research
and development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,
as well as laboratory and other supplies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table identifies our current major research and
development projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><B>Project</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: center"><B>Status</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: Black 1pt solid; text-align: center"><B>Expected Near Term Milestones</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>PRX-102 &ndash; pegunigalsidase alfa</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase III clinical trial, ongoing</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completion of enrollment in trial and interim data analysis&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>PRX-110 &ndash; alidornase alfa </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase IIa completed</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Design of next clinical trial</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>OPRX-106 &ndash; Oral antiTNF</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase IIa completed</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">F<FONT STYLE="font-family: Times New Roman, Times, Serif">ull results for the study </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We anticipate incurring increasing costs in connection with
the continued development of all of the product candidates in our pipeline. Our internal resources, employees and infrastructure
are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record
and maintain research and development costs per project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The costs and expenses of our projects are partially funded
by grants we have received from NATI. Each grant is deducted from the related research and development expenses as the costs are
incurred. For additional information regarding the grant process, see &ldquo;Business&mdash;Israeli Government Programs&mdash;
Encouragement of Industrial Research, Development and Technology Innovation, 1984&rdquo; in Item 1 of this Annual Report. There
can be no assurance that we will continue to receive grants from NATI in amounts sufficient for our operations, if at all. In addition,
<FONT STYLE="font-family: Times New Roman, Times, Serif">under the Chiesi Agreement, Protalix Ltd. is entitled to payments of up
to $25 million to cover development costs for pegunigalsidase alfa, capped at $10 million per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At this time, due to the inherently unpredictable nature of
preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are
unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline
for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially
from expectations. The current focus of our product development efforts are on pegunigalsidase alfa. Our future research and development
expenses for pegunigalsidase alfa and the other product candidates will depend on the clinical success of each product candidate,
as well as ongoing assessments of each product candidate&rsquo;s commercial potential. In addition, we cannot forecast with any
degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if
at all, and to what degree such arrangements would affect our development plans and capital requirements. See &ldquo;Risk Factors&mdash;If
we are unable to develop and commercialize our product candidates, our business will be adversely affected&rdquo; and &ldquo;&mdash;We
may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely
manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expenses to continue
to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development
programs for our product candidates, particularly with respect to the development of pegunigalsidase alfa. The lengthy process
of completing clinical trials and seeking regulatory approvals for our product candidates requires expenditure of substantial resources.
Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product
revenue and cause our research and development expense to increase and, in turn, have a material adverse effect on our operations.
Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows
from our projects. See &ldquo;Risk Factors&mdash;Clinical trials are very expensive, time-consuming and difficult to design and
implement and may result in unforeseen costs which may have a material adverse effect on our business, results of operations and
financial condition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The discussion below regarding share-based
compensation relates to our share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In accordance with the guidance, we record
the benefit of any grant to a non-employee and remeasure the benefit in any future vesting period for the unvested portion of the
grants, as applicable. In addition, we use the straight-line accounting method for recording the benefit of the entire grant, unlike
the graded method we use to record grants made to employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We measure share-based compensation cost for
all share-based awards at the fair value on the grant date and recognition of share-based compensation over the service period
for awards that we expect will vest. The fair value of stock options is determined based on the number of shares granted and the
price of our ordinary shares, and calculated based on the Black-Scholes valuation model. We recognize such value as expense over
the service period, net of estimated forfeitures, using the accelerated method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The guidance requires companies to estimate
the expected term of the option rather than simply using the contractual term of an option. Because of lack of data on past option
exercises by employees, the expected term of the options could not be based on historic exercise patterns. Accordingly, we adopted
the simplified method, according to which companies may calculate the expected term as the average between the vesting date and
the expiration date, assuming the option was granted as a &ldquo;plain vanilla&rdquo; option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In performing the valuation, we assumed an
expected 0% dividend yield in the previous years and in the next years. We do not have a dividend policy and given the lack of
profitability, dividends are not expected in the foreseeable future, if at all. The guidance stipulates a number of factors that
should be considered when estimating the expected volatility, including the implied volatility of traded options, historical volatility
and the period that the shares of the company are being publicly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
risk-free interest rate used in the valuation of the options is based on the implied yield of U.S. federal reserve zero&ndash;coupon
government bonds. The remaining</FONT> term of the bonds used for each valuation was equal to the expected term of the grant. This
methodology has been applied to all grants valued by us. The guidance requires the use of a risk&ndash;free interest rate based
on the implied yield currently available on zero&ndash;coupon government issues of the country in whose currency the exercise price
is expressed, with a remaining term equal to the expected life of the option being valued. This requirement has been applied for
all grants valued as part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All outstanding convertible notes are accounted for using the
guidance set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification (ASC) 815 requiring
that we determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt
with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion
to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects
the issuer&rsquo;s nonconvertible debt borrowing rate. We account for the 4.5% convertible notes as liability, on an aggregated
basis, in their entirety. The conversion feature for our 7.5% convertible notes is accounted for as a derivative which is bifurcated
from the debt host contract and is measured at fair value through the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuance costs regarding the issuance of our 7.5% convertible
notes were allocated to the liability, equity component, derivative and shares of common stock based on their relative fair values.
Issuance costs that were allocated to liability will be amortized using the effective interest rate, other than issuance costs
that were allocated to derivative, which were expensed immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The debt discount and debt issuance costs regarding the issuance
of 4.5% convertible notes are deferred and amortized over the applicable convertible period (5 years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2017 Compared to the Year
Ended December&nbsp;31, 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenues of $19.2 million for
the year ended December&nbsp;31, 2017, an increase of approximately $10.0 million, or 109%, compared to revenues of $9.2 million
for the year ended December 31, 2016. Revenues include $7.1 million of products sold in Brazil and $12.1 million of drug substance
sold to Pfizer The increase resulted from an increase in the amount of $3.1 million of product sold to Brazil and $7.0 million
of drug substance sold to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $15.2 million for the year ended December
31, 2017, an increase of $6.8 million or 81%, compared to the cost of revenues of $8.4 million for the year ended December 31,
2016. The increase resulted primarily from costs related to the production of drug substance for sale to Pfizer, and of drug product
for sale to Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $32.2&nbsp;million for
the year ended December&nbsp;31, 2017, an increase of $1.8 million, or 6% from $30.4&nbsp;million for the year ended December&nbsp;31,
2016. The increase resulted primarily from an increase of $2.4 million in clinical trial related costs, which was partially offset
by a decrease of $0.7 million in materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates, primarily with respect to pegunigalsidase alfa<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were $11.5&nbsp;million
for the year ended December&nbsp;31, 2017, an increase of $2.2&nbsp;million, or 23%, from $9.4&nbsp;million for the year ended
December&nbsp;31, 2016. The increase resulted primarily from an increase in sales and marketing activities in connection with the
sale of alfataliglicerase in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expense was $48.9&nbsp;million for the year ended
December 31, 2017, compared to financial income of $4.0&nbsp;million for the year ended December 31, 2016. Financial expenses included a charge
of $38.1&nbsp;million as a result of the re-measurement of the fair value of the 7.5% convertible notes embedded derivative. In
addition, financial expenses is comprised primarily from interest expense on convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2016 Compared to the Year
Ended December&nbsp;31, 2015</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenues of $9.2 million for the
year ended December&nbsp;31, 2016, an increase of approximately $4.8&nbsp;million, or 111%, compared to revenues of $4.4 million
for the year ended December 31, 2015. Revenues represent products sold in Brazil and drug substance sold to Pfizer. The increase
is mainly due to an increase of $4.8 million of drug substance sold to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $8.4 million for the year ended December
31, 2016 compared to the cost of revenues of $730,000 for the year ended December 31, 2015. The increase is mainly due to cost
of revenues that were attributed to an increase in the amount of drug substance sold to Pfizer at cost during the period and that
a substantial portion of activities performed during 2015 were attributed to the development and production of PRX-102 for the
entire period during which the phase III clinical trial is to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $30.4&nbsp;million for
the year ended December&nbsp;31, 2016, an increase of $5.5 million, or 22% from $24.9&nbsp;million for the year ended December&nbsp;31,
2015. The increase resulted primarily from an increase of $3.7 million in clinical trial related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were $9.4&nbsp;million
for the year ended December&nbsp;31, 2016, an increase of $2.1&nbsp;million, or 29%, from $7.3&nbsp;million for the year ended
December&nbsp;31, 2015. The increase resulted primarily from an increase in sales and marketing activities in connection with the
sale of alfataliglicerase in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial income was $4.0&nbsp;million for the year ended December
31, 2016, compared to financial expense of $3.6&nbsp;million for the year ended December 31, 2015. Financial income for the year
ended December 31, 2016 resulted primarily from the exchange of $54.1 million of our 4.5% notes into $40.2 million aggregate principal
amount of 7.5% senior secured notes and 23.8 million shares of our common stock. The exchange was accounted for as extinguishment
of notes, and the difference between the net carrying value of the 4.5% notes exchanged and the fair value of the new notes and
shares issued were accounted for as a gain on extinguishment of $14.1 million. The financial income was partially offset by $3.2
million of expenses resulting primarily from interest expense related to our outstanding convertible notes and by $6.5 million
of change in fair value of convertible notes embedded derivative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses
from our continuing operations since our inception. To date, we have funded our operations primarily with proceeds equal to $31.3&nbsp;million
from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd., and an additional $14.1&nbsp;million in
connection with the exercise of warrants issued in connection with the sale of such shares, through December 31, 2008. In addition,
on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection with an underwritten public offering of our
common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds of $22.0 million and $27.2 million,
respectively, in connection with underwritten public offerings of our common stock. We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for at least 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our public
funding sources since 2007:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"><B>Security</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Year</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Number of Shares</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Amount</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2007</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">10,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,168,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September 18, 2013, we completed
a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, including $9.0 million
aggregate principal amount of Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option, which was
exercised in full. In December 2016, we completed a private placement of $22.5 million in aggregate principal amount of 7.5% convertible
notes due 2021. Finally, on July 25, 2017, we completed a private placement of an additional $10.0 million in aggregate principal
amount of 7.5% convertible notes due 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.&rsquo;s meeting a certain milestone. Protalix Ltd. also received
a milestone payment of $25.0&nbsp;million in connection with the FDA&rsquo;s approval of taliglucerase alfa in May 2012. Pfizer
has also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones under a clinical
development agreement between Pfizer and Protalix Ltd. In connection with the execution of the Amended Pfizer Agreement, we received
a $36.0 million payment from Pfizer, and Pfizer purchased 5,649,079 shares of our common stock for $10.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the fourth
quarter of 2017, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the Chiesi
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $10.0&nbsp;million
for the year ended December 31, 2017. The net loss from continuing operations for the year ended December 31, 2017 of $85.3&nbsp;million
was partially offset by a change of $38.1&nbsp;million in the fair value of convertible notes embedded derivative and an increase
of $26&nbsp;million in deferred revenues. Net cash used in investing activities for the year ended December 31, 2017 was $1.1&nbsp;million
and consisted primarily of purchase of property and equipment. Net cash used in financing activities was $1.4 million which consisted
of cash settlement of $11.0 million for certain conversions of our convertible notes which was partially offset by $9.5&nbsp;million
of net proceeds from the issuance of our 7.5% convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $32.1 million
for the year ended December 31, 2016. The net loss from continuing operations for the year ended December 31, 2016 of $29.2 million
was further increased by $7.6 million non cash financial income, but was partially offset by $2.0 million in depreciation and a
$2.1 million increase in accounts payable. Net cash used in investing activities for the year ended December 31, 2016 was $967,000
and consisted primarily of equipment purchases. Net cash provided by financing activities was $19.7 million and consisted primarily
of proceeds from the private offering of our 7.5% convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future, including significant research and development expenses related primarily to the clinical trials of PRX-102. We believe
that our existing cash and cash equivalents will be sufficient for at least 12 months. We have based this estimate on assumptions
that are subject to change and may prove to be wrong, and we may be required to use our available capital resources sooner than
we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our
product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with
our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many other factors, including our progress in commercializing <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil, the progress and results of our clinical trials, the duration and cost of discovery and preclinical development and
laboratory testing and clinical trials for our product candidates, conversions of our convertible notes from time to time, the
timing and outcome of regulatory review of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining,
defending and enforcing patent claims and other intellectual property rights, the number and development requirements of other
product candidates that we pursue and the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through corporat<FONT STYLE="font-family: Times New Roman, Times, Serif">e</FONT> collaboration, licensing or similar arrangements,
public or private equity offerings or debt financings. We currently do not have any commitments for future external funding, except
with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreement. We
may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand
our product development efforts more rapidly than we presently anticipate. We may also decide to raise additional funds even before
we need them if the conditions for raising capital are favorable. Any sale of additional equity or debt securities will likely
result in dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also
result in covenants that would restrict our operations. Additional equity or debt financing, grants or corporate collaboration
and licensing arrangements may not be available on acceptable terms, if at all. If adequate funds are not available, we may be
required to delay, reduce the scope of or eliminate our research and development programs, reduce our planned commercialization
efforts or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain product
candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the years ended December&nbsp;31, 2015, 2016 or 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us by increased
or decreased costs mainly for goods and services acquired outside of Israel. We do not believe currency fluctuations have had a
material effect on our results of operations during the years ended December&nbsp;31, 2015, 2016 or 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of December&nbsp;31, 2016 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Certain recently issued accounting pronouncements
are discussed in Note 1(q) of the financial statements included in Item 8 of this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our significant
contractual obligations at December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less than 1 year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3-5 years</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">More than 5 years</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in">Convertible notes&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">83,004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,646</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,860</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">63,498</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Operating lease obligations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Purchase obligations (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Certain clinical contract</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt; padding-bottom: 1pt">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,586</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,586</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-bottom: 2.5pt">Total&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">112,363</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">24,277</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">21,293</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">64,207</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,586</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1) Represents open purchase orders issued
to certain suppliers and other vendors mainly in connection with our research and development activities that were outstanding
as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The foregoing table does not include
(i) annual license fees, which are immaterial, (ii) payments we may be required to make to certain of our licensors in the
time periods set forth above upon the achievement of agreed-upon milestones and (iii) royalty payments payable by us to
certain of our licensors in connection with the commercial sale of our product candidates, if any. If all of the
contingencies with respect to milestone payments under our research and license agreements are met, the aggregate milestone
payments payable would be approximately $14.3 million and would be payable, if at all, as our projects progress over the
course of a number of years. The royalty payments payable in connection with sales of each of our product candidates, if any,
shall not exceed low, single-digit percentages of net sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Quarterly Financial Data (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="30" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="30" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Sept. 30</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Dec. 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Sept. 30</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Dec. 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">679</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,769</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,670</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,081</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,889</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,358</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,526</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,469</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross profit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">94</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">801</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">835</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,460</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">915</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Loss) income from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,526</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,736</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,290</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,624</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(59,148</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,437</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,141</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income (loss) from discontinued operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(72</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(117</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net (loss) profit for the period</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,598</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,853</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,290</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,624</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(59,148</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,437</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,141</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Earnings (loss) per share of common
    stock, basic and diluted:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.48</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income (loss) from discontinued operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net basic income (loss) per share of
    common     stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.48</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net diluted loss per share of common
    stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.48</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.06</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.11</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_013"></A>Item 7A.</B></TD><TD><B>Quantitative and Qualitative Disclosures about Market
Risk</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. Most of our revenues and approximately 50% of our expenses and capital expenditures
are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional
currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at
the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured
at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are
recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.887</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.841</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at year-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.845</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.467</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_014"></A>Item 8.</B></TD><TD><B>Financial Statements and Supplementary Data</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">See the Index to Consolidated Financial Statements
on Page F-1 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.05pt; text-indent: -40.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_015"></A>Item 9.</B></TD><TD><B>Changes in and Disagreements with Accountants
                                         on Accounting and Financial Disclosure</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt; text-indent: -40.8pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_016"></A>Item 9A.</B></TD><TD><B>Controls and Procedures</B></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluation of Disclosure Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. The
controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure
that information required to be disclosed in our reports filed under the Exchange Act, such as this Form 10-K, is recorded, processed,
summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms. Disclosure controls and procedures
are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief
Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The evaluation of our disclosure controls
and procedures included a review of the controls&rsquo; objectives and design, our implementation of the controls and their effect
on the information generated for use in this Form 10-K. In the course of the controls evaluation, we reviewed identified data errors,
control problems or acts of fraud, and sought to confirm that appropriate corrective actions, including process improvements, were
being undertaken. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including
the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures
can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these various evaluation activities are
to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls
and procedures as dynamic systems that change as conditions warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-K, our disclosure controls
and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports
is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information
related to our company and our consolidated subsidiaries are made known to management, including the Chief Executive Officer and
Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management&rsquo;s Report on Internal Control over Financial
Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made
only in accordance with authorizations of management and our directors; and (iii) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Management assessed our internal control
over financial reporting as of December 31, 2017, the end of our fiscal year. Management based its assessment on criteria established
in Internal Control&mdash;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). Management&rsquo;s assessment included evaluation of elements such as the design and operating effectiveness of key financial
reporting controls, process documentation, accounting policies and our overall control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on our assessment, management
has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes
in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&rsquo;s assessment with
the Audit Committee of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The effectiveness of our internal control
over financial reporting as of December 31, 2017 has been audited by Kesselman &amp; Kesselman, an independent registered public
accounting firm, as stated in their report included herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in our internal control over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the year ended December 31, 2017
that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_017"></A>Item 9B.</TD><TD>Other Information</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A>PART III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_019"></A>Item 10.</B></TD><TD><B>Directors,
                                         Executive Officers and Corporate Governance</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The information in our 2018 Proxy Statement
regarding directors and executive officers appearing under the headings &ldquo;Security Ownership of Certain Beneficial Owners
and Management&mdash; Section 16(a) Beneficial Ownership Reporting Compliance&rdquo; and &ldquo;Proposal&nbsp;1: Election of Directors&rdquo;
is incorporated by reference in this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.3pt; text-indent: -42.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_020"></A>Item 11.</B></TD><TD><B>Executive Compensation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The information appearing in our&nbsp;2018
Proxy Statement under the headings &ldquo;Director Compensation,&rdquo; &ldquo;Compensation Discussion and Analysis,&rdquo; &ldquo;Report
of the Compensation Committee,&rdquo; and &ldquo;Executive Compensation&rdquo; is incorporated by reference in this section.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_021"></A>Item 12.</TD><TD>Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The information appearing in our 2018 Proxy
Statement under the heading &ldquo;Security Ownership of Certain Beneficial Owners and Management&rdquo; is incorporated by reference
in this section.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity Compensation Plan Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table provides information as
of December&nbsp;31, 2017 with respect to the shares of our common stock that may be issued under our existing equity compensation
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">B</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">C</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Plan Category</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number&nbsp;of&nbsp;Securities<BR>
to&nbsp;be Issued<BR> Upon Exercise of<BR> Outstanding Options</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Weighted&nbsp;Average<BR>
    Exercise Price of<BR> Outstanding&nbsp;Options</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number&nbsp;of&nbsp;Securities&nbsp;Remaining<BR>
    Available for Future Issuance<BR> Under&nbsp;Equity&nbsp;Compensation&nbsp;Plans<BR> (Excluding Securities Reflected in<BR>
    Column A)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 8pt">Equity Compensation
    Plans Approved by Stockholders&#9;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">4,929,617</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">3.59</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">2,554,075</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Equity
    Compensation Plans Not Approved by Stockholders&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.5in; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Total&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 8pt">4,929,617</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 8pt">3.59</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 8pt">2,554,075</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-indent: -45.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><A NAME="a_022"></A>Item 13.</TD><TD>Certain Relationships and Related Transactions, and Director
Independence</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information appearing in our 2018 Proxy Statement under
the headings &ldquo;Proposal&nbsp;1: Election of Directors&mdash;Corporate Governance&rdquo; and &ldquo;&mdash;Certain Relationships
and Related Transactions&rdquo; is incorporated by reference in this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-indent: -40.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-weight: bold"><A NAME="a_023"></A>Item 14.</FONT></TD><TD><FONT STYLE="font-weight: bold">Principal Accountant
Fees and Services</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information appearing in our 2018 Proxy Statement under
the heading &ldquo;Proposal&nbsp;4: Ratification of Appointment of Independent Registered Public Accounting Firm&rdquo; is incorporated
by reference in this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_024"></A>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.75pt; text-indent: -42.75pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_025"></A>Item 15.</B></TD><TD><B>Exhibits
                                         and Financial Statement Schedules</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">The following documents are filed as part
of this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<I>&nbsp;&nbsp;Financial Statements</I>.
The following Consolidated Financial Statements of Protalix BioTherapeutics, Inc. are included in Item&nbsp;8 of this Annual Report
on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-right: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-left: 0.1in; text-align: center; border-bottom: Black 1pt solid"><B>Page</B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Report of Independent Registered Public Accounting Firm</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Consolidated Balance Sheets as of December 31, 2016 and 2017</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-4</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Consolidated Statements of Operations for the years ended December 31, 2015, 2016 and 2017&#9;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) for the years ended December 31, 2015, 2016 and 2017</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2016 and 2017&#9;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-7</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Notes to Consolidated Financial Statements&#9;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">F-9</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<I>&nbsp;&nbsp;Financial Statement Schedule.
</I>Financial statement schedules have been omitted since they are either not required, are not applicable or the required information
is shown in the consolidated financial statements or related notes. <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">3.<I>&nbsp;&nbsp;Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: bottom; padding-left: 0; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Incorporated by Reference</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
 Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Description</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File<BR>
 Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed<BR>
 Herewith</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Company</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-48677</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Certificate of Incorporation of the Company</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Def 14A</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appen. A</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Company</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Agreement/Notice</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2012</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indenture, dated as of September 18, 2013, between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2013</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 4.50% Convertible Note due 2018</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2013</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indenture, dated as of December 7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 7.50% Convertible Note due 2018 (Issued in Financing)</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 15%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 7.50% Convertible Note due 2018 (Issued in Exchange)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Supplemental to Indenture, dated as of July 24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2017</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Supplemental Indenture, dated as of November 27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 1, 2017</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006 Stock Incentive Plan, as amended</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Def 14A</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex A</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414060401/v390771_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 9, 2014</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Protalix Ltd. and Yoseph Shaaltiel, dated as of September 1, 2004</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 8, 2007</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Protalix Ltd. and Einat Almon, dated as of December 19, 2004</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 8, 2007</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Protalix Ltd. and Yossi Maimon, dated as of October 15, 2006</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 8, 2007</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement between Protalix Ltd. and Angel Science Park (99) Ltd., dated as of October 28, 2003 as amended on April 18, 2005</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 8, 2007</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unprotected Lease Agreement</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 17, 2008</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement by and between Protalix Ltd., and Tzvi Palash dated as of August 29, 2010</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310084127/y03926exv10w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 7, 2010</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&dagger;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Agreement between Protalix Ltd. and Comercio e Servi&ccedil;os Ltda. dated June 17, 2013</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2014</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&dagger;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology Transfer and Supply Agreement made as of June 18, 2013 by and between Protalix Ltd. and Funda&ccedil;&atilde;o Oswaldo Cruz</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414028653/v376666_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2014</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 75; Value: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with Moshe Manor dated September 28, 2014</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 15%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420414058399/v390212_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 29, 2014</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&dagger;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Exclusive License and Supply Agreement by and between Pfizer Inc. and Protalix Ltd., dated October 12, 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q/A</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note Purchase Agreement, dated of December 1, 2016 among Protalix BioTherapeutics, Inc. and the Purchasers</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exchange Agreement, dated of December 1, 2016 among Protalix BioTherapeutics, Inc. and the Existing Holders</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of U.S. Security Agreement, dated of December 7, 2016 among Protalix BioTherapeutics, Inc., the guarantors party thereto and Wilmington Savings Fund Society, FSB, as collateral agent</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Security Agreement/Debenture, dated of December 7, 2016 between Protalix BioTherapeutics, Inc. and Altshuler Shaham Trusts Ltd., as security trustee</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 7, 2016</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="tv486893_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&dagger;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv486893_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License and Supply Agreement dated as of October 17, 2017, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv486893_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-33357</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 26, 2010</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="tv486893_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv486893_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), A member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv486893_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="tv486893_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv486893_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv486893_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="tv486893_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv486893_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv486893_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 76; Value: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; width: 10%"><A HREF="tv486893_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%"><A HREF="tv486893_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 15%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%"><A HREF="tv486893_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><A HREF="tv486893_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv486893_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv486893_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL INSTANCE FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL SHEMA FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL CALCULATION FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL DEFINITION FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL LABEL FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL PRESENTATION FILE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&dagger; Portions of this exhibit were omitted
and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&rsquo;s
application requesting confidential treatment under Rule 24b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B><A NAME="a_026"></A>Item 16.</B></TD><TD><B>Form 10-K Summary</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_027"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, as of March 6, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Moshe Manor</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints Moshe Manor and Yossi Maimon, and each of them, as his true and lawful
attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in
any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: center"><B>Signature</B></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 32%; border-bottom: Black 1pt solid; text-align: center"><B>Title</B></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 32%; border-bottom: Black 1pt solid; text-align: center"><B>Date</B></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">President, Chief Executive Officer</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Moshe Manor</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">(Principal Executive Officer) and Director</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Chief Financial Officer, Treasurer and Secretary (Principal Financial</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Yossi Maimon</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">and Accounting Officer)</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Shlomo Yanai</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Chairman of the Board</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Shlomo Yanai</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Amos Bar Shalev</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Director</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Amos Bar Shalev</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Zeev Bronfeld</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Director</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Zeev Bronfeld</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Yodfat Harel Buchris</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Director</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Yodfat Harel Buchris</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">/s/ Aharon Schwartz</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">Director</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: right">March 6, 2018</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">Aharon Schwartz, Ph.D.</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 78; Value: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-right: 0.25in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 86%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 5%"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#fin_001"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></A></TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_001">F-2</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#fin_002">Consolidated Balance Sheets as of December 31, 2016 and 2017</A></TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#fin_002"><FONT STYLE="text-transform: uppercase">F-4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#fin_003">Consolidated Statements of Operations for the years ended December 31, 2015, 2016 and 2017</A></TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_003"><FONT STYLE="text-transform: uppercase">F-5</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#fin_004">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) &nbsp;for the years ended December 31, 2015, 2016 and 2017</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_004"><FONT STYLE="text-transform: uppercase">F-6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#fin_005">Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2016 and 2017</A></TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_005"><FONT STYLE="text-transform: uppercase">F-7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt"><A HREF="#fin_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#fin_006"><FONT STYLE="text-transform: uppercase">F-9</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tv486893_img8.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the board of directors and stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Opinions on the Financial Statements  and Internal
Control over Financial Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets
of Protalix BioTherapeutics, Inc. and its subsidiaries as of December 31, 2017 and 2016, and the related consolidated statements
of operations, changes in stockholders&rsquo; equity (capital deficiency) and cash flows for each of the three years in the period
ended December 31, 2017 including the related notes (collectively referred to as the &ldquo;consolidated financial statements&rdquo;).
We also have audited the Company&rsquo;s internal control over financial reporting as of December 31, 2017 based on criteria established
in <I>Internal Control - Integrated Framework</I> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016 and the
results of their operations and their cash flows for each of the three years in the period ended December 31, 2017 in conformity
with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in
all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established
in <I>Internal Control - Integrated Framework</I> (2013) issued by the COSO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis for Opinions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s management is responsible for these consolidated
financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness
of internal control over financial reporting, included in the accompanying Management&rsquo;s Annual Report on Internal Control
over Financial Reporting. Our responsibility is to express opinions on the Company&rsquo;s consolidated financial statements and
on the Company&rsquo;s internal control over financial reporting based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of
the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over
financial reporting was maintained in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits of the consolidated financial statements included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered
necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street,
Tel-Aviv 6812508, Israel, P.O Box 5005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="tv486893_img8.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Definition and Limitations of Internal Control over Financial
Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company&rsquo;s internal control over financial reporting
is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s internal control
over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect on the financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>/s/ Kesselman &amp; Kesselman</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certified Public Accountants (Isr.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A member of PricewaterhouseCoopers International Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 6, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street,
Tel-Aviv 6812508, Israel, P.O Box 5005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>PROTALIX BIOTHERAPEUTICS, INC. </B><BR>
<B>CONSOLIDATED BALANCE SHEETS </B><BR>
(U.S. dollars in thousands, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 14.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">63,281</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">51,163</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 14.2pt">Accounts receivable &ndash; Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">693</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 14.2pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 14.2pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,833</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,887</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">82,247</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -14.2pt; padding-left: 14.2pt">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.3in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,521</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.3in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,921</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 13.3pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">837</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,212</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,851</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,586</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Other long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,051</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,992</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">80,755</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">92,204</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103,507</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><B>COMMITMENTS</B> (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CAPITAL DEFICIENCY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt"><P STYLE="margin-top: 0; margin-bottom: 0">Common Stock, $0.001 par value:</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.25in">Authorized - as of December 31, 2016 and 2017, 250,000,000 shares; issued and outstanding, respectively - as of December 31, 2016 and 2017, 124,134,085 shares and 143,728,797 shares, respectively</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266,495</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212,656</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(297,932</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Total capital deficiency</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.3pt">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">82,247</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying
notes are an integral part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>PROTALIX BIOTHERAPEUTICS, INC. </B><BR>
<B>CONSOLIDATED STATEMENTS OF OPERATIONS </B><BR>
(U.S. dollars in thousands, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,364</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9,199</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19,242</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(730</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,398</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,231</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,634</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">801</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,011</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,889</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,412</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,170</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt">Less &ndash; grants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,864</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,804</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,336</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,025</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,608</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>SELLING, GENERAL AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">EXPENSES</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,356</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,530</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,670</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,163</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,353</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left">FINANCIAL EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,192</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,725</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left">FINANCIAL INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,473</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,061</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1pt">(LOSS) GAIN oN EXTINGUISHMENT OF CONVERTIBLE NOTES</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">14,063</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,325</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt">FINANCIAL (EXPENSES) INCOME &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,612</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,987</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(48,923</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt">LOSS FROM CONTINUING OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,282</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,176</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(85,276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt">(LOSS) Income FROM DISCONTINUED OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET (LOSS) INCOME&nbsp;&nbsp;FOR THE YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,037</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,365</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,276</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Net
    (loss) INCOME per share of common stock &ndash; basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12.6pt"><B>Loss from continuing operations</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.65</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt"><B>Income from discontinued operations</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.90</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Net (loss) income per share of common stock</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.61</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.65</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">Weighted average number of shares of common stock used in computing loss per share of common stock, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">94,922,390</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">101,387,704</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">131,085,958</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_004"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN
SHAREHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(CAPITAL DEFICIENCY)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">paid&ndash;in</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">deficit</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number
    of <BR>
    shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-weight: bold; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Balance at January
    1, 2015</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">93,603,819</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">94</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">185,633</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(241,328</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(55,601</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Changes
    during 2015:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Issuance of common stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,649,079</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,095</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Share-based compensation
    related to stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Share-based compensation
    related to restricted stock award, net of forfeitures of 2,501 shares</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2,501</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">529</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">529</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Exercise of options granted
    to employee</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">550,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">534</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">534</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Net loss from continuing
    operations</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(27,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(27,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Net
    income from discontinued operations</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">85,319</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">85,319</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Balance at December 31, 2015</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">99,800,397</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">100</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">194,064</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(183,291</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">10,873</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Changes
    during 2016:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Issuance of common stock,
    net of issuance cost</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">23,846,735</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,824</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,848</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Equity component of convertible
    notes</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">685</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">685</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Share-based compensation
    related to stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Share-based compensation
    related to restricted stock award</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">68</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">68</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Exercise of options granted
    to employee (including net exercise)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">479,110</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Net loss from continuing
    operations</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(29,176</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(29,176</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Net
    loss from discontinued operations</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(189</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(189</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Balance at December 31, 2016</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">124,134,085</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">124</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">202,575</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(212,656</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(9,957</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Changes
    during 2017:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Share-based compensation
    related to stock options</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">337</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">337</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Reclassification of embedded
    derivative</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">43,634</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">43,634</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Convertible note conversions</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">19,594,712</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,634</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,654</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Equity component of convertible
    notes</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,315</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,315</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in"><FONT STYLE="font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(85,276</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(85,276</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Balance
    at December 31, 2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">143,728,797</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">144</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">266,495</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(297,932</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(31,293</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">* Represents an amount of less than $1
thousand.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: 9pt">Net (loss) income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">58,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(29,365</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(85,276</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">(Loss) income from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,276</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Adjustments required to reconcile net (loss) income to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 9pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,983</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">Financial (income) expenses, net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">(Gain) loss on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Loss (gain) on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">Loss (gain) on extinguishment of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,063</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,325</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Net income in connection with conversions of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(116</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Change in fair value of convertible notes embedded derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,061</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Amortization of debt issuance costs and debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Issuance of shares for interest payment in
    connection with conversions of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10.35pt; padding-left: 28.35pt">Increase (decrease) in deferred revenues (including non-current potion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(411</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">(Increase) decrease in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">523</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,133</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Decrease (increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,316</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,588</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase (decrease) in accounts payable and accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,873</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,139</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,902</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Increase in other long term liabilities</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25in; padding-left: 0.125in">Net cash used in continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,770</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,087</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,994</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25in; padding-left: 0.125in">Net cash provided by (used in) discontinued
    operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,284</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,098</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING&nbsp;&nbsp;ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(464</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(849</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(971</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Proceeds from sale of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">(Increase) decrease in restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(146</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Amounts funded in respect of employee rights upon
    retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(96</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Net cash used in continuing operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(512</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Net cash provided by discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,899</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Net cash (used in) provided by investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,387</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 9pt">Net payment for conversion of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,961</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9pt">Net proceeds from issuance of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,681</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,542</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 9pt">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 9pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">534</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Net cash (used in) provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,635</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,419</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(131</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">277</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,607</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,093</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,118</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,767</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">76,374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">76,374</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">63,281</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,163</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(CONTINUED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12.05pt; padding-left: 12.05pt">SUPPLEMENTARY INFORMATION ON
    INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">489</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">595</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">526</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Issuance of promissory note</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Issuance of common stock, &nbsp;net of issuance cost</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Convertible note conversions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.2pt; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.2pt; padding-left: 0.25in">As to extinguishment of convertible notes see note 8.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.2pt; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12.05pt; padding-left: 12.05pt">SUPPLEMENTARY DISCLOSURE ON
    CASH FLOWS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Interest paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,659</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,854</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_006"></A>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Protalix BioTherapeutics, Inc.
(collectively with its subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix
B.V. (the &ldquo;Subsidiaries&rdquo;), are biopharmaceutical companies focused on the development and commercialization of recombinant
therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;).
To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain
other Latin American countries and Elelyso<SUP>&reg;</SUP> in the rest of the territories) for the treatment of Gaucher disease
that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product
candidates in varying stages of the clinical development process. The Company&rsquo;s current strategy is to develop proprietary
recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">The Company&rsquo;s product pipeline
currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(1) pegunigalsidase alfa, or PRX-102,
a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(2) alidornase alfa, or PRX-110,
a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis,
to be administered by inhalation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(3) OPRX-106, the Company&rsquo;s
oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as
a natural capsule for the expressed protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Obtaining marketing approval with
respect to any product candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary
regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Since its approval by the FDA,
taliglucerase alfa has been marketed by Pfizer Inc. (&ldquo;Pfizer&rdquo;), as provided in the exclusive license and supply agreement
by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered
into an Amended and Restated Exclusive License and Supply Agreement (the &ldquo;Amended Pfizer Agreement&rdquo;) which amends and
restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in
the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal
to $36.0 million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full
rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100%
of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.
For further details see note 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">On June 18, 2013, the Company entered
into a Supply and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;),
an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz&rsquo;s purchases of alfataliglicerase to date have
been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil
Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz
under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher
patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that
Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes
to be the course of action that is in the best interest of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In 2017, the Company
received a purchase order from the Brazilian Ministry of Health (the &ldquo;Brazilian Ministry&rdquo;) for the purchase
of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3 million. The purchase
order consists of a number of shipments in increasing volumes. Shipments started in June 2017. The Company has recorded
revenues of $7.1 million for sales of alfataliglicerase to Fiocruz in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">On October 19, 2017, Protalix Ltd.
and Chiesi Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;) entered into an Ex-US license (the &ldquo;Chiesi Agreement&rdquo;) pursuant
to which Chiesi was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase
alfa. Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase
in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Under the Chiesi Agreement,
Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the agreement and
Protalix Ltd. is entitled to additional payments of up to $25 million in development costs, capped at $10 million per year.
Protalix Ltd. is also eligible to receive additional payments of up to $320 million, in the aggregate, in regulatory and
commercial milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Under the terms of the agreement,
Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and
Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi will make tiered payments
of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Based on its current cash
resources and commitments, the Company believes it will be able to maintain its current planned development activities and
the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements as of December 31, 2017,
although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected
increases in general and administrative expenses or research and development expenses, the Company may need to seek
additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&rsquo;s financial statements have been
prepared in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Use of estimates in the preparation of financial statements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD><B>Functional currency</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The dollar is the currency of the primary economic
environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&rsquo;s revenues are
derived in dollars. Most of the Company&rsquo;s expenses and capital expenditures are incurred in dollars, and the major source
of the Company&rsquo;s financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Transactions and balances originally denominated
in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical
and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated
below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &ndash; exchange
rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as
depreciation and amortization, etc.) &ndash; historical exchange rates. Currency transaction gains and losses are recorded as financial
income or expenses, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD><B>Cash equivalents</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company considers all short-term, highly liquid
investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase,
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>f.</B></TD><TD><B>Inventories</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Inventories are valued at the lower of cost or net
realizable value. Cost of raw and packaging materials and purchased products is determined using the &ldquo;moving average&rdquo;
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Cost of finished products is determined as follows:
the value of the raw and packaging materials component is determined primarily using the &ldquo;moving average&rdquo; basis; the
value of the labor and overhead component is determined on an average basis over the production period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Inventory is written down for estimated obsolescence
based upon management assumptions about future demand and market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>g.</B></TD><TD><B>Property and equipment</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Property and equipment are stated at cost, net of accumulated depreciation and amortization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>The Company&rsquo;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.9in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; padding-left: 81.1pt">&nbsp;</TD>
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid; text-align: center"><B>Years</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Laboratory equipment</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Furniture</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">10-15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">Computer equipment&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Leasehold improvements are amortized by the straight-line
method over the expected lease term, which is shorter than the estimated useful life of the improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>h.</B></TD><TD><B>Impairment in value of long-lived assets </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company tests long-lived assets for impairment
if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without
interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the
assets to their estimated fair values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>i.</B></TD><TD><B>Income taxes</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Deferred income taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Deferred taxes are determined utilizing the assets and
liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases
of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be
in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the
weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The
Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used tax rates of 39%, 24%
and 23%. See note 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Uncertainty in income taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Tax benefits recognized in the financial statements
are those that the Company&rsquo;s management deems at least more likely than not to be sustained, based on technical merits. The
amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&rsquo;s management deems more
likely than not to be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>j.</B></TD><TD><B>Revenue Recognition</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Revenues from supply agreements and from selling products</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company recognizes revenues from supply agreements
and from selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Revenues from Chiesi Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">As Chiesi is obligated to acquire pegunigalsidase alfa from
the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product
to be commercialized by Chiesi is viewed as one unit of account. Since there is only one unit of account, all payments received
by Chiesi prior to the satisfaction of Protalix's obligation will be deferred. Therefore, the $25 million upfront payment and future
research and development reimbursement payments (up to $25 million) and any potential additional development milestone payments
will be deferred until the commencement of commercial manufacturing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>k.</B></TD><TD><B>Research and development costs</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Research and development costs are expensed as incurred
and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment
and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for
Technological Innovation (&ldquo;NATI&rdquo;), which has replaced many of the functions of the Office of the Chief Scientist of
Israel&rsquo;s Ministry of Industry, Trade and Labor (the &ldquo;OCS&rdquo;), are recognized when the grant becomes receivable,
provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant
and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses
as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used
in a particular research and development project that have no alternative future use are charged to research and development costs
at the purchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the
goods are consumed or the related services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>l.</B></TD><TD><B>Concentration of credit risks and trade receivable</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly
rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any
one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed
to any significant credit risk on these instruments. The Company&rsquo;s trade receivables represent amounts to be received from
Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>m.</B></TD><TD><B>Share-based compensation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company accounts for employee&rsquo;s share-based
payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions
is recognized as an expense over the requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company elected to recognize compensation cost
for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option
award approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">When stock options are granted as consideration for
services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options
issued. Options granted are measured on a final basis at the end of the related service period and is recognized over the related
service period using the straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>n.</B></TD><TD><B>Net (loss) earnings per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS is calculated in continuing operations.
The calculation of diluted LPS does not include 19,778,424, 23,532,492 and 76,848,199 shares of Common Stock underlying outstanding
options, restricted shares of Common Stock and shares issuable upon conversion of the convertible notes for the fiscal years ended
December 31, 2015, 2016 and 2017, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>o.</B></TD><TD><B>Convertible notes</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">All outstanding convertible notes
are accounted for using the guidance set forth in the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards
Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted
for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument
that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components
of the instrument in a manner that reflects the issuer&rsquo;s nonconvertible debt borrowing rate. The Company accounts for the
2013 Notes (as defined in note 8a) as a liability, on an aggregated basis, in their entirety. The 2016 Notes (as defined in note
8b) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with
an embedded derivative resulting from the conversion feature. During the year ended December 31, 2017, the embedded derivative
was reclassified to additional paid in capital, see note 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Issuance costs regarding the issuance
of the 2016 Notes and the 2017 Notes (as defined in note 8c) were allocated to the liability, equity component, derivative and
shares based on their relative fair values. Issuance costs that were allocated to the liability are amortized using the effective
interest rate, other than issuance costs that were allocated to the derivative which were expensed immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">The debt discount and debt issuance
costs regarding the issuance of the 2013 Notes are deferred and amortized over the 2013 Notes period (5 years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>p.</B></TD><TD><B>Recently adopted standards</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In March 2016, the FASB
issued ASU 2016-09, &ldquo;Compensation - Stock Compensation (Topic 718)&rdquo; (&ldquo;ASU 2016-09&rdquo;) which simplifies
certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards
as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting
policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur.
ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal
years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued,
and all amendments in the ASU that apply must be adopted in the same period. The Company adopted this standard in the fourth
quarter of 2016. The Company elected to account for forfeitures as they occur. The implementation of this ASU did not have a
material impact on the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>q.</B></TD><TD><B>Recently issued accounting pronouncements </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In May 2014, the FASB issued guidance
on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific
guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in
an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services.
The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions
require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing
estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also
requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&rsquo;s
contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017.
The implementation of this ASU did not have a material impact on the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In January&nbsp;2016, the FASB
issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation
and disclosure requirements of financial instruments. The guidance is effective in annual reporting periods beginning after December
15, 2017. The implementation of this ASU is expected to have no material impact on the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In February 2016, the FASB issued
ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires
lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU
are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application
is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into
after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating
the impact of this new standard on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 2 - COMMERCIALIZATION AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>On November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June 2013) pursuant to
which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and
Brazil. Under the Pfizer Agreement Protalix was entitled to 40% of the results (profits or losses) earned on Pfizer&rsquo;s sales
of taliglucerase alfa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">In October 2015, the Company entered
into the following agreements with Pfizer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Amended Pfizer Agreement - Pursuant to the amendment,
the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all
the information, knowledge and permission to manufacture and sell Elelyso.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix also agreed to provide Pfizer with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed
price per unit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in
consideration of an agreed hourly rate plus reimbursement of expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Stock Purchase Agreement - the
Company issued 5,649,079 shares of Common Stock to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - COMMERCIALIZATION AGREEMENTS</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Promissory note &ndash; as of the date of the amendment,
the Company owed Pfizer $4.3 million as a result of the accumulated losses incurred by the Collaboration Operation. Following the
new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a) November 12, 2020 and (b)
the date upon which it becomes due pursuant to any event of default, as defined. The promissory note is presented in &quot;other
long term liabilities&quot;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">The Amended Pfizer Agreement resulted
in a discontinued operation as defined under ASU 2014-08 because it represented a strategic shift for the Company that has a major
effect on the entity&rsquo;s operations and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Revenues from the Pfizer Agreements
as well as revenues from sales of Elelyso in Israel were presented as discontinued operations. See note 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>In October 2017, Protalix Ltd. entered into the Chiesi Agreement with respect to the commercialization
                                                                of                                                                 pegunigalsidase alfa (hereafter &ndash; the drug) for
                                                                treatment of the Fabry disease. Under the terms of the Chiesi
                                                                Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all
                                                                markets outside of the United States. Protalix Ltd. maintains the exclusive commercialization rights to the drug in the
                                                                United                                                                 States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Protalix Ltd. will be mainly
responsible for (i) continuing the development of the drug until a regulatory approval is granted and (ii) manufacture and
supply the drug to Chiesi, based on Chiesi&rsquo;s requests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">The consideration consists of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">a. Upfront, non-refundable payment
of $25 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">b. Additional payments of up to $25
million in development costs, capped at $10 million per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">c. Milestone payments of up to $320
million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">d. Additional payments as consideration
for the supply of the drug. The payment will vary from 15% to 35% of Chiesi&rsquo;s average selling price of the drug, depending
on the amount of annual sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">e. Protalix will be the sole manufacturer
of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Chiesi does not have sublicensing
rights (except for certain territories).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">The Company analyzed the agreement
terms and concluded that the Chiesi Agreement qualifies as a contract with customer under ASC 605. Chiesi is a customer of the
Company as it contracted with the entity to obtain goods or services that are an output of the entity&rsquo;s ordinary activities
in exchange for consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">As Chiesi is obligated to acquire pegunigalsidase alfa from
the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product
to be commercialized by Chiesi is viewed as one unit of account. Therefore, all payments received prior to the fulfillment of the
one unit of account will be deferred until the commencement of commercial manufacturing. The Company will recognize revenues after
the commencement of the drug supply over the period of the product&rsquo;s sales according to the Company&rsquo;s best estimate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">On June 18, 2013, the Company entered into the Brazil Agreement
with Fiocruz for taliglucerase alfa. Fiocruz&rsquo;s purchases of alfataliglicerase to date have been significantly below certain
agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement,
and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are
currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply
with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of
action that is in the best interest of the Company.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 3 - PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>a.</B></TD><TD>Composition of property and equipment grouped by major classifications is as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.9in; border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><B>(<I>U.S. dollars in thousands)</I></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">16,265</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">16,561</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,438</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,123</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equipment under construction</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 7.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34,304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,141</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Less &ndash; accumulated depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,601</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,465</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,703</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,676</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>b.</B></TD><TD>Depreciation in respect of property and equipment totaled approximately $2.4 million, $2.0 million and $1.9 million for the
years ended December 31, 2015, 2016 and 2017, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 4 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inventories at December&nbsp;31, 2016 and
2017 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.9in; border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><B>(<I>U.S. dollars in thousands)</I></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">3,838</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,259</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,245</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,833</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS
UPON RETIREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Israeli Subsidiary is required to make a severance
payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to
the employees (based upon length of service and the latest monthly salary - one month&rsquo;s salary for each year employed) is
recorded on the Company&rsquo;s balance sheets under &ldquo;Liability for employee rights upon retirement.&rdquo; The liability
is recorded as if it were payable at each balance sheet date on an undiscounted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The liability is funded in part from the purchase
of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these
liabilities are included in the Company&rsquo;s balance sheets under &ldquo;Funds in respect of employee rights upon retirement.&rdquo;
These policies are the Company&rsquo;s assets. However, under labor agreements and subject to certain limitations, any policy may
be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December
31, 2015, 2016 and 2017, the Company deposited approximately $168,000, $164,000 and $166,000, respectively, with insurance companies
in connection with its severance payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In accordance with the current employment agreements
with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable
employee in order to secure the employee&rsquo;s rights upon retirement. The Company is fully relieved from any severance pay liability
with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these
employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&rsquo;s balance sheets,
as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been
irrevocably transferred to the applicable insurance companies (the &ldquo;Contribution Plans&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The amounts of severance pay expenses were approximately
$800,000, $842,000 and $906,000 for each of the years ended December 31, 2015, 2016 and 2017, respectively, of which approximately
$675,000, $675,000 and $746,000 in the years ended December 31, 2015, 2016 and 2017, respectively, were in respect of the Contribution
Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately ($18,000), ($7,000) and
$21,000 for the years ended December 31, 2015, 2016 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company expects to contribute approximately $830,000
in the year ending December 31, 2018 to insurance companies in connection with its severance liabilities for its operations for
that year, approximately $664,000 of which will be contributed to one or more Contribution Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the five-year period following December 31,
2017, the Company expects to pay future benefits to three employees upon each such employee&rsquo;s normal retirement age. The
Company anticipates that the benefits payable will be approximately $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 - COMMITMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>Royalty Commitments</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>The Company is obligated to pay royalties to the National Authority for Technological Innovation (&ldquo;NATI&rdquo;)
                                                                on                                                                 proceeds from the sale of products developed from
                                                                research                                                                 and development activities that were funded,
                                                                partially, by grants
                                                                from NATI or its predecessor, the Office of the Chief Scientist of the Israeli Department of Labor (&ldquo;OCS&rdquo;). At
                                                                the time                                                                 the
                                                                grants                                                                                                                were
                                                                received,                                                                 successful
                                                                development of the related projects                                                                             was not
                                                                assured.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In the case of failure of a project that was partly
financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the
OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under the terms of the applicable funding arrangements,
royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the OCS, which payments shall
not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&nbsp;1, 2001,
interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with
government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to
300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel,
and, possibly, an increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Royalty expenses to NATI or the OCS are included in
the statement of operations as a component of the cost of revenues both in continuing and discontinued operations and were approximately
$2.2&nbsp;million, $288,000 and $1,384,000 during the years ended December&nbsp;31, 2015, 2016 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">At December 31, 2016 and 2017, the maximum total royalty
amount payable by the Company under these funding arrangements is approximately $38.5 million and $42.2 million, respectively (without
interest, assuming 100% of the funds are payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>The Company is a party to certain research and license agreements.
Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties
payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses
under the agreements are included in the statement of operations as a component of the cost of revenues both in continuing and
discontinued operations and were approximately $51,000, $286,000 and $0 during the years ended December&nbsp;31, 2015, 2016 and
2017, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under each agreement, the Company is also obligated
to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for
varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the
research and license agreements are met, the aggregate milestone payments total payable would be approximately $14.3 million and
would be payable, if at all, as the Company&rsquo;s projects progress over the course of a number of years. Milestone payments
of $0, $300,000 and $0 were made during the years ended December&nbsp;31, 2015, 2016 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 - COMMITMENTS </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">None of the agreements has a fixed termination date.
Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first
commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial
sales of any product under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Subcontracting Agreements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company has entered into sub-contracting agreements
with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its
primary product development process. As of December 31, 2017, total commitments under said agreements were approximately $19.2
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Lease Agreements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company is a party to a number of lease agreements
for its facilities, the latest of which has been extended until 2021. The Company has the option to extend certain of such agreements
on two additional occasions for additional five-year periods each, for a total of 10 additional years. Under the leases, the aggregate
monthly rental payments are approximately $65,000. As of December 31, 2017, the Company provided bank guarantees of approximately
$306,000 in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments
required under the operating leases for such premises are approximately $783,000, $717,000, $717,000, $580,000, for fiscal years
2018 through 2021, respectively. Lease expenses totaled approximately $1.0 million for each of the years ended December 31, 2015,
2016 and approximately $775,000 for the year ended December 31,2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD><B>Vehicle Lease and Maintenance Agreements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company entered into several three-year lease
and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees
aggregate approximately $52,000. The expected lease payments for the years ending December 31, 2018, 2019 and 2020 are approximately
$565,000, $385,000 and $186,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 7 - SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>Rights of the Company&rsquo;s Common Stock</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&rsquo;s Common Stock is listed on the
NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of
Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of
Directors. Since its inception, the Company has not declared any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Stock based compensation </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">On December 14, 2006, the Board of Directors adopted
the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &ldquo;Plan&rdquo;). The Plan has since been amended
to, among other things, increase the number of shares of common stock available under the Plan to 13,841,655 shares. The grant
of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&nbsp;102 and 102A of the Israeli
Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the
Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes,
the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&rsquo;s accounts,
in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined
on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7  - SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">As of December 31, 2017, 2,554,075 shares of Common
Stock remain available for grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">For purposes of determining the fair value of the
options and restricted stock granted to employees and non-employees, the Company&rsquo;s management uses the fair value of the
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">From January 1, 2015 through December 31, 2017, the
Company granted options and shares of restricted stock to certain employees and non-employees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD><B>Options and restricted stock granted to employees:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD>Below is a table summarizing all of the options grants
to employees during the year ended December 31, 2015:</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 82%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year of <BR>
grant</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No. of options <BR>
granted</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise <BR>
price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value<BR>
 at grant <BR>
(U.S. <BR>
dollars in <BR>
thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration <BR>
period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: center">2015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: center">1,909,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1.72</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: center">4 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: center">10 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.85pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Set forth below are grants made by the Company to
employees (including related parties) during the three-year period ended December 31, 2017 (such grants appear in the table above):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in">On March 23, 2015, the Company&rsquo;s
compensation committee approved the grant of a 10-year option to purchase 1,909,000 shares of Common Stock to its officers and
other employees with an exercise price equal to $1.72 per share under the Plan. The options vest over a four-year period; the first
25% shares vest on the first anniversary of the grant date and the remaining shares vest in 12 equal quarterly increments over
the subsequent three-year period. Vesting of the options granted to certain executive officers is subject to acceleration in full
upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value
of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9 million based on the
following weighted average assumptions: dividend yield of 0% for all years; expected volatility of 61.7%; risk-free interest rates
of 1.6%; and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>The total unrecognized compensation cost of employee stock options at December 31, 2017 is approximately $130,000. The unrecognized
compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.54 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in">The total cash received from employees
as a result of employee stock option exercises for the years ended December 31, 2015, 2016 and 2017 was approximately $534,000,
$14,000 and $0, respectively. The Company did not realize any tax benefit in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD><B>Options granted to consultants, directors, and other
service providers:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">During the three years ended December
31, 2017 there were no option grants by the Company to its consultants, directors, and other service providers. In addition, during
the three years ended December 31, 2017, there were no option exercises by any of the Company&rsquo;s consultants, directors, and
other service providers and, consequently, no shares of Common Stock were issued in connection with exercises of options by, nor
was any cash received from, the Company&rsquo;s consultants, directors, and other service providers during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7  - SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD>A summary of share option plans, and related information, under all of the Company&rsquo;s equity incentive plans for the
                                                                                  years ended December&nbsp;31, 2015, 2016 and 2017 is as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD>Options granted to employees:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-indent: -0.125in; padding-left: 0.125in">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,870,309</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,952,293</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.363</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,884,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.617</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 15.95pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,909,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 15.95pt">Forfeited and Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">277,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,514,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 15.95pt">Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">550,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.972</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">553,125</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.067</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,952,293</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3.363</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,884,211</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3.617</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,729,617</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3.604</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4,477,043</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4.182</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">3,498,492</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4.296</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4,457,461</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">3.696</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"><FONT STYLE="font-size: 10pt">(*)
The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately </FONT>$675,000,
$213,000 and $0<FONT STYLE="font-size: 10pt">, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD>Restricted stock granted to employees:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of restricted stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">386,124</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">127,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 15.95pt">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,749</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,874</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 15.95pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">127,874</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD>Options and restricted stocks granted to consultants, directors,
and other service providers:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">options/</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">options/</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">options/</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">restricted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">restricted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">restricted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Outstanding at beginning of Year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,208,592</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6.136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">637,209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11.638</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">208,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.156</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">466,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,209</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Vested restricted stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">104,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">637,209</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11.638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">208,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.156</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">200,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">549,709</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12.954</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">170,500</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.109</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">200,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 7  - SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in">&nbsp;</TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD>The following tables summarize information concerning outstanding
and exercisable options and restricted stock as of December 31, 2017:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options outstanding</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> prices</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> options<BR>
outstanding<BR> at end of<BR> year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> average<BR> remaining<BR> contractual<BR> life</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> options <BR> exercisable</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> average<BR> remaining<BR> contractual<BR> life</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a (Restricted Stock)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1.720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,720,685</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">7.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,617,279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">7.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">731,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,682</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,682</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.370</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">949,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">949,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">680,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">680,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">9.660</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2.83</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">68,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2.83</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,929,617</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,657,461</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">e.</TD><TD>The following table illustrates the effect of share-based
compensation on the statement of operations:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt"><B>(U.S. dollars in thousands)</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2015</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">904</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">571</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">182</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12.6pt; padding-left: 12.6pt">Selling, general and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">155</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,802</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">988</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">337</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>c.</B></TD><TD><B>Private and 144A Offerings</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD>On October 12, 2015, the Company completed a private offering
of 5,649,079 shares of the Company&rsquo;s common stock to Pfizer. See also note 2.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD>On December 7, 2016, the Company exchanged with certain
existing note holders $54.052 million aggregate principal amount of the Company&rsquo;s outstanding 4.50% Convertible Senior Notes
due 2018 for, among other consideration, $40.186 million aggregate principal amount of convertible notes due 2021 (as described
in note 8b) and for 23,846,735 shares of common stock. See also note 8b.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD>On July 24, 2017, the Company entered into a Note Purchase
Agreement with certain institutional investors relating to the private issuance and sale by the Company of $10 million in aggregate
principal amount of its 7.5% secured convertible promissory notes due 2021. The 7.5% convertible notes were issued pursuant to
the base indenture dated December 7, 2016 (the existing 2016 Notes). Concurrently, the Company exchanged with certain existing
note holders $9.0 million aggregate principal amount of the Company&rsquo;s outstanding 4.50% Convertible Senior Notes due 2018
for $8.55 million aggregate principal amount of newly issued 4.50% Senior Convertible Notes due 2022. See also note 8c.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0in"><B>NOTE 8 - CONVERTIBLE
NOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>a.</B></TD><TD><B>4.5% Convertible Notes (&ldquo;2013 Notes&rdquo;)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On September 18, 2013, the Company
completed a private placement of $69.0 million in aggregate principal amount of Senior Convertible Notes (the &ldquo;2013 Notes&rdquo;),
including $9.0 million aggregate principal amount of 2013 Notes related to the initial purchaser&rsquo;s over-allotment option,
which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture with The
Bank of New York Mellon Trust Company, N.A., as trustee, governing the 2013 Notes. The 2013 Notes accrue interest at a rate of
4.50% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. In December
2016, $54.1 million aggregate principal amount of 2013 Notes were exchanged for 2016 Notes and shares of common stock (see also
note 8b) and in July 2017, $9.0 million aggregate principal amount of 2013 Notes were exchanged for 2017 Notes as defined in note
8c (see also note 8c). Accordingly, $5.9 million aggregate principal amount of 2013 Notes remain outstanding as of December 31,
2017. The 2013 Notes mature on September 15, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Holders may convert their 2013
Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion
rate for the 2013 Notes is 173.6593 shares of the Common Stock for each $1,000 principal amount of 2013 Notes (equivalent to an
initial conversion price of approximately $5.76 per share of the Common Stock). Upon conversion, the Company will deliver a number
of shares of Common Stock, per $1,000 principal amount of 2013 Notes, equal to the conversion rate. The conversion rate is subject
to adjustment for certain events but will not be adjusted for any accrued and unpaid interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table sets forth
total interest expense recognized for the years ended December 31, 2015, 2016 and 2017 related to the 2013 Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B><I>(U.S. Dollars in thousands)</I></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B><I>&nbsp;</I></B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2015</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -10pt; padding-left: 10pt">Contractual interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,943</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">501</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Amortization of debt issuance costs and debt discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">421</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">71</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,549</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,364</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">572</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-indent: -99.55pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD><B>7.5% Convertible Notes (&ldquo;2016 Notes&rdquo;)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On December 1, 2016, the Company
entered into a note purchase agreement with institutional investors, which held part of the 2013 Notes (the &ldquo;2016 Purchasers&rdquo;),
relating to the sale by the Company of $22.5 million aggregate principal amount of 7.50% Senior Secured Convertible Notes due 2021
in a private placement pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
Concurrently with the consummation of the private placement of the 2016 Notes, the Company entered into a privately negotiated
exchange agreement (the &ldquo;2016 Exchange Agreement&rdquo;) with certain existing note holders identified therein to exchange
$54.1 million aggregate principal amount of the Company&rsquo;s outstanding 2013 Notes for (i) $40.186 million aggregate principal
amount of 2016 Notes, (ii) 23,846,735 shares of Common Stock and (iii) cash, equal to the accrued and unpaid interest on the 2013
Notes and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December 7, 2016.
The issuance of the 2016 Notes and shares in the exchange and the private placement were made in reliance on the exemption from
the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof. The net proceeds from the private placement
were $19.7 million, after deducting the placement agent&rsquo;s fees and the Company&rsquo;s estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In connection with the completion of the exchange
and the private placement, the Company entered into an indenture (the &ldquo;2016 Indenture&rdquo;) with The Bank of New York Mellon
Trust Company, N.A., as trustee, governing the 2016 Notes. The 2016 Notes accrue interest at a rate of 7.50% per year, payable
semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2017. A portion of the interest payable may
be made in shares of Common Stock at the Company&rsquo;s
election. The Notes will mature on November 15, 2021; provided that all of the then-outstanding 2013 Notes, or any Permitted Refinancing
Indebtedness (as defined in the 2016 Indenture) have been redeemed, repurchased, otherwise retired, discharged in accordance with
their terms or converted into common stock of the Company, or have been effectively discharged, in each case on or prior to June
16, 2018 or the scheduled maturity date of the 2013 Notes (or any Permitted Refinancing Indebtedness incurred in respect thereof)
is extended to a date that is after February 15, 2022, otherwise the 2016 Notes will mature on June 15, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 8  - CONVERTIBLE NOTES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">On July 24, 2017, the Company
entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by
the Company of $10.0 million in aggregate principal amount of its 2016 Notes. The 2016 Notes were issued pursuant to the 2016 Indenture
dated (December 7, 2016). The net proceeds from this purchase agreement were $9.5 million, after deducting the Company&rsquo;s
offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">Holders may convert their 2016
Notes at any time. The initial conversion rate for the 2016 Notes is 1,176.4706 shares of the Common Stock for each $1,000 principal
amount of 2016 Notes (equivalent to an initial conversion price of approximately $0.85 per share of the Common Stock). Upon conversion,
the Company may settle the 2016 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination
thereof, at the Company&rsquo;s election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">During 2017, approximately $13.6
million aggregate principal amount of the Company&rsquo;s 2016 Notes were converted. Settlement of the
conversions resulted in the issuance of 8,827,624 shares of Common Stock and cash payments of approximately $11 million, in the
aggregate. A total of $59.1 million aggregate principal amount of the 2016 Notes remains outstanding as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">Prior to the maturity date, the
Company may redeem in cash:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 18pt">a)</TD><TD>any or all of the 2016 Notes if the last reported sale price of the common stock for at least 20 trading days (whether or not
consecutive) during the period of 30 consecutive trading days exceeds 150% of the conversion price on each applicable trading day,
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 18pt">b)</TD><TD>all of the 2016 Notes then outstanding if the aggregate principal amount of the 2016 Notes then outstanding is less than 15%
of the aggregate principal amount of the notes issued.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">No redemption was made during
the years 2016 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The 2016 Notes are guaranteed by
the Restricted Subsidiaries (as defined in the 2016 Indenture) and are secured by a first-priority security interest in all of
the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &ldquo;Collateral&rdquo;), including,
but not limited to, (i) 100% of the capital stock of the Guarantors (as defined in the 2016 Indenture) and each Restricted Subsidiary
of the Company that is held by the Company or any Restricted Subsidiary, (ii) intellectual property, including all copyrights,
copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary
information, including, but not limited to, domain names, (iii) all cash, deposit accounts, securities accounts, commodities accounts
and contract rights, (iv) all real property and leased property, subject to applicable minimum thresholds, as set forth in the
2016 Indenture, and (v) all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such
liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United
States, and with Altshuler Shaham Trusts Ltd., as security trustee in Israel. The 2016 Indenture restricts the ability of the Company,
the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&rsquo;s assets that
constitute collateral securing the 2016 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 8  - CONVERTIBLE NOTES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Upon (i) the occurrence of a fundamental
change (as defined in the 2016 Indenture) or (ii) if the Company calls the 2016 Notes for redemption as described below (either
event, a &ldquo;make-whole fundamental change&rdquo;) and a holder elects to convert its 2016 Notes in connection with such make-whole
fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the
&ldquo;Additional Shares&rdquo;). In no event will the conversion rate exceed the maximum conversion rate, which is 1,787.3100
shares per $1,000 principal amount of 2016 Notes, which amount is inclusive of repayment of the principal of the 2016 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">If a fundamental change occurs at
any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2016 Notes,
or any portion of the principal amount thereof, that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on
a date of the Company&rsquo;s choosing that is not less than 20 calendar days nor more than 35 calendar days after the date of
the applicable fundamental change company notice. The price the Company is required to pay for a 2016 Note is equal to 100% of
the principal amount of such 2016 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">For accounting purposes, since the
terms of the 2013 Notes and the 2016 Notes are substantially different, the 2016 Exchange Agreement was considered as an extinguishment,
which in essence means recording a gain due to the 2013 Notes that were exchanged for the 2016 Notes recorded at fair value as
of the closing date. The gain on extinguishment of $14.1 million was recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">As the settlement upon conversion
was subject to compliance with the listing standards of the NYSE American, until the Company&rsquo;s stockholders&rsquo; approval
was obtained, the Company was prohibited by these rules from issuing shares in excess of 20% of its outstanding shares (calculated
as of December 1, 2016). The accounting guidance assumed that the conversion will be settled in cash and, as such, is precluded
from equity classification for any part of the 2016 Notes that may have cash settlement. As such, that part of the conversion feature
was accounted for as a derivative which is bifurcated from the debt host contract and was measured at fair value through the statement
of operations until the Company&rsquo;s stockholders approved, in April 2017, the issuance of shares in excess of 20% of its outstanding
shares. On April 12, 2017, the Company&rsquo;s stockholders approved the issuance of shares of the Company&rsquo;s Common Stock
in excess of 20% of the Company&rsquo;s outstanding shares of Common Stock to settle conversion requests and pay interest on the
Company&rsquo;s issued 7.5% convertible notes. As a result, the Company reclassified the embedded derivative to additional paid
in capital. During 2017, the measurement of the derivative resulted in a non-cash charge to the Company&rsquo;s statement of operations
of $38,061 thousand. The conversion feature of the 7.5% convertible notes issued in July 2017 is accounted for as equity, which
is bifurcated from the debt host contract. With respect to the remainder of the 2016 Notes, for which the conversion feature qualifies
for equity classification (since upon conversion the Company at its election may settle the 2016 Notes by paying cash, shares of
Common Stock or a combination of cash and shares of Common Stock) separate liability (debt) and equity (conversion option) components
of such 2016 Notes were recorded. The Company measures the liability according to amortized cost using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company prepared a valuation
of the fair value of the 2016 Notes (a Level 3 valuation) for the issuance dates. The value of the 2016 Notes was estimated by
implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were
used:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 7, 2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">July 24, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-indent: -10pt; padding-left: 10pt">Stock price (USD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Expected term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.86</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.74</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54.12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63.79</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.98</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.56</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8  - CONVERTIBLE NOTES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table sets forth total interest expense
recognized related to the 2016 Notes:<BR>
<BR>
</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-style: italic"><B>(U.S. Dollars in thousands)</B></TD><TD STYLE="font-weight: bold"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -10pt; padding-left: 10pt">Contractual interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">313</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,434</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Debt discount amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Gain on extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,063</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in fair value of convertible note embedded derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,061</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest payment in connection with conversions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,918</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income in connection with conversions</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,643</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,130</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">47,079</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>c.</B></TD><TD><B>4.5% Convertible Notes Due 2022 (&ldquo;2017 Notes&rdquo;)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On July 24, 2017, the Company entered into a privately
negotiated exchange agreement (the &ldquo;2017 Exchange Agreement&rdquo;) with certain existing note holders identified therein
to exchange $9.0 million aggregate principal amount of the Company&rsquo;s outstanding 2013 Notes for (i) $8.55 million aggregate
principal amount of the Company&rsquo;s 4.5% convertible promissory notes due 2022, (ii) $275,000 in cash consideration and (iii)
cash, equal to the accrued and unpaid interest on the exchanged 2013 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As the terms of the 2013 Notes and the 2017 Notes
are substantially different, the 2017 Exchange Agreement was considered an extinguishment of debt, which in essence means recording
a loss due to the 2013 Notes that were exchanged for the 2017 Notes recorded at fair value as of the closing date. The Company
recognized a loss of $1.3 million due to the extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company prepared a valuation
of the fair value of the 2017 Notes (a Level 3 valuation) for the issuance date. The value of the 2017 Notes was estimated by implementing
the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">July 24, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-indent: -10pt; padding-left: 10pt">Stock price (USD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Expected term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.78</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62.68</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.21</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company accounts for the convertible notes as
a liability, on an aggregated basis, in their entirely. The debt discount and debt issuance costs are deferred and amortized over
the applicable convertible period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">All of the 2017 Notes were converted
during the year ended December 31, 2017 into 11,239,641 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The following table sets forth total interest expense
recognized related to the 2017 Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt"><B>(U.S. Dollars in thousands)</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; text-indent: -10pt; padding-left: 10pt">Contractual interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">55</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Debt premium amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Loss on extinguishment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,325</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0in"><B>NOTE 9 - FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company discloses fair value measurements for
financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to
transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the convertible notes derivative
is based on level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the remaining $5.9 million 2013
Notes and the $59.1 million 2016 Notes as of December 31, 2017 is approximately $5.7 million and $76.6 million, respectively, based
on a level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company prepared a valuation of the fair value
of the 2013 Notes and the 2016 Notes (a Level 3 valuation) as of December 31, 2017. The value of these notes were estimated by
implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were
used:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013 Notes</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016 Notes</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-indent: -10pt; padding-left: 10pt">Stock price (USD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.6612</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.6612</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Expected term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.88</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.66</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.08</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79.57</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68.89</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.86</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.89</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 10 - TAXES ON INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>a.</B></TD><TD><B>The Company</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Protalix BioTherapeutics, Inc. is taxed according
to U.S. tax laws. The Company&rsquo;s income is taxed in the United States at the rate of up to 39%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">On December 22, 2017, President Trump signed into
law the Tax Cuts and Jobs Act, which among other changes reduces the federal corporate tax rate to 21%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 10  - TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>b.</B></TD><TD><B>Protalix Ltd.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Israeli Subsidiary is taxed according to Israeli
tax laws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD><B>Tax rates</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The income of the Israeli Subsidiary, other than income
from &ldquo;Approved Enterprises,&rdquo; is taxed in Israel at the regular corporate tax rates which were 26.5% for fiscal year
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In January 2016, the Law for the Amendment of the
Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter,
from 26.5% to 25%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In December 2016, the Economic Efficiency Law (Legislative
Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction
in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017
at 24%. As a result, the corporate tax rate was 24% in 2017 and will be 23% in 2018 and thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Capital gain is subject to capital gain tax according
to the corporate tax rate for the year during which the assets are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD><B>The Law for the Encouragement of Capital Investments,
1959 (the &ldquo;Encouragement of Capital Investments Law&rdquo;)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under the Encouragement of Capital Investments Law,
including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &ldquo;Approved
Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; status the Israeli Subsidiary is entitled to various tax benefits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD><B>Reduced tax rates</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Income derived from the Approved Enterprise during
a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the
maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary has an &ldquo;Approved Enterprise&rdquo;
plan since 2004 and &ldquo;Benefited Enterprise&rdquo; plan since 2009. The period of benefits in respect of the main enterprise
of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">If the Israeli Subsidiary subsequently pays a dividend
out of income derived from the &ldquo;Approved Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; during the tax exemption
period, it will be subject to  tax on the gross amount distributed (including the company tax on these amounts), at the rate which
would have been applicable had such income not been exempted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD><B>Accelerated depreciation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery
and equipment used by the Approved Enterprise and the Benefited Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 10  - TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD><B>Conditions for entitlement to the benefits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary&rsquo;s entitlement to the
benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply
with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to
refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to
its &ldquo;Approved Enterprise&rdquo; from the Investment Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD><B>Amendment of the Law for the Encouragement of Capital
Investments, 1959</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In recent years, several amendments have been made to the Encouragement
of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Encouragement of Capital Investments Law was amended as
part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010. The amendment
sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.
On December 29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit
tracks, inter alia, &ldquo;Preferred Technological Enterprise&rdquo; and &ldquo;Special Preferred Technological Enterprise&rdquo;
(the &ldquo;Capital Investments Law Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Company elected not to have the Capital Investments Law Amendment apply to the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>c.</B></TD><TD><B>Tax losses carried forward to future years</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">As of December 31, 2017, the Company had
aggregate net operating loss (&ldquo;NOL&rdquo;) carry-forwards equal to approximately $207 million that are available to
reduce future taxable income as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD><B>The Company</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company&rsquo;s carry-forward NOLs, equal to approximately $23 million (as of December 31, 2016, approximately $20 million), may be restricted under Section 382
of the Internal Revenue Code (&ldquo;IRC&rdquo;). IRC Section 382 applies whenever a corporation with NOL experiences an
ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a
pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity
multiplied by the IRC long-term tax exempt rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD><B>Protalix Ltd.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">At December 31, 2017, the Israeli Subsidiary had
approximately $184 million (as of December 31, 2016, approximately $133 million) of carry-forward NOLs that are available to
reduce future taxable income with no limited period of use.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>d.</B></TD><TD><B>Deferred income taxes:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">The components of the Company&rsquo;s
net deferred tax assets at December 31, 2016 and 2017 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B>(U.S. dollars in thousands)</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In respect of:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: justify; padding-left: 12.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Timing
    Differences</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,520</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,335</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 12.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net operating
    loss carry forwards</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,515</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,033</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(42,035</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(58,368</FONT></P></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Deferred taxes are computed using
the tax rates expected to be in effect when those differences reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 10  - TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>e.</B></TD><TD><B>Reconciliation of the theoretical tax expense to actual
tax expense</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The main reconciling item between the statutory tax
rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry
forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>f.</B></TD><TD><B>Tax assessments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In accordance with the Income Tax Ordinance, as of
December 31, 2017, all of Protalix Ltd.&rsquo;s tax assessments through tax year 2012 are considered final.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">A summary of open tax years by major jurisdiction
is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; border-bottom: Black 1pt solid"><B>Jurisdiction:</B></TD>
    <TD STYLE="width: 9%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 39%; text-align: center; border-bottom: Black 1pt solid"><B>Years:</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Israel</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2013-2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>United States (*)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2013-2017</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">(*) Includes federal, state and local (or similar
provincial jurisdictions) tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0in"><B>NOTE 11 - SUPPLEMENTARY FINANCIAL
STATEMENT INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>Balance sheets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B>(U.S. dollars in thousands)</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -26.45pt; padding-left: 26.45pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 0.75in; text-align: left; text-indent: -0.125in">Institutions</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">394</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">State of Israel (see note&nbsp;6a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">623</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Assets of discontinued operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Sundry</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,648</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,934</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B>(U.S. dollars in thousands)</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accruals &ndash; other:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in; width: 74%">Payroll and related expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Interest payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">645</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Provision for vacation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Royalties payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Property and equipment suppliers</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">526</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,496</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,310</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>Statements of operations:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B><I>(U.S. dollars in thousands)</I></B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in; width: 61%">Pfizer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,226</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12,181</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.75in; text-align: left; text-indent: -0.125in">Brazil</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,364</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,973</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,364</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,199</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,242</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B></B></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 12 - DISCONTINUED OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">As mentioned in note 2, the Company
accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with
ASU No.&nbsp;2014-08.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The following summarizes financial information related
to the Company&rsquo;s discontinued operations, in the Company&rsquo;s consolidated statements of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B>(U.S. dollars in thousands)</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">48,674</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT (LOSS)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,025</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(586</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt">Less &ndash;reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">545</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>SELLING, GENERAL AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">EXPENSES</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,420</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GAIN ON THE DISPOSAL</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,899</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET (LOSS) INCOME</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">85,319</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 13 - RELATED PARTY TRANSACTIONS</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><B><I>(U.S. dollars in thousands)</I></B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in">Compensation (including share based compensation) <BR>to the non-executive directors (includes the <BR>interim Chairman of the Board through 2015 and <BR>the Chairman of the Board for part of 2015)</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">631</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">560</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">499</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 108; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>tv486893_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><U>Exhibit 10.16</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><U>EXECUTION VERSION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Portions of this exhibit have been omitted
pursuant to a request for confidential treatment pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). The omitted portions,
marked by [***], have been separately filed with the Securities and Exchange Commission.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>by and between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHIESI FARMACEUTICI S.p.A.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>October 17, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 13%; padding-left: 0">Section 1.</TD>
    <TD STYLE="width: 79%">DEFINITIONS</TD>
    <TD STYLE="width: 8%; text-align: right; vertical-align: bottom">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0">Section 2.</TD>
    <TD>LICENSE</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.1</TD>
    <TD>Exclusive License</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.2</TD>
    <TD>Other License Provisions</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.3</TD>
    <TD>Non-Assertion of Rights</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.4</TD>
    <TD>Sublicensing and Subcontracting</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.5</TD>
    <TD>New Indications</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.6</TD>
    <TD>Patent Challenges</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">2.7</TD>
    <TD>No Implied License</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0">Section 3.</TD>
    <TD>DEVELOPMENT, REGULATORY APPROVALS AND MARKETING</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.1</TD>
    <TD>Development Plan</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.2</TD>
    <TD>Development Responsibilities</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.3</TD>
    <TD>Steering Committee</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.4</TD>
    <TD>Records</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.5</TD>
    <TD>Diligence</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.6</TD>
    <TD>Regulatory Affairs</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.7</TD>
    <TD>Commercialization and Pricing</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.8</TD>
    <TD>Early Access Programs</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.9</TD>
    <TD>Trademarks</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.10</TD>
    <TD>Use of Names</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">3.11</TD>
    <TD>[***]</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0">Section 4.</TD>
    <TD>MANUFACTURE AND SUPPLY.</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.1</TD>
    <TD>Commercial Supply of Licensed Product</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.2</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.3</TD>
    <TD>Protalix Manufacturing Activities</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.4</TD>
    <TD>Compliance of Third Parties</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.5</TD>
    <TD>Forecasting and Ordering</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.6</TD>
    <TD>Pricing, Invoicing and Supply Price Reconciliation</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.7</TD>
    <TD>Shipping and Delivery</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.8</TD>
    <TD>Certificate of Analysis; Acceptance and Returns</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.9</TD>
    <TD>Product Specification and Manufacturing Changes</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.10</TD>
    <TD>Labeling</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.11</TD>
    <TD>Shortages</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.12</TD>
    <TD>Safety Stock Obligations</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">4.13</TD>
    <TD>[***]</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">4.14</TD>
    <TD>Failure to Supply</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0">Section 5.</TD>
    <TD>FINANCIAL PROVISIONS</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">5.1</TD>
    <TD>Effective Date Payment</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">5.2</TD>
    <TD>Event Milestone Payments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">5.3</TD>
    <TD>Development Costs</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0">Section 6.</TD>
    <TD>ACCOUNTING AND PROCEDURES FOR PAYMENT</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">6.1</TD>
    <TD>Periodic Reporting and Reconciliation Payments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">48</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in">[***] Redacted
pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 13%; padding-left: 0.375in">6.2</TD>
    <TD STYLE="width: 79%">Currency</TD>
    <TD STYLE="width: 8%; text-align: right; vertical-align: bottom">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">6.3</TD>
    <TD>Method of Payments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">6.4</TD>
    <TD>No Set-Off</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">6.5</TD>
    <TD>Interest for Late Payments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">6.6</TD>
    <TD>Inspection of Records</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">6.7</TD>
    <TD>Tax Matters</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Section 7.</TD>
    <TD>PATENTS AND INFRINGEMENT</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">7.1</TD>
    <TD>Filing and Prosecution</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">7.2</TD>
    <TD>Correspondence</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">7.3</TD>
    <TD>Maintenance</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">7.4</TD>
    <TD>Notices</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">7.5</TD>
    <TD>Interpretation of Patent Judgments</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">7.6</TD>
    <TD>Third Party Royalty Obligations</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">7.7</TD>
    <TD>Third-Party Infringement</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">7.8</TD>
    <TD>Other Actions by a Third Party</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">7.9</TD>
    <TD>Patent Marking</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Section 8.</TD>
    <TD>CONFIDENTIALITY; PUBLICATION</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">8.1</TD>
    <TD>Confidentiality</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">8.2</TD>
    <TD>Permitted Disclosures</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">8.3</TD>
    <TD>Terms of Agreement</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">8.4</TD>
    <TD>Mandatory Disclosure</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">56</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">8.5</TD>
    <TD>Publication</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">57</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">8.6</TD>
    <TD>Publicity.</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">57</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">8.7</TD>
    <TD>Filing, Registration or Notification of the Agreement</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Section 9.</TD>
    <TD>REPRESENTATIONS, WARRANTIES AND COVENANTS</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">9.1</TD>
    <TD>Mutual Representations, Warranties and Covenants</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">9.2</TD>
    <TD>Additional Representations, Warranties and Covenants of Protalix</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">9.3</TD>
    <TD>Additional Representation and Warranty of Chiesi</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">9.4</TD>
    <TD>Disclaimer of Warranty</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0in">Section 10.</TD>
    <TD>NON-COMPETITION</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">10.1</TD>
    <TD>Chiesi Non-Compete</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0in">Section 11.</TD>
    <TD>TERM</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Section 12.</TD>
    <TD>TERMINATION</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">12.1</TD>
    <TD>Termination Rights</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">12.2</TD>
    <TD>Continuing and Accrued Obligations</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">12.3</TD>
    <TD>Effects of Termination</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">12.4</TD>
    <TD>Following termination of this Agreement</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0in">Section 13.</TD>
    <TD>INDEMNIFICATION AND INSURANCE</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">13.1</TD>
    <TD>Indemnification by Chiesi</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">13.2</TD>
    <TD>Indemnification by Protalix</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">13.3</TD>
    <TD>Indemnification of Product Liability Claims</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">13.4</TD>
    <TD>Defense Procedures; Procedures for Third Party Claims</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">13.5</TD>
    <TD>Insurance</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">13.6</TD>
    <TD>Disclaimer of Liability for Consequential Damages</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">13.7</TD>
    <TD>Sole Remedy</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">71</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in; width: 13%">Section 14.</TD>
    <TD STYLE="width: 79%">GOVERNING LAW AND JURISDICTION</TD>
    <TD STYLE="width: 8%; text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">14.1</TD>
    <TD>Governing Law</TD>
    <TD STYLE="text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">14.2</TD>
    <TD>Jurisdiction and Dispute Resolution Process</TD>
    <TD STYLE="text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">14.3</TD>
    <TD>Expert Legal Determination</TD>
    <TD STYLE="text-align: right">72</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Section 15.</TD>
    <TD>MISCELLANEOUS</TD>
    <TD STYLE="text-align: right">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.1</TD>
    <TD>Force Majeure</TD>
    <TD STYLE="text-align: right">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.2</TD>
    <TD>Severability</TD>
    <TD STYLE="text-align: right">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.3</TD>
    <TD>Waivers</TD>
    <TD STYLE="text-align: right">74</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.4</TD>
    <TD>Entire Agreements; Amendments</TD>
    <TD STYLE="text-align: right">74</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.5</TD>
    <TD>Survival</TD>
    <TD STYLE="text-align: right">74</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.6</TD>
    <TD>Assignment; Binding Effect</TD>
    <TD STYLE="text-align: right">74</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.7</TD>
    <TD>Independent Contractor</TD>
    <TD STYLE="text-align: right">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.8</TD>
    <TD>Notices</TD>
    <TD STYLE="text-align: right">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.9</TD>
    <TD>Third-Party Beneficiaries</TD>
    <TD STYLE="text-align: right">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.10</TD>
    <TD>Binding Effect</TD>
    <TD STYLE="text-align: right">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.11</TD>
    <TD>Performance by Affiliates</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.12</TD>
    <TD>Counterparts</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.375in">15.13</TD>
    <TD>Headings</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in">15.14</TD>
    <TD>Equitable Remedies</TD>
    <TD STYLE="text-align: right">76</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Exhibits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exhibit A</P></TD>
    <TD STYLE="width: 3%; text-align: left; vertical-align: bottom">&ndash;</TD>
    <TD STYLE="width: 82%; text-align: left; vertical-align: bottom">Protalix Patent Rights</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit B </TD>
    <TD>&ndash;</TD>
    <TD>Third Party Licenses</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit C </TD>
    <TD><FONT STYLE="text-transform: uppercase"><B>&ndash;</B></FONT></TD>
    <TD>Press Release</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit D </TD>
    <TD><FONT STYLE="text-transform: uppercase"><B>&ndash;</B></FONT></TD>
    <TD>Chiesi Anti-Bribery Policy</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit E</TD>
    <TD><FONT STYLE="text-transform: uppercase"><B>&ndash;</B></FONT></TD>
    <TD>Chiesi Code of Ethics and Conduct</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit F</TD>
    <TD><FONT STYLE="text-transform: uppercase"><B>&ndash;</B></FONT></TD>
    <TD>Select Matters</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Schedules</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Schedule 3.1</P></TD>
    <TD STYLE="width: 3%; text-align: left; vertical-align: bottom">&ndash;</TD>
    <TD STYLE="width: 82%; text-align: left; vertical-align: bottom">CONFIDENTIAL &ndash; Draft Development Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Schedule 3.7 </TD>
    <TD>&ndash;</TD>
    <TD>CONFIDENTIAL &ndash; Initial Draft Commercialization Plan</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Exclusive License and Supply Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) dated as of the 17<SUP>th</SUP> day of October, 2017 is made by and between Protalix Ltd.,
a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O. Box
455, Carmiel 20100, Israel (&ldquo;<U>Protalix</U>&rdquo;), and Chiesi Farmaceutici S.p.A., a company incorporated under the laws
of Italy with offices located at Largo F. Belloli, 11/A - 43122 Parma, Italy (&ldquo;<U>Chiesi</U>&rdquo;) (each, a &ldquo;<U>Party</U>&rdquo;
and collectively, the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Protalix owns or otherwise controls
certain patents, patent applications, technology, know-how and scientific and technical information relating to an enzyme replacement
therapy for the treatment of Fabry Disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Chiesi has extensive experience and
expertise in the development and commercialization of drug products, and desires to acquire an exclusive license in the Territory
(as defined below) to such patents, patent applications, technology, know-how and scientific and technical information, upon the
terms and subject to the conditions set forth herein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Protalix desires to grant such license
to Chiesi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the mutual
covenants and agreements provided herein, Protalix and Chiesi hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 1. &nbsp;&nbsp;&nbsp;<U>DEFINITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For purposes of this Agreement, the following
definitions shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Acquisition</U>&rdquo;
means, with respect to Protalix Parent (i) a completed Business Combination Transaction, unless, immediately following such completed
Business Combination Transaction all or substantially all of the individuals and entities who were the beneficial owners of the
outstanding voting securities of Protalix Parent immediately prior to such completed Business Combination Transaction beneficially
own, directly or indirectly (including through one more holding companies or subsidiaries) at least fifty percent (50%) of the
then-outstanding voting securities entitled to vote generally in the election of directors of the corporation or other entity resulting
from such completed Business Combination Transaction (including a corporation or other entity that as a result of such transaction
owns Protalix Parent or all or substantially all of a Protalix Parent&rsquo;s assets either directly or through one or more subsidiaries);
(ii) the acquisition, directly or indirectly, by any Person (other than Chiesi or its Affiliates) of beneficial ownership of at
least fifty percent (50%) or more of the outstanding voting securities of Protalix Parent, or (iii) the acquisition by a Third
Party of all or substantially all of the assets of Protalix or Protalix Parent. As used in this Agreement, &ldquo;voting securities&rdquo;
means any securities of Protalix Parent entitled to vote on the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Additional
Studies</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">[***] Redacted pursuant to confidential
treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Affiliate</U>&rdquo;
means any entity directly or indirectly controlled by, controlling, or under common control with, a Party to this Agreement, but
only for so long as such control shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative
meanings, &ldquo;controlled by&rdquo;, &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means (a) possession,
direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership
of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least fifty-percent (50%)
of the voting securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement)
or other comparable equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership
of voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members
of) an entity&rsquo;s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction
of the management or policies of such entity. With respect to the definition of Protalix Patent Rights and the definition of Protalix
Technology, and with respect to the grant of license rights by Protalix to Chiesi under <U>Section 2</U> in respect of such Protalix
Patent Rights and Protalix Technology, &ldquo;Affiliates&rdquo; of Protalix shall exclude any Third Party that becomes an Affiliate
due to such Third Party&rsquo;s acquisition of Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Alliance
Manager</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Annual
Cap</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.3(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Annual
Net Sales</U>&rdquo; means Net Sales for any Commercial Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Applicable
Rate</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Audit</U>&rdquo;
shall have the meaning assigned to it in <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Average
Sales Price</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Business
Combination Transaction</U>&rdquo; means any tender or exchange offer to Protalix Parent&rsquo;s stockholders, or any other offer
or proposal to Protalix Parent or its stockholders for any merger, consolidation, restructuring, recapitalization or similar transaction
with or involving Protalix Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Business
Day</U>&rdquo; means a day other than a Saturday, Sunday, or bank or other public holiday in New York, New York, Parma, Italy or
Carmiel, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Buy-Back
Payment</U>&rdquo; shall have the meaning assigned to it in <U>Section 12.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Calendar
Quarter</U>&rdquo; means each of the four (4) three (3) month periods commencing on January 1 of any Calendar Year and ending on
(respectively) March 31, June 30, September 30, and December 31 of such Calendar Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Calendar
Year</U>&rdquo; means the twelve (12) month period commencing on January 1 and ending on December 31 of any calendar year; <U>provided</U>
that the first Calendar Year of the Term, shall commence on the Effective Date and end on December 31 of such calendar year and
the last Calendar Year of the Term shall end on the date of expiration or termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means the occurrence of any of the following: (a) any consolidation or merger of a Party with or into
any Third Party, or any other corporate reorganization involving a Third Party, in which those persons or entities that are
stockholders of such Party immediately prior to such consolidation, merger or reorganization own less than fifty percent
(50%) of the surviving entity&rsquo;s voting power immediately after such consolidation, merger or reorganization; (b) a
change in the legal or beneficial ownership of fifty percent (50%) or more of the voting securities of any Party (whether in
a single transaction or series of related transactions) where, immediately after giving effect to such change, the legal or
beneficial owner of more than fifty percent (50%) of the voting securities of such Party is a Third Party; or (c) the sale,
transfer, lease, license or other disposition of all or substantially all of a Party&rsquo;s assets related to this Agreement
in one or a series of related transactions to a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Chiesi
Chair</U>&rdquo; means one of the Chiesi representatives on the Steering Committee designated by Chiesi as Chiesi&rsquo;s chair
for Steering Committee Meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Chiesi
Confidential Information</U>&rdquo; means all information or data of a proprietary or confidential nature relating to the Commercialization
of the Licensed Product in the Field in the Territory, as well as any other information regarding the business, operations, Technology
and Commercialization activities of Chiesi, whether in oral, written, graphic, machine-readable form, or any other form, (provided
that data and information disclosed orally or visually are confirmed in writing by Chiesi within thirty (30) days after the date
of such disclosure), disclosed and/or made available by or on behalf of Chiesi to Protalix, Protalix&rsquo;s Affiliates, and its
and their respective directors, officers, employees, consultants, contractors and agents or otherwise acquired by any such Persons
as a result of or in connection with this Agreement and/or the Parties&rsquo; discussions (whether prior to the execution hereof
or thereafter). Notwithstanding the foregoing, unmarked information and un-confirmed information will be considered Chiesi Confidential
Information under this Agreement if a reasonable person familiar with the Licensed Product and given the nature of information
and the circumstances of disclosure would consider such information to be confidential. Such information shall not be considered
to be Chiesi Confidential Information to the extent that such information is: (a) as of the date of disclosure known to Protalix
or its Affiliates, as demonstrable in any tangible medium in existence at the time of disclosure; or (b) wholly disclosed in published
literature, or otherwise is or becomes generally known to the public through no breach by Protalix of this Agreement; or (c) obtained
by Protalix or its Affiliates from a Third Party free from any obligation of confidentiality to Chiesi; or (d) independently developed
by Protalix or its Affiliates without use of or reference to the Chiesi Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercial
Medical Affairs and Pharmacovigilance</U>&rdquo; has the meaning assigned to it in <U>Section 3.6(d)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercial
Quarter</U>&rdquo; means each of the four (4) consecutive three (3) month periods of each Commercial Year, with the first Commercial
Quarter commencing on first day of such Commercial Year (other than the first Commercial Quarter of the first Commercial Year,
which shall commence on the first day of such Commercial Year, but end on the last day of the subsequent Calendar Quarter, <U>i.e.</U>,
including the period from Launch through the end of the subsequent full Calendar Quarter) and the last Commercial Quarter ending
on the last day of such Commercial Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercial
Year</U>&rdquo; means (a) for the sole purpose of calculating whether an Event Milestone under <U>Section 5.2</U> has been achieved,
the twelve (12) month period commencing on either (i) the Launch date, or (ii) January 1 of the subsequent Calendar Year, if during
such first twelve (12) month period starting from the Launch date, Event Milestone 2 has not been achieved; or (b) for all other
purposes, the period commencing on the Launch Date and ending twelve (12) months after the first day of the subsequent Calendar
Quarter, and (in each case (a) and (b)) any subsequent twelve (12) month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercialization</U>&rdquo;
means any and all activities directed to and including marketing, promoting, advertising, distributing, disposing, offering for
sale, selling, Labelling and Packaging, final product release testing, exporting and importing of a Licensed Product for commercial
sale (to the extent applicable). When used as a verb, &ldquo;<U>Commercialize</U>&rdquo; means to engage in Commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercialization
Plan</U>&rdquo; shall have the meaning set forth in <U>Section 3.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Commercially
Reasonable Efforts</U>&rdquo; means, with respect to the efforts to be expended by a Party with respect to the objective that is
the subject of such efforts, reasonable, good faith efforts and resources to accomplish such objective that such Party would normally
use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the Commercialization
of the Licensed Product in the Field in the Territory by Chiesi, such efforts shall be similar to those efforts and resources consistent
with the usual practice of Chiesi in pursuing the Commercialization of drug products owned by it or to which it otherwise has rights
that are of similar market potential as a Licensed Product in the Territory, taking into account all relevant factors, including
the orphan drug status (if any) of the Licensed Product and other regulatory matters, safety and efficacy matters, product labeling
or anticipated labeling, pricing, present and future market potential, past performance of the Licensed Product, past performance
of Chiesi&rsquo;s own drug products that are of similar market potential (taking into account that the Licensed Product is intended
for the treatment of a rare disease), financial return [***], medical and clinical considerations, present and future regulatory
environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due.
It is anticipated that the level of effort constituting Commercially Reasonable Efforts may change over time. With respect to the
Commercialization of the Licensed Product in the Field in the Territory by Chiesi, such efforts shall include [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Competing
Product</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Compliance
Records</U>&rdquo; shall have the meaning assigned to it in <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Compound</U>&rdquo;
means (a) a plant cell-expressed recombinant form of human alpha-Galactosidase-A, including pegunigalsidase alfa (PRX-102) and
(b) any analogs, derivatives and variants thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Confidential
Information</U>&rdquo; means the Protalix Confidential Information or the Chiesi Confidential Information, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Control</U>&rdquo;
or &ldquo;<U>Controlled</U>&rdquo; means, with respect to any compound, material, information, or intellectual property right,
that a Party owns or has a license to use, commercialize, manufacture, market, distribute or sell, and has the ability to grant
to the other Party access and/or a license or a sublicense (as applicable under this Agreement) to, such compound, material, information,
or intellectual property right as provided for herein without violating (a) the terms of any agreement or other arrangements with
any Third Party existing before or after the Effective Date or (b) any Law applicable to such license or sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Country</U>&rdquo;
means any generally recognized sovereign entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>CMC</U>&rdquo;
means, in respect of a regulatory filing, &ldquo;Chemistry, Manufacturing, and Controls&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Deferred
Milestone</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.2(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Development</U>&rdquo;
or &ldquo;<U>Develop</U>&rdquo; means conducting non-clinical (including pre-clinical studies and CMC activities) and
clinical trials (including the Ongoing Clinical Studies and the Required Studies), collecting, validating and analyzing
pre-clinical and clinical trial data, preparing and submitting any regulatory filings prior to obtaining Regulatory
Approvals, preparing the clinical and Manufacturing portions of any regulatory filing seeking Regulatory Approval (including
portions relating to CMC), and regulatory affairs related to the foregoing. When used as a verb, &ldquo;Develop&rdquo; means
to engage in Development. For clarity, Development does not include any regulatory affairs or commitments in respect of the
Licensed Product in a Country following Regulatory Approval for such Licensed Product in such Country, or any of the
foregoing in connection therewith. When used as a verb, &ldquo;<U>Developing</U>&rdquo; means to engage in Development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Development
Costs</U>&rdquo; means Protalix&rsquo;s fully-loaded costs related to the Development of (and obtaining Regulatory Approval
from the EMA for) the Licensed Product, excluding Patent Costs, and including any (a) direct, out-of-pocket costs and
expenses, including clinical or medical grants, clinical laboratory fees, positive controls and the cost of pre-clinical and
clinical studies conducted and services provided by contract research organizations, and (b) the conduct of clinical studies,
including costs and expenses associated with data management, statistical designs and studies, document preparation and any
and all other costs and expenses associated with preparing and submitting regulatory filings, obtaining (including, solely
with respect to approvals granted upon specific conditions requiring the conduct of specified additional required studies to
maintain such granted Regulatory Approval, maintaining) Regulatory Approval for the Licensed Product, and the conduct of the
clinical Development program for the Licensed Product, including as set out in the Development Plan [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Development
Costs Cap</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Development
Plan</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Direct
Sublicensee Revenue A</U>&rdquo; means all amounts paid or due from Sublicensees to Chiesi or its Affiliates [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Direct
Sublicensee Revenue B</U>&rdquo; means all amounts paid or due from Sublicensees to Chiesi or its [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Drug
Substance</U>&rdquo; means the Compound component of a pharmaceutical drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Drug
Product</U>&rdquo; means unlabeled vials of Licensed Product [***], but not Labeling and Packaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Early
Access Program</U>&rdquo; means any program to provide patients with the Licensed Product prior to Regulatory Approval and prior
to Launch in any Country in the Territory. Early Access Programs include, for example, any named patient programs in the EU and
compassionate use or other expanded access programs in other Countries in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Effective
Date</U>&rdquo; means the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>EMA</U>&rdquo;
means the European Medicine Agency or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>European
Economic Area</U>&rdquo; means&nbsp;the member states of the EU together with Iceland, Norway and Liechtenstein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>European
Union</U>&rdquo; or &ldquo;<U>EU</U>&rdquo; means the Countries that are members of the European Union as of the Effective Date
or that become members of the European Union thereafter, and includes, for the avoidance of doubt, any Countries that as of the
Effective Date, or at any point during the Term thereafter, cease being members of the European Union, but that remain subject
to any applicable Law of the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Event
Milestone</U>&rdquo; shall have the meaning set forth in <U>Section 5.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Event
Milestone 1a</U>&rdquo;, &ldquo;<U>Event Milestone 1b</U>&rdquo;, &ldquo;<U>Event Milestone 2</U>&rdquo;, &ldquo;<U>Event Milestone
3</U>&rdquo;, &ldquo;<U>Event Milestone 4</U>&rdquo;, &ldquo;<U>Event Milestone 5</U>&rdquo;, &ldquo;<U>Event Milestone 6</U>&rdquo;,
&ldquo;<U>Event Milestone 7</U>&rdquo;, &ldquo;<U>Event Milestone 8</U>&rdquo;, &ldquo;<U>Event Milestone 9</U>&rdquo;, and &ldquo;<U>Event
Milestone 10</U>&rdquo; shall each have the meanings assigned to those terms in <U>Section 5.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Event
Milestone 1a Studies</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<U>Event Milestone Payments</U>&rdquo; means the amounts set forth in <U>Section 5.2(a)</U> opposite the respective Event
Milestones, subject to <U>Sections 5.2(b)</U>, <U>5.2(c)</U> and <U>5.2(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Facility</U>&rdquo;
means, as applicable, Protalix&rsquo;s Manufacturing facility and such other facilities used by Protalix (or its Affiliates, licensees,
sublicensees or designees [***]) in the Manufacture or storage of (a) Drug Substance, (b) Drug Product or (c) materials utilized
in the Manufacture of Drug Substance or Drug Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Failure
to Supply</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.14(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Field</U>&rdquo;
means enzyme replacement therapy for the treatment of Fabry Disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Financial
Records</U>&rdquo; shall have the meaning assigned to it in <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Force
Majeure Event</U>&rdquo; shall have the meaning assigned to it in <U>Section 15.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Forecast</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>FTE</U>&rdquo;
shall mean one or more persons allocated on a full-time basis to the Commercialization of the Licensed Product in the Territory
(both at a headquarter and country level, and including, for clarity, any product specialists, key asset managers, sales representatives,
medical science liaisons, or medical, regulatory, market access and marketing personnel).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Manufacturing Practices</U>&rdquo; or &ldquo;<U>GMP</U>&rdquo; means all applicable Good Manufacturing Practices including, (i)
the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the
quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals
and guidelines of good manufacturing practice, (ii) the principles detailed in the U.S. Current Good Manufacturing Practices, 21
C.F.R. Sections 210 and 211, (iii) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing
Practice for Medicinal Products, (iv) the principles detailed in the ICH Q7A guidelines, and (v) the equivalent Laws in any relevant
Country, each as may be amended and applicable from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Governmental
Authority</U>&rdquo; means any court, agency, department, authority or other instrumentality of any national, supra national, state,
county, city or other political subdivision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>ICC
Rules</U>&rdquo; shall have the meaning assigned to it in <U>Section 14.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Included
Sublicensee Revenue</U>&rdquo; means, with respect to a Licensed [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>IND</U>&rdquo;
means&nbsp;(i) an investigational new drug application as defined in 21 CFR 312.3 and all amendments and supplements thereto filed
with the FDA or (ii) an equivalent application filed with any equivalent foreign agency or Governmental Authority including all
documents, data and other information concerning use of an investigational pharmaceutical product which are necessary for gaining
authorization from such equivalent foreign agency or Governmental Authority to ship and use such product in clinical investigations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 13.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 13.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Initial
Forecast</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Initiation</U>&rdquo;
means, with respect to the Phase 1 Clinical Trial for a New Use<I>, </I>the first study-specific screening activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Joint
Legal Counsel</U>&rdquo; shall have the meaning assigned to it in <U>Section 14.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Joint
Legal Opinion</U>&rdquo; shall have the meaning assigned to it in <U>Section 14.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Label</U>&rdquo;
means, with respect to a Licensed Product, all labels and other written, printed, or graphic matter (a) on the Licensed Product
containers or wrappers, or (b) accompanying the Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Labeling
and Packaging</U>&rdquo; means the final product labeling and packaging of the Drug Product, including materials to be inserted
such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying
the Drug Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Launch</U>&rdquo;
with respect to any Country or jurisdiction in the Territory, means the first shipment of a Licensed Product in commercial quantities
for commercial sale by Chiesi, its Affiliates or its Sublicensees to a Third Party in such Country or jurisdiction in the Territory
after receipt of the first Regulatory Approval (and Price Approval and Governmental Authority or Third Party reimbursement approval
where applicable and required) for such Licensed Product in such Country. &ldquo;<U>Launched</U>&rdquo;, when used in respect of
the Licensed Product in a Country, means that the Launch of such Licensed Product has already occurred in such Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Laws</U>&rdquo;
means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or
ordinances of any Governmental Authority, and common law or other legal requirements of any kind, whether currently in existence
or hereafter promulgated, enacted, adopted or amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Licensed
Product</U>&rdquo; means any finished dosage form of a drug product that contains the Drug Substance and either: (a) the manufacture,
sale, offer for sale, importation, or use of which (i) would, absent the license granted by Protalix to Chiesi herein, infringe
at least one Valid Claim of a Protalix Patent Right or (ii) embodies, incorporates or uses Protalix Technology, or (b) is supplied
by Protalix to Chiesi under this Agreement as Drug Product or, after the [***] (subject to Chiesi performing Labeling and Packaging
in respect of such Drug Product and, after [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Long
Range Forecast</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Manufacture</U>&rdquo;
or &ldquo;<U>Manufacturing</U>&rdquo; means all activities related to the manufacturing of the Drug Substance, Drug Product or
Licensed Product (as applicable), and/or any ingredient thereof, including manufacturing for clinical use or commercial sale, in-process
and finished product testing, the final product labeling and packaging of the product, release of product, quality assurance activities
related to manufacturing and release of product and ongoing stability tests and regulatory activities related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Manufacturing
Certificate of Analysis</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.8(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Material
Change</U>&rdquo; shall have the meaning assigned to it in <U>Section 7.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Maximum
Order Quantity</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Minimum
Batch Size</U>&rdquo; means the minimum batch size for Drug Product (as may be updated by Protalix from time to time, in its sole
discretion for any variance of [***] or less, and only with Chiesi&rsquo;s prior consent for any variance of more than [****],
such consent not to be unreasonably withheld, conditioned or delayed), which currently is [***] of Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Minimum
Payment</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>NDA</U>&rdquo;
means a New Drug Application or Biologics License Application (as applicable) filed with the United States Food and Drug Administration
(or any successor agency thereto) with respect to a drug product or an analogous application or filing with any Regulatory Authority
outside of the United States (including any supra-national entity such as the European Union) for the purpose of obtaining approval
to market and sell a drug product in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Negotiation
Period</U>&rdquo; means the ninety (90)-day period beginning on the date as set forth in <U>Section 2.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<U>Net Sales</U>&rdquo; means, with respect to a Licensed Product, the gross amounts invoiced by Chiesi or its Affiliates
for sale of Licensed Product, less the following customary deductions, determined in accordance with GAAP and standard internal
policies and procedures and accounting standards and methods consistently applied throughout Chiesi&rsquo;s organization, to the
extent specifically and solely allocated to such Licensed Product and actually taken, paid, accrued, allowed, included or allocated:
[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>New
Indication</U>&rdquo; means a distinct type of disease or medical condition in humans to which a Licensed Product is directed that
is not the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>New
Use</U>&rdquo; shall have the meaning assigned to it in <U>Section 2.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Notice
of Non-Conformance</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.8(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Ongoing
Clinical Study</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Other
Patent Challenge</U>&rdquo; shall have the meaning assigned to it in <U>Section 2.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Other
Sublicensee Revenue</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Other
Sublicensee Revenue Payment</U>&rdquo; [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Outside
of the Scope Product</U>&rdquo; shall have the meaning assigned to it in <U>Section 7.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Application</U>&rdquo; means any application for a Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Costs</U>&rdquo; means any and all costs and expenses incurred by Protalix in respect of the exercise of any of its rights and
obligations under <U>Section 7</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Rights</U>&rdquo; means Patents and Patent Applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patents</U>&rdquo;
means issued patents, whether domestic or foreign, including all continuations, continuations-in-part, divisions, provisionals
and renewals, and letters of patent granted with respect to any of the foregoing, patents of addition, supplementary protection
certificates, registration or confirmation patents and all reissues, re-examination and extensions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Patent
Ownership Challenge</U>&rdquo; shall have the meaning assigned to it in <U>Section 2.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>PCT</U>&rdquo;
means&nbsp;the Patent Cooperation Treaty, opened for signature June 19, 1970, 28 U.S.T. 7645.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company or
partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Pharmacovigilance
Agreement</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.6(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Phase
1 Clinical Trial</U>&rdquo; means a human clinical trial of the initial Licensed Product that would satisfy the requirements of
21 C.F.R. &sect;&nbsp;312.21(a) or any other equivalent foreign requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Post-Approval
Studies</U>&rdquo; means any pre-clinical or clinical studies for a Licensed Product (or for the Drug Substance therein) commenced
after receipt of Regulatory Approval for such Licensed Product, that are not Required Studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Price</U>&rdquo;
means the price to be charged by Protalix and paid by Chiesi for Drug Product [***] sold by Protalix to Chiesi under this Agreement
as specifically determined in accordance with <U>Section 4.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Price
Approval</U>&rdquo; means, in any Country where a Governmental Authority authorizes reimbursement for, or approves or determines
pricing for, drug products, receipt (or, if required to make such authorization, approval or determination effective, publication)
of such reimbursement authorization or pricing approval or determination (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Product
Specifications</U>&rdquo; means those Manufacturing, performance, quality - control release, and other specifications for Drug
Substance, Drug Product or Licensed Product in the Territory, which are initially as set forth in the applicable Regulatory Approval
for a Licensed Product, as such specifications may be amended from time to time pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Chair</U>&rdquo; means one of the Protalix representatives on the Steering Committee designated by Protalix as Protalix&rsquo;s
chair for Steering Committee Meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Confidential Information</U>&rdquo; means all information or data of a proprietary or confidential nature relating to the
Protalix Technology, Compound or Licensed Product as well as any other information, including proprietary information and
materials, regarding the business, operations, research, Technology and the supply, Manufacture, Development and
Commercialization activities of Protalix, whether in oral, written, graphic, machine-readable form, or any other form,
(provided that data and information disclosed orally or visually are confirmed in writing by Protalix within thirty (30) days
after the date of such disclosure), disclosed and/or made available by or on behalf of Protalix to Chiesi, Chiesi&rsquo;s
Affiliates, and its and their respective directors, officers, employees, consultants, contractors and agents or otherwise
acquired by any such Persons as a result of or in connection with this Agreement and/or the Parties&rsquo; discussions
(whether prior to the execution hereof or thereafter). Notwithstanding the foregoing, unmarked information and un-confirmed
information will be considered Protalix Confidential Information under this Agreement if a reasonable person familiar with
the Licensed Product and given the nature of information and the circumstances of disclosure would consider such information
to be confidential. Such information shall not be considered to be Protalix Confidential Information to the extent that such
information is: (a) as of the date of disclosure known to Chiesi or its Affiliates, as demonstrable in any tangible medium in
existence at the time of disclosure; or (b) wholly disclosed in published literature, or otherwise is or becomes generally
known to the public through no breach by Chiesi of this Agreement; or (c) obtained by Chiesi or its Affiliates from a Third
Party free from any obligation of confidentiality to Protalix; or (d) independently developed by Chiesi or its
Affiliates without use of or reference to the Protalix Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Parent</U>&rdquo; means Protalix Biotherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Patent Rights</U>&rdquo; means all Patent Rights owned or otherwise Controlled by Protalix or any of its Affiliates as of the Effective
Date or at any time during the Term that claim the composition of matter, manufacture or use of the Compound, Drug Substance or
a drug product that contains Drug Substance, including the Patent Rights listed in <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
System Patent Rights</U>&rdquo; means Protalix Patent Rights that relate primarily to the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Trademarks</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Protalix
Technology</U>&rdquo; means any Technology owned or otherwise Controlled by Protalix or any of its Affiliates as of the Effective
Date or at any time during the Term that is necessary or useful for the Development, Manufacture, use or Commercialization of Compound,
Drug Substance or a drug product that contains Drug Substance, including the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<U>Purchase Order</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Quality
Agreement</U>&rdquo; means the Quality Agreement(s) to be entered into between Protalix and Chiesi (which the Parties shall use
Commercially Reasonable Efforts to finalize within one hundred and eighty (180) days from the Effective Date) with respect to the
Drug Product (and, after the [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Reconciliation
Adjustment</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Referent
Person</U>&rdquo; shall have the meaning assigned to it in <U>Section 8.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Registry</U>&rdquo;
shall mean an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified
outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific,
clinical, or policy purposes and meets the requirements of the applicable Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Reimbursed
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.3(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Reimbursing
Party</U>&rdquo; shall have the meaning assigned to it in <U>Section 5.3(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory
Approval</U>&rdquo; means any and all approvals, with respect to any Country, or authorizations (other than Price Approvals) of
a Regulatory Authority, that are necessary for the commercial Manufacture, distribution, use, marketing or sale of a drug product
in such Country, including but not limited to any NDAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory
Authority</U>&rdquo; means, in respect of a particular Country or jurisdiction, the Governmental Authority having responsibility
for granting Regulatory Approvals in such Country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Regulatory
Exclusivity</U>&rdquo; means any rights or protections which are recognized, afforded or granted by a Regulatory Authority in any
Country or region of the Territory, in association with the Regulatory Approval of a Licensed Product, providing such Licensed
Product: (a) a period of marketing exclusivity, during which the Regulatory Authority recognizing, affording or granting such marketing
exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission,
submitted by a Person other than Chiesi, its Affiliates or its Sublicensees seeking to market a drug product in which the Drug
Substance is the primary ingredient, or during which such an application or submission may be reviewed or approved by a Regulatory
Authority, but the product may not be placed on the market or (b) a period of data exclusivity, during which a Person, other than
Chiesi, its Affiliates or its Sublicensees, seeking to market a drug product in which the Drug Substance is the primary ingredient,
is precluded from either referencing or relying upon a Licensed Product&rsquo;s clinical dossier or relying on previous findings
of safety or effectiveness with respect to a Licensed Product to support the submission, review or approval of a marketing authorization
application or similar regulatory submission before the applicable Regulatory Authority. Regulatory Exclusivity shall include rights
conferred in the European Union/European Economic Area pursuant to Section 10.1 of Directive 2001/EC/83 or section 14.11 of Regulation
(EC) No. 726/2004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Required
Registry</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.2(c).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT>[***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[****].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Safety
Stock</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.12(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Safety
Stock Amount</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.12(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Shortage</U>&rdquo;
shall have the meaning assigned to it in <U>Section 4.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Standby
License</U>&rdquo; shall have the meaning assigned to in <U>Section 2.2(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Steering
Committee</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Steering
Committee Meeting</U>&rdquo; shall have the meaning assigned to it in <U>Section 3.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicense</U>&rdquo;
means the grant by Chiesi of a sublicense under, or an agreement of Chiesi not to assert, any of the rights licensed by Protalix
to Chiesi pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicensee</U>&rdquo;
means a Third Party to whom Chiesi has granted a Sublicense in accordance with the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicensee
Net Sales</U>&rdquo; means, with respect to a Licensed Product, the gross amounts invoiced by Sublicensees for sale of Licensed
Product, less the following customary deductions, determined in accordance with GAAP and standard internal policies and procedures
and accounting standards and methods consistently applied throughout such Sublicensee&rsquo;s organization, to the extent specifically
and solely allocated to such Licensed Product and actually taken, paid, accrued, allowed, included or allocated: [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Sublicense
Threshold</U>&rdquo; means
an amount, where [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>System</U>&rdquo;
means Protalix&rsquo;s proprietary protein expression system, ProCellEx&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Technology</U>&rdquo;
means proprietary materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible
or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications,
formulations, formulae, including any intellectual property rights embodying any of the foregoing, but excluding Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Term</U>&rdquo;
shall have the meaning assigned to it in <U>Section 11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Territory</U>&rdquo;
means the entire world, excluding the United States (and its territories and possessions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<U>Third Party</U>&rdquo; means any Person other than Chiesi, Protalix, or any of their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Third
Party Claim</U>&rdquo; shall have the meaning assigned to it in <U>Section 13.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Third
Party License</U>&rdquo; means each license agreement between Protalix and a Third Party pursuant to which or from which Protalix
licenses Protalix Patent Rights or Protalix Technology, including those listed on <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Top
5 EU</U>&rdquo; means each of the following Countries: [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.152&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>United
States</U>&rdquo; or &ldquo;<U>U.S.</U>&rdquo; means the United States of America, its territories and possessions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.153&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.154&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Valid
Claim</U>&rdquo; means (a) a claim of an issued and unexpired Patent (including the term of any patent term extension, supplemental
protection certificate, renewal or other extension) which has not been held unpatentable, invalid or unenforceable in a final decision
of a court or other Governmental Authority of competent jurisdiction from which no appeal may be or has been taken, and which has
not been admitted to be invalid or unenforceable through reissue, re-examination or disclaimer; or (b) a claim of a Patent Application,
which claim has been pending less than seven (7) years from the original priority date of such claim in a given jurisdiction, unless
or until such claim thereafter issues as a claim of an issued Patent (from and after which time the same shall be deemed a Valid
Claim subject to paragraph (a) above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.155&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Yearly
Reconciliation</U>&rdquo; shall have the meaning assigned to it in <U>Section 4.6(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.156&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) &ldquo;include&rdquo;,
&ldquo;includes&rdquo; and &ldquo;including&rdquo; are not limiting and mean include, includes and including, without limitation;
(b) definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (c) references
to an agreement, statute or instrument mean such agreement, statute or instrument as from time to time amended, modified or supplemented;
(d) references to a Person are also to its permitted successors and assigns; (e) references to an &ldquo;Article&rdquo;, &ldquo;Section&rdquo;,
&ldquo;Exhibit&rdquo; or &ldquo;Schedule&rdquo; refer to an Article or Section of, or any Exhibit or Schedule to, this Agreement
unless otherwise indicated; (f) the word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word
&ldquo;shall&rdquo;; and (g) the word &ldquo;any&rdquo; shall mean &ldquo;any and all&rdquo; unless otherwise indicated by context.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>LICENSE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusive
License</U>. Subject to the terms of this Agreement, including <U>Section 2.2</U>, Protalix hereby grants to Chiesi, and Chiesi
hereby accepts, an exclusive (including as to Protalix and its Affiliates, except as set forth in <U>Section 2.2</U>), non-transferable,
license during the Term, solely in the Territory and within the Field, including the right to Sublicense (solely as permitted under
and in accordance with <U>Section 2.4</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under
the Protalix Patent Rights to (i) Commercialize the Licensed Product in the Field in the Territory, (ii) on a non-exclusive basis,
following the completion of [***] (if any), carry out [***] activities with respect to the Licensed Product in the Field in the
Territory, and (iii) seek and obtain Regulatory Approval, Price Approval and Governmental Authority or Third Party reimbursement
approval (where applicable and required) for the Licensed Product in the Field in the Territory (in each case, in accordance with
<U>Section 3)</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
use Protalix Technology as necessary to (i) seek and obtain Regulatory Approval, Price Approval and Governmental Authority or Third
Party reimbursement approval (where applicable and required) for the Licensed Product in the Field in the Territory, including
following the transfer contemplated by <U>Section 3.6(c)</U>, to prepare and submit any regulatory filings and communicate with
Regulatory Authorities with respect to the Licensed Product in the Field in the Territory (in each case, in accordance with <U>Section
3)</U>, (ii) following completion of the transfers contemplated by <U>Section 3.6(d)(iv)</U>, on a non-exclusive basis, carry out
its Commercial Medical Affairs and Pharmacovigilance responsibilities, (iii) on a non-exclusive basis, following the completion
of [***] (if any), carry out [***] activities with respect to the Licensed Product in the Field in the Territory, and (iv) Commercialize
the Licensed Product in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
License Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
licenses granted to Chiesi pursuant to <U>Section 2.1</U> shall be co-exclusive with Protalix to the extent it is necessary or
useful for Protalix to perform its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties expressly acknowledge and agree that, the exclusivity grant in favor of Chiesi in <U>Section 2.1</U> shall not be construed
as limiting (i) Protalix&rsquo;s right to Develop or Manufacture the Licensed Product (or the Compound, Drug Substance or Drug
Product for use in the Licensed Product), (ii) Protalix&rsquo;s right to Commercialize the Licensed Product outside of the Field
or outside of the Territory, or (iii) any of Protalix&rsquo;s rights in respect of the Licensed Product (including its rights under
the Protalix Patent Rights) outside of the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of clarity, Chiesi acknowledges that in the event Protalix does not have exclusive rights to Protalix Patent Rights or
Protalix Technology licensed or obtained by Protalix from Third Parties vis &agrave; vis the Third Party licensor, Chiesi&rsquo;s
rights to such Protalix Patent Rights or Protalix Technology under the sublicenses granted under <U>Section 2.1</U> would not be
exclusive vis &agrave; vis the Third Party licensor or its licensees (but would have the same scope of rights licensed or obtained
by Protalix thereunder to the extent such rights are granted to Chiesi by Protalix hereunder and permitted to be granted by Protalix
to Chiesi under such Third Party License).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall use Commercially Reasonable Efforts to obtain an agreement between Chiesi and such Third Party licensor pursuant to which,
in the event that the applicable Third Party License is terminated for any reason, such Third Party licensor would grant Chiesi
a license to the Protalix Patent Rights or Protalix Technology (as applicable) that Protalix has licensed from that Third Party
licensor to the extent included in, and solely for the purpose of, the license granted to Chiesi hereunder (each such agreement,
a &ldquo;<U>Standby License</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Assertion
of Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term, Chiesi shall not, and shall cause its Affiliates not to, assert any Patent Rights or Technology owned or Controlled by
Chiesi and its Affiliates against Protalix, its Affiliates or permitted sublicensees for (i) exercising its rights and performing
its obligations pursuant to this Agreement or (ii) using, making, having made, selling, offering for sale, supplying, causing to
be supplied and importing the Drug Substance or Licensed Product outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
covenant not to sue in <U>Section 2.3(a)</U> shall inure to the benefit of any permitted assignee of this Agreement pursuant to
<U>Section 15.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term, Protalix shall not, and shall cause its Affiliates not to, assert any Protalix System Patent Rights owned or Controlled
by Protalix and its Affiliates against Chiesi, its Affiliates or permitted Sublicensees for exercising its rights and performing
its obligations pursuant to and in accordance with this Agreement and the license granted herein. Such covenant not to sue shall
inure to the benefit of any permitted assignee of this Agreement pursuant to <U>Section 15.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing
and Subcontracting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
may only grant Sublicenses to (i) its Affiliates, which Sublicense shall automatically terminate when such Affiliate ceases to
be an Affiliate of Chiesi, and (ii) reputable Third Parties [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Sublicense granted by Chiesi pursuant to <U>Section 2.4(a)</U> shall be subject and subordinate to the terms and conditions of
this Agreement and shall contain terms and conditions consistent with, and at least as protective of Protalix, the Protalix Patent
Rights, the Protalix Technology and the Protalix Confidential Information as, those set forth in this Agreement, and shall not
in any way diminish, reduce or eliminate any of Chiesi&rsquo;s obligations under this Agreement. Without limiting the foregoing,
each Sublicense agreement with permitted Sublicensees shall contain the following provisions: (i) a requirement that such Sublicensee
submit applicable sales or other reports consistent with the requirements set forth in <U>Section 6.1</U>, (ii) a requirement to
keep books and records, and permit Protalix to audit (either directly or through an independent auditor) such books and records,
consistent with the requirement set forth in <U>Section 6.6</U>, (iii) a requirement that such Sublicensee comply with the confidentiality
and non-use provisions of <U>Section 8</U> with respect to both Parties&rsquo; Confidential Information, (iv) a requirement to
comply with all other applicable terms of this Agreement, and (v) a provision prohibiting such Sublicensee from further sublicensing
the rights granted to it under the Sublicense. Chiesi shall provide Protalix with a copy of each such Sublicense agreement within
thirty (30) days after the execution thereof; <U>provided</U> that Chiesi may redact confidential information from such Sublicense
agreement that is not reasonably necessary to demonstrate Chiesi&rsquo;s compliance with the obligations set forth in this Agreement,
including this <U>Section 2.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
to Subcontract</U>. Each Party may, subject to <U>Section 4.3</U> and <U>Section 8</U>, subcontract its rights and obligations
under this Agreement to an Affiliate or Third Party as it would in the normal course of its business without the prior written
consent of the other Party, except that Chiesi may not subcontract to any Third Party (including sub-distributors and contract
sales organizations), without the prior written consent of Protalix, such consent not to be unreasonably delayed, withheld or conditioned,
its rights or obligations to promote the Licensed Product (and the majority of the members of Chiesi&rsquo;s sales force shall
be employees of Chiesi or its Affiliate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liability
for Affiliates, Sublicensees and Subcontractors</U>. Each Party shall ensure that each of its Affiliates, permitted Sublicensees
(in the case of Chiesi) and permitted subcontractors accepts and complies with all of the applicable terms and conditions of this
Agreement as if such Affiliates or permitted Sublicensees or subcontractors were Parties to this Agreement and each Party shall
remain fully responsible and fully liable for its Affiliates&rsquo; and permitted Sublicensees&rsquo; or subcontractors&rsquo;
performance under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Indications</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall notify the Steering Committee, at least every six (6) months during the Term, of any material updates with respect to any
material Development activities, with respect to the Licensed Product for a New Indication (a &ldquo;<U>New Use</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Challenges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term of this Agreement, Chiesi and its Affiliates hereby covenant and agree not to, directly or indirectly, commence any legal
proceeding, or to, directly or indirectly, provide support or assistance in respect of any legal proceeding commenced by a Third
Party, that challenges the ownership of any Protalix Patent Right, including any Protalix System Patent Right, to the extent such
Protalix Patent Right relates to the Compound or Licensed Product or the Development, Manufacture or Commercialization of the Compound
or Licensed Product (a &ldquo;<U>Patent Ownership Challenge</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Chiesi, its Affiliate or Sublicensee directly or indirectly commences (or provides any support or assistance in respect of) any
Patent Ownership Challenge or any Other Patent Challenge, Protalix shall have the right to immediately terminate this Agreement
by written notice effective upon receipt by Chiesi. The foregoing right of Protalix to terminate this Agreement shall not apply
to any such challenge that arises out of or is in connection with any legal action commenced by Protalix against Chiesi, in which
Protalix asserts any Protalix Patent Rights or other Patent Rights against Chiesi, whether arising out of or in connection with
this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of this <U>Section 2.6</U>, the term &ldquo;<U>Other Patent Challenges</U>&rdquo; means any legal proceeding that challenges
the validity or enforceability of any Protalix Patent Right, including any Protalix System Patent Right, to the extent such Protalix
Patent Right relates to the Compound or Licensed Product or the Development, Manufacture or Commercialization of the Compound or
Licensed Product (&ldquo;<U>Other Patent Challenge</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the generality of the foregoing, Chiesi specifically agrees that filing a request for re-examination, knowingly copying
patent claims so as to institute an interference, or filing an opposition with respect to any of the Protalix Patent Rights shall
be deemed an Other Patent Challenge hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Implied License</U>.
Except for the licenses and other rights expressly granted to Chiesi herein, all right, title and interest in and to the Protalix
Patent Rights, Protalix Technology, and Protalix Confidential Information (and all modifications, derivatives and improvements
thereof), and any other rights of Protalix and its Affiliates not expressly granted to Chiesi hereunder (including, for clarity,
all of the foregoing with respect to any Outside of the Scope Products), shall remain solely with Protalix, its Affiliates and
its Third Party licensors, as applicable. To the extent any such rights vest in Chiesi (by operation of Chiesi&rsquo;s exercise
of its step-in rights under <U>Section 3.2(b)</U> or otherwise), then Chiesi shall, and hereby does, irrevocably assign all such
right, title and interest in and to the Protalix Patent Rights, Protalix Technology, and Protalix Confidential Information (and
all modifications, derivatives and improvements thereof) to Protalix, and hereby acknowledges and agrees that any such rights
are and shall remain owned solely by Protalix. Except as expressly provided in this <U>Section 2</U> or elsewhere in this Agreement,
neither Party will be deemed by this Agreement to have been granted any license or other rights to the other Party&rsquo;s intellectual
property rights, either expressly or by implication, estoppel or otherwise. Notwithstanding anything to the contrary in this Agreement,
the Parties acknowledge and agree that the Development and Commercialization of any Outside of the Scope Products (including any
New Uses) shall not be within the scope of the licenses granted to Chiesi pursuant to <U>Section 2</U> hereunder (except as expressly
provided in <U>Section 2.5</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DEVELOPMENT, REGULATORY APPROVALS
AND MARKETING</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Development
Plan</U>. The Development of the Licensed Product in the Field shall be governed by a development plan to be prepared by Protalix
that describes the proposed Development program of the Licensed Product in the Field, including the continuing conduct by Protalix
of each Ongoing Clinical Study (the &ldquo;<U>Development Plan</U>&rdquo;). [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Development
Responsibilities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Clinical
Development by Protalix</U>. Pursuant to the Development Plan, and subject to the oversight of the Steering Committee, Protalix
will be responsible for the Development of the Licensed Product in the Field, including continuing to conduct the Ongoing Clinical
Studies. Protalix will also be responsible for preparing and promptly submitting to Chiesi the clinical sections of any regulatory
filings in respect of obtaining Regulatory Approval with the EMA for the Licensed Product and, subject to Chiesi&rsquo;s approval
rights in respect of such regulatory filing as a whole, Protalix shall consider in good faith any proposed revision reasonably
made by Chiesi thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chiesi
Step-in Right.</U> Notwithstanding <U>Section 3.2(a)</U>, but subject to <U>Section 3.2(f)</U>, in the event of a delay, for reasons
within Protalix&rsquo;s reasonable control (and, for clarity, not for reasons outside Protalix&rsquo;s reasonable control, <U>i.e.</U>,
a Force Majeure Event [***], of more than [***] (as compared to the timelines expressly identified as &ldquo;step-in&rdquo; timelines
in the Development Plan) that occurs in the course of conducting the Ongoing Clinical Studies and/or a Required Study being conducted
by Protalix, Chiesi shall have the right (subject to <U>Section 5.3(g)</U>) to assume responsibility for conducting, or having
conducted on its behalf, and to be the sponsor of, such Ongoing Clinical Studies and/or [***] (as applicable), upon no less than
sixty (60)&nbsp;days&rsquo; prior written notice to Protalix. Promptly following Protalix&rsquo;s receipt of such notice, the Parties
shall cooperate in good faith to develop a written plan for the orderly transfer of responsibility for conducting the Ongoing Clinical
Studies and/or [***] to Chiesi, with due regard for patient safety and the rights of any subjects that are participants in the
Ongoing Clinical Studies and/or the [***], and in compliance with all applicable
Laws and agreements with Third Parties; <U>provided</U>, that Chiesi shall assume sole responsibility for the conduct of, and any
liability arising out of, the conduct of the Ongoing Clinical Studies and/or [***] immediately upon the completion of such transfer,
including responsibility for all Development Costs (subject to <U>Section 5.3(g))</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chiesi&rsquo;s
Regulatory Approval Responsibilities</U>. Except as described in <U>Sections 3.2(a)</U> and <U>3.2(b)</U>, Chiesi shall be responsible
for conducting [***]. For the avoidance of doubt, Chiesi shall be solely responsible for conducting [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chiesi&rsquo;s
Post-Regulatory Approval Responsibilities</U>. Except as described in <U>Sections 3.2(a)</U> and <U>3.2(b)</U>, immediately following
any obtained Regulatory Approval for which Chiesi submitted a regulatory filing in its own name in a given Country in the Territory,
Chiesi will assume sole responsibility for (i) the Commercialization of the Licensed Product in the Field in such Country in the
Territory, and (ii) all post-approval commitments in respect of the Licensed Product in the Field in such Country in the Territory,
including interactions or communications with the applicable Regulatory Authority (subject to <U>Section 3.6(g)</U>), the conduct
of any Post-Approval Studies (subject to <U>Section 5.3(f)</U>), pharmacovigilance reporting (subject to <U>Section 3.6(f)</U>),
medical affairs (subject to <U>Section 3.6(d)(iv)</U>) and related requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibility
for Costs.</U> Each Party&rsquo;s responsibility for paying the costs associated with such Development activities is set forth
in <U>Section 5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights
Outside the Territory.</U> Notwithstanding anything to the contrary herein, Chiesi acknowledges and agrees that, at all relevant
times during the Term, Protalix shall remain the sole and unencumbered owner of any IND, NDA or any other regulatory filing relating
to the Compound, Drug Substance or Licensed Product outside of the Territory. Prior to (and as a condition of) the exercise of
any step-in right under <U>Section 3.2(b)</U>, Chiesi must first take all necessary steps, to the extent required, to ensure that
Protalix remains, and is able to remain, the sole and unencumbered owner of any IND, NDA or any other regulatory filing relating
to the Compound, Drug Substance or Licensed Product outside of the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Steering
Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Formation
and Membership</U>. The Parties shall, within sixty (60) days after the Effective Date, form a steering committee (the &ldquo;<U>Steering
Committee</U>&rdquo;). The Steering Committee shall consist of three (3) representatives appointed by Protalix and three (3) representatives
appointed by Chiesi; <U>provided</U> that at least one (1) person appointed by each Party is a senior officer of such Party, vested
with the appropriate decision-making and resource-allocating authority, and the requisite experience, to participate in discussion
of, and decide on, the matters set out in <U>Section 3.3(c)</U> below. Each Party shall nominate a representative as contact point
to discuss the agenda (such representative, the &ldquo;<U>Alliance Manager</U>&rdquo;), who can be selected or not among the three
members nominated by the Parties as Steering Committee representatives. The Steering Committee shall be chaired by the Protalix
Chair. From time to time, each Party may substitute its representatives on the Steering Committee in its sole discretion (but subject
to the terms of this section), effective upon written notice to the other Party of such change. Additional representatives or consultants
may from time to time, in the Steering Committee&rsquo;s discretion, be invited to attend Steering Committee Meetings, subject
to such representatives&rsquo; and consultants&rsquo; written agreement to comply with the requirements of <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings</U>.
During the Term, the Steering Committee shall meet at least once each Calendar Quarter or as otherwise determined by the Parties
(each such meeting, a &ldquo;<U>Steering Committee Meeting</U>&rdquo;). Upon the reasonable request of the Steering Committee,
Protalix will provide written materials relating to its activities under the Development Plan in advance of a Steering Committee
Meeting. All Steering Committee Meetings may be conducted in person, by videoconference or by teleconference at such times and
such Chiesi or Protalix locations as shall be determined by the Steering Committee Alliance Managers. In-person meetings of the
Steering Committee shall be held at least once every six (6) months (unless otherwise agreed by the Parties) and will alternate
between appropriate offices of each Party. The Parties shall each bear all expenses of their respective representatives relating
to their participation on the Steering Committee. The members of the Steering Committee also may convene or be polled or consulted
from time to time by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary or
appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibilities</U>.
The Steering Committee shall have the following roles and responsibilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review
and approve any material amendments to the Development Plan (subject to <U>Section 3.3(d)</U>). Any proposed material amendment
to the Development Plan, including arguments to support such amendment, shall be made available to the Steering Committee with
reasonable advance notice and at least five (5) Business Days ahead of the scheduled meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provide
reasonably detailed updates, data and other information regarding Protalix&rsquo;s progress in Developing the Licensed Product
in the Field;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;
provide updates in respect of any New Use in accordance with <U>Section 2.5</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;discuss
the timing of transferring any regulatory filings in the Territory with respect to the Compound, Drug Substance, Drug Product or
Licensed Product from Protalix to Chiesi in accordance with the terms of <U>Section 3.6(c)</U>, and discuss and agree upon appropriate
timelines for, and the responsibilities of each Party in respect of, preparing any regulatory filings for obtaining Regulatory
Approval in any Country in the Territory. As part of such discussions, the Steering Committee shall discuss and agree on appropriate
timelines and processes for the orderly transfer of all medical affairs functions from Protalix to Chiesi in accordance with <U>Section
3.6(d)(iv)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;act
as a forum pursuant to which the Parties will review and discuss plans and strategies relating to (x) the Development of the Licensed
Product in the Field, (y) regulatory matters with respect to the Licensed Product in the Field in the Territory, and (z) Commercialization
of the Licensed Product in the Field in the respective territories of the Parties, to ensure aligned communication at medical congresses
and other scientific events as well as scientific publication plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;modify
the division of regulatory responsibilities as between the Parties in accordance with <U>Section 3.6(d)(v)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the terms of <U>Section 8.5</U>, review and/or approval of each Party&rsquo;s scientific publication plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;oversee
any Early Access Programs for the Licensed Product in the Field in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review
and agree upon the final version of the Initial Commercialization Plan, in accordance with <U>Section 3.7(a)</U>, and review and
provide comment upon any proposed revisions to, or any subsequent versions of, the Commercialization Plan (such comments to be
considered in good faith by Chiesi);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;receiving
from Chiesi reasonably detailed updates, data and other information regarding the status and details of any Price Approvals or
Governmental Authority and Third Party reimbursement approvals in the Territory, in accordance with <U>Section 3.7(c)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to <U>Section 4.8(c)</U>, review and in good faith seek to resolve any disputes regarding any Notice of Non-Conformance issued
in respect of a shipment of Drug Substance or Drug Product under the terms of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to <U>Section 7.6(a)</U>, discuss any pertinent Third Party Patent Rights and decide upon whether a license to or acquisition of
such Third Party Patent Rights or Technology is appropriate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;discuss
the possibility, from time to time, of sharing Licensed Product positioning and promotional materials for the Licensed Product
in the Field, inside and outside the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;define
the manner and timelines for Chiesi&rsquo;s access to sites and records of the Ongoing Clinical Studies and [***] conducted by
Protalix;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;appoint
the Referent Persons in accordance with <U>Section 8.5</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;establish,
if deemed necessary, the creation of a Joint Project Team (&ldquo;<U>JPT</U>&rdquo;) to oversee operations or activities. The composition
of the JPT will be decided by the Steering Committee according to the type of activity and decision making in accordance with <U>Section
3.3(d)</U>. The JPT shall be comprised of representatives from each Party with appropriate competence and level of decision-making
authority. The JPT shall meet with a frequency to be agreed on by the Parties; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;such
other roles and responsibilities provided for in this Agreement or as may be assigned to the Steering Committee in writing by mutual
agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 81pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Decision-Making
by the Steering Committee</U>. All decisions of the Steering Committee made pursuant to this Agreement shall be made by consensus
with each Party having one vote; <U>provided</U>, <U>however</U>, that in the event of a disagreement between Chiesi and Protalix
with respect to any such proposed decision for which another decision-making mechanism is not expressly provided for herein and
subject to the relevant provisions hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 81pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Chiesi Chair shall have the final decision-making authority with respect to (A) Commercialization of the Licensed Product in the
Field in the Territory, (B) regulatory plans and strategies relating to the Licensed Product in the Field in the Territory, (C)
following Launch in a Country, Commercial Medical Affairs and Pharmacovigilance in such Country, and (D) following the transfer
contemplated in <U>Section 3.6(c)</U>, on a Country-by-Country basis, any and all regulatory matters concerning the Licensed Product,
including in respect of any Regulatory Approvals, associated regulatory filings, or post-approval communications with or requirements
of any Regulatory Authorities, subject to the obligation to consider the other Party&rsquo;s comments in good faith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Protalix Chair shall have the final decision-making authority with respect to (A) the Development of the Licensed Product (and
the Ongoing Clinical Studies but not the [***], Registry, Required Registry or [***], which shall be addressed as otherwise expressly
provided herein), including any regulatory matters concerning the Licensed Product prior to the transfers contemplated in <U>Section
3.6(c)</U>, any medical affairs and pharmacovigilance functions prior to the transfers contemplated in <U>Section 3.6(d)</U> (and,
for the avoidance of doubt, any issues relating to the Licensed Product outside the Field or outside the Territory), subject to
the obligation to consider the other Party&rsquo;s comments in good faith, (B) the Protalix Patent Rights and Protalix Technology
and Protalix&rsquo;s rights in or to the Protalix Patent Rights and Protalix Technology, and (C) [***] or other issues relating
to the Licensed Product outside the Territory or outside the Field; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event of a disagreement in respect of a matter unrelated to the subject-matter of <U>Sections 3.3(d)(i)</U> or <U>3.3(d)(ii)</U>,
such matters shall be subject to the escalation and dispute resolution procedures set out in <U>Section 14.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For the avoidance of doubt, to the extent that Protalix, in its
sole discretion, deems it necessary due to a request or demand of a Regulatory Authority (but only where such request is mandatory
or where failure to comply with such request could result in a penalty or actions against Protalix being imposed by such Regulatory
Authority or a violation of applicable Law) or identified and immediate risk to patient safety, Protalix shall have the sole authority
and the exclusive right to decide any matter in respect of the Development of the Licensed Product in the Field (other than with
respect to (i) approving regulatory plans and strategies, and (ii) preparing and submitting regulatory filings and obtaining Regulatory
Approvals after the transfer contemplated in <U>Section 3.6(c))</U> without the approval of or any decision by the Steering Committee;
<U>provided</U>, <U>however</U>, that Protalix shall use its reasonable efforts to provide notice to, and consult with, members
of the Steering Committee, prior to exercising such discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Minutes</U>.
The Alliance Managers will coordinate and alternate in preparing draft of the minutes collecting input from the attendees and distributing
to all members of the Steering Committee the final minutes of each meeting reasonably promptly after a Steering Committee Meeting.
Such minutes will report in reasonable detail actions taken by the Steering Committee during such meeting, issues requiring resolution
and resolutions of previously reported issues. Such minutes will be reviewed and, if reasonably complete and accurate, signed by
one Steering Committee member from each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Records</U>.
During the Term, each Party will prepare and maintain accurate records and books relating to the progress and status of its activities
under the Development Plan and otherwise in relation to the Development of the Drug Substance and Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Diligence</U>.
Subject to Chiesi&rsquo;s compliance with <U>Section 5.3</U>, Protalix will use Commercially Reasonable Efforts to carry out the
Development Plan in order to Develop the Licensed Product in the Field in the Territory. Subject to Protalix&rsquo;s compliance
with <U>Section 3.6(c)</U>, Chiesi will use Commercially Reasonable Efforts to seek as soon as reasonably practicable Regulatory
Approval, Price Approval and Governmental Authority or Third Party reimbursement approval (where applicable) for the Licensed Product
in the Field in the Territory. Chiesi will use Commercially Reasonable Efforts to Launch and Commercialize the Licensed Product
in each such Country in the Territory for which Regulatory Approval is obtained, promptly following such Regulatory Approval of
the Licensed Product in the Field in such Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Affairs</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of Regulatory Filings</U>. Protalix shall provide to Chiesi, at Chiesi&rsquo;s expense, copies in electronic form of any regulatory
filings in the Territory relating to the Licensed Product, including any clinical trial authorizations (including any regulatory
filings in the Territory seeking approval to conduct a study or clinical trial of the Licensed Product), other filings with Regulatory
Authorities, supplements or amendments thereto, written correspondence with Regulatory Authorities regarding such regulatory filings,
and existing written minutes of meetings and memoranda of formal conversations between Protalix (including, to the extent practicable,
Protalix&rsquo;s investigators) and Regulatory Authorities and any other document required to maintain the Regulatory Approvals
(e.g. Trial Master Files) in Protalix&rsquo;s possession (but, for clarity, excluding any informal communications, <U>i.e.</U>,
e-mails) to the extent Protalix has the right to access and provide to Chiesi such materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Responsibilities</U>. Subject to <U>Section 3.3(d)</U>, and prior to the transfer contemplated in <U>Section 3.6(c)</U> below,
Protalix shall, subject to Chiesi&rsquo;s direction and approval (by and through the Steering Committee or otherwise), be responsible
for implementing all pre-Regulatory Approval regulatory plans and strategies for, and making any regulatory filings in respect
of, the Licensed Product in the Field in the Territory (excluding, for the avoidance of doubt, any application to a Regulatory
Authority seeking Regulatory Approval, which shall in each case, be in the name of, and submitted by, Chiesi). Without limiting
the foregoing, following the transfer contemplated in <U>Section 3.6(c)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
(or one or more of its designated Affiliates) will own and be responsible for preparing, seeking, and submitting such regulatory
filings as are necessary to obtain Regulatory Approval and then maintaining all Regulatory Approvals and any post-approval regulatory
filings, for the Licensed Product in the Field in such Country in the Territory, including preparing all reports necessary as part
of such Regulatory Approvals or post-approval regulatory filings. Protalix shall have the right and be responsible to prepare and
promptly submit to Chiesi any non-clinical, clinical and Manufacturing portions (including CMC) of such regulatory filings and
any related reports (subject to Chiesi&rsquo;s approval rights with respect to such regulatory filing as a whole), at Chiesi&rsquo;s
sole cost and expense (unless such costs are Development Costs or other costs expressly addressed hereunder or by a separate agreement
between the Parties, such as in relation to [***] or costs for Event Milestone 1a Studies). Protalix shall consider in good faith
any proposed revision reasonably made by Chiesi thereto and Protalix shall otherwise provide such assistance as Chiesi reasonably
requires, at Chiesi&rsquo;s sole cost and expense (unless such costs are Development Costs or other costs expressly addressed hereunder
or by a separate agreement between the Parties, such as in relation to [***] or costs for Event Milestone 1a Studies), to obtain
Regulatory Approvals for the Licensed Product in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the transfer contemplated in <U>Section 3.6(c)</U>, but in any event, no later than the grant of Regulatory Approval, on a Country-by-Country
basis, Chiesi shall (A) subject to <U>Section 5.3(d)</U>, assume sole responsibility for seeking authorization in respect of, conducting,
and otherwise interacting with Regulatory Authorities in respect of, any Post-Approval Studies, and (B) have the right to apply
for, and secure, exclusivity rights that may be available under the Laws of such Countries in the Territory, including any Regulatory
Exclusivity. Protalix shall reasonably cooperate with Chiesi, and take such reasonable actions to assist Chiesi, at Chiesi&rsquo;s
sole cost and expense, in obtaining such exclusivity rights in each Country, as Chiesi may reasonably request from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For the avoidance of doubt (A) at all relevant times during the
Term, Chiesi shall have the final decision-making authority in respect of all regulatory plans and strategies for the Licensed
Product in the Field in the Territory; <U>provided</U> that Chiesi shall reasonably consider any comments on such plans and strategies
that Protalix may communicate (through the Steering Committee or otherwise); and (B) following a Regulatory Approval in a Country
in the Territory, Chiesi shall be solely responsible for any such activities as are initiated after the date of such Regulatory
Approval that would otherwise constitute Development activities had they been initiated prior to the grant of such Regulatory Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Regulatory Filings</U>. To the extent permitted by applicable Law, at a time to be agreed by and through the Steering Committee
and on a Country-by-Country basis, with such time to be prior to any application to a Regulatory Authority seeking Regulatory Approval
for the Licensed Product in the Field in any Country in the Territory [***], and at Chiesi&rsquo;s sole cost and expense, Protalix
shall assign and transfer to Chiesi Protalix&rsquo;s entire right, title and interest in and to all regulatory filings in such
Country with respect to the Compound, Drug Substance, Drug Product or Licensed Product in the Field, and shall perform all other
actions reasonably requested by Chiesi to effect and confirm such assignment and transfer, at Chiesi&rsquo;s sole cost and expense;
<U>provided</U>, <U>however</U>, that, for the avoidance of doubt, all right, title and interest in and to any clinical trial authorizations
or other clinical regulatory filings as are necessary to support the continued conduct of and completion of the Ongoing Clinical
Studies and any [***] (including as necessary to obtain Regulatory Approval with the EMA or outside the Territory) shall remain
vested in Protalix until completion of such studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Regulatory Responsibilities</U>. Subject to the terms of the Development Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties shall cooperate through the Steering Committee to ensure that any such assignments and transfers under <U>Section 3.6(c)</U>,
do not impede Protalix&rsquo;s ability to conduct and complete the Ongoing Clinical Studies and [***]. After each such assignment
and transfer is effective, Chiesi shall (and does hereby) grant Protalix a right to use and make reference to such regulatory filings
so assigned and transferred (and any subsequent regulatory filings made or Regulatory Approvals in such Countries as are obtained
by Chiesi in respect of the Licensed Product in the Field) as necessary for Protalix (x) to conduct and complete the Ongoing Clinical
Studies and any [***], and (y) to conduct and complete any other clinical studies as necessary for Protalix to complete in order
to file, and to file, for Regulatory Approval for (A) the Licensed Product outside the Territory, or (B) any New Use (or other
drug product containing the Drug Substance outside of the Field) anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
such transfer of ownership of such regulatory filings relating to the Drug Substance (or Drug Product) as incorporated into the
Licensed Product (and for the avoidance of doubt, excluding any regulatory filings and Regulatory Approvals with respect to the
Drug Substance (or Drug Product) as part of any New Use), or Licensed Product in the Field in the Territory, during the Term, all
regulatory filings seeking Regulatory Approval in such Countries in the Territory and all subsequent post-approval regulatory filings
that are filed with the applicable Regulatory Authorities and which pertain to the Drug Substance (or Drug Product) as incorporated
into the Licensed Product (and for the avoidance of doubt, excluding any such regulatory filings with respect to the Drug Substance
(or Drug Product) as part of any New Use), or Licensed Product in the Field, in each case, in the Territory, shall be made in the
name of Chiesi or its Affiliates in accordance with <U>Section 3.6(e)</U>, and any Post-Approval Studies shall be conducted in
the name of, and shall be the sole responsibility of, Chiesi and its Affiliates (subject to <U>Section 5.3(f)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt, Protalix shall remain responsible for the preparation of any non-clinical (including pre-clinical and CMC),
clinical, and Manufacturing portions of regulatory filings submitted by Chiesi seeking Regulatory Approval with the EMA, and shall
otherwise provide reasonable assistance to Chiesi in finalizing such regulatory filings for submission to the applicable Regulatory
Authority (in each case subject to Chiesi&rsquo;s approval rights with respect to the regulatory filing as a whole).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the process of fixing a time for the regulatory transfer contemplated under <U>Section 3.6(c)</U>, and subject to the terms
of the Pharmacovigilance Agreement, on a Country-by-Country basis, the Steering Committee shall also set out a timeline for the
orderly transfer of any pharmacovigilance (for post-Launch Commercialization) and medical affairs functions from Protalix to Chiesi
(as well as the role of primary contact for KOL management and patient advocacy) (such functions, following the completion of such
transfer from Protalix to Chiesi, to be referred to as &ldquo;<U>Commercial Medical Affairs and Pharmacovigilance</U>&rdquo;),
with such medical affairs functions to be fully transferred within twelve (12) months of the Effective Date, but prior to the grant
of Regulatory Approval in such Country, and with such pharmacovigilance functions to be fully transferred upon Launch; <U>provided</U>,
that until such time as each of the Ongoing Clinical Trials and any [***] are completed, and the clinical study reports for each
such clinical study are finalized, Protalix shall retain responsibility for patient safety monitoring, and shall remain the primary
contact with each applicable KOL, in respect of such clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary herein, but subject to the terms of the Pharmacovigilance Agreement, the Steering Committee may by mutual
agreement modify the division of regulatory responsibilities as between the Parties, including by having Protalix retain certain
regulatory responsibilities following the transfer contemplated by <U>Section 3.6(c)</U>, or by having Chiesi assume certain regulatory
responsibilities prior to the transfer contemplated by <U>Section 3.6(c)</U> (including, for the avoidance of doubt, where such
division of responsibilities differs from the terms of the Development Plan); <U>provided</U>, <U>however</U>, that (i) in no circumstances
may Chiesi assume responsibility for or control over any clinical aspects of the Development Plan, including the conduct of the
Ongoing Clinical Studies (except in the case of Chiesi exercising its step-in rights as provided for in <U>Section 3.2</U> or the
conduct by Chiesi of any [***], Additional Studies, Registry, Required Registry or [***] as provided hereunder); and (ii) in any
event, all regulatory responsibilities in respect of the Licensed Product in the Field in the Territory (including, for clarity,
each of the transfers of regulatory responsibility contemplated in this <U>Section 3.6</U>), on a Country-by-Country basis, must
be completely assumed by Chiesi within [***]; <U>provided</U>, that until such time as each of the Ongoing Clinical Trials and
any [***] are completed, and the clinical study reports for each such clinical study are finalized, Protalix shall retain responsibility
for patient safety monitoring, and shall remain the primary contact with each applicable KOL, in respect of such clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights
of Reference and Access to Data</U>. Chiesi shall (and does hereby) grant to Protalix a non-exclusive &ldquo;<U>Right of Reference</U>,&rdquo;
as that term is defined in 21 C.F.R. &sect; 314.3(b), or an equivalent non-exclusive right of access/reference in the United States
and in the EU and in each other Country in the Territory (A) solely for use by Protalix in connection with the Development and/or
Commercialization of any Licensed Product outside of the Territory or any New Use (or other drug product containing the Drug Substance
outside of the Field), to any data in any regulatory filing in the EU or any other Country in the Territory Controlled by Chiesi
that relates to the Drug Substance or Licensed Product, and (B) solely for use by Protalix in connection with the Development of
drug products made using the System, to any safety data (but not efficacy data) in any regulatory filing in the EU or any other
Country in the Territory Controlled by Chiesi that relates to the Drug Substance or Licensed Product. Chiesi shall provide a signed
statement to this effect, if requested by Protalix, in accordance with 21 C.F.R. &sect; 314.50(g)(3) or the equivalent as required
in the EU or any other Country in the Territory, or otherwise provide appropriate notification of such right of Protalix to the
applicable Regulatory Authority. To the extent Chiesi shall need an equivalent &ldquo;<U>Right of Reference</U>,&rdquo; as that
term is defined in 21 C.F.R. &sect; 314.3(b), to exploit the rights granted hereunder in the Territory, Protalix shall (and does
hereby) grant to Chiesi a non-exclusive Right of Reference, or an equivalent non-exclusive right of access/reference in the United
States and in the EU and in each other Country in the Territory, solely for use by Chiesi in connection with the Development and/or
Commercialization of the Licensed Product in the Field in the Territory, and solely if and to the extent that Chiesi is authorized
under this Agreement to conduct such Development and/or Commercialization, (A) to any data in any regulatory filing Controlled
by Protalix that relates to the Drug Substance or Licensed Product, and (B) to any safety data (but not efficacy data) in any regulatory
filing that relates to the Drug Substance or Licensed Product. Protalix shall provide a signed statement to this effect, if requested
by Chiesi, in accordance with 21 C.F.R. &sect; 314.50(g)(3) or the equivalent as required in the EU or any other Country in the
Territory, or otherwise provide appropriate notification of such right of Chiesi to the applicable Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pharmacovigilance</U>.
After the Effective Date [***], the safety units of each of the Parties shall meet and agree upon a written pharmacovigilance agreement
that defines Chiesi&rsquo;s pharmacovigilance responsibilities for the post-Launch Commercialization of Licensed Product in the
Territory and Protalix&rsquo;s pharmacovigilance responsibilities for the Licensed Product outside the Territory and for pre-Launch
Development activities in the Territory, and the process for exchanging adverse event reports and other safety information relating
to a Licensed Product that will permit each Party to comply with applicable Laws and requirements of Regulatory Authorities (such
agreement, the &ldquo;<U>Pharmacovigilance Agreement</U>&rdquo;); <U>provided</U>, that until such time as each of the Ongoing
Clinical Trials and any [***] conducted by Protalix are completed, and the clinical study reports for each such clinical study
are finalized, Protalix shall retain sole responsibility and be the primary contact for pharmacovigilance matters in respect of
the Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Communications
with Regulatory Authorities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
so long as [***], Protalix, and after the assignment and transfer to Chiesi of such regulatory filings pursuant to <U>Section 3.6(c)</U>,
Chiesi, shall provide the other Party with notice of all meetings, conferences, and discussions (including advisory committee meetings
or any other meeting of experts convened by a Regulatory Authority concerning any topic relevant to the Licensed Product) scheduled
with a Regulatory Authority concerning any regulatory matters relating to the Licensed Product in the Field promptly after the
scheduling of such meeting, conference, or discussion. The Party that does not, at the time of such meeting, own the regulatory
filings described in <U>Section 3.6(c)</U> for the Licensed Product shall be entitled to have one or more representatives present
at all such meetings to the extent permissible under applicable Law and reasonably practicable under the circumstances. Protalix
and Chiesi shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions
and on the objectives to be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences
and discussions with the applicable Regulatory Authority, if any [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
so long as [***], Protalix, and after [***], Chiesi, shall provide the other Party with copies, which copies may be in draft form,
of all material submissions to any Regulatory Authority relating to the Licensed Product in the Field. Such copies shall be provided
sufficiently in advance of such planned submission to the applicable Regulatory Authority in order to allow such other Party to
provide comments regarding such submission. The Party making the submission shall consider the other Party&rsquo;s comments in
good faith with respect to such submission [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall provide to the other Party, as soon as reasonably practicable but in no event more than [***] after its receipt, copies
of any material documents or other material correspondence received from a Regulatory Authority pertaining to the Licensed Product
in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Information</U>. Each Party agrees to provide the other with all reasonable assistance and take all actions reasonably requested
by the other Party that are necessary or desirable to enable the other Party to comply with any Law applicable to the Licensed
Product. For clarity, to the extent that either Party provides reasonably requested assistance to the other Party in compliance
with this <U>Section 3.6(h)</U>, the requesting Party shall reimburse such Party for any reasonable costs and expenses incurred
in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recalls
or Other Corrective Action</U>. Each Party shall promptly notify the other Party of any material actions to be taken by such Party
in the Territory or outside the Territory (as the case may be), with respect to any recall or market withdrawal or other corrective
action related to the Licensed Product prior to such action, if reasonably practicable under the circumstances, to permit the other
Party a reasonable opportunity to consult with such Party with respect thereto. [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commercialization
and Pricing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
initial draft Commercialization plan for the Licensed Product in the Field in the Territory prepared by Chiesi is attached as <U>Schedule
3.7</U> hereto, and the final version of such Commercialization plan shall be discussed and agreed upon between the Parties within
[***] from the first Steering Committee Meeting (the &ldquo;<U>Initial Commercialization Plan</U>&rdquo;). Chiesi shall update
such plan (any such updated plan, the &ldquo;<U>Commercialization Plan</U>&rdquo;) at least once per Calendar Year. Each such subsequent
Commercialization Plan shall be submitted to the Steering Committee for review and discussion no later than thirty (30) days prior
to the beginning of the immediately succeeding Calendar Year. Protalix may, through its representatives on the Steering Committee,
propose to Chiesi revisions to any such subsequent Commercialization Plan, and any proposed material updates or amendments to the
Initial Commercialization Plan and any subsequent Commercialization Plan, that Protalix reasonably believes are appropriate, and
Chiesi shall consider any such proposed revisions in good faith, but such Initial Commercialization Plan or Commercialization Plan,
or any material amendments or updates thereto, shall not require approval of the Steering Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
shall have the sole authority and exclusive right to Commercialize, and shall be responsible for paying all costs and expenses
associated with the Commercialization of, the Licensed Product in the Field in the Territory, including marketing, promoting, advertising,
distributing, disposing, offering for sale, selling, Labeling and Packaging, final product release testing, exporting and importing,
and [***] and obtaining any necessary Price Approvals at its sole discretion. Chiesi hereby agrees to refrain from selling the
Licensed Product in the Territory to any Person if Chiesi has knowledge or reason to believe that such Licensed Product is intended
for transshipment or delivery by such Person outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
meetings of the Steering Committee, Chiesi will provide Protalix with periodic updates regarding the status and details of Price
Approvals and Governmental Authority and Third Party reimbursement approvals in each applicable Country in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Early
Access Programs</U>. The Parties shall discuss at the Steering Committee the appropriate mechanism for considering, approving,
providing for supply of Licensed Product in respect of, and otherwise administering, any Early Access Programs [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trademarks</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>License
to Chiesi</U>. Protalix hereby grants to Chiesi an exclusive (except as to Protalix) license, free of charge, to use the Protalix
Trademarks in the Territory solely in connection with the Commercialization of the Licensed Product in the Field during the Term
in the Territory, solely to the extent requested to be used by Protalix pursuant to, and solely for the purposes set forth in,
<U>Section 3.10</U>. If Chiesi decides to use the Protalix Trademarks in the Territory, then Chiesi shall cooperate with Protalix
in respect of [***] recording the trademark license instrument with the appropriate Governmental Authorities throughout the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice
of Trademarks</U>. Chiesi may choose, in its sole discretion, to use any trademarks to Commercialize the Licensed Product in the
Field in the Territory, and Chiesi shall own all such trademarks, other than the Protalix Trademarks or any other trademark owned
or Controlled by Protalix at such time (such trademarks of Chiesi, the &ldquo;<U>Product Marks</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>License
to Protalix</U>. Chiesi hereby grants to Protalix an exclusive (except as to Chiesi) license, free of charge, to use the Product
Marks outside the Territory solely in connection with the packaging, sale, marketing, promotion, advertising, disposition and distribution
of the Licensed Product in the Field during the Term outside the Territory. If Protalix decides to use the Product Marks outside
the Territory, Protalix shall cooperate with Chiesi in respect of [***] recording the trademark license instrument with the appropriate
Governmental Authorities outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quality
Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
quality of the Licensed Product sold by Protalix outside the Territory under or in connection with the Product Marks must be of
a sufficiently high quality to be generally comparable to the quality of the Licensed Product sold by Chiesi in the Territory under
or in connection with the Product Marks. The quality of the Licensed Product sold by Chiesi in the Territory under or in connection
with the Protalix Trademarks must be of a sufficiently high quality to be generally comparable to the quality of the Licensed Product
sold by Protalix outside of the Territory under or in connection with the Protalix Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall comply with all applicable Laws pertaining to the proper use and designation of the Product Marks. Chiesi shall comply with
all applicable Laws pertaining to the proper use and designation of the Protalix Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
agrees to use the Product Marks only in the form and manner and with appropriate legends as prescribed from time to time during
the Term by Chiesi. Chiesi agrees to use the Protalix Trademarks only in the form and manner and with appropriate legends as prescribed
from time to time during the Term by Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall display the proper form of trademark notice associated with the Product Marks. Chiesi shall display the proper form of trademark
notice associated with the Protalix Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall not use any Product Mark as a corporate name, business name, or trade name. Chiesi shall not use any Protalix Trademark as
a corporate name, business name, or trade name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall not use any Product Mark in a manner that would reasonably be expected to materially impair the validity, reputation, or
distinctiveness of any Product Mark. Chiesi shall not use any Protalix Trademark in a manner that would reasonably be expected
to materially impair the validity, reputation, or distinctiveness of any Protalix Trademark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall not use any Product Mark in a manner that would reasonably be expected to materially impair the reputation of Chiesi or any
of its Affiliates. Chiesi shall not use any Protalix Trademark in a manner that would reasonably be expected to materially impair
the reputation of Protalix or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prosecution
and Maintenance of Trademarks</U>. Chiesi shall have the sole right, but not the obligation, through counsel of its choosing, to
prosecute and maintain the Product Marks in the Territory. [***] Protalix shall have the sole right, but not the obligation, through
counsel of its choosing, to prosecute and maintain the Protalix Trademarks and the first right, but not the obligation, through
counsel of its choosing, to prosecute and maintain the Product Marks outside of the Territory on behalf of Chiesi. In the event
Protalix elects not to prosecute or maintain any Product Marks outside of the Territory, Protalix shall provide reasonable prior
written notice to Chiesi of its intention not to prosecute or maintain any such Product Marks outside of the Territory, and Chiesi
shall have the right to do so directly. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement
of Trademarks</U>. Each Party will promptly notify the other in the event of any actual, potential or suspected infringement of
a Protalix Trademark or Product Mark by any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of Product Marks in the Territory. Any recoveries obtained by Chiesi resulting from such litigation or other
appropriate action in the Territory in relation to the Product Marks, will be deemed Net Sales after having deducted any amount
necessary to cover all costs and expenses incurred by Chiesi pursuant to the following sentence. All costs and expenses incurred
by Chiesi in enforcing the Product Marks in the Territory shall be at Chiesi&rsquo;s sole cost and expense. Protalix shall have
the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party
infringement of Protalix Trademarks in the Territory. Upon request of Protalix, Chiesi agrees to timely join as party-plaintiff
in any litigation in the Territory in relation to the Protalix Trademarks, and in any event to cooperate with Protalix in connection
with any infringement action in the Territory in relation to the Protalix Trademarks, at Protalix&rsquo;s cost and expense. All
costs and expenses incurred by Protalix in enforcing the Protalix Trademarks in the Territory [***]. Protalix shall retain all
recoveries received by Protalix as a result of its enforcement of the Protalix Trademarks in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix shall have
the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party
infringement of Protalix Trademarks outside the Territory and the first right, but not the obligation, to institute litigation
or take other remedial measures in connection with Third Party infringement of Product Marks outside the Territory. If Protalix
declines to initiate litigation or take other remedial measures against a Third Party who is alleged to be infringing a Product
Mark outside the Territory within ninety (90) days after becoming aware of the basis for such litigation or action, then Chiesi
may, in its discretion, have the right to initiate litigation or take other appropriate action that it believes is reasonably required
to protect its rights to the Product Marks outside the Territory. Upon request of Chiesi, Protalix agrees to timely join as party-plaintiff
in any such litigation, and in any event to cooperate with Chiesi in connection with such infringement action at Chiesi&rsquo;s
cost and expense. Any recoveries obtained by Protalix resulting from such litigation or other appropriate action outside of the
Territory in relation to the Product Marks or Protalix Trademarks shall be retained by Protalix. All costs and expenses incurred
by Protalix in enforcing the Product Marks and Protalix Trademarks outside the Territory shall be at Protalix&rsquo;s sole expense.
All costs and expenses incurred by Chiesi in enforcing the Product Marks outside the Territory [***]. Chiesi shall retain all recoveries
received by Chiesi as a result of its enforcement of the Product Marks outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Names</U>. No right, expressed or implied, is granted by this Agreement to a Party to use in any manner the name or any other
trade name of the other Party or its Affiliates in connection with this Agreement. Notwithstanding the foregoing, Chiesi agrees,
during the Term, to display the Protalix corporate name and logo (the &ldquo;<U>Protalix Trademarks</U>&rdquo;) on the trade packaging
used for the Licensed Product in the Field in the Territory in a reasonable manner in each applicable Country in which the Licensed
Product has been Launched (or as may be required under applicable Law in any such Country), unless to do so would be prohibited
under applicable Laws, would not be reasonable from a commercial perspective in such Country, or is not in accordance with the
request of a Regulatory Authority, subject to Protalix&rsquo;s trademark usage guidelines applicable to the Protalix Trademarks
provided from time to time during the Term, including at least sixty (60) days prior to the date of Chiesi&rsquo;s first use of
the Protalix Trademarks. Upon the written request of Protalix, Chiesi shall submit to Protalix a sample of each proposed use of
the Protalix Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[***]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>MANUFACTURE AND SUPPLY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commercial
Supply of Licensed Product</U>. In respect of each Country in the Territory, other than to the extent this provision would be a
violation of any applicable Laws in such Country, Protalix shall Manufacture and supply, and Chiesi shall purchase from Protalix,
all of Chiesi&rsquo;s and its Affiliates&rsquo; and Sublicensees&rsquo; requirements of the Drug Product (and, after [***] for
incorporation into Licensed Product for commercial sale in the Field in the Territory pursuant to and in accordance with this Agreement.
Such supply shall be subject to and in accordance with the terms of this <U>Section 4</U> and the Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[***]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior to [***]</U>.
Prior to [***], (i) Protalix shall be responsible for delivery of Drug Substance to [***] with respect to commercial supply of
Licensed Product for sale in the Territory and shall use Commercially Reasonable Efforts to cause [***] to conduct, pursuant and
subject to and in accordance with the terms and conditions of the [***], [***] activities for supply of Drug Product to Chiesi,
and (ii) Chiesi shall be responsible for Labeling and Packaging with respect to commercial supply of Licensed Product for sale
in the Territory and shall ensure, in all material respects, that Labeling and Packaging activities for commercial supply of Licensed
Product for sale in the Territory comply with applicable Law, GMP and the Regulatory Approvals for the Licensed Product in the
Territory, including the Product Specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protalix
Manufacturing Activities</U>. Protalix shall have the sole authority and exclusive right for, and Protalix shall be responsible
for, the Manufacture of Drug Product and, after [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
of Third Parties</U>. In the event that Protalix conducts any Manufacturing activities through an Affiliate or Third Party, Protalix
shall be responsible for the performance of such Affiliate or Third Party in accordance with the terms of this <U>Section 4</U>.
In the event that Chiesi conducts any Labeling and Packaging or, after [***] activities through an Affiliate or Third Party (such
performance by an Affiliate or Third Party to comply with the terms of <U>Section 2.4)</U>, Chiesi shall be responsible for the
performance of such Affiliate or Third Party in accordance with the terms of this <U>Section 4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forecasting
and Ordering</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forecasts; Purchase
Orders</U>. [***], Chiesi shall deliver to Protalix Chiesi&rsquo;s quarterly projection of the quantities of Drug Product [***]
that Chiesi anticipates ordering from Protalix pursuant to this Agreement for the four (4) Commercial Quarters commencing with
the first Commercial Quarter that includes the first requested delivery date (the &ldquo;<U>Initial Forecast</U>&rdquo;), together
with a firm purchase order (a &ldquo;<U>Purchase Order</U>&rdquo;) for such Drug Product [***] for the first Commercial Quarter
covered by such Initial Forecast and for at least [***] of the second Commercial Quarter covered by such Initial Forecast. The
quantities of Drug Product [***] specified for the following [***] of such Initial Forecast shall be non-binding. Thereafter, [***]
prior to the first Business Day of each subsequent Commercial Quarter during the Term, Chiesi shall deliver to Protalix a rolling
[***] Commercial Quarter forecast updating the prior forecast (together with the Initial Forecast, each a &ldquo;<U>Forecast</U>&rdquo;),
together with a Purchase Order for such Drug Product [***] for the first Commercial Quarter covered by such Forecast and for at
least [***] of the second Commercial Quarter covered by such Forecast. The quantities of Drug Product [***] specified for the following
two (2) Commercial Quarters of such Forecast shall be non-binding. Unless agreed separately between the Parties, each Purchase
Order shall (i) specify no more than one (1) delivery date for the Drug Product [***] in each Commercial Quarter (unless each such
delivery date in such Commercial Quarter is for a quantity of vials equal to the Minimum Batch Size or an exact multiple thereof),
and (ii) be for a minimum quantity of the Minimum Batch Size. Purchase Orders shall be in writing and no verbal communications
or e-mail shall be construed to mean a commitment to purchase or sell. Each Purchase Order delivered by Chiesi to Protalix pursuant
to this <U>Section 4.5(a)</U> shall be binding on Protalix, unless Protalix notifies Chiesi in writing of its rejection thereof
within [***] of receipt of such Purchase Order; <U>provided</U> that Protalix may only reject Purchase Orders that do not comply
with the terms of this Agreement or are otherwise not valid Purchase Orders (<U>e.g.</U>, do not contain the requisite details).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Long
Range Capacity Planning</U>. Concurrent with the Initial Forecast, for the purposes of discussion and planning of Manufacturing
capacity, Chiesi shall provide a non-binding forecast of its projected Drug Product [***] needs for the [***] Commercial Quarters
following that specified in the Initial Forecast as described in <U>Section 4.5(a)</U> (a &ldquo;<U>Long Range Forecast</U>&rdquo;).
Each Long Range Forecast shall be deemed to be revised by any subsequent Forecast. In the event Protalix anticipates that it will
be unable to supply the quantities of Drug Product [***] reflected in a Long Range Forecast, Protalix shall promptly notify Chiesi
and the Parties shall work to remedy the shortfall in accordance with and subject to the terms of this <U>Section 4</U> in an effort
to assure that the necessary capacity exists. Unless otherwise agreed to by the Parties during the Term, the Long Range Forecast
shall be updated by Chiesi annually by July 1 of each Commercial Year during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Receipt
and Acceptance</U>. Chiesi shall purchase all Drug Product [***] ordered and specified in a Purchase Order. Purchase Orders may
be delivered electronically or by other means to such location as Protalix shall designate. Nothing in any such Purchase Order
or written acceptance shall supersede the terms and conditions of this Agreement or the Quality Agreement. All Purchase Orders,
confirmations of receipt of Purchase Orders and other notices contemplated under this <U>Section 4.5(c)</U> shall be sent to the
attention of such persons as each Party may identify to the other in writing from time to time in accordance with <U>Section 15.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>First-Expired
First-Out</U>. Chiesi shall use its inventory of Licensed Product, and any shipments of Drug Product [***], and each Party shall
use its Safety Stock Amounts (as and when necessary), in each case, on a first-expired first-out (FEFO) basis in order to ensure
that the Licensed Product in Chiesi&rsquo;s inventory (and the supply of Drug Product or, after [***], [***], used in the production
of such Licensed Product inventory) always has the maximum period of time remaining on the retest period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pricing,
Invoicing and Supply Price Reconciliation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Delivery Price; Invoices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each delivery of Drug Product [***] under a Purchase Order hereunder shall be accompanied by an invoice. Protalix shall invoice
such Drug Product [***] at the Price as at the date of such invoice. Chiesi shall issue payment against such invoices within [***]
of the invoice date. Protalix shall include the following information, where applicable, on all invoices: the type, description,
and quantity of the product delivered; the date of shipment; the prices; any applicable taxes, transportation charges or other
charges provided for in the applicable Purchase Order; and the applicable Purchase Order number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
All sales and use taxes which Protalix is required by applicable Law to collect from Chiesi with respect to the Manufacture and
supply of Drug Product [***] to Chiesi shall be separately stated in Protalix&rsquo;s invoice and shall be paid by Chiesi to Protalix.
For the avoidance of doubt, any and all applicable taxes shall be payable by Chiesi in addition to the Price payable on such Licensed
Products. Protalix shall be solely responsible for the timely payment of all such taxes to the applicable taxing authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial
Price</U>. Subject to the terms and conditions of this Agreement, before the start of the first Commercial Year in which Protalix
is obligated to deliver Drug Product [***] pursuant to a Purchase Order issued by Chiesi, Protalix shall sell, and Chiesi shall
purchase, the amount of Drug Product [***] ordered for delivery in the first Commercial Year at a Price determined by the Parties
in good faith on a Country-by-Country basis at least one Commercial Quarter prior to the anticipated start of the first Commercial
Year in such Country, reflecting [***] in all relevant Countries of the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ongoing
Price</U>. Subject to the terms and conditions of this Agreement, in any Commercial Year other than the first Commercial Year,
Protalix shall sell, and Chiesi shall purchase, the amount of Drug Product [***] ordered for delivery in such Commercial Year at
a Price determined on a Country-by-Country basis equal to [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this Agreement, the &ldquo;<U>Applicable Rate</U>&rdquo; shall mean [***]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 71%; text-align: center"><B>Aggregate Annual Net Sales of Licensed Products </B>(together with <BR>
Direct Sublicensee Revenue B)</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; text-align: center"><B>Applicable Rates</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Less than [***]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Equal to or greater than [***] and less than [***]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Equal to or greater than [***] and less than [***]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Equal to or greater than [***] and less than [***]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Equal to or greater than [***] </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quarterly
Reconciliation</U>. Notwithstanding the foregoing, in no event shall the Price paid by Chiesi for the Drug Product [***] ordered
for delivery in any Commercial Quarter be less than [***]. If, at the end of a Commercial Quarter, the Price paid by Chiesi for
the supply of Drug Product [***] during any Commercial Quarter is less than [***], Chiesi shall pay Protalix the difference between
such amounts against receipt of a proper invoice within [***] of the invoice date. In addition to the foregoing and any other payments
provided for herein, [***], Chiesi shall pay to Protalix an amount equal to the Applicable Rate for such Commercial Year, <U>multiplied
by</U> the Other Sublicensee Revenue received during such Commercial Quarter (the &ldquo;<U>Other Sublicensee Revenue Payment</U>&rdquo;),
subject to <U>Section 5.3(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Yearly
Reconciliation</U>. The amounts due from Chiesi for Drug Product [***] ordered for delivery in each Commercial Year, as listed
on the first invoice delivered to Chiesi for such Commercial Year, shall be increased or decreased, as the case may be, by the
amount of a Reconciliation Adjustment aggregated for all Countries in the Territory and meant to compensate in such Commercial
Year for any inaccuracy in the Price paid in each such Country in the prior Commercial Year (the &ldquo;<U>Yearly Reconciliation</U>&rdquo;);
<U>provided</U> that, notwithstanding anything to the contrary herein, in no event shall the amount due from Chiesi for the Drug
Product [***] ordered for delivery in any Commercial Year be less than [***] for any Commercial Year (the &ldquo;<U>Minimum Payment</U>&rdquo;),
subject to the potential pro rata reduction of the Minimum Payment for failure to supply provided for in <U>Section 4.14(f)</U>.
For purposes of this Agreement, the &ldquo;<U>Reconciliation Adjustment</U>&rdquo; shall mean the aggregate for all Countries in
the Territory of the difference for each Country between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***];
and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each Reconciliation Adjustment shall be settled against receipt
of a proper credit note or debit note within [***] of the note date; <U>provided</U> that if any Reconciliation Amount is in the
favor of Chiesi, such amounts shall be credited against the amount stated on the next issued invoice relating to the delivery of
Drug Product [***] by Protalix to Chiesi under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maximum
Order Quantity</U>. [***], the Parties shall agree in good faith on a maximum order quantity for the [***] and subsequent Commercial
Years in such Country (the &ldquo;<U>Maximum Order Quantity</U>&rdquo;), expressed as a percentage above the amount of vials sold
in such Country in the prior Commercial Year [***] to mitigate the risk to Protalix of Chiesi ordering more Licensed Product than
will be sold in such Commercial Year. If the Parties are unable to reach agreement on the Maximum Order Quantity for a given Country
by [***], the issue shall be escalated to the Parties&rsquo; respective Chief Executive Officers, who shall attempt to resolve
the issue within thirty (30) days. Notwithstanding anything to the contrary in this Agreement, Protalix shall have no obligation
to supply Drug Product [***] in excess of the Maximum Order Quantity for any Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shipping
and Delivery</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery</U>.
Protalix shall deliver (or have delivered) to Chiesi in accordance with this <U>Section 4.7</U> the quantities of the Drug Product
[***] specified for a given delivery date in each Purchase Order, [***]. Protalix shall deliver (or have delivered) (i) after [***],
[***] with a remaining shelf life of [***], or (ii) prior to [***], with a remaining shelf life of [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
Terms</U>. The Drug Product [***] shall be supplied to Chiesi [***]. The Drug Product [***] shall be shipped at [***]. Chiesi shall
be [***]. For the avoidance of doubt, Protalix shall be responsible for the importation of the Drug Substance in the EU with respect
to the shipment of Drug Substance from Protalix to [***], and for compliance with all applicable Laws relating to such importation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Retention</U>.
Unless the Parties agree otherwise, Protalix shall maintain analytical samples of each batch of Drug Product (or, if necessary,
Drug Substance) in storage for a time period based upon Protalix&rsquo;s sample retention policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Analysis; Acceptance and Returns</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Analysis; Notice of Non-Conformance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall supply to Chiesi the applicable batch number for the Drug Product [***] delivered, as well as such other information as the
Parties may set forth in the Quality Agreement with respect to Manufacture (a &ldquo;<U>Manufacturing Certificate of Analysis</U>&rdquo;)
for all Drug Product [***] shipped to Chiesi hereunder. Chiesi shall (within the time period specified in <U>Section 4.8(b)</U>)
inspect, or cause to have inspected, each shipment of the Drug Product [***] for any material damage, defect or shortage and give
Protalix written notice of any such material damaged, defective or short shipment (a &ldquo;<U>Notice of Non-Conformance</U>&rdquo;)
within the time periods specified in <U>Sections 4.8(a)(ii)</U> and <U>4.8(b)</U>, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Latent
defects shall be communicated to Protalix, together with appropriate detail, within fifteen (15) Business Days of the date on which
such latent defect was first discovered by Chiesi or was notified to Chiesi by the relevant Party discovering the defect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rejection</U>.
Chiesi shall have [***] following its receipt of each shipment of the Drug Product [***] to inspect such shipment. If Chiesi determines
that any shipment of the Drug Product [***] does not conform to the Product Specifications (or is otherwise a short shipment) in
any material respect, it shall promptly notify Protalix within [***] following such determination in compliance with the procedures
set forth in the Quality Agreement(s). Failure to provide such written notice with such time periods specified in <U>Sections 4.8(a)(ii)</U>
and this <U>4.8(b)</U>, as applicable, shall be deemed acceptance of such shipment of Drug Product [***] by Chiesi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U>.
If Chiesi delivers a Notice of Non-Conformance in respect of all or any part of a shipment of the Drug Product [***], and Protalix
does not agree with Chiesi&rsquo;s determination that such shipment fails to meet the Product Specifications (or is otherwise a
short shipment) in any material respect, the Parties shall in good faith attempt to resolve such dispute at the Steering Committee;
<U>provided</U>, <U>however</U>, that the Steering Committee must resolve any such dispute by consensus, and for the avoidance
of doubt, neither the Protalix Chair nor Chiesi Chair shall have final decision-making authority in respect of such Steering Committee
discussions; <U>provided</U>, <U>however</U>, that for the duration of such Steering Committee discussions, Protalix shall use
Commercially Reasonable Efforts to promptly replace such alleged non-conforming Drug Product [***] (or short shipment) in order
to avoid any possible out-of-stock situation. The dispute shall be resolved at the Steering Committee within thirty (30) days,
unless otherwise agreed in writing by the Parties, from the date of Protalix&rsquo;s receipt of a Notice of Non-Conformance to
resolve such dispute regarding whether all or any part of such shipment was not Manufactured in conformance with the Product Specifications
(or was otherwise a short shipment) in any material respect. If the dispute regarding whether all or any part of a shipment rejected
by Chiesi was not Manufactured in conformance with the Product Specifications (or was otherwise a short shipment) in any material
respect is not resolved by the Steering Committee in such thirty (30) day period, [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In the event any shipment of Drug Product [***] is rejected pursuant to this <U>Section 4.8</U> as a result of any act or omission
of Protalix, then (i) Chiesi shall, at the direction of Protalix, either (x) destroy such rejected Drug Product [***] (in accordance
with applicable Law) or (y) return such rejected Drug Product [***] to Protalix, at a location designated by Protalix [***]; and
(ii) Protalix [***] shall (in its sole discretion) either (x) use its Commercially Reasonable Efforts to promptly replace such
non-conforming Drug Product [***] (or short shipment) or (y) give Chiesi a credit in an amount equal to the amount paid or payable
by Chiesi with respect to such rejected Drug Product [***] (or short shipment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Product
Specification and Manufacturing Changes</U>. Prior to the Parties entering into the Quality Agreement, Protalix shall inform Chiesi
of material Product Specification and Manufacturing changes, including those resulting from a request received by Protalix from
a Governmental Authority. Protalix shall notify Chiesi within a reasonable time prior to implementing such change, to allow Chiesi
to assess the potential impact of such change upon the Drug Product supplied or its use by Chiesi and the implementation of such
change shall not occur prior Chiesi&rsquo;s written approval (which approval shall not be unreasonably withheld, conditioned or
delayed). After the Parties enter into the Quality Agreement, Product Specification and Manufacturing changes, including those
resulting from a request received by either Party from a Governmental Authority, shall be dealt with pursuant to the Quality Agreement;
<U>provided</U> that all applicable Regulatory Approvals shall be prepared and filed by the Parties in accordance with the provisions
of <U>Section 3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labeling</U>.
Chiesi shall be responsible for the design of the Label for the Licensed Product in each Country in the Territory and for ensuring
that such Label is accurate and complies with all applicable Laws. Chiesi shall be responsible for obtaining approval from applicable
Governmental Authorities for any new Label or packaging or change to Label or packaging and shall bear all costs arising therefrom,
including in respect of any write-off of materials and work-in-progress unless otherwise included or required as part of the Development
of the Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shortages</U>.
In the event that the materials and/or Manufacturing capacity required to Manufacture and to deliver in a timely manner to Chiesi
the Drug Product [***] required under outstanding Purchase Orders are in short supply (&ldquo;<U>Shortage</U>&rdquo;), Protalix
shall notify Chiesi of such Shortage and the Steering Committee shall promptly meet to discuss the Shortage. Protalix shall provide
to the Steering Committee a written plan of action stating in reasonable detail the proposed measures to address such Shortage
and the date such Shortage is expected to end. Protalix shall use its Commercially Reasonable Efforts to minimize the duration
of any Shortage. During any such Shortage, Protalix shall allocate the materials and resources used in the supply of the Drug Product
[***], such that Chiesi receives [***] for the Territory and Protalix receives [***] for outside the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Safety
Stock Obligations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Build-Up</U>.
[***], Protalix shall operate its Facility in order to start building inventory of [***], Drug Substance and Drug Product (the
&ldquo;<U>Safety Stock</U>&rdquo;) with the quantity of [***], Drug Substance and Drug Substance remaining after Protalix supplies
the quantities of Drug Product and, if applicable, Drug Substance necessary to conduct the Ongoing Clinical Studies and any [***]
and, after the first Launch in the Territory, to meet commercial demand. Protalix shall operate its Facility in such manner until
there is a quantity of Safety Stock consisting of (i) Drug Product capable of fulfilling the [***] commercial needs for Licensed
Product in the Territory [***], based on the rolling Forecasts submitted by Chiesi pursuant to <U>Section 4.5</U>, (ii) Drug Substance
capable of fulfilling the [***] commercial needs for Licensed Product in the Territory, based on the rolling Forecasts submitted
by Chiesi pursuant to <U>Section 4.5</U>, and (iii) [***] capable of fulfilling the [***] commercial needs for Licensed Product
in the Territory, based on the rolling Forecasts submitted by Chiesi pursuant to <U>Section 4.5</U> (collectively, the &ldquo;<U>Safety
Stock Amount</U>&rdquo;). Thereafter, subject to <U>Section 4.12(b)</U>, Protalix shall operate its Facility as necessary to maintain
the Safety Stock Amount. The Safety Stock may be used to fulfill Protalix&rsquo;s obligations to supply in the event there is a
shortage as described in <U>Section 4.11</U> or a Supply Failure (so long as such Safety Stock complies with the remaining shelf
life required under <U>Section 4.7(a)</U>, unless otherwise reasonably agreed by the Parties in a given circumstance); <U>provided
</U>that [***] of such Safety Stock Amount shall be maintained for the exclusive use of Chiesi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sharing
of Responsibility and Cost</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
so long as subclause (x) of <U>Section 4.6(h)(ii)</U> applies in a given Country in the Territory, (A) Chiesi shall bear the [***]
responsibility for maintaining the Drug Product included in the Safety Stock Amount for such Country through the inclusion of and
payment for such Drug Product (as part of, and not in addition to) in applicable Purchase Orders placed in accordance with <U>Section
4.5</U> and, for clarity, in the Yearly Reconciliation provided for under <U>Section 4.6(h)</U>, and (B) Protalix shall bear the
[***] responsibility for maintaining the Drug Substance included in the Safety Stock Amount for such Country. On and from the date
that such subclause (x) of <U>Section 4.6(h)(ii)</U> no longer applies in a given Country in the Territory in accordance with such
Section, the Parties shall share equally the responsibility [***] of building and maintaining the Safety Stock Amount for Drug
Substance and Drug Product for such Country, in a manner to be mutually agreed upon by the Parties in good faith at the same time
the Maximum Order Quantity is agreed upon in accordance with <U>Section 4.6(i)</U> (and, for clarity, such Safety Stock Amount
shall not be included in the Drug Product [***] ordered for such Country for purposes of the Yearly Reconciliation). For clarity,
following [***], Chiesi shall be solely responsible for the maintenance of any Safety Stock Amount of Drug Product [***]. Chiesi
shall reimburse Protalix for its [***] share of the Safety Stock consisting of [***] within [***] of Protalix providing Chiesi
an invoice therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Forecasts and Purchase Orders submitted by Chiesi pursuant to <U>Section 4.5</U> shall make a distinction between the amounts of
Drug Product and Drug Substance required by Chiesi for commercial needs in the Territory and the amounts of Drug Product and Drug
Substance needed for Safety Stock. For the avoidance of doubt, Protalix shall hold and keep the Safety Stock Amount of Drug Substance
and, at Chiesi&rsquo;s option, Chiesi or [***] shall hold and keep the Safety Stock Amount (or a portion thereof) of Drug Product.
Protalix shall, upon reasonable request and during regular business hours with as minimal disruption to Protalix&rsquo;s operations
as reasonably practicable, allow Chiesi to audit the quantity of Safety Stock in Protalix&rsquo;s possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business
Continuity Plan. Within [***], Protalix shall provide Chiesi with a copy of a business continuity risk assessment and plan for
Protalix in relation to the Manufacture and supply of the Drug Product by Protalix hereunder. Such plan (i) shall include an assessment
regarding a potential alternative to the current quality control laboratory, and (ii) is intended to be reviewed by Protalix on
a yearly basis. Upon Chiesi&rsquo;s request, Protalix shall provide Chiesi information regarding the results of any such review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Failure
to Supply</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Failure
to Supply</U>&rdquo; shall occur in the event that Protalix does not supply according to the terms of this Agreement (to the Person
responsible for Fill/Finish) for reasons within Protalix&rsquo;s reasonable control (and, for clarity, not for reasons outside
Protalix&rsquo;s reasonable control, <U>i.e.</U>, a Force Majeure Event) at least [***] of the quantities of Drug Substance specified
by Chiesi on Purchase Orders covering [***] (a &ldquo;<U>Supply Failure</U>&rdquo;), and such Supply Failure is not cured in the
following [***] (whether by using Safety Stock or otherwise). For clarity, notwithstanding anything to the contrary herein, a failure
to supply will not be treated as a Supply Failure under this <U>Section 4.14(a)</U> if such failure to supply was due to the failure
to conduct Fill/Finish activities or Labeling and Packaging. For the sake of this <U>Section 4.14(a)</U>, &ldquo;cure&rdquo; means
supplying at least [***] of the quantities of Drug Substance specified by Chiesi on the applicable Purchase Orders that are the
subject of the Supply Failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights
of Chiesi upon Failure to Supply</U>. In the event of a Failure to Supply, at the option of Chiesi by giving written notice to
Protalix, Chiesi shall have the right to, in compliance with applicable Laws and each Party&rsquo;s agreements with Third Parties,
[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation
of Costs</U>. Protalix shall be responsible for [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
of Protalix to Resume Manufacturing</U>. Should Protalix provide Chiesi with commercially reasonable evidence that it is ready,
willing and able, directly or through subcontractors reasonably acceptable to Chiesi, to resume its supply obligations hereunder,
Chiesi and Protalix will work together in good faith to [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINANCIAL PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date Payment</U>. In consideration for and as reimbursement of the costs sustained by Protalix up to the Effective Date for the
Development of the Compound, Drug Substance, Drug Product and Licensed Product (such costs hereby acknowledged and accepted by
Chiesi, without any right of further review, challenge or audit with respect to such costs) and in a manner consistent with <U>Section
5.3(a)</U> and <U>Section 5.3(h)</U>, Chiesi shall pay to Protalix within twenty (20) days after the Effective Date, the non-refundable,
non-creditable amount of Twenty-Five Million Dollars (US $25,000,000). For the avoidance of doubt and notwithstanding the foregoing
reference to <U>Section 5.3(a)</U>, such amount shall not be included in or subject to the Development Costs Cap, Annual Cap, Required
Studies Cap or any other cap on reimbursement provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Event
Milestone Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of this Agreement, Chiesi shall pay to Protalix the amount set forth in the table below opposite the
corresponding event milestone (each an &ldquo;<U>Event Milestone</U>&rdquo;) within thirty (30) days after the occurrence of such
Event Milestone:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 71%; text-align: center"><B>Event Milestone</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 28%; text-align: center"><B>Event Milestone Payment</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[***] (&ldquo;<U>Event Milestone 1a</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[***] (&ldquo;<U>Event Milestone 1b</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 2</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 3</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 4</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 5</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 6</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 7</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 8</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Annual Net Sales of the Licensed Product in the Territory (together
        with the Direct Sublicensee Revenue B) equal to or in excess of [***] (&ldquo;<U>Event Milestone 9</U>&rdquo;)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">[***]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment
        request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 71%">Annual Net Sales of the Licensed Product in the Territory (together with the Direct Sublicensee Revenue B) equal to or in excess of (&ldquo;<U>Event Milestone 10</U>&rdquo;)</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; text-align: center">[***]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt: (i) subject to <U>Section 5.2(d)</U> below, each Event Milestone Payment shall be payable only on the first
occurrence of the corresponding Event Milestone; and (ii) none of the Event Milestone Payments shall be payable more than once.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In respect of Event
Milestones 2 through 10, should more than one Event Milestone occur in any Commercial Year, then only the highest of such Event
Milestone Payments shall be due and payable in such Commercial Year (however, any Deferred Milestones may also be due and payable
in such Commercial Year, subject to the below). For example, if Protalix achieves Event Milestone 2, Event Milestone 3, Event Milestone
4, and Event Milestone 5 in the first Commercial Year of this Agreement, only the Event Milestone Payment for Event Milestone 5
shall be due and the Event Milestone Payments for Event Milestone 2, Event Milestone 3 and Event Milestone 4 shall be deferred
as set forth below and not paid in that Commercial Year (each, a &ldquo;<U>Deferred Milestone</U>&rdquo;). Such Deferred Milestones
shall become due and payable in any subsequent Commercial Year in which the corresponding Event Milestone for each such Deferred
Milestone is again achieved (irrespective of whether a higher Event Milestone is also achieved in such Commercial Year); provided,
that the aggregate Net Sales (together with Direct Sublicensee Revenue B) for such subsequent Commercial Year have not decreased,
as compared to the highest amount of Net Sales (together with Direct Sublicensee Revenue B) achieved in any previous Commercial
Year. If the aggregate Net Sales (together with Direct Sublicensee Revenue B) for such subsequent Commercial Year has decreased,
than only the highest Event Milestone achieved in such year will be payable (<U>i.e.</U>, any unpaid Deferred Milestones again
shall be deferred to the next Commercial Year). Following on from the above example, if in the subsequent Commercial Year Protalix
achieves Event Milestone 2 and Event Milestone 3 only (meaning that there has been a decrease), then in such Commercial Year, the
Deferred Milestone for Event Milestone 3 shall be due and payable (being the highest unpaid Event Milestone achieved in such Commercial
Year), but the Deferred Milestone for Event Milestone 4 shall remain unpaid (as the corresponding Event Milestone was not achieved
in that Commercial Year), and the Deferred Milestone for Event Milestone 2 shall also remain unpaid (as there was a decrease in
Net Sales (together with Direct Sublicensee Revenue B)). If instead, the Net Sales (together with Direct Sublicensee Revenue B)
increased (for example, Event Milestone 6 had been achieved), than each of the Deferred Milestones for Event Milestone 2, Event
Milestone 3 and Event Milestone 4 will be due and payable in such Commercial Year (in addition to the Event Milestone Payment for
Event Milestone 6). Following the above example, and assuming that in that second Commercial Year there had been a decrease in
aggregate Net Sales (together with Direct Sublicensee Revenue B), but that in the third Commercial Year, Protalix achieves each
of Event Milestone 2, Event Milestone 3, Event Milestone 4, Event Milestone 5, and Event Milestone 6, then in such year, the Event
Milestone Payment for Event Milestone 6 shall be due (as that is the highest of the Event Milestones achieved), as well as any
unpaid Deferred Milestones (in the above example, the remaining Deferred Milestones would be Event Milestone 2 and Event Milestone
4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
acknowledges and agrees that the right to receive Event Milestone Payments is not a security, shall not be represented by a certificate
or other instrument and shall not represent a security or ownership interest in Chiesi, its Affiliates or any of their respective
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTWITHSTANDING
THIS <U>SECTION 5.2</U>, PROTALIX MAKES NO REPRESENTATION, WARRANTY OR COVENANT, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE
TO SUCCESSFULLY DEVELOP AND CHIESI MAKES NO REPRESENTATION, WARRANTY OR COVENANT, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE
TO SUCCESSFULLY COMMERCIALIZE THE LICENSED PRODUCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Development
Costs</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share
of Costs</U>. Subject to the Development Costs Cap and Annual Cap, and subject to <U>Section 5.3(d)</U>, Chiesi shall reimburse
Protalix for [***] of all Development Costs, within [***] of a receipt of an invoice therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Development
Costs Cap</U>. Notwithstanding <U>Section 5.3(a)</U>, if Chiesi&rsquo;s reimbursement obligation in respect of its share of the
Development Costs under <U>Section 5.3(a)</U> at any point during the Term exceeds twenty-five million dollars (US$25,000,000)
in the aggregate during the Term (the &ldquo;<U>Development Costs Cap</U>&rdquo;), then Chiesi shall have the right but not the
obligation to reimburse the amount exceeding the Development Costs Cap. If Chiesi decides to so reimburse, then Chiesi shall be
entitled to credit any such amounts in excess of the Development Costs Cap that it pays to Protalix in accordance with <U>Section
5.3(a)</U> against any future payment obligations of Chiesi to Protalix in respect of the Event Milestone Payments and the Price
to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Cap</U>.
Notwithstanding <U>Sections 5.3(a)</U>, and subject to <U>Section 5.3(b)</U> above, Chiesi&rsquo;s reimbursement obligation in
respect of its share of the Development Costs under <U>Section 5.3(a)</U> shall not, in any single Calendar Year during the Term,
exceed ten million dollars (US$10,000,000) (the &ldquo;<U>Annual Cap</U>&rdquo;); <U>provided</U>, <U>however</U>, that if in any
Calendar Year during the Term Chiesi&rsquo;s reimbursement obligation in respect of its share of the Development Costs is less
than the Annual Cap, the difference between Chiesi&rsquo;s actual reimbursement obligation for such Calendar Year and the Annual
Cap for that Calendar Year shall carry forward to the next Calendar Year, such that the Annual Cap for that next Calendar Year
shall increase by such amount (and in respect of such next Calendar Year, any references in this Agreement to Annual Cap shall
be read as referring to such increased amount). If fifty percent (50%) of Development Costs for any Calendar Year exceeds the Annual
Cap for that Calendar Year, then the difference between such actual Development Costs in that Calendar Year and twice the Annual
Cap for such Calendar Year shall be deemed added to such Development Costs for the next Calendar Year (<U>i.e.</U>, such amount
will be subject to Chiesi&rsquo;s reimbursement obligation of [***] (per <U>Section 5.3(a)</U>) of such amount during the next
Calendar Year, subject to the Annual Cap for such Calendar Year and the Development Costs Cap).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[***]</U>.
In the event that either Party is obligated to undertake one or more [***] under the terms of this Agreement, subject to this <U>Section
5.3(d)</U>, [***] for such [***] (&ldquo;<U>[***]</U>&rdquo;), within [***] of a receipt of an invoice therefor. A separately established
cap (the &ldquo;<U>Required Studies Cap</U>&rdquo;) shall apply to any such [***], on the same terms and amounts set forth in <U>Sections
5.3(b)</U> and <U>5.3(c) </U>(applying <I>mutatis mutandis</I>). For the avoidance of doubt, such Required Studies Cap for the
[***] shall be calculated and accounted for separate from, and the [***] shall not in any event be included as a part of, the Development
Costs Cap or Annual Cap under <U>Sections 5.3(b)</U> and <U>5.3(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[***].</U>
In the event that one or more Additional Studies are required by a Regulatory Authority in [***] for the purposes of obtaining
(including, solely with respect to approvals granted upon specific conditions requiring the conduct of specified additional required
studies to maintain such granted Regulatory Approval, maintaining) Regulatory Approval for the Licensed Product from a Regulatory
Authority in [***], then, prior to proceeding with any such [***], both Parties must agree in writing (such agreement not to be
unreasonably withheld, conditioned or delayed) whether to conduct such [***] and to any applicable terms thereto, including as
to who will conduct such [***], the sharing or bearing of any costs and expenses associated with the conduct and completion of
such [***] and the respective obligations of each Party in respect of the conduct of such [***]. With respect to any Country where
a [***] is required by a Regulatory Authority, at the time the Parties agree on the conduct of, and cost-sharing (if any) between
the Parties relating to, such [***] in accordance with the foregoing, the Parties shall also agree in writing in good faith on
the appropriate financial provisions as between Chiesi and Protalix to apply to sublicensing in such Countries (including with
respect to whether and to what extent, for such Country, the Other Sublicensee Revenue Payment (or some other method of addressing
Other Sublicensee Revenue in such Country) should apply thereto, and how the Event Milestones and Applicable Rate provisions should
apply thereto, with the understanding that if Protalix does not agree to share or bear at least [***] of the costs and expenses
associated with the conduct and completion of the [***] for any such Country, such agreement [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Clinical
Studies Following Regulatory Approval and Additional Studies</U>. Notwithstanding anything to the contrary herein, other than in
respect of [***] as provided in <U>Section 5.3(e)</U>, (i) Chiesi may only conduct Post-Approval Studies or Additional Studies
with the prior written consent of Protalix, such consent not to be unreasonably delayed, withheld or conditioned; and (ii) Chiesi
shall be responsible for paying [***], and to the extent Protalix is required to (or is requested by Chiesi to) provide assistance
in relation to the conduct of such Post-Approval Studies or Additional Studies, Chiesi shall [***] incurred in providing such assistance
(and such reimbursement shall not be subject to the Development Costs Cap, Annual Cap, Required Studies Cap or any other cap on
reimbursement provided for herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chiesi
Step-in Rights</U>. In the event that Chiesi exercises its step-in rights under <U>Section 3.2(b)</U>, each of <U>Sections 5.3(a)</U>
through <U>5.3(f)</U>, as applicable shall continue to apply with the obligation shifting to Protalix to reimburse Chiesi for [***]
of all Development Costs and/or [***] (as applicable) incurred by Chiesi after the exercise of such step-in rights (<U>i.e.</U>,
replacing references to &ldquo;Chiesi&rdquo; with &ldquo;Protalix&rdquo; and vice-versa) in relation thereto, subject to the balances
remaining under each of the Development Costs Cap, the Annual Cap, and the Required Studies Cap, as applicable, as of the date
on which Chiesi first exercises such step-in rights; <U>provided</U> that any such reimbursement obligation of Protalix shall not
be required to be paid by Protalix, but rather shall only be applied by deducting such amounts from immediately applicable future
payment obligations of Chiesi to Protalix under this Agreement. For example, if one million dollars ($1,000,000) remains in the
Development Costs Cap for the Ongoing Clinical Studies at the time Chiesi exercises its step-in rights, Protalix&rsquo;s responsibility
to reimburse [***] of Chiesi&rsquo;s Development Costs in relation thereto shall be limited to a maximum of one million dollars
($1,000,000). In the event that the remaining amounts of the Development Costs Cap or [***] are exceeded during the course of Chiesi&rsquo;s
exercise of its step-in rights, Chiesi shall be responsible for [***] of the Development Costs incurred in excess of either such
cap. For the avoidance of doubt, [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursement
Payments</U>. Where either Party is required to reimburse the other Party in accordance with the terms of this Agreement (including,
for the avoidance of doubt, if Protalix has incurred certain Development Costs but Chiesi is responsible for paying such Development
Costs pursuant to this <U>Section 5.3</U>), then the Party to whom such reimbursement is owed (the &ldquo;<U>Reimbursed Party</U>&rdquo;)
may, on a monthly basis, send an invoice to such other Party (the &ldquo;<U>Reimbursing Party</U>&rdquo;) with respect to such
reimbursable amounts, along with reasonable evidence thereof, and such Reimbursing Party shall issue payment against such invoices
within forty five (45) days of the invoice date (other than as set forth in this <U>Section 5.3 </U>or elsewhere in this Agreement,
including <U>Section 5.1</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ACCOUNTING AND PROCEDURES FOR PAYMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic
Reporting and Reconciliation Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports;
Payments</U>. Within [***], Chiesi shall provide Protalix with a report stating the Net Sales, Direct Sublicensee Revenue A, Direct
Sublicensee Revenue B and Sublicensee Net Sales and computation thereof (including sales in units and in value of the Licensed
Product made by or on behalf of Chiesi and its Affiliates and its Sublicensees (together with the calculation of Included Sublicensee
Revenue) as applicable, in the Territory, and any permitted deductions from Net Sales and Sublicensee Net Sales), on a Country-by-Country
basis, during such preceding Commercial Quarter, together with the calculation of the Price reconciliations as set out in <U>Section
4.6(g)</U> and, if applicable, <U>Section 4.6(h)</U> and the exchange rates used (together with any other supporting documentation
reasonably requested by Protalix).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U>.
In the event of a dispute regarding any amount reported by a Party pursuant to <U>Section 6.1(a)</U>, the disputing Party shall
provide a notice of the dispute to the other Party, and the Parties will promptly meet and negotiate in good faith a resolution
to such dispute. In the event that the Parties are unable to resolve such dispute within thirty (30) days after notice by the disputing
Party, the Parties will (i) use Commercially Reasonable Efforts to reach agreement on the appointment of one internationally-recognized
independent accounting firm to determine the matter, or (ii) if the Parties cannot reach agreement on such accounting firm within
sixty (60) days after notice by the disputing Party, then each Party will appoint one internationally-recognized accounting firm
and such firms will choose a third internationally-recognized independent accounting firm to make the final determination, which
shall be binding on the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Currency</U>.
All payments to be made hereunder by one Party to the other Party shall be computed and paid in United States dollars. For the
purposes of determining Net Sales, Direct Sublicensee Revenue A, Direct Sublicensee Revenue B and Sublicensee Net Sales, amounts
received in any foreign currency shall be converted into United States dollars using the average rate of exchange of the currency
of such Country for the applicable calendar month in which such Net Sales, Direct Sublicensee Revenue A, Direct Sublicensee Revenue
B or Sublicensee Net Sales occur, as published in the official Bank of Italy website (<U>http://cambi.bancaditalia.it/cambi/cambi.do?lingua=en&amp;to=cambiMedieMForm</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Method
of Payments</U>. Each payment to be made hereunder by either Party to the other Party shall be made by electronic transfer in immediately
available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic
funds transfer, at the other Party&rsquo;s election, to the account designated (in writing) by the other Party on or before the
Effective Date. With respect to any payment invoiced by either Party to the other Party, the other Party may designate a different
bank account on such invoice. With respect to any other payment, either Party may designate a different bank account at least thirty
(30) days before such payment is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Set-Off</U>. All payments which either Party is required to make under this Agreement shall be made without any set-off, counterclaim
or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest
for Late Payments</U>. If either Party fails to make any payment due under this Agreement within [***] of the date upon
which such payment is due, then interest shall accrue on such payment on a daily basis from the date such payment was
originally due at a rate equal to weekly LIBOR (as published in <U>The Wall Street Journal</U>, New York edition and as
officially confirmed by an officer of the respective Party) plus [***], or at the maximum rate permitted by applicable Law,
whichever is the lower, and such interest shall be paid when such payment is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspection
of Records</U>. Chiesi shall, and shall cause its Affiliates and Sublicensees to, keep accurate books and records with respect
to the Commercialization of Licensed Product hereunder, setting forth gross sales of the Licensed Product and Net Sales, Direct
Sublicensee Revenue A, Direct Sublicensee Revenue B and Sublicensee Net Sales sufficient to enable the calculation of amounts payable
hereunder to be verified. Protalix shall, and shall cause its Affiliates and sublicensees to, keep accurate books and records setting
forth the Price for the Licensed Products purchased by Chiesi from Protalix hereunder, sufficient to enable the calculation of
the Price to be verified (the foregoing books and records of Chiesi and Protalix and their respective Affiliates and sublicensees,
the &ldquo;<U>Financial Records</U>&rdquo;). Additionally, each Party shall keep sufficiently detailed books and records to enable
the other Party to monitor such Party&rsquo;s compliance with the provisions of <U>Sections 9.1(i)</U> and <U>9.1(j)</U> below
(such additional books and records, &ldquo;<U>Compliance Records</U>&rdquo;). Each Party will retain such Financial Records and
Compliance Records for [***] after the end of the Calendar Year, in which they are generated in order to enable audit of such records
as set forth below. Each Party will have the right to request that an independent certified public accountant selected by it examine
the other Party&rsquo;s Financial Records, or that such Party&rsquo;s nominated representative examine the other Party&rsquo;s
Compliance Records, in each case, at any reasonable time, upon reasonable notice and at the facility(ies) where the other Party&rsquo;s
Financial Records or Compliance Records are normally kept (an &ldquo;<U>Audit</U>&rdquo;). The foregoing rights of examination
may be exercised only [***] during each twelve (12)-month period of the Term and only [***] during each twelve (12)-month period
in the three (3) years after final payment has been made. The audited Party may require such accountants (or nominated representative)
to enter into a reasonably acceptable confidentiality agreement. In respect of an Audit of a Party&rsquo;s Financial Records, the
opinion of said independent accountants regarding such payments shall be binding on the Parties, other than in the case of manifest
error. Except as set forth below, [***] shall bear the cost of any such examination and review. In respect of a Party&rsquo;s Financial
Records, if such Audit by either Party of the other Party&rsquo;s books and records reveals that such other Party has made an underpayment
(or received an overpayment) under this Agreement, then the Party in receipt of any such overpayment, or the Party responsible
for any such underpayment, shall promptly reimburse the other Party in the amount of such overpayment or underpayment (as applicable)
as was revealed by such Audit. If the discrepancy revealed by the Audit is greater than [***] of the amount due, then the Party
responsible for the inaccurate reporting resulting in such overpayment or underpayment shall also promptly reimburse the other
Party for any and all costs incurred in connection with such Audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
Subject to <U>Section 6.7(c)</U> below, Chiesi shall assume and pay any and all taxes, customs, duties, assessments, excises and
other charges levied upon the importation of or assessed against the Drug Product [***] supplied or rights licensed by Protalix
hereunder, or for or on account of the Commercialization of the Licensed Product in the Territory. Prior to [***], Protalix shall
assume and pay any and all taxes, customs, duties, assessments, excises and other charges levied upon the importation of or assessed
against the Drug Substance in the EU with respect to the shipment of Drug Substance from Protalix to [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>VAT</U>.
It is understood and agreed between the Parties that any payments made by Chiesi under this Agreement are exclusive of any value
added or similar tax imposed upon such payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding
Tax</U>. Payments made by Chiesi to Protalix pursuant to this Agreement shall be made free and clear of any withholding in respect
of taxes. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>.
Each Party shall provide the other with reasonable assistance to enable a reduction in, elimination of, or the recovery, as permitted
by applicable Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery
to be for the benefit of the Party bearing such withholding tax or VAT. Chiesi shall provide reasonable notice to Protalix of its
intent to withhold any amount in respect of taxes, and Protalix shall provide to Chiesi any tax forms that may be reasonably requested
by and necessary for Chiesi not to withhold tax or to withhold tax at a reduced rate under applicable Law (including an applicable
income tax treaty). Each Party further agrees to provide reasonable cooperation to the other Party, at the other Party&rsquo;s
expense, in connection with any official or unofficial tax audit or contest relating to payments made by Chiesi to Protalix under
this Agreement. Chiesi assumes the sole responsibility of procuring any required permits, authorizations, licenses or consents
of Governmental Authorities for the export of funds as may be required in the Territory; <U>provided</U>, <U>however</U>, that
to the extent that it is impossible to make such payments due to the &ldquo;blocking&rdquo; of funds by applicable Law, such &ldquo;blocked&rdquo;
funds shall be deposited to the credit of Protalix in such depository as Protalix designates subject to such applicable Law or
Chiesi or its Affiliates shall otherwise pay Protalix an amount equal to such &ldquo;blocked&rdquo; funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PATENTS AND INFRINGEMENT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing
and Prosecution</U>. Protalix shall have the exclusive right, subject to <U>Sections 7.2</U> through <U>7.5</U>, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file
Patent Applications on any invention included in the Protalix Patent Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;take
all reasonable steps to prosecute all pending and new Patent Applications included within the Protalix Patent Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;respond
to oppositions, interferences, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties
against the grant of Patents for such Patent Applications; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maintain
in force any patents in the Territory included within the Protalix Patent Rights by duly filing all necessary papers and paying
any fees required by the relevant patent Laws of the particular Country in which the patent was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Correspondence</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will keep Chiesi informed of the status of the Protalix Patent Rights to the extent the Protalix Patent Rights [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
will, upon Chiesi&rsquo;s request, provide Chiesi with copies of all substantive documentation submitted to, or received from,
the patent offices in the Territory in connection therewith. With respect to any Protalix Patent Rights that are not Protalix System
Patent Rights, Protalix shall consider in good faith all comments provided by Chiesi with respect to a Protalix Patent Right in
the Territory to the extent relating to the Compound or Licensed Product in the Field in the Territory or the Commercialization
of the Licensed Product in the Field in the Territory. Protalix shall have final-decision making authority with respect to filings
and prosecution of Protalix Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance</U>.
Protalix will [***] to maintain for the full life thereof all Patent Rights under the Protalix Patent Rights where the abandonment
for non-payment [***]. Protalix will notify Chiesi of any decision (a) not to file applications for, or (b) not to enter the national
phase for a PCT Patent Application (or not to validate a patent in a particular Country) for, or (c) to cease prosecution and/or
maintenance (including the occurrences as set out in <U>Section 7.2</U>) of, or (d) not to pursue, or (e) to cease to pay the expenses
of prosecution or maintenance of, any Protalix Patent Rights in any Country in the Territory. In such event, Chiesi shall have
the right to make the filing, or to continue the prosecution and maintenance of such Patent Rights (other than Protalix System
Patent Rights) in Protalix&rsquo;s name [***]. Notwithstanding the foregoing, Protalix shall have no obligation to provide such
notice where the subject Protalix Patent Rights are directed [***] or otherwise where loss of the subject Protalix Patent Rights
would not reasonably be expected to impair the Licensed Product in the Field in the Territory in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Protalix agrees that it will, and will cause its Affiliates to execute and file those notices and other filings as Chiesi shall
reasonably request be made, from time to time with any patent office in the Territory with respect to the rights granted under
this Agreement, at Chiesi&rsquo;s sole cost and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation of
Patent Judgments</U>. If any claim relating to a Patent under the Protalix Patent Rights becomes the subject of a judgment, decree
or decision of a court, tribunal, or other authority of competent jurisdiction in any Country, which judgment, decree, or decision
is or becomes final (there being no further right of review) and adjudicates the validity, enforceability, scope, or infringement
of the same, the construction of such claim in such judgment, decree or decision shall be followed thereafter in such Country not
only as to such claim but also as to all other claims in such Country to which such construction reasonably applies, in determining
whether there are any Valid Claims in such Country. If at any time there are two or more conflicting final judgments, decrees,
or decisions with respect to the same claim, the decision of the higher tribunal shall thereafter control, but if the tribunal
be of equal rank, then the final judgment, decree, or decision more favorable to such claim shall control unless and until the
majority of such tribunals of equal rank adopt or follow a less favorable final judgment, decree, or decision, in which event the
latter shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third
Party Royalty Obligations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
either Party reasonably determines in good faith that in order to avoid infringement of any Patent Right not licensed hereunder,
it is reasonably necessary to obtain a license or acquire the relevant Patent Right or Technology from a Third Party in order to
make, use, sell, offer for sale, supply, cause to be supplied, or import the Licensed Product in a Country in the Territory and
to pay a royalty or other consideration under such license or acquisition (including in connection with the settlement of a patent
infringement claim), then the Steering Committee shall discuss the pertinent Third Party Patent Right and/or Technology and such
Party&rsquo;s determination. If the Steering Committee decides (by mutual agreement of the Steering Committee members) that Chiesi
should enter into such license or acquisition, Chiesi shall use Commercially Reasonable Efforts to negotiate and enter into a license
or acquisition for such Third Party Patent Right and/or Technology. The Steering Committee (by mutual agreement of the Steering
Committee members) shall determine each Party&rsquo;s respective share of any payments to the relevant Third Party, other than
as provided in <U>Section 13.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than as provided in <U>Section 13.2</U>, if Chiesi is subject to a final court or other binding order or ruling requiring any payments,
including the payment of a royalty to a Third Party Patent holder in respect of Commercialization of the Licensed Product in a
Country in the Territory, then the amount of such payments made by Chiesi to the Third Party shall be in addition to, and separate
from, any payments due to Protalix under this Agreement; <U>provided</U> that the Steering Committee (by mutual agreement of the
Steering Committee members) shall determine each Party&rsquo;s respective share of any such payments to the relevant Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party
Infringement</U>. Each Party will promptly notify the other in the event of any actual, potential or suspected infringement
of a Patent under the Protalix Patent Rights by any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement
of Protalix Patent Rights in the Field</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
shall have the first right, but not the obligation, to institute litigation or take other remedial measures in connection with
Third Party infringement of the Protalix Patent Rights occurring in the Field within the Territory [***], where such Third Party
infringement would reasonably be expected to impair or has impaired the Commercialization of the Licensed Product in the Field
in the Territory in any material respect. In order to establish standing, Protalix, upon request of Chiesi, agrees to timely commence
or to join in any such litigation, at Chiesi&rsquo;s cost and expense, and in any event to reasonably cooperate with Chiesi at
Chiesi&rsquo;s cost and expense. [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of any Protalix Patent Rights occurring outside of the Territory and with respect to Third Party infringement
of any Protalix Patent Rights directed solely to any Outside of the Scope Product or occurring outside the Field (within or outside
of the Territory) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Actions by a Third Party</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall promptly notify the other in the event of any (i) claims by a Third Party of alleged patent infringement by Chiesi
or Protalix or any of their respective Affiliates with respect to the research, Development, Manufacture, use, sale, offer for
sale or importation of a Compound (other than as used in New Use) or the Licensed Product or (ii) legal or administrative action
by any Third Party involving a Protalix Patent Right [***] of which it becomes aware, including any nullity, revocation, reexamination
or compulsory license proceeding. Unless subject to the indemnity provided by Protalix under <U>Section 13.2</U> (in which case
Protalix shall have sole control of such action and the defense thereof) or by Chiesi under <U>Section 13.1</U> (in which case
Chiesi shall have sole control of such action and the defense thereof), Chiesi shall have the first right, but no obligation, to
defend against any such action involving such Protalix Patent Right in the Territory when the alleged patent infringement would
reasonably be expected to impair the Commercialization of the Licensed Product in the Field in the Territory in any material respect
[***]. Protalix, upon request of Chiesi, agrees to join in any such action [***] and in any event to reasonably cooperate with
Chiesi [***]. If Chiesi declines to defend Protalix against any such action involving a Protalix Patent Right, then Protalix shall
have the right to defend such action [***]. Chiesi, upon request of Protalix, shall reasonably cooperate with Protalix in any such
action [***]. The Party defending against such action in accordance with this <U>Section 7.8</U> shall assume direction and control
of the defense, litigation, settlement, appeal or other disposition of such Claim (including the right to settle the Claim solely
for monetary consideration for which such Party will be responsible) with counsel selected by such Party and reasonably acceptable
to the other Party. The other Party shall have the right to join in (including the right to conduct discovery, interview and examine
witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Claim that such
Party is defending as provided in this <U>Section 7.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Party will enter into any settlement of any suit involving Licensed Products that materially affects the other Party&rsquo;s
rights or obligations with respect to the Licensed Product without the other Party&rsquo;s prior written consent (which
consent shall not be unreasonably withheld, delayed or conditioned). Without limiting the foregoing, neither Party shall,
without the written consent of the other Party (which consent shall not be unreasonably withheld, delayed or conditioned),
effect any settlement of any pending or threatened litigation in which the other Party has any potential liability, unless
such settlement involves solely monetary damages and includes an unconditional release of such other Party from all liability
on Claims that are the subject matter of such litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Marking</U>. Each Party shall comply with the patent marking statutes in each Country in which a Licensed Product in the Field
is made, offered for sale, sold or imported by such Party, its Affiliates and sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CONFIDENTIALITY; PUBLICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that
for the Term and for [***] years thereafter, each Party shall keep confidential and shall not publish or otherwise disclose and
shall not use for any purpose any Confidential Information furnished to it by the other Party pursuant to this Agreement, in a
manner no less protective than the actions it would customarily take to preserve the confidentiality of its own similar types of
confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Disclosures</U>. Notwithstanding the foregoing, each Party may disclose the other Party&rsquo;s Confidential Information (a) to
such Party&rsquo;s employees, consultants (including, for greater certainty, financial advisors), Affiliates, agents, contractors,
or permitted sublicensees who are bound by obligations relating to confidentiality at least as restrictive of those contained herein
and who have a need to know such information in connection with such Party&rsquo;s performance of its obligations or practice or
enforcement of its rights under this Agreement, (b) to Regulatory Authorities in connection with any Regulatory Approvals required
for Development of Licensed Product pursuant to the Development Plan or in compliance with applicable Law, including any requirements
under or pursuant to the Food and Drug Administration Amendments Act of 2007, or (c) pursuant to <U>Sections 8.3</U> and <U>8.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms of Agreement</U>.
The Parties agree that the material terms of this Agreement will be considered Confidential Information of both Parties. Subject
to <U>Section 8.4</U> below, no Party shall, without the prior written consent of the other Party, disclose in any manner to any
Third Party the material terms and conditions of this Agreement, except for terms or subject matter which has been the subject
of prior public disclosure or has been mutually approved for such disclosure and except as set forth below. Chiesi acknowledges
that Protalix or its Affiliates may be legally required to file this Agreement as an exhibit to filings with the U.S. Securities
and Exchange Commission. In addition: (a) either Party may disclose such terms as are required to be disclosed in its publicly-filed
financial statements or other public statements, pursuant to applicable Laws, regulations and stock exchange rules (<U>e.g.</U>,
the rules of the U.S. Securities and Exchange Commission, the NYSE American, the NYSE, NASDAQ, or any other stock exchange on which
securities issued by either Party may be listed); <U>provided</U> that such Party shall provide the other Party with a copy of
the proposed text of such statements or disclosure (including any exhibits containing this Agreement) sufficiently in advance of
the scheduled release or publication thereof to afford such other Party a reasonable opportunity to review and comment upon the
proposed text (including redacted versions of this Agreement), (b) either Party shall have the further right to disclose the terms
of this Agreement under a confidentiality obligation no less protective than those set forth in this Agreement, to any potential
sublicensee, acquirer, merger partner, investor, business partner or potential providers of financing and their advisors or, in
the case of Protalix, to the owner of any Protalix Patent Rights or Protalix Technology Controlled by Protalix, and (c) Protalix
and Chiesi shall have the right to disclose information regarding the development or commercialization status of the Licensed Product
in the Field in the Territory to the extent such disclosure by Protalix or Chiesi, as applicable, is required by applicable Laws
or stock exchange rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory
Disclosure</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 67.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification
and Consultation</U>. In the event that a Party is required by applicable Law (including rules of an applicable stock exchange),
or pursuant to legal, governmental or self-regulatory organization proceedings (including by court order or judicial or administrative
process) to disclose any part of the other Party&rsquo;s Confidential Information (including material terms or conditions of this
Agreement), such Party shall (i) promptly notify the other Party of each such requirement and identify the documents so required
thereby, so that the other Party may seek an appropriate protective order, confidential treatment or other remedy concerning any
such disclosure and/or waive compliance by such Party with the provisions of this Agreement and (ii) consult with the other Party
with respect to taking legally available steps to resist or narrow the scope of such requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 67.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-indent: 67.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limited
Disclosure</U>. If, in the absence of such a protective order, confidential treatment request, other remedy or waiver by the other
Party, such Party is nonetheless required to disclose any part of the other Party&rsquo;s Confidential Information or any material
terms or conditions of this Agreement, such Party may disclose such Confidential Information or material terms or conditions without
liability under this Agreement, except that such Party shall furnish only that portion of the Confidential Information or material
terms or conditions that in its good faith judgment, after consultation with legal counsel, it is legally required to provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publication</U>.
Subject to the restrictions set out below, nothing herein shall prevent Protalix and its Affiliates (and their respective employees,
consultants, contractors, licensees and agents) from publishing or presenting information relating to the development or use of
the System, Compound or Licensed Product or otherwise (a) limit the rights of Protalix&rsquo;s Third Party clinical investigators
to publish the results of their studies or (b) prevent Protalix or its Affiliates from complying with applicable Law with respect
to the disclosure of clinical study data and results or of any other material matter or information. Each Party recognizes that
the publications regarding results of and other information regarding Development of Licensed Products in the Field in the Territory,
including oral presentations and abstracts, may be beneficial to both Parties, provided that publications are subject to reasonable
controls to protect Confidential Information and the Parties&rsquo; mutual interest in obtaining rights in patent and protecting
trade secret information. The Steering Committee shall appoint one referent person for each Party for reviewing and approving such
publications (&ldquo;<U>Referent Person</U>&rdquo;). Accordingly, the Party proposing to submit any such publication or presentation
shall first deliver to the Referent Person for review a copy of such Party&rsquo;s proposed publication or presentation that pertains
to the Compound, Drug Substance, Drug Product or Licensed Product in the Field in the Territory prior to submitting the material
to a publisher or initiating any such publication thereof. The Referent Person of the non-proposing Party must make a reasonable,
good faith determination as to (solely in respect of publications to scientific journals or similar mediums and submission of abstracts
to medical congresses) whether the proposing Party may submit such publication, and may (x) require modifications of such publication
prior to it being submitted (i) to protect each Party&rsquo;s respective Confidential Information, or (ii) for trade secret reasons
or other material commercial reasons; (y) request that the proposing Party delay such submission for an additional period as may
be reasonably necessary to seek patent protection for the information disclosed in such proposed written submission; and (z) withhold
its approval for such publication if it makes a reasonable, good faith determination that such publication will have an adverse
effect on the non-publishing Party&rsquo;s ability to procure a patent or Develop or Commercialize any Licensed Product. The Referent
Person of the non-publishing Party shall conduct its review and provide its approval as promptly as reasonably practicable, but
in any event within [***] days in case of publications to scientific journals or similar medium and any abstracts to medical congresses
(and the failure to provide any such response with such [***] day period shall be deemed approval hereunder). If the Parties are
unable to reach agreement on whether the proposing Party may submit such publication, or on the scope of any reasonably necessary
modifications or delay in respect of such publication, the issue shall be escalated to the Parties&rsquo; respective Chief Executive
Officers, who shall attempt to resolve the issue within [***] days. In respect of any oral or in-person presentations at medical
conferences or medical congresses, posters, trade shows, or similar activities (but, for clarity, excluding business forums), the
Referent Person of the non-publishing Party shall be afforded at least [***] Business Days to review and provide comment on any
initial working draft thereto and [***] Business Days to review and provide comment on any revised draft (unless a working draft
or revised draft is not available or, acting in good faith, the publishing Party considers such review period would risk delaying
submission or missing a relevant deadline), and the publishing Party shall consider any such comments received during such [***]
Business Day period in good faith; <U>provided</U>, <U>however</U>, that in respect of such oral or in-person presentations, the
publishing Party shall not require the approval of the Referent Person of the non-publishing Party to proceed with such presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; text-indent: 31.5pt">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity</U>.
A draft public announcement of the execution of this Agreement is set forth on <U>Exhibit C</U> attached hereto and, subject to
Protalix&rsquo;s further review and comment, shall be promptly disseminated as a press release following the execution of this
Agreement by both Parties and the approval by Protalix of the final form thereof. Other than with respect to the matters addressed
in <U>Section 8.5</U> and disclosures required by applicable Law or stock exchange rules, each Party shall only issue press releases
that contain material new information (<U>i.e.</U>, material information that has not been previously disclosed) concerning the
terms of, or events related to, this Agreement or concerning the Compound, Drug Substance, Drug Product or Licensed Product after
having provided the other Party with an opportunity to review and approve (such approval not to be unreasonably withheld, conditioned
or delayed) such statement; <U>provided</U> that failure to disapprove of such press release in writing within two (2) Business
Days shall be deemed approval hereunder. Such Party shall give due consideration to any specific reasonable comments of the other
Party on such text timely received from the other Party, subject to such Party&rsquo;s compliance with applicable Laws and stock
exchange rules with respect to disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; text-indent: 31.5pt">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing,
Registration or Notification of the Agreement</U>. Protalix shall provide Chiesi with a proposed form of redacted copy of this
Agreement (the &ldquo;<U>Redacted Agreement</U>&rdquo;) for Chiesi&rsquo;s review and comment as soon as reasonably practicable
after the Effective Date, and Protalix shall consider any comments from Chiesi in good faith; <U>provided</U>, <U>however</U>,
that the final form of such Redacted Agreement shall be determined by Protalix. If a Party determines that it is required by Law
to publicly file, register or notify this Agreement with a Governmental Authority, such Party shall (a) initially file the Redacted
Agreement, (b) request, and use Commercially Reasonable Efforts to obtain, confidential treatment of all terms redacted from this
Agreement, as reflected in the Redacted Agreement, for a period of at least [***] years, (c) permit the other Party to review and
approve such request for confidential treatment and any subsequent correspondence with respect thereto at least [***] Business
Days prior to its submission to such Governmental Authority, (d) promptly deliver to the other Party any written correspondence
received by it or its representatives from such Governmental Authority with respect to such confidential treatment request and
promptly advise the other Party of any other communications between it or its representatives with such Governmental Authority
with respect to such confidential treatment request, (e) upon the written request of the other Party, request an appropriate extension
of the term of the confidential treatment period, and (f) if such Governmental Authority requests any changes to the redactions
set forth in the Redacted Agreement, use Commercially Reasonable Efforts to support the redactions in the Redacted Agreement as
originally filed and shall not agree to any changes to the Redacted Agreement without first discussing such changes with the other
Party and taking the other Party&rsquo;s comments into consideration when deciding whether to agree to such changes. Each Party
shall be responsible for its own legal and other external costs in connection with any such filing, registration or notification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>REPRESENTATIONS, WARRANTIES AND COVENANTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mutual
Representations, Warranties and Covenants</U>. Each of Chiesi and Protalix hereby represents and warrants to the other Party as
of the Effective Date (and covenants as set forth in <U>Sections 9.1(h)</U>, <U>9.1(i)</U>, <U>9.1(j)</U>, <U>9.1(k)</U>, and <U>9.1(l)</U>
below) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation,
as applicable. It has the requisite corporate power and authority to conduct its business as presently being conducted and as proposed
to be conducted by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
has the requisite corporate power and authority to enter into this Agreement and to perform its obligations hereunder. All corporate
actions on its part, necessary for (i) the authorization, execution, delivery and performance by it of this Agreement, and (ii)
the consummation of the transactions contemplated hereby, have been duly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
the due authorization, execution and delivery by the other Party, this Agreement constitutes a legally valid and binding obligation
of such Party, enforceable against it in accordance with its terms (except in all cases as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, or similar Laws affecting the enforcement of creditors&rsquo; rights
generally and except that the availability of the equitable remedy of specific performance or injunctive relief is subject to the
discretion of the court or other tribunal before which any proceeding may be brought).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no contractual restriction or obligation binding on such Party which would be materially contravened by execution and delivery
of this Agreement or by the performance of its terms. Apart from expiration or termination of any applicable waiting periods (including
any extensions thereof) required by any applicable Law or governmental entity for antitrust purposes in the Territory, there are
no governmental filings or consents necessary for the consummation of this Agreement and the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Party is not debarred, and such Party in relation to the Licensed Product is not using, has not used, and will not use in any capacity
the services of any person debarred, in each case under Subsection 306(a), (b) of the Generic Drug Enforcement Act of 1992, or
any non-U.S. equivalent Law to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
such Party&rsquo;s knowledge, no representation or warranty made by it in this Agreement, nor any statement contained in any schedule
hereto furnished by it, contains any untrue statement of a material fact or omits any material fact necessary to make the statements
contained herein or therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no litigation, proceeding or investigation pending or, to such Party&rsquo;s knowledge, threatened against such Party in any
court or before any agency or regulatory body which would reasonably be expected to materially adversely affect such Party&rsquo;s
ability or right to carry out the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term, each Party shall promptly notify the other Party in writing upon learning of any actual or threatened investigation,
inquiry, action or proceeding before the EMA or any other Regulatory Authority in the Territory with respect to the Compound, Drug
Substance, Drug Product or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall (i) comply in all material respects with applicable anti-bribery Laws and the Chiesi Anti-Bribery Policy, attached
hereto as <U>Exhibit D</U>, and (ii) adopt, implement and keep for the Term, reasonably adequate measures aimed at preventing the
commission, even attempted, of conduct in violation in any material respect of anti-bribery Laws by its Affiliates, directors,
representatives, employees, and/or consultants involved in the performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party and its Affiliates, directors, representatives, employees, and/or consultants involved in the performance of this Agreement,
in performing their obligations under this Agreement shall not, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;offer,
transfer, promise or pay money, commissions, compensation or any other benefit (including gifts, entertainment, or any other similar
benefit, even low value or non-material benefits, unless they can be considered as low value courtesy benefits) in favor of public
or private parties, in violation of applicable anti-bribery Laws, the Chiesi Anti-Bribery Policy and/or with the intention of or
as a condition to obtaining illegal benefits in favor of Chiesi or Protalix;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;direct
a Third Party to carry out the activities set out in subsection (i) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;give,
transfer or promise money, commissions, compensation and rewards in kind (including gifts, entertainment or any other similar benefit,
even low value or non-material benefits, unless they can be considered as low value courtesy benefits) to the other Party&rsquo;s
directors, legal representatives, employees or whoever acts on behalf of such other Party, in violation of any applicable anti-bribery
Law and beyond the limits set forth within the Chiesi Anti-Bribery Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
to the extent this provision would be a violation of any applicable Laws, Protalix shall promptly notify Chiesi at the following
Chiesi e-mail address: groupcompliance@chiesi.com, and Chiesi shall promptly notify Protalix at the following Protalix e-mail address:
moshe.manor@protalix.com, if such Party becomes aware of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
request, promise, offer, or donation of money, commission, compensation or rewards in kind (including gifts, entertainments, or
any other similar benefit, even low value or non-material benefits) made to public officers, private parties or the other Party&rsquo;s
directors, legal representatives or employees (or whoever acts on behalf of such other Party), in relation to the activities prohibited
under <U>Section 9.1(j)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
gift, entertainment or any other similar benefit, even non-material benefits, carried out by either Party in breach of the provisions
of <U>Section 9.1(j)</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
investigation, administrative suit, law suit or other procedure involving such Party in relation to corruption, bribery or any
other similar harmful act to the public treasury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall conduct, and shall use reasonable efforts to cause its Affiliates to conduct, all its activities contemplated under
this Agreement in accordance with all applicable Laws of the Country in which such activities are conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Representations, Warranties and Covenants of Protalix</U>. Protalix hereby further represents and warrants to Chiesi as of the
Effective Date (and covenants as set forth in <U>Sections 9.2(f)</U>, <U>9.2(g)</U>, <U>9.2(h)</U>, <U>9.2(i)</U>, <U>9.2(n)</U>,
<U>9.2(r)</U> and <U>9.2(s)</U> below), that, except as set forth in any publically available filings of Protalix or its Affiliates,
and solely in respect of the Territory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibit
A</U> contains a complete and correct list as of the Effective Date of all Patents and Patent Applications owned by Protalix covering
the Compound, any Licensed Product and the System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
is the sole and exclusive owner of, or has exclusive rights to, all of the Protalix Patent Rights in existence on the Effective
Date that relate to the Compound and/or the Licensed Product in the Field, and the Protalix Patent Rights set forth on <U>Exhibit
A</U> are in full force and effect and free and clear of all liens and other encumbrances, security interests or options (other
than pursuant to any agreements, secured debt or other financing referenced in Protalix&rsquo;s or its Affiliates&rsquo; publically
available filings).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has the right to grant the licenses and rights in the Protalix Technology it purports to grant to Chiesi hereunder. For the avoidance
of doubt, the foregoing representation and warranty shall not be deemed a representation or warranty with respect to non-infringement,
which representation and warranty is solely addressed in <U>Section 9.2(k)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Protalix Patent Rights and Protalix Technology include all of the Patent and other intellectual property rights owned or Controlled
by Protalix or its Affiliates that are necessary for the Commercialization of the Licensed Product. The Protalix Patent Rights
have been prosecuted and maintained in accordance with all applicable Laws in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
government funding, facilities or resources of a university, college, other educational institution, research center or Regulatory
Authority was used in the creation or development of any Protalix Patent Rights and Protalix Technology, other than grants received
from the Office of Chief Scientist of the Israeli Ministry of Industry, Trade and Labor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Third Party License relating to the rights licensed to Chiesi under <U>Section 2.1</U> (and, as a consequence, may also relate
to other provisions of this Agreement) is a legal and valid obligation binding upon Protalix and, to Protalix&rsquo;s knowledge,
the relevant Third Party licensor (in each case, subject to the effect of any applicable bankruptcy, reorganization, insolvency,
moratorium or similar laws affecting creditors&rsquo; rights generally and subject, as to enforceability, to the effect of general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law)), and authorizes,
as necessary, Protalix to grant the sublicense(s) granted to Chiesi under this Agreement. As of the Effective Date, Protalix is
in compliance in all material respects with any such Third Party License and Protalix covenants that during the Term it shall not
modify or amend any Third Party License in a manner that would materially adversely affect Chiesi&rsquo;s access or rights hereunder
without the prior written consent of Chiesi. Protalix has received no notices, whether written or oral, from any Third Party licensor
alleging any past or present breach by Protalix of the terms of any such Third Party License. Protalix has issued no notices, whether
written or oral, to any Third Party licensor alleging any past or present breach by any Third Party licensor of the terms of the
relevant Third Party License. Protalix has provided Chiesi with true, correct and complete copy of any Third Party License, including
any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall not take any action that would materially adversely affect the rights granted to Chiesi hereunder with respect to any Third
Party License, including selling, assigning or transferring the rights of Protalix under any Third Party License with respect to
the Protalix Patent Rights and Protalix Technology, in each case, as relate to the Compound and/or the Licensed Product in the
Field in the Territory, without Chiesi&rsquo;s prior written consent. Protalix shall: (i) comply in all material respects with
and perform all of its material duties and obligations under any Third Party License relating to the Protalix Patent Rights and
Protalix Technology, in each case, as relate to the Compound and/or the Licensed Product in the Field in the Territory; (ii) not
intentionally take or fail to take any action within Protalix&rsquo;s reasonable control under any Third Party License that would
materially adversely affect Chiesi&rsquo;s rights under this Agreement; (iii) use its Commercially Reasonable Efforts to enforce
the provisions of any Third Party License against the relevant Third Party licensor; and (iv) not modify, amend or terminate any
Third Party License with respect to the Protalix Patent Rights or Protalix Technology, in each case, as relate to the Compound
and/or the Licensed Product in the Field in the Territory, in a manner that would materially adversely affect Chiesi&rsquo;s rights
under this Agreement, without the prior written consent of Chiesi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 8</U>, Protalix shall promptly notify Chiesi (other than to the extent Protalix, acting reasonably, determines that
such notice could waive attorney-client privilege or any other legal privilege held by Protalix, or would otherwise breach a confidentiality
provision or obligation) in writing of (i) any actual or threatened in writing default (including failure to pay royalties when
due, if applicable), breach, suspension of compliance or performance, or termination (in whole or in part) under any Third Party
License that relates to the Protalix Patent Rights or Protalix Technology, in each case, as relates to the Compound and/or the
Licensed Product in the Field in the Territory, and which would materially adversely affect Chiesi&rsquo;s rights under this Agreement;
and (ii) the actual or threatened in writing commencement of any dispute, claim, suit, litigation or arbitration proceeding related
to the any Third Party License that relates to the Protalix Patent Rights or Protalix Technology, in each case, as relates to the
Compound and/or the Licensed Product in the Field in the Territory, and which would materially adversely affect Chiesi&rsquo;s
rights under this Agreement. Each such notification shall contain a summary of the event described therein. At the request of Chiesi,
and subject to <U>Section 8</U>, Protalix shall (other than to the extent Protalix, acting reasonably, determines that to do so
could waive attorney-client privilege or any other legal privilege held by Protalix, or would otherwise breach a confidentiality
provision or obligation) (x) promptly provide to Chiesi full particulars, of which it is aware, in writing of the applicable matter;
and (y) keep Chiesi reasonably informed as to the status and proposed resolution of each such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that Protalix receives notice of any default (including failure to pay royalties or other amounts when due) or breach
under any Third Party License that relates to the Protalix Patent Rights or Protalix Technology, in each case, as relates to the
Compound and/or the Licensed Product in the Field in the Territory and which would materially adversely affect Chiesi&rsquo;s rights
under this Agreement, and (i) has not cured such breach or default within ten (10) Business Days of receiving such notice, (ii)
has not procured the entry by Chiesi into a Standby License as described in <U>Section 2.2(d)</U>, and (iii) the amount of, and
liability for, such breach or default is not disputed by Protalix (acting in good faith) or has been resolved in Chiesi&rsquo;s
favor under <U>Section 14.3</U>, then Chiesi shall be entitled, but not obligated, to undertake payment or performance of the applicable
underlying obligation on behalf of Protalix as necessary to cure such default or breach and to offset, against amounts payable
to Protalix under this Agreement, any reasonable out-of-pocket costs and expenses incurred by Chiesi in the course thereof. In
the event and to the extent that Protalix disputes the existence of such breach or default (acting in good faith), either Party
may by written notice escalate the matter for discussions between the Chief Executive Officers of each Party to negotiate an agreed
approach to the alleged breach or default and, to the extent the Parties cannot reach such agreement within thirty (30) days of
the receipt of such notice, the Parties shall refer the matter for expert determination in accordance with <U>Section 14.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no material active, pending or, to Protalix&rsquo;s knowledge, threatened litigation or re-examination, pre- or post-grant or
inter partes review, interference, derivation, opposition, claim of invalidity or other claim or proceeding (including in the form
of any offer to obtain a license) alleging the invalidity, misuse, unregisterability, unenforceability or non-infringement of any
Protalix Patent Rights, or challenging Protalix&rsquo;s ownership of, or Protalix&rsquo;s right to practice or license, any Protalix
Patent Rights, or alleging any adverse right, title or interest with respect thereto (in each case, solely as relates to the Compound
and/or the Licensed Product in the Field in the Territory).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Protalix after a reasonable internal inquiry of its executive officers and legal personnel, the practice of the
Protalix Patent Rights and Protalix Technology in relation to the Compound and/or the Licensed Product in the Field in the Territory,
and the Manufacture, use of the Compound, Drug Substance and/or Drug Product or Commercialization of Licensed Product (as now formulated)
as contemplated under this Agreement, does not and will not infringe any issued Patent of any Third Party that exists on the Effective
Date or, if and when issued, any Valid Claim within any Third Party Patent Application published before the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
and its Affiliates have complied in all material respects with all applicable Laws, with respect to the Development, Manufacture,
use and handling of Compound, Drug Substance, Drug Product and Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has not received any Form 483 observations, warning letters or other communications from a Regulatory Authority which would reasonably
be expected to adversely impact the Development, Manufacture, use, handling of Compound, Drug Substance and/or Drug Product or
the Commercialization of Licensed Product in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drug
Product (and Compound and Drug Substance) supplied by Protalix to Chiesi hereunder, prior to delivery by Protalix under <U>Section
4.7</U>: (i) will be Manufactured and stored in material compliance with the Product Specifications, GMP and all other provisions
of this Agreement, the Quality Agreement and applicable Laws, including applicable environmental Laws, in force at the time of
Manufacture, (ii) will not contain any material that would cause the Compound, Drug Substance and/or Drug Product to be adulterated
or misbranded within the meaning of any applicable Laws and (iii) shall be free from defects in material and workmanship in all
material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
Protalix&rsquo;s knowledge, there are no material investigations, inquiries, actions or other proceedings pending before FDA, EMA
or any other Regulatory Authority with respect to the Compound, Drug Substance, Drug Product or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has not withheld any data or information known to Protalix related to the Compound, Drug Substance, Drug Product or Licensed Product,
including, but not limited to, preclinical and clinical data, regulatory filings and regulatory communications, in each case, that
would reasonably be expected to be material to Chiesi&rsquo;s decision to enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the excel file provided by Protalix to Chiesi via e-mail on October 10, 2017 relating to the costs
sustained by Protalix through June 30, 2017 for the Development of the Compound, Drug Substance, Drug Product and Licensed Product
is accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term, Protalix shall not grant any rights in violation of the rights and licenses granted herein, and Protalix shall not assign
the Protalix Patent Rights and/or material Protalix Technology in the Territory except to a permitted assignee of this Agreement
pursuant to <U>Section 15.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
shall perform its obligations under this Agreement in compliance in all material respects with applicable provisions of the International
Federal of Pharmaceutical Manufacturers &amp; Associations Code of Practice and applicable provisions of the Chiesi Code of Ethics
and Conduct, attached hereto as <U>Exhibit E</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
has obtained the assignment from the inventors of all inventorship rights in the Protalix Patent Rights owned by Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Representation and Warranty of Chiesi</U>. Chiesi hereby further represents and warrants to Protalix as of the Effective Date,
that to the knowledge of Chiesi, neither Chiesi nor any of its Affiliates (a) is engaged in the Development or Commercialization
of a Competing Product on the Effective Date nor (b) has in effect on the Effective Date a written plan to Develop a Competing
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer
of Warranty</U>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY, AND EACH PARTY DISCLAIMS ALL,
REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE, LICENSED PRODUCT,
SUCH PARTY&rsquo;S TECHNOLOGY OR PATENT RIGHTS, OR ANY OTHER MATTER, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>NON-COMPETITION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chiesi
Non-Compete</U>. In respect of each Country, other than to the extent this provision would be a violation of any applicable Laws
in such Country, from the Effective Date and throughout the Term, neither Chiesi nor any of its Affiliates (including through any
acquisition) shall, directly or indirectly, alone or in collaboration with any Third Party, Develop or Commercialize in any Country
any Competing Product; <U>provided</U> that to the extent any of the foregoing restrictions are not permissible under applicable
Law in a given Country, such restriction shall not apply only in such Country (and, if possible, shall be modified as necessary
to conform to applicable Law in such Country in a manner intended to achieve the original intent of the Parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TERM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Agreement shall be effective as of the
Effective Date and shall remain in effect until the later of (i) the expiration of the last enforceable Protalix Patent Right,
or (ii) the 15<SUP>th</SUP> anniversary of Launch on a Country-by-Country basis, unless earlier terminated pursuant to <U>Section
12</U> (the &ldquo;<U>Term</U>&rdquo;); [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TERMINATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Rights</U>. This Agreement may be terminated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mutual
Agreement</U>. This Agreement may be terminated in its entirety at any time upon mutual written agreement between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Breach</U>. Either Party may terminate this Agreement at any time upon written notice to the other Party if the other Party is
in material default or breach of this Agreement and such material default or breach is not cured within (i) thirty (30) days after
written notice thereof is delivered to the defaulting or breaching Party, or (ii) in the case of a breach that cannot be cured
within thirty (30) days, within a reasonable period not exceeding ninety (90) days after written notice thereof is delivered to
the defaulting or breaching Party, so long as the breaching Party is making a good faith effort to cure such default. For the avoidance
of doubt, a [***] does not constitute a material breach of this Agreement and shall not entitle Chiesi to terminate this Agreement.
Termination shall not be the sole remedy for material breach of this Agreement, and a Party may choose to continue to perform hereunder
and in response to any material breach may bring a claim for damages and other available remedies under this Agreement including,
where applicable, a claim for injunctive relief, and bringing such a claim in good faith shall not constitute a breach of this
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insolvency</U>.
Either Party may terminate this Agreement upon written notice to the other Party, if the other Party (i) files, or has filed against
it, a petition for voluntary or involuntary bankruptcy or pursuant to any other insolvency Law, or (ii) applies for, or consents
to, the appointment of a trustee, receiver or custodian for a substantial part of its property or business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
of Control</U>. Protalix may terminate this Agreement upon written notice, and agreement to pay the Buy-Back Payment, to Chiesi,
upon the occurrence of a Change of Control in respect of Chiesi; <U>provided</U>, <U>however</U>, that such written notice must
be provided within thirty (30) days of Protalix first becoming aware of the Change of Control. For purposes of this <U>Section
12.1(d)</U>, &ldquo;<U>Buy-Back Payment</U>&rdquo; means [***]. Upon receipt of the termination notice from Protalix, Chiesi must
within [***] issue an invoice for the applicable Buy-Back Payment. Such termination will take effect on the first Business Day
following written agreement by Protalix to pay the applicable Buy-Back Payment, which must be delivered within [***] of receipt
of an invoice provided by Chiesi for a Buy-Back Payment amount that is not disputed by Protalix in good faith. For the avoidance
of doubt, until such dispute is resolved pursuant to <U>Section 14.2</U>, such termination will not take effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Challenge</U>. Protalix may terminate this Agreement as provided in and in accordance with <U>Section 2.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[***].</U>
Without limiting its rights under <U>Section 12.1(b)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
may terminate this Agreement (i) in its entirety, upon at least [***] written notice to Chiesi if within [***] of receipt of Regulatory
Approval (and Price Approval and Governmental Authority or Third Party reimbursement approval where applicable and required) of
the Licensed Product in the [***], Chiesi has not Launched for reasons within its reasonable control (and, for clarity, not for
reasons outside Chiesi&rsquo;s reasonable control, <U>i.e.</U>, a Force Majeure Event) the Licensed Product in at least one Country
[***], or (ii) on a Country-by-Country basis, upon at least thirty (30) days&rsquo; written notice to Chiesi, if for a period of
[***] at any time following Launch of the Licensed Product in [***], Chiesi has [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
may terminate this Agreement in its entirety (or, at Protalix&rsquo;s option, with respect to the applicable Country), in the event
that Chiesi or any of its Affiliates (including through any acquisition), directly or indirectly, alone or in collaboration with
any Third Party, Develop or Commercialize in any Country any Competing Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuing
and Accrued Obligations</U>. After notice of termination is given and, subject to the further provisions of this <U>Section 12.2</U>,
prior to the effective date of termination, this Agreement, including all payment obligations hereunder, shall continue in full
force and effect, and the Parties shall continue to carry out and perform their respective Development, Manufacturing and Commercialization
activities in accordance with this Agreement through the effective date of termination. Without limitation of the foregoing, expiration
or termination of this Agreement for any reason (i) shall be without prejudice to and shall not impair or limit in any manner (A)
Protalix&rsquo;s right to receive payment from Chiesi of the Price (and any reconciliation amounts calculated in accordance with
<U>Section 4.6(h)</U>) in respect of sales of Licensed Product in the Territory occurring prior to the effective date of such expiration
or termination, whether or not the due date for such payment is after such effective date of expiration or termination, (B) Protalix&rsquo;s
right to receive the applicable Event Milestone Payment in respect of any Event Milestone which occurs prior to the effective date
of expiration or termination, whether or not the due date for such payment is after such effective date of expiration or termination,
(C) Protalix&rsquo;s right to receive payment from Chiesi in accordance with this Agreement for any Licensed Product ordered by
Chiesi pursuant to this Agreement prior to the effective date of such expiration or termination, whether or not the due date for
such payment is after such effective date of expiration or termination, and (D) any remedies that either Party may have and (ii)
shall not release a Party hereto from any indebtedness, liability, payment or other obligation incurred hereunder (including liability
for breach of this Agreement) by such Party prior to the effective date of expiration or termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effects
of Termination</U>. Upon expiration or the earlier effective date of termination of this Agreement in accordance with this <U>Section
12</U> or <U>Section 4.14(e)</U>, all licenses and rights provided for herein, and all obligations of the Parties hereunder, shall
terminate and this Agreement shall cease to be of further force or effect except as otherwise provided for in <U>Section 15.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
expiration or termination of this Agreement for any reason:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
shall, promptly after such expiration or termination, provide to Protalix or its designee the following materials; <U>provided
</U>that such materials shall be provided in the form and format in which such materials are maintained by Chiesi in the ordinary
course of business (<U>provided</U> that Chiesi shall use Commercially Reasonable Efforts to provide such materials in a form
and format useable by Protalix), and Chiesi shall not be required to prepare any new data, reports or information solely for purposes
of transfer to Protalix:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
regulatory filings, Regulatory Approvals, Price Approvals and Governmental Authority and Third Party reimbursement approvals to
the extent related to the Drug Substance, Drug Product or Licensed Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
pre-clinical and clinical data, reports and information (including drug master files) in Chiesi&rsquo;s possession or control to
the extent relating to a Licensed Product, Drug Product or Drug Substance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
reports, records, regulatory correspondence and other materials in Chiesi&rsquo;s possession or control to the extent relating
to the pre-clinical and clinical development of the Drug Substance, Drug Product or Licensed Product, and also including, if applicable,
any information contained in the global safety database established and maintained by Chiesi for the Licensed Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Product Marks actually used in commerce by Chiesi or its Affiliates for the Licensed Product, excluding the corporate or trade
name or logo of Chiesi or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
upon such expiration or termination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
hereby does (and shall) assign to Protalix, or a Protalix Affiliate identified by Protalix, all of Chiesi&rsquo;s right, title
and interest in and to the materials transferred or delivered or deliverable by Chiesi pursuant to <U>Section 12.3(a)(i)</U>, including
the goodwill attendant to any Product Marks, to the extent Chiesi Controls such materials; with respect to the Product Marks, Chiesi
shall execute an assignment of such Product Marks in favor of Protalix and Protalix shall be responsible for recording such assignment
with the appropriate governmental trademark authorities. Chiesi shall cooperate in facilitating such assignment and recordation
by timely executing all necessary documents provided to it by Protalix;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chiesi
hereby does (and shall) assign to Protalix any applicable sublicenses to the extent related to the Licensed Product and/or Third
Party agreements, with respect to significant services to be performed by Third Parties to the extent related to the Licensed Product
in the Field, unless Protalix has advised Chiesi that it will not require such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limitation of the generality of the foregoing, the Parties shall use diligent efforts to complete the transition of the Commercialization
of the Licensed Product in the Field in the Territory hereunder to Protalix (or its sublicensee or Third Party designee) as soon
as is reasonably possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
any expiration or termination of this Agreement, each of Chiesi and Protalix shall, upon request of the other Party, return or
destroy all Protalix Confidential Information and Chiesi Confidential Information, respectively, disclosed to it pursuant to this
Agreement, including all copies and extracts of documents, as promptly as practicable following receipt of such request, except
(i) that one (1) copy may be kept for the purpose of complying with continuing obligations under this Agreement and (ii) to the
extent and for so long as necessary to perform its obligations or exercise its rights under this <U>Section 12.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">12.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
termination of this Agreement, other than termination by Protalix pursuant to <U>Sections 12.1(b)</U>, <U>12.1(c)</U>, <U>12.1(d)</U>,
<U>12.1(e)</U>, or <U>12.1(f)</U>, notwithstanding the termination of the licenses and rights granted by Protalix to Chiesi hereunder,
Chiesi, its Affiliates and its Sublicensees shall have the right to continue to sell their existing inventories of the Licensed
Product for a period not to exceed [***] after the effective date of such termination and Protalix shall continue to receive any
amounts due hereunder in respect of such Net Sales, Direct Sublicensee Revenue A, Direct Sublicensee Revenue B and Sublicensee
Net Sales, including any applicable Event Milestone Payments, or reconciliation amounts calculated in accordance with <U>Section
4.6(h)</U>. Following termination of this Agreement (or, in the event of termination by Protalix pursuant to <U>Sections 12.1(b)</U>,
<U>12.1(c)</U>, <U>12.1(d)</U>, <U>12.1(e)</U> or <U>12.1(f)</U>, following such [***] period), Chiesi, its Affiliates and its
Sublicensees shall promptly return to Protalix or destroy (at Protalix&rsquo;s sole discretion) all inventory of Licensed Products
in its possession as of the effective date of termination (or as of the end of such [***] period, as applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>INDEMNIFICATION AND INSURANCE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by Chiesi</U>. Subject to <U>Sections 13.3</U> and <U>13.4</U>, Chiesi shall indemnify, defend and hold Protalix, its Affiliates,
and their respective directors, officers, employees, consultants, contractors, sublicensees and agents (collectively, the &ldquo;<U>Protalix
Indemnitees</U>&rdquo;) harmless from and against any and all claims, suits, proceedings or causes of action (&ldquo;<U>Claims</U>&rdquo;)
brought by a Third Party against such Protalix Indemnitee, including any damages or other amounts payable to such Third Party and
reasonable attorneys&rsquo; fees and costs of litigation (collectively, &ldquo;<U>Damages</U>&rdquo;), in each case to the extent
resulting from or based on: (a) the Commercialization of the Licensed Product or the performance of [***] activities after [***]
or Commercial Medical Affairs and Pharmacovigilance activities by Chiesi or any of its Affiliates or Sublicensees; (b) any taxes
for which Chiesi is responsible under <U>Sections 4.6(b)</U> and <U>6.7</U>); (c) Chiesi&rsquo;s breach of this Agreement or of
any of its representations, warranties or covenants herein; or (d) the negligence or willful misconduct of, or violation of applicable
Law by, Chiesi, its Affiliates or its Sublicensees, or their respective employees, contractors or agents in the performance of
this Agreement; in each case, to the extent not resulting from or related to Protalix&rsquo;s breach of its obligations under this
Agreement or its negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by Protalix</U>. Subject to <U>Sections 13.3</U> and <U>13.4</U>, Protalix shall indemnify, defend and hold Chiesi, its Affiliates,
and their respective directors, officers, employees, consultants, contractors, Sublicensees and agents (collectively, the &ldquo;<U>Chiesi
Indemnitees</U>&rdquo;) harmless from and against any and all Claims brought by a Third Party against such Chiesi Indemnitee, including
any Damages, in each case to the extent resulting from or based on: (a) any Development work conducted by Protalix for the Licensed
Product; (b) Protalix&rsquo;s breach of this Agreement or of any of its representations, warranties or covenants herein; (c) any
claim of infringement of an issued Patent or Technology to the extent such claim arises from a breach or alleged breach of <U>Section
9.2(k)</U>; or (d) the negligence or willful misconduct of, or violation of applicable Law by, Protalix, its Affiliates or sublicensees,
or their respective employees, contractors or agents in the performance of this Agreement; in each case, to the extent not resulting
from or related to Chiesi&rsquo;s breach of its obligations under this Agreement or its negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Product Liability Claims</U>. Notwithstanding any other provision of this Agreement, this <U>Section 13.3</U> shall govern the
allocation of liability with respect to any Third Party product liability Claim, including Claims of property injury, bodily injury
or deaths related to the Licensed Product in the Territory (a &ldquo;<U>Third Party Product Claim</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 13.4</U>, Protalix shall indemnify and hold harmless the Chiesi Indemnitees from and against any and all Damages
which a Chiesi Indemnitee may incur or suffer arising out of any Third Party Product Claim to the extent caused by or arisen from
any defect in the Manufacturing of the Licensed Product by Protalix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to <U>Section 13.4</U> and except to the extent provided in subsection (a) above, Chiesi shall defend, indemnify and hold harmless
the Protalix Indemnitees from and against any and all Damages arising out of any Third Party Product Claims to the extent caused
by or arising out of any sale, use, importation, storage, handling, distribution, offer for sale (or other Commercialization) or
sale of Licensed Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Defense
Procedures; Procedures for Third Party Claims</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Agreement, &ldquo;<U>Third Party Claim</U>&rdquo; means a Claim asserted by a Third Party (in no event to include
any Affiliate of either Party) against a Party or any of its Affiliates, or any of their respective directors, officers, employees,
consultants, contractors, sublicensees and agents. In the event a Third Party Claim is asserted with respect to any matter for
which a Party or any of its Affiliates, or any of their respective directors, officers, employees, consultants, contractors, sublicensees
and agents (the &ldquo;<U>Indemnified Party</U>&rdquo;) is entitled to indemnification hereunder, then the Indemnified Party shall
promptly notify in writing the Party obligated to indemnify the Indemnified Party hereunder (the &ldquo;<U>Indemnifying Party</U>&rdquo;)
thereof; <U>provided</U>, <U>however</U>, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party
shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party
is prejudiced thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Indemnifying Party shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the Claim solely for monetary consideration) with counsel selected by the Indemnifying
Party and reasonably acceptable to the Indemnified Party. The Indemnified Party shall have the right to join in (including the
right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at
its own expense, the defense of any Third Party Claim that the Indemnifying Party is defending as provided in this Agreement. Notwithstanding
anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the defense of any Third Party Claim
with respect to the Indemnified Party, upon written notice to the Indemnifying Party, in which case the Indemnifying Party shall
be relieved of liability under <U>Section 13.1</U>, as applicable, solely for such Third Party Claim and related Damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Party will enter into any settlement of any suit involving Licensed Products that materially affects the other Party&rsquo;s rights
or obligations with respect to the Licensed Product without the other Party&rsquo;s prior written consent (which consent shall
not be unreasonably withheld, delayed or conditioned). Without limiting the foregoing, the Indemnifying Party shall not, without
the written consent of the Indemnified Party (which consent shall not be unreasonably withheld, delayed or conditioned), effect
any settlement of any pending or threatened litigation in which the Indemnified Party has sought indemnification hereunder by the
Indemnifying Party, unless such settlement involves solely monetary damages and includes an unconditional release of the Indemnified
Party from all liability on Claims that are the subject matter of such litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Parties shall maintain insurance with creditworthy insurance companies in full force and effect during the Term and, with
respect to &ldquo;claims made&rdquo; policies, for a period of [***] after expiration or termination of this Agreement as follows:
worker&rsquo;s compensation (if applicable), general liability, employers liability, clinical trial liability and product liability
insurance coverage in such amounts and with such scope of coverages as are adequate to cover such Party&rsquo;s obligations under
this Agreement and as are customary in the industry for companies of like size and activities. Upon written request, each Party
shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no less than thirty (30)
days&rsquo; notice of any cancellation or material change in such coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer
of Liability for Consequential Damages</U>. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER
THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT
LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE, SUFFERED BY CHIESI, PROTALIX OR ANY OF THEIR RESPECTIVE AFFILIATES.
THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY
CLAIMS UNDER <FONT STYLE="text-transform: uppercase"><U>Section </U></FONT><U>13</U> OR LIABILITIES RESULTING FROM A BREACH OF
THE CONFIDENTIALITY OBLIGATIONS UNDER <U>Section 8</U> ABOVE, OR ANY LIABILITY ARISING OUT OF THE INFRINGEMENT OF THE PROTALIX
PATENT RIGHTS OR PROTALIX TECHNOLOGY INCLUDING, FOR CLARITY, ANY USE BY CHIESI, ITS AFFILIATES OR ITS SUBLICENSEES OF THE PROTALIX
PATENT RIGHTS OR PROTALIX TECHNOLOGY OTHER THAN AS EXPRESSLY PROVIDED FOR IN <U>Section 2</U> AND PROVIDED THAT THIS <U>SECTION
13.6</U> SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">13.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sole
Remedy</U>. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT AND EXCEPT FOR ANY EQUITABLE REMEDIES THAT MAY BE AVAILABLE TO A PARTY,
INDEMNIFICATION PURSUANT TO <FONT STYLE="text-transform: uppercase"><U>Section </U></FONT><U>13</U> SHALL BE THE SOLE AND EXCLUSIVE
REMEDY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY) AVAILABLE TO PROTALIX OR CHIESI FOR THE MATTERS COVERED THEREIN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>GOVERNING LAW AND JURISDICTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the substantive Laws of the State of New York, without
regard to conflicts of law rules. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall
not apply to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction
and Dispute Resolution Process</U>. With the exception of those matters referred for resolution by independent accountants under
<U>Section 6.1(b)</U>, <U>Section 6.6</U> or <U>Section 6.7(c)</U> or by independent consultants under <U>Section 4.8(c)</U> or
by Joint Legal Counsel under <U>Section 14.3</U>, any dispute, controversy or claim arising out of or relating to this Agreement,
or the interpretation or breach thereof, including disputes regarding the existence, validity or termination of this Agreement
or the scope of the agreement to arbitrate herein (each, a &ldquo;<U>Dispute</U>&rdquo;), shall be determined in accordance with
the provisions of this <U>Section 14.2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any Dispute arises, either Party may provide written notice of the Dispute to the other Party and request negotiation between the
executive officers of each Party (&ldquo;<U>Dispute Notice</U>&rdquo;). Within fifteen (15) days after the delivery of a Dispute
Notice, the executive officers shall confer in person or by teleconference to attempt to settle the Dispute. All communication
between such executive officers shall not be construed as an admission or agreement as to the liability of any Party, nor be admitted
in evidence in any related arbitration, litigation, or other adversary proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
within thirty (30) days after the delivery of a Dispute Notice, the Parties are unable to resolve the Dispute in writing, upon
written notice by any Party to the other Party, such Dispute shall be determined exclusively by arbitration in London, England,
before a panel of three (3) arbitrators in accordance with the Rules of Arbitration of the International Chamber of Commerce (&ldquo;<U>ICC
Rules</U>&rdquo;), except as modified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
any arbitration commenced pursuant to this <U>Section 14.2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
shall be three arbitrators, one of which shall be nominated by Protalix and another of which shall be nominated by Chiesi, as provided
in the ICC Rules. The third arbitrator, who shall serve as the president of the tribunal, shall be jointly nominated by the two
Party-nominated arbitrators within twenty (20) days of the date of confirmation of the second arbitrator by the ICC. Any arbitrator
not timely nominated as provided herein shall be appointed by the ICC Court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
seat of arbitration shall be London, England. The language of the arbitration shall be English. The Parties agree that the award
rendered by the arbitral tribunal shall be final and binding and enforceable against the Parties and their respective assets in
any court of competent jurisdiction. Unless determined otherwise by the arbitral tribunal, [***]. The arbitral tribunal shall not
award any damages excluded by <U>Section 13.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
arbitration hereunder shall be confidential, and neither the Parties nor their agents shall disclose to any Third Party the existence
or status of the arbitration, any information made known or documents produced in the arbitration not otherwise available to them
or in the public domain, or any awards arising from the arbitration, except and to the extent that disclosure is required by applicable
Law or is required to protect or pursue a legal right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
any proceeding in aid of arbitration or for preliminary relief to preserve the status quo or avoid irreparable harm prior to the
appointment of an arbitral tribunal, each Party irrevocably and unconditionally consents and submits to the exclusive jurisdiction
and venue of the courts located in England, and waives, to the fullest extent possible, any objection to the laying of venue in
such courts. The arbitral tribunal also shall have full authority to grant provisional remedies and to direct the Parties to request
that any court modify or vacate any provisional, temporary or preliminary relief issued by a court hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
any action pursuant to <U>Section 14.2</U> and in any action with respect to any arbitration award obtained pursuant to this Agreement
or to the enforcement of such an award, the Parties agree to accept service of process in the manner provided for notices in this
Agreement, and to waive any other requirements for service of process in any jurisdiction to the fullest extent permitted by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall continue to perform obligations hereunder, when any bona fide Dispute is pending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expert
Legal Determination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the Parties are unable to agree on an approach to an alleged breach or default by Protalix of a Third Party License
(in accordance with <U>Section 9.2(i)</U>), the Parties shall jointly engage an agreed-upon, independent law firm of reputable
stature with relevant licensing expertise (specifically in respect of life science agreements) in the relevant jurisdiction (&quot;<U>Joint
Legal Counsel</U>&quot;) to provide its legal opinion as to existence of, and liability in respect of, such alleged breach or default
of such Third Party License (&quot;<U>Joint Legal Opinion</U>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].
Communications with Joint Legal Counsel, its work product, and the Joint Legal Opinion shall be privileged and confidential and
shall not be disclosed to anyone other than the Parties, who will be Joint Legal Counsel's joint clients, except that a Party may
disclose the Joint Legal Opinion in confidence to a court or arbitration tribunal if necessary to enforce its rights under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Joint Legal Counsel takes the position in the Joint Legal Opinion that the alleged breach or default exists and is able to
quantify the amount of liability relating to such breach or default, Chiesi shall be entitled to (but not obligated to) exercise
the right set out in <U>Section 9.2(i)</U> to undertake payment or performance of the underlying obligation on behalf of Protalix
as necessary to cure such default or breach and to offset, against amounts payable to Protalix under this Agreement, any reasonable
out-of-pocket costs and expenses incurred by Chiesi in the course thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Joint Legal Counsel takes the position in the Joint Legal Opinion that the alleged breach or default does not exist (or if
the Joint Legal Counsel is unable to reach a conclusion in the Joint Legal Opinion as to the existence or otherwise of the alleged
breach or default), then Chiesi may not exercise the right set out in <U>Section 9.2(i)</U>, and such alleged breach or default
may not be again referred for determination under this <U>Section 14.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>MISCELLANEOUS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Force
Majeure</U>. Neither Party hereto shall be liable to the other Party for any losses or damages attributable to a default under
or breach of this Agreement that is the result of war (whether declared or undeclared), acts of God, revolution, acts of terror,
fire, earthquake, flood, pestilence, riot, enactment or change of Law (following the Effective Date), accident(s), labor trouble,
shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable control of such Party
(each, a &ldquo;<U>Force Majeure Event</U>&rdquo;); <U>provided </U>that if such a cause occurs, then the Party affected will
promptly notify the other Party of the nature and likely result and duration (if known) of such cause and use its Commercially
Reasonable Efforts to avoid or remove such causes of nonperformance as soon as is reasonably practicable. Upon termination of
the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. If the event lasts for
a period of longer than one (1) month, the Parties shall meet and work diligently to implement appropriate remedial measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire
Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the enforceability
or validity of the remainder of this Agreement or any of its provisions; <U>provided</U>, <U>however</U>, the Parties shall use
their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes the
original intentions of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers</U>.
Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such
term or condition. Neither the waiver by any Party of any term or condition of this Agreement nor the failure on the part of any
Party, in one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall
be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none
of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreements; Amendments</U>. This Agreement, together with the Quality Agreement(s), sets forth the entire agreement and understanding
between the Parties as to the subject matter hereof and supersedes all agreements or understandings, verbal or written, made between
Protalix and Chiesi before the date hereof with respect to the subject matter hereof, including the Confidential Disclosure Agreement
between the Parties, dated May 24, 2017. All Confidential Information disclosed by either Party to the other Party prior to the
Effective Date will be deemed to have been disclosed pursuant to this Agreement. None of the terms of this Agreement shall be
amended, supplemented or modified except in writing signed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The provisions of <U>Section 2.3</U> (Non-Assertion of Rights), <U>Section 6.6 </U>(Inspection of Records), <U>Sections 8.1</U>-<U>8.6</U>
and <U>8.7</U> (Confidentiality), <U>Section 9.4</U> (Disclaimer of Warranty), <U>Sections 12.2</U> and <U>12.3</U> (Continuing
and Accrued Obligations; Effects of Termination), <U>Section 13.1</U>-<U>13.4</U>, <U>13.6</U> and <U>13.7</U> (Indemnification;
Disclaimer of Liability for Consequential Damages; Sole Remedy), <U>Section 14</U> (Governing Law and Jurisdiction), and <U>Section
15</U> (Miscellaneous), as well as (x) any other Sections or defined terms referred to in such Sections or necessary to give them
effect and (y) any other provision that by its terms expressly survives termination of this Agreement, shall survive termination
of this Agreement and remain in force until discharged in full.&nbsp; Furthermore, any other provisions required to interpret and
enforce the Parties&rsquo; rights and obligations or to wind up their outstanding obligations under this Agreement shall survive
to the extent required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment;
Binding Effect</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
this Agreement nor any rights or obligations of either Party to this Agreement may be assigned or otherwise transferred by either
Party without the consent of the other Party; <U>provided</U>, <U>however</U>, either Party may, without such consent, assign
this Agreement, in whole or in part: (i) to any of its respective Affiliates; <U>provided</U> that such assigning Party shall
remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (ii) to a Third Party successor
to all or substantially all of the assets of such Party whether by merger, sale of stock, all or substantially all of a Party&rsquo;s
assets or other similar transaction, so long as such Third Party agrees in writing to be bound by the terms of this Agreement.
Notwithstanding anything to the contrary herein, nothing herein shall prevent Protalix or Protalix Parent from engaging in any
merger, consolidation, reorganization, sale or purchase of stock, or sale or purchase of assets, or undergoing any Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
purported assignment in violation of this <U>Section 15.6</U> shall be void. Any permitted assignee shall assume all obligations
of its assignor under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Contractor</U>. The relationship between Protalix and Chiesi is that of independent contractors. Protalix and Chiesi are not joint
venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Each communication and document made or delivered by one Party to another under this Agreement shall be made in the English language.
All notices, consents, approvals, requests or other communications required hereunder given by one Party to the other hereunder
shall be in writing and made by registered or certified air mail, facsimile, express overnight courier or delivered personally
to the following addresses of the respective Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-indent: -1in">If to Protalix:&#9;<BR>
Moshe Manor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">P.O. Box 455,<BR>
Carmiel 20100, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-indent: -1in">with a copy to:<BR>
Yossi Maimon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">If to Chiesi:&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Chief Executive Officer<BR>
Largo F. Belloli, 11/A -<BR>
43122 Parma, Italy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-indent: -76.3pt">with a copy to:<BR>
General Counsel; and<BR>
Head of Global Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notices hereunder shall be deemed to be effective (a) upon receipt
if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent by registered or certified
air mail and (c) on the second (2nd) Business Day following the date of transmission or delivery to the overnight courier if sent
by facsimile or overnight courier. A Party may change its address listed above by sending notice to the other Party in accordance
with this <U>Section 15.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party
Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including
any creditor of either Party. No Third Party shall obtain any right under any provision of this Agreement or shall by reason of
any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding
Effect</U>. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective heirs, successors
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance
by Affiliates</U>. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause
its Affiliates to perform such obligations. Chiesi may use one or more of its Affiliates to exercise its rights or perform its
obligations and duties hereunder, <U>provided</U> that Chiesi shall remain liable hereunder for the prompt payment and performance
of all of its obligations hereunder, including, for the avoidance of doubt, in respect of any Net Sales, Direct Sublicensee Revenue
A, or Direct Sublicense Revenue B (or, as applicable, Sublicensee Net Sales) of Licensed Products attributable to the Commercialization
activities of any of Chiesi&rsquo;s Affiliates or Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in any counterparts, each of which, when executed, shall be deemed to be an original and which
together shall constitute one and the same document. Signatures provided by facsimile transmission or in Adobe&trade; Portable
Document Format (PDF) sent by electronic mail shall be deemed to be original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
Headings in this Agreement are included herein for ease of reference only and shall have no legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">15.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equitable
Remedies</U>. The Parties agree that irreparable damage may occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached.&nbsp; It is accordingly agreed that, without
limitation of other remedies which may be available to a Party for breach of this Agreement by the other Party, the Parties shall
be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF the Parties hereto have caused
this Agreement to be executed by their duly authorized officers upon the date set out below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">CHIESI FARMACEUTICI S.p.A.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">CHIESI FARMACEUTICI S.p.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid"> /s/ Alberto Chiesi</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Ugo Di Francesco</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name: &nbsp;&nbsp;Alberto Chiesi</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:&nbsp;&nbsp;&nbsp;Ugo Di Francesco</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">PROTALIX LTD.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 52%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PROTALIX PATENT RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">THIRD PARTY LICENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">[***] Redacted pursuant to confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRESS RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CHIESI ANTI-BRIBERY POLICY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CHIESI CODE OF ETHICS AND CONDUCT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SELECT MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Schedule
3.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL DRAFT DEVELOPMENT PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Schedule
3.7</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL INITIAL DRAFT COMMERCIALIZATION
PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[***] Redacted pursuant to confidential treatment
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tv486893_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">We hereby consent to the incorporation by reference
in the Registration Statements on Form S-3 (No. 333-208004) and on Form S-8 (No. 333-148983, No. 333-182677 and No. 333-203960)
of Protalix BioTherapeutics, Inc. of our report dated March 6, 2018, relating to the financial statements and the effectiveness
of internal control over financial reporting, which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kesselman &amp; Kesselman</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Kesselman &amp; Kesselman</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Certified Public Accountants (lsr.)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">A member firm of PricewaterhouseCoopers International Limited</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Tel-Aviv, Israel</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>March 6, 2018</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tv486893_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Protalix
BioTherapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<B>) </B>for
the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated: March 6, 2018</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tv486893_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Protalix
BioTherapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<B>) </B>for
the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: March 6, 2018</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Yossi Maimon</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yossi Maimon</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer, Treasurer</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tv486893_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2017 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certificate is being
furnished to the Securities and Exchange Commission as an exhibit to the Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: March 6, 2018</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Moshe Manor</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Moshe Manor</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tv486893_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2017 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to my
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certificate is being
furnished to the Securities and Exchange Commission as an exhibit to the Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: March 6, 2018</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Yossi Maimon</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yossi Maimon</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vice President and Chief Financial Officer</FONT></TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv486893_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!%0)_ P$1  (1 0,1 ?_$ .L  0 !! ,! 0
M       ( 08'"0,$!0H" 0$  04! 0$              0(#! 4&!P@)$
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M"E2!4TV574]WXOAJ_1:]2>P]G9E:HT/">=&5?D'3^[+CE92)&(J\ZP^^K@@
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M?@_%RU"+G2I52Y4E0(4JA<N7*2$:%"C(&J6K5BHT)*9(C2D!,/4JE!P[ ++
M&XQBO:UK7O>J7OCC8Z25P;&T5<20  -I))V #NDJ6L=(\1Q@ND<: "I))W
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M$39.I.YWF1[FR^CR7)7.0RV<R>&GCBBR>;L[G2R=T,L]G# (YH#,UA=;/>X
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MSMOC,C#D;&SNI+S.37T3>OW#)K?5;QQQ217I8Z7C,>PAY=4N::@TZ*RY^9K
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MBMO-*G!:J*WK6"/FU"HXXO>#:][!%N#MMM:][6O7L5M&8K>*)U-;(V-/\0T
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MUCY>'SC/"G5+OR,OX'>!.K,HX?[LR3R_T \</%_(J=>L?+P^<;X4ZI=^1E_
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M[W-*M80VD8KC!:Z>X@@P^0>?F<T,9@<](&\RM ;#,XT%T -D<A[EP-S7&@E
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M?4J%;F\YQM+HNNC3D$;6Y-A2%QN4F4#W515P6&$5KWO5-2-R5(W+.FG73R#
M164#CY](\BO>6<BJLFR9]DJ5N2*[2!P8F1G<"4A+864F);C#&?G22@A"%. R
MQ0+;@ U).RB=RBD?4(E$2B)1$HB41*(E$6N/Q 17"KP#<-[VOUIGW#:^R_\
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M9HP@OF7<,ECD+G'7(+9+.IN'[3' T2&+7(\; TO!#:5<[2XM:0UQ&!92LO\
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MF@ J2LVUMGW3W-8YC6LAEE<YQTM:R&-TLCB?J8QQ[YI0;2N##6:4^8V%U?\
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MTJ=P[*O:] N.W[/'WB\OZZ\=3\I^2/*Y2G_,@]"I]R,MVRW\R[TJ=P[*O:]
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M@9%$P49&P;FM'>[I)VN)+G$DDKU[#X>SPEF+.S!WU<X[7R..][W=TG[ *-
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M).I7GYO'YX&@5*F+FAI!WW=ECEB48RWPANR:]=R;7EU2^P=<WMZ+>[CTD$-
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M[Q@ZPG"<#U$0EQR*J:=+;@Q9%U"870XUD;=+'>7:+YBXD$RB0I\HG(#WQ(G
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(HXZO2P&Z8LY%&E@-*,QW("S"C
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MW/*63N87BH#XIK>"2)Y:=K7:7;0?%-=I&U<WDLBZZY#RT-'17=KGK*UG:'5
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M+3JF82*22 .83 RND/:72"JF#X@GBHY!T(NLD>NXUE#+N"\;,".5Y6S@1FG
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MC=X:BT:Z^9(^T!D;&'$T[H9XY;7QVL_K<S4&$$.(H:47;A8F-MY^F9=&FO\
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MM;IE!+0'#HEP .MH-6&@< 2O8FTTBF.(?)Y_.GYNB\+A;"Z2>521V.Z.V,3
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MD:88 HLO'4@,,-,&$LLLL"7>,&8,5[! 6 %KW%>_!:VVL[&M<^]8Q@+GD.
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M@&JE U&*RY*8&ES\1D+N6Y:*?IQOM((V;Z ZY&.: TFA%30;5J.;="?B)J_
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M'6R7;I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7D(Y
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M 6JQ0L5D^&9XO+6O&J:Y-[=M<" +&N6EA?&]REZX@439^:)5G"+6O8G9,!
MH8@JA'E\Q<=AAO?(N6?_ ([R=#$1(X.QL1+03J?'FW:VTH':FMVN:X!S6^.
M%E6SC'S9G)K@<-IA?/1U.C$[#1N#SI)&GHOHX$M):ZA-%V';,,WP#J5U(N,-
M;T*2=SJ#>%O@A,_21()0T8[6Y9<99!54ZDC>,9%W F'6<1GV2'&D%GJK%E&&
M! (5;;AG*9;)8FVF;%%>\X77ZH:'T9#AVW1$8J&NDF$'!BK4:Y&FCJ:3HP6V
M7+^#R=S&Z1]CR7)+PMH+W^TFQ .(VM8QTG$E<-HC8ZE#M$@,^9_U>XPR-AG2
M1 G^0YJRE.X=E3(#SF?&N.]/31*"4..E$,3)8B=!\S9HQIBT3\J-EEU*^R-4
M-8!J+ 82C!??/K1QF6]N+A]M%I@L+.*9XU LF?)<20C42>(R(!@;*Z/46S.:
M-3&D-6X= RRL8KNZD:\W60= UM'!\;!;FX);I!:7;*1\0@.9J/2<VJYXKJ&U
MGY S7@3$\T>X!IQ/<-*,RS_G!N11^*9;>2'['V:6F%EM+)(6.6O\)0MDGBJB
MYKF6E4.@F\TX1292(TKG+Y4SL?:OS&4?('XG&6>+FTZ7AO$O+>^DN6EQ#9'0
M1/MQPW-:U\@8T@Z7N6N)NN)C,:QA=?Y&\R4 <=(.BW-IU:0,!<ULSA.=;7.,
M8+G MZ+:8%8M<FH7*4_=L=,LKDJ7&VIK1SG[/. \QKL?8CBEXU[/&V-%,LAQ
M9$&/)TQR<[Q5W+E C+7G;:S. #R07($.U[VM@9C&WEORSS%#>%UOE\3C[:YH
M2.,67#YFN8\Q$PL!9&.&^-_%:7$N;J;4;G&.C',N%?'PY\9=YB6Q?0$P\2!@
M<7,<ZCW%LC7B1KFF)XII--A_.GZ8:CT6%?##9W;)<8S3F+,^!\Y2:*98RKBN
M+N4XA$E0Z;4;U#TC4^64C<]\<@'8MZ7#/LM>D8Q%*!VMPUU&=:(,CF6V,;6W
M-E@8Y^CT!<.Z[95C>UE (WQOT:6[.(&3[7M 6CPIB=9PS9%[GX^7F,1.83L9
M&.O@N:34ZPZ/4QQ_MM<8VC2LA9'\1_-2#$#UG''<29GUCQ_@C##?/8J2G9E2
MY'JDS;D]J@;A'U;H[R6--3(QX<1MR\]<%:M1)%)B]/<Y2247<5]1<PQ/R9M;
M,2G'Y++65KCY &AX@F@==2W#N(6QN<8Y[2!C'.&BX9,QU74:KL+KBWM&G(-!
MR%C89"YO6@/#'NM9.K0Q1$,=*T2S0W,Y(B+C:\%[:!Y<)J:-9OJR?G3*<6U+
MPM[:6N-#BB['<RFQV FC(DG*?R'8V0MTA@NGS*^6HFRM+ >C3A;%QBM*>X%&
MF;Q0KE7,%);;.QK9#1F09</C+07.#HPUCF2.):&LEU%S7L:YPH&. 96A@F5M
MTP,)?:2V^LDAK0V0/TEL9#BZ2-S:.#G-!8ZK2Y]1ICCHY@6)\[CU$YGU*1J(
M2W/\!U<9NAZR23<92B48-CT-EP&K&<5@#VXC3NN,(\H@J9L6E^:C$(':ZP2D
MT:@1MQWLV %MRS@LC;="_O+!LD\C:!\MXZ>03PO<-KA'(!"+9Q+&- 8&4<=5
MS+.=<YS*8^_#3C;21K+9A #!9FVCD9< ;@^77+(ZX%'UK1[0P!MH$ZRM1"V,
M%ZI6Z7Q,_&U]8?=5)TIWA+>&3'M0,W@PL<]#R#YV.E%LK<T ;^4WV(LVB07
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MR;MT4:B )IU,&4^.2J4HR0I^91O$A8E1J18:4$%SR#1@'ML(6VVWHV[+0?\
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MX\?EOP?Q5/EC\1OV+*[^SR>!/;N&[3#^)/:+!/2MF_TXO)Q_Q?DI\L?B-O\
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ME$2B)1$HB41:5\4:T<VQI:1C]+&@YPG.:=?VK;!D&6SB>AAC%CJ,XP8G&8L
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ME#38O,"H006>AD"*T@(?6]<E.MT 1(;&BRXL>3<7MO))&]]I//%2(\1W_3D
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12B)1$HB41*(E$2B)1$HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv486893_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!#@*! P$1  (1 0,1 ?_$ /   0 !! (# 0
M       (!08'"00* @,+ 0$!  $% 0$!              4! @,$!@<("1
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M-3T#LOS3'^(OO4^@1PD]4WCU\TM*]Y\?MEU9]I9OY:3\:GH'9?FF/\1?>I]
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MA$P]G4E(*'41ZCT*6& I0_@   ,I^V75G9Z2S?RTGXU5] [+\TQ_R:^]7Y]
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MA5",2;6 4^8U1FW/;A"\])_FO+OC8X#2K!I*;<%'=.O%"ZWC7[;SMD]N9BV
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MI.6AD<J@+$E45F(!-E4GL%1&V[@,[:6WB5>5BQAS(2;K&JRF(,S6 "EM(N;
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MX\:;Y&5*"L=8K>YM?UZ_Q%=MK1-E9(5K/LDW81DN@@HLV%TT.8Q!42.=%8H
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M5R]R3.'I4[LG8U3IT3;9.12(NR9UQ_.RK)M,K.4%"G+YN90!(8#=>@@.4_\
MY!-J_P#Y-S98O^H2"%("?"^$0O9VFW;0,IP'W0$';8UU-*.,8!%P2X[O8">W
ML!/943YGQ8>%]>YTQG 6;W!K^,VO,ZTA[S&R[W8E$;P#VU6*QM(:NZ=:-E)\
M)MSL^>B'R,RS8$;#YQ%J%5(8>T #FV>"3>Y,_'P@6S,'(2$Q6O)*Y29IN6HN
M3X4PE<@&QC9E!';:FZ2P;3M^%N>7(@Q,PN0VH 1QA8C%+(QX"/),NF!@3K96
M \EY45SECQAM^QD=/U7D'INQ;7<.;NT1UM"[&JDE>3N=:/\ W+V"@%6:2BLT
M"E+D?Y"2 40\S5 2J=D0'-?'9<N!LK%(DQDQER&93=5@=S&DK$<!&TBE%8\"
MP(O>LF0CX<@AR@8Y6GY ##23-RA-R@#Q+\IEDTCCH(:UC5&UUS4X@;>V=8]*
MZKY0:#V+MZHJND+-K.E;9H]DO$*NQ.=-ZD^K,3-NI9)1D=,P+!W0BD)1[73H
M.9,56S<4YN&#+B+VNHU*.WB2.%C8V/9[-691&#DKAYGR64XN$?NL>SL!XWXC
MAV\>RJ=4^5VO"0UXF=OWO1NLVE9Y!V/0,4[:;NK%FBGMB9*('K$%8Y5=K7FM
M1V?.L%>^<U=7OG<?Y"BJKUZACB='P<')9@,C,QYI=(XI\@\XEY4G 3)''"7D
MD 4(PD0CY,DWS1R19F7!I/A\40L6/!A'-'"5>5.V(-++RX[D\Q>6X/R@46_(
M^(/PQ)H7</).K\EM'7_4FC&DL.Q+?2MJT:=@:_-1A#$;U>5G&<XK$Q,],R/=
MLV:+E9(5W*Q"%ZB.:FZYAVK9UWF2.1\:96Y 4<<AP#\G#>P>1B+!0;WM>PXU
ML8&*,[=SLHD2/+C=5FU'^P4VO)*!<JB*=3,18"K;XN>)'Q%Y6<66/+FE[GUM
M ZN90$9+;+<V+8M'(&EI=_%MI9Q3MJ2S&=<P55M,4V>)^<-EW!3%$Y>G4#!U
MF]\PAL163*EC.#*0(Y@;12M9=2QL;!RC'0P%R&!%1>U9#;L[P8\<@S(]1>(B
M\BH&=5D91>R.$+HQX%./GK/&N>4G&O;^JY+>6K-^:>V'IJ&1DG$SM.G[%J<_
M089&'(9264E[5&RKB&BRQJ9!,OWZR?=E\IN@>7-/.5MMQUR]P'(Q74,KOW5*
MD@ AC8&Y( MY2!VULXC+GSG%PCS<E6TE4[S \>! XCL/W 3Y*A/R:\9+@5QP
MXUU[E.AOO56X]96W9U=U55WNJ=JZXG"S]AE9^,B+&:*D%K*A%O$M?1<B,M-)
MD6%=I&('5$G3L]2J%WC;=HRB(&W)^Y(_"-(1</DN>WD(X6-W .EW53Q-9L:-
M,O$W#+A="-NA=G6]V:58S(F,H'_7F"GE(;:[$C@+U*&!Y8:^O=ZT8VUC>-(7
M[4.]-;[%O]3V1"[KK;F9LR5#7A"F5UM2F+-_Z1JJFUD'"DK+LY!-&(,BD50B
MG?@)+VA;&DSDW &'P>%#DFXN1'*]M<H-N3#H*-'*;K(6TBUKG525<G%Q<K!M
M*L^:^,WD"NL;MH0\>9/S$9'A[K(%9R>Z5KDU/G'PSO=[J&KJ7RKX]6K9.P(5
M:Q4>A0&WJ)*V^V0B"Z[963@*ZSG%964:D<-5"]44C>5,WVAQ#!-D22PP(SRP
MQ++(%!)2-U5T=K=BLK*P)X:6![#63((Q%5LDB-7G>%=7"\T9(DC%_OT((9>T
M$6[:J-[YF<2-7[7K>B=C\FM$43=%O,W3K&JK;M6E0%_G%'8=6B<?59.9;3*Z
MCP! 42@CVE0$.P ]0S'A [ED/B;?\OE1_"1.\PMQL0MS>WD[?8J[+!P,9<W-
M^1Q&['?NJ>-K@FP(OPOV7X7JTF7(NU.>>L]Q0/!UXM*BN*=?WVA9"C(_"E6R
MR^U9NA+PRH"[&)]PDHV+(L3H@#COS#U.).A<LVL^.AW>23NMMV7@1);L9<J#
M*E<O?RJT"A;6%BU[FUJ;G;".T"+O#<$W$O?[WP;8 CT6\C>+?7JO\%--N]?*
M&\^3G'/C%#0EBY&;TU-HN"LLPG7Z]+;8O]8H3"<FU2]LL7$N;+)1R<@] @]H
MR:0F,4H@(] '$;I+FQ;=$0V?,;)&#WW\G=7M/'A[?#MK)R9?#29FEO"P@%WL
M=*@FPN>P7\E7G6-K:RNLO:8"H; IUGFZ.VKKRX14#8HJ5?5EE;H4MCJKV:;,
MG2RD>RL<"<'C%90"INFW\HF8Q?+E\JM!!)E3@IC12RQ.S< DD(4RQL3\%XPR
MEU-BH8$@7%8499'BCC(:2>%98P.)>)V9%D3\)&=&4,+@LI':*PG9^=/"^DUU
MO;KCRKX_56KO*8?8K*P6+;-)AHA]0T[$XJ)K>Q?R,RW;O:]\*&JD>#I(QTC.
MTS)@(F 0RR1EB)64A6!Q[@FQ_P TADQN!X_+Q@O'^&@+#AQK,L4C?!4FSSIP
M'WV*RIDK[<#NJRC[QF56L2*J3+FEQ!DKGK774=R@T"_ONY(5*R:GIS+;=%=6
M78\"X1\X;2]+AT)Q1]8F#I'VR2C4BA50 >SUZ#FRN-D/F3;<B,<_&75+& 2\
M:VO=U'%1;CQ^]X]G&M:2>&+#CW"5U7!EDY:2$@(SW(TJQX$W!6WX7=[>%>G:
MW-GA[HJ2LD/NGE#H35$O3W-79VF*V'M6EU"1@'5V2.O44)1C.S#%RT4L;=,R
MC,#E#OTP$Q>H!US4BEBG95A969YVA !!)E55=HQ_/575B.T!E)[16S)#+$NN
M565.1SKD6'*UM'S+_@F1'0'RLK#M!J-W);Q:>$_%+>O&W1.VMT:Y@I3DE'3=
M@B+8^V50(JJTBI-()>6JURN+N6L+-9"K[%?MCQL&\;D61>OBB0IN@"(;&W1/
MN._9/3L8*;EC8^LJP-VF,L4:8@7X7B9!)S$C(!*(Q\U]?+=L;9L7?45I=NR\
MH0HZ<5TA'>2?5V&&(JJ2,"=+RH#VFTF=P<S^(O'VP4ZJ;TY-Z'T_9]@@B>D5
M_9.U:53)BU).5$TFZ\)'3\RP=/VRZJQ2D5(44S&'H!NN8XQS<]MKB[VY*;&(
M<7!\Q7M!]@\:O8Z-O&ZMPVUK6E^\-Q<6;L-QQX5=FR>2?'K3:,.YVUO#5&M&
MMAKL[;H%W>K_ %>JLYJKUAJQ>V&?BG<U)LV\A$P[23;*.%TC'33(NF(CT.7K
MCFFBQVF6=@CXZ!Y W QJS\L,X/%07[@)[6X=M988I<E(I,=3)'-)HC*\0[Z2
M^E2.!.@%N'WH)[*QFESZX/+M-5/T>7O&Q5GO-\2-TVY3W3KTZ6SI!1P=H1G2
M#%GQ^$3@SQ,R/9;=X/?!V/X_DS=&'EMGC:EC<[D8>:(K'F&.VK6%[2I4W! L
M1V5J\^'P+;D6 V])#&TAX('7X2ENP,OE!XCM/:*OK9_*OC+I.\4+6>X>0.F]
M7;#VDZ\RUQ2+]L>IU.TWAT*Z;4J-8@YN592,P<[I8J1>Y3.!E# 0.IAZ9K8O
M^>SCMN%\KN(748D[SVL3?2+MQ )'#C8VK+DD8>%Z2R_D]OU:>8W=2_ 6U'AV
MD>7A<7[:S[BJTQ2F*4Q2F*4Q2OG:^3^#_P!K/N#W:\#KN\^'5]1WC'^:F!^Z
MXSY*ZY_>[</I+?R5[)T_]2XW]T*FCG*5,4Q2F*5^&\I1#^ ?N9BG4O ZKQ8H
M0/<JH[:ZZWAK>#[#5ZC!>>8Z'(>3N,3RHWSN&K<:K[R"L=BXQ5N06WG;;9JK
M9D+HJMV)SK<)\\2Y;2:!G0.13=+BJJB5</:2VVY";-L^Q-A,7WG$V+%B:22\
MDF)/R#'/% S7$04,R QWTJ2(W%[U;OU]YZAWYG&C9\S=I741?)KE06B*-,!9
MG#,O>#V+:!J73PJ^^0_'?F8W7\6NU:+TO3;O:-YV?BE):8B]D,]<VJ"O]=H-
M3AXW93RN5B\R*E-7NM82;KFA4+.FVC%99% RG;2#KG/0B2#IG"P95D[G5>=E
M3B(1MD+AS1X@2;'YIY7-9XB%U'4JAR &T7E9Y$FWLY<$B!QTNF-&9#((#E"7
M-)AGY8YO**2KJT#2VL*3IUVA=PJX,<L(S:WB ;#Y!\;=][!UCR0X3TW54)0M
MZ6GAKJ+9NRI6-LEJ:677+DO#_P!Q]7T1\%=E!&,?/ 4<@FJ0%GI0Z$2DYEQX
MNCMSVN53+ES;W@Y4:Q,3(R1P.K3:I+1<Z%PC-& L;E5!#W8U#XLF4.LMJWF%
MA#CXNTYT#%U7EI*\\,D<01;R<B4:U61BSJ"YLNE0:_&\6N<>P.!/B:Z19\5;
M/0*9L7C-&ZLXJTO=*/%N,Y>VRTLH*6CYBIWR[<=IA+6EJU[%]^W3KTE.O$IL
M1.N#@PEZ*&V=UY>Y;1CG<6CEW.3J/#R)%B!2-\-,C&:67*CX1+DA4DN(!I:$
M#NAB%K=Z=DQ=IZCAFQ4># AV?*B9G(<)D-',(8\9^,S0G6"W.O:0@J;:K2GF
M_#*J*G-+PK;['\0]5EU5H?C;N>I[H?(T[7*,%5[R\I^MBZ\:ST"!B*6651LS
M&449NTVK\&K@5515(*G;-)#*Q4ZQZFW*,J,#+VY8\1K=TN-P)M&MNX1B$BY"
MVC.@'[VH+'QG'JZV?:IE)WJ#<\:2=2;N(O!R"<L]^\IR!$774VIPK:3:XP+8
M.)'-O4?$3E9K_0_'. 4/9O%$V'N"MT!E6^/]MM##C!9'["16OO&RD[??KZ)C
M=FA)E%Q%-K$#5)N)UU11!;L=>5QC.-CZ5Q,[G7P<;-CR6BY;9,#-/FG$5'EN
M@A*2QK+RRSK"^A .\!T65X:7?>H\R#EMXJ# .*'U#'EDC@PUR>:$L^I3'(R7
M 5IT1F)%B<T^"7Q.Y2<=MO>()?\ D51MI52%Y!6[05OUG*;B=<;DM@V-E7]?
MST)8C6VM<54F&HJS8XAX9!!PBP9I@<@IB99RH!U,Z=)<>#HK%V4M%Z1AWC<)
M66/F%>7.N(8W#2=NLJ^H+I4.K (!8F"R^9E]10[G&LOA/0\4),@C5A)'/,=%
MDXD*C H7+-I;X0OI&9>2VD.1.C>8&Y^5FG>.KOF'I'EIQ\J&D.2VE*5L>O:T
MWG67^L26N/J5KUA(7>RTVIV.%L5;N[QA),0FX:1:+)INFZYA 2YSF*T<>V;E
MTYN,,DFUYN='F0O&0#'/R(L::*92RL8Y$ABD22-B48.I0JP-3V5/+/-M.Z8,
MB1;IM44\!5Q=9(9)AE(Z'2PYL<VI621=#HRV((-M=^D_#TY#0G&#QCH76W%'
M9W&S77+'0$/2^*O%G:O("/V]L1K;XO5=MK%I<2\HZVSM.!J?PLL\FBHD12QJ
ME[LX"/=E+T"_=8\E^B$V7(>/+W3]H(\I%4<(L/FX;"%G94N0(Y&<#5;B+L;7
MS[%FX4/7>%OH23&P(=LEAG=CQDRB\[<U(U9@%*-&BGNWT@D+<VR_HGBER NF
M^_#7CP\/ACPECN [%>9V]OU.T:(?,-R(/M)KZ^6UAK8FJIN1NUDA[?97A).9
M7L+*+(U.S*/876$#YT[;CCOU;O/540$>!/@9V+%BG@TKY$\;0&RWB6#&6,O%
M(3J.L!8T)85PZ[?/%T?MW33+S=P7,P,IYSV0C&5FFOJ.LY&1KY+H T8&LEW4
M(U<3;'&S?>U>7,/MG2'AU;NXM<LB[OH=KN?->R\LJA=^."VN8"<CHV\IL-8(
M;<M#BUA=]9M7$<A$(T*!71<.RJG<(G2,<\+TE(N#GX^1(?#;+S)6SH) )'G2
M5)'DAA(YG%IV4K,LD0CMJ *C170]56R,/+Q(!XS<#!R\"9?DQ"Z,JPSR@Z0N
MA%U/'IE:0#1J).H;B/$7K._+CPWW36^,M"H&SMQR4-%%K5&V5#U2PUR=;-K%
M$O)U%M!7PZ5$EK.WA&ZZT0A-')%GDTT/.# 3KD+N FYF(\:N<=,V)IFC$9G2
M$$ZWQQ+\GSUX:"W "Y'>M4GMAQA)*)RHE;&E6+676(S,A$8F:/Y00DGY31Q(
MX=A-=?[B;P:YQL]A>(5LO8.I=_-([D%X<DAIK61M^EX55+8DSM!D^NR#>EN:
MGP^&%UO"-@"43/'.9'OW(MUOY5V0/Y,N??<1G]7^^[)C:)-QS-QQ)X55G+2(
MN.Z.TA>T:2J2JN(]([+EB+C7VS( ZOV#=,GN8N%%EI.=*B.,R2X[HL86\CQ'
M2Y766*D$ *#QE?6?#LM^M*EX%"NK>,]5HEPXR[&JTKRCDZ;&:_KL]3(20XUW
M.LWI6TSD:^:/;8WE=AR39-\FT7DC.W1BK&*<I>\+W6=N.%_\EYVZ8<@'3TNR
M[GC(5!5"T@QCBQZ+7MJ1REULI!)()N>:V/$E_P#C0[=NZ:NI1G;;. ]FD#19
M1;(D#\0&$!(8AKLA*"XX5#/=O!KEJ'&/G_PQ;^'"AO7;.X]U[EW=K_G.XNO'
MY"%N4'>]B,+I3W+F0M=F)N6.VU3H(Q8-M%^YZ4>1%B44WR* @4>(VL,VT]+X
MS(,.?8<G &3QOSS!G<Z;)BT#Y3Q$9+S<THRDLIYA !Z?=B)-VWW,69LK&WK$
MREQPW#PXEV[P\>+*"+)'CS+\B8PX8%&TJQ=AV2^0.OKA<N$6Y=65N%6DK[:.
M+]\H<'7B.&2*[ZV3&KI. CH<KMRY1CDE7$NX(CWAUBH@(]1.!?+F#UA1R[MB
M[HNV*9GFED:,"PU@RZA;58"X\]J>K>5-ES-CEW0\E,4XO-OQT<L)KOIO?38_
M!O>W"]:G-!5/>W)/@-7/#SY#<#^1'%M[K[BI3:U$<A-FVKCE-T"%W/J"O5U.
ME62KCKG<=WNC1]'7*&1E&3A:*;E(W;'!4Z9A #=)UQNPW'<<[KK:I5Q=RP<M
M,_$62X8R1-K"EA=%4H&CF+,!RW:USPJ+Z5@&V"#8=QB?)VS-Y^-DB,7'(R3)
MK[I(9FLXY8"L>:$-K"]69QHI>QN<O"CE/S&Y!\?Y?=%_Y94FL:6KFA:=L.NT
MR=<:5T0^)49)QK+8DX_;U>.=['V<QGKM'@X7;L'X#')+J=CRAK;_  X^!M>*
M,&&=9\_<(MYD$>@3XQ?1)ML6F2R2-@8RQ$QOP+SS@ANQKMD?)DWB7%S9X3#M
M6'D;4DC%WBR7 D7/E9D 91F2MX8NH)C&.K!AVC&K[B!SXWSP?W[097CQ%U-@
MUY)\<-JZDTON@O':@;[Y(Z>T]-5Z<V+J7DU8>."[C1LD[L00WN?!OW(]IVS3
M*23(!3 (U?(3%R=BWO<(H<V?"W?)R<G&@!$;020M'CRB.:T0S(Y'Y\D:'DLT
M46EE>^G#BP3N-VVC;\F?!Q,O98\3'R9>_+#,'9YHP\=Y3B.@Y2.29EY\Q((J
M1^F^-NWN27-2O\BU^&%O\,O5%(XN;?X_6L6=TT[5MZ;AG-GOZZ:#/ EXXVBW
M1%:K^I4X==_#S3V0"0)(.0\V;HE*<PX\:!4V_>O$Y<H3=H<2..&)G5U>">29
M\N5[6CF*,($5&=BCL7;39:V)<@\S:(H<2$S;;F2Y#RN$:/0\')&(BD:I(G<B
M634(T!C2REC<9>W_ .&;L&"XV5^"XW[SW=O+>6E.2FL.6NIS\W=_WK<K>QVW
M5JA45]5.;U8P?RU+J5Q@%G:":B*2R+*27*Z,0P=O+!N.1A;KM6[P8T,OHYLI
M'10L<L^/FPR03@R^66-9-4!?NKIT&RM69,+$S\'<-HSLB6#'W""%0]C(D,N-
M.N1#)RN!*M(@68(0[1GNG4HJ%LYQVY$<G/$0XG<H(/PZ=^\.=C:PWG"W'E9N
MK8_*FFV766P=8P-&G:P-'U[1->[VN,5:DG4NHU436-4H-15!,JBW9,=0H9.F
MH\;:MYFW**0Q[%+@[BKPR*3++DY4(3'<I>14$3@L;2!5U74$@5']4'.W39<?
M;F"R;Q%F;<R2QFT4>-CY'.G35:-F+JU@&0LQ!0M;MP_>>'O)V/@?%-TTIX6[
M'>%@YY<H=_2>FN1[ZY\=VL/1:K>82NP-.N^R%;79$=DUBO5)\U5F8P89K)/%
M%T^SYNV6Z&&&QL>7.Z0V/IE?^W;CB2-+-D=H6VYRY DO$>8<A8=*QH!8J5',
M7O*.DGS(,+J[,ZF:^?M[86)"N-:Q<Q[='$\8YA"<F24LLCEE965B%(T.9H<S
MN-TO8:)QOTEN;PX^07/TFEM-5"F4W>FB^4]<T\NUV&2H0]<N$I>*W-;NTK(M
M&J\E MW:,@NC94Q*<Q@;E.!TU);?\P[QU9N>\[/$</-R9I3C2NP$2HSM+'JM
MS!&T;N;CDM<+P++85 [!B'9.D]MVG-F7)B@A09$00E@Z )I2Y4RQM&MN,J$<
M >)+#:-P+H6_]7\1=&T'E#/,K%NZKT].,N#MC(-)HK%-)^]&NUYU86+"+9V:
M3K-9,SCW<FDV1(_<MCK@7H?J,AO>3CY>:L\+"24P0B:0+RUER!$@R)4C/]FD
MDVMU3R ]@[!J;7#+#',&C,.(V5.T$)8.T&,TK&"%G'!VCC*J6X]EKFUZEYD1
M4G3%*8I3%*8I3%*8I3%*BIQ\^5SFO^L;5?V6>.>=!O'U;M?T)_\ 5Y-1F!^M
M9GTA?T,-2KSGZDZ8I40^>'U4]H_?:#^DVF9TG27[P8_M2?HGJ*WOZLE_H_UU
MJ7F<W4K3%*8I3%*8I3%*BSS;XW$Y?<3-^\:1L'P4<;@US.5.+LID#ND8.<63
M(\@)-VU3,4[I@TFF:!W"11[2B &*'E$,C]QARI(X<G T>D<3+Q\J'7?09<:9
M)T5[<=#-&%:W$ W'$5O[;/BP9#+GHTF!-!-!*JFS&+(B>"32?(P20E>(X@<;
M5UU.<_''FQS:U)1-27+PSMJU/G'K*NT:DT'F5KCEW4Z[Q8J[: N%8D[1<XR/
MA]X52ZR#6RPL$X.E&3%'?/V9W0( J;L]L>CV_)Q,CKS$ZMQU?!@;=<7(S4G(
MD)ABD,DL$87F)*!S&56"Q&0#O@$"H?&@&V=-OT]N87<8(L#)@Q^2"FJ1X3%!
M+)S#&T9ND;R(7D52+*65C67/%2XS^(/NS=MRJ.KM.VR?U#=N,L;KZC;%X^U3
M@T^M4SL(8:R,[?5^4-\Y=1\K>:]K/SF1;C#_  +:J.  ZZHG3<=D<Y;<<5MP
M&]HJ%6R,GF0H=*8\L B6Q<Q$3G*5U:-!J1 FA587)$UM,T.UXNP22.S3XT(3
M*8=^>.3FKIY D^1Y!0F24N&)DN2K#NFA;#XF\G:3P^\.N%K?"_<6Q>6>E>&$
M+I-*[4VW\5+E2-?79W7:U'3VL.16KN1TX>K7#5$A*PZ2[J9KIW4L@1%0&RA!
M$H'[/K+<#N77^Z[GL31'&S1  \X)Q9XT<N1* /$0O$2VAHQJ?6;EM(%0O3T*
M8O34&#NX?DX^X94P2(A<J(R.X22 @#'D$L9 >.0A%TJ JAB1)LO'+D9K?Q%.
M(?)^Q\,J-M2+M/!NG<;-SR6DE=2PE;X^;QB;]"6Z0O1HW8$K7YEWKR%A458^
M-<PGNA*(HH%;IH]WV ''A3X4'474>%CR2IMFY96+DXV9(22!CQY:3));Y;FS
MF9&!TGF<.:002N#,.5/T?L@R(HWW?;\G+,^/&% >/(CQEAT7/*M$T3LZZ@J'
M48[ZA?V\8_#QV5$<8?%#J[N@5O2/)?D_R6YURFIMSO&%:=W)2E[:7D6.J;>-
MNKCF0L$?!N6<@<Z;87"#EJDH?M(D.80'E-SPWF]6>S=/;>$7<(MI1<J&Y0/,
M,V662&9EX-SH5BC9@64*5_!('6X.XXT'K2S>I<]3D;2,[%>%CQ^3CP<>)C&K
M7TZ)A+P*@L0>T$&HR:\XG\C-ILO#RT+'^&5%\*)_A3MC2]XVCRW7M_'MS!O(
MK4<*K'W**T0OJ^?F]HWH-X+)G;O33C"#(1F].H[!54.F=HFY8N;UU^VREL3:
M$AS1X,CY249..\,6$RQWA&/ SJY<L1:%-$=SPX67;\K#Z+R.D%;G;ID/C:<B
M/C$ABRX\A\DM(4E$S(K*%5+EI'#$*.-S[@\/W?FSM>;%H5CT(6WUJ\>.[5N3
MTQ5)J0I;^&L7%Y)U7!FKQ*,7L]YH\KQF[)4%8Y4/=!4I1#S4P#T&&Z8&-BY'
M1AW,*(MKQ=W&1J&H0R3ONC8I(L=19IH673J"E@6M8VZ7>)GD_:I\)SS<_9MM
MAQBMP9)81@"50>&DKRI02VD'2;$W%Y7+<$[$CSPYTS--TA2J=QZW[X>NN=15
MQZQAJ7$:ZL^ZX6Q['1[F8IT4 KGDZ]#2T<;SYQ&]@K<"$24,).R$!EX^=F]!
M]4;*6_[GF[M%-AJS=H.V-#)*C<1&3/I5CW6+6?C;55^/-CXG6O3.[!?^VX&W
M3QY)4#NWW&"9(RO#5>%7*@74+=21>U:YK!P1YG;8\*[B+HN%XU[!XU[8X3[P
MU'.;,U[6)OBG*V/DW#ZKI\W7):_ZQ^$SN\Z6L$BG*RC>3A6]_:-0>K-![U-%
M0$5<ZOJ+<8L[J?;NL,7FC"\+DHV*BQF;%DFQHX4D*R?($\Q'#&%^:(I6=663
MA47L>&V%LN[=-9#1#+FD5ER27$60@S6R#CEDM,$:(K\-1'S$1'1HM=9'XX<$
M-M-^/W/ZS[GXX<S]JN.2D'J2)=Z.W)L+@MIS;%]4UK)/EBV:AP?%QE#:.IUP
MK1>X<,G$Y(]N<%LB@Y[*0& =#-*8NPXF%%WY4WH9P,)+S8SB- )5$UH3K>./
MF8ZZE;2SO<V#;.'KEW_QK,%5=HFPR)@%@E25C>%C%>:QCDF F(#1EM*?AI0=
MB<,^</(3PZ.1M,LG%2OL+?%\DM&[@XW:YV3#<8J=R:V)KC5%EH\];HG<LOI)
M4V@S;,EV%==140^3<M3/X\4R2!T^V(9F?*&!F],[]D1IE9VW;T^1EPX]PGA7
M+A="RD()GUB3(B0\IBBE>]P&QMC8X;?-L3F0;?F=/R8F/)-I=ERWAD7X:7<X
M\;%1"\@YJ%G[0%)V,3.IMS[7Y3>'IOR-XT6'1]'HG''F!7=@Z]F9/6)9#3MA
MV7"T=E1:A--:):)BN.)">5AUS_\ HRKYFW-U!54@^4=#<,9XUZI@249#YW3$
M&- ZZK23C*$K0J6 (,:<-360Z>ZQ%KVX&2IVK:(I(S#+B]2">1#;A F-D1&?
MNW&EW96 _M+."R Z@-?%$\,79U'\,3@51JYQ8K59Y9ZUYH:.W+MQU#,M;Q^R
M(2(B>0TS8+]<I+8#64*,FX#7SD@N0;22ZZ[,W<$3/T[H.CBS,;'ZWZ6S,=A'
MLF!APQ9!6X1 =FD@F1E !<-EL%< ,&>S\5&H1'4L4NX;3UBD ,F;N.7D/B<>
M](#N<,L+*3\ C'5F75ITK=; FQP3XHO#'Q+.2VS^7],IV@+RYJ=QM]4LFF)?
M1];X%5_3.RJ+7 IKKS_?.Q]KIK<L%]UM'4,NDBE"JQ[4J2"*:#@J741YCIN-
MXLG;LS.^3R,/?4GF5CIA6$9FM),00 2/(8CS,CG'C(7N&6R'H]UFC99HL8JV
M+/L[0*5N\YG;&=)$GYUXT@YAT0B($Z+-W7.H;\J)IG:,9XBY]TRE4>(:T/P!
MU[J,UN5?Q2K<VR8C;TW8Y2LF:$D%9@SMM#.R.#+BAYJ8#= 5,?J&2D3Q)F=3
MR7 BSMUP)<?_ -R.&'/61A^"%:6,6;23J%@0#;FQ#-Z)Z7QR#S\'"W%,@</D
MWF&U<H'\(OX>:VDD#0;VNMXR^*_I_:UTM^JK_H_B7N'=>W:K1+_5=?;4U?8>
M+\S5JC)W)5@#ND;STWRDD6%7M.J+"I%M7#N1BBJR[;NSD1,D(]3P48SDW')]
M'K$F1DX\41;(&O$E2.1G"S:+Y$31,[,CPB[!S<DJ$KH6;#?;H/'R2F''S&E"
M077*B8Q!3+"3:&36!H:.8Z1I4@#5J$6.8])Y3Z76X@R='@]<T?DAS\T=6/#D
MY%UC4;QO T^@6A2 5M,+NG7$7_).7[#0\ 2UM$2H>U;,'B %,"29!#I7Q-IW
MGJS<>D$DG?I'=&3<))'+,Z+MH7QFKB&";AAL,/5\/6N.S]X6J'P<K<MHZ5P^
MJ\Q(3U+L;O#'&H&B8[BY3'0=BZH,U8<YE'!E\6J"SF\J$O#RA&GB;<?;@\X^
MU&V\5]#>&Z\T%2+!:H:G6"OU?8S':<4,7#L:Y+K.I)*==T0KE0[XC$4A365*
M*P*'$HXH,M,Z7JO<]S55W'<YMOY'"Y,2IEC(C0CX$::H$*G3=0H4%5(&&?$;
M%VGIO:\)W>/ RMPDR#<@ZY(<41327/?>259FO=B'NQL;&M?54\*K8E)\.%UK
MZI<2JI6^2$?XF#?=M>"(9:W9WB,U)"\O6]HKUIB;JG+]J.BXC3B("U9IR!'"
M$> MB(%.(I#7:,KPF9T#.[E!MD&*-P(N#&QQ<N/*YEN,NMGC633KU@J.(7A+
M=0IB94W6_@E1H=R@G7" %ED)CQ3&(U( C^569EU!+/K?@6N:Q>7,]#^,?XGL
MY ^'TESU64X]<.JP:$C9?2#.T4M2Q4VY-DD@8[QEJY$J4ZRF+V99U'/5'C9-
ML41:."B'9Y[;<:;,Z#WC A@0/E]2940R&8!0W@<6T<Q'RBQIJYBLBN"Y(TJ0
M&.YN\ZP;_P!/9#SL!!L,DAB )8CTG..9$#W&D%M!5RG=(LQ!9:YK#P\^2W&O
M57@YV9YQ?AN6%KXA3VZXW?.K:/,ZI4L56J^[8.S!2:]59S;,G5:W:Z9I*2GD
M679%\D*:+7OVB1O:AG5+G0X_6PG5FEQ)NFH-K.78K_FX#@WS9@Q,H608\I#J
MKS#5Q6[&_*-@39?3F2ZE<:5>I9-UCP[DVQI3F!L2$C5'S!XB-V5F6)F4A6 1
M+97OVAN0FEN3W/&U6/PTDO$)A.:TI59G4>PFUHX\)-M65MAJB%H2FAMMDW39
MX><J5#KMA9+OD7E>;S+9=-ZLH#8%B@!N4;$DRNE,GHY!'%N+Y^?+XQB1%D+E
ML##/(5!F67&4<L(4X*B<ME)-=6V; F_;=U2%*8F-MF# V.@!GBDQWE>8(ITP
MNLVL,6$GPN# @"N9J[PS-L5:X>"K1]Y:\JV]J?P]TWR,B=TV*8" ME'HMVM-
M;@%-9Q+".M:B<E/M:PZ*>)B':3!;NTH\BI@1ZDZ=A+GXTO6N\;QK9X).F<;#
MAR)%M)/DQ3XR32$=XI)/$DLS%CV.REBQ-^0.+FITK@;:.$K=3Y&7-"I[L6+-
M'F21QD]CI#))!'I!(U*"!H'#!%W\*:WI\2/&WJU-X@4=OMW?_)6^7#B82.A]
M9-+!.TDT;KB1I[^B3JDBFG1&+2U-I9TU05<Q9V[L55>[(*@&-!8+'$Z:Z2QH
MF,>YX&])/E6OJCC3>#(KLWWP7!"@ ,Q$7R8%[K788S8<W7.Z9FX!'V'*V2*$
M:QJC>4[7)',G+L;:LHJ&.D!GLUR%##-O-3C[R<<[UJMPXX\*[Q=]WV?56BJ+
M/;BN<]Q:V'Q$NL13G"+J;KG(O7FX)4=NTF0IGG+XK.6HR)GKLRI#]XJ( 4DC
MBY"CK'+GA9(=FFWQ<F4O?2T*Z5&3B21#GQ90C "1D!-4:$@ZBU0$*.G1N!CY
MP:7<L7:7@C6,CFQS.MS#.DA&/+C-+9G<L7L\@!&E5;L9,@= S: ^*W*]!L@#
MPK,5!:%==T3S@K450!46X*]>QV@ W9Z=?+FC/RN<_(U&#4=.JVK3?AJMPO;M
MMPO63&$JXT8G"+.$74%OI#6%PM^.D'LOQM7)S%6>F*4Q2F*4Q2OG;_\ 6'_B
M'_3GW!PKP*N[OX=7U'>,7YJ8'[KC/DKKC][MP^DM_)7LO3_U+C?W0J:.<I4Q
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*I\M%1L[%24',
MLF\E$3,>\BI6.>)E6:2$;(-U&CYDZ1-U*JW=-EC)G*/D,4PAF'(QX<J!\;)5
M7QY%*LK"X92+$$>4$<"/**RP3S8LZ9..Q3(C8,K V*LIN"#Y"" 0?/5,J%/J
MNOZM7Z/1J[#5&G52)8P-9K%>CVT3!P,+&H$;,(N*C62:+5DQ9MTP(FFF4I2E
M#R!FYD9.1ES-D93M).W:S&Y-A87)\P  ]CA6K!!#C1B''54B!)L!87)+$^V2
M22?*22:N/,-9:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*BIQ\^5SFO^L;
M5?V6>.>=!O'U;M?T)_\ 5Y-1F!^M9GTA?T,-2KSGZDZ8I40^>'U4]H_?:#^D
MVF9TG27[P8_M2?HGJ*WOZLE_H_UUJ7F<W4K3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I5FS6NZ)8[;3;[/U&O3-UUV$]\!+3)1
M31Y.5 ;1'DBK&:NR*Z1W$2>;C$P;N3(F(99$.P81+Y,K$3!))-"=,LL/*<C@
M6CUK)RV/E3F(KZ>S4H/:!5) )HE@E[T*2B4*>($BJRJX'X2J[ 'M 8V[:O+*
M56F*5CZ%U/K.M[!NNV("AU6&V;LB.K<1?KY'0K%I:KC%TY!TVJC"QS2*)7TL
MTKS=\L1F18YBH%5,!.G4<NB9H,5L*$E<1YS.R#@IF951I".PN415+=I50.P4
ME^7FCR)N]-#"8D8\2D1<R&-3Y$,C%RHX:B3VUD'+:4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*5\[?J/\/\ X?\ 7GW!P\U>!<*[N_AU?4=XQ?FI@?NN,^2>N/WNW#Z2
MW\E>R]/_ %+C?W0J:.<K4Q3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I45./GRN<
MU_UC:K^RSQSSH-X^K=K^A/\ ZO)J,P/UK,^D+^AAJ5><_4G3%*B'SP^JGM'[
M[0?TFTS.DZ2_>#']J3]$]16]_5DO]'^NM2\SFZE:]#I0J39PJ<ZB9$T%E#J(
MIF56(4B9C&.DD1)8ZBA0#J4H$.(CY */L9AR&TX[M<BR,;CM' \196-_-W6_
M\)[*OB4O*J@ DL!8FP[?*218><W'MBM--"Y"<KTM"\R'S1/:UTO<'9Y-#C%+
M3&K+!,NY2+-5$962:U]:3T5H>0M\E6C,WBY$I.J,V@/3(L$'LJ)NV;;@BC;9
M]K.YR<F67-(RGC ,L>"N1C(\P7Y0,RQRRE',<4LNECX11%=['=X^HLT8J1S8
M8QU\-%(QCB;+,>2RQ22@7B21XX@X$DT<*D'Q),EEP^???.4+"DPK-AY'SM-2
MLC#Z-%BG..K5E+<A4EMFTN,L\7R%(KI^$]&T+ T-],+L5UF=*.[10\Z[Y0Z!
M4E=O98VFSUCW:.!)N?&K1\RT7@C-G+)E<P-;Q"P1X4@363KD"^'/,81ZSR#F
M2JQ==N\+.PE5;R#-7!Q)(,<1V:T3YSY4).EU"1V,X"AVWD7RV2%*JSZS-:K*
M6WW*;KOI*,A7T$Q>-XYDQ=/GSXBE@E(EDN1N5MV03*J*IS'#H40 PAH&UR!V
M5GCUE%,@ DL+CS&W$>[5?@)AM8H*%L#,BR3.=B8Z8:IN"E*X3;2;-%Z@1<I#
MJ$*L1)< , &, &Z]!'*5=56Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5\[7H'_0P?Z,^W^%>!
MUW>?#J^H[QC_ #4P/W7&?)?7/[W;A]);^2O9.G_J7&_NA4T<Y2IBF*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2HJ<?/E<YK_ *QM5_99XYYT&\?5NU_0G_U>349@
M?K69](7]##4J\Y^I.F*5$/GA]5/:/WV@_I-IF=)TE^\&/[4GZ)ZBM[^K)?Z/
M]=:EYG-U*TQ2F*4Q2K'V;\FVP?R'MG_ 7^*#MKPU=\F6NOR$J/\ 9^/Q0]M7
MWBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4KYV_0?M?_9_T9]P5X%>N[OX=/U'>,7YJ8'[KC/DG
MKC][MP^DM_)7LO3_ -2XW]T*FCG*U,4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M5%3CY\KG-?\ 6-JO[+/'/.@WCZMVOZ$_^KR:C,#]:S/I"_H8:E7G/U)TQ2HA
M\\/JI[1^^T'])M,SI.DOW@Q_:D_1/45O?U9+_1_KK4O,YNI6M''/KQ3-P<2N
M4<9H^CZAKUY@U-4%MK1B6O;:N>Q=AWFQQM[+3:Y4V>M:],P58AB6>JLHUXM,
M'*Y75E2*-T^Y144S#L\C[EN61@:"SIDQPHJ\""R8\IEE=[1JC)+*B*#J5X&>
M0B-EOGSXH\/%Q9V;EQ3*TDDK\46-9&B9413S&>.R2NU@I1UC35(&MNIJLG)S
M57K<Q-1"U>F9:!AY*6@'!P47A)-]'MW3^(64  !16-=*G1,/0.HDZY(Y\$&-
MG38V-()<:.5U1QV.JL0KCV& !^[4;@3S9.##DY*&+(DB1F0]J,R@LI_\))''
MCPJO9J5MU8^S?DVV#^0]L_X"_P "@[:\-7?)EKK\A*C_ &?C\4/;5]XI3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*^=MU_A#_VL^W[5X%:N[QX=7U'>,?YJ8'[KC/DOKG][MP^D
MM_)7LO3_ -2XW]T*FCG*5,4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5%3CY\KG
M-?\ 6-JO[+/'/.@WCZMVOZ$_^KR:C,#]:S/I"_H8:E7G/U)TQ2HA\\/JI[1^
M^T'])M,SI.DOW@Q_:D_1/45O?U9+_1_KK4O,YNI6NJMXO.Q*#K3FW,7=")DZ
M1;Z3QFHL]L>TJ>(3M#A?;MZZW0N5W5AM9<:]>46MS$1O?:M<F$W G2?N&PD6
MDFS0IB]Z!ALZ;=H]TR2NIL-]WQ(WQX_E\B3(>&%8\A<1K*<8(XB=M0,IBF7[
MRM_<XC+@X*%HQE>%RFCEE BQH8TDU2Q2Y(U,LKD!PNDJB\MS?5:MWM,YPT)?
M0^[=M6#6>ZJ$TXRUA*6V%2K]'U)?8)HUO0V-Y9"V<Q-WG*V[FGU?=)F7;OI1
MF^9.#"603:F'-K?'3;L=]S=HI(CFRX[",JJK-',D3J"Q6+EAI$(D1VATZ@KD
MHP$=TUCR[UGXVPXRR1Y,N+CRHTVJS13J_+8FQD+'E/J#()+V)7OB]JH^)5J-
M2O:_LX4'8SZ&N$)%VZS2E5F=*["A-44BP7MEK:MVZ]6;7FW;369!C.6R0313
M:5UY.R;=,BRKELB1!42;*;=(VZG:2Z+*IQT9VU!!/E"8P07*W9I.1(%D53!?
M0.;\HE\,$_B<094".S-%DRJ@MK:'#CCER9+7LHB25"T;LLI-PL9L:F+N:QUZ
MN:MO#VPST- LWE3LD>T=S4HRBFSI^ZK\F=LQ;KOUVZ2SQP5(PD2*(G.!1Z /
M0<T+$&Q[:SHRNH=3=2+CVJJ^K@$-9Z[ 0$!"BU$! ?(("$!']0$/MY2JGMJ^
ML4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KC>>LQ5% ';85P/W8H]^EWH
M*=!'L"GV^WV^@=>G3KE-2WM<7K)RI=.O2VBU[V-K>W7)RM8Z8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I7SM^@_;'_L_][/N"O KBN[OX=7U'>,7YJ8'
M[KC/DKKC][MP^DM_)7LO3_U+C?W0J:.<I4Q3%*ILR\-'1$J_(JV0.QCGKPBS
MTJYV:)FS958JKLK4IG)FR8DZJ F J"4![(=>F8IWY<+." 0#Q-R![8'$CVJR
MP())DC8$JS $"US<^2_"_FOP\]:FW_./D0I2:1.U;7L!;+%)1-Q.,-%ZZV<B
MUV7>H':OP3CM;55=^];JT1V]UZLE8 D)3SQ-5(0[*8$[0ERL' C=$)9\/"EY
M1X/\M&3ER:O@A<.12K16+FVDL"5):(PDRR.JLF;EQ!^)4)$-6+=>UCEFR*X(
M4'B!Y*EEQ&W?M#=,;;W>Q*_'L$H8E.4CY6+J=HIC9.<G:^$G<:&XB[8_D'[^
M3US,B#!Q()F20=F, @DF("&;<D,"8W-B<2#GNB.. FB5(F6=5[8PSO)'H8L;
MQ$WXUIEY1FM RZ5$6IE[3&_.GCY9;L<F*.*8$ 6$P'$ $YO+N&JGW>OH$$)G
MX;M]5-=PG<BS0^#_ ,%7=N>4M) LAYYYT,R$NR.84?-^[!#H;O.H]D-2L]95
MQ2F*5X"HF4P$,<A3&Z=DHF*!AZCT#H41ZCU'%Q50K$7 -JB7.<]>&59F)FOV
M#DOJ&(FZ])R$+-QCZWQR+N+E8ITLRDH]XD8_5%RR=H'34*/E*8H@.0LG4>Q1
M.T<F7 '4D$%A<$<"#[(\M>D8GJ=]:6?C19N%L.YRXLR*\;K"Q5U<!D93Y0RD
M$>P:E6SD&,@V:O&+MN[:OFR#QFN@J11-RU<HD<-W"(E'VZ2R!P.40\@E$!R7
M#H4U@W6U_;';7G<L$T$C13*RR(Q5@1V$&Q!]D'A6"M+\F-6;QUPPVC79)S6J
MS*[#N.K8PM[-%5N1D;E2KU.Z\>Q;! 95XW>+2UAKK@(]--4R[I(2""93") V
M1!(T&'.O$9V''DQ*.+<N2,RBZ_A*@+.!<* 3>PO5,N-L+/S=OF_M<"<Q2M]X
M& 0W#&W=/,4 D"[&UNR][S^YM/U1T+*T[6UK6GH3Z%4%I/WJKP[H+0Z:M7S:
MMBWD91LK[ON&3Y%9-GT\X.DL0X$$IRB.*(&:2.*'ORRE@@7B7*-I8*!Q8JW=
M8"]FX&QK'-_EXVFG[D**K,S< JM<JS$V 5@K:2>!L;=AJH-MHZS>75UK5IL2
MBNMC,6HOGM ;6Z 7NK-B!"J"\=55*0-.MVH)G*;O#H 3H(#UZ#B(&97>'OI&
M;.5XA3V68CX)OY#:JR@PZ.=W.9\#5PU=OP;_  NP]E^PUAO:G*>JZ\V.QTO5
MZ+L?=^Z'51](#S6&I&%4<35=HAI)6';6RV3M]MU"HU8C925;K-V";R62>2"J
M"H-D5>[.);(->29F@1FQ\9XUFDX!(WE#,B&Y#/(R*7Y<:NX2SLH4@FZ5!!'$
M\[!6R-?*7B6DY942,  =*(74-(Y6/4P0,7[M8^BN=FL0WN.CM@1KK2;\VCZ?
MN5*6W/8*O0G'G5PV%8]=M: I#24H)5+&WDJZ*A56KMTV=$7("!E $#&RX:IG
M-F1X[J\V+/BQ*JW+2^*@GG!5"%<&-82'1EU@L+@6K#D,^,N(\J.L>4N:2QMI
MC\%)B(UV!*LLOBPT;JVDK&QN;BKHVOS!J.F=FZ^U]==;;;0@]EW^HZLK>UX^
M$JS[7ZE_O(*?!J"%D2Y$V2]:.CIB5>495YU$,C=?.7212G,5MR'<=P]&):/-
M99S&LAMS?#0F>73:^BT:L5,O+5RI5"6*@LUO!X1W&W-PT2-Y&2Q$:RR")";Z
M=9ULH*1<QP&#%;7M+?+*OIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K'M'
MV"G>UITT?5[-&1$+-3\ A89@*^G&3LA6;#*5B9"(;Q\_(S)$6TI$+ 4[MHU!
M1/LF+UZ] 4J(V[.7DMIWE+6--G/0[5#V+CON#:T5K*O.C.N0ELN6NG=3]PJS
M4X%:>;-I$MO;2[U)BU28+.'*[4YBJ 5)0,PXSRS1[KH0S9.'!!)$L=S_ &DH
MC?G6#, @(D8JO<B[Y#< =V;'@CQ,+)EE6%<C<1CN9" -!Q\J75&+K<ZX4C%S
M9G?E\"0:_?#SY0;0Y2ZPV78MPTI:B7>A;NNNNUX,VM-C:Q0;Q$8S@Y>&:*16
MRSGG)&8BFLT+1^[(""*[A#O"MVY3E3"7R,.&+:=NSH9!(^3CRF0BP!DBRLC'
M9XTN62)Q$K(&+$$NI8E2!SN)N,F7N^YX31&*#%R8UB![QY<N+!.%D<61IE:1
M@^@* N@@68,T^LCJE:8I45./GRN<U_UC:K^RSQSSH-X^K=K^A/\ ZO)J,P/U
MK,^D+^AAJ5><_4G3%*B'SP^JGM'[[0?TFTS.DZ2_>#']J3]$]16]_5DO]'^N
MM2\SFZE:ZI_B7[XX[WC:5CMM0Y(W98=H5._\=]JZ^K_$MQR:NVCZ'QNL\VGM
MSDSK X7:HR.@(FG2%F,E(69PTD$W;EHU<M6ZYVI0S'L*IF3PHK?]HSI,/<SD
M*>4\"F5,/%BDRQJ,,65-%I2$H75Y)I#I$C6W<^5X8V0(IW;;VR,%,=AS%RY9
M(1ES*F/PY\L$)!:0.$T!(RUP-6]C0O$36^M=01=2USN;D7/4^PQ:,Y'V:>W=
M;9^P2"=AK2K,T^A/2)S2 .Y=.2]TC*&$3B_["_\ &(4 E-X,[ROM^3&L#0M+
M'I0:3'>16* C_P!-HRJ'C8/)Q)D8F$VIX6A@W"!S,)!'+J;LE[A 9U[+,K"Z
M]@"QJ  B@41IX;G%UHI6U_<6\N'<1*R$U:';C9-Q,MMY_)7!EL%PINDJ4FDW
MV4D6[QK>333?D,FDY2#L@"8F(;#BY<F%DID8BQQK&D2I&%'*1H>;R950@@2Q
MF><I)\(-*QXG3;<R ^5J:=W.0ZR(9-1$G*ECCAEAUBQY4D444;IV%$4>>\M]
MH(I*:UOY5$DU"DI%K$I3D*<I1" D"@)2F 0 0*(A_D'-;M/&JJ H"J %'DKR
MU=\F>NOR%J/]GX_*54]M7UBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE1
M/E=<:\1Y=:_L*5#IB4^ZT_N"QN9M.KPA)AQ86MWTHR:SR\D5B#Q:9;,Y%PDF
MZ,<5R)+J%*8"G, PCXF*-\BE$<?,./*U](OJ#P@->U[V)%^WB:]&QM\WIO5K
MFX39F4<-=SPHA&99- C./G,8PNK2(RRJ2EM)*J;7 J6&3=><TQ2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2OG;= _^B/_ &Y]O\?8KP+CYZ[O'AU?4=XQ
M?FI@?NN,^2NN/WNW#Z2W\E>R]/\ U+C?W0J:.<K4Q3%*8I7B)BE$H"8H"81
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MLFS,0'*J*:2:JP&,4I2B !R$GJWS"[<K)CY1)MJ5B;$FUR#Q-NTCRU]!X?\
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MP+/"TND\H-'VBV6)X$? UZ%V+6GLK+OS)J*D9Q[1)^*KITHFD82ID 3&$.@
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M*JC8WL]E,@*#]@ RH;J]SQ7 0>W*WO=E6M'_ ,?L=19^J\E[<;#"C!/L @D
M^R37#6HOBDR8G*KOGB?5R'0 I5835%WG5D5RFZ]LI)N8;)*%4+Y!Z_Q?L!E#
MC]7/P.1AI[*QNW]8BKUW;U 8]BFT=1Y+ ]DF7CQ@CVXXR1[%ONFO:GHGQ$Y
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M96#4EN7?1;=1NL?LKM2J,UF_E*!4QSWK;O73-O\ AQCJ["V_J#;R.$DJ"/)
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MVO[)'W*SG?/49U-8;MM.Y;!G-\*7!F&3C@V[>1. ZK?CI5R?)>O!3G[?-8J
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MW_IV<9.QYF1BS WO'(R@^V ;'[H->/[CM&U;O"8-TQX9XB+6= WN$BX^X14
M7/AIVS3SH\SP;Y8;BXYBDH9PCJNW2*V[-%.C]LAB,AIMV=.)6$9B4HD$[-Z"
MI2C[7V #/1E]:>'O:<CK_9L'=+BQR(U\+ECV>;$ KG_QH1PKC3T+/MC<WI/<
M<K!MQ$+GQ&.3YC'(=2C_ ,+@UXGY0>('QT3*AR:XC,M]5%D)2/-Q</)@\P^2
M9(]V"\K-:9MAVMH*;LB90X,%E"E .A2#TRO[)^K?J8ZNE-Z;;LQNS&W)=(N;
MV5,J(&,^8:P/9-/3W6>S=W?=M7,QAVS83:B!Y2T$EGOY>X3Y@*D7HCQ#>(?(
MET$)1-P0D5>"#W;[6>PTW.NMCQSD!Z*,UZG;DXM^Z72-Y#"T\Y3 ?)VNO4,Y
MGJ'U:]:=,KS]PPI'V\_!GAM/ P\XDB+*!_XM)MQM4UM'6G36]MR</)1<L=L4
MEXI0?-H?23YN[<7X7J:@" @ @(" AU 0\H" ^P(#]K.$KJ:_<4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4J/''B-G6\';)%[93R$(^V?N<L171B(
M]J2".CN2^%<J$E4 \_D?/% $P@MY$^O0OD#![:'MJ,'*GB5MO=V[AN="'4]2
MK<UQ:WGQ]L-]D;#;6VTVLCMI.O&B):.@8>DK1,I!U5Q6B=I!2>9K."/5A(9$
MR9>\PXL?).X<Q4,65X-@G:DK8F3'D:9P;=R94..Y765C.K2]RE;[YB^%P\=0
M_-@SC*T@;3)$C8V5C$P&SCFQG)&1&6"KS8P#;X=4/C_$6+AZ2]UJ;U*_L=PV
M1+0%M2UAQ3HL[):?H3&"J$)2RJM;3:(K7T$A,V]Q!'D7Q!0;J LJ!1!42BNI
MV6#M8WC :V5C8^*N=DS%LF54*>)97&/$BZI'B@"]U@B@EW(5+Z:XK(E;9L_G
MNN5E2RX6-"JQ(79O"JZM/*QLB/,S]X,Y;N#OOVB:&K=YL=ERTC776N]J:YL<
M4R!^YC-A4]:*:K-^^30/[G6&.<RU<?N$3JD[Q CKOR@8#"3L^7-7=NG9-KQE
MS8\K#RL1GTWAENP/'MC8+( ;&S:2MQ:]^%;>!O:YN1X27&R\>?3<<V.RFUNQ
MU+)>QO8D$CB 16<LYVINHJ<?/E<YK_K&U7]EGCGG0;Q]6[7]"?\ U>349@?K
M69](7]##4J\Y^I.F*5$/GA]5/:/WV@_I-IF=)TE^\&/[4GZ)ZBM[^K)?Z/\
M76I>9S=2M,4IBE,4JQ]F_)ML'\A[9_P%_@4';7AJ[Y,M=?D)4?[/Q^*'MJ^\
M4IBE,4IBE1TFWFSR[TKQ&%<H2T86EW%)DY>72PM7ZT >S:\]T7SIDC0G;=M,
M-S@0$&I%U45@$PF<)=  8F5-I/5^&9)<D3>B,RX$2$!^?AZ0"9@2I\K$ CR*
M:BI'W'QH"1P&.QL3(P.FZW)'+(##R+<@^5A4B\EJE:8I3%*8I3%*8I3%*8I3
M%*8I6,)#Y9JG^;/8']J=:YS61^^.)_\ C<K]-AU@/ZRO_@;^-:R?G2UGIBE,
M4IBE?@@ @(" " AT$!\H" ^R A]D!Q2HV[3X>\8=T 938^D-?ST@(G.G/(0:
M$'9D%5![0N&]EK_N7.HK@< ,!@<=0,'7(O+V3:<[CE8\3/Y[68>TRV8>[7<=
M/^LOKWI?N['NV;#!Y8S(7B([+&*37&1;A8KV5&0WA_W?6G1QQ9Y?[WU"1 P*
MMZ9>)1'=6MS&*J94&PP%Q$)%DT$IA)_(/"G[/V1Z!TBCTW/BV.T9N3!;[UCS
M4^*_$?<-=X/7'M6^CE^L#IK:-S)[9X$.#E=EK\R#NL?+WHR+^2N2&PO$FTZ0
MP7G2FH>4T"W'VTYI>V+:QO"J/;*'>K5&\$<0KIP"0"84FSD@=KVH&'R#@Y/5
M. /EX(<R,>6)N6_Q7X?<!JWT+ZC.IS_VG==RZ>S&[(\Z$96.#;LY\%G47^^9
M#P\@KFP?B<: 92A*WO*!VKQAM7\D16-WAK^<@(COU3BF";:W1J$K7%T>V'D7
M,NDB)1 0-T'+DZLVQ'Y6X";$F\TR%1]QA=3[=[5ARO4-UG- <WI*7;]_V[B0
M^!D1R/8<>,+%)0?YNDM[%3EI6QM?[(BT)O7UWJEVB'*0+H2-5L$7/-%$C>0#
M]]&.G)"AU\@]>@@/D'.@@R<?)028\B2(1VJ01_!7DVZ;)O&R9!Q=YQ<C$R5-
MBLT;QM<>2S@5@^6M]3)RFI:A[172)H:%VHT7.>;C"D1=#L;4  V5,+D 3<"*
M!_:#T-[0?)Y!R/>>$;NEW7]7D\H_#CKK<;;-R/J^R@,><D[OB,/DVXCPV9Q'
M#LXCCV<14H@$! ! 0$!#J AY0$!]@0'[(#DO7G]?N*4Q2F*4Q2OG:_\ 4'^?
M_7GW!PKP.N[SX=7U'>,7YJ8'[KC/DKKC][MP^DM_)7LG3_U+C?W0J:.<I4Q6
MNCQ$8JS-M62UNG=JZ @N/S6-BX':VK>3&K9VY:MN+F8M,2TK#V1M-(E&=TK"
MI+ Y9H@)&K]H B511( *8V<3U7&ZJ),Z7 ?:9)(U$.4C*@E!9E99D)*L;<-:
M,JE01;R_0W_'W)P9.IXMLVO;.H).O]4LV'G;-F109L"1P.TZKCY*-CS#DB1O
M[2*0BZJ22!6#> /(73L7MV<XL4W0FI]4VF9HK7<*ULX][/A]FZ=O$24K-C'O
M6LDNTK]EBYQRP=%6)&KLE5V[4.VJ8H"41W^EMPQL@Y6RX^*,23#59F5762)^
M:475'(MBYL8RW= 4%03<@'I?7KT'U7)TQB>L_=][W/==M\<^W+%N>%)A;AC.
MO,D=7CU2Q-$KJZ<U90'DN%7@;;8+#>*9474*QM-JK]>>V1Z$;7V<S+L8YU-/
MQ[/_ )2+0=+I*OEP[8=2I@80ZAU]G.F5E>7DJ09M!:WETKQ+6\BBW$]E?*I4
MK&9F%H@;7\ESY+^?V*]-/V!1=A-7[ZAW*L7-E%2"T3)NZO.QLZW82;< %9@\
M6C'+E-N[3*8!$AQ W0>O3IEP5C$DX!Y,@NK>1@/,>PU1NY*T#\)DMJ4]HOV7
M':/+[A\U0^0__LZD_P!0^#_:"L.4I4\,4IBE,4J*O)7B%J_DLQC9&:"3I&TZ
MH?SS7NYZ,X&#V)29-(#&;*,YEJ**TC% J/\ *L7!CH*%$>G8,/;"(W79L7=5
M5GO'F)Q25.#H?8/E'G!X&O0NA?63U!T++)!B<O*Z?R1IR<&<<S&G0]H9#<*]
MO@R* R^R.%17J'+7;G%2R0>G>?+)L: E'K>"UWR\K3$Z6N;D<X DP8;,9(I]
M:';5?(154Y2LU3^WZE((J#$0;QG;1(N%U&!RV.E,E?@-Y )!]XQ\I-@3[%>@
M;EZNNG/6%A3=3>IYF\7&ADR=FE:^3!Y6;%8G_,P#[T F0#@0385M)9O&D@T;
M/V#IL^8O4$G3-ZS72<M';5PF55!RV<(F.BN@LD8#$.41*8H@("(9UJLK*&4@
MJ1P([#7@$D<D,C0S*R2J2&4@@@C@00>((/ @\17)RM65'#>'$+C-R0:&;[KT
MK0KVY\@H3TA"HL[6P5*'1->-MT2+"S1ZZ(@ D,BZ()1#.HV#K3JOI9]6PY^3
MC)Y45R8SYPT;7C8'RW4WJ$W7IS8M[6VZXD,S>1F4:Q[*N+,"/(0014*C< ^1
MVAU!>\)>:>P:G"H*&50TKR135WGJL4_Y0WN?%R\DHE>:HUZG I3-G"QBE*':
M[8AG=?\ R+TQU"O+Z]V+&FR#VY6#;$R/)Q95!AD/;?4H]BU<M^QV][0=72NZ
MSQ0C_H97^9A]I2Q$B#R<&/LW-?JW.;E;Q]*+?F3PJN*M>9G,5YNSBH^'<5#\
MS()R^Z<M1U :7^MH=@@'/VR.>R!O8+TPOJ_Z/ZE.KH??H!DMV8NXCPLU_,LH
MU0R?<*_=H>K.H]G.GJ;:93 /^OAGGQV\YC-I4'W&]FU3!T+S2XN\F6XCIC<]
M,MDJCV2OJFI(>X=WBUA .TA)4R>)&V1JHF?J41%L*?: 0 PYQ/470W5O2C?]
M^P9X(3V2:=43#SK*FJ,_&OYQ72[1U1T_OP_[5EPRR#M2^F0>W&UG'W14H#=K
MLF['9 _9'LB8!$H&Z>U[0 (")>OL]!#.3J?J"'$';7)[;-OWRCN20T,-1T[N
M"\:19M=94C84!8YJ?JL?1YQI:G4C:MDVV,;0[R-M"Z*D>1H98BZ2:A70E$R>
M*5/'%*8I3%*8I3%*8I3%*8I3%*8I3%*M.\4R'V%59:G6!S9F</-)MDGKBG76
MXZ[LB9&KUL_($9<]?SM9N$&=19J4JAV+YN=5$3I&,*9SE,I4%?"P:2*O#NG6
MF>N.RKU9K;==R.)NQ;/VCL7:<TZ+6MR7^DU]%G);$L]F=1$:QJU;8H$:LC-V
MIS)"N9,RZJRJE65E.E@0WF/"J @BXXBI8:&_Y$DOSI;Q_33?L&KC69LI5*A5
MS0LMVUW4(?85:VOL:CL&\M%U-2M:_J&KIY6?F[/($:1+V5FMG(IQ-;8-%0[L
M[A5T@V+VR@;J8Q<[;H;%PMRW4[3DXF-D2RHSAIY9XUC6)&=](@[TC%1<( 6-
MNZ.VN?ZHER<7:'W#'GE@7'[S<M(W:36R1HORG=4!FN6)  )+&PKV\(V,H%#O
M=BGY.XS%BN6RY>Q3LC=9#6#Z0</U(>#8"9H34LK+55C'@BQ(!$0,FL!@,)B
M E$=OU@/ F1@X.(F/'AXV&418ER +&:5SJ.2JR,UV/$76UA>X(J)Z.\5+)G9
MV:\\F5--'<R''/".".-=(QV90-*\=5F)X\00:FAGGU=M45./GRN<U_UC:K^R
MSQSSH-X^K=K^A/\ ZO)J,P/UK,^D+^AAJ5><_4G3%*B'SP^JGM'[[0?TFTS.
MDZ2_>#']J3]$]16]_5DO]'^NM2\SFZE:\%#"5-0P&(02D.8#J?[,@@41 RGM
MB>T+[(^4/)]G,<S%(7<,JD*3=O@BP[6XC@.T\1P\HJY!J< @D$C@.T^P.WCY
MN!K4UK+F[9=G<9^5DY6]W\<IO>NM=@[PH6KIHDM#U772CRJ0)INC.YM&>M+U
M%*,!FBNNNZ</0;JMVRBICE(0Y@Q99F_93;=WQNYEY./))*6*@#E;A+ [#5I5
M3X?P[ ,0-4T;'A(M9MG$2]9YNS]0*Z;;!N4<**JMS&C?"@F*BUV=A.<A"5%_
MDG4"Z-478_Q$.0SZ!TVI$6U \T]*GYHSMVK:K(J<M+H3=L-KRTT/3UCUC:YF
MC.*O5J=(+3#.;@7+Y5^W(5T<I6R#G.CP\7'R=^&(\4BXS)AZ86)CF$.0,OGY
MLP<7C\-R(F9+<K3*+M>6*\=\K#BE<N6-)1#F.TZD/ L\&/CS8V(C V9LN25X
MK,1,KQL@74C5NRW9/*0.JKJ["!L$Z9W5K$Q,SKK)"0>-/.*[*',]=)+NV9",
M&XI=E0X&$0,8H 4>ODAB &L.(O6>-F9%9AI8@$CS'S?<[*KVKPZ:SUV'4!Z4
M6HAU#V!_] C_ "A_!E*N/;5]8I3%*8I3%*A9=N2M#I_(J%JD]&6UE*1U7GZV
M<ZL9'(1[@;'-TR18S3>0=3#=L$$FSA7)U553)JE!/VJ9NH=?+-WZTV#:_6-B
M;3GR\K*]'3KWM*H#)+ Z7<L +K"YXV/ <.(K8\'B^/ABDS<&-I,1Y26D("$&
MXB<Z.$SZ>XG$&Z]X7J4K38%#?@ L;M4G@&#M%%K8X=?M% >SV@[IX;J7M>3K
M[&=]%OFR3_V.9BO_ .&6,_Q-6H)8V[&4_=%5Y*7BG'^PDX];J(!_)/6RGE$.
MH![10?*(9O)E8LG]G)&WM,#_ !&K@RGL(KG%,4X 8ABF*/L&*(& ?L>00Z@/
MES/V]E5KRQ2F*4Q2F*4Q2F*4Q2H<K[J?..3\#3!UI=$46<5<J<6R*,U@AW*#
MV5I\B:QHJBS AH=L:(!$YP.( HX(':\O08+)V_=%ZLQ,AH8_"G:\I@WB,<DI
MS\,%N6)>8""0.65$AN2%(5B,K-L',0)N%\_DM>+PN6+2ZDM%S3#RC==3<T.8
MAITEPS*#,;)VL5,4IBE,4IBE,4IBE,4JCSM>@+1'+1%E@XBPQ+CR.(R<C64M
M'K].H!WK)^BX;*=.OV2CEDD44RZ)55D/D(!'N&MG$S<S F&3@RRPY ['C9D8
M>TRD$>[4)[EX;?$^R2JEEJM)E])W(R@+$N&A[7.ZKETG *]\5?S2N.T:\LJ"
MH]H159'$>OE'(&?I?9I9#-#&8,C\*%C&?/\ >]WW17JFV>O'UB86,-OW'+CW
M7:APY&X0QY:$6M:\JF0"WD605U>K=X;?,U/9=CA6&A+G.BYLEKFXB4?S5(7D
MK%7&%M%LG:'SE6S)F6>/TY%LNL90"*G4<";L=>UT\=GZ=W==U."(7;(?7(H)
M6[1HZJ7)U6[76]S<ENSMK[[V[U_^J7T7CQ3[WAPY9PX]42QY 6-A&H:-0(B
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MM\/'QG_C2J^#R1\'(D^Z!3T5\JV9BBQY/0[\I14-V9W4, H93K_LTSJ1DBP
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M=" HH3%YBKRR+T'V%F4Y#)HN Z>3VV9%]8F%/PW/8-EF![2D30G[C(UQ6/\
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MO7J?M:/3$G7L$6=2C)B[%'IY# 4 $?9 0',_[<=,9EAO'3FWM?M;'>7';V2
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MQ"GY+:/ QPE.:\?/EYK8?#JTR9RU*9 X=Y(R>G)AZ952EV90I1.1EVRM%U
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MO<@O8V[9^2W[%?!Y]*IE!5(BQ0 %EAZG&3DR(WQ1"J!"9WD"#X$*M'$@@B/
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M/UK,^D+^AAJ5><_4G3%*B'SP^JGM'[[0?TFTS.DZ2_>#']J3]$]16]_5DO\
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M6:W;QK)&^M%<@BX!L>T7\A]D5CS7&VG;77=!;AJ3;[D$*55$@<-:W"*-EP)
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MQ0&$TK+9R0"\WPZKIN#G+.8W/Q9V9LJ0OFQ(_C?R1YK1=<%7D)-_"UOQRW%
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MNSC5VEA-%CD'GS@F)?OI &TDH.UP&[I*@V;@>-<JF7>E[&K<=<M>V^KWRH3
M.#1%JID_$VBMRA6CI=B[-'3D([?1CX&KYLHBH*2INPJF8@]#%$ S212Q:>:K
M+J176X(NCJ&1A?M5E(96'!E(()!K$DL<A98V5BCLC6(.EU-F5K=C*>#*>(/
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MA/E9%BC[TKR:% XEGL&T #B6TD'2.-B#:QJZ16BB:>4%8%C,A8\%"!M)<D\
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M88.9@8SJHNS2[B[1XXC'WPU*=?$%1:P:LZ8[/X+BH7/AS)8R38*F#"DTY?\
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M==H1]PM25AKRL:H3_P P91 .\4*  (#US8WO'DZ>P9LS<[)+C&<2P_\ 7C,
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M=/;8FW7QGA>S#!)O<<X)RN?R"+B3PW/A.0.Z8Q*O;WK;NX'T9CXF3E<(\QE
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M']H8?Q<K_;5*^+G^;3^[#_BT],&PO56WU\8N,'[Q^/1N']H8?Q<K_;4\7/\
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D_P")^H/_ )K=7_\ !&?7/BG^;Y7YC_<5XURO_<B_.?X=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tv486893_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!# *! P$1  (1 0,1 ?_$ 0@  0 !! ,! 0$
M       (!@<)"@0%"P," 0$!   ' 0$               $" P0%!@<("1
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M+Z^GP7-3_/&W_P 8_D7]M3'T@W'M8WR;&^]4^;,7MS>ZR^OI\%S4_P \;?\
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M'=, $OV3:Y/ &LOT4S[UNFUP*6CV_-:$-V2BQQ/K?L+QDT]@<@Y34HM!<E-
M\IJ.79/'3;]!W-1A?+QBEDH%B83[%I)-AZ+QT@#14SB-?$#H;Q+@B2@D$#@
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M=!]3;G#H0JME:2)3J&2;GC&<DFFB8ZS5(/#E;*FP(&B2*4F24'F,NEP0UB"
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M;;3LX:/V+?5WO-R0Z]UT3C%.,VL=D.DQ"WNAN2!J%5-T?(S=[5[E]G79\6$
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MU:EH!@H\1@6\X[9R#6)5DE2%2!PH@J1(3=H2B =,M<N:>%8EQ8C-E39./ B
MA2SY$\<"\3PX-(#QY;6N.6KK#QTR9625Q'$D,LC,1>RQ1/*> [80CS+WK'EN
M;O@*/JW@14>9T+I2W7J[6M>9A5>,K:TPD)>ZQ;M>^VRV[8*SV-9A(QL6RU P
MKDBY?OA:&3723;B0A?*TLS>7@+%O^%M&'*L^#FF*09(!"+BR/'$9RIO<I--'
MCF(-J,Y,0:ZDUC]HD;/VW)S<]3B96-=#">>S3E3)%"I7@>FA!G1[!1#SVMR5
M.,.:'')M:(.CS.Q&<1;9B0J%>=-5(>S/*U7;M>HR,E*M0+/L-E!+:_K=WG4)
M=N#**D))K(.Q72!)$PJI@:C)B.-PEP(#TCI-/&I L)6Q^DZ80WX2M&(W,B1E
MV0(VH#2UJ466K;9#NF0.BAEQX9B";F-)](C:2W&-&9U59'"JUP0;$5Q9KG%Q
M=K+O8K&T;.&JN-5T"S;4N/NII6PZV@GK>EN465MNU;=3=38M;U7:V]<II/7,
M$>1(W44(4_03EZV2NC0')! C5X4(/!E.2_1P%D-G599.8CE0C-P#5E(<3(R,
MJ'"@75/D-(L=B-+M$G22('OHUH@+LFK4%!)%@;5WI[DMI7?4A:XC5MQ4G)JD
M(5U[9H*5K%PID['1-P9.)&HV$D+=X"N2DA5[4Q9K*QLJV26CGI45/$K'$AP"
MZFQ,K'@;(E0B-9GB:]KI+&%+Q2+W4;@,K:7"L58, 5(-6"9$,C1A&N)81+&?
MN9(B2H>-NY==0*DJ3I;@UC:HF5+O&8>P:ET/NR6U/*US7VX.4UNXN6.85MK%
M\75\U&;)OFHZ1<9L"PC4DI7[U?JBS8"!3-AC5)E 3G5 AA&IC8AR<K:L35I?
M=]F3-B-N E?#3-3$/'C(\73*CC@\D2H$O(+39K^!IN[VU_,^?T$H'#5")DAE
MR1RV6$R)(Z&Y$>M]7,-[0\F>]MCN.EJDT$>/%KV5K6O\GXOC=9-C5J\0[(\>
M6&U+(;:W?L)E5WL$HI+0FC(UH5K)M4WI5G2I7(IG3%J=,U/9XH=S?".1*N-B
M9OAK"5N<B18N1!AQS/;CT>1F2M I%] B:1KJ1:ZRL;)BBRQB)T^9B08C=&"
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M68B6<TW%LL^CDY!%PQ.[0*/4@*D,3K[(80Z,K&RAW>+FXV2H[!;&R(\A5/\
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M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KA27]7/\
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M.!.V)Q[.63+.,ML%8I#D)")G%@ D1;2LCEB %=N:EB2[<%!-72M"<;PMY$6
MS=$#<DM+:YC55!)91SGX61;%B 15"7/G*PHT?JQ"9XY<CR[ V]<K%1ZIJ8:W
M06=W/*UB"-8Y)ZHZDMC,J6YA#19!,D[:RSA,YBF+X!*(!$ RYBX6+[+*V)+D
MG3PT1PND;ZPVE@=4BE>!#+S@2+5(76/&?*R/8HER88!JXZWF1W305U BR,&X
MC2W-(O>J/V'WD5 U=8[77[?I#D U)K.CT/8&XYEE T"1C=1P6P>T6'+;$VNQ
M3R4@]:J%$KE.&;R@$$!$AC@ CB/HY)I5#J,6+,BQ3,;]&9ID5XU%@7L2P2Y0
M#4#V+$S,LJPP,4;PG(QILA8N'2"*"1HY&/'1PTEP Y)4CAJN!D*C)%I,1L?+
M1ZHKL)1BTD62PIJ)"LT>H)N6RHI*E(JF*B*I1[)B@8.O00 <J3P28T[XTPM-
M&Y5ARV*FQ%QP/$51QYXLK'3)A-X9$5E/)=6 (-CQ' USLI56IBE,4JT6]-Z:
MPXWZRL6WMOV5"JT:L)MQD9%1%9VY6</7";5C'1D>U(H\DY-\X4 B+=$AU%!]
M@/ .49<B*%HTD-GED"*.VQ_H !9CR*H+'@#5QCXTN2S+%:R(68DV 4=DD\!<
MV [;$ <2*IV&Y5\:Y\*.$7O752[C9,9%R]$8&O-=1DK5'S+EVRCG$)'JR!'<
M@5R^CW" >*(;HN@H0?DB& +R7'EBRI,-A?(CXL!QL.C,NKA]R8@9 W(4YPX<
M:L$R(GQERR=,+6XMS;$LL>DWY&$C*A4\0Y"D7KFQ_)OCG+15LG8O>NI)&$HD
MDUB+K+LM@U9S&U23>O"1S-G8'J,F=M$K.WZI44P7,0#JCV0ZCX,H!E,,60#[
M!.X2-NP[D$A5/(6(!('*0">Q5PX,<LD,G":*,NZ]E4! +$<H4$@$\@) -?I#
MDSQU=469V>VWIJ5?7-=ECP,]>4=@5=2J0\V18J Q,C.EDQCFDD*Q@*")U 4,
M(^ !R+^QI%))S8YS:,G@'/)9?[1\P<G9HJEY984XRPB\@'$H+7NP[ \T\*I_
MC5R1K?)JN;!M=2CBM8*D;9N>KV,HWFX^?C;8E40CC$M<._C2%;#%3*4B4Z)
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M7;= Q%E@GAT%FIW</.,$).-<G;.")N&YEV;DAA(<I3EZ]! !S.QNLJ+(G%&
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M9\/*@Q9TQ]#R"+23"CJPYDKL"2P*W6Q /$$6/J9<5/5BX[>A#5?F1"9V[!_
MH>]+ZD5\S>M/UFW'QZ?X5JOYEU6!IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KA
M27]7/_H)U\H4R>/VQ?/'HU!NY/G5YRF>WZ\^UO@\!O4CXF?@]:F\RH?/(/7'
MZV;EX[-ZMJ[=L7D;%\7C]2*EOFMUE:8I3%*LA=N16I==3=KK]RL3J#D*726V
MP9TSN!G2L"5Q[-,ZZR4CI/VN]KYF0=S<@W:D:M%%EQ66(02@8>@04ZX7F0$A
M)XH;#NC+-JZ-57E.K0W$<T6-R+54,3*4#6 DCED!N+!(0#*S'[G0I#$'C;B
M1:_51_)W54A9:Q4P=61G,6D(!)OY;5)Q*.B)*V)R:U4@[),IM%HF"G+,A#.#
MLFRZQ5%BD#V.V0#54B9Y6A6VI2R\M@SI$)Y$4G@SQPD2.HN0O&K=I%2 9#7Z
M,V\\*TO0([#E5'F]C0GNFY.0VD$8Q2  F,4H"8I0$P@4!,<0*4H=>G4QC#T
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M>1#V! H^S'_$,/3X^/F3/[>/\HQ_OM3?/F/\6W3_ .W9_P#RU?;X?/#OP_\
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M9'K:A_J/L9Y,2<CQB'UE/_7-Y)E$2J<3J@0X#X2I.=\OB?M=',=IYVU,/[(
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MS%FM--FTF[D%XC5Y4=,)1*4?((.2-%C3369<>3()]A0BG:4-3/VA=3F-VWK
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M)C[Y:WQ2M<#%*S9]VE]A>X^DV2\V:MBE::/>Y_I&>47T[,?-V(SBW6;RY/\
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MH0U#Y^ZT=G(SA_\ &D]=7V4V[/JG,HKQ)U*HH;PF.IOK1!SF'ITZF,9F(CX
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MBDU-]->O/^9[C\KG]=7W2:[X6Z^)XI</E>S^Z\5N)<_9Z^QU[&@1Z=<@>J$
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M-G+:]SCEKTY^*GJQ<=O0AJOS(A,[[@_@4/>E]2*^4?6GZS;CX]/\*U7\RZK
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M_O>F;^NOQ\!:]?="5C\4+B]_\BX^?IO_ !OE$WKZ>%-_O>G;^NN,XX%7!WV
M=;\JB_B^O8\9Q!XOCV>U[/3I1P]GIDPZP9"]STWRB;U]1&6XY-7IV_KKK%>
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M\D6/I_+:.(H(=>R*I6/,%$JA@Z] $P"(![&1^DTO9Z0^>,<^CCT\-/\ O?\
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MUV-B2-()JYM_<-VD3%.G:Z+5JWM].6<.7"I$4$$B6..$ZJRRABII)E#V3&$
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M(_S1/WN*4\G;_P @C_-$_>XI3R=O_((_S1/WN*4\G;_R"/\ -$_>XI3R=O\
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M<5WOTD67G8ZL>)>*+()C-^SHZ1H@>/","_"JNXG3OS:+Z)]NPLAAV%D=)(F
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MB"HNSI#V14Z]L2^#KTPO- "\  0+=@-W0\X]GM]FAYW=<;V_Z/)_-V.UV*_
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MZJAN.N@X28V31(J9CM,ZV92$1)6N#8RC%XPIT(V?-'D>Z?).VSADY#Q:Q#D
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MI[O9#%$O3P=! >N0(*DJ>4&U01E=0Z&Z, 0>V#Q!J^>0J:F*4Q2N%)?U<_\
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M9#A1-CUK:$<2?HU<V16)>2@(2P0J<19:;:>D5,1*[:R*J=D3$.FNDF<H_(B
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M$!_8'++DX'EJZ!# ,INI' U_<5&F*58S7_V9>0/T;K'S'3Q2KU/'2;%HZ>K
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M^F2U[<;>=7Y_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\
MB?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X
M/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;
MC]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>
M\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\
MB?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X
M/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;
MC]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>
M\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\
MB?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X
M/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>\4_/_P")^^4_.#_>;>_;
MC]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\ B?OE/S@_WFWOVX_8S]*>
M\4_/_P")^^4_.#_>;>_;C]C/TI[Q3\__ (G[Y3\X/]YM[]N/V,_2GO%/S_\
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9_P#Y!_\ U//7OL/^_P#[*XA[+_N_[:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv486893_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!/ *2 P$1  (1 0,1 ?_$ .,  0 " @(# 0
M       &" <)! 4" PH! 0$  @,! 0$!            ! 4" P8' 0@)$
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MODQ2&$AR#G('23.LU5E&,+9<H*QU^*>HWE!T_=*Q=<4DT44R.VQQ451.H40
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MA^3D9(%W_K-LW78QVT3T&S7/B--:EGN'C_ZIE[/7J'EX,43R67]-%8H C/\
M[2SJVT Z&]]#5J\XZKRF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2JV\OM_EXM\:]O;[]P+6=;6]2>SC."2$Y2R$AWI-6"
M3I1/ZZ3(KMP0RQ@^L"8#T\>F7G;'"/W-W-Q_;<4BQ29^6D(<^";KDM^T*IL/
MXK7TK&::+$Q,C/G#M!C0/*RJ+NP1;[5'F2;7^ N?*M;G#*]>IAR'K>H^42W(
MCC=:-1;&=MI6S:!B]<IL7M,KKARJW?1;+9;!=Q+NK+%))]X(NTB?6, '$0SV
M[O\ X7[3=D\EF=C9'&<M]8Q5VKR!GTD?:&#C&($9C8G:2I\C:QKR7MGFN].\
M..3NGCLK"AQ6+6PC'N.C;=LDUR\;V!<#7\M]#6QB^\T.+.KK=>:)L7=U(IEN
MUM4XZ\W:$L#QU'.82K2[DK.,E#*+M"MGWMKDX$31:G7<&'_X>>.\;V5W7S/&
M0\QQ6#/D<;/F'%C>,!MV0J[VCL#N!"^HL0% \6KTK)YCB\+DAQ&9/'%R#8WN
M KG;^CN*A]QLEBRD %MQ(T%=EJ?EOQLWGKJQ[8U)N&H7O7]0:2#^T6"$<NCE
M@&<6T7?/7,I&.&C>9:(D:-5%"&.W %2IF\ONZ#CN+LONKM+-BX_N3!GQ,N<@
M1AP+.6(4!6!*DW(!%[BXO:XK7P/.\1W/(8>!R(\F4,%*J=;GPT:QL? 'POYU
MYP?+'CM9-#O>3L'M.!D=#1K23?/MDHMY@L(W:0THI"RBYT%8Q.5$C.42,B;H
MW$1,'AU#QSYR?9G<_#]Q1]I<GAR0]QS&,) 2N]C,H>, ABOK4@B[?MM6?%\S
MQ?-X<O(<5,LV'#U-[+>R]%2\E[@'T*"38>6EZU]<_P#U;=:<7-.:>V!I>=UW
MM&T;H<U:STVOV%2TLFDYIV5=N6TSL",,P:,G!4H\4  A%S)G[A\4Q#/2?MM]
MEN:[L[VRNV>Y8LK!X_CNI'F2ITV:#( 0Q1-<L"7!8W4,++XBN5[M[XQ.&[%;
MNSA#'EY.067"0[@N0Z F0#P8;/2#?;\PUJUU;]1;AW.:>HN[5=ZTY*B7NV,]
M;Q%A0;V-2,=[,4(V3>4YJ'N47H/FKYP"7<HF5+K_ )^<OG?:COK&[IE[2AX[
M(;EE@DR$C)C#MBH6_6^?;M*B]KW_  J?QG>G!9O;K=Q39$2XD'13(8;BL,TP
M&V,Z7)+7 L#X:FLZ;&Y&:3U)=-8:\V-L&'JMTW--?#VL*^_1DU'=PFNY$GN^
M..S8.FR2W<N0.JZB1?K?3G+<+VMS_<,.;D<+C/D0\=CF?)*E1THA>[MN(N!8
M_+<_A5[R/+<=Q.)#G\C*L6)D3K#&QO9Y64LJ"P)N5!.H _&H'>N;G$[6,_L6
MK;"WM1*=8M31,=-[ B)]\YCWD!&RP$-'+@FLT+[V5=E4 2HL1<K=!ZB0,E\;
MV/W;S.%C<CQ6!D9&%EY+01/& P>51=ET-UM;5F"H/XJ9G+<;Q^<>-S9HXLT8
M?NBK&W^'W]/J;CZ;%_2!?<3X"HBZ]1G@XRU,RWBZY,ZP1U=(R:D,QLII9P)W
M,HBJ1%5DG E9C9?.2.J43=68 4ARF$>TP"-FWVN^X*<^.V&XG,^N-'O$>T'T
M6ON+@],#0^+C4$>.E5F/W?VSE<3+SD&9">*A?8\ER &)L!M(#$G6UE-P"1H"
M:LWK;9E W#2X/8FL+9"W>DV1K[9"6.!=%=Q[Y'N$ANTW0BJ*R2A1*HDH4BJ9
M@$IB@(=,Y?FN$Y;MWD9.(YS'DQN2B-FC<6(OJ#\"#Y$$@^1JSXKEN-YO"3D>
M*F2?#?P9;_V$&Q!_ @'\*U:.^7>^-6^K.TXK[4LD.]X^[LUH-@T:V"M0\;)Q
M=KCFB*K^-6GVC9.2E_:';9XD!5U#=H)E$ \<]9X3LKMWN/[*<AW1QT4@[SX?
M. R6WL4;&=KJ1&3M!5'CN0+DWN:Y+NGG>3[>[YX: R+_ $MRL#1[-@+)DJ-M
MS+Y!V1GVDBRNH^%^TYT\LMXT[EKPQXE\;K!&P5LW!;%['M:0>UJ'M L-412Z
M3=^!499NY+&*+' YO/3 JI2>(#FO[3]F=O\ -<)W'W=W=$\O!\1@?IJLC1%L
MMP60!E(+66WIO8G0U]^X_/<EP?&\;Q_ NL?<?+<@L,19-X2)2-[[3=2"QV$M
M\OB*F/$ZR*L.2_-E6R\YTM[0M;L3%TXTW*1TC#-.-C$B NSL7DI+BG%>29IX
M"9D*;<2?74 3^.5G<L41^V?;TL7 >SFD,@^HA@QSSN<6"B[W!_CN;K9=-*G1
M&:3[F<CCIR)91BQVXT*?T#MA/5W?*=WC9?\ ::ZBK%:@YX</M^["E=4Z>Y 4
M"^[#A@>B^JL,]>%D1+'"?VXS$7K)HUE2MBIF,86JBP 0HG_0AUSG^7^VW??
M\,O</,<7E8_#,%/591M&[1=P!+)<D#U :D#QJ=%W9VW/RWT.',@?E3>T8:][
M $A6'I8V-[!B?'X&FY>>/#WCW<XG7FY>06O:%=9M=%LQKDK(N7$B5=P=!-%.
M1)&-'Z<,*@NDQ 7AD [# ;]#XYJ[;^WO>O=^++G=M\;DY>'""6=% 72]]I8J
M'(VD$)N((L==*D<UW#PO;W3'-9,6.TWR!CJ1IK87(!N+$@ ^(O60=M\F^/\
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M5MW5>_ZAK[2UAY\:TL]H@JKKVYOKA26>QVS245A)*(FG[*+< ^DGB#\7*?E
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MHJ)]X)G'Z0')_:N0Z?YP>8Q^H5@D?D+KN(5F!@M=;V) O:XN!>U<[R4$L_\
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MACP^=[JX_&&W#AYPA%\E'1C%A\!Z1I\;GSK]]<ZBSE4HW'GFC1D');?Q:V_
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MQ(I(,2>:*"46=4=E5Q:UG (#:::WTTK&?&QLK8,J-)!&VY=RAMK7!W+<&QN
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M5\-RJUOV7!MX#PJ< 4I2@0I2E(4H% H  % H!T H%#P H!X=,@$EB2VI-;U
M4 +H!X6\JZ" J54JA9 E6K->K1)9ZI)RA8"%C88LE(J@!59"0+'-FP/'JA2@
M!E5.Y00#Q')&1FYF6L:94LLJ1+M0.S,$7^%02=J_@+"M:P0)*\Z(HGE-W8 !
MG/Q8^+'4ZFYUKPDJ93YJ:B;),52MRUB@>X8*?DH*+?34+W=_=[IE'355]'=W
MFFZ^2H3KW#^:.?8,_.Q89,?%FEC@F%I%5V57'P< @,/^\#2:"#)"KD(DBHVY
M0P#;6TU6]['0:C705U\EK?7<S/-+5,4*ERMG8&3.QL<E5H-]/,CHCW(G:3#I
MBK(-S)&'J42* )1^C-F/RG)XF.^+BY$\6+)\R)(ZHU_'<H(!O^(K'(Q<7*97
MRHXY'064NH8J/'TD@VU^%<JST6D78C).YTZJVY..6%S'IV>O1$\1@X'H KLB
M2K-V5JL( 'UB=IO#Z<PP^0S^.D,O'SS02L+$QNR$CX$J02/PK*:&')A]OD(L
MD%[[6 9;_&QN+_C:O:%+IP3[6UA4ZT%I8, BF-E""B_?[.+ ATPC6LQ[+[Q;
ML 34,4$2* GT,(=.@C@<AGC'DQ!/,,25]SIO;8[:'<RWLS7 -R"=!\*P.)BL
MT3M'&7@%HSM%XP18A#;T C2RVTTKB3>O:#99>.L-CH]/L$_#BB:(G)NM0LK+
MQ9FR_M+<8Z2?LEWK$6[D?,)Y1R]A_K!T'QS/$Y/DL"-X<'(GAADOO6.1T#7&
MT[@I :XT-[Z:>%?<C&QLM57+C254)*AU#!2;7(N#8FPO;X#X5SINGU*RNHA]
M8ZO7; ]K[KVZ!>3<)&2KJ$?=4S>V1#A^V75C775(H^8B)#]2AX^ 9KQ<[-PM
M_LII8>JNU]CLF]=?2VTC<NIT-QJ?C7V?'Q\J,0Y*))"&#!64, PU# $$7!\#
MXCRKT6>CTJ[)M$;E3ZM;48];VE@E9Z_$SR;)P/;U7:)RK1V5LL/:'UB 4W@'
MCGW#S\[CI#-Q\TL$Q%BT;LA(^!*D$C\*^SPPY4)Q\E%DQR;E6 92?CM-Q?\
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M,O[H?<'.R,K*S.6RY)LS$;%FW,"'QW(+1[;;5#$"Y4!OQJ%'V7VM#AK@18,
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M-!?C,6=FS%F+9N_!=XLS*FD+!'IY22?ZV'7*2?NCG\GMW'[2GRI&[<Q93)%
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MJ5_RAXI3X:W+_*K4OYJ5_P H>*4^&MR_RJU+^:E?\H>*4^&MR_RJU+^:E?\
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M0N[NOCL;B.Y,[C<,$8L.2ZH";D*";*3YD#0DZZ:TXJ25\/;/-'DRQR21F9
MDW2D:,3( 2 LH4. I(LVA(J+<"-\:LVKR+]2_8]4L;MG5+)R(T8G#+7VK6_5
M$X[]S<,N/L-(*FI^TX&FW!JV)),54TUEF":2X$$Z1CDZ&'EWR\6-BDDL:N/$
M%@"+ZBX)\Q748W;_ #V; N5AX.9+BO?:Z0R,C;3M;:RJ0=K:&QT.AUK:!\=T
M?^&54_"*(_[YF/OL+_;1?^=?^VI']*]T?_3<_P#_ (\W_N5S&EKJS_O]ALL
M\\OIYGLDQ'./+Z_1W^2Y/V]?N=<S3*Q9/DDC-O@P/_74;(X#G<6WNL++COX;
MX9%O^RZB]<&QWJHU. F;-.V&(8PT#&NY62=JR+,I$&;)$RRQQ$RP!U$I>A0^
MZ80#[N:\G.Q,6!\F>1%AC4L3<: 5*X;M7N'G^6QN$XO#R)>1RYDBC01O=G<@
M >'XW/P%S5<=&[IV1/W!U6=RP<;5U=C1;G9>DF;5FZ9O$J FHW:.:;;3N%%4
M#; @4%FL@Z(F8O>E(&(0@@T44-SO"<SR,^8<;F$6(Y"F;& !!Z6@,<E].JH*
MLUO)R /037LOW1^VG9?$]NIS?VWRILZ/AIUXWFG9U=#GD,ZYF(% ;V$[++!$
M6!LV.K,U\A$%N\ZVOSU7J771;(K.7*R3=NW2477774(DB@BD05%5EE5!*1-)
M,A1,8QA   .HY\9@H+,0% N2?*LXHI)I%AA5GF=@JJH)+$FP  U))T &I-5_
MT/R.J._?B[X=AK+7S5F7,E'I6J.-$N+;4W)U4H._UYJN)72U9GE&JQ43*$(H
M0R70Y2]Q.M!P7<6)SW6]NDD9B?3>-IDC/RRH#KL:QM<7TU\17KGW5^S7</VF
M^G_6,G"S%S<>\AQ9!*N)EJ 9\#(9;J,F ,A<*2I#74G:UK"YT%>05Z7+A!FW
M7=NEDV[9JBJX<+JF B2"")#**JJG,(%(FFF41$1\  ,^,RHI=C90+D_ "MD,
M,N1,F/ I>=V"JH%RS,;  >9)-@*P-HCD+6=\MK4K#0=@K#NM3'DHQEH1:M7]
M@J$EYJU.V-"(MW"YEZ=>&")UH]<_8<?*43.4ITS%"BX+N#&YU93"DD3Q/\KV
M!>,ZQS* 3>.0 E#XZ$$ @UZM]U?M!S?VHGP(^2RL3.Q\W&N9<8LT>/EQV7,X
MZ9F5=N9A2,J3H+J-R.K,KJ:S_E]7DM1:[7&#U_4K!=+*Z*SA*Y&N))\J)B <
MY4@ J+1L"ATRJO7[DY$$$^H"HLH4@>)@R+FYD&!B29N2;0QJ2?\ J _$G0#S
M) J][8[<Y3N[N#$[:X6,R<GFSK&@UL+^+M8$A(U!>1K>E%9CH*A6D=OQF[**
MUN#.!G:=)$>/(JQT>UI-FULITVR4^^PMC:-%W*#:0]D427[2*'+Y:Q?'J @$
M+A>7BYK!&8D<D,ERKQ/821L/RN 2 ;6/CX&NF^YWV[SOMEW3)VYDY>+R.$8T
MEQ\W%+-BYD+C2;'=U5FCWATN5!W(=+6)R]EO7GE<9X\:1S-U(/W*#)BQ;+O'
MCQTJ1!LU:MDS+.'+A902IHH()$$QS&$ *4!$<Q=TC0R2$*B@DDZ  >))^ K=
MC8V1F9$>)B(\N5*ZHB*"S,S$!551J68D  :DFPK'BUOK%^UBC<Z7.QMFJEEB
M6$M S\0Y([C96-=N&ZC=XS<)B)5452CX#](?0/CFG$R\;/QDS,)UEQ9%#*RF
MX8'P(-6?</;W.=I\YE=M=RXLV#SV%,T4\$RE)(I$-F1U.H(-8;R15-7&>O&D
M<S=R#]PBT8L&R[UZ[<'!-!JT:I'7<.%E#="D211()C"/T &8NZ1H9)" B@DD
M^  U)K?C8V1F9,>'B(TF5*ZHB*+LSL0JJ!YDD@ ?&N+"S438XF.GH&1:2\++
MM4GT9*,%BN&3YFL BDX;+D$2*I'Z> A^9F$,T61$L\#!X7%U8:@CX@UOY+C>
M0X;D)N)Y6&3'Y+'D*2Q2 JZ./%64Z@CX5V>;:@TQ2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*5[4/UY/].7\_%*C/IU?T'.,'XIJ[^I6Q2KHXI3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*KUQD_BWF_QS\AO]NNP\4JPN*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2N"SE(R14?)1\BQ?*QCLT?))LW;=TI'
MOR)IJG9/B(*',T=D26(84U *<"F >G00S6DL4A81LK%38V(-C\#;P/X'6M44
M\$Q=871VC;:P4@[6M?:UO V(-CK8USLV5MIBE,4IBE,4IBE:)_\ %HQ2M[&*
M4Q2HE/T*F6F8KU@L=9AIJ;J8305J4D623EY"!8XEQ SP1RR@"9N$M#.U6R_3
M]<1.)1\!S':NR>.PV96.8)1_M(2ZR&-OBF]$>WAN4'RKX0&:)SJ\$PEC/\$@
M5D#K\&"NRW^#$>=5(#TT> Q=?3&J2\3M,%UU/W-OL*8J1:HW+%/KHT;+LFMA
M53!0%0?MV3I5$G:<I"I*&(!>TP@.5SLPT.J8!8XX\1$7"A]OQW!%#7O?:M_
M5NZ\ON<S,W'W6>JKD-YRJLC2J&/P61F<6M9F)'B:NC"PT37(>*K\#'-(B#@X
MYE$0\5'H$;,8V,CFZ;1BQ9MTP*F@U:-DBD(0H !2E  S=DY,^9D/EY3M)DR.
M6=F-RS,;DD^9)-S4/%QL?"QDQ,1%CQ8D"HJBRJJBP 'D -!6F6H4;<UIYN^I
M3.Z]A]&W:'@MV\=V,A2]MP$^:9>@GPMT7(J(U"ZPTJDUKAGJT@F E>L'S<I@
M.IV@8WC53<7QV1(TT\$;2M:Y*@DV%AK^ TKLN.[Z[RXC"BXWB^3S8./A#;(T
ME947>Q=[*-!N8EC^)/QK.D3N765*)'L>5W$>1XW23HJ*+BTI1K3;>ER23@ZH
M(QJ.T*9$HKMU102\U1:1AXYH@3J!U@$,U_1>)_\ EXO_ "BI_P#S-^X/_P!8
MY#_XS?\ ;5MXK4?&O94'$VBOU'6ETKDBW]IA;!7_ '9,0S]JJ/Z\PDXE=9D[
M2,(?HB','4.F:I.W^$EMU,6$V_U:FX?W?^Y_'AAA\YR*!O&TI-[?MO6.MI\,
MM9W&/KB%(A*M0'\';H.S.W2%;1DDIQM!N/;DH"11573[XE\\23]I3ZB"Z)3)
MF#M,.4_*=G<;F1QKA)%CR),KDA =P4WV$7^4FVX>8T\Z]'[$_P R7>W;F9FR
M]SY6?RV)E<?/C(K9#1F!IUV&>,A3:5$+=-O%'(<:J*ZC=G%*T<BH*MU3;MWJ
M-CK5>NU:N96 Z^:][@\$^*J]BC'-(!V,I^*.NQ<]!Z^2N82_6*40T\UVKE=P
MP1XO+3PR8T<R26Z0UVG5?'P9;J?P/QJQ^V7W[X+[.<KF\_\ ;WB^0P^:S.,R
M<,O[]K*)T(26PCU>"4)/'Y;T /I)!['_ )>'"7[O&S6G7[O2+<]/^K]FYM_Y
M?=E__3<;_P I_P"VH?\ _L'_ #.?_P#:<W_\5?\ W*QIO[B%1F5$K%-TQH^,
M5BI2SP\1<TX2:<1+NOZV;^8[G$:VV>OQ9G?RHH),@((=A6RZP_3VY6\]VE@I
M@Q8?#82F)I563:Q4I"-6" FUVL%M\":[7[2_YANZ,GNK.[C^Y/=$ZY\&#-+A
MF:%94R.1:R0-DLD>\1Q;FFW#4R)&/"]>>S:!;]@6W3D] Z&L5;6HSYC3Y@@W
M)C$L'FIWP%;R40JM%.2.3*UX4B.X\H]0!8# /TXY/ R\_+PYX,"2,P,(V_4"
M@P'0KZ3?T:,GXUCV1W;V[VEV_P!Q\5RW=>'FQ\I$^7"?9O+(G*I=HY@)5*@9
M%VBR#H2A%O"K*'XV4$INK"8V/#%, >:E#;&M<<DN8/T*BY$9  44( B "/T
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MFXGH^*721DV7<P!\0B!@ 5TQ!2KNXI3%*8I3%*8I3%*8I3%*8I3%*X#N*C)
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M1E=4_(9/%X0L;W%(6QLBE4<^;T234:E[0ZG,(Y0#EX,^5\7&5<*;UL'<:2:
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M29+V6: Q_B#N5@?V  BWG>K2*18V#,-Q# C_ *_WGXU5'7/!:V4JS:S]IO\
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M91<04?,4_8%C'=-@574K8-BE,4IBE,4IBE,4IBE,4IBE,4J+77]Z\M_HD/\
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M41$1$<VY^=E<GG2\CFMOS)Y&=VL!=F-R;"P&I\ +#RJ%@8.-QN''@8:E<:)
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M<]-'"B0!ELJDM&1K67=BM'S'*X^-Z9$YC#Q\9HO3#C]2*%I(\@6 /44OLNK
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M]DRXX,:1XR"2W7(!L%-X0NZZ&4GJ ;ET-0.C<Y-\VAW19V1K.I6-'NO)N_\
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MTJCP,J;(OO,,D852)(F+1L3N#IJ 0\+*4D&J[OE)&M62R!5A3%*8I6O/B?\
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M6B$+JX)&_J(/6;@EB6\:K>.QL?!XN?AIEZV!DHZR"^TW=S)N0B^PHYO&!<*
M!J*QE:>!\9?Z5L&)ONU):<V'M?96L-C[!V5&U",@2R9M3S,=*5FM0M/)+OV-
M?ABMV!D#=KM<X'745\1$"AAB20\?E<9-A(5Q^-Y"3-",Q8RSRJ%<N]@0"%7:
M #M"[=;DUMR>IF09\6209,WB3QX8"W2A.\[@+D,^Z1F8FVXV&EJOY^8 ?0
M ?\ 0 =,T>)O7U5"J%'@!:O:A^O)_IR_GXK[49].K^@YQ@_%-7?U*V*5='%*
M8I3%*8I3%*8I3%*8I3%*8I6G?EMO+@++[U?5;:?"+9',+;6F"PJ,W:]:<*YO
MD6GKA_),T;!#5F4NT?69)"/E_87*3PD>*QQ2*J4_:439HXM[9#<QQ\;Q,9FB
M&1MV+))"W3?8YMO,+@HSCY&4J#Z:D9P)@7B,R5'5HA*8"^XI'+JK.GY!*/4
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M5C5%5XYUW=KRK3>M=GP>WJVW>S\M&RM@LK>5@&S).",BU320CBD"5(J0YSI
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M8U1Z5X;M'HGFG$1LW>,?5TC:0 ^DND8O(\0:QE5!\YC#!?.M^4K8<)GR 1"
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M7*:$-:+_  Y&]1)M)_4M=/TP(OE(<:B#B8L.+'F\2CM]*R\7-A$I7=*ONQ(
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M=J^:D*/EF4J\.*4Q2F*4Q2F*5%KK^]>6_P!$A_K;?%*KQBE!\ $?S $?^GH
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M*(>.?(0<EMF-^HYW:+ZCZ+;]!?Y+C?\ PW&ZUZ2,L*&28A$4*26T #WV$DZ
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MD9,I&FW#>2/;(W_I,@;36X\5\*^2+UX8XIQN3^C!BL#J/=!7_2/_ *@8BQ\
M3HWC6\ED54K)F5?N!<K1L58#CU."Q4$P4 P^/4P' >O^7(.04:=S';IEVM^R
MYM6O!61,&%)KB81(&OXW"B]_QO7*S34JF*4Q2F*4Q2F*5[4/UY/].7\_%*C/
MIU?T'.,'XIJ[^I6Q2KHXI3%*8I3%*8I3%*8I3%*8I7B8I3E,0Y2G(<HE,0P
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M2\557;C5+]=^S".?+;=W\J\CRN4WH,72F\=@F7: \2(FDZ!NJ(E\PI2@?IU
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M:OT.LVE:>WMFO]Q;IKT=96]3E(>4L3F^RJ,;(RT,SDF--KL<U'W:HJ87J\P
M%*/00&NQ92N=EYF.43EL)1(% N\V,J*5C6WS/F9;+B1"QZ9CDE\0*N.E_P ,
MABE:0X&5+)%HQ"#(;IB.]O5&L4(ER99;A&"1Q$WO;;]QEMTE?>/FG+E+0496
M7MCU]6Y0T)"H-VD.R;N(](67NMDU_8S!@Y8@FLDW)]5N10$PZ]O7.J[AQAB<
MQ-!=]XVE@Q+,CLBM)&6.K&-RT98ZMMOYUQ?;F5)F<-%/*%#$R %;!65)'1)
M!<#J*HDL#INM6<\IJO*8I3%*UY\3_P"F+ZI?^\)QX_X'^.6*5L,Q2F*4Q2F*
M4Q2F*4Q2F*4Q2J]<H=22NY-.V"OU-ZC#;*K[F,ONI+$J8R18'9])>)SU0<+N
M4R'<(1,H_:>[I0$^AEXEZY1_0J" J5(>/^X(;>^HJ7LZ'^\'GXLJ<]$*]I']
M9MT8H>,MM5EVP&,=A,UNP-7#-TW4Z*(K)"4P (8I69,4IBE,4IBE1:Z_O7EO
M]$A_K;?%*KQBE,4KV>2L'8 I* *GZW]0WU_TGA];_JQ^'G3ROY4%%8!( I*
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M2@@ @("'4!\! ?$! ?I 0Q2L;OM=-F[H96F23FF2G4YU$8XA%*](G/\ 2$I
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M 2=-;%2KAF# AD\P VM5':5\G'[<@RMQAR<+D1.&O=P'D*"0GU J0-IN&%K
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M&#.K[E7,7FYQGLK9/HOM&T!3&I1=OY=J;5*_E(())%ZXKM@X1X2+Z>C)BAI
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MP7+/LM^4+#^&NQ_PL7_[OGJ=>[T^4+#^&NQ_PL7_ .[XI3Y0L/X:['_"Q?\
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MF6X]^<RW<YM**BZW*S$6%'V;;)5G6:^WMT//UHDK/*N3'.=TS6Z-6ZH)@!Q
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M-WVSJJ^/(9E79VQZ?NR=.>6J"C'*SN+B[,DYAIQI)MXU=PH* @FFH0%#!W"
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M/82LA*2$=LZ$;KN)RMD@RL&4?!;4?-TV[)JV[3-T#E.3M,4TB-S&A0>!U_\
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M"#Y$5A=IQHT<P:-V#&@1[-BT0(U:LFK^:0:MFR9.Q-N@@G)E2213('0"E
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M%RV?K]-PGKA+4S.A6:7"(<1,5?=DHVR/FH:;B%7*#4\\C4JDFZ8'>E(9$1>
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M3%*8I3%*8I3%*8I706NSP=)J]DN5GD4(>MU.!E[+8)9SU!M&0L&P<2<I(+]
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M5V!+F28^WD42/D8W>*9%;<JRQ.T<@5OS*'4[3YK8U4/BUR6XY1_+CU-I-_R
MTDRCIS?N@'4*_=[6H;=G+M6G"SCW&.G,8Y6GB(OV[:29+-U#I&,4BZ)R"(&(
M8 IJF5?K[5_%K^LIH'^>/7?_ -QXI56Y.I>EI)7AS?Y.S\5%K0ZGD+1(>;MV
MEIPS^QH=#H3<E5"W E9>R)1'O\Q5F;O./>;N-T'%*M+]JOBXF4G7DCH(A3$
MR?\ ^<.NRE,GU$H"3_U$ "3J40#IX>&*5PY+DUQ,EF*T;,<@^.TE&R")DW#"
M2VOK5XQ>MS&$IDUFKJ?4;N43&*("!BF*(A@:,KC1T8,I\PRD%6!\BI ((U!
M(UKXP#*R,+HRE2#X%6%B"/,$$@@Z$&QKKK'O[AM;HE>NV[=?&6SP?<@JZ@K'
ML?5DU$][-4AFRB\9)S+EGW-5P*)!,3J0_3IT'IGP@-(LS:RHVY6\U;^('Q#:
M^(UKZ/3&T(TB9=I7R*_PD>!73P.E<!ONGA&W;@S:;9XK(-7#=%L#5O?-2)-U
MVK!\,DW;@@E*E34;LI(!<$)T$J:X=X !O'-JS2J5*LP*,&6Q/I8+L!'P(3T
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MRKVTPE6W/9Z3&Q^HKE::5#O9ZRU6N/BV5>]JRK.+C7*J"SF ;1T@"!_8W+@
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MOOS<B+C\[%P96WIF++T95'Z<CXZQ-D1#=M<21+-$6O&(V#WC=P#:WF::D5^
M4I>O:4I>XPF-T  ZF'Z3#T^DP_FXI7[BE4@YJ[BWOK4G'ND\=GFJH;8>^MXM
M-5I6?<50ME[I]:BRT*\W=_)*5:F7C7<S)OE0J!6Z0!*H)I^<)S 8"],TXR96
M;SL/&0-&D'L\O(D+*2Q&-&'"(0P"EB=68, !X58QX^,O <ER\^\R8@Q BJ0
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M+?7FOZ39+_1Y?:KZ$6FXVV3E J<RG9G59J%B@):(D*K.RD]%L!+(%.<444E
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M_$581\A+#P7(\1 627.7%7>#HJP9N/E.I'B1(D+1:$6+@Z@6/0[ZXBRTC4]
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MNG^I?;M\JB9G2ME^_P!MNCF>YZEOY6Q??];=_=]/9[O?Z=FWJ^FU8/I7R?\
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M_JC8=_6_WG;<7W;_ -2U[7OIX57NG?*/[<?/'W]\*?*CY><>OGW\Q/</P/\
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(,4IBE,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tv486893_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img5.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!, )! P$1  (1 0,1 ?_$ 04  0 !!0 # 0$
M       (!08'"0H!! L# @$! 0 !! ,!              $$ @4&"0,'" H0
M   %!  " @<0"@L+" <)  (#! 4&  $'"!$)(1(Q(A,4U9<9\$%183(5M19V
M-[=8>#E9"B.T)35UE3875SAQ@9&AL<%"8F8G=]'A4G(S)";69Q@HU%5&5I;7
M*1KQ@L*4989'TD-3DS1%A:9($0 ! P($ P('!PL."P@#     0(#$00A,1(%
M06$&\!-1<8&A(A0'D;'A,B,W",'18G)S)#05-78)\4)2DK+B,[-4M"5U&#B"
MHL+20V.3PY06&5-TU"969A<HHU6U_]H # ,!  (1 Q$ /P#=]RGN4]RR\K<L
MS0W)62M#-5)SD"=:J83E$SF4HPK!WJ1RB2/,%9UKN^OCLO:#UKBZN:TT9IYQ
MHQ#,,%>][T!L%\B]RE?HXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3
M;Q!8\\!T \B]RE?HXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8
M\\!T \B]RE?HXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T
M \B]RE?HXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]
MRE?HXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?H
MXM-O$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O
M$%CSP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CS
MP'0#R+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CSP'0#
MR+W*5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CSP'0#R+W*
M5^CBTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CSP'0#R+W*5^CB
MTV\06// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CSP'0#R+W*5^CBTV\0
M6// = /(O<I7Z.+3;Q!8\\!T \B]RE?HXM-O$%CSP'0#R+W*5^CBTV\06//
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MJN**VE.-37O#6[9N&U6+:O\ QCM=Q=JJX:%ANFVZ,3PHY':E7"BX$X:\)H%
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M52ANVQ[='NNZP[?*YS&2JJ*J)54HU5P1?$4S57,3EL-K1@/.[PQHHTZYAQ%
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MXA;1%19>\BA:]45%1R0I*LVE:HJQHBHY*M6S=A=6L>:[:4;CK,=RW,3@C?\
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M-W% * 4 H!0"@% * 4!9&3/>WR#[B)7[ KZ B;ROOFU>7U\BC5OX$810$Z:
M4 H!0"@% * 4 H!0&LKDO?-*\N+Y&V O@\8Z SEM[O!@#2^+HG?-DO=XNLE#
M?(?:8!LQUDB?%N#JS-9ZZQ2VV/XG)O6PCK@#:XU=R"[VOZKAQO8#3%C+GM->
M9-6]3I%CQ_9W79G(^P^M6/,UQ5=BG)T?B+- \L[&LN)I0MC<@DD<:(NO=2F!
M]3B362+U1@#QW%<'  ^J]\4\BG3!0"@% 1+WIMFT6J.7K:YE3,[,?K;'+Q(K
M'1C,5.QDAFD;%* Q$<A7-C)Z_P!X?9P[VLI4$EB-X6N.U[VO0&!>7KER,RE7
MF?%BR:[:+,O8\=(HXSS&NY25C1Y.A#3)&6Y\:<V6T7=)#&U<2E*<L9Y9J1Q5
M?90WL9W,7:W4PKP")1*\"$$WR#M=F7%7,)W#B&U^0\1_[IN0LT1O ^$XVR0(
MK&92#7F%L$H7CRP6YQE6]S@[)3T-44MLL4W+;VT9=T5B1W$*Y%"*;T,5S(>1
M,98]GQJ.[>;-85&)4:AOUN*,U^943F8F[:P1<"1J;AMQM:_"U%Y9!<\,CUIM
M.HRR(WMH<EBPE?=F6"L44R/JTK@H1'=ROWTA;5*2W6X]/;\0^?PI6@JB%>A'
M1"XA;T(NP>Q*2JN95S+HJ$% * P3$=:\.0?)V<,P1Z*"(GFQH8L#+[DL>'ET
M12HJ&QRT38"?61Q7JF9J)3,-NX& 1D$!/MVQEA"Z:QTM+=-@FZ85J+LEQ=W%
MS)&N.J:ZCCCG=J7TD1[(F)I1=+:*K4156ODDFEEW>WWU7*FZVME%:Q2)Z*LA
MAGFN(VHB434V:XE?K5-:ZD17*C6HF+('H%JCC'6&4:<P/%Y4:UZF1\L4R*#-
MTBDY9B]1-WLV0R4^\A$\"DA!K@ZG7'UBU8;E!X !U06L&V3N#G[K:V-G?N=)
M!ML5K';U5:L;9N:ZW153%ZL<QJJKU57_ *]7546TK[3<;S=;>C;V_EG?,M$H
MY;ACHY4:WXK&Z'*UC&(UL:4T(VB%V93T_P $Y?C./8[*8Z^MBO$C<0U8MG<%
MF\QQWE7':(IH*8#"X;E.%/;'/& 2YG)"G5"3KP75%]!O6K7>S3WV[3[Y))(S
M=+K4DTD;EC65CY$F?'(C%:CHG2(CUC5%95$P,6RM[>PV>'88HV/VBW2/NHY&
MI(V-T3.[CD9KU*V5C*M;*BZT15]+%3T3]*M=7/$4FPI*88X3Z'S0YE7RYQR-
M+Y=/9Y)7N-')%49D[SD>4O3I.%TJC:Y 0H0.0U]UB102$TLP([<:TW+G3]TL
M7WN^"598W6_R#HYG-1CIF.BT*V5S$TND14<YOHJJH9%C))83R7$;G2230K#)
MWJ]ZCX%U5@<DFI'0>F^D2IH34M$0M/&7+[UIQ7EJ,9Z9V;(,IS7$8/(L;-.5
M,HYCRKE>=&063K"ESA&760Y"ETA7O38F4$A[S J$;WB'B$BY8;WM7F]9D2TO
M[&-&,MMTA@BND8UK>^2WU]V]ZHB*LJ=XY'2HJ2/2B/<NE*8LUK'<26<DZO<F
MWRRR6S5>[3"Z9J,D1C:Z48J(E&4THM51$554KK/HQK.PZV3C4AK@BQ/@?(JB
M;*I;$12Z7'*W$_(;VID,K&7)3GLR2H?7!V5F&!L0K+L1:_5*Z@;6M;QW,K[N
M';H)Z.CVJ.W9;)2FAMJ[7!6GQ]#L55^I7?KJFY6EY<6.\W>_VKM.Z7UQ)-,^
MB+JDEC2)[D:M6MJQJ(B-1$2E41%Q)0MC T-$?;XLB1@LQ-C.D8$C>>(:HNS2
MB1%MY",X2D1IBD%D9=@"N9<5QV]5>_&]3<Y%WB2XEW%&RK=.>LJ*B:7]XJJ]
M%:B4HZJU2E*+0V_;H(]IMX+;;ZQQ6S&-CHJU:D:(C*.5:U1$3&M>-37PMY3V
MDKFA;F%Q@$U7PB.3>.9%@.,5>9LNGXJQ5+XJ\"?6=VQ)C8<TO#L9W XC$(XI
MF1HR5 !7 8$0+\*R=NO[S;+^RW6"1S]VV][E@GE^6F8U\3H%B[R34]T/=.TI
M"Y5C2C51J*U%35ND3-XMKVSO*I:;BVERR->Z;,NMLBR/;'I195>U'+)\=55V
M/I+7).1.7UK+DK*$^S>YL$ZB^9LEM<0895E7&67<HXNR ='H2C5H&:.M<H@4
MM8'5B83TBXT"Y(C,)(<;"_SD)G"W# B8V"T6QB2ED^>2:1GZV9TFG6V9,I8_
M1:J1R:F-5*HU*J;A-?3W#;9L^AZV<+XH%5C5="DC];GQN5*LE5<$E14D1M6H
MY$54+D6Z2:\_FEBV%XK&Y)BN(0E6YN$27X8R%/,13E@<GY8>X25S;LB8^D,?
MFI+E*ERHTUT/[^N:X#.'<\0^M?CYK^6;<KQE]</>DT=ND#48JQL2!NC3!H9I
M9W+>[9ICII32BTJ85FUEG#+ UK9&S3+,]9425SIU:YO?J^34Y9]+W(DM=:5P
M5,#PDT:U:2X+>-<S,3M#EBV1/:F6R)O>EKN\R%_G:MRL]J,CO4U<EZF7.61S
M7RUEUWTU:)SLLM8VQW7MQK7>7$UVMJK7+;K8HB6OJ_WOZK1')][=SH[G![T7
MN]-=;J_&6LM6^K/GD>KKB2Z:UMPMPJW"W#&HQK67'>Z^^8C8V-1LFIJ-8U$3
M!#V\-::X0PB_KIBP)I_-9\M85$3#D?-66,DYQR,W1!6>%4HB+).,K2>621DB
MYJHL)MT"504FN8&PNKQM:I),Z7;I]K5&MM;K^'THC7ST14:LTC41\BL151FM
MRZ:^C0J(J3Q3ZG*D$FN%BJJQ0O5-*NAB7Y.-7-]%RL:BN;Z*X8%LI>7YJDBU
MQ,U13XV.!A:TM>Y\W,HI9+C)!'IT^S5?D0^8Q:<#>Q3*,R9NF;D:O;UJ)<0>
MWF]6R<180!M:W=S<WDNWW#Y'LN]KMX8+62-RQR0QP0^KL:U[-+OX%5C>JJJO
M8KD>KJJ>:WF6WN;ZY1L<GXSEDDNF2-;)%.LNE7I)$]%C5BJQJZ-.E%1%1$4J
M6)M&-=,,9539SB,=E;CF0N #QFX9/G62\A9$FTCB0EJ5<!++'^;25\7RAP(,
M0D@*6KA'JRR2PEA,L"W5I!,MKZZVT;'#'N'<+.UC&L:]UNLJQOTM1$1]9I%>
M]J(Z15]-742F#/:Q73[.2ZU22V#IUMW.<YSHFW*1MEC:JK7NJ1,T1?$C5%5C
M6JYU?;AVD>NT$?\ ,CO'8J^%,.?+OYV4<6+YU-7?"#\Y2TPLR6/R;"SH_*\:
M,DBE BK>N"]$V)U2NU[V,&*U[UBMBC39F[!(B2[7&K>[;)Z:PL8Y7,B@>ZKX
M86.57-BC5K&NHY&HJ(IG/FD=NOX[8JQ[HN+I(_0=([1W>N733O7Z/15[]3E3
M-3T\3:.X&PP^-SQ$2\GN**.F)3(-#)WFK+&1L<8SLA3F(T!6+\=S>7OL/QXG
M;T1MR""VE&E"23P &UK6M:V:V\NM;KB9[IMP?KU7$ORERJ2(K9$6=]9=+VJK
M7IJHY%HN!ARVMM(U(6,;%9(K52"-.[@JQR/8[N64CU,>U'M=IJUU7)BJD@LG
M8Q@.9H')<990BK1-8)+V\39(8T^)@JFYQ2W,+/+[H"_ 19Z922 XDT%PF$G%
MA& 01!M>VVW5I!>-:V9%U1R-D8YKE:^.1BZF21O:J.8]CDJUS5147B9]M<S6
MLBR0JGI,<QR*B.:YCVJQ['M5%1S'M56N:J*BHJHJ$<8AH=K[$H;/(,:3E&<L
M^1H,[XQD"S*V;\N95DB7'3VF&E70F,RB?3)_?XE&NXF7[DE;5"8LF]K7!8-[
M6O61?M;N=D^QO41\<LC9)'T1)97L>DC'2RI2216O2J:G+Q\*F/MZKM=[#?62
MJQ]LJK"RM8H:L[M>ZB6L<=6>BNEJ52E2ZG73C7UZQ#A#!3C#5A^,]=7[$\FQ
M(Q!E,I*/C;SA)2WJ\;JCW@IX \/86,]K(N,M<>H+5]3@?8RU[\=VN-ZW&ZZH
M;UE,]%Z@:ZX5)-+42MU!);3_ ":)W?I0RO:GH^BJZFT<B*F!%MEG#L<W3D;:
M;1<-1LC*K5429)T]*NI/E6H[!4_8Y8&,<G<MS4[+<CRF_P NB$Q*0YR;ER+-
M,#B^6<H0S%66%;@T@8SY'D'%L5EC3!)5, -9))13NK0&.!5DY5PFVN6"]M@]
M3MUL/Q5(WO-M1[GQQ/57L@>^7OW26[7*J0/=-6171:55[G+6KEKO+;V=E]#N
M<2M9N,*M^5:U&OE8QG=LBN'(B+<0M9Z#8IM<:-P1M#)+7ICKPS2W7";ML*5I
MY'J;#I' <%++2F4C)B$6EC&BCCXW*$1CP)'(Q*F=O)*":X@5'%=7K $$5[WO
MOLF\;A-NFX[U+)JW+=;>."Y>J)\I''+WS$I2C%23TE<Q&N7)55,#9H-MLK;9
M;7IZ!FG:+*Y]8AC15]"5&JU%K74J(U51&JJMY$<]UM*D<TP;NLX8"Q]&'[.V
MV,$B47R.WSIW7KHWD1C@Z98THV EO?#W*-1MU%%GAP3HU)20)7?9Q9AX1]2U
M[<>N&-99[?M$L/?]-0=0Q;C<PMIWKFOF@=>.A>JHY)71P,[M$>U&JWT%8YU3
M?K29S=REWF-[8]_;L\]G:RO35$QZQR^KI-'BU\*3/1945KE<RK753 A%AK5-
ME49WUBD6GV@TYY=C?B2=A?-BYW(V+'>-+Y8QN1!)0Q!Q8E:L:3F8?G62N<L<
M$2P:EX FLDLEL>6&YAE[!Y5M=YW6[76Z74J+T[/MUW&EHOHNDNI)+=UM(^"B
MQPI Q)7)(QZO1U8D]!55>-7=FD>P1[,L7>]2,N+73=M?5L$<2JMRYL_HR3=^
MC4B6)6-:]'I*ZCF(TV=./+_UM6SM]G;>TY#B(9<\KY%/,?0+,F58)AK(LA=S
M!&O#[D/#45ES5C6:.[R8+BK4.#8>:IO:W=+BX5L5BUFWPLM8D22RA2D,4J=[
M%!14<GJ\<FID.ER:V]VC=+_22BF\[A)+N<WK-TYR7:M:UTC%5DDC6HK4;*]E
M'2)H564>JU;Z*X$P"F5K3LI<=3(B$C*0U@94[<D#WLF3-9:2R$I$F 3U.X$$
MI V "P>'5#:W#APK3N#$W2.>._59$N$>DBJJU=WE==53&KJK5:UQ-%I2Q[OU
M5$8D.G0B)@W332E,J)1,"(#)R^=4H[ < 8R:<=K4T,UARPIS=A=KO-)H<9%\
MD*U,I5GO:E><_&+Y 0,^9N N]' Q2DMW:UK%\"R^KN+=QNV;E:;LUR>OV6V^
MH0NHGHVOJ[+7NZ4HY>XC8S6Y%?5-6K4JJ>-\4;[/<K!R?>N[WWKETG_:3^M)
M>ZT7-B>L-1^EBM;1---.!FX. L6ASV;LS:/G_GD.QBFP\9)_7EY[WO $DA62
MDAGLP=_^L 3@O:\TVZJR;OJ]A=2YG4M8-L6TD?8P7=M;+IAOI8I)DSU/A9HC
M5%6JMHW"C:(N:HJF1=2OO8;2"X75%8OF?"F6ETZ-;*N'QM2,:GI5I3"E5("<
MT75>6;6.^BD;:\< R1!(+N5CW(&8$BA2WIT+%CME0.GKF^K.^UB14,*0\PON
M=DEC%-C+VN&UN'&W@V:&*/KW;]VO-3+&VVO=T25%5'17,MB]EHYCFJCVR+/I
M[M[?BNHJJF9-WDDEZ!WC9[54=?7D^V-2-414EB9N,$ERUU45JQI U[I&N^,Q
M%1&N5:$A672S$6&XKG.08Q89A*LN9.QK(XDOGV3LCS?+>2GEK T.]XW!D\YR
MA(Y&^((BVN2\7>386I*;TPC+W" -JV;JUE]=]![ET[MC$5UQ:S>BU&H^XG=$
M]C'S2+1TTM':4DE<Y41:51#<>GW6L'5FW;M?O5(+6[C5FI7+';1K+$Z5((\6
MPL=W;7/;$U$<K46BJ0;Y<'*PQ9CO434MLV Q=*F?)F.X='Y#,,*NN3IBNPVW
MY<3+CW<V;O6&6R5JL/.^1DCD;8[UXNWJ%83^V"=>]N->S.J-PL8^JEW'87L?
M';Q0LMI**[U;3;MB>EHLB:K=%J]J]UHJBKX3AFWVDUS87MKN;%9%>7L[I&I1
MBSP^L.?"D^A?E6HU&4:]741K47(VH)==<2H]A'+:1/'#P9K=L8)L.KI3Z^/@
MDQN/TC\5)B&:T=$X7CQ1H'DD)O?04ME5[6ZES.IT5Q.SE?86MY96OHV]_<PS
MSI2NN6WB=#$ZJU5NF-[FJC51'5JY%5$4WV[:V^=9ON?2=8-F;!PT).J+*F%-
M6I6I35733T:%G[,Z@X5VU0X[39<23DEQQ+-@Y$QO*L:Y0R'B&;P^7A9G2/W=
MF69XRDD6DB41C0\J21EV4W*&$SC<-[VM>V+%"D&Y-W>W=)'?LMY8-3'N;6&?
M0LL;D141S7]VVJ*BY&2MPY^W3;5*UDEA/)%(YCVM<FN!^N)[55%5KF.Q1S51
M?(5_!>N44U_)?R8Q/<_S@,B,1FJQYSV(S/GLY!=$$T!86 [+LTF!L>+.L;>Y
MP4=R0G7M:X["N&W#-6X<MLEKICT)(K]6ANNJHB45]-2M335&*NE%551$5RJN
M ENQ+I;O5)K6-&:=;M%$5752.NA'K6BO1-2HB(JT1$2VL1Z7:U8*SCG38[%>
M,VZ)YAV16-B_,,L2.#PH%*5;2'@0<6UK7!0T,HE!MK&J>\2$]E1P;&&]<=K7
MKQV$C]LV->G+)=&SK>/N>[S3OGHJ*J*M7(U$549&BZ&:G:6I53S[@UNZ;O%O
MM]Z>Z0V+;1C\J0-<CD:J)1%6J)5ZHKU1$1740LG;KE^Z_;PMP8_L&MS<\PX2
M- C7X^A>Q><,78\>[M3L2^M:^00?',[C,:?7=N=DQ1Q"M4F-4%B*!U1VL&W#
M$BMHX-P9N<:O]=AFCFB<KG+W,T-5CEA15I%(U5KJ8B+6BJM4,SUV?U-UBW2V
MW?%-%)I:U'2Q3L1DL4KD35)&]E6JQZJU&N<B(FIU9#8:Q!'\'P=# (Q(\FRA
MG;U"H],YY:RID#,<NX*C+F72FS/)<ADTG/0IN/4((&J$407:P"PA#:UJW*ZO
M);O0LJ1HYC=-6L:U78JNIZM1%>]57%[JN7BIM=M:0VFI(-2,<J4;J<K6HUJ-
M1K&JJHQM$3T6HB5JM*JJF5:Q3)% * 4 H!0"@% * 4!9&3/>WR#[B)7[ KZ
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M9=%0@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M5Y=W59*7O)CZQ .6+#'=&-"6&SHK6+1'$CO8=B0EW$'"ATET H!0"@% * 4
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M[H_^FZCI_P#Y?_%X_P /]WU-U\G](Q?<E[9*=/OZ0KYR]J_JM?XQ31MYO/\
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M18Z/1LJ53$KS=RC:=(Y]8RX;-2M61;K]>W&I3PFI*)3%3H[P')LSR_%[$_;
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M4M%7(H4FV7PM'W.>Q1+D2&2#(^.X@_3)]QDSREC.FP&V/MICHM*]9[K.^"5
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MOBTGAJY/+F(QY*<&QK?&29K[DGH[!-2*! %8L=K7M3GQ'&OZZA3$7)TR*OR
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MA>HBUY%1%KX$,C\M)A9,:;;@BV;="$^GNS62]99-D3%3RGV4E.QQKI@]%/H
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MNW;X?-_[G\=*K7/M[H0='\'\7I^;^$BK7MRYD[=NWP9YU6_6?UP_MYQ!Y_\
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MIR< UJQ'U@%6ZX!=TO;JWL+A1"IF<Q^(X_HU"+J\]-;CS3LTRB-Y,UIEN.]
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MM^Q>UN-J _6@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M=8N@<LB2-U$<-S1QU^B[8Y,Z-Q,47N>:N2(% "SABO>XS WOQOQXWA#+M *
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MBYG[Y[WGU.U>E48A>?\ -4;Q?()C=O\ 6$B1(9%ZW'V=G*S.V"7OZ!E6Q]C
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M&XXQP^.L,2C#8D9(U%V5KCL>9D!?<D+2QLJ$AM:FQ&7Q%<M*@0)BRBP\;\
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M"*X2G$[FV+98_LF6U^7FH<N,?243>!,YY868LCSDVM,B.2'NZ%HN>L**M81
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M-]OA;&S7D2*9$S$QN,^CKLVM1#(?CYH78];XL.72V+I;G-22YR=(I6F +!8
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M#M3U!TK=DE/D6*-ZM+DC($OR 6K-52HF<'#3B3)#2PW0A(OQ&,0Q7NJ*DT:
M4 H!0"@% * YB?K*GY&:A^['+W1;U5_N!">QT]CT:=N9.W/R?5.47T?_ &?/
M[/\ D^GH].G;#ZA>V'U!Z/[?'AQZ>@70#IZ!>C3M[^7,=O?RYC^_V.Q_*Z ]
M/^4IV[<QV]_+F77 ?? Q_P"[V$]GL</;2T]%^GU=./;M4)GV[5/J"T H!0"@
M% * 4 H!0%D9,][?(/N(E?L"OH")O*^^;5Y?7R*-6_@1A% 3IH!0"@% * 4
MH!0"@% :RN2]\TKRXOD;8"^#QCH"9NQF6%&"<#9=S(D8#I2KQI )+,4D=(N8
M$;NJ9&T]8G1#&2 9I:<TXL/=1A#<0"K"O:W&U :6,9\R;9B-0";K\SR_6G)F
M1B-J])\:PQCPV)P*8'W'NUSYCI'(66)&JG)4]2M\QXQS54N+<;DE%GE-PQ'
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MX];I!VO2*].WOY89A4[>#/+#,</2['&_[''K=M;M?5^E3M\.68IV]W'+,NN
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M^TCZ!,RGP?\ (N(>Y>/^Q*2JN95S+HJ$% * 4 H!0"@% * 4 H!0"@% * 4
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M1X\,D2QI7)W!*$\ 8& 1A%STP;##:]NL'C;C;LT'US>+0"@% * 4 H!0"@%
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M5<RZ*A!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@+(R9[V^0?<1*_8%?0$3>5]\VKR^OD4:M_ C"* G30"
M@% * 4 H!0"@% * UE<E[YI7EQ?(VP%\'C'0&S6@% * 4!XO:U[7M?L7M>U^
M'1T7Z.SYU :XLR\LS#N5,<3O'#+/\S8U1Y+R#"LA35RC>07IR4/:N"OBR3-,
M?/1R!0X(2HLHD"@I4J1%@ 4H&E*".UPAZM"9*86UPTNVTU+E^[V3XCF!#GF8
MY[R% Y#C5BS,Y'-T< WLK<VM#^\RM5%TA2Y/(;-83B$P2+6)N62385NSP*N'
M,U*N',LV<:5[JQYIW&UPPD^X*_W;=S9S.9A;($I%*D^4,%)<R1ABB>6FI+'T
MA@F2:G@*;5+@P'6$38I6KN%5818 U#3ED;D81$FN!0V*0=D",+/#XXRQEK"9
M>XC+(&-N3MJ3N@KWO>X[D)@WOZ=4IZ[SC^&2%?=S>X\WN2\0"BQ*5(#!&"+)
MMP*!?@8$-P@MT<.%!0NTHHLDLLDD 2RB@ **+ &P0%EEAL$  !MPL$( VM:U
MK=BU ?W0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MP[PE0#RN7+!^/KJQXXX=X2H!Y7+E@_'UU8\<<.\)4 \KERP?CZZL>..'>$J
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M75CQQP[PE0%HY YLW+*<('-F]%O=JZI6+HC)$:1,1E^(G'*%*EF6DD$$E%.
MS#3331V"$(;7$*]^%K7O0&7.6&4:1RVN7\0>4:0>3I7J\6<0>6,DXDP&$X2$
C99I1@0F%& %;@((K6O:_1>@)RT H!0"@% * 4 H!0"@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tv486893_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img6.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!.0*& P$1  (1 0,1 ?_$ .X  0 !! ,! 0
M       '!@@)"@,$!0(! 0$  04! 0$             !0(#! 8(!P$)$
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MN2QN:[CP9Y8\,'OB?:LDJ5??M+*4MO1*YF6;5.VN^F9:=*E\6;&M-#)HA6&
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M:G%\9:<;F^TQ8<;* #>H]EMMAWTG0>F5M*-7O.X '</";+R?,4\OW'RW+YU
M?BN:XG'X_)QMS#6FBI4)%JZ,&9E6P>7RE=/,"9Z%E]TAR7Y$<1K&XV<J^\LG
M]^R:;26JG1CL)RX_UQ!XY!F:K)>EE*9 UUK"7MJ)=I!(PI0IU[NM=C3QZUH6
M@>#L[R;7QK.2XCEEJ SN-YJOD;&U/TS5UE/011HN/2=2^BJ^CDGKK-=PEOPL
M?D<%;7/'YO"7\=77T^B];36]W.KWV*!M 8J-HT\>LF"_N["G,_YC\>N;%!\N
M93QPM&I*Z1TS8J!-5</M"/7#4Q2M$K6QDQOEKBG(ACFL$E&'3@0!883XS0@
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M]3)QP4'R?6K)(U.F1=C68]6-=?M2K*N-:DD (!5?<;;2?ZNG9C9!]5M%)IL
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M\^B2LO?\A_I,?_CYV]_CLO\ W4C^<_+_ .#Q_P#>:/XX]\^B2LO?\A_I,?\
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MXYA53.F*X7:0$R&HEU K2T=P1RTBF)K=H2!2S$2!N7+E<=?I-'EJ!T9E19Q
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M;5K=1J[H-3H%4Z@B5?0-@W!7O=_R'?)*U^9]3PJ4W?)4])77%H(^V!?$#I%
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M3HN;FVLC<O>'EP0M+0UI%#@YNCFK(0-S<@2%"/5K5RU484F2)$I !#,,,$$
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MJ57#(4:I0D#$VC28]0C+J!:6E/-)UH0RPG&A +>]:&+6NUO\Y.Y-?WBS]?\
M&W_M6G;O!_<N']5J_9K)0\X^1GHGJCUU23[E\A9*1YQ\C/1/5'KJDGW+XB/.
M/D9Z)ZH]=4D^Y?$1YQ\C/1/5'KJDGW+XB/./D9Z)ZH]=4D^Y?$1YQ\C/1/5'
MKJDOW+8B3*V&.)S<@-=TB1 ZF(TQCDB0+37)$D7#) )6F2.!R)M.7)B#]B"
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M[BWK"SDBU$K3F"+-*, (!@!;"+6];Z91977:NRU59-0=" 1JI# Z'XB 1\1
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M%)!2P]:SJ5UU,DL7+6OB^2X\V74VYN$:4LJT#HV]'!W$@A2%(8#4,#H1IU%
M]W)PLF'%:36.ZR3B?W>O'%/*V1K0)G'A8CL-,_20Y&N\HVBFHYK%8ZG$TI ;
MV,C1 C!^.]W6M9L"Y:CB'P?5O#G)2P5]/1(".I=NNOJ@L%7IIM+:]=)K38CG
MEJ\WTZ"BXSUFSKZH+.C;%Z:>DVTEM3KN5--1K+VN0')VM.."6+>>R::R!^FZ
MUU21&$UO"WN?3:0 CS:-ZDSB@CS$G.4;:HTS%[5+E Q +))Z>'8MA#N!MY#$
MIR3C7-M*8UF3:Q^13C5,B69%S>"5(]M:ENIU<: ]=)H8]S8_M*C56R*\= /E
M6Y%P<U45KXM;8M5A5?#1&)(TD;6KW@/%NH*;K&\Y+8:9="+I,0$5+IC+*5/-
M@*G!-I8%)'6]>I;2SE*5+U&>$TTKQ6@[UOP^#)+D,:_C.X4[6RT(YNPL16.I
M"(%+V$^ K4.A+=20PV@S"XV^KEN$?N+$)^R*R@:Q@RA7=F1*V!&JNSHZZ,
M5.I&DNWCCZCE$?9)(W 4%H']I;WE$6K+ 4J E<DA2P@"DHLPX!9X2CM:&'0Q
M:T+KK6]^[E67C68>39B6Z&VMRIT\-0=#IX=/]$IQ<FO,QTRJ=?2<:C7XO]&O
M^V0C' []J>V1=-]-TE273?3?3_KC=GX?<_\ 9W_YLQYD2XC$1B(Q$8B:R_?H
M:WJY*/WO6]:W7<EZ;Z>#?20(-;Z?R]-YUA_EZ^X^1^M5_,:<\>^C[TPO[!_G
M+,&V=!SQ>,1&(C$1B)PJ?]F4?Z W^;%E2?+'XQ*6^2?Q3?=H+]1-*_9+7'Z'
M,V?G)W)_$6?]=O\ VK3MW@_N3#^JU?LUDM9"R4C$1B(Q$8B,1&(C$1B(Q$PU
M=Y;I(^<M>ZMK^Q0:54',N0MA>>C*[;&.%R:R&6 %K*@8)>B.UII=2E#F8O,1
M)%?C"CU!>_\ -BV'69':-"97?>6F0H>RGM7/MQ58!E-PMH6ZQ01_6TTD%"/,
MH=B-/&?>X+;<7W?W7XKO6UG<'%4Y#(2&]DL.2;$8CPHLM2H7$E5Z("3KI*8X
M?*H33G>/=YDU1MRB-<<=$A?&(H2(IT9XO6K1?LF9I$ED32SI3%**/M<M>T^D
M6EB1,$LTX\1.A@V8(/6]VT6O]W9INU>]^[<ZK"!\SO4*:3=75XLR+=IM1=0I
MW!!H&EGN2LU]WX-]:A57M5;<P@:!0F2PQK;M %7^[^II8WB@))T$Z_+ZHI+0
M+GS+YU0J9<-[,C3(P(+!L.H+^HQ/(Y(G7U9 @$[@C1>:*S@"@JZ4H22=I"%<
M77; K4E[T6+1FMYK.+EGM3 ]>VI\O!RN;:]!CCT\AWRCC8IKH?SK?;592IK3
M126WUZH?,)ZO!_>WF\7 QKUP^0KXZG$9[?I:*TKNR<H76H#6U2,F4WJ/N("*
MMFC ;9Y_,UID'*WA-,K/J3CQQ1+EMB<527ZU"N04BVAN"E&9\A(']$VL#,E@
M;LU$OK1'#C3VPQR>XTGTK*(-V/Q8>NL_OSC*^UN1Y&O(R''"8O(5V79>)I[3
M:^-:F_9N9$%NQ%0?2NVI916S:!L+W><E=W#C<-GU8^SE<NATQL?(!]G"6[T7
M7:&9Z3>QWA:@"O0N-3MO_P"[CF\3L;@GQ4ET&/GBN*.-+PQ*S*[/)))GBM.S
M-P&0Q5) ICE*4Q:H4MPQZ,*--*,+V$0!B#O0M[UW_7?7W=FMD"I;+'2W2O7:
M%MK2Q/$ A]C+Z@(!W[N@\)IG9]7L_ 589+-;CV75.200;*[K$LV%25->\,*R
M"1L"C74&7JYITV>,1&(C$1B(Q$8B,1&(C$1GPD*"S'0")J3<SVBSK1Y17%>?
M(SNU.[*MR@F5M8ZZI3D+?W,&%0/3B)$XN*,;>*?GPAYTH>%1H-[51S19>VTP
MO8?*#?#O(GAZ&^S+;<JJG$[EY/)0U;6W>I5[.H1D4:>U5J_F%P*C4FL+H-TD
M^5ML?D*,3$LNR."X['M%H*_U=QR"6W^/LUA3R^D0Q;I86U.R;!O=\5]+:NX>
M4C"IJU4JQ/C;'%BO3'QW'M13;,TO3XZ/3"UPAP\!;PW(65P(+&N+" I:>$9P
M Z"/6LW?N:Y;>3"A\FRZK&HKL:]=MC6UTHEAV>*(64[$.I5=!-6X@ I?DU)3
M7BWY5ME2UL'"ULWE#6#H[]#N8#KT'B#+S,U^2T8B,1(!Y,?JL!]IE&_\;*^Q
M$G[$1B(Q$8B:R??H?KHH_P"SB2_I$@SK#_+S]Q<C]:K^8TYW]]'WM@_5W^>L
MP=9T'/&(Q$8B,1&(F8_N2_[S\U^RU9_6Z7/#/?\ ?PGC?7!\PSUSW.?Q#D?5
M?Z4VHLX_G2<8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(EL7(
MSBW&^11L%>%%@655,VKA5(QQ2>U8Y1I'($C9,V44>E\?5HYG%II&')GD+3L(
M#='MXSR3"BS2#"C :%F!=QN+D95F1>"U5^#;AWUD^2_%O>JRRI]-'75Z4(LJ
M:NQ="%<!B#E)EW)C+CIH&JS*<NIQKNJR<=;5JM7KM8JMUJE+%>M@WF0Z#2WN
M==V!0TVK&L*E!))]&HI1P/(Z7*:TM7O!E;LKA%MQ*6L;8DFU:RME?4<U;S##
M5ISPD<5J949LQ">DZ!"&6YO(L[@Y<\YR?FY"RN^JXC51=1<4^A;0ZHM2UHM5
ME)KO4#5K68ECB\,6X+B#PF"S>PFRB[1B6/M./8]U>0Q/]8YLL=GKLWX[ZZ&G
M0 "^*L*TBU15O#:JAR=45$8+&VZ*L9#BK,<%GQ6V)@I2=+%9O02@XP >H]]
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MNHZZ$^,VD<Y%G1L8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(!Y,?JL!]IE&_\
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M<*G_ &91_H#?YL65)\L?C$I;Y)_%-]V@OU$TK]DM<?H<S9^<G<G\19_UV_\
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M\7>]]?\ !B)..(C$1B(Q$8B6[1O^]1;/V)4E^F%UXB7$XB,1&(C$366[\_\
M7+2'V=R7]($&=8?Y>ON/D?K5?S&G/'OH^],+^P?YRS!OG0<\7C$1B(Q$8B<*
MG_9E'^@-_FQ94GRQ^,2EODG\4WW:!_432OV2UQ^AS-GYR=R?Q%G_ %V_]JT[
M=X/[DP_JM7[-9+60LE(Q$8B,1&(C$1B(Q$Z3E_\ ;G#_ .25?S!F7*OZU?\
MQ#_;*7^0?Q&: 4V_ZYR[_M.__P!:JL_2/CON^C^Q3YHG#O(?]??_ &S_ #C*
M8S,F)&(C$1B(Q$RM]S9_?%3_ &>2O_FI<\;]^O\  _\ \W7_ -L]1]T?\5'Z
ML_\ M6;:V<83IZ,1&(C$1B(Q$8B,1&(C$1B(Q$\H3"QC</C8;,U"==ZZ;<Q-
MR,3AO7BMD=/+=D[4]/$[V#_&_P 7?3W,^ !0RKT# @_AU\=?CUT&NOC/I);3
M<2=NFGX-#J-/BT))&GPS[2LK.A))3HFEM1D)SC%"<A*A2IR2%!W:V<>2644
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MDC6/,!R0P]GEBBA:3E\L;XS8KJR:=@KY\)+1]KM1M=(V\XI0[_%2$T?E/:1
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M/(<BV3C@BOTZEU(T9VKJ2MK6 UT:YE-K#4Z,YZGQD1PF#?QV![-D-NL-]]@
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MC$1B(Q$8B6N<V?[IM^?9R]_\TO-M[#_C'COK237^Z_X<S?J[?[)HW@_Q ?\
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MX_NSCL"T$Z)8<@+D57(!^3L!6W'M+J6\I9T,DN$I>WO#![?N*KB\OP7(9:D
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M)8H^OTO<9Q4ABP+9(9EKQC4AL>%$/2D#,W/I#8G)0QA*>8<:60#9)98CNNC
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M+Z<JE,C'=7H=0RLIU# ]001T((\#.J:_L1"]0U'/344ZHVT3RJ;!N"0+BF:
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M[9;7#P%=:G--N+K5P=F1[F#I(%UC2XJ,M['"B#EDC.DAST83M#HA+Y06=V3
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M'4MC=K8',@M=R7)<@:LEO2#545UXE5B;%5E3%&3:S('V/JR[5*,2QZ;OR3Y
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MT;?B:8O:F%1L]WEC/KQ71IDSD:VB6/S;KQ /\PJ&:5^('\7P:SY2?9D-6/\
M1U&Y;=%\H]5#JEF@T'J*22K_ "E)U!$K=FML2ZPEKJZV1&/4JC?*12>JJWY2
MC0'X1."04S3\L=D3]*JHK63/C<V?$K>]2""Q=Y=D#-L R]M*)Q<6M2L2MFRS
M!!\0 82NR+>NSTWO*D9J[GR*R5R+""[#HS$$$%F'5B"H())T(!'4"4L ]%>,
MW7&J)*(?DH2-"57P74=#H!TZ3TWBLJWD*R,N#_7T(?%\*&49#5SQ$V%S61(P
MD(0$CC*E:@/.81E  '0=I1%;#K6M:]S 9ADOF GVQT9&L_+96UW*S?**MJ=P
M)T.IU$^: 8XQ /[H""$_(!'@0OAJ/@.G2?+C6%:.\4.@;M7D&=(,I/-5*(8X
MQ)@6Q0]2>L,<3U!T=4MYK0:><X'#/&,1.Q".%L>]]K>]Y1<JY&SV@!_2"A-W
MFV!!M0+KKM"CHH&FT=!H)<KLLI=[*69++=V\@D%]WRMQ'5MWY6NNOPSL):[K
M]#'FB(HH+#D<48%"-6Q1A+&&1/'F54W&>.;U+0RE(0-K:H0G?CDC)* (H7A#
MO6\O-=<^0F6[L<JO7:Y)+KJI4[6\1JK%3H?DDCP)ECT:?1?'V+Z%GRUT&UO,
M&\P\&\RJW4'S 'Q GMDL#$G>5<C(96DB0N"-.WKWXEM1EO*U D%L:5"K= $A
M7*4:88M[+*&,0 ;WUUK66D^C5D3RH[AF Z!F VAF'PL%\H)Z@=/"5L [K8_5
MT4JI/4JI.XJI^!2WF('0GJ>L];$^QB(Q$^1@ 8 99@ F%F!$ 8!AT( P"UL(
M@#"+6PB"(.^F];\&]92RJZE' *$:$'J"#X@CX09]!*D,IT8>!E+[@D(W&R8;
MN&Q7</3"3B3Q3<>:-QL@21:!R2B)8O(_BLH29Q+"H+V$K78.#H>N@M:WE>X[
MJWU.^K;L/PIL&U-A_)VKY5TTVCH-!"LRFQE)!NW^II^7ZNILW_G>H68OKKOU
M.[74SYF$"@MALNXW/X7$YS'1'$J!,$PCC/)F79Z?PIS]M;TC6H=G$;W^(+Q?
M:#^#>LMO7798MMBJUJ$E6(!*D^)!/4$_"1*J[+*4:NEF2MEVD D K\1 \1^
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M-L UT"ZZ[=-3IIIXF>H.!P<QK>60R&10QED;B>\2%H''6@36^NRI2!8J='E
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MNYM-G'U+=E>5"UJM\=34G'#"X?\ "W>U4&O?IZ@?5=0#/1L_ESQZIZ;1^N[
MLR-L<N?W E$)H/<T.CXZ0J;CW-(]2X)BDL49CJPA.(!*]5H"8P[H4$>Q[[.6
M\5Z\N]J*6&JUW,6)T0&@5%ZR_@+B+JRE7RW!U4'26,IO8Z:KK@WT]U52*!JS
M&XV*K!1U-:FI_4L^37IYB-9<&V.;>]-R!W:5B=Q:W1&F<&Y>D-"<E6HE90#T
MJI,<#>P&D'DF!$$6O!L.^N7K:K:+6IN4K:A(((T((\01\!$IJMKNK%M+!JF&
MH(.H(^,$="/PSO9;ER<1YY*4@Y2H, 2G3E&'GG&"T$LHDH&S#3!BWX @  .]
M[W^#6LLY%].+0^5D,$QZT+,Q\%502Q/X  297559=8M-0+6NP50/$DG0 ?A)
MZ2RBK.\<X77;+V6#5/=J&=R"1NJUE8OB&&6.H8G1R;5*E&N(1RTR'%1(T"94
MB-+$;I=XGME[#VNNLSL?%R,H?1(W]1ZVC#8?3V>IOT?:="A##X6!&@.LQLO)
MHP6*9+ ,+Q2=/-I:6V;#MUT(;H=>@^$B7N9CR]&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C?AUTSX1J"/CB8MV#NF^/3!S(<>9Q+K+U%A*D34>C..?
M'[S@321(^R)R=%2R3_'PDKG#W9J>R4&F 38!(G A+-"9LS?75[MVUNV<+)P>
M/Z4Y!7<#U#+L8/ZH;<;+&L(L6S537M"*-FHE_F;EYJJM,A=+%:TNWP^;V;TE
MJ&@]%:10X\NXV>T6%B#U/M<L>ZXH3E]==97A9"V1#DE=NR)4!*)S?#DP&MN2
M&:2)(;I!(&5/!7KXUV6K-="R5B@[9>BA!\7OIK'XNM.+Y-N2IW>H]=X)!T?U
M+!4M;BS0D5TBM_H=NVSU6+$'QQN5#\KQM/'6$"JG(J?0C<CUH;3;6Z:C<UOJ
M*!;NUK%:[03($Y&&V"K[S;A3Q79;KN>$4M,>*=^+)Q'8)8+U%%\N60P^.)V)
MS7O[.:E=VZ0)BA"T%T0&I7(K1@_$GE;%US[Q!^V^X.YOM L:<?AL3(K1&:M4
MNMSUJ9EV$,NBMX*0&T"N&353E<BR\'VEP+8"(,J[N:S':QU%C&A.+R;_ $F#
MAEL5G1>EBMM.CKHX#"/J"Y \D([&N\8J.(3JSK 6\3N6D>J^F9&_U;)N7]KD
MU[):\@4Q5LDB8MV;5\NL4QK<GY9HMT7R':Q,F&'QHC]%:UN^<BW.[*[?YPHJ
MY^1E<CC9#)4-MJ8>3?738X0HE3E!6CV!"'9!JN^PL+%^'3QO=/(<56[MA_96
M!F5K9:2:[<H'UEK+AG>O5"RU%_)N;:P1 DG+C7>/+"R)^XQ:]72Q6VNED)EH
MG5QF/=U2WC*PMY@6P0"EZJTY%RUMAK0^2 ,&9Y*8T[TIT'>O'%=.N[.?QN%R
MO;G)8.4ZU/=C&I'-@4J;M:R5K*GUCHWR=]>G0ZGPGW&S<CC^3P\O'4N:\JMB
MH4MN"G=M)!&P$@#?HVGAM.LA2'!O_NGJGXK5@FN>JN65$RNX8I2D,@C%3CM6
M]W#:+;G2UQ#+XQ)VVXK'CMB@AY<@&I6$A9VH@2 OQNSP?AV"KD;NYN\,+M_F
MT"<CE835FY"46C[/P@!9=2^XBIEI46OZH-9.JJ^H61N3A?9O;_*]Q\8X]#%M
MLRVJL\PN.1D:MCTV+II>SV$4(48.058KXS/'D!)",1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B)AFOC_\ >^X%?_I*Y3__ -=&\H[1^_N[/_XY
MQ_\ ]TKE[NC^%.W/_P"7Y'_V7+GUW9'][;OB_P#];D8__P"?JRR0X;__ )7P
M?_\ D>:_^X-+/</_ /T"_P#_ (_Q'[.^97K._5O8'_8N4?U(MS7>;^Z[?Q#Y
MPF9Q_P#UU/\ :+_M$TE>Y-__ '-IM_\ W"0?S9^;9V=_!MW_ /5\VR0G?7\8
M_P#]Q/VU4WH\B)GQB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
DB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tv486893_img7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img7.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!M (B P$1  (1 0,1 ?_$ (\  0 " P # 0$!
M       '" 4&"0,$"@(!"P$!                     !    8#  $# P("
M" 0" PT) @,$!08'  $("1$2$Q05%R$6(A@Q(R17I]<9"L(E=C=!,E%#)H%"
M,S1$9#4V5B<XV#E985)CU)58F)D1 0                    #_V@ , P$
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MQJ^9WJZU3^B.A43K<O(K-:,@I%W:V^U9&G8V=B<&&SXVW;=8\VA E<"PI="
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M?Z Y-@=.ZH#JN/,3@VNU9713Y+20W6-%D1+G]^:T#TB0GHEB0I<$T:-4+6C
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MD)^Z.\9_D+6^0FZ^Z.'>Y*=YQ47E3]25)+(I8G.9-QK!MM6$JQ)5!"]TD*5
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M& P& P& P*F];<G1OL*/5?75CR$_5-Q:X(E:%L5.:QMSU&.@&2"DN3K&*ML
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MG559 :9XK3T2\<N[K!)39!&H?#(@EY^=Q,J$]&<8N2+0_<-F&F^PL 5-8?\
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M<VQ(N2:BZHE_:-1<?K(9 T;=#[\F#_*YP<M<+L1I0V3*J_8['L%^?$#"I]@
M*%X"CCSR2- &%YHCRFTQ+J3I_IXF9NBUTZ9JBA:K<X@:U(BFR(I:)#;84#RV
MN8% ECFJD?Y8-^<HX  $?1 ]FQ?(+T"@JCPGU!(J)YLYXGENSN2U_0'"U_\
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M$ONQP*Z2<^%Q]O10Y2F5+CD348Z)CM'B=CS@!TNP& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P&!!W2]SE<Z\^W'>ZAM8'A/4E>R:?*&N4SEI
MK2.KB(TVG.1R9XGSZD<&F*(C"B-Z$L.3GA+_ / L8MZ#L/GDKKSO]1SE-+8>
MW\EU)([<+Z&XJJ*JSF^?WC7=2VG$>T3+I;(Q.VA]NJAH#/BV6-.U.'F?="V
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MHDC/.9BAD9#4:T+ER1='M)S1FA-//3$AGYEY4>H8WTA9T9;^9J=7\N4YY$*
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M:0MXUR=F:GK3$6N)&X"(T/\ 0)%YI\L%#=/7DS4S%ZYOJ%-5F(K8=.:+IL:
MI&&H.J&JB9 &-VXX4X\HW]TD("HDL, H &0-C&8Y-P]*D83BOUP.H6 P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P&!7;K6H93?G-MQ4W"G:",TFL*&K8\VG
MVA VNS*X<-'G)CET;G<)=RSDCQ$Y:W$'-2\00#4I$RP:E-K:@DK6!\Z=9^)+
MR),7C<@G)(I-R38L#L1ALA%8?'G7K1/+)K#F5/8#/'!5HOHJWFQ ^V:XR+GZ
M1M*YS2M"CZ)M,6/RDI N0!0HE&PG&?\ A_Z\^JEM,03H*I)ISMTS"?'Q&^I;
M5M]LG>^EV-[X,98)'U,FK%J9AND'FSE>K?6[>>L-?W%&-D7JE1FOKP;+#H)>
MXK\9O5=%WMS%NX[,HE[YSX C_5<:YC75RVSDNY;?2=1R),K,6WJVR(@F&051
M7<71@2@*8%3H%V7"VHV-*5KX,#KM?K(C.KZ22@*AZ1/L79%:UD7-,CD+)](J
M 82< XU,SNB%&OV PO6]:4%FA]/77I[=[UL)PP& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P&!$U[?]G[#_ .FEO_!@2S@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,")KV_[/V'_P!-+?\ @P)9P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P&!XCSR$I!RI4<4F3)BC#U"@\P!)!!!(-F&G'&F;"64446'
M8A"%O6@ZUZ[_ $P([37-4"R&Q6Q4MJ5R?7\Y$WEPJ;ES:-[B4N,=@&F-94:D
M7W+[0^'.("#-D 3'&B-]@O;K?MWZ!D7JSJVCDE:H9(;"@[#,'[:,+'%'J6,+
M7)7D3@I&B0!:F)<O(='':Y84(HG1)0_E-#L(?46MZP,FU3.'OKV_1EDE<:>)
M'%1I2Y1'VI]:W![C9BX S$0'YJ2*CE[.-666(16E!9>S-!WL/KZ;P-+O;_L_
M8?\ TTM_X,"6<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4)\H<)W8W '4
M4*];H 6_5P-.H/Y]:&N2VHC2)WUF6K%[-$GEQ:D$X86]*F&?(&#9VC7Z.EKF
M\D!IRDLH8?'?&K&YN;/&_P M-ER\<UJ=T!+-754?+\ZD];=%2+A-MKJ1,]>M
M\\\BB_G]NA,B)A$W/,$:@;&I PIGAVD[8X',YJ5L7[6;"SUOQ1VIKNND;8J]
MSFG5UM)ZH\8L+XEA'1G!".Y"NCZ3BT?9VJ?3>#=@R%$OFG.MBPIR>7Z>2-R<
MP1-R;'H19BLA:087[ EGQ05VT,W97%+/"Z5M2%=64O"O(.V^6*PG^MYY#G&5
M2:=V(D54CNZ[7D"1)'+[<Y/)2#G:,G)'%_V2@_M"<2=,'VA#ZENBE<G(K&6D
ML[(S.+2?'UH7I>X2)4U+FTGY" [,;VPF.NI+N9HG8A: -4DUL0=!]WIOW:">
M<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@11,;XHZNA* 6!<M4P8:78
M]*@3"PXC&1I]E^OR:/ ].Z(16P;U^NA:UO6!B8)TKSW:4(F5E5A=E7V37]>F
M/)$XF4 FT?F<<BJB/-!;^]I7IUC:]S2(5;8RG 5'$C%HP! PC]OH+7J%'3_-
MEXN"A!T5UO$G$(@Z%\K'#+6D"<'KO>M .4L<"<$Y!V_3U]@Q!'Z?KZ>F];P+
M:J.R.9T7.*/KAPMAD:^=%[>G=$UH.S=(FII$A5OHHRF.-;'%F2R)-LY]#],$
M!J,!FQ_K[?;O6\"K#QYI?%@SPF93D7<G/:U-!XN]RUUC"6P6,BP5K<Q-ZAP/
M2,4 =5+;+'IW6A3[*2)24HC%*@02P>HMX%?UODL[5KJN&7K>^. FFO\ B9W2
ML\ID+BQ7VV2_J*H*B?C$AB2X+)IY-$D<57M#*S+R7-^9V.0+W5F0;.&+1^TQ
M@=AVT;') \MS>[M2LA>UNJ)(Y-JY*/1J9:@7$%JD:M.:'^$PA2G-", M?IL(
MM;P/=P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!C6=G:(\
MTMK"P-;>R,;,A2M;0SM*-.WM;6VH20)D3>W($A925$B2)RPEE%%A" L =:#K
M6M8&2P&!$U[?]G[#_P"FEO\ P8$LX# 8# 8# 8# 8# 8# 8# 8# 8# 8# I%
MU+WC5O+\P@52[A-O7ST#:#4\2.#<^<]0G4^M!QAT=-+3/T]>DZMS8HU"X&UK
MCRTHG5Y<4"4U89H@D1IFAA"'H49Y%N:;GCEA.3\_/'.4OIU];8U<E4=2(45(
MV/6#P]H=N<=W(FJ4.86E8QRIN"(]I=6U:N;'(H O@/$( PA#?>G.MH]S,@A0
MS*<Z,OB0V*H=$D/B'-M.2&V'56:U)$JLX]\=F_:&(PQJ- M*T6L>')"F'ZBV
M$>] %Z!"U)]%][W+9D8%(>"&_FOG\XU8;)95>70D.=KM-0_0J1-X62HJC:9U
M'FUQ$XA)"<6X2;0-$C$+0O<'01!G.@N7>K;PLM8NBWD%LWG*C#FMI2%5A1]0
MU 18 G$@@8'EU,NRPF.>.R43@>+0B24S6260']-_)O7NP-UYHXQ8.:I%)IB&
M_NL+WETM9$3"\/'1U]R>S&\I(B6[< *&&$ *8JZBSD<I%OY53:SI3S"OZK8_
MCUH&@P97C,\>89:^SU9Q3S*_362OKG)WN52VG(1,GY:_O*PYP='7;G*V=Y5)
MU2U8I&8/90B];V+?IK6OTP+9PZO(!73**-5]!H=!8Z,P9PV"'1EEC#*,TPDM
M.,T34R(D*$1@R"@@V+9?KL =:_HUK6!GTS0TH@"+1M;<D ,7N&!,B3$ $+6O
M;H0@E% T(7IKT]=_^&![1Z5*J($E4IB%"48= &F/)+-(& .];"$1)@1%B#K>
MM>FMZ]/TP*?]B\0TGV/SQ<5"S2)1)I':4$?HJWSLB%1ERD4+>UR;8V*6,YB]
MO$(:U@>BB%>B_D!H[16R]BUH6]Z#CIT]QGY"/(11T%X=ZNY2Y.8V:**6V/OW
M=4?O%_>T"*+(D9#!)YU1W.3;%([+8U9DVB2<:9,WOKN:PMBE2+9GU))0 "#H
MY2WCC>N99I7:[GSM?K9@IZ(J6Q+(N<[=FS3T36DCBK<BVCW'H\]6JSNUG5T,
M[0"]@.;7[9"4)>BR$Q97\&@W?I/MF<\K6+_]XG(=Z3'F,3&W+573=%D-]R_L
MYY,V?M[2611<9+!;L>C+,4$L?WIL1OJ<81BV:6GT7O>PLC0?2="=209-9//-
MM0>W86H'\!KQ"WQ*YB:UP=C":T2)KT(MXC#ZE&4()Z!Q3I5I P["84$6MZP)
MNP& P& P& P& P& P& P& P& P*%H/*'X]W2Y@<_-_6]-JK7-E)D%(CY<DW]
ML5SDHT2<R#HIF),&#+IF%4#9/VDER&X?/K9?P^_^' OI@,!@,!@,!@,!@,!@
M,!@,!@1->W_9^P_^FEO_  8$LX# 8# 8# 8# 8# 8# 8# 8# 8# _(Q@* ,P
MP6@%E@$,8Q;] A #6Q"%O?\ X:"'7K@<GEGE!=+?<G2-\"\C7OV&L;5ZUH66
MJY-X><.8FYR0'#2K"MW3<:%J6RX2%66,)@(PQ/NA>S]!Z", ]A1Z]X)VG55V
M2_I>[*RN,I%UIS-65'6]/?&%\US7ER-+Z6M2:S2.):[:)_!QS"5UQ;D-F/T;
MXY-4?4*FQZ2[, GT6(A4$-8X!\6U.6QUI;/:UT\IVV?68:V@%64@W>2!S>KL
MZ1LN8QN42"6RKHJ;Q&UW:7&5844!R1,D9:#B4BE,D2'* (T.C0%B#Z:0  6
M)980@+ $(   '00  '6@A"$(=:"$(0Z]-:U^FM8'ZP& P& P& P& P& P(>C
M]"U'!I=9-DUK7,"KNTK9;T"6>6%%X>R-K_+5;(2O!'7*6FH4R/<H5LACB8(L
M:P0S! W[-C]OIK0<T#>R.R.'E)C;Y#ZA3W#0R,P04W=W)$/D#NSQYLT=H);C
MTGS4E&_SVL2TQ ]"5OD:,D#"'>MB&!('>]!#K1")K$K)AT6L&!2%KED)FS T
MRF)2=D5 6L\@CKZA)<F=X;%9>]@4(7!"H :6/7](1:P-HP& P& P& P& P&
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M& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!$U[?]G[#_P"FEO\
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MHC[^S2MA9)1'')(\QZ2-#:_L+P@-T<A=69X1$N+6Y(SM?H:D7(5!9I8M?^8
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MYYG-F=+I'1FN9Z3R4EN)5RJ(5_7;L_UI&ED9^1R*&8K6KOET!,8G+V(1H0]
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M!98 ZT$  !UK6M:UK6M:P/W@,!@,!@,!@,!@,!@,!@,")KV_[/V'_P!-+?\
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M93 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MXI*RC"]Z]VC &,+LO (&P[]?76_3TP)/UO6]:WK>MZWKUUO7ZZWK?]&];_\
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M:D<0O!9)+NB8K"BK3+FA(Z%)SE"<IQ3-[N6 \)9@P!-"+01"UZ;V$G8# 8#
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M2KT"I.M0K4Y*M$M2'%J4BM(I+"<G5)5!(ADJ$Z@D>A@&#>PC#O6];WK>![&
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M\ZO]WHY7&%L_:G%\.8)O";X@D->G^+B:-(E#!/&#:B*2H U/V\8PIACP.RV
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M,ZYU/5CU,XW8[Q6D =K#AJ-0W1">N<-CJ^9Q5O5E&D*D,;E"IM-?&-&I(/&
MPI*>4 8!BUO6];W@8E91-(.,0D5>N%-U4N@,O?%DGED'65Y$5,0E$E<5R=S<
M)#(HT<T#97M\7N20I0<K4D&J#3RP&"'L0=;T%5.S."&WK&+51&(U=]A\Z(:>
M<%:N.QRNX?2TYJ=\2*6Q,T)&^;4?==:6-5<H#%T:;_D)QK: UE,--&FV$0_7
M04TAO@GI&,-G.4+=+^O.85%2?0KSV#8=1/B6L"8CTIUB[R%WE +FM?[9!$:U
MO+:G1Q("DCC"-KCI*="4'23Y1&GC#N7@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#'.SNTL+:M>7US;F5G;4XU3B
MZNRU,W-J!*7KU,4K5RPTE*E3EZ_\PQB"'7_CO ]-ZE$:C9C05(I$Q,!L@="6
M-A+>G9 UF/;TI+,-3L[0!<H($Y.AY1(Q 3DZ&:((-[T'>M;P,P,\@LTH@9Q0
M#C]&;()&8 )IVB=:$;LHO>]#,T4$6MB]-;]NM_K@>(:Y$6L);S%B4"]22<H3
MH1J"@K#TZ<183SR4PAZ.-)($:'0Q!#L(=BUZ[UZZP'UR+:W;;I8EVXA2A7"0
M?4%?6A1#-$G LVE]_P ^DHCP"!HSV^S8];UZ^NL##I9A$ELI=X,BE,<5S9@9
MV>0OT/2O;8HE+(P2)2ZHX^^.\?*5#=FUG?5;$M*1J3B0$JC$9X2Q"$49H(;%
M@,!@,#6WB8Q"//$8CS_*HVQO\W7K6J&,;P^-C8\2YT;6Q4]N+;&&Q:J(6OZ]
MO9D)ZL\E( TPI*2,T6M%@$+0;)@,#\C& L C#!!   1#&,8M!   =;$(0A"W
MK00AUKUWO?Z:U@>N<O0ITFUZA8D(0:++-VM.4$E)-%&[#HHS:D8PDZ+,V/7M
MW[O3?KKT_IP/6<WIF96X;N\.S8TM)>TVC'-S7I4#<#:P\I,DT-:J-*3!VJ4G
M@++]1?QC&$(?7>]:P/.F<6]:<K3HUR-6>WFZ(7D)E1!YR(_>MBT2K+*&,:8W
M>M;W[1Z#OTP/.4>0?\GPG%'?":(@[XC &?$>#6MC),]F]^PT&A:]0[]-Z]<#
MT$#XRNI6CVQX:W(C;@XM&CD#@D6%;=6A2J1NS9HQ.<8#;@UJT)Y2@GU^0@PD
M81Z"( M:#VAK41:HE"8K2EK5 !FIT8U!051Y9>M[,,)3B'HXT!>M;]VPZWK7
MI^N!AM3"([EPX!J4QS<\+CA<P'"=/;9N7 B)SF:RE2D<;TJ^\ACAKR2-(%=L
MGZ82D BM#]^MAP-CP& P,0_R!ABC&[R:4O;1&XW'VU8\/TA?W)&SL;(T-Q U
M3@ZN[LXG)D#:VH4I0C#CSC %%%AV(0M:UO>![3:Y-SRW('=H7HG5I=425R:W
M1M5$+FYR;EQ!:I$O0+4IAJ98B6)C0F%&EB$ P M"#O>MZW@>[@,#78I,(E/&
M)+*(/*([,XRN/<DJ*111[;)$Q+%+,Z+61X3)7=H4K&]0>U/3<H1J0 ,V(A40
M84/03 "#H/S+9C$(!'W"6SN51N%15IT0)TDTM?&R-Q]M"J4DHDPG!Y>52-N1
MZ4+%!91>S# ^\T80Z]1"UK8;)@,#7);,(E 8ZYR^=RF.0J)LI9)SQ*):]MD<
MCK24H5$(DYKF]/"I&VH"SUJDLD C30:$:8$&O40M:V&QX&%D<DCL.8'B5RY_
M98M%XZW*WB0221NJ%C8&-I0$B4+G1X>',]*W-C<B3@$,T\\P!18-;$(6M:]<
M#(HEJ-R1I'%N5IE[>O3$+4*Y$>4J1K4:HH!Z56D5$#,(4IE)!@1EF $( P"U
MO6]ZW@862S&(PQ.V*YA*8Y$TKV_LT59E,E?&QB3N\HD:TMLCT;;#G14E+7O[
M\Y' 3HD96QJ%1X]%E $+>M8']C4OB<S3.2V'RB.RM&S/[[%'=7&GMM?4S5*8
MNXGL\EC3D>UJ512%_CKNE,2KD9NPJ$BDL11H ##L.@V+ 8# UR,S")35&N<8
M;*8Y+6]K?7V+N:Z,O;8_(VZ31=S4LDFCJY4U*E9"1]CKRC.2+DA@@J$BHH91
MH #"(.@V/ 8# 8# 8# 8&C(K0K1RG;K5K=8<&7V:Q-I;R]UTBEK JG;.SFA0
MC*=G6(D.!D@;VTP#HFV$\Y. K>E!6]"_K >H;S@,!@,!@,!@,!@,!@,!@,!@
M,!@,#GUY&^0YYV+3D>A==V4?7$@B$L<)>6-.-U2FRH"B"3"(%QC;JD=RV1G(
M4*906H./=F62HOA3B ! !2,A:D#AGW/Q4ZT^^<[2"23> =N0>B(!&ZCZ.YVG
M9#LQ6/&HB]#Z$L\N\N=I;.I[.D]9V+-(JF=A.H7MQ,^_JX2S%I7)!\!>DX=
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M1&XF?5& 4;T+0@OSRI?5\R;L3L[F.Y9##9H@HFO>3+,BLIBL'50,1*WH5HN
MR5Q(+6?(Y,-1&H\OJXDQJ-5*CW/VK#P*3S_86((<4NH.Y^Q+1K^=UVZSBS^:
M)JS]%\B!1MY%.,29BF,0F'DBJ.B#'_GSH:(3>2P>YZ4-C2XD+LVK (Y )0ZE
MI%OSH5)Q907SZ'[]Z5KT_M2;5NIASDQ>.*P^?(E/*9D=?'N4[ZIAUKP.N)+*
M)=$79DE*%=$GUZ6SI0W0/:) -K6R)A7HE@%18O[$$-W_ -&VYUAS)Y<3'FS:
M-9*CIHGR.\ENG,3W$V]YF[JTTGSE-5<9LE%,#9"6]!L)_E3>!_VV'LXVPF,#
M%\&A*$P%YP71\3=RRNX*D2)Y'-UC#NLJPHN IN6Y1!F6.6'3S8@J6(%L$]DT
MF2+5JB;L%W)41\@CR]$8>SZ:E84H5!BY&M*3A$TD[^Z,%*)=:L2)AVZQJSR8
MQ_QT3CFYS@;BML]VCTML.NZP:+U8Y6WRH#FBE6W>=DRU*WJ&\#,MKL>E&@!4
MA K."</%G;/772]#L_1_05P5A(V^:'75!VRMH)2:F#HHU*JEZ2MNKTTPU*E5
MCR5T>FU]BL-1A-:S$Y/PGA$8%3O8]AP.<G)W;/9MGI./JXCDDY^J5EMSE[R9
MV[/C('SOM,!#.N5^R$%6L3C7T>_?Z>-QXJ1-<O*/5$K4[EHU:-6H4;4'*2A)
MPJ?UYV]<O?\ XNNB7"8JJ_@;+7'CZ\<O0EM0T5>IW=LLBT>OGM'80W6(25ZE
M0W2#L-=(X<42SA G.4"=U1HSCCBB2BA!T8@O8_D!Z:N+HY+3<TYCJ2H:YZLZ
M,Y! OG[W%WM[KDJI4![)$+B*BQBQ!*)S.WR:MA3L=&UIS6T.$1=MZ2J25"<E
MP5!;/QU](W=TDIG[W=-@QV/OM.EQNEYS1B*,LB0]VL%$B2"#TXP2H]*RR113
M'1Q/_-Z_3;0$DFLYV]C-,5!,3I WCRVVW,Z(\>_0UMP)IKE_D4*;X&O Q6O!
MB;&@[NW+;1A+.[(G.)JG%N1KE(FYR,&D-/V:4F5@+.$49[-!P*'2OO/LZ-63
MTFZ&RZIE=>4CY>N4.&HQ!4=2N:5UD%2]([Y;1/*F4S-5/' W]P1-OOXU4WJ$
M"%+L]T2Z$?[D1H$A0138W1]N]I^*#ON]Y_9E(.5;63QOY)T)?+2.*-JB>4^^
M4<JGL%@QJ26[D"IQEBAM:HN-?)ANC0D-2NJ] :A"B+!\9H>C,_(+T]1_._D&
M%#)?!4!7$].>+-^I+3[!4"X*)!T+!8@&R8K,3#'='^X2%FQCV@4_V56B^;6O
M4WVA]0\?D!O29]%RYS+7/T08J@Y%\TWC$YY9H"\0EI4R1[EFK(YQMA_N)NL<
M^1&+6=0X$7 4V(4Y"(I.!F;EORZ-&K^5.&WTEV5V%+[QY]HF(OW/E8-MU=R^
M8.FK0>XYS^>$T]'RC,GP4*FD;;"K!;T"2;NH4YRAR6.NG7;DZ#T>LTH#\A)@
M1"T^6[MF=4G44D8#*U8K:>N0Y7<$!BS)53O9>^LNDXYTO8E%1ZC7V-LDF*>>
M>X9+&JNT1XW]2<E2*EDB7*$2TI)&7 @8=9^[>@.HZ$YQY;DT(<ZRBES6AU-Q
M=1%L&NL'=)G$VQ+?EF16MK$!#V8J<HSTIS2Z2/9B T]Q7Z^$C9?N$,P)X IB
M;UWY$TO6=N\PQ*:<U3];QDV<Q+K9DUC*8Y0S;>[3>FW:9S.5+&4]QFD@K5NB
M\ T6T,9C)MR2F21 :<M&:2I^B2AH-#=D]@S2Y.:J+B#_ ,^U:U7CV!YC*JLY
MZC?/AI!QA7)5I.Z"%32+LQ5@H6UNF;N3\RER4N@7;[@ZCV>LTIULPH8:G3/D
MQ[(E<9YDL*RYQ$FIG["XLZ'54I&8?5+,:>X]N498Z:KFB,D'N+NYN"U%9#._
MHI(D;E.T",ER1*6\M2H+5$EI0F2,=O>0J7WKT1'X*?S ]0KC>[XWS59K)9T[
MBU5'6&:BHJ(3"47&::H,4R:(R"96#8"4<;;0@3QPYO;%"$:G9Y@UZ4*T)^R.
MLNBK:X#CC]:%T\_R '>M7Q*RJEGM!L58S(35+.*NI;B4[>W5EETLJ^]:8=W>
M%_%&7=F. F%IM,4K4_UR-,>8$W5MW?WQ,3^:EJ^RJ)+_ #YY0.R^#CF]'1#[
MMEC]?T:HZG5L-@A.';(W9VFR0GGY.0B*"I3-NR%I@EI:PTOWB#0HWY+N^K<E
M==<WU6KH]!<0]^1QS563.0Q^&M]D XRZZ=.8*X8#HU(5^VA &0H]D/TPTR#,
M< D$&:;P(B@C,P-D@7D+[[=F]TFL^F//B5*V>72E_'X?!*QKYSD+ 3"+MC%*
MA>GU!:3Q+S#9B?7SE:HE<?<B&IL+=C4OO7$"3*2TR<+Z^$63V7-O&9S--K=M
M>17#.9JP2:5N$KEP4HY'M,Y3N4IR4[BX$C,5/?O5(#S@+%(A&CT;LO6]%E #
MH('2]^]+R-[@%LL XD55$T\CEA^-N7T!^/5*FW*W,0V++JRA-[$28$H5;U)F
MQ3'")@]M+JW::3H"X%JB"B#2=*5@93PT4ZF?*<E%RVZX(+<MJ ]L^2F-5U8\
MGA,>:YI!VYZZ]M.(V(F9'Y 6)QT@GYD,1FJ4PS-DHR4Q"$C04R4D(0[AX# 8
M# 8# 8# 8# 8# 8# 8# 8# _!AA918S31@+*+ (PPPP6@%EE@UL0QC&+>@@
M .O7>]_IK6!1FR:$\>W9LQ@TAL&,<^WW-3XF3,88J(DC!(G66US$)"M:2W4Q
M+''S_P"\.LH]*I2H2B M+<&1.O<!E"#HT_81!)%L41R4"<0GIJYX95C1-*:
MT-$"N"<KD,=%7!;H](&MI:V*0.3BW-D>+?WU:D1:( (O3B<-.G&$W?Q%X&W3
MB#\[M-CPFX;%::S9K,$YM< @,VEJEE:'MPD+\8J11Z+L"IU4I0/,I7#6*"&P
M@L)R_7SG%IM:T:8$0;,33%4I[.4W.1 8R5::MJ^S*9N!M)"^&HO@+2"V(_7]
M7I>8WD%I1J]!TK&C+ G$9L@ 2]!$-G<.<BW1))W+[6Y]K:>R:SFR#LUA/4D8
MPKULQ::S=4[]7C:_F#-UIP10E]3 7-98];"B6>IY6@FB$/8>O'^<^,K+:K]?
MHQ7%+V&P]1;5P_HUV90,<P9+E-AI"^ +X[8:Q&J<F^0JXL0F4,QR<\6S46B!
M)1Z!\7L"&TWCR+R[TNW0)IZ#H"IKE;:M>2)#72.Q80PRDF%O"<@E,!9'=.J-
M1ML]Z=,4 PLO>BC@E%Z,"+V ] U<//7%RE\G*_\ &M$JW>W&J3L-@)3$,65D
M3QNG7RDS A^8S##6YX/E9)@DZ\X9 CUB?6B#!B*"$&@U8OCGQ_6RX5RX HCG
M"SGGDV6NT;KUTW'8?-WJD9RB7-,E?8\4YBTZ.4<E*1SVB<%:-69I4!0,H\P&
MAC"/82*HXUY15VNDO-7SU4JNWF^;?DIML%5"F53)&NQ-QP<2.G34M.2C^V2Y
M9'!:2J'$@):M2645LTP8BBA #.]#UUSK.X,4[=,LE<+(#6[H"=IY/9BQL9&:
MOW9(@7LVY6FEKDL;-1)2%I>52,U6!4G]Z56:2,6RS1@$&LNW&?)DF=UTG<*!
MJM6YO=+K^>U:])&&Y$2KH9Z.,6.-3E$-@4R$JO7%0>(TQM* %*,8O=[?7]<#
M=5W.5&N5'D<U+:QBQ]")8JVP9/5'T0RX:5#&@"<IMBH6HHT /V^D3I"R0I/7
MX-D!^+8=E^H<"+YMP1QG9-+0GG.P>;ZLFM$UNX%.L$J>41PE[@\57IBUQ"-0
MSL+@,]&EVW$.9Y:4.@^U*69L!6@!UK6@WVCN5N;N:(YJ(\^T?65.1G36-E$R
M5Y$6B,(#6LQX>I -&H);$Q&E)8WF1KE&]F>X6S%(OU]/36@_-*\J\Y<Y(3VZ
MC*9@-7I#VT++L$38D[>80Q & TN/(5']8I;8X2H+T:!O3C*1 .]3 E:'O8MA
MBJRX[Y@II+)457TC!(8DF,Y8;.E29I:Q:)?[&C#P&0,4[="U)R@*N7('LL"K
M3@+U5#/+ ,8Q; #T#49] >(+YM*JYM/@T;9%O5[.9)#:<>%LOC[E+XS9D,;W
M%]F<5@Y2-\TL33N-L>E9SPB2@^X)VWYM*@:3?)K Q%J^-S@F]+;W?%S<CT1:
M=Q;51Y9NQ9[7[)*9,(Z)@3%QL(ESPG5[$F9PHR]$$[U\(?3?\/\ $+U#=;9X
MEY+O:22F87%0%:V/)IO7J&II>\RM@*=%<DK%M?T\I0P%X$</V+HDFDB0M<%"
M,.T_U0?DV'8M[WL,U$JIYBJVSIC:$1CM9P^V9ZQ1*!SF7I%[:DELH8J\0E,\
M,C3^K/7;5N!$21:T2B)-T(2;1H]!]-FF>X,07Q1R63')I#RN>ZM!%;""@U+H
MZ&+(=,SH)L?BY6A/*;_9],U*T\M)+=]'(PIS=NQ8%NQ;5 ";H,R9R3S*;,XU
M89M&5J9-(A'XO%H^_CB[>)6C8(.H7K(0W' V5M,Y%PM<Z*5#0-46<8V*3QG)
MA%&"V+ Q,JXJY(F\SM:QI7SE3[Y/[T@/XMN.:K(,Q[E-EUUM.2C,ALR?BDA;
MF^L"E"F*3G)SS! /3%%E&>XL 0Z#/0;E?G.L)RS6? J@A$1G\:J5AHEDF#0V
M!2O;53,4. IC=:IEWR;&7#F%07\J5%OU)(,V(8=:$(6]AAXO2?)MAS95TS"H
M-3LXF4M/W]1<$5*C\D^_N\5*%!]O 7]H.6-2Z61M*QB9?N8-B<T1"42+Y@%E
MB*T&_4_0].\_U\35%*UW&:SK=.N?7)/#(BATU,*=PDZ]2ZR)8G1%#]A"AZ=5
MIRI2('ILU2<8:+U&,0MA"\0\?W%E?F,1T*YMJZ+&Q:(61 8X:RL.D V&%7 J
M7.%IQEI&0<':!GL!Q<CE3L47[0K50_G,]QH0CT&)5>/W@B;0.'PE9S!0DKKB
M&P4ZL8?'3X8P/<5;:Y^^_N,J#)D8BU+>KBC7(P;6(D!NC4S>K]3$P"A[WO89
M60\#\/3R>3&X7[EVB'ZQK-@'XVF=BZ@$<_<\MKPYM;6G]LN$B1)"EJIG.8VE
M*BWH)FMB0DA3^[9&O9@8N[?'QRG?*U>^3*IXL&7O+16$3?)XC;"@SA;!*BF+
M7.X/$$<F,$-S9$L>DS24K;E:092YK5"&I1FD*A?/H+#W)2E3]"UZ]5/=T C5
MGUK)!MQC_"9>W@=8Z\B:'%*[MGW%N.W\*L*)S1$G@"/6PZ-*"+T]=:P(87<&
M\<N:*4MSASO6BU%-[2BEWR\A2R[.U([@@I 4L-LMW$,_9BV:1@@LL*%P'O:A
M/H@GV"UL@GV!DU'$?(2D5^F#YMIPLWJ@K1'1YZ2"L2%1=A&RS"CB+'4(DB<Z
M3D+0G&?4@4B&%4(TP1VAB&/8@P4O\?O$U@)RD4XY?IN6H2X/$*U-;Y##6UV;
MG"#5\'VP2./3>M+.1/R*& U[6O:TM0:@#_"0(&OTP-FGW%W)=IS%+8%C\Z4_
M-Y@B-@2A.^26"L3L?I75KK]ZK=>:0J2&(U#E!5_KMJ4F%C/0DB$24,)(A%[#
M"1K@[CJ&RF.3>+<[5FPRZ'RVRIY%Y&VL?TSNP36Y$VDEKRIK6 .^5(_6*G#[
M7E4#>C7#>][.V/>][V% [,\*O/4KF8C6"H>+'6HFR.-$<K>K+KY+W9>J11?<
M7M[FK=5S]'[:KHA-'IW*7T]]5(G) O$!Y/4&_,,@T"<D.BYO(-"/E*TW0MB0
MA!;$#HG\=+*^(LCW2->VR6JD!"*#S(2LW90A2I@$0$]*KUK1B=1K1A?M$$.]
M!E+ Y)YAM:X*ZZ!LJ@JFG5W5&#159VK*(.PO,ZA)8%!ZP@M@D2U$:XH@(UJD
MP]/K0]Z3'F",*]@Q;%L-/B_!G',*DL9F,3YUK./RJ&2*RY=%) ULGTSK'I3<
MR?Z6V9"TK '_ "HGBQR?_IE0#>C7 7\1VQB_7 VN%\B<Q5U%*F@T'HRMXS$*
M'FCG8M,1ULC:(IKK"<O*"3-;I*84F$$86!Y7MTT=B3#D_L$(#@?K_P!8+U#U
M)3QGR=-[JUT=+^=*=DE\ZB"R [MUW@4>6SXR'.#6Y,:Q@.DAR$3B>A/9'A4B
MW[QB'I(>(G0M%[]N!ZH>*.3 Q%- ]<^UA^T$$M:)TUL.XTD$B995'V]2SL3H
MP^[6SF+3*RK5"%*0C$0F3H52A, L)!YQ8PQ\<X3X]B)4!(C'.M7L)%66M(+S
MKDALCQ*0B%7#*PE@DUD1TDH82FV6OP ""K6%ZT8>$T[0][T>=[PUI\\<'!<H
MAC+7DHY(HB3PF-V@_P!U,$:DE?,;\UL]K2LP!\JG;<2[)EFTL@E"DO1SD<#>
MOKSM?(?HP?\ %@;&HX2X\5%.Q!_.M7B(?;N:NDW<@,>*+)77XQEZ*9;=.**&
M O\ ?C04$ 4SAK6CR E%:!L.BB_:$P571]04<W/C13U;Q"MFJ2/[A)GILA[*
MC9$"QZ=%)ZU:JTC1EEITQ(U:HXP"<D):<D9QFRRP[,'[@U4KEGG0BQ93;9%,
MP!/94V-5JY3,B&!*2].[HOCJ>(+W\X\K0 DRA=%$A;8<ZE!+<34 -)Q'[*_@
MP/?H[FZBN:6-[C-"UA%JKCTC?5DG?&:))#$#<YR-R//5.;XI2B.-*$ZNJQ4:
M>K/UK1BI0:,TW8S!B%L)NP& P& P& P& P& P& P& P& P&!SXZ\O*?,=_\
M'/)E=/3+"7+JE=?CS)+!D<+;; :&Z#4!7+=*GV%%QEV>69"<YS]QEB H9YFS
MPDM"-PT$ 3ADGDAP;\6UE=%GT;R1SUSHMIF-2ER\.W1]KU!-U%2,DGE;'=<%
M[.8XLV1A5(G:4-J534,D"_$ISH_\R "=1H*HQ6(THH106"G'?W0=I^/%9UI$
M9'7$XB;'5?!#3/H9:E(L,JC"WHZVNE*^:[R92B@GQTL+S5#%(D*)*4:C&C3K
MA)7(D!@AE[ 'J]JWC-.CK0@#Z[OL68*IY9\]_#'+D7K=Y@[1N3&2:&N%9363
M6TGL<Z0FN"-;*%MFC1I$9:(E,6P(AZ& 9Z@9Y81*J\J7DTDO'1';4(6\DQ^O
M;1?X\A9(M)G%'-)=5;DY]<PJF6V'QB#1=WCTEFZHJ$R%6GEHGY:B6-3DCTK3
M%$@,$C("ZCKW;U4R]26%Q"ZSJ$:ECOW30G.L$OI!524@$0B%D<2/?9\\2GP1
MPERAD<%Y0H.MC,:4*E"PXDMS)/7!7G)_4X.?_(W7%X<L\\PN$0A(L;:Q6=3]
MZZF=OU51[';U85[,G3R96O7@!W56+%/45HU%2*J/.H%;&^L9#BD0*OF"KVJ3
MI!%;#Z\R3TZHL0TYQ*DK1AQ QDF .+T:08(D\D0@;$'1A)H! &'?ZA%K>M_K
MK ^83D#DI#:UN=N14'*G*DSH-#YC+F1SZ1O;.G;+CA$4B%8UI-& %=IT,79R
M8^UQVT$# K1G-C^6K*&<H$%'L(C!;"2#^[.H('$NGG:+UGN3#A/E+ZAI*3'<
MGT)"Y5:X:SKJF8O8$5FI]'22Q8ZZW8\J'<Y.@F+BVKC'\38(*E. @).MEA/?
M,O:M\=-WS-8VS]!4!$XCSLV\-%R.-N\ 6-Q_331TQS[#KEF5D,I4CD[//:G$
M\J)X!NAC5I*LT0Y,QQ#@)8,\PE$'([J7NF]>F.-^_*;M615_<U0S[Q*71U=!
M[$9JP20:-O<EA=]*ZP12"F&-<]/4K642Y)?@61MWE914@<36P#B1HD@P C [
MV^0FW>@^:^=JGZ4J*>LL8K&EIK43OU?%72ND,Q=9!S:^2N&1RT93&7Y:Y(@0
M5TJ>+N"N0+%AI*M/MG2+=[*^8LCU"A4R[R[OD]O5G1=!2FEE+_;?.]W]OUM+
M[5_9\*:9-5N[K!!>>JQ/*5&B3N</*@)Z1\DKVT[,?E:5S)-3Z1@*W\X17<7E
M.[/B=AO!$#F]'2QL=G_L&N%1<:@HY72U4V!0/ DUZH:8;$IVID<7L6]YY"YE
M A)Y:[E)&R(A2.Q"=,#2O1A:8.VW!+_T'8'.M:W+T%:L0LAXO*L*:MM@:8?5
M0*R05T1-ZGB#[(XELS]Y2X^6D;E:Y8I2K#OI#B4QP$X@&;+^48<'+/\ *9Y)
ME/+W579]4F<JQNLZWD/8D):81-7QLD4KKU9SC/WZ!P@YHB+.M;9G,; E&J\7
MKWMM?#V](4WOJ=>C*"G0Z)< MG8_?O5E5]"VIRA(9=!GB52>TO&A6596^S50
M%L;*M>>XG*_"["5*H.YS9>5)(]#V:@S01H"]Q/6[=W8&EQBP@O16PI]QW9-F
M5#?;-5$-W23[^3?,[Y>8A+I&[U E7N33+H;RO+++BDL@)3;)TVZX^O?(J,+^
MD1&;4.J)4>G*4I2A#T(-]@7E.[N9.>N4[NE)E(6Y+.EO%OTYV$5 118JEH>Q
M6A11O/XH<D!,WF>.(=H).3<BL+P6K5)$RDQ(D*;PHS#A;&'3?QW]#](7Q/+X
M33>7QZWN;X,QT\"HK[,I"24+.+'L>8192_6[%E<$?9#OZ.+U8H @)3J]-!.U
M"EV-0C5GJ6E6,P*_5ESESK9?E7\L39:U)5!+XTJY^X'<77<PK^)."8DZ8LW5
M@9H];<7!K$:W.,B(0!$X+BS2E"C:4L9AF]D@V *'43U_UU &*AN,N9Y4Q+8E
M9=N^2QSY4O2]YDGD[W-^4.8YK"&WGANCLOM5S5"MA@D!ML&*BGH9ZAS70Z+;
M"B%\8ON907\YG[7ZHZ#N*Z4<MLKEVJ%')<WH>M;3Y_B:L-GM%Q*[!YWC=NSF
M4UW;2UVB\M2_=)3.]-,*^)G-1'"C"L"H*TU29]"%"&+R@^3N6<LT'URQN?(+
M37_4\OY>*8FAS6I9]*:R5W?UA753K8#&H+#GZ.O4J9&.#V5I#(ECVY)GEH>V
M4SV +$O^%M"T,M[D[3@<AZ:3NT_JZ7QGF3R8<4\=A;1TN-G=;1@_62SE,$R-
MDKD3-UR!A+A:#H]66P:;D>E9AC<E$X*%83#0#"H?%/7-V<*\:<[K8JU1:VJ2
ME[+YD92@J!HB HNMJL_D2P^F[OC;P&;1\UY-6,DV>HW^V5Z=0VITJ0U[;=H_
MC,)VG7A,31W3Y05;=PVL<+'Y(1POM:Y^;8PWSIB1,MGSQB;+HJ6TY=-$,=@$
M0D[/'2:]8%L5;E3$]N+@M<?J3#$*W2@'H>,/H620=[7TBW0"\9>UV1(S(8V,
M=DS)J;5]2,,[>R4J<I[<0,3+(W=9#V&3+BQ:.;BG)8$"4\:<1AP!"T(.+/ U
M>',D5\NO*UT<]PZKY>SW(YV;-HY34A?'/EF8Q^[:59W:#.-'MAK7&W.MU2MJ
M@X5LIC0]C6)WQ:)R$8$AU3$E!=[P\*2R/%'XW_K% "C5?&O.91&U1V@&*CSJ
MLCQQ996SA:&><:4'8]:UZB$'6]_T8'2K 8# 8# 8# 8# 8# 8# 8# 8# 8#
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tv486893_img8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv486893_img8.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3 !D P$1  (1 0,1 ?_$ ,8  0 !! ,! 0
M       )!@<*"P(#" 4$ 0$  00# 0$             !0,&" D"!PH$ 1
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MR+L^$QVWE3EZQ3N;9B2W[%WM/5-*%OZX5C]#_OD=_4_Q!-7+I0]5U.R^D?\
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M.=SOG'N^'\9\;H"<KW4[[P'._@K[^'\OCV5Y"]E_M^]D?L!]H/M(A?2'LY]
I_P 8^G?2?IKF>!^:^9XOQ'QW+T!FU: : : : : : : : : : : __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>16
<FILENAME>plx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:plx="http://www.protalix.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20171231.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2015To12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_23_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_01_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2017To04_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>

      <xbrli:endDate>2017-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_24_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_18_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_07_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_14_2006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2006-12-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRusgaapStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_31_2015_PfizerAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_BRusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_31_2015_PfizerMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FurnitureAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FurnitureAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_EquipmentUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquipmentUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_EmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_EmployeesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_12_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_07_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_07_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_07_2016_ConvertibleNotesDueTwoThousandTwentyOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDueTwoThousandTwentyOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_18_2013_ConvertibleNotes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_18_2013_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_31_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_Notes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_Notes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_02_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_07_2016_ConvertibleNotesDueTwoThousandTwentyOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDueTwoThousandTwentyOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_UsIsraelMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_UsIsraelMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_USusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_USusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandFifteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:GrantYearTwoThousandFifteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_SubsidiariesMemberusgaapConsolidatedEntitiesAxis_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-10-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_19_2017_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-10-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2017To10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>

      <xbrli:endDate>2017-10-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2017To10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>

      <xbrli:endDate>2017-10-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To01_31_2016_TaxYearTwoThousandNineMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearTwoThousandNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To01_31_2016_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2015To10_31_2015_PfizerMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2009_ProtalixBioTherapeuticsIncorporationMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2009-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_RestrictedAmountMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:RestrictedAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RestrictedAmountMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:RestrictedAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SubsidiariesMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SubsidiariesMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SubsidiariesMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis_SubsidiariesMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:OnePointSevenTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeSevenZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointThreeSevenZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:FivePointZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NinePointSixSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:OnePointSevenTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointThreeSevenZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ThreePointThreeSevenZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:FivePointZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SixPointNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NinePointSixSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_TwentyThirteenAndTwentySixteenNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:TwentyThirteenAndTwentySixteenNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2013MemberusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">plx:Notes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2016MemberusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">plx:Notes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2017MemberusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">plx:Notes2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2017MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_31_2017_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotes2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_24_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotes2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SubsidiariesMemberusgaapConsolidatedEntitiesAxis_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_BRusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_PfizerMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:PfizerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_BRusgaapStatementGeographicalAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_PfizerMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:PfizerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_DefinedBenefitPostretirementLifeInsuranceMemberusgaapRetirementPlanTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ProductsManufacturedOutsideOfIsraelMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ProductsManufacturedOutsideOfIsraelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:ProductsManufacturedOutsideOfIsraelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ContributionPlansMemberusgaapRetirementPlanTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotes2013Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotes2016Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2017To12_31_2017" id="Factid_1">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2017To12_31_2017" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2017To12_31_2017" id="Factid_3">2017-12-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2017To12_31_2017" id="Factid_4">2017</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2017To12_31_2017" id="Factid_5">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2017To12_31_2017" id="Factid_6">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2017To12_31_2017" id="Factid_7">0001006281</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2017To12_31_2017" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2017To12_31_2017" id="Factid_9">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P01_01_2017To12_31_2017" id="Factid_10">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P01_01_2017To12_31_2017" id="Factid_11">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P01_01_2017To12_31_2017" id="Factid_12">Accelerated Filer</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn06_30_2017" id="Factid_13" unitRef="USD" decimals="-5">105400000</dei:EntityPublicFloat>

  <dei:TradingSymbol contextRef="P01_01_2017To12_31_2017" id="Factid_14">PLX</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn03_01_2018" id="Factid_15" unitRef="shares" decimals="INF">145569955</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_16" unitRef="USD" decimals="-3">63281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2017" id="Factid_17" unitRef="USD" decimals="-3">51163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_18" unitRef="USD" decimals="-3">2648000</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_19" unitRef="USD" decimals="-3">1934000</us-gaap:OtherAssetsCurrent>

  <us-gaap:InventoryNet contextRef="PAsOn12_31_2016" id="Factid_20" unitRef="USD" decimals="-3">5245000</us-gaap:InventoryNet>

  <us-gaap:InventoryNet contextRef="PAsOn12_31_2017" id="Factid_21" unitRef="USD" decimals="-3">7833000</us-gaap:InventoryNet>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_22" unitRef="USD" decimals="-3">71867000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_23" unitRef="USD" decimals="-3">62651000</us-gaap:AssetsCurrent>

  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="PAsOn12_31_2016" id="Factid_24" unitRef="USD" decimals="-3">1677000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>

  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="PAsOn12_31_2017" id="Factid_25" unitRef="USD" decimals="-3">1887000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2016" id="Factid_26" unitRef="USD" decimals="-3">8703000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2017" id="Factid_27" unitRef="USD" decimals="-3">7676000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:Assets contextRef="PAsOn12_31_2016" id="Factid_28" unitRef="USD" decimals="-3">82247000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2017" id="Factid_29" unitRef="USD" decimals="-3">72214000</us-gaap:Assets>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2016" id="Factid_30" unitRef="USD" decimals="-3">4007000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2017" id="Factid_31" unitRef="USD" decimals="-3">7521000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2016" id="Factid_32" unitRef="USD" decimals="-3">7496000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2017" id="Factid_33" unitRef="USD" decimals="-3">9310000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2016" id="Factid_34" unitRef="USD" decimals="-3">837000</us-gaap:DeferredRevenueCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_35" unitRef="USD" decimals="-3">66212000</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_36" unitRef="USD" decimals="-3">22752000</us-gaap:LiabilitiesCurrent>

  <us-gaap:ConvertibleDebtNoncurrent contextRef="PAsOn12_31_2016" id="Factid_37" unitRef="USD" decimals="-3">19343000</us-gaap:ConvertibleDebtNoncurrent>

  <us-gaap:ConvertibleDebtNoncurrent contextRef="PAsOn12_31_2017" id="Factid_38" unitRef="USD" decimals="-3">46267000</us-gaap:ConvertibleDebtNoncurrent>

  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="PAsOn12_31_2016" id="Factid_39" unitRef="USD" decimals="-3">2348000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>

  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_40" unitRef="USD" decimals="-3">2586000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2017" id="Factid_41" unitRef="USD" decimals="-3">103507000</us-gaap:Liabilities>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2016" id="Factid_42" unitRef="USD" decimals="-3">202575000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2017" id="Factid_43" unitRef="USD" decimals="-3">266495000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2016" id="Factid_44" unitRef="USD" decimals="-3">-212656000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2017" id="Factid_45" unitRef="USD" decimals="-3">-297932000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_46" unitRef="USD" decimals="-3">-9957000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_47" unitRef="USD" decimals="-3">-31293000</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_48" unitRef="USD" decimals="-3">82247000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_49" unitRef="USD" decimals="-3">72214000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn12_31_2016" id="Factid_50" unitRef="USD" decimals="-3">25992000</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_51" unitRef="USD" decimals="-3">80755000</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2016" id="Factid_52" unitRef="USD" decimals="-3">92204000</us-gaap:Liabilities>

  <us-gaap:ConvertibleDebtCurrent contextRef="PAsOn12_31_2017" id="Factid_53" unitRef="USD" decimals="-3">5921000</us-gaap:ConvertibleDebtCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2017" id="Factid_54" unitRef="USD" decimals="-3">1721000</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:Revenues contextRef="P01_01_2015To12_31_2015" id="Factid_55" unitRef="USD" decimals="-3">4364000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2016To12_31_2016" id="Factid_56" unitRef="USD" decimals="-3">9199000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2017To12_31_2017" id="Factid_57" unitRef="USD" decimals="-3">19242000</us-gaap:Revenues>

  <us-gaap:CostOfRevenue contextRef="P01_01_2015To12_31_2015" id="Factid_58" unitRef="USD" decimals="-3">730000</us-gaap:CostOfRevenue>

  <us-gaap:CostOfRevenue contextRef="P01_01_2016To12_31_2016" id="Factid_59" unitRef="USD" decimals="-3">8398000</us-gaap:CostOfRevenue>

  <us-gaap:CostOfRevenue contextRef="P01_01_2017To12_31_2017" id="Factid_60" unitRef="USD" decimals="-3">15231000</us-gaap:CostOfRevenue>

  <us-gaap:GrossProfit contextRef="P01_01_2015To12_31_2015" id="Factid_61" unitRef="USD" decimals="-3">3634000</us-gaap:GrossProfit>

  <us-gaap:GrossProfit contextRef="P01_01_2016To12_31_2016" id="Factid_62" unitRef="USD" decimals="-3">801000</us-gaap:GrossProfit>

  <us-gaap:GrossProfit contextRef="P01_01_2017To12_31_2017" id="Factid_63" unitRef="USD" decimals="-3">4011000</us-gaap:GrossProfit>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2015To12_31_2015" id="Factid_64" unitRef="USD" decimals="-3">24889000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To12_31_2016" id="Factid_65" unitRef="USD" decimals="-3">30412000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To12_31_2017" id="Factid_66" unitRef="USD" decimals="-3">32170000</us-gaap:ResearchAndDevelopmentExpense>

  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="P01_01_2015To12_31_2015" id="Factid_67" unitRef="USD" decimals="-3">20025000</plx:ResearchDevelopmentAndEngineeringExpenseNet>

  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="P01_01_2016To12_31_2016" id="Factid_68" unitRef="USD" decimals="-3">24608000</plx:ResearchDevelopmentAndEngineeringExpenseNet>

  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="P01_01_2017To12_31_2017" id="Factid_69" unitRef="USD" decimals="-3">28834000</plx:ResearchDevelopmentAndEngineeringExpenseNet>

  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="P01_01_2015To12_31_2015" id="Factid_70" unitRef="USD" decimals="-3">4864000</plx:GrantsAndReimbursementsReceivedOrReceivable>

  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="P01_01_2016To12_31_2016" id="Factid_71" unitRef="USD" decimals="-3">5804000</plx:GrantsAndReimbursementsReceivedOrReceivable>

  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="P01_01_2017To12_31_2017" id="Factid_72" unitRef="USD" decimals="-3">3336000</plx:GrantsAndReimbursementsReceivedOrReceivable>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P01_01_2015To12_31_2015" id="Factid_73" unitRef="USD" decimals="-3">7279000</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P01_01_2016To12_31_2016" id="Factid_74" unitRef="USD" decimals="-3">9356000</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P01_01_2017To12_31_2017" id="Factid_75" unitRef="USD" decimals="-3">11530000</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2015To12_31_2015" id="Factid_76" unitRef="USD" decimals="-3">-23670000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_77" unitRef="USD" decimals="-3">-33163000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2017To12_31_2017" id="Factid_78" unitRef="USD" decimals="-3">-36353000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2015To12_31_2015" id="Factid_79" unitRef="USD" decimals="-3">3735000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2016To12_31_2016" id="Factid_80" unitRef="USD" decimals="-3">4192000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2017To12_31_2017" id="Factid_81" unitRef="USD" decimals="-3">9725000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2015To12_31_2015" id="Factid_82" unitRef="USD" decimals="-3">123000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2016To12_31_2016" id="Factid_83" unitRef="USD" decimals="-3">589000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2017To12_31_2017" id="Factid_84" unitRef="USD" decimals="-3">188000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2015To12_31_2015" id="Factid_85" unitRef="USD" decimals="-3">-3612000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2016To12_31_2016" id="Factid_86" unitRef="USD" decimals="-3">3987000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2017To12_31_2017" id="Factid_87" unitRef="USD" decimals="-3">-48923000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2015To12_31_2015" id="Factid_88" unitRef="USD" decimals="-3">58037000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_89" unitRef="USD" decimals="-3">-29365000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2017To12_31_2017" id="Factid_90" unitRef="USD_per_Share" decimals="2">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2015To12_31_2015" id="Factid_91" unitRef="shares" decimals="INF">94922390</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_92" unitRef="shares" decimals="INF">101387704</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2017To12_31_2017" id="Factid_93" unitRef="shares" decimals="INF">131085958</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017" id="Factid_94" unitRef="USD" decimals="-3">-85276000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2015To12_31_2015" id="Factid_95" unitRef="USD_per_Share" decimals="2">0.61</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_96" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_97" unitRef="USD" decimals="-3">-29176000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2017To12_31_2017" id="Factid_98" unitRef="USD" decimals="-3">-85276000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2015To12_31_2015" id="Factid_99" unitRef="USD" decimals="-3">85319000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2016To12_31_2016" id="Factid_100" unitRef="USD" decimals="-3">-189000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2017To12_31_2017" id="Factid_101" unitRef="USD" xsi:nil="true" />

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2015To12_31_2015" id="Factid_102" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2016To12_31_2016" id="Factid_103" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2017To12_31_2017" id="Factid_104" unitRef="USD_per_Share" decimals="2">-0.65</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P01_01_2015To12_31_2015" id="Factid_105" unitRef="USD_per_Share" decimals="1">0.9</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P01_01_2016To12_31_2016" id="Factid_106" unitRef="USD_per_Share" decimals="2">-0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="P01_01_2017To12_31_2017" id="Factid_107" unitRef="USD_per_Share" xsi:nil="true" />

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2015To12_31_2015" id="Factid_108" unitRef="USD" decimals="-3">-27282000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2017To12_31_2017" id="Factid_109" unitRef="USD" decimals="-3">-1325000</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2015To12_31_2015" id="Factid_110" unitRef="USD" decimals="-3">1802000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To12_31_2016" id="Factid_111" unitRef="USD" decimals="-3">988000</us-gaap:ShareBasedCompensation>

  <us-gaap:Depreciation contextRef="P01_01_2015To12_31_2015" id="Factid_112" unitRef="USD" decimals="-3">2370000</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2016To12_31_2016" id="Factid_113" unitRef="USD" decimals="-3">1983000</us-gaap:Depreciation>

  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="P01_01_2015To12_31_2015" id="Factid_114" unitRef="USD" decimals="-3">-124000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>

  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="P01_01_2016To12_31_2016" id="Factid_115" unitRef="USD" decimals="-3">-13000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2016To12_31_2016" id="Factid_116" unitRef="USD" decimals="-3">-411000</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2015To12_31_2015" id="Factid_117" unitRef="USD" decimals="-3">-523000</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2016To12_31_2016" id="Factid_118" unitRef="USD" decimals="-3">1133000</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInInventories contextRef="P01_01_2016To12_31_2016" id="Factid_119" unitRef="USD" decimals="-3">-522000</us-gaap:IncreaseDecreaseInInventories>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2015To12_31_2015" id="Factid_120" unitRef="USD" decimals="-3">-1873000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To12_31_2016" id="Factid_121" unitRef="USD" decimals="-3">2139000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2015To12_31_2015" id="Factid_122" unitRef="USD" decimals="-3">464000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_123" unitRef="USD" decimals="-3">849000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2016To12_31_2016" id="Factid_124" unitRef="USD" decimals="-3">106000</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="P01_01_2015To12_31_2015" id="Factid_125" unitRef="USD" decimals="-3">96000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>

  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_126" unitRef="USD" decimals="-3">32000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2015To12_31_2015" id="Factid_127" unitRef="USD" decimals="-3">6635000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_128" unitRef="USD" decimals="-3">19695000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="P01_01_2015To12_31_2015" id="Factid_129" unitRef="USD" decimals="-3">-131000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="P01_01_2016To12_31_2016" id="Factid_130" unitRef="USD" decimals="-3">277000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2015To12_31_2015" id="Factid_131" unitRef="USD" decimals="-3">21607000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2016To12_31_2016" id="Factid_132" unitRef="USD" decimals="-3">-13093000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2014" id="Factid_133" unitRef="USD" decimals="-3">54767000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2015" id="Factid_134" unitRef="USD" decimals="-3">76374000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2015To12_31_2015" id="Factid_135" unitRef="USD" decimals="-3">534000</us-gaap:ProceedsFromStockOptionsExercised>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2016To12_31_2016" id="Factid_136" unitRef="USD" decimals="-3">14000</us-gaap:ProceedsFromStockOptionsExercised>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To12_31_2017" id="Factid_137" unitRef="USD" decimals="-3">337000</us-gaap:ShareBasedCompensation>

  <us-gaap:Depreciation contextRef="P01_01_2017To12_31_2017" id="Factid_138" unitRef="USD" decimals="-3">1920000</us-gaap:Depreciation>

  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="P01_01_2017To12_31_2017" id="Factid_139" unitRef="USD" decimals="-3">40000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2017To12_31_2017" id="Factid_140" unitRef="USD" decimals="-3">26014000</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2017To12_31_2017" id="Factid_141" unitRef="USD" decimals="-3">-25000</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInInventories contextRef="P01_01_2017To12_31_2017" id="Factid_142" unitRef="USD" decimals="-3">2588000</us-gaap:IncreaseDecreaseInInventories>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2017To12_31_2017" id="Factid_143" unitRef="USD" decimals="-3">4902000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2017To12_31_2017" id="Factid_144" unitRef="USD" decimals="-3">971000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2017To12_31_2017" id="Factid_145" unitRef="USD" decimals="-3">146000</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_146" unitRef="USD" decimals="-3">5000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_147" unitRef="USD" decimals="-3">-1419000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="P01_01_2017To12_31_2017" id="Factid_148" unitRef="USD" decimals="-3">414000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2017To12_31_2017" id="Factid_149" unitRef="USD" decimals="-3">-12118000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2015To12_31_2015" id="Factid_150" unitRef="USD" decimals="-3">-25770000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_151" unitRef="USD" decimals="-3">-32087000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2017To12_31_2017" id="Factid_152" unitRef="USD" decimals="-3">-9994000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P01_01_2015To12_31_2015" id="Factid_153" unitRef="USD" decimals="-3">1486000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="P01_01_2016To12_31_2016" id="Factid_154" unitRef="USD" decimals="-3">-11000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2015To12_31_2015" id="Factid_155" unitRef="USD" decimals="-3">-24284000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_156" unitRef="USD" decimals="-3">-32098000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_157" unitRef="USD" decimals="-3">-9994000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_158" unitRef="USD" decimals="-3">20000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2015To12_31_2015" id="Factid_159" unitRef="USD" decimals="-3">-512000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_160" unitRef="USD" decimals="-3">-967000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2017To12_31_2017" id="Factid_161" unitRef="USD" decimals="-3">-1119000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2015To12_31_2015" id="Factid_162" unitRef="USD" decimals="-3">39387000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_163" unitRef="USD" decimals="-3">-967000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_164" unitRef="USD" decimals="-3">-1119000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="P01_01_2017To12_31_2017" id="Factid_165" unitRef="USD" decimals="-3">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>

  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2015To12_31_2015" id="Factid_166" unitRef="USD" decimals="-3">-45000</us-gaap:IncreaseDecreaseInRestrictedCash>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2015To12_31_2015" id="Factid_167" unitRef="USD" decimals="-3">362000</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInInventories contextRef="P01_01_2015To12_31_2015" id="Factid_168" unitRef="USD" decimals="-3">2316000</us-gaap:IncreaseDecreaseInInventories>

  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="P01_01_2015To12_31_2015" id="Factid_169" unitRef="USD" decimals="-3">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P01_01_2017To12_31_2017" id="Factid_170" unitRef="USD" decimals="-3">9542000</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:AmortizationOfFinancingCosts contextRef="P01_01_2015To12_31_2015" id="Factid_171" unitRef="USD" decimals="-3">445000</us-gaap:AmortizationOfFinancingCosts>

  <us-gaap:AmortizationOfFinancingCosts contextRef="P01_01_2016To12_31_2016" id="Factid_172" unitRef="USD" decimals="-3">568000</us-gaap:AmortizationOfFinancingCosts>

  <us-gaap:AmortizationOfFinancingCosts contextRef="P01_01_2017To12_31_2017" id="Factid_173" unitRef="USD" decimals="-3">2334000</us-gaap:AmortizationOfFinancingCosts>

  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage contextRef="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRusgaapStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis" id="Factid_174" unitRef="pure" decimals="0">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>

  <plx:ProceedsFromExchangeForRightsToRoyalties contextRef="P10_01_2015To10_31_2015_PfizerAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_175" unitRef="USD" decimals="-5">36000000</plx:ProceedsFromExchangeForRightsToRoyalties>

  <plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase contextRef="P01_01_2017To12_31_2017_BRusgaapStatementGeographicalAxis" id="Factid_176" unitRef="pure" decimals="1">0.1</plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017" id="Factid_177" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To12_31_2015" id="Factid_178" unitRef="shares" decimals="INF">19778424</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017" id="Factid_179" unitRef="shares" decimals="INF">76848199</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016" id="Factid_180" unitRef="shares" decimals="INF">23532492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn10_31_2015_PfizerMemberusgaapTypeOfArrangementAxis" id="Factid_181" unitRef="USD" decimals="-5">4300000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_182" unitRef="USD" decimals="-3">16265000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_183" unitRef="USD" decimals="-3">16561000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_FurnitureAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_184" unitRef="USD" decimals="-3">2342000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_FurnitureAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_185" unitRef="USD" decimals="-3">2438000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_186" unitRef="USD" decimals="-3">15678000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_187" unitRef="USD" decimals="-3">16123000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_EquipmentUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_188" unitRef="USD" decimals="-3">19000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_EquipmentUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_189" unitRef="USD" decimals="-3">19000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2016" id="Factid_190" unitRef="USD" decimals="-3">25601000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2017" id="Factid_191" unitRef="USD" decimals="-3">27465000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="PAsOn12_31_2016" id="Factid_192" unitRef="USD" decimals="-3">2591000</us-gaap:InventoryRawMaterialsNetOfReserves>

  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="PAsOn12_31_2017" id="Factid_193" unitRef="USD" decimals="-3">3838000</us-gaap:InventoryRawMaterialsNetOfReserves>

  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="PAsOn12_31_2016" id="Factid_194" unitRef="USD" decimals="-3">2259000</us-gaap:InventoryFinishedGoodsNetOfReserves>

  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="PAsOn12_31_2017" id="Factid_195" unitRef="USD" decimals="-3">3510000</us-gaap:InventoryFinishedGoodsNetOfReserves>

  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="PAsOn12_31_2017" id="Factid_196" unitRef="USD" decimals="-3">485000</us-gaap:InventoryWorkInProcessNetOfReserves>

  <plx:EmployeeSeveranceObligationPayment contextRef="P01_01_2015To12_31_2015" id="Factid_197" unitRef="USD" decimals="0">168000</plx:EmployeeSeveranceObligationPayment>

  <plx:EmployeeSeveranceObligationPayment contextRef="P01_01_2016To12_31_2016" id="Factid_198" unitRef="USD" decimals="0">164000</plx:EmployeeSeveranceObligationPayment>

  <plx:EmployeeSeveranceObligationPayment contextRef="P01_01_2017To12_31_2017" id="Factid_199" unitRef="USD" decimals="0">166000</plx:EmployeeSeveranceObligationPayment>

  <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="P01_01_2015To12_31_2015" id="Factid_200" unitRef="USD" decimals="0">800000</us-gaap:PostemploymentBenefitsPeriodExpense>

  <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="P01_01_2017To12_31_2017" id="Factid_201" unitRef="USD" decimals="0">906000</us-gaap:PostemploymentBenefitsPeriodExpense>

  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="P01_01_2015To12_31_2015" id="Factid_202" unitRef="USD" decimals="0">675000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>

  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="P01_01_2016To12_31_2016" id="Factid_203" unitRef="USD" decimals="0">675000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>

  <us-gaap:PostemploymentBenefitsPeriodExpense contextRef="P01_01_2016To12_31_2016" id="Factid_204" unitRef="USD" decimals="0">842000</us-gaap:PostemploymentBenefitsPeriodExpense>

  <plx:BenefitsPayableDuringNextFiveYears contextRef="PAsOn12_31_2017" id="Factid_205" unitRef="USD" decimals="0">250000</plx:BenefitsPayableDuringNextFiveYears>

  <plx:RoyaltiesOnSaleOfProducts contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_206" unitRef="pure" decimals="2">0.03</plx:RoyaltiesOnSaleOfProducts>

  <plx:RoyaltiesOnSaleOfProducts contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_207" unitRef="pure" decimals="2">0.06</plx:RoyaltiesOnSaleOfProducts>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2015To12_31_2015_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_208" unitRef="USD" decimals="-5">2200000</us-gaap:RoyaltyExpense>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2016To12_31_2016_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_209" unitRef="USD" decimals="0">288000</us-gaap:RoyaltyExpense>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2017To12_31_2017_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_210" unitRef="USD" decimals="0">1384000</us-gaap:RoyaltyExpense>

  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="PAsOn12_31_2017_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_211" unitRef="USD" decimals="-5">42200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>

  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="PAsOn12_31_2016_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_212" unitRef="USD" decimals="-5">38500000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2015To12_31_2015_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_213" unitRef="USD" decimals="0">51000</us-gaap:RoyaltyExpense>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2016To12_31_2016_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_214" unitRef="USD" decimals="0">286000</us-gaap:RoyaltyExpense>

  <plx:MilestonePotentialPayable contextRef="P01_01_2017To12_31_2017" id="Factid_215" unitRef="USD" decimals="-5">14300000</plx:MilestonePotentialPayable>

  <plx:MilestonePaymentAmountPaid contextRef="P01_01_2016To12_31_2016" id="Factid_216" unitRef="USD" decimals="0">300000</plx:MilestonePaymentAmountPaid>

  <plx:CommitmentAmount contextRef="P01_01_2017To12_31_2017" id="Factid_217" unitRef="USD" decimals="-5">19200000</plx:CommitmentAmount>

  <plx:MonthlyRentLeaseExpense contextRef="P01_01_2017To12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_218" unitRef="USD" decimals="0">65000</plx:MonthlyRentLeaseExpense>

  <us-gaap:SecurityDeposit contextRef="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_219" unitRef="USD" decimals="0">306000</us-gaap:SecurityDeposit>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_220" unitRef="USD" decimals="0">783000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_221" unitRef="USD" decimals="0">717000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_222" unitRef="USD" decimals="0">717000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="PAsOn12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_223" unitRef="USD" decimals="0">580000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>

  <plx:MonthlyRentLeaseExpense contextRef="P01_01_2017To12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_224" unitRef="USD" decimals="0">52000</plx:MonthlyRentLeaseExpense>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="PAsOn12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_225" unitRef="USD" decimals="0">565000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="PAsOn12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_226" unitRef="USD" decimals="0">186000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="PAsOn12_31_2017_VehicleLeaseAndMaintenanceAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_227" unitRef="USD" decimals="0">385000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn12_31_2017" id="Factid_228" unitRef="shares" decimals="INF">2554075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn12_31_2017" id="Factid_229" unitRef="USD" decimals="0">130000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2017To12_31_2017" id="Factid_230">P6M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2014_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_231" unitRef="shares" decimals="INF">5870309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_232" unitRef="shares" decimals="INF">6952293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_233" unitRef="shares" decimals="INF">4884211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_234" unitRef="USD_per_Share" decimals="2">3.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_235" unitRef="USD_per_Share" decimals="3">3.363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_236" unitRef="USD_per_Share" decimals="3">3.617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_237" unitRef="USD_per_Share" decimals="2">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_238" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_239" unitRef="shares" decimals="INF">1909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_240" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_241" unitRef="shares" decimals="INF">277016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_242" unitRef="shares" decimals="INF">1514957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_243" unitRef="shares" decimals="INF">154594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_244" unitRef="USD_per_Share" decimals="3">5.395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_245" unitRef="USD_per_Share" decimals="3">3.748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_246" unitRef="USD_per_Share" decimals="3">4.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_247" unitRef="USD_per_Share" decimals="3">0.972</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_248" unitRef="USD_per_Share" decimals="3">0.067</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_249" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_250" unitRef="shares" decimals="INF">550000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_251" unitRef="shares" decimals="INF">553125</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_252" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_253" unitRef="shares" decimals="INF">4729617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_254" unitRef="USD_per_Share" decimals="3">3.604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2014_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_255" unitRef="shares" decimals="INF">386124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_256" unitRef="shares" decimals="INF">127874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2015To12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_257" unitRef="shares" decimals="INF">255749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2016To12_31_2016_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_258" unitRef="shares" decimals="INF">127874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2015To12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_259" unitRef="shares" decimals="INF">2501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2016To12_31_2016_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_260" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2016_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_261" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2014_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_262" unitRef="shares" decimals="INF">1208592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_263" unitRef="shares" decimals="INF">637209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_264" unitRef="shares" decimals="INF">208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_265" unitRef="USD_per_Share" decimals="3">6.136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_266" unitRef="USD_per_Share" decimals="3">11.638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_267" unitRef="USD_per_Share" decimals="3">3.156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <plx:StockIssuedDuringPeriodSharesStockExpired contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_268" unitRef="shares" decimals="INF">429209</plx:StockIssuedDuringPeriodSharesStockExpired>

  <plx:StockIssuedDuringPeriodSharesStockExpired contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_269" unitRef="shares" decimals="INF">8000</plx:StockIssuedDuringPeriodSharesStockExpired>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_270" unitRef="USD_per_Share" decimals="3">15.748</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_271" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_272" unitRef="USD_per_Share" decimals="3">3.282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_273" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="P01_01_2016To12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_274" unitRef="shares" decimals="INF">0</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2015To12_31_2015_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_275" unitRef="USD" decimals="-3">904000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2015To12_31_2015_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_276" unitRef="USD" decimals="-3">898000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2016To12_31_2016_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_277" unitRef="USD" decimals="-3">571000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2016To12_31_2016_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_278" unitRef="USD" decimals="-3">417000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_279" unitRef="USD" decimals="-3">182000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_280" unitRef="USD" decimals="-3">155000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P10_01_2015To10_12_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_281" unitRef="shares" decimals="INF">5649079</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P12_01_2016To12_07_2016" id="Factid_282" unitRef="shares" decimals="INF">23846735</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P12_01_2016To12_07_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_283" unitRef="USD" decimals="-3">54052000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_07_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_284" unitRef="pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P12_01_2016To12_07_2016_ConvertibleNotesDueTwoThousandTwentyOneMemberusgaapDebtInstrumentAxis" id="Factid_285" unitRef="USD" decimals="-3">40186000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <plx:DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption contextRef="PAsOn09_18_2013" id="Factid_286" unitRef="USD" decimals="-5">9000000</plx:DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn09_18_2013_ConvertibleNotes2013MemberusgaapDebtInstrumentAxis" id="Factid_287" unitRef="pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn09_18_2013_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_288" unitRef="USD" decimals="-5">69000000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P12_01_2016To12_31_2016_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_289" unitRef="USD" decimals="-5">54100000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <plx:DebtInstrumentConvertibleConversionShareNumber contextRef="PAsOn09_18_2013" id="Factid_290" unitRef="shares" decimals="INF">173.6593</plx:DebtInstrumentConvertibleConversionShareNumber>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn09_18_2013_ConvertibleNotes2013MemberusgaapDebtInstrumentAxis" id="Factid_291" unitRef="USD_per_Share" decimals="2">5.76</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2015To12_31_2015_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_292" unitRef="USD" decimals="-3">3105000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <plx:AmortizationOfDebtIssuanceCosts contextRef="P01_01_2015To12_31_2015_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_293" unitRef="USD" decimals="-3">444000</plx:AmortizationOfDebtIssuanceCosts>

  <plx:AmortizationOfDebtIssuanceCosts contextRef="P01_01_2016To12_31_2016_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_294" unitRef="USD" decimals="-3">421000</plx:AmortizationOfDebtIssuanceCosts>

  <plx:AmortizationOfDebtIssuanceCosts contextRef="P01_01_2017To12_31_2017_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_295" unitRef="USD" decimals="-3">71000</plx:AmortizationOfDebtIssuanceCosts>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2016To12_31_2016_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_296" unitRef="USD" decimals="-3">2943000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2017To12_31_2017_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_297" unitRef="USD" decimals="-3">501000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <us-gaap:InterestExpense contextRef="P01_01_2015To12_31_2015_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_298" unitRef="USD" decimals="-3">3549000</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2016To12_31_2016_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_299" unitRef="USD" decimals="-3">3364000</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2017To12_31_2017_Notes2013MemberusgaapDebtInstrumentAxis" id="Factid_300" unitRef="USD" decimals="-3">572000</us-gaap:InterestExpense>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn12_02_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_301" unitRef="USD" decimals="-5">22500000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn12_07_2016_ConvertibleNotesDueTwoThousandTwentyOneMemberusgaapDebtInstrumentAxis" id="Factid_302" unitRef="USD" decimals="-3">40186000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_303" unitRef="pure" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_304" unitRef="USD_per_Share" decimals="2">0.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <plx:DebtInstrumentConvertibleBaseValueForConversionRate contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_305" unitRef="USD" decimals="0">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_306" unitRef="USD" decimals="-5">14100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <plx:PercentageOfExcessSharesOutstanding contextRef="P01_01_2017To12_31_2017" id="Factid_307" unitRef="pure" decimals="1">0.2</plx:PercentageOfExcessSharesOutstanding>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P12_01_2016To12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_308">P4Y11M8D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P07_01_2017To07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_309">P4Y3M25D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P12_01_2016To12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_310" unitRef="pure" decimals="4">0.0186</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2017To07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_311" unitRef="pure" decimals="4">0.0174</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P12_01_2016To12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_312" unitRef="pure" decimals="4">0.5412</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2017To07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_313" unitRef="pure" decimals="4">0.6379</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P12_01_2016To12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_314" unitRef="pure" decimals="4">0.1398</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:SharePrice contextRef="PAsOn07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_315" unitRef="USD_per_Share" decimals="2">0.77</us-gaap:SharePrice>

  <us-gaap:SharePrice contextRef="PAsOn12_07_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_316" unitRef="USD_per_Share" decimals="1">0.3</us-gaap:SharePrice>

  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_317" unitRef="USD" decimals="-5">5700000</us-gaap:ConvertibleDebtFairValueDisclosures>

  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_318" unitRef="USD" decimals="-5">76600000</us-gaap:ConvertibleDebtFairValueDisclosures>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2016" id="Factid_319" unitRef="USD" decimals="-3">693000</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:ConvertibleDebtCurrent contextRef="PAsOn12_31_2016" id="Factid_320" unitRef="USD" decimals="-3">53872000</us-gaap:ConvertibleDebtCurrent>

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2017" id="Factid_321" unitRef="USD" decimals="-3">26851000</us-gaap:DeferredRevenueNoncurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2017" id="Factid_322" unitRef="USD" xsi:nil="true" />

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2016" id="Factid_323" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2016" id="Factid_324" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2017" id="Factid_325" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016" id="Factid_326" unitRef="USD" decimals="-3">124000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2017" id="Factid_327" unitRef="USD" decimals="-3">144000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_328" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2017" id="Factid_329" unitRef="shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_330" unitRef="shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_331" unitRef="shares" decimals="INF">124134085</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2017" id="Factid_332" unitRef="shares" decimals="INF">143728797</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_333" unitRef="shares" decimals="INF">124134085</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2017" id="Factid_334" unitRef="shares" decimals="INF">143728797</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="P01_01_2015To12_31_2015" id="Factid_335" unitRef="USD" xsi:nil="true" />

  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="P01_01_2016To12_31_2016" id="Factid_336" unitRef="USD" decimals="-3">-6473000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>

  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="P01_01_2017To12_31_2017" id="Factid_337" unitRef="USD" decimals="-3">-38061000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2015To12_31_2015" id="Factid_338" unitRef="USD" xsi:nil="true" />

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2016To12_31_2016" id="Factid_339" unitRef="USD" decimals="-3">14063000</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_340">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 13 - RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;TEXT-INDENT: -13px; MARGIN-LEFT: 13px"&gt; Compensation (including share based compensation)&lt;br/&gt; to the non-executive directors (includes the&lt;br/&gt; interim Chairman of the Board through 2015 and&lt;br/&gt; the Chairman of the Board for part of 2015)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;631&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;560&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;499&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_341">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month&amp;#8217;s salary for each year employed) is recorded on the Company&amp;#8217;s balance sheets under &amp;#8220;Liability for employee rights upon retirement.&amp;#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&amp;#8217;s balance sheets under &amp;#8220;Funds in respect of employee rights upon retirement.&amp;#8221; These policies are the Company&amp;#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2015, 2016 and 2017, the Company deposited approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;168,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;164,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;166,000&lt;/font&gt;, respectively, with insurance companies in connection with its severance payment obligations.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&amp;#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&amp;#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &amp;#8220;Contribution Plans&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The amounts of severance pay expenses were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;800,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;842,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;906,000&lt;/font&gt; for each of the years ended December 31, 2015, 2016 and 2017, respectively, of which approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;675,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;675,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;746,000&lt;/font&gt; in the years ended December 31, 2015, 2016 and 2017, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately ($18,000), ($7,000) and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;21,000&lt;/font&gt; for the years ended December 31, 2015, 2016 and 2017, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company expects to contribute approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;830,000&lt;/font&gt; in the year ending December 31, 2018 to insurance companies in connection with its severance liabilities for its operations for that year, approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;664,000&lt;/font&gt; of which will be contributed to one or more Contribution Plans.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;During the five-year period following December 31, 2017, the Company expects to pay future benefits to three employees upon each such employee&amp;#8217;s normal retirement age. The Company anticipates that the benefits payable will be approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>

  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="P01_01_2015To12_31_2015_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_342" unitRef="USD" decimals="-3">631000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>

  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="P01_01_2016To12_31_2016_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_343" unitRef="USD" decimals="-3">560000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>

  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="P01_01_2017To12_31_2017_CompensationToTheNon-executiveDirectorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_344" unitRef="USD" decimals="-3">499000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014" id="Factid_345" unitRef="USD" decimals="-3">-55601000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_346" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_347" unitRef="USD" decimals="-3">185633000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_348" unitRef="USD" decimals="-3">-241328000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_349" unitRef="shares" decimals="INF">93603819</us-gaap:SharesOutstanding>

  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="P01_01_2017To12_31_2017" id="Factid_350" unitRef="USD" decimals="0">746000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015" id="Factid_351" unitRef="USD" decimals="-3">10873000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_352" unitRef="USD" decimals="-3">100000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_353" unitRef="USD" decimals="-3">194064000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_354" unitRef="USD" decimals="-3">-183291000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_355" unitRef="USD" decimals="-3">124000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_356" unitRef="USD" decimals="-3">-212656000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_357" unitRef="USD" decimals="-3">202575000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_358" unitRef="USD" decimals="-3">-297932000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_359" unitRef="USD" decimals="-3">266495000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_360" unitRef="USD" decimals="-3">144000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_361" unitRef="shares" decimals="INF">143728797</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_362" unitRef="shares" decimals="INF">124134085</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_363" unitRef="shares" decimals="INF">99800397</us-gaap:SharesOutstanding>

  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_364">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 12 - DISCONTINUED OPERATIONS&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As mentioned in note 2, the Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No.&amp;#160;2014-08.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The following summarizes financial information related to the Company&amp;#8217;s discontinued operations, in the Company&amp;#8217;s consolidated statements of operations:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;REVENUES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;48,674&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;COMPANY&amp;#8217;S SHARE IN COLLABORATION AGREEMENT&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,048&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;COST OF REVENUES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,697)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(373)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;GROSS PROFIT (LOSS)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;46,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(164)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(586)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Less &amp;#150;reimbursements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;545&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;RESEARCH AND DEVELOPMENT EXPENSES, NET&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(41)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(564)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(25)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;45,420&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(189)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;GAIN ON THE DISPOSAL&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;39,899&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;NET (LOSS) INCOME&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85,319&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(189)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2015To12_31_2015" id="Factid_365" unitRef="USD" decimals="-3">6101000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016" id="Factid_366" unitRef="USD" decimals="-3">6848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_367" unitRef="USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2015To12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_368" unitRef="USD" decimals="-3">6095000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_369" unitRef="USD" decimals="-3">24000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_370" unitRef="USD" decimals="-3">6824000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_371" unitRef="shares" decimals="INF">5649079</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_372" unitRef="shares" decimals="INF">23846735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax contextRef="P01_01_2017To12_31_2017" id="Factid_373" unitRef="USD" decimals="0">21000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="P01_01_2016To12_31_2016" id="Factid_374" unitRef="USD" decimals="-3">685000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="P01_01_2017To12_31_2017" id="Factid_375" unitRef="USD" decimals="-3">1315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_376" unitRef="USD" decimals="-3">685000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_377" unitRef="USD" decimals="-3">1315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2015To12_31_2015" id="Factid_378" unitRef="USD" decimals="-3">1273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016" id="Factid_379" unitRef="USD" decimals="-3">920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017" id="Factid_380" unitRef="USD" decimals="-3">337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2015To12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_381" unitRef="USD" decimals="-3">1273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_382" unitRef="USD" decimals="-3">920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_383" unitRef="USD" decimals="-3">337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="P01_01_2015To12_31_2015" id="Factid_384" unitRef="USD" decimals="-3">529000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="P01_01_2016To12_31_2016" id="Factid_385" unitRef="USD" decimals="-3">68000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="P01_01_2015To12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_386" unitRef="USD" decimals="-3">529000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_387" unitRef="USD" decimals="-3">68000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_388" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_389">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 6 - COMMITMENTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Royalty Commitments&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company is obligated to pay royalties to the National Authority for Technological Innovation (&amp;#8220;NATI&amp;#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Chief Scientist of the Israeli Department of Labor&amp;#160;&amp;#160;(&amp;#8220;OCS&amp;#8221;). At the time the grants were received, successful development of the related projects was not assured.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the OCS.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the terms of the applicable funding arrangements, royalties of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;% are payable on the sale of products developed from projects funded by NATI or the OCS, which payments shall not exceed, in the aggregate, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;&lt;/font&gt;% of the amount of the grant received (dollar linked), plus, commencing upon January&amp;#160;1, 2001, interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 300&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Royalty expenses to NATI or the OCS are included in the statement of operations as a component of the cost of revenues both in continuing and discontinued operations and were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.2&lt;/font&gt;&amp;#160;million, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;288,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,384,000&lt;/font&gt; during the years ended December&amp;#160;31, 2015, 2016 and 2017, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;At December 31, 2016 and 2017, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;38.5&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;42.2&lt;/font&gt; million, respectively (without interest, assuming &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of the funds are payable).&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues both in continuing and discontinued operations and were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;51,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;286,000&lt;/font&gt; and&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; during the years ended December&amp;#160;31, 2015, 2016 and 2017, respectively.&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments total payable would be approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.3&lt;/font&gt; million and would be payable, if at all, as the Company&amp;#8217;s projects progress over the course of a number of years. Milestone payments of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;300,000&lt;/font&gt; and &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/font&gt; were made during the years ended December&amp;#160;31, 2015, 2016 and 2017, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Subcontracting Agreements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December 31, 2017, total commitments under said agreements were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19.2&lt;/font&gt; million.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Lease Agreements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each, for a total of 10 additional years. Under the leases, the aggregate monthly rental payments are approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;65,000&lt;/font&gt;. As of December 31, 2017, the Company provided bank guarantees of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;306,000&lt;/font&gt; in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required under the operating leases for such premises are approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;783,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;717,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;717,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;580,000&lt;/font&gt;, for fiscal years 2018 through 2021, respectively. Lease expenses totaled approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt;&lt;/font&gt; million for each of the years ended December 31, 2015, 2016 and approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;775,000&lt;/font&gt; for the year ended December 31,2017, respectively.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Vehicle Lease and Maintenance Agreements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;52,000&lt;/font&gt;. The expected lease payments for the years ending December 31, 2018, 2019 and 2020 are approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;565,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;385,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;186,000&lt;/font&gt;, respectively.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsDisclosureTextBlock>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares contextRef="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_390" unitRef="shares" decimals="INF">2501</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>

  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_391" unitRef="shares" decimals="INF">-7843</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2015To12_31_2015" id="Factid_392" unitRef="USD" decimals="-3">534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2016To12_31_2016" id="Factid_393" unitRef="USD" decimals="-3">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2015To12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_394" unitRef="USD" decimals="-3">534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_395" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_396" unitRef="USD" xsi:nil="true" />

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_397" unitRef="USD" decimals="-3">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2015To12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_398" unitRef="shares" decimals="INF">550000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_399" unitRef="shares" decimals="INF">479110</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2015To12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_400" unitRef="USD" decimals="-3">-27282000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_401" unitRef="USD" decimals="-3">-29176000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2015To12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_402" unitRef="USD" decimals="-3">85319000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_403" unitRef="USD" decimals="-3">-189000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="P01_01_2015To12_31_2015" id="Factid_404" unitRef="USD" decimals="-3">48674000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="P01_01_2016To12_31_2016" id="Factid_405" unitRef="USD" decimals="-3">209000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>

  <plx:DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement contextRef="P01_01_2015To12_31_2015" id="Factid_406" unitRef="USD" decimals="-3">5048000</plx:DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="P01_01_2015To12_31_2015" id="Factid_407" unitRef="USD" decimals="-3">7697000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="P01_01_2016To12_31_2016" id="Factid_408" unitRef="USD" decimals="-3">373000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="P01_01_2017To12_31_2017" id="Factid_409" unitRef="USD" decimals="-3">43634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_410" unitRef="USD" decimals="-3">43634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="P01_01_2015To12_31_2015" id="Factid_411" unitRef="USD" decimals="-3">46025000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="P01_01_2016To12_31_2016" id="Factid_412" unitRef="USD" decimals="-3">-164000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>

  <plx:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense contextRef="P01_01_2015To12_31_2015" id="Factid_413" unitRef="USD" decimals="-3">-586000</plx:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>

  <plx:DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable contextRef="P01_01_2015To12_31_2015" id="Factid_414" unitRef="USD" decimals="-3">545000</plx:DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable>

  <plx:DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet contextRef="P01_01_2015To12_31_2015" id="Factid_415" unitRef="USD" decimals="-3">-41000</plx:DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="P01_01_2015To12_31_2015" id="Factid_416" unitRef="USD" decimals="-3">564000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>

  <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="P01_01_2016To12_31_2016" id="Factid_417" unitRef="USD" decimals="-3">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017" id="Factid_418" unitRef="USD" decimals="-3">18654000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_419" unitRef="USD" decimals="-3">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_420" unitRef="USD" decimals="-3">18634000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P01_01_2015To12_31_2015" id="Factid_421" unitRef="USD" decimals="-3">45420000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="P01_01_2016To12_31_2016" id="Factid_422" unitRef="USD" decimals="-3">-189000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>

  <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax contextRef="P01_01_2015To12_31_2015" id="Factid_423" unitRef="USD" decimals="-3">-39899000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_424" unitRef="shares" decimals="INF">19594712</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_425">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The following summarizes financial information related to the Company&amp;#8217;s discontinued operations, in the Company&amp;#8217;s consolidated statements of operations:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;REVENUES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;48,674&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;COMPANY&amp;#8217;S SHARE IN COLLABORATION AGREEMENT&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,048&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;COST OF REVENUES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,697)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(373)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;GROSS PROFIT (LOSS)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;46,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(164)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(586)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Less &amp;#150;reimbursements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;545&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;RESEARCH AND DEVELOPMENT EXPENSES, NET&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(41)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(564)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(25)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;45,420&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(189)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;GAIN ON THE DISPOSAL&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;39,899&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;NET (LOSS) INCOME&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85,319&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(189)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="P01_01_2015To12_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_426" unitRef="shares" decimals="INF">2501</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>

  <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_427">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 11 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Balance sheets:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other&amp;#160;assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Institutions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;394&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;State of Israel (see note 6a)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,046&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;195&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;477&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;623&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;433&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets of discontinued operation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;327&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Sundry&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;49&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,648&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,934&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accounts&amp;#160;payable&amp;#160;and&amp;#160;accruals&amp;#160;&amp;#150;&amp;#160;other:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Payroll and related expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,190&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,386&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Interest payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;511&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;645&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Provision for vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,399&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,575&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,802&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Royalties payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;226&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;301&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property and equipment suppliers&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;595&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;526&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,496&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,310&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Statements of operations:&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 28.4pt"&gt; &amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 15px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Revenues:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Pfizer&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,226&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;12,181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,973&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,061&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,199&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19,242&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>

  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="P01_01_2015To12_31_2015" id="Factid_428" unitRef="USD" decimals="-3">59000</us-gaap:PensionAndOtherPostretirementBenefitExpense>

  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="P01_01_2016To12_31_2016" id="Factid_429" unitRef="USD" decimals="-3">10000</us-gaap:PensionAndOtherPostretirementBenefitExpense>

  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="P01_01_2017To12_31_2017" id="Factid_430" unitRef="USD" decimals="-3">-18000</us-gaap:PensionAndOtherPostretirementBenefitExpense>

  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement contextRef="P01_01_2015To12_31_2015" id="Factid_431" unitRef="USD" decimals="-3">-18000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>

  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement contextRef="P01_01_2016To12_31_2016" id="Factid_432" unitRef="USD" decimals="-3">-7000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>

  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement contextRef="P01_01_2017To12_31_2017" id="Factid_433" unitRef="USD" decimals="-3">21000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>

  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="P01_01_2015To12_31_2015" id="Factid_434" unitRef="USD" decimals="-3">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>

  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_435" unitRef="USD" decimals="-3">7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>

  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="P01_01_2017To12_31_2017" id="Factid_436" unitRef="USD" decimals="-3">-6000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2015To12_31_2015_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_437" unitRef="USD" decimals="-5">1000000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2016To12_31_2016_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_438" unitRef="USD" decimals="-5">1000000</us-gaap:OperatingLeasesRentExpenseNet>

  <plx:IncomeOnConversionOfConvertibleNotes contextRef="P01_01_2017To12_31_2017" id="Factid_439" unitRef="USD" decimals="-3">116000</plx:IncomeOnConversionOfConvertibleNotes>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2017To12_31_2017_LeaseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_440" unitRef="USD" decimals="0">775000</us-gaap:OperatingLeasesRentExpenseNet>

  <plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes contextRef="P01_01_2017To12_31_2017" id="Factid_441" unitRef="USD" decimals="-3">2391000</plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="P01_01_2017To12_31_2017" id="Factid_442" unitRef="USD" decimals="-3">750000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>

  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="P01_01_2015To12_31_2015" id="Factid_443" unitRef="USD" decimals="-3">39899000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>

  <us-gaap:RepaymentsOfConvertibleDebt contextRef="P01_01_2017To12_31_2017" id="Factid_444" unitRef="USD" decimals="-3">10961000</us-gaap:RepaymentsOfConvertibleDebt>

  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_445" unitRef="USD" decimals="-3">1190000</us-gaap:EmployeeRelatedLiabilitiesCurrent>

  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_446" unitRef="USD" decimals="-3">1386000</us-gaap:EmployeeRelatedLiabilitiesCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_447" unitRef="USD" decimals="-3">511000</us-gaap:InterestPayableCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_448" unitRef="USD" decimals="-3">645000</us-gaap:InterestPayableCurrent>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P01_01_2016To12_31_2016" id="Factid_449" unitRef="USD" decimals="-3">19681000</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:AccruedVacationCurrent contextRef="PAsOn12_31_2016" id="Factid_450" unitRef="USD" decimals="-3">1399000</us-gaap:AccruedVacationCurrent>

  <us-gaap:AccruedVacationCurrent contextRef="PAsOn12_31_2017" id="Factid_451" unitRef="USD" decimals="-3">1650000</us-gaap:AccruedVacationCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_452" unitRef="USD" decimals="-3">3575000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_453" unitRef="USD" decimals="-3">4802000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedRoyaltiesCurrent contextRef="PAsOn12_31_2016" id="Factid_454" unitRef="USD" decimals="-3">226000</us-gaap:AccruedRoyaltiesCurrent>

  <us-gaap:AccruedRoyaltiesCurrent contextRef="PAsOn12_31_2017" id="Factid_455" unitRef="USD" decimals="-3">301000</us-gaap:AccruedRoyaltiesCurrent>

  <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent contextRef="PAsOn12_31_2016" id="Factid_456" unitRef="USD" decimals="-3">595000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>

  <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent contextRef="PAsOn12_31_2017" id="Factid_457" unitRef="USD" decimals="-3">526000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>

  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses contextRef="P01_01_2015To12_31_2015" id="Factid_458" unitRef="USD" decimals="-3">6101000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_459" unitRef="USD" decimals="-3">7496000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_460" unitRef="USD" decimals="-3">9310000</us-gaap:AccountsPayableCurrent>

  <plx:MilestonePaymentAmountPaid contextRef="P01_01_2015To12_31_2015" id="Factid_461" unitRef="USD" decimals="0">0</plx:MilestonePaymentAmountPaid>

  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="P01_01_2015To12_31_2015" id="Factid_462" unitRef="USD" decimals="-3">489000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>

  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_463" unitRef="USD" decimals="-3">595000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>

  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="P01_01_2017To12_31_2017" id="Factid_464" unitRef="USD" decimals="-3">526000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>

  <us-gaap:NotesIssued1 contextRef="P01_01_2015To12_31_2015" id="Factid_465" unitRef="USD" decimals="-3">4301000</us-gaap:NotesIssued1>

  <us-gaap:StockIssued1 contextRef="P01_01_2016To12_31_2016" id="Factid_466" unitRef="USD" decimals="-3">6848000</us-gaap:StockIssued1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2017To12_31_2017" id="Factid_467" unitRef="USD" decimals="-3">16263000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_468">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 7 - SHARE CAPITAL&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Rights of the Company&amp;#8217;s Common Stock&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s Common Stock is listed on the NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Stock based compensation&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &amp;#8220;Plan&amp;#8221;). The Plan has since been amended to, among other things, increase the number of shares of common stock available under the Plan to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 13,841,655&lt;/font&gt; shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&amp;#160;102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&amp;#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2017, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,554,075&lt;/font&gt; shares of Common Stock remain available for grant under the Plan.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&amp;#8217;s management uses the fair value of the Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;From January 1, 2015 through December 31, 2017, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Options and restricted stock granted to employees:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Below is a table summarizing all of the options grants to employees during the year ended December 31, 2015:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt; &lt;div&gt;Year&amp;#160;of&lt;br/&gt; grant&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;No.&amp;#160;of&amp;#160;options&lt;br/&gt; granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Vesting&amp;#160;period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&lt;br/&gt; at&amp;#160;grant&lt;br/&gt; (U.S.&amp;#160;&lt;br/&gt; dollars&amp;#160;in&lt;br/&gt; thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Expiration&lt;br/&gt; period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,909,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1.72&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;4 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,900&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;10 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2017 (such grants appear in the table above):&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On March 23, 2015, the Company&amp;#8217;s compensation committee approved the grant of a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;-year option to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,909,000&lt;/font&gt; shares of Common Stock to its officers and other employees with an exercise price equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.72&lt;/font&gt; per share under the Plan. The options vest over a four-year period; the first &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% shares vest on the first anniversary of the grant date and the remaining shares vest in 12 equal quarterly increments over the subsequent three-year period. Vesting of the options granted to certain executive officers is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.9&lt;/font&gt; million based on the following weighted average assumptions: dividend yield of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% for all years; expected volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 61.7&lt;/font&gt;%; risk-free interest rates of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.6&lt;/font&gt;%; and expected life of six years.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The total unrecognized compensation cost of employee stock options at December 31, 2017 is approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;130,000&lt;/font&gt;. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.54&lt;/font&gt; years.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2015, 2016 and 2017 was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;534,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, respectively. The Company did not realize any tax benefit in connection with these exercises.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Options granted to consultants, directors, and other service providers:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;During the three years ended December 31, 2017 there were no option grants by the Company to its consultants, directors, and other service providers. In addition, during the three years ended December 31, 2017, there were no option exercises by any of the Company&amp;#8217;s consultants, directors, and other service providers and, consequently, no shares of Common Stock were issued in connection with exercises of options by, nor was any cash received from, the Company&amp;#8217;s consultants, directors, and other service providers during such period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;3.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;A summary of share option plans, and related information, under all of the Company&amp;#8217;s equity incentive plans for the years ended December&amp;#160;31, 2015, 2016 and 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Options granted to employees:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,870,309&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.770&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,952,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.363&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,884,211&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,909,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.72&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Forfeited and Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;277,016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.395&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,514,957&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.748&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;154,594&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercised (*)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;550,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.972&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;553,125&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.067&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,952,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.363&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,884,211&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,729,617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.604&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercisable at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,477,043&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.182&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,498,492&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.296&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,457,461&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(*) The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;675,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;213,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, respectively.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Restricted stock granted to employees:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;restricted&amp;#160;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;386,124&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;255,749&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Options and restricted stocks granted to consultants, directors, and other service providers:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at beginning of Year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,208,592&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.136&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;637,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.638&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;208,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.156&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;466,883&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;429,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.748&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Vested restricted stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;104,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;637,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.638&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;208,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.156&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.282&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercisable at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;549,709&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;170,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.282&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2017:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%" colspan="14"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="50%" colspan="8"&gt; &lt;div&gt;Options&amp;#160;outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%" colspan="5"&gt; &lt;div&gt;Options&amp;#160;exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercise&lt;br/&gt; prices&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;br/&gt; outstanding&lt;br/&gt; at&amp;#160;end&amp;#160;of&lt;br/&gt; year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;br/&gt; exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&amp;#160;(Restricted&amp;#160;Stock)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.720&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1,720,685&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1,617,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;900,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;731,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;211,682&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;211,682&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3.020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3.370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;150,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;150,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;5.000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;949,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;949,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.900&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;680,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;680,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.550&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;9.660&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;68,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;68,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4,929,617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4,657,461&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;e.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;904&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;571&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;182&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;Selling, general and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;898&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,802&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;988&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Private and 144A Offerings&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On October 12, 2015, the Company completed a private offering of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,649,079&lt;/font&gt; shares of the Company&amp;#8217;s common stock to Pfizer. See also note 2.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 7, 2016, the Company exchanged with certain existing note holders $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;54.052&lt;/font&gt; million aggregate principal amount of the Company&amp;#8217;s outstanding &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.50&lt;/font&gt;% Convertible Senior Notes due 2018 for, among other consideration, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40.186&lt;/font&gt; million aggregate principal amount of convertible notes due 2021 (as described in note 8b) and for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23,846,735&lt;/font&gt; shares of common stock. See also note 8b.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;3.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On July 24, 2017, the Company entered into a Note Purchase Agreement with certain institutional investors relating to the private issuance and sale by the Company of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; million in aggregate principal amount of its &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7.5&lt;/font&gt;% secured convertible promissory notes due &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2021&lt;/font&gt;. The 7.5% convertible notes were issued pursuant to the base indenture dated December 7, 2016 (the existing 2016 Notes). Concurrently, the Company exchanged with certain existing note holders $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0&lt;/font&gt; million aggregate principal amount of the Company&amp;#8217;s outstanding &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.50&lt;/font&gt;% Convertible Senior Notes due &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2018&lt;/font&gt; for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.55&lt;/font&gt; million aggregate principal amount of newly issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.50&lt;/font&gt;% Senior Convertible Notes due &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2022&lt;/font&gt;. See also note 8c.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:InterestPaidNet contextRef="P01_01_2015To12_31_2015" id="Factid_469" unitRef="USD" decimals="-3">3105000</us-gaap:InterestPaidNet>

  <us-gaap:InterestPaidNet contextRef="P01_01_2016To12_31_2016" id="Factid_470" unitRef="USD" decimals="-3">3659000</us-gaap:InterestPaidNet>

  <us-gaap:InterestPaidNet contextRef="P01_01_2017To12_31_2017" id="Factid_471" unitRef="USD" decimals="-3">4854000</us-gaap:InterestPaidNet>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_472">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 10 - TAXES ON INCOME&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company&amp;#8217;s income is taxed in the United States at the rate of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 39&lt;/font&gt;%.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act, which among other changes reduces the federal corporate tax rate to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 21&lt;/font&gt;%.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Protalix Ltd.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Tax rates&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The income of the Israeli Subsidiary, other than income from &amp;#8220;Approved Enterprises,&amp;#8221; is taxed in Israel at the regular corporate tax rates which were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 26.5&lt;/font&gt;% for fiscal year 2015.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 26.5&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;%.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23&lt;/font&gt;%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate was &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 24&lt;/font&gt;% in 2017 and will be &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23&lt;/font&gt;% in 2018 and thereafter.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Capital gain is subject to capital gain tax according to the corporate tax rate for the year during which the assets are sold.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Law for the Encouragement of Capital Investments, 1959 (the &amp;#8220;Encouragement of Capital Investments Law&amp;#8221;)&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &amp;#8220;Approved Enterprise&amp;#8221; or &amp;#8220;Benefited Enterprise&amp;#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.1pt; MARGIN: 0in 0in 0pt 1.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Reduced tax rates&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Israeli Subsidiary has an &amp;#8220;Approved Enterprise&amp;#8221; plan since 2004 and &amp;#8220;Benefited Enterprise&amp;#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &amp;#8220;Approved Enterprise&amp;#8221; or &amp;#8220;Benefited Enterprise&amp;#8221; during the tax exemption period, it will be subject to&amp;#160;tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable had such income not been exempted.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Accelerated depreciation&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Conditions for entitlement to the benefits&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Israeli Subsidiary&amp;#8217;s entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &amp;#8220;Approved Enterprise&amp;#8221; from the Investment Center.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In recent years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The amendment&amp;#160;sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.On December 29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &amp;#8220;Preferred Technological Enterprise&amp;#8221; and &amp;#8220;Special Preferred Technological Enterprise&amp;#8221; (the &amp;#8220;Capital Investments Law Amendment&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company elected not to have the Capital Investments Law Amendment apply to the Company.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Tax losses carried forward to future years&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2017, the Company had aggregate net operating loss (&amp;#8220;NOL&amp;#8221;) carry-forwards equal to approximately $207 million that are available to reduce future taxable income as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s carry-forward NOLs, equal to approximately $23 million (as of December 31, 2016, approximately $20 million), may be restricted under Section 382 of the Internal Revenue Code (&amp;#8220;IRC&amp;#8221;). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Protalix Ltd.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;At December 31, 2017, the Israeli Subsidiary had approximately $184 million (as of December 31, 2016, approximately $133 million) of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred income taxes:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The components of the Company&amp;#8217;s net deferred tax assets at December 31, 2016 and 2017 were as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In respect of:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Timing Differences&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net operating loss carry forwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;38,515&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;47,033&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(42,035)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(58,368)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;e.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Reconciliation of the theoretical tax expense to actual tax expense&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;f.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Tax assessments&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In accordance with the Income Tax Ordinance, as of December 31, 2017, all of Protalix Ltd.&amp;#8217;s tax assessments through tax year 2012 are considered final.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of open tax years by major jurisdiction is presented below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="MARGIN: auto auto auto 1in; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="65%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 52%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="52%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Jurisdiction:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 1pt; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="9%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 39%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="39%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Years:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Israel&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2013-2017&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;United States (*)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2013-2017&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_473">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; Below is a table summarizing all of the options grants to employees during the year ended December 31, 2015: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt; &lt;div&gt;Year&amp;#160;of&lt;br/&gt; grant&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;No.&amp;#160;of&amp;#160;options&lt;br/&gt; granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Vesting&amp;#160;period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&lt;br/&gt; at&amp;#160;grant&lt;br/&gt; (U.S.&amp;#160;&lt;br/&gt; dollars&amp;#160;in&lt;br/&gt; thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Expiration&lt;br/&gt; period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,909,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1.72&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;4 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;1,900&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;10 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_474">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Options granted to employees:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,870,309&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.770&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,952,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.363&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,884,211&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,909,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.72&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Forfeited and Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;277,016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.395&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,514,957&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.748&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;154,594&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercised (*)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;550,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.972&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;553,125&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.067&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,952,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.363&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,884,211&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,729,617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.604&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercisable at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,477,043&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.182&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,498,492&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.296&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,457,461&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(*) The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;675,000&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;213,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, respectively.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_475">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; Options and restricted stocks granted to consultants, directors, and other service providers: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;options/&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;restricted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at beginning of Year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,208,592&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.136&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;637,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.638&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;208,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.156&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;466,883&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;429,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.748&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Vested restricted stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;104,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;637,209&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.638&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;208,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.156&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.282&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"&gt; &lt;div&gt;Exercisable at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;549,709&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;170,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;200,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.282&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock>

  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_476">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;General&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s current strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&amp;#8220;Pfizer&amp;#8221;), as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &amp;#8220;Amended Pfizer Agreement&amp;#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36.0&lt;/font&gt; million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues. For further details see note 2.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#8220;Fiocruz&amp;#8221;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In 2017, the Company received a purchase order from the Brazilian Ministry of Health (the &amp;#8220;Brazilian Ministry&amp;#8221;) for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3 million. The purchase order consists of a number of shipments in increasing volumes. Shipments started in June 2017. The Company has recorded revenues of $7.1 million for sales of alfataliglicerase to Fiocruz in 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Ex-US license (the &amp;#8220;Chiesi Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase alfa. Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase in the United States.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25.0&lt;/font&gt; million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million in development costs, capped at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; million per year. Protalix Ltd. is also eligible to receive&amp;#160;additional paymentS of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;320&lt;/font&gt; million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the terms of the agreement, Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi will make tiered payments of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 35&lt;/font&gt;% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"&gt; as of December 31, 2017&lt;/font&gt;, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Basis of presentation&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Use of estimates in the preparation of financial statements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Functional currency&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&amp;#8217;s revenues are derived in dollars. Most of the Company&amp;#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&amp;#8217;s financing has been provided in dollars.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &amp;#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &amp;#150; historical exchange rates. Currency transaction gains and losses are recorded as financial income or expenses, as appropriate.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;e.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Cash equivalents&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;f.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Inventories&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &amp;#8220;moving average&amp;#8221; basis.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &amp;#8220;moving average&amp;#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;g.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Years&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;h.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Impairment in value of long-lived assets&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;i.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Income taxes&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used tax rates of 39%, 24% and 23%. See note 10.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Uncertainty in income taxes&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Tax benefits recognized in the financial statements are those that the Company&amp;#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&amp;#8217;s management deems more likely than not to be sustained.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;j.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenue Recognition&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenues from supply agreements and from selling products&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company recognizes revenues from supply agreements and from selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenues from Chiesi Agreement&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Since there is only one unit of account, all payments received by Chiesi prior to the satisfaction of Protalix's obligation will be deferred. Therefore,&amp;#160;the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million upfront payment and future research and development reimbursement payments (up to $25 million) and any potential additional development milestone payments will be deferred until the commencement of commercial manufacturing.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;k.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Research and development costs&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&amp;#8220;NATI&amp;#8221;), which has replaced many of the functions of the Office of the Chief Scientist of Israel&amp;#8217;s Ministry of Industry, Trade and Labor (the &amp;#8220;OCS&amp;#8221;), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;l.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Concentration of credit risks and trade receivable&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&amp;#8217;s trade receivables represent amounts to be received from Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;m.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Share-based compensation&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for employee&amp;#8217;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted are measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;n.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Net (loss) earnings per share&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s Common Stock, par value $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt; per share (the &amp;#8220;Common Stock&amp;#8221;) outstanding for each period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 19,778,424&lt;/font&gt;, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23,532,492&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 76,848,199&lt;/font&gt; shares of Common Stock underlying outstanding options, restricted shares of Common Stock and shares issuable upon conversion of the convertible notes for the fiscal years ended December 31, 2015, 2016 and 2017, respectively, because the effect would be anti-dilutive.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;o.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;All outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&amp;#8217;s nonconvertible debt borrowing rate. The Company accounts for the 2013 Notes (as defined in note 8a) as a liability, on an aggregated basis, in their entirety. The 2016 Notes (as defined in note 8b) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December 31, 2017, the embedded derivative was reclassified to additional paid in capital, see note 8.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Issuance costs regarding the issuance of the 2016 Notes and the 2017 Notes (as defined in note 8c) were allocated to the liability, equity component, derivative and shares based on their relative fair values. Issuance costs that were allocated to the liability are amortized using the effective interest rate, other than issuance costs that were allocated to the derivative which were expensed immediately.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The debt discount and debt issuance costs regarding the issuance of the 2013 Notes are deferred and amortized over the 2013 Notes period (5 years).&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;p.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Recently adopted standards&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued ASU 2016-09, &amp;#8220;Compensation - Stock Compensation (Topic 718)&amp;#8221; (&amp;#8220;ASU 2016-09&amp;#8221;) which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted this standard in the fourth quarter of 2016. The Company elected to account for forfeitures as they occur. The implementation of this ASU did not have a material impact on the consolidated financial statements.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;q.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Recently issued accounting pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; In May 2014, the FASB issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&amp;#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017. The implementation of this ASU did not have a material impact on the consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In January&amp;#160;2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in annual reporting periods beginning after December 15, 2017. The implementation of this ASU&amp;#160;is expected to have&amp;#160;no material impact on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>

  <plx:NatureOfOperationsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_477">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;General&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s current strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&amp;#8220;Pfizer&amp;#8221;), as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &amp;#8220;Amended Pfizer Agreement&amp;#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36.0&lt;/font&gt; million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues. For further details see note 2.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#8220;Fiocruz&amp;#8221;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In 2017, the Company received a purchase order from the Brazilian Ministry of Health (the &amp;#8220;Brazilian Ministry&amp;#8221;) for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3 million. The purchase order consists of a number of shipments in increasing volumes. Shipments started in June 2017. The Company has recorded revenues of $7.1 million for sales of alfataliglicerase to Fiocruz in 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Ex-US license (the &amp;#8220;Chiesi Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase alfa. Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase in the United States.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25.0&lt;/font&gt; million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million in development costs, capped at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; million per year. Protalix Ltd. is also eligible to receive&amp;#160;additional paymentS of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;320&lt;/font&gt; million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Under the terms of the agreement, Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi will make tiered payments of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 35&lt;/font&gt;% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"&gt; as of December 31, 2017&lt;/font&gt;, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:NatureOfOperationsPolicyTextBlock>

  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_478">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Basis of presentation&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2016" id="Factid_479" unitRef="USD" decimals="-3">3520000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <us-gaap:UseOfEstimates contextRef="P01_01_2017To12_31_2017" id="Factid_480">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Use of estimates in the preparation of financial statements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2016" id="Factid_481" unitRef="USD" decimals="-3">38515000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_482">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Functional currency&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&amp;#8217;s revenues are derived in dollars. Most of the Company&amp;#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&amp;#8217;s financing has been provided in dollars.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &amp;#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &amp;#150; historical exchange rates. Currency transaction gains and losses are recorded as financial income or expenses, as appropriate.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_483">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;e.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Cash equivalents&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_484">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2017: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%" colspan="14"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="50%" colspan="8"&gt; &lt;div&gt;Options&amp;#160;outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%" colspan="5"&gt; &lt;div&gt;Options&amp;#160;exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercise&lt;br/&gt; prices&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;br/&gt; outstanding&lt;br/&gt; at&amp;#160;end&amp;#160;of&lt;br/&gt; year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;br/&gt; exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&amp;#160;(Restricted&amp;#160;Stock)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.720&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1,720,685&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1,617,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;900,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;731,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;211,682&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;211,682&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3.020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3.370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;150,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;150,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;5.000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;949,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;949,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;0.10&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;6.900&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;680,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;680,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.550&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;9.660&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;68,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;68,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;2.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4,929,617&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4,657,461&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2016" id="Factid_485" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2017" id="Factid_486" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_487">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;f.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Inventories&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &amp;#8220;moving average&amp;#8221; basis.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &amp;#8220;moving average&amp;#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_488">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;g.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Years&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_489">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table illustrates the effect of share-based compensation on the statement of operations: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;904&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;571&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;182&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;Selling, general and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;898&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;155&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,802&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;988&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;337&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>

  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_490">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;h.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Impairment in value of long-lived assets&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_491">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;i.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Income taxes&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used tax rates of 39%, 24% and 23%. See note 10.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Uncertainty in income taxes&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Tax benefits recognized in the financial statements are those that the Company&amp;#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&amp;#8217;s management deems more likely than not to be sustained.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_492">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;j.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenue Recognition&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenues from supply agreements and from selling products&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company recognizes revenues from supply agreements and from selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Revenues from Chiesi Agreement&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Since there is only one unit of account, all payments received by Chiesi prior to the satisfaction of Protalix's obligation will be deferred. Therefore,&amp;#160;the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million upfront payment and future research and development reimbursement payments (up to $25 million) and any potential additional development milestone payments will be deferred until the commencement of commercial manufacturing.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2017To12_31_2017" id="Factid_493">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;k.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Research and development costs&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&amp;#8220;NATI&amp;#8221;), which has replaced many of the functions of the Office of the Chief Scientist of Israel&amp;#8217;s Ministry of Industry, Trade and Labor (the &amp;#8220;OCS&amp;#8221;), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2017To12_31_2017" id="Factid_494">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;l.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Concentration of credit risks and trade receivable&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&amp;#8217;s trade receivables represent amounts to be received from Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2017To12_31_2017" id="Factid_495">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;m.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Share-based compensation&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for employee&amp;#8217;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted are measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_496">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;n.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Net (loss) earnings per share&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s Common Stock, par value $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt; per share (the &amp;#8220;Common Stock&amp;#8221;) outstanding for each period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 19,778,424&lt;/font&gt;, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23,532,492&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 76,848,199&lt;/font&gt; shares of Common Stock underlying outstanding options, restricted shares of Common Stock and shares issuable upon conversion of the convertible notes for the fiscal years ended December 31, 2015, 2016 and 2017, respectively, because the effect would be anti-dilutive.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_497">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;o.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Convertible notes&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;All outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&amp;#8217;s nonconvertible debt borrowing rate. The Company accounts for the 2013 Notes (as defined in note 8a) as a liability, on an aggregated basis, in their entirety. The 2016 Notes (as defined in note 8b) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December 31, 2017, the embedded derivative was reclassified to additional paid in capital, see note 8.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Issuance costs regarding the issuance of the 2016 Notes and the 2017 Notes (as defined in note 8c) were allocated to the liability, equity component, derivative and shares based on their relative fair values. Issuance costs that were allocated to the liability are amortized using the effective interest rate, other than issuance costs that were allocated to the derivative which were expensed immediately.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The debt discount and debt issuance costs regarding the issuance of the 2013 Notes are deferred and amortized over the 2013 Notes period (5 years).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtPolicyTextBlock>

  <plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_498">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;p.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Recently adopted standards&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued ASU 2016-09, &amp;#8220;Compensation - Stock Compensation (Topic 718)&amp;#8221; (&amp;#8220;ASU 2016-09&amp;#8221;) which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted this standard in the fourth quarter of 2016. The Company elected to account for forfeitures as they occur. The implementation of this ASU did not have a material impact on the consolidated financial statements.&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_499">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;q.&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Recently issued accounting pronouncements&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; In May 2014, the FASB issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&amp;#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017. The implementation of this ASU did not have a material impact on the consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In January&amp;#160;2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in annual reporting periods beginning after December 15, 2017. The implementation of this ASU&amp;#160;is expected to have&amp;#160;no material impact on the consolidated financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:OpenTaxYear contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_UsIsraelMemberusgaapIncomeTaxAuthorityAxis" id="Factid_500">2013</us-gaap:OpenTaxYear>

  <plx:ScheduleOfUsefulLifeTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_501">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company&amp;#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Years&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;-&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Computer equipment&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>

  <us-gaap:OpenTaxYear contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_UsIsraelMemberusgaapIncomeTaxAuthorityAxis" id="Factid_502">2017</us-gaap:OpenTaxYear>

  <us-gaap:OpenTaxYear contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_USusgaapIncomeTaxAuthorityAxis" id="Factid_503">2013</us-gaap:OpenTaxYear>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_504">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_505">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_506">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_507">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2015To12_31_2015_EmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_508" unitRef="shares" decimals="INF">1909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:OpenTaxYear contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_USusgaapIncomeTaxAuthorityAxis" id="Factid_509">2017</us-gaap:OpenTaxYear>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis" id="Factid_510" unitRef="USD_per_Share" decimals="2">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="PAsOn12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis" id="Factid_511" unitRef="USD" decimals="-3">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2015To12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis" id="Factid_512">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm contextRef="P01_01_2015To12_31_2015_GrantYearTwoThousandFifteenMemberusgaapPlanNameAxis" id="Factid_513">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>

  <plx:FutureResearchAndDevelopmentReimbursement contextRef="P01_01_2017To12_31_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_514" unitRef="USD" decimals="-6">25000000</plx:FutureResearchAndDevelopmentReimbursement>

  <plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal contextRef="P01_01_2017To12_31_2017" id="Factid_515">The Company used tax rates of 39%, 24% and 23%.</plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal>

  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_516">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 2 - COMMERCIALIZATION AGREEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;1.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On November&amp;#160;30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June 2013) pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and Brazil. Under the Pfizer Agreement Protalix was entitled to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% of the results (profits or losses) earned on Pfizer&amp;#8217;s sales of taliglucerase alfa.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In October 2015, the Company entered into the following agreements with Pfizer:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Amended Pfizer Agreement - Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Protalix also agreed to provide Pfizer with:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Stock Purchase Agreement - the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,649,079&lt;/font&gt; shares of Common Stock to Pfizer.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Promissory note &amp;#150; as of the date of the amendment, the Company owed Pfizer $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.3&lt;/font&gt; million as a result of the accumulated losses incurred by the Collaboration Operation. Following the new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a) November 12, 2020 and (b) the date upon which it becomes due pursuant to any event of default, as defined. The promissory note is presented in "other long term liabilities".&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Amended Pfizer Agreement resulted in a discontinued operation as defined under ASU 2014-08 because it represented a strategic shift for the Company that has a major effect on the entity&amp;#8217;s operations and financial results.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Revenues from the Pfizer Agreements as well as revenues from sales of Elelyso in Israel were presented as discontinued operations. See&amp;#160;note 12.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In October 2017, Protalix Ltd. entered into the Chiesi Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter &amp;#150; the drug) for treatment of the Fabry disease. Under the terms of the Chiesi Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. Protalix Ltd. maintains the exclusive commercialization rights to the drug in the United States.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Protalix Ltd. will be mainly responsible for (i) continuing the development of the drug until a regulatory approval is granted and (ii) manufacture and supply the drug to Chiesi, based on Chiesi&amp;#8217;s requests.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The consideration consists of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;a. Upfront, non-refundable payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;b. Additional payments of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; million in development costs, capped at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; million per year.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;c. Milestone payments of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;320&lt;/font&gt; million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;d. Additional payments as consideration for the supply of the drug. The payment will vary from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 35&lt;/font&gt;% of Chiesi&amp;#8217;s average selling price of the drug, depending on the amount of annual sales.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;e. Protalix will be the sole manufacturer of the drug.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Chiesi does not have sublicensing rights (except for certain territories).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company analyzed the agreement terms and concluded that the Chiesi Agreement qualifies as a contract with customer under ASC 605. Chiesi is a customer of the Company as it contracted with the entity to obtain goods or services that are an output of the entity&amp;#8217;s ordinary activities in exchange for consideration.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Therefore, all payments received prior to the fulfillment of the one unit of account will be deferred until the commencement of commercial manufacturing. The Company will recognize revenues after the commencement of the drug supply over the period of the product&amp;#8217;s sales according to the Company&amp;#8217;s best estimate.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;On June 18, 2013, the Company entered into the Brazil Agreement with Fiocruz for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>

  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_517" unitRef="shares" decimals="INF">104500</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_518" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2015To12_31_2015_SubsidiariesMemberusgaapConsolidatedEntitiesAxis_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis" id="Factid_519" unitRef="pure" decimals="3">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <plx:AdditionalAmountsPayableToCoverDevelopmentCosts contextRef="PAsOn10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_520" unitRef="USD" decimals="-6">25000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>

  <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear contextRef="PAsOn10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_521" unitRef="USD" decimals="-6">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>

  <plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones contextRef="PAsOn10_19_2017_MaximumMemberusgaapRangeAxis" id="Factid_522" unitRef="USD" decimals="-6">320000000</plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones>

  <plx:PaymentOnNetSalesPercentage contextRef="P10_01_2017To10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis_MinimumMemberusgaapRangeAxis" id="Factid_523" unitRef="pure" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>

  <plx:PaymentOnNetSalesPercentage contextRef="P10_01_2017To10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis_MaximumMemberusgaapRangeAxis" id="Factid_524" unitRef="pure" decimals="2">0.35</plx:PaymentOnNetSalesPercentage>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To01_31_2016_TaxYearTwoThousandNineMemberusgaapIncomeTaxAuthorityAxis" id="Factid_525" unitRef="pure" decimals="3">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To01_31_2016_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis" id="Factid_526" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P10_01_2015To10_31_2015_PfizerMemberusgaapTypeOfArrangementAxis" id="Factid_527" unitRef="shares" decimals="INF">5649079</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <plx:CollaborativeArrangementProfitSharePercentage contextRef="PAsOn11_30_2009_ProtalixBioTherapeuticsIncorporationMemberusgaapTypeOfArrangementAxis" id="Factid_528" unitRef="pure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To12_31_2016_MaximumMemberusgaapRangeAxis" id="Factid_529" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis" id="Factid_530" unitRef="pure" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2017" id="Factid_531" unitRef="USD" decimals="-6">207000000</us-gaap:OperatingLossCarryforwards>

  <plx:UpfrontNonrefundableNoncreditablePaymentReceivable contextRef="PAsOn10_19_2017_ChiesiAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_532" unitRef="USD" decimals="-5">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2017_RestrictedAmountMemberusgaapIncomeTaxAuthorityAxis" id="Factid_533" unitRef="USD" decimals="-6">23000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2016_RestrictedAmountMemberusgaapIncomeTaxAuthorityAxis" id="Factid_534" unitRef="USD" decimals="-6">20000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OtherLiabilitiesNoncurrent contextRef="PAsOn12_31_2016" id="Factid_535" unitRef="USD" decimals="-3">4301000</us-gaap:OtherLiabilitiesNoncurrent>

  <us-gaap:OtherLiabilitiesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_536" unitRef="USD" decimals="-3">5051000</us-gaap:OtherLiabilitiesNoncurrent>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2017_SubsidiariesMemberusgaapConsolidatedEntitiesAxis" id="Factid_537" unitRef="USD" decimals="-6">184000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2016_SubsidiariesMemberusgaapConsolidatedEntitiesAxis" id="Factid_538" unitRef="USD" decimals="-6">133000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_539">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,561&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Furniture and computer equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,342&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,438&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,678&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,123&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Equipment under construction&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;35,141&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Less &amp;#150; accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(25,601)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(27,465)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,676&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.3pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Depreciation in respect of property and equipment totaled approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.4&lt;/font&gt; million, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.0&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.9&lt;/font&gt; million for the years ended December 31, 2015, 2016 and 2017, respectively.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_540">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; Composition of property and equipment grouped by major classifications is as follows: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,561&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Furniture and computer equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,342&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,438&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,678&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,123&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Equipment under construction&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;35,141&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Less &amp;#150; accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(25,601)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(27,465)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,676&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016" id="Factid_541" unitRef="USD" decimals="-3">34304000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017" id="Factid_542" unitRef="USD" decimals="-3">35141000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_543">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventories at December&amp;#160;31, 2016 and 2017 consisted of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Raw materials&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,591&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,838&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;395&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;485&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Finished goods&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,259&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,510&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Total inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,245&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,833&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_544" unitRef="pure" decimals="2">0.39</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis" id="Factid_545" unitRef="pure" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017_SubsidiariesMemberusgaapConsolidatedEntitiesAxis" id="Factid_546" unitRef="pure" decimals="2">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis_SubsidiariesMemberusgaapConsolidatedEntitiesAxis" id="Factid_547" unitRef="pure" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_548">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 4 - INVENTORIES&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Inventories at December&amp;#160;31, 2016 and 2017 consisted of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Raw materials&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,591&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,838&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Work in progress&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;395&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;485&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Finished goods&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,259&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,510&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Total inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,245&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,833&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>

  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="PAsOn12_31_2016" id="Factid_549" unitRef="USD" decimals="-3">395000</us-gaap:InventoryWorkInProcessNetOfReserves>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_550" unitRef="USD_per_Share" decimals="3">1.720</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_551" unitRef="USD_per_Share" decimals="3">2.350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_552" unitRef="USD_per_Share" decimals="3">2.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_553" unitRef="USD_per_Share" decimals="3">2.650</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_554" unitRef="USD_per_Share" decimals="3">3.020</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_555" unitRef="USD_per_Share" decimals="3">3.370</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_556" unitRef="USD_per_Share" decimals="3">5.000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_557" unitRef="USD_per_Share" decimals="3">6.900</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_558" unitRef="USD_per_Share" decimals="3">7.550</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P01_01_2017To12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_559" unitRef="USD_per_Share" decimals="3">9.660</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_560" unitRef="shares" decimals="INF">1720685</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_561" unitRef="shares" decimals="INF">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_562" unitRef="shares" decimals="INF">900000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_563" unitRef="shares" decimals="INF">211682</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_564" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_565" unitRef="shares" decimals="INF">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_566" unitRef="shares" decimals="INF">949250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_567" unitRef="shares" decimals="INF">680000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_568" unitRef="shares" decimals="INF">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_569" unitRef="shares" decimals="INF">68000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_570">P7Y2M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_571">P9M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_572">P6Y8M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_573">P1Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_574">P1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_575">P6Y6M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_576">P1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_577">P2Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_578">P2Y7M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_579">P2Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_580">P7Y2M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_581">P9M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_582">P6Y8M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_583">P1Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_584">P1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_585">P6Y6M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_586">P1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_587">P2Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_588">P2Y7M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_589">P2Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OnePointSevenTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_590" unitRef="shares" decimals="INF">1617279</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeFiveZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_591" unitRef="shares" decimals="INF">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_592" unitRef="shares" decimals="INF">731250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_TwoPointSixFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_593" unitRef="shares" decimals="INF">211682</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointZeroTwoZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_594" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_ThreePointThreeSevenZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_595" unitRef="shares" decimals="INF">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_FivePointZeroMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_596" unitRef="shares" decimals="INF">949250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SixPointNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_597" unitRef="shares" decimals="INF">680000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis_SevenPointFiveFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_598" unitRef="shares" decimals="INF">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_NinePointSixSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_599" unitRef="shares" decimals="INF">68000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_600" unitRef="shares" decimals="INF">4929617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockMemberusgaapAwardTypeAxis" id="Factid_601" unitRef="shares" decimals="INF">4657461</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2015To12_31_2015" id="Factid_602" unitRef="USD" decimals="-3">1802000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2016To12_31_2016" id="Factid_603" unitRef="USD" decimals="-3">988000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To12_31_2017" id="Factid_604" unitRef="USD" decimals="-3">337000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn12_14_2006" id="Factid_605" unitRef="shares" decimals="INF">13841655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

  <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_606">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 9 - FAIR VALUE MEASUREMENT&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The fair value of the convertible notes derivative is based on level 3 measurement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The fair value of the remaining $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.9&lt;/font&gt; million 2013 Notes and the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;59.1&lt;/font&gt; million 2016 Notes as of December 31, 2017 is approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.7&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;76.6&lt;/font&gt; million, respectively, based on a level 3 measurement.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company prepared a valuation of the fair value of the 2013 Notes and the 2016 Notes (a Level 3 valuation) as of December 31, 2017. The value of these notes were estimated by implementing the binomial model. The liability component was valued based on the Income Approach. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following parameters were used:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&amp;#160;Notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&amp;#160;Notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.6612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.6612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.08&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;79.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>

  <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_607">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 8 - CONVERTIBLE NOTES&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;4.5% Convertible Notes (&amp;#8220;2013 Notes&amp;#8221;)&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On September 18, 2013, the Company completed a private placement of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;69.0&lt;/font&gt; million in aggregate principal amount of Senior Convertible Notes (the &amp;#8220;2013 Notes&amp;#8221;), including $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0&lt;/font&gt; million aggregate principal amount of 2013 Notes related to the initial purchaser&amp;#8217;s over-allotment option, which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 2013 Notes. The 2013 Notes accrue interest at a rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.50&lt;/font&gt;% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. In December 2016, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;54.1&lt;/font&gt; million aggregate principal amount of 2013 Notes were exchanged for 2016 Notes and shares of common stock (see also note 8b) and in July 2017, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0&lt;/font&gt; million aggregate principal amount of 2013 Notes were exchanged for 2017 Notes as defined in note 8c (see also note 8c). Accordingly, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.9&lt;/font&gt; million aggregate principal amount of 2013 Notes remain outstanding as of December 31, 2017. The 2013 Notes mature on September 15, 2018.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Holders may convert their 2013 Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the 2013 Notes is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 173.6593&lt;/font&gt; shares of the Common Stock for each $1,000 principal amount of 2013 Notes (equivalent to an initial conversion price of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.76&lt;/font&gt; per share of the Common Stock). Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of 2013 Notes, equal to the conversion rate. The conversion rate is subject to adjustment for certain events but will not be adjusted for any accrued and unpaid interest.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table sets forth total interest expense recognized for the years ended December 31, 2015, 2016 and 2017 related to the 2013 Notes:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,943&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Amortization of debt issuance costs and debt discount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;444&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;421&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;3,549&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;572&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -99.55pt; MARGIN: 0in 0in 0pt 127.6pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;7.5% Convertible Notes (&amp;#8220;2016 Notes&amp;#8221;)&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;On December 1, 2016, the Company entered into a note purchase agreement with institutional investors, which held part of the 2013 Notes (the &amp;#8220;2016 Purchasers&amp;#8221;), relating to the sale by the Company of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22.5&lt;/font&gt; million aggregate principal amount of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7.50&lt;/font&gt;% Senior Secured Convertible Notes due 2021 in a private placement pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;). Concurrently with the consummation of the private placement of the 2016 Notes, the Company entered into a privately negotiated exchange agreement (the &amp;#8220;2016 Exchange Agreement&amp;#8221;) with certain existing note holders identified therein to exchange $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;54.1&lt;/font&gt; million aggregate principal amount of the Company&amp;#8217;s outstanding 2013 Notes for (i) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40.186&lt;/font&gt; million aggregate principal amount of 2016 Notes, (ii) &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 23,846,735&lt;/font&gt; shares of Common Stock and (iii) cash, equal to the accrued and unpaid interest on the 2013 Notes and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December 7, 2016. The issuance of the 2016 Notes and shares in the exchange and the private placement were made in reliance on the exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof. The net proceeds from the private placement were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19.7&lt;/font&gt; million, after deducting the placement agent&amp;#8217;s fees and the Company&amp;#8217;s estimated offering expenses.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;In connection with the completion of the exchange and the private placement, the Company entered into an indenture (the &amp;#8220;2016 Indenture&amp;#8221;) with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 2016 Notes. The 2016 Notes accrue interest at a rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7.50&lt;/font&gt;% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2017. A portion of the interest payable may be made in shares of Common Stock at the Company&amp;#8217;s election. The Notes will mature on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;November 15, 2021&lt;/font&gt;; provided that all of the then-outstanding 2013 Notes, or any Permitted Refinancing Indebtedness (as defined in the 2016 Indenture) have been redeemed, repurchased, otherwise retired, discharged in accordance with their terms or converted into common stock of the Company, or have been effectively discharged, in each case on or prior to June 16, 2018 or the scheduled maturity date of the 2013 Notes (or any Permitted Refinancing Indebtedness incurred in respect thereof) is extended to a date that is after February 15, 2022, otherwise the 2016 Notes will mature on June 15, 2018.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On July 24, 2017, the Company entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.0&lt;/font&gt; million in aggregate principal amount of its 2016 Notes. The 2016 Notes were issued pursuant to the 2016 Indenture dated (December 7, 2016). The net proceeds from this purchase agreement were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.5&lt;/font&gt; million, after deducting the Company&amp;#8217;s offering expenses.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Holders may convert their 2016 Notes at any time. The initial conversion rate for the 2016 Notes is 1,176.4706 shares of the Common Stock for each $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000&lt;/font&gt; principal amount of 2016 Notes (equivalent to an initial conversion price of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.85&lt;/font&gt; per share of the Common Stock). Upon conversion, the Company may settle the 2016 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&amp;#8217;s election.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;During 2017, approximately $13.6 million aggregate principal amount of the Company&amp;#8217;s 2016 Notes were&amp;#160;converted. Settlement of the conversions resulted in the issuance of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8,827,624&lt;/font&gt; shares of Common Stock and cash payments of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11&lt;/font&gt; million, in the aggregate. A total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;59.1&lt;/font&gt; million aggregate principal amount of the 2016 Notes remains outstanding as of December 31, 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Prior to the maturity date, the Company may redeem in cash:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 53.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 35.45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="47"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;a)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;any or all of the 2016 Notes if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days exceeds 150% of the conversion price on each applicable trading day, or&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 53.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 35.45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="47"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;all of the 2016 Notes then outstanding if the aggregate principal amount of the 2016 Notes then outstanding is less than 15% of the aggregate principal amount of the notes issued.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;No redemption was made during the years 2016 and 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The 2016 Notes are guaranteed by the Restricted Subsidiaries (as defined in the 2016 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &amp;#8220;Collateral&amp;#8221;), including, but not limited to, (i) 100% of the capital stock of the Guarantors (as defined in the 2016 Indenture) and each Restricted Subsidiary of the Company that is held by the Company or any Restricted Subsidiary, (ii) intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii) all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv) all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2016 Indenture, and (v) all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United States, and with Altshuler Shaham Trusts Ltd., as security trustee in Israel. The 2016 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&amp;#8217;s assets that constitute collateral securing the 2016 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Upon (i) the occurrence of a fundamental change (as defined in the 2016 Indenture) or (ii) if the Company calls the 2016 Notes for redemption as described below (either event, a &amp;#8220;make-whole fundamental change&amp;#8221;) and a holder elects to convert its 2016 Notes in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &amp;#8220;Additional Shares&amp;#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is 1,787.3100 shares per $1,000 principal amount of 2016 Notes, which amount is inclusive of repayment of the principal of the 2016 Notes.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2016 Notes, or any portion of the principal amount thereof, that is equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000&lt;/font&gt; or an integral multiple of $1,000 in excess thereof, on a date of the Company&amp;#8217;s choosing that is not less than 20 calendar days nor more than 35 calendar days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2016 Note is equal to 100% of the principal amount of such 2016 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;For accounting purposes, since the terms of the 2013 Notes and the 2016 Notes are substantially different, the 2016 Exchange Agreement was considered as an extinguishment, which in essence means recording a gain due to the 2013 Notes that were exchanged for the 2016 Notes recorded at fair value as of the closing date. The gain on extinguishment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.1&lt;/font&gt; million was recognized.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;As the settlement upon conversion was subject to compliance with the listing standards of the NYSE American, until the Company&amp;#8217;s stockholders&amp;#8217; approval was obtained, the Company was prohibited by these rules from issuing shares in excess of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 20&lt;/font&gt;% of its outstanding shares (calculated as of December 1, 2016). The accounting guidance assumed that the conversion will be settled in cash and, as such, is precluded from equity classification for any part of the 2016 Notes that may have cash settlement. As such, that part of the conversion feature was accounted for as a derivative which is bifurcated from the debt host contract and was measured at fair value through the statement of operations until the Company&amp;#8217;s stockholders approved, in April 2017, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;the issuance of shares in excess of 20% of its outstanding shares. On April 12, 2017, the Company&amp;#8217;s stockholders approved the issuance of shares of the Company&amp;#8217;s Common Stock in excess of 20% of the Company&amp;#8217;s outstanding shares of Common Stock to settle conversion requests and pay interest on the Company&amp;#8217;s issued 7.5% convertible notes.&lt;/font&gt; As a result, the Company reclassified the embedded derivative to additional paid in capital. During 2017, the measurement of the derivative resulted in a non-cash charge to the Company&amp;#8217;s statement of operations of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;38,061&lt;/font&gt; thousand. The conversion feature of the 7.5% convertible notes issued in July 2017 is accounted for as equity, which is bifurcated from the debt host contract. With respect to the remainder of the 2016 Notes, for which the conversion feature qualifies for equity classification (since upon conversion the Company at its election may settle the 2016 Notes by paying cash, shares of Common Stock or a combination of cash and shares of Common Stock) separate liability (debt) and equity (conversion option) components of such 2016 Notes were recorded. The Company measures the liability according to amortized cost using the effective interest method.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The Company prepared a valuation of the fair value of the 2016 Notes (a Level 3 valuation) for the issuance dates. The value of the 2016 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;7,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;July&amp;#160;24,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.94&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54.12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table sets forth total interest expense recognized related to the 2016 Notes:&lt;br/&gt; &lt;br/&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;313&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Debt discount amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;147&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,309&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Gain on extinguishment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(14,063)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Change in fair value of convertible note embedded derivative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,473&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,061&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Interest payment in connection with conversions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,918&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Income in connection with conversions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,643)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,130)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;47,079&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/strong&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;4.5% Convertible Notes Due 2022 (&amp;#8220;2017 Notes&amp;#8221;)&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;On July 24, 2017, the Company entered into a privately negotiated exchange agreement (the &amp;#8220;2017 Exchange Agreement&amp;#8221;) with certain existing note holders identified therein to exchange $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0&lt;/font&gt; million aggregate principal amount of the Company&amp;#8217;s outstanding 2013 Notes for (i) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.55&lt;/font&gt; million aggregate principal amount of the Company&amp;#8217;s &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.5&lt;/font&gt;% convertible promissory notes due &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2022&lt;/font&gt;, (ii) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;275,000&lt;/font&gt; in cash consideration and (iii) cash, equal to the accrued and unpaid interest on the exchanged 2013 Notes.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;As the terms of the 2013 Notes and the 2017 Notes are substantially different, the 2017 Exchange Agreement was considered an extinguishment of debt, which in essence means recording a loss due to the 2013 Notes that were exchanged for the 2017 Notes recorded at fair value as of the closing date. The Company recognized a loss of $1.3 million due to the extinguishment.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company prepared a valuation of the fair value of the 2017 Notes (a Level 3 valuation) for the issuance date. The value of the 2017 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;July&amp;#160;24,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;62.68&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely. The debt discount and debt issuance costs are deferred and amortized over the applicable convertible period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;All of the 2017 Notes were converted during the year ended December 31, 2017 into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 11,239,641&lt;/font&gt; shares of Common Stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table sets forth total interest expense recognized related to the 2017 Notes:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Debt premium amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(46)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Loss on extinguishment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,325&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>

  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2017To12_31_2017_TwentyThirteenAndTwentySixteenNotesMemberusgaapDebtInstrumentAxis" id="Factid_608">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The following parameters were used:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&amp;#160;Notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&amp;#160;Notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.6612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.6612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.08&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;79.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;68.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>

  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="P01_01_2017To12_31_2017_Notes2013MemberusgaapStatementGeographicalAxis" id="Factid_609">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table sets forth total interest expense recognized for the years ended December 31, 2015, 2016 and 2017 related to the 2013 Notes: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,943&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Amortization of debt issuance costs and debt discount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;444&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;421&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;3,549&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;572&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" id="Factid_610" unitRef="pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>

  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="PAsOn03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_611" unitRef="USD" decimals="-5">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_612" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_613" unitRef="pure" decimals="3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_614" unitRef="pure" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_615">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>

  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapStatementGeographicalAxis" id="Factid_616">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table sets forth total interest expense recognized related to the 2016 Notes:&lt;br/&gt; &lt;br/&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;313&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Debt discount amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;147&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,309&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Gain on extinguishment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(14,063)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Change in fair value of convertible note embedded derivative&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,473&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,061&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Interest payment in connection with conversions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,918&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Income in connection with conversions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,643)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,130)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;47,079&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P03_01_2015To03_23_2015" id="Factid_617" unitRef="shares" decimals="INF">1909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P03_01_2015To03_23_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_618" unitRef="USD_per_Share" decimals="2">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="P01_01_2017To12_31_2017_Notes2017MemberusgaapStatementGeographicalAxis" id="Factid_619">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table sets forth total interest expense recognized related to the 2017 Notes: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;(U.S.&amp;#160;Dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Contractual interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Debt premium amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(46)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Loss on extinguishment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,325&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,334&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>

  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_620">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company prepared a valuation of the fair value of the 2016 Notes (a Level 3 valuation) for the issuance dates. The value of the 2016 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;7,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;July&amp;#160;24,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.94&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54.12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>

  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2017To12_31_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_621">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company prepared a valuation of the fair value of the 2017 Notes (a Level 3 valuation) for the issuance date. The value of the 2017 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;July&amp;#160;24,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Stock price (USD)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Expected term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Risk free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;62.68&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_622">P8M16D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_623">P3Y10M17D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_624" unitRef="pure" decimals="4">0.0166</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_625" unitRef="pure" decimals="4">0.0208</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_626" unitRef="pure" decimals="4">0.6889</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_627" unitRef="pure" decimals="4">0.7957</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_628" unitRef="pure" decimals="4">0.1189</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_629" unitRef="pure" decimals="4">0.1186</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_630" unitRef="pure" decimals="3">0</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn06_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_631" unitRef="USD" decimals="-6">10000000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_632" unitRef="USD" decimals="-5">9000000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_633" unitRef="pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_634" unitRef="USD" decimals="-4">8550000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_635" unitRef="pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P07_01_2017To07_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_636" unitRef="pure" decimals="4">0.1156</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <plx:DebtInstrumentMaturityYear contextRef="P06_01_2017To06_24_2017_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_637">P2021Y</plx:DebtInstrumentMaturityYear>

  <plx:DebtInstrumentMaturityYear contextRef="P06_01_2017To06_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_638">P2018Y</plx:DebtInstrumentMaturityYear>

  <plx:DebtInstrumentMaturityYear contextRef="P06_01_2017To06_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_639">P2022Y</plx:DebtInstrumentMaturityYear>

  <us-gaap:SharePrice contextRef="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_640" unitRef="USD_per_Share" decimals="2">0.77</us-gaap:SharePrice>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_641">P4Y6M25D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_642" unitRef="pure" decimals="4">0.0178</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_643" unitRef="pure" decimals="4">0.6268</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_644" unitRef="pure" decimals="4">0.1521</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_645" unitRef="USD" decimals="-3">313000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2017To12_31_2017_Notes2017MemberusgaapDebtInstrumentAxis" id="Factid_646" unitRef="USD" decimals="-3">55000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2017To12_31_2017_Notes2017MemberusgaapDebtInstrumentAxis" id="Factid_647" unitRef="USD" decimals="-3">-46000</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2017To12_31_2017_Notes2017MemberusgaapDebtInstrumentAxis" id="Factid_648" unitRef="USD" decimals="-3">-1325000</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:InterestIncomeExpenseNet contextRef="P01_01_2017To12_31_2017_Notes2017MemberusgaapDebtInstrumentAxis" id="Factid_649" unitRef="USD" decimals="-3">1334000</us-gaap:InterestIncomeExpenseNet>

  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_650" unitRef="USD" decimals="-3">4434000</us-gaap:InterestExpenseDebtExcludingAmortization>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_651" unitRef="USD" decimals="-3">147000</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_652" unitRef="USD" decimals="-3">2309000</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_653" unitRef="USD" decimals="-3">14063000</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_654" unitRef="USD" decimals="-3">6473000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>

  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_655" unitRef="USD" decimals="-3">38061000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>

  <us-gaap:InterestExpenseDebt contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_656" unitRef="USD" decimals="-3">3918000</us-gaap:InterestExpenseDebt>

  <plx:GainLossOnConversionOfDebt contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_657" unitRef="USD" decimals="-3">-1643000</plx:GainLossOnConversionOfDebt>

  <us-gaap:InterestIncomeExpenseNet contextRef="P01_01_2016To12_31_2016_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_658" unitRef="USD" decimals="-3">-7130000</us-gaap:InterestIncomeExpenseNet>

  <us-gaap:InterestIncomeExpenseNet contextRef="P01_01_2017To12_31_2017_Notes2016MemberusgaapDebtInstrumentAxis" id="Factid_659" unitRef="USD" decimals="-3">47079000</us-gaap:InterestIncomeExpenseNet>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_660" unitRef="shares" decimals="INF">4477043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_661" unitRef="shares" decimals="INF">3498492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_662" unitRef="shares" decimals="INF">4457461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2015_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_663" unitRef="USD_per_Share" decimals="3">4.182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2016_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_664" unitRef="USD_per_Share" decimals="3">4.296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_OptionsAndRestrictedStockGrantedToEmployeesMemberusgaapTitleOfIndividualAxis" id="Factid_665" unitRef="USD_per_Share" decimals="3">3.696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_666" unitRef="shares" decimals="INF">549709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_667" unitRef="shares" decimals="INF">170500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_668" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_669" unitRef="USD_per_Share" decimals="3">12.954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2016_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_670" unitRef="USD_per_Share" decimals="3">3.109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_671" unitRef="USD_per_Share" decimals="3">3.282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P01_01_2017To12_31_2017_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis" id="Factid_672" unitRef="USD" decimals="-5">5900000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtInstrumentRedemptionDescription contextRef="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_673">Prior to the maturity date, the Company may redeem in cash: a) any or all of the 2016 Notes if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days exceeds 150% of the conversion price on each applicable trading day, or b) all of the 2016 Notes then outstanding if the aggregate principal amount of the 2016 Notes then outstanding is less than 15% of the aggregate principal amount of the notes issued.</us-gaap:DebtInstrumentRedemptionDescription>

  <us-gaap:DebtInstrumentMaturityDate contextRef="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_674">2021-11-15</us-gaap:DebtInstrumentMaturityDate>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P07_01_2017To07_31_2017_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis" id="Factid_675" unitRef="USD" decimals="-5">9000000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn07_24_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_676" unitRef="USD" decimals="-5">10000000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_677" unitRef="shares" decimals="INF">8827624</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:RepaymentsOfConvertibleDebt contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_678" unitRef="USD" decimals="-6">11000000</us-gaap:RepaymentsOfConvertibleDebt>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_679" unitRef="USD" decimals="-5">59100000</us-gaap:DebtInstrumentCarryingAmount>

  <plx:StockholdersApprovalDescriptionForCommonStockIssuance contextRef="P04_01_2017To04_30_2017" id="Factid_680">the issuance of shares in excess of 20% of its outstanding shares. On April 12, 2017, the Companys stockholders approved the issuance of shares of the Companys Common Stock in excess of 20% of the Companys outstanding shares of Common Stock to settle conversion requests and pay interest on the Companys issued 7.5% convertible notes.</plx:StockholdersApprovalDescriptionForCommonStockIssuance>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_681">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The components of the Company&amp;#8217;s net deferred tax assets at December 31, 2016 and 2017 were as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In respect of:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Timing Differences&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net operating loss carry forwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;38,515&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;47,033&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(42,035)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(58,368)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <plx:ScheduleOfOpenTaxYearsTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_682">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of open tax years by major jurisdiction is presented below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="MARGIN: auto auto auto 1in; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="65%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 52%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="52%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Jurisdiction:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 1pt; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="9%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 39%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="39%"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"&gt;&lt;strong&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Years:&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Israel&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2013-2017&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;United States (*)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;2013-2017&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_683" unitRef="USD" decimals="-5">9000000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_684" unitRef="USD" decimals="-4">8550000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_685" unitRef="pure" decimals="3">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:RepaymentsOfConvertibleDebt contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_686" unitRef="USD" decimals="0">275000</us-gaap:RepaymentsOfConvertibleDebt>

  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_687">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div&gt;(U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;TEXT-INDENT: -13px; MARGIN-LEFT: 13px"&gt; Compensation (including share based compensation)&lt;br/&gt; to the non-executive directors (includes the&lt;br/&gt; interim Chairman of the Board through 2015 and&lt;br/&gt; the Chairman of the Board for part of 2015)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;631&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;560&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;499&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>

  <plx:DebtInstrumentMaturityYear contextRef="P07_01_2017To07_24_2017_FourPointFivePercentageConvertibleNotesOneMemberusgaapDebtInstrumentAxis" id="Factid_688">P2022Y</plx:DebtInstrumentMaturityYear>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P01_01_2017To12_31_2017" id="Factid_689" unitRef="shares" decimals="INF">11239641</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <plx:DebtInstrumentConvertibleBaseValueForConversionRate contextRef="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_690" unitRef="USD" decimals="0">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_691" unitRef="shares" decimals="INF">1176.4706</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <plx:MaximumDebtInstrumentConvertibleConversionShareNumber contextRef="P12_01_2016To12_31_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_692" unitRef="USD_per_Share" decimals="4">1787.3100</plx:MaximumDebtInstrumentConvertibleConversionShareNumber>

  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax contextRef="P01_01_2015To12_31_2015" id="Factid_693" unitRef="USD" decimals="0">-18000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>

  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax contextRef="P01_01_2016To12_31_2016" id="Factid_694" unitRef="USD" decimals="0">-7000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>

  <plx:StockIssuedDuringPeriodSharesStockExpired contextRef="P01_01_2015To12_31_2015_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMemberusgaapTitleOfIndividualAxis" id="Factid_695" unitRef="shares" decimals="INF">466883</plx:StockIssuedDuringPeriodSharesStockExpired>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To12_31_2016_SubsidiariesMemberusgaapConsolidatedEntitiesAxis_TaxYearThereafterMemberusgaapIncomeTaxAuthorityAxis" id="Factid_696" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:SharePrice contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_697" unitRef="USD_per_Share" decimals="4">0.6612</us-gaap:SharePrice>

  <us-gaap:SharePrice contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_698" unitRef="USD_per_Share" decimals="4">0.6612</us-gaap:SharePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2015To12_31_2015" id="Factid_699" unitRef="USD" decimals="0">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2016To12_31_2016" id="Factid_700" unitRef="USD" decimals="0">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2017To12_31_2017" id="Factid_701" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_02_2016_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" id="Factid_702" unitRef="pure" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P07_01_2017To07_24_2017" id="Factid_703" unitRef="USD" decimals="-5">9500000</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_704">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Restricted stock granted to employees:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;restricted&amp;#160;stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;386,124&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Changes during the year:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;255,749&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;127,874&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>

  <plx:OtherAssetsInstitutionsCurrent contextRef="PAsOn12_31_2016" id="Factid_705" unitRef="USD" decimals="-3">333000</plx:OtherAssetsInstitutionsCurrent>

  <plx:OtherAssetsInstitutionsCurrent contextRef="PAsOn12_31_2017" id="Factid_706" unitRef="USD" decimals="-3">394000</plx:OtherAssetsInstitutionsCurrent>

  <us-gaap:PrepaidRoyalties contextRef="PAsOn12_31_2016" id="Factid_707" unitRef="USD" decimals="-3">1046000</us-gaap:PrepaidRoyalties>

  <us-gaap:PrepaidRoyalties contextRef="PAsOn12_31_2017" id="Factid_708" unitRef="USD" decimals="-3">195000</us-gaap:PrepaidRoyalties>

  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_709" unitRef="USD" decimals="-3">477000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2017" id="Factid_710" unitRef="USD" decimals="-3">623000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2016" id="Factid_711" unitRef="USD" decimals="-3">416000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2017" id="Factid_712" unitRef="USD" decimals="-3">433000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="PAsOn12_31_2016" id="Factid_713" unitRef="USD" decimals="-3">327000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>

  <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="PAsOn12_31_2017" id="Factid_714" unitRef="USD" decimals="-3">215000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>

  <plx:OtherAssetsSundryCurrent contextRef="PAsOn12_31_2016" id="Factid_715" unitRef="USD" decimals="-3">49000</plx:OtherAssetsSundryCurrent>

  <plx:OtherAssetsSundryCurrent contextRef="PAsOn12_31_2017" id="Factid_716" unitRef="USD" decimals="-3">74000</plx:OtherAssetsSundryCurrent>

  <us-gaap:Revenues contextRef="P01_01_2015To12_31_2015_BRusgaapStatementGeographicalAxis" id="Factid_717" unitRef="USD" decimals="-3">4364000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2016To12_31_2016_PfizerMemberdeiLegalEntityAxis" id="Factid_718" unitRef="USD" decimals="-3">5226000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2016To12_31_2016_BRusgaapStatementGeographicalAxis" id="Factid_719" unitRef="USD" decimals="-3">3973000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2017To12_31_2017_PfizerMemberdeiLegalEntityAxis" id="Factid_720" unitRef="USD" decimals="-3">12181000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P01_01_2017To12_31_2017_BRusgaapStatementGeographicalAxis" id="Factid_721" unitRef="USD" decimals="-3">7061000</us-gaap:Revenues>

  <plx:MilestonePaymentAmountPaid contextRef="P01_01_2017To12_31_2017" id="Factid_722" unitRef="USD" decimals="0">0</plx:MilestonePaymentAmountPaid>

  <us-gaap:RoyaltyExpense contextRef="P01_01_2017To12_31_2017_ResearchAndLicenseAgreementsMemberplxCommitmentsAndContingenciesAxis" id="Factid_723" unitRef="USD" decimals="0">0</us-gaap:RoyaltyExpense>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2017" id="Factid_724" unitRef="USD" decimals="-3">11335000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2017" id="Factid_725" unitRef="USD" decimals="-3">47033000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:IncomeLossFromContinuingOperations contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_726" unitRef="USD" decimals="-3">-85276000</us-gaap:IncomeLossFromContinuingOperations>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2017" id="Factid_727" unitRef="USD" decimals="-3">58368000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2016" id="Factid_728" unitRef="USD" decimals="-3">42035000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="PAsOn12_31_2017_DefinedBenefitPostretirementLifeInsuranceMemberusgaapRetirementPlanTypeAxis" id="Factid_729" unitRef="USD" decimals="0">830000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2017_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_730" unitRef="pure" decimals="0">1</plx:PercentageOfRoyaltiesToGrantReceived>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2016_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis" id="Factid_731" unitRef="pure" decimals="0">3</plx:PercentageOfRoyaltiesToGrantReceived>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2017_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis" id="Factid_732" unitRef="pure" decimals="0">3</plx:PercentageOfRoyaltiesToGrantReceived>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2017To12_31_2017" id="Factid_733" unitRef="USD" xsi:nil="true" />

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P01_01_2017To12_31_2017_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_734" unitRef="USD" decimals="-5">13600000</us-gaap:DebtConversionOriginalDebtAmount1>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2015_MaximumMemberusgaapRangeAxis_ProductsManufacturedOutsideOfIsraelMemberplxCommitmentsAndContingenciesAxis" id="Factid_735" unitRef="pure" decimals="0">3</plx:PercentageOfRoyaltiesToGrantReceived>

  <plx:SupplementaryBalanceSheetsInformationTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_736">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Balance sheets:&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other&amp;#160;assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Institutions&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;394&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;State of Israel (see note 6a)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,046&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;195&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;477&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;623&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;433&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets of discontinued operation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;327&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Sundry&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;49&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,648&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,934&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accounts&amp;#160;payable&amp;#160;and&amp;#160;accruals&amp;#160;&amp;#150;&amp;#160;other:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Payroll and related expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,190&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,386&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Interest payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;511&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;645&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Provision for vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,399&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,575&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,802&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Royalties payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;226&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;301&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property and equipment suppliers&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;595&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;526&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,496&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,310&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>

  <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="PAsOn12_31_2017_ContributionPlansMemberusgaapRetirementPlanTypeAxis" id="Factid_737" unitRef="USD" decimals="0">664000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2016_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_738" unitRef="pure" decimals="0">1</plx:PercentageOfRoyaltiesToGrantReceived>

  <plx:PercentageOfRoyaltiesToGrantReceived contextRef="PAsOn12_31_2015_MaximumMemberusgaapRangeAxis_OCSMemberplxCommitmentsAndContingenciesAxis" id="Factid_739" unitRef="pure" decimals="0">1</plx:PercentageOfRoyaltiesToGrantReceived>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FourPointFivePercentageConvertibleNotes2013MemberusgaapDebtInstrumentAxis" id="Factid_740" unitRef="USD" decimals="-5">5900000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotes2016MemberusgaapDebtInstrumentAxis" id="Factid_741" unitRef="USD" decimals="-5">59100000</us-gaap:DebtInstrumentFaceAmount>

  <plx:SupplementaryIncomeStatementInformationTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_742">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Statements of operations:&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 28.4pt"&gt; &amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 15px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; (U.S.&amp;#160;dollars&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Revenues:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Pfizer&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,226&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;12,181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Brazil&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,973&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,061&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,364&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,199&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19,242&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_247" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $675,000, $213,000 and $0, respectively.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_248" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_249" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_250" xlink:type="locator" xlink:label="loc_5" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_251" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_252" xlink:type="locator" xlink:label="loc_7" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_388" xlink:type="locator" xlink:label="loc_8" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_8">Represents an amount of less than $1 thousand.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_8" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_395" xlink:type="locator" xlink:label="loc_10" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_8" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_396" xlink:type="locator" xlink:label="loc_11" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_8" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_503" xlink:type="locator" xlink:label="loc_12" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_12">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_509" xlink:type="locator" xlink:label="loc_14" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_605" xlink:type="locator" xlink:label="loc_15" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>plx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.protalix.com/20171231" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20171231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>102 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" id="ConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" id="ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#39; EQUITY [Parenthetical]</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>108 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/CommercializationAgreements" id="CommercializationAgreements">
        <link:definition>109 - Disclosure - COMMERCIALIZATION AGREEMENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>110 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="Inventories">
        <link:definition>111 - Disclosure - INVENTORIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" id="LiabilityForEmployeeRightsUponRetirement">
        <link:definition>112 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/Commitments" id="Commitments">
        <link:definition>113 - Disclosure - COMMITMENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapital" id="ShareCapital">
        <link:definition>114 - Disclosure - SHARE CAPITAL</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotes" id="ConvertibleNotes">
        <link:definition>115 - Disclosure - CONVERTIBLE NOTES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurement" id="FairValueMeasurement">
        <link:definition>116 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncome" id="TaxesOnIncome">
        <link:definition>117 - Disclosure - TAXES ON INCOME</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" id="SupplementaryFinancialStatementInformation">
        <link:definition>118 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
        <link:definition>119 - Disclosure - DISCONTINUED OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>120 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>121 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <link:definition>122 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>123 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="InventoriesTables">
        <link:definition>124 - Disclosure - INVENTORIES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>125 - Disclosure - SHARE CAPITAL (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesTables" id="ConvertibleNotesTables">
        <link:definition>126 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
        <link:definition>127 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
        <link:definition>128 - Disclosure - TAXES ON INCOME (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" id="SupplementaryFinancialStatementInformationTables">
        <link:definition>129 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
        <link:definition>130 - Disclosure - DISCONTINUED OPERATIONS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
        <link:definition>131 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>132 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>133 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails" id="CommercializationAgreementsNarrativeDetails">
        <link:definition>134 - Disclosure - COMMERCIALIZATION AGREEMENTS (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>135 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails" id="PropertyAndEquipmentNarrativeDetails">
        <link:definition>136 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/InventoriesDetails" id="InventoriesDetails">
        <link:definition>137 - Disclosure - INVENTORIES (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails" id="LiabilityForEmployeeRightsUponRetirementNarrativeDetails">
        <link:definition>138 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/CommitmentsNarrativeDetails" id="CommitmentsNarrativeDetails">
        <link:definition>139 - Disclosure - COMMITMENTS (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" id="ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails">
        <link:definition>140 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" id="ShareCapitalOptionsGrantedToEmployeesDetails">
        <link:definition>141 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" id="ShareCapitalRestrictedStockGrantedToEmployeesDetails">
        <link:definition>142 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" id="ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails">
        <link:definition>143 - Disclosure - SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" id="ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails">
        <link:definition>144 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" id="ShareCapitalShareBasedCompensationExpenseAllocationDetails">
        <link:definition>145 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>146 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" id="ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
        <link:definition>147 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails" id="ConvertibleNotesFairValueIncomeApproachDetails">
        <link:definition>148 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails" id="ConvertibleNotesScheduleOfDebtInterestExpensesDetails">
        <link:definition>149 - Disclosure - CONVERTIBLE NOTES (Schedule Of Debt Interest Expenses) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" id="ConvertibleNotesNarrativeDetails">
        <link:definition>150 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>151 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" id="FairValueMeasurementNarrativeDetails">
        <link:definition>152 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" id="TaxesOnIncomeDeferredIncomeTaxesDetails">
        <link:definition>153 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" id="TaxesOnIncomeOpenTaxYearsDetails">
        <link:definition>154 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" id="TaxesOnIncomeNarrativeDetails">
        <link:definition>155 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails" id="SupplementaryFinancialStatementInformationOtherAssetsDetails">
        <link:definition>156 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>157 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails" id="SupplementaryFinancialStatementInformationStatementsOfOperationsDetails">
        <link:definition>158 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Statements Of Operations) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails" id="DiscontinuedOperationsOperationsDetails">
        <link:definition>159 - Disclosure - DISCONTINUED OPERATIONS (Operations) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails" id="RelatedPartyTransactionsCompensationDetails">
        <link:definition>160 - Disclosure - RELATED PARTY TRANSACTIONS (Compensation) (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_DocumentAndEntityInformationAbstract" />

  <element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="plx_CommitmentsAndContingenciesTable" />

  <element name="CommitmentsAndContingenciesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="plx_CommitmentsAndContingenciesAxis" />

  <element name="CommitmentsAndContingenciesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_CommitmentsAndContingenciesDomain" />

  <element name="OCSMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OCSMember" />

  <element name="ProductsManufacturedOutsideOfIsraelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ProductsManufacturedOutsideOfIsraelMember" />

  <element name="ResearchAndLicenseAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ResearchAndLicenseAgreementsMember" />

  <element name="VehicleLeaseAndMaintenanceAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" />

  <element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_CommitmentsAndContingenciesLineItems" />

  <element name="RoyaltiesOnSaleOfProducts" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_RoyaltiesOnSaleOfProducts" />

  <element name="CommitmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_CommitmentAmount" />

  <element name="MonthlyRentLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_MonthlyRentLeaseExpense" />

  <element name="PresidentAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PresidentAndChiefExecutiveOfficerMember" />

  <element name="OfficersAndCertainEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OfficersAndCertainEmployeesMember" />

  <element name="EmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_EmployeesMember" />

  <element name="OnePointSevenTwoZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OnePointSevenTwoZeroMember" />

  <element name="TwoPointThreeFiveZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TwoPointThreeFiveZeroMember" />

  <element name="TwoPointThreeSevenZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TwoPointThreeSevenZeroMember" />

  <element name="TwoPointSixFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TwoPointSixFiveMember" />

  <element name="ThreePointZeroTwoZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ThreePointZeroTwoZeroMember" />

  <element name="ThreePointThreeSevenZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ThreePointThreeSevenZeroMember" />

  <element name="FivePointZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_FivePointZeroMember" />

  <element name="SixPointNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SixPointNineMember" />

  <element name="SevenPointFiveFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SevenPointFiveFiveMember" />

  <element name="NinePointSixSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_NinePointSixSixMember" />

  <element name="OptionsAndRestrictedStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OptionsAndRestrictedStockMember" />

  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="plx_SignificantAccountingPoliciesTable" />

  <element name="PfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PfizerAgreementMember" />

  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_AmendedPfizerAgreementMember" />

  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ProtalixBioTherapeuticsIncorporationMember" />

  <element name="PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />

  <element name="CollaborativeArrangementRevenuesExpensesSharingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />

  <element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="plx_IncomeTaxDisclosureTable" />

  <element name="TaxYearTwoThousandNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TaxYearTwoThousandNineMember" />

  <element name="TaxYearThereafterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TaxYearThereafterMember" />

  <element name="RestrictedAmountMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_RestrictedAmountMember" />

  <element name="SupplementalInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SupplementalInformationAbstract" />

  <element name="SupplementaryBalanceSheetsInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />

  <element name="SupplementaryIncomeStatementInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" />

  <element name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />

  <element name="OtherAssetsInstitutionsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_OtherAssetsInstitutionsCurrent" />

  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_NatureOfOperationsPolicyTextBlock" />

  <element name="RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />

  <element name="ScheduleOfUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ScheduleOfUsefulLifeTableTextBlock" />

  <element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_LaboratoryEquipmentMember" />

  <element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />

  <element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />

  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />

  <element name="AmortizationOfDebtIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_AmortizationOfDebtIssuanceCosts" />

  <element name="DebtInstrumentConvertibleConversionShareNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="plx_DebtInstrumentConvertibleConversionShareNumber" />

  <element name="DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" />

  <element name="DebtInstrumentConvertibleBaseValueForConversionRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />

  <element name="EmployeeSeveranceObligationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_EmployeeSeveranceObligationPayment" />

  <element name="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />

  <element name="OptionsAndRestrictedStockGrantedToEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />

  <element name="StockIssuedDuringPeriodSharesStockExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_StockIssuedDuringPeriodSharesStockExpired" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />

  <element name="OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />

  <element name="GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_GrantsAndReimbursementsReceivedOrReceivable" />

  <element name="ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" />

  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />

  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />

  <element name="ScheduleOfOpenTaxYearsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ScheduleOfOpenTaxYearsTableTextBlock" />

  <element name="UsIsraelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_UsIsraelMember" />

  <element name="FurnitureAndComputerEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_FurnitureAndComputerEquipmentMember" />

  <element name="EquipmentUnderConstructionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_EquipmentUnderConstructionMember" />

  <element name="CompensationToTheNon-executiveDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_CompensationToTheNon-executiveDirectorsMember" />

  <element name="OtherAssetsSundryCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_OtherAssetsSundryCurrent" />

  <element name="GrantYearTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_GrantYearTwoThousandFifteenMember" />

  <element name="DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" />

  <element name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />

  <element name="DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" />

  <element name="DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" />

  <element name="IncomeOnConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_IncomeOnConversionOfConvertibleNotes" />

  <element name="CommercializationAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_CommercializationAgreementsAbstract" />

  <element name="AgreementsWithPfizerAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_AgreementsWithPfizerAbstract" />

  <element name="CollaborativeArrangementProfitSharePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="plx_CollaborativeArrangementProfitSharePercentage" />

  <element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PfizerMember" />

  <element name="MilestonePotentialPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_MilestonePotentialPayable" />

  <element name="MilestonePaymentAmountPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_MilestonePaymentAmountPaid" />

  <element name="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />

  <element name="FourPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_FourPointFivePercentageConvertibleNotesMember" />

  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SevenPointFivePercentageConvertibleNotesMember" />

  <element name="ConvertibleNotesDueTwoThousandTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" />

  <element name="MaximumDebtInstrumentConvertibleConversionShareNumber" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />

  <element name="Notes2016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_Notes2016Member" />

  <element name="Notes2013Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_Notes2013Member" />

  <element name="ConvertibleNotes2013Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ConvertibleNotes2013Member" />

  <element name="PercentageOfExcessSharesOutstanding" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PercentageOfExcessSharesOutstanding" />

  <element name="BenefitsPayableDuringNextFiveYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_BenefitsPayableDuringNextFiveYears" />

  <element name="ProceedsFromExchangeForRightsToRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_ProceedsFromExchangeForRightsToRoyalties" />

  <element name="IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />

  <element name="FutureResearchAndDevelopmentReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_FutureResearchAndDevelopmentReimbursement" />

  <element name="ChiesiAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ChiesiAgreementMember" />

  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SignificantAccountingPoliciesLineItems" />

  <element name="UpfrontNonrefundableNoncreditablePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />

  <element name="AdditionalAmountsPayableToCoverDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />

  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />

  <element name="AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />

  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_PaymentOnNetSalesPercentage" />

  <element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_IncomeTaxDisclosureLineItems" />

  <element name="Notes2017Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_Notes2017Member" />

  <element name="FourPointFivePercentageConvertibleNotesOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_FourPointFivePercentageConvertibleNotesOneMember" />

  <element name="DebtInstrumentMaturityYear" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_DebtInstrumentMaturityYear" />

  <element name="GainLossOnConversionOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="plx_GainLossOnConversionOfDebt" />

  <element name="FourPointFivePercentageConvertibleNotes2013Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_FourPointFivePercentageConvertibleNotes2013Member" />

  <element name="SevenPointFivePercentageConvertibleNotes2016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_SevenPointFivePercentageConvertibleNotes2016Member" />

  <element name="StockholdersApprovalDescriptionForCommonStockIssuance" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_StockholdersApprovalDescriptionForCommonStockIssuance" />

  <element name="PercentageOfRoyaltiesToGrantReceived" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="plx_PercentageOfRoyaltiesToGrantReceived" />

  <element name="TwentyThirteenAndTwentySixteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_TwentyThirteenAndTwentySixteenNotesMember" />

  <element name="ContributionPlansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="plx_ContributionPlansMember" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>plx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotes" roleURI="http://www.protalix.com/role/ConvertibleNotes" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeDeferredIncomeTaxesDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncome" roleURI="http://www.protalix.com/role/TaxesOnIncome" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#Inventories" roleURI="http://www.protalix.com/role/Inventories" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipment" roleURI="http://www.protalix.com/role/PropertyAndEquipment" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperations" roleURI="http://www.protalix.com/role/DiscontinuedOperations" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperationsOperationsDetails" roleURI="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails" />

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleDebtCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="80" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="100" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="110" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="120" weight="-1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeOnConversionOfConvertibleNotes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_IncomeOnConversionOfConvertibleNotes" use="optional" order="130" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" use="optional" order="140" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="150" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" use="optional" order="160" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="170" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="30" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_Revenues" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingExpense" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_us-gaap_AccruedVacationCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" use="optional" order="60" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="loc_plx_OtherAssetsInstitutionsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_plx_OtherAssetsInstitutionsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="loc_us-gaap_PrepaidRoyalties" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidRoyalties" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="loc_plx_OtherAssetsSundryCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_plx_OtherAssetsSundryCurrent" use="optional" order="60" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>plx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#CommitmentsNarrativeDetails" roleURI="http://www.protalix.com/role/CommitmentsNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalRestrictedStockGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeNarrativeDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesNarrativeDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesTables" roleURI="http://www.protalix.com/role/ConvertibleNotesTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#LiabilityForEmployeeRightsUponRetirementNarrativeDetails" roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalShareBasedCompensationExpenseAllocationDetails" roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalOptionsGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" roleURI="http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeDeferredIncomeTaxesDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#RelatedPartyTransactionsCompensationDetails" roleURI="http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperationsOperationsDetails" roleURI="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#CommercializationAgreementsNarrativeDetails" roleURI="http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesFairValueIncomeApproachDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesScheduleOfDebtInterestExpensesDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipmentNarrativeDetails" roleURI="http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1135" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentInformationTable_1134" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1134" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1201" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1201" xlink:to="loc_us-gaap_ClassOfStockDomain_1203" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1203_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1201" xlink:to="loc_us-gaap_ClassOfStockDomain_1203_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentType_1136" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_AmendmentFlag_1137" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentPeriodEndDate_1138" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentFiscalYearFocus_1139" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1140" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityRegistrantName_1141" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCentralIndexKey_1142" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_CurrentFiscalYearEndDate_1143" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1144" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_1145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityVoluntaryFilers_1145" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCurrentReportingStatus_1146" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityFilerCategory_1147" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityPublicFloat_1148" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_TradingSymbol_1149" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1150" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CommitmentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="loc_plx_CommitmentsAndContingenciesLineItems_41" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="loc_plx_CommitmentsAndContingenciesTable_25" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_CommitmentsAndContingenciesTable_25" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_CommitmentsAndContingenciesTable_25" xlink:to="loc_us-gaap_RangeAxis_26" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_27" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_26" xlink:to="loc_us-gaap_RangeMember_27" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_27_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_26" xlink:to="loc_us-gaap_RangeMember_27_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_28" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_27" xlink:to="loc_us-gaap_MinimumMember_28" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_29" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_27" xlink:to="loc_us-gaap_MaximumMember_29" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis_30" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_CommitmentsAndContingenciesTable_25" xlink:to="loc_plx_CommitmentsAndContingenciesAxis_30" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_30" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_31" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_31_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_30" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_31_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OCSMember" xlink:label="loc_plx_OCSMember_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_OCSMember_32" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="loc_plx_ProductsManufacturedOutsideOfIsraelMember_33" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_ProductsManufacturedOutsideOfIsraelMember_33" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="loc_plx_ResearchAndLicenseAgreementsMember_35" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_ResearchAndLicenseAgreementsMember_35" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_us-gaap_LeaseAgreementsMember_38" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_39" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_39" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="loc_plx_RoyaltiesOnSaleOfProducts_42" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_RoyaltiesOnSaleOfProducts_42" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_RoyaltyExpense_44" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_45" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_45" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentAmount" xlink:label="loc_plx_CommitmentAmount_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_CommitmentAmount_46" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="loc_plx_MonthlyRentLeaseExpense_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MonthlyRentLeaseExpense_47" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_48" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_48" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_49" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_49" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_50" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_55" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_SecurityDeposit_55" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_56" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePotentialPayable" xlink:label="loc_plx_MilestonePotentialPayable_1007" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MilestonePotentialPayable_1007" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePaymentAmountPaid" xlink:label="loc_plx_MilestonePaymentAmountPaid_1008" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MilestonePaymentAmountPaid_1008" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1092" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1092" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="loc_plx_PercentageOfRoyaltiesToGrantReceived_1294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_PercentageOfRoyaltiesToGrantReceived_1294" use="optional" order="28" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_63" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63" xlink:to="loc_us-gaap_StatementTable_59" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_59" xlink:to="loc_us-gaap_AwardTypeAxis_60" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" xlink:to="loc_us-gaap_RestrictedStockMember_62" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_64" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_AwardTypeAxis_72" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_VestingAxis_76" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_76" xlink:to="loc_us-gaap_VestingDomain_77" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_77_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_76" xlink:to="loc_us-gaap_VestingDomain_77_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_77" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_78" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_TitleOfIndividualAxis_80" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_80" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_80" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="loc_plx_PresidentAndChiefExecutiveOfficerMember_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_plx_PresidentAndChiefExecutiveOfficerMember_100" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="loc_plx_OfficersAndCertainEmployeesMember_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_plx_OfficersAndCertainEmployeesMember_102" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_us-gaap_ExecutiveOfficerMember_103" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_96" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_964" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_964" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_999" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_964" xlink:to="loc_us-gaap_EquityComponentDomain_999" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_999_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_964" xlink:to="loc_us-gaap_EquityComponentDomain_999_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1000" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_999" xlink:to="loc_us-gaap_CommonStockMember_1000" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_998" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_DebtInstrumentAxis_998" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_998" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1101" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1101_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_998" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1101_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1102" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1103" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1235" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1241" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_949" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_949" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_950" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_950" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_952" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_952" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_953" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_953" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_954" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_954" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_955" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_955" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_956" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_958" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_958" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_959" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_959" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_992" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_992" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1104" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1105" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1236" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentMaturityYear" xlink:label="loc_plx_DebtInstrumentMaturityYear_1242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_plx_DebtInstrumentMaturityYear_1242" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1269" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1269" use="optional" order="48" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" xlink:to="loc_us-gaap_AwardTypeAxis_107" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" xlink:to="loc_us-gaap_TitleOfIndividualAxis_110" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeesMember" xlink:label="loc_plx_EmployeesMember_118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" xlink:to="loc_plx_EmployeesMember_118" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_111" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_115" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_113" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OnePointSevenTwoZeroMember" xlink:label="loc_plx_OnePointSevenTwoZeroMember_947" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_OnePointSevenTwoZeroMember_947" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="loc_plx_TwoPointThreeFiveZeroMember_128" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointThreeFiveZeroMember_128" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="loc_plx_TwoPointThreeSevenZeroMember_137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointThreeSevenZeroMember_137" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointSixFiveMember" xlink:label="loc_plx_TwoPointSixFiveMember_129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointSixFiveMember_129" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="loc_plx_ThreePointZeroTwoZeroMember_130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_ThreePointZeroTwoZeroMember_130" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="loc_plx_ThreePointThreeSevenZeroMember_138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_ThreePointThreeSevenZeroMember_138" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FivePointZeroMember" xlink:label="loc_plx_FivePointZeroMember_131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_FivePointZeroMember_131" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SixPointNineMember" xlink:label="loc_plx_SixPointNineMember_133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_SixPointNineMember_133" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFiveFiveMember" xlink:label="loc_plx_SevenPointFiveFiveMember_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_SevenPointFiveFiveMember_134" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_NinePointSixSixMember" xlink:label="loc_plx_NinePointSixSixMember_135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_NinePointSixSixMember_135" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" xlink:to="loc_us-gaap_AwardTypeAxis_139" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="loc_plx_OptionsAndRestrictedStockMember_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" xlink:to="loc_plx_OptionsAndRestrictedStockMember_150" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_140" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_141" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_142" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_143" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_144" use="optional" order="23" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_1167" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_SignificantAccountingPoliciesTable_198" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_199" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_200" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_200_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_200_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_202" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_PfizerAgreementMember_205" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_206" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_AmendedPfizerAgreementMember_206" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ChiesiAgreementMember" xlink:label="loc_plx_ChiesiAgreementMember_1164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_ChiesiAgreementMember_1164" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_dei_LegalEntityAxis_207" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_207" xlink:to="loc_dei_EntityDomain_208" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_207" xlink:to="loc_dei_EntityDomain_208_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_208" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_210" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_CounterpartyNameAxis_211" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_211" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_211" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_StatementGeographicalAxis_215" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_215" xlink:to="loc_us-gaap_SegmentGeographicalDomain_216" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_216_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_215" xlink:to="loc_us-gaap_SegmentGeographicalDomain_216_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_216" xlink:to="loc_country_BR_217" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_StatementScenarioAxis_219" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_219" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_220" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_220_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_219" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_220_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_849" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_RangeAxis_849" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_849" xlink:to="loc_us-gaap_RangeMember_1168" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1168_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_849" xlink:to="loc_us-gaap_RangeMember_1168_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1168" xlink:to="loc_us-gaap_MinimumMember_1169" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1168" xlink:to="loc_us-gaap_MaximumMember_1170" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_237" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_239" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_242" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1046" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1046" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties_1121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_ProceedsFromExchangeForRightsToRoyalties_1121" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FutureResearchAndDevelopmentReimbursement" xlink:label="loc_plx_FutureResearchAndDevelopmentReimbursement_1163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_FutureResearchAndDevelopmentReimbursement_1163" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1181" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1182" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1183" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1184" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_1185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_PaymentOnNetSalesPercentage_1185" use="optional" order="47" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="loc_plx_IncomeTaxDisclosureLineItems_1187" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="loc_plx_IncomeTaxDisclosureTable_286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_IncomeTaxDisclosureLineItems_1187" xlink:to="loc_plx_IncomeTaxDisclosureTable_286" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_RangeAxis_287" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_287" xlink:to="loc_us-gaap_RangeMember_288" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_288_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_287" xlink:to="loc_us-gaap_RangeMember_288_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_288" xlink:to="loc_us-gaap_MinimumMember_289" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_288" xlink:to="loc_us-gaap_MaximumMember_290" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_291" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_291" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_303" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_303_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_291" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_303_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_303" xlink:to="loc_us-gaap_SubsidiariesMember_304" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_302" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_302" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_302" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_306" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_306_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_302" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_306_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="loc_plx_TaxYearTwoThousandNineMember_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_TaxYearTwoThousandNineMember_307" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearThereafterMember" xlink:label="loc_plx_TaxYearThereafterMember_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_TaxYearThereafterMember_309" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RestrictedAmountMember" xlink:label="loc_plx_RestrictedAmountMember_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_RestrictedAmountMember_310" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_StatementScenarioAxis_1108" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_1108" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1188" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1188_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_1108" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1188_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_1189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1188" xlink:to="loc_us-gaap_ScenarioPlanMember_1189" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_IncomeTaxDisclosureLineItems_1187" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_292" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_IncomeTaxDisclosureLineItems_1187" xlink:to="loc_us-gaap_OperatingLossCarryforwards_299" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_812" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_812" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_InterestPayableCurrent_325" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedVacationCurrent_326" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_327" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_328" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_328" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_330" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1009" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccountsPayableCurrent_1009" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_812" xlink:to="loc_us-gaap_StatementTable_809" use="optional" order="9" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_810" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_809" xlink:to="loc_us-gaap_StatementClassOfStockAxis_810" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_811" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_810" xlink:to="loc_us-gaap_ClassOfStockDomain_811" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_811_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_810" xlink:to="loc_us-gaap_ClassOfStockDomain_811_default" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_808" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_808" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="loc_plx_OtherAssetsInstitutionsCurrent_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_plx_OtherAssetsInstitutionsCurrent_337" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="loc_us-gaap_PrepaidRoyalties_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_PrepaidRoyalties_338" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_339" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_340" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1268" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1268" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="loc_plx_OtherAssetsSundryCurrent_341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_plx_OtherAssetsSundryCurrent_341" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_818" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_OtherAssetsCurrent_818" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_805" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_808" xlink:to="loc_us-gaap_StatementTable_805" use="optional" order="9" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_806" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_806" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_807" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_806" xlink:to="loc_us-gaap_ClassOfStockDomain_807" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_807_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_806" xlink:to="loc_us-gaap_ClassOfStockDomain_807_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_805" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1270" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1270" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1271" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1271_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1270" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1271_default" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_LaboratoryEquipmentMember" xlink:label="loc_plx_LaboratoryEquipmentMember_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_plx_LaboratoryEquipmentMember_371" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_373" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_ComputerEquipmentMember_372" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_RangeAxis_374" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_374" xlink:to="loc_us-gaap_RangeMember_375" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_375_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_374" xlink:to="loc_us-gaap_RangeMember_375_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_375" xlink:to="loc_us-gaap_MinimumMember_376" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_375" xlink:to="loc_us-gaap_MaximumMember_377" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_379" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_725" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_722" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_725" xlink:to="loc_us-gaap_StatementTable_722" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_723" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementClassOfStockAxis_723" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_724" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_724" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_724_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_724_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_382" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_725" xlink:to="loc_us-gaap_AssetsAbstract_382" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_AssetsCurrentAbstract_383" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_385" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_OtherAssetsCurrent_388" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_InventoryNet_386" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_AssetsCurrent_387" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_391" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_389" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_Assets_390" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_725" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_394" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_396" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_397" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_1039" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_1039" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_DeferredRevenueCurrent_398" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_LiabilitiesCurrent_399" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_403" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_404" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_402" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1186" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_405" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_406" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_Liabilities_406" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_CommitmentsAndContingencies_407" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_StockholdersEquityAbstract_409" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_CommonStockValue_410" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_411" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_412" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_StockholdersEquity_413" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_408" use="optional" order="36" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_733" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_730" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_StatementTable_730" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_731" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_730" xlink:to="loc_us-gaap_StatementClassOfStockAxis_731" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_732" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731" xlink:to="loc_us-gaap_ClassOfStockDomain_732" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_732_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731" xlink:to="loc_us-gaap_ClassOfStockDomain_732_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetIncomeLoss_417" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_840" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_840" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_841" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_841" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_ShareBasedCompensation_419" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_420" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_Depreciation_420" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_421" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_421" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_429" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_422" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_842" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_842" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1042" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1042" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeOnConversionOfConvertibleNotes_1155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_IncomeOnConversionOfConvertibleNotes_1155" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1043" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1043" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_430" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_1156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_1156" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_424" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_425" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_426" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_427" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1157" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_431" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_843" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_843" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_844" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_844" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_433" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_435" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_436" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_437" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_434" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_845" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_845" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1158" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_439" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_440" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_441" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_443" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_444" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_445" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_450" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_1002" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_NotesIssued1_1002" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1044" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_StockIssued1_1044" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1159" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" xlink:to="loc_us-gaap_InterestPaidNet_448" use="optional" order="53" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_822" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_460" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_460" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="loc_plx_AmortizationOfDebtIssuanceCosts_459" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_plx_AmortizationOfDebtIssuanceCosts_459" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_us-gaap_InterestExpense_458" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_819" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_us-gaap_StatementTable_819" use="optional" order="4" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_820" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_820" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_821" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820" xlink:to="loc_us-gaap_ClassOfStockDomain_821" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_821_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820" xlink:to="loc_us-gaap_ClassOfStockDomain_821_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_1112" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1112" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1113" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1113_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1112" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1113_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2013Member" xlink:label="loc_plx_Notes2013Member_1114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1113" xlink:to="loc_plx_Notes2013Member_1114" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1004" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_463" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_463" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_DebtInstrumentConvertibleConversionShareNumber_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentConvertibleConversionShareNumber_464" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_465" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xlink:label="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption_466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption_466" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_467" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_468" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_468" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_469" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_469" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate_470" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate_470" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_823" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_StatementTable_823" use="optional" order="9" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_824" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_823" xlink:to="loc_us-gaap_DebtInstrumentAxis_824" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_825" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_824" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_825" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_825_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_824" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_825_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1088" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1088" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1090" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1090" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1091" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1091" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotes2013Member" xlink:label="loc_plx_ConvertibleNotes2013Member_1115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_ConvertibleNotes2013Member_1115" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1248" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1249" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1249" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1255" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_826" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_823" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_826" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1005" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_826" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1005" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1005_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_826" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1005_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1006" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1005" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1006" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1089" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1089" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1093" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1093" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber_1094" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber_1094" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfExcessSharesOutstanding" xlink:label="loc_plx_PercentageOfExcessSharesOutstanding_1116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_PercentageOfExcessSharesOutstanding_1116" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1120" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1250" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1251" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1251" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockholdersApprovalDescriptionForCommonStockIssuance" xlink:label="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance_1252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance_1252" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1253" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1253" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentMaturityYear" xlink:label="loc_plx_DebtInstrumentMaturityYear_1256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentMaturityYear_1256" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1295" use="optional" order="35" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1223" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_476" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1223" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_476" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1057" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1223" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1057" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1223" xlink:to="loc_us-gaap_StatementTable_1208" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1209" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1209" xlink:to="loc_us-gaap_ClassOfStockDomain_1210" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1210_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1209" xlink:to="loc_us-gaap_ClassOfStockDomain_1210_default" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_1211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_StatementGeographicalAxis_1211" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1213" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_1211" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1213" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1213_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_1211" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1213_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2013Member" xlink:label="loc_plx_Notes2013Member_1214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2013Member_1214" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2016Member" xlink:label="loc_plx_Notes2016Member_1215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2016Member_1215" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2017Member" xlink:label="loc_plx_Notes2017Member_1216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2017Member_1216" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_DebtInstrumentAxis_1212" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1212" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1224" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1224_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1212" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1224_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1224" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1225" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1224" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1230" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1306" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="loc_plx_EmployeeSeveranceObligationPayment_479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_plx_EmployeeSeveranceObligationPayment_479" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_480" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="loc_us-gaap_PostemploymentBenefitsPeriodExpense_483" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_PostemploymentBenefitsPeriodExpense_483" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_484" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_484" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_855" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_StatementTable_855" use="optional" order="5" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_858" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementScenarioAxis_858" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_858" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1263" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1263_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_858" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1263_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_1262" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_1262" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1262" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1307" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1307_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1262" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1307_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_1308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1307" xlink:to="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_1308" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ContributionPlansMember" xlink:label="loc_plx_ContributionPlansMember_1309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1307" xlink:to="loc_plx_ContributionPlansMember_1309" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="loc_plx_BenefitsPayableDuringNextFiveYears_1119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_plx_BenefitsPayableDuringNextFiveYears_1119" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1293" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1293" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_507" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_507" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_509" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_509_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_507" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_509_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_509" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_511" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_509" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_512" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_948" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_516" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" xlink:to="loc_us-gaap_PlanNameAxis_516" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_516" xlink:to="loc_us-gaap_PlanNameDomain_517" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_516" xlink:to="loc_us-gaap_PlanNameDomain_517_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantYearTwoThousandFifteenMember" xlink:label="loc_plx_GrantYearTwoThousandFifteenMember_830" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_517" xlink:to="loc_plx_GrantYearTwoThousandFifteenMember_830" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" xlink:to="loc_us-gaap_TitleOfIndividualAxis_521" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_521" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_521" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeesMember" xlink:label="loc_plx_EmployeesMember_530" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" xlink:to="loc_plx_EmployeesMember_530" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_522" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_525" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_525" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_526" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_526" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_527" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_527" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" xlink:to="loc_us-gaap_TitleOfIndividualAxis_534" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_534" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_534" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" xlink:to="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_553" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_538" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_539" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_541" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_541" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_543" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_545" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_546" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_547" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_548" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_557" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" xlink:to="loc_us-gaap_TitleOfIndividualAxis_557" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_557" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_557" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" xlink:to="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_574" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="loc_plx_StockIssuedDuringPeriodSharesStockExpired_927" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_plx_StockIssuedDuringPeriodSharesStockExpired_927" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_931" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_931" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_563" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_566" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_937" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_937" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_729" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_726" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_StatementTable_726" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_727" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_726" xlink:to="loc_us-gaap_StatementClassOfStockAxis_727" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_728" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_727" xlink:to="loc_us-gaap_ClassOfStockDomain_728" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_728_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_727" xlink:to="loc_us-gaap_ClassOfStockDomain_728_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_Revenues_577" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_CostOfRevenue_579" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_580" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_GrossProfit_580" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_581" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_582" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_583" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_583" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_584" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OperatingIncomeLoss_585" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OtherNonoperatingExpense_586" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OtherNonoperatingIncome_587" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1151" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1041" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1041" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_588" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_588" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_831" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_831" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_832" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_832" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_NetIncomeLoss_589" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_833" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_833" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_834" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_834" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_591" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_593" use="optional" order="25" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_611" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StatementTable_605" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_606" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_606" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_607" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_606" xlink:to="loc_us-gaap_EquityComponentDomain_607" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_607_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_606" xlink:to="loc_us-gaap_EquityComponentDomain_607_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_CommonStockMember_608" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_609" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_609" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_RetainedEarningsMember_610" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_613" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockholdersEquity_613" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_615" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_SharesOutstanding_615" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_838" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_838" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_839" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_839" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1040" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1040" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_612" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_612" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_614" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_614" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_616" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_616" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1152" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1153" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1154" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_617" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_618" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_618" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_836" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_836" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_837" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_837" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1096" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1096" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_626" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_745" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1096" xlink:to="loc_us-gaap_StatementTable_745" use="optional" order="2" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747_default" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1052" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1052" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_748" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_DebtInstrumentAxis_748" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1054" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_748" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1054" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1054_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_748" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1054_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1055" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1055" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1056" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1056" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1296" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1297" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1096" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1310" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_816" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_813" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_816" xlink:to="loc_us-gaap_StatementTable_813" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_814" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_813" xlink:to="loc_us-gaap_StatementClassOfStockAxis_814" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_815" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_814" xlink:to="loc_us-gaap_ClassOfStockDomain_815" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_815_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_814" xlink:to="loc_us-gaap_ClassOfStockDomain_815_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_816" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_641" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_641" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_642" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_642" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_643" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_643" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_657" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_657" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_649" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_649" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_650" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_651" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_650" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_651" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_651_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_650" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_651_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UsIsraelMember" xlink:label="loc_plx_UsIsraelMember_990" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_651" xlink:to="loc_plx_UsIsraelMember_990" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_651" xlink:to="loc_country_US_653" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_649" xlink:to="loc_us-gaap_RangeAxis_655" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_655" xlink:to="loc_us-gaap_RangeMember_658" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_655" xlink:to="loc_us-gaap_RangeMember_658_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MinimumMember_659" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MaximumMember_660" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_656" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_657" xlink:to="loc_us-gaap_OpenTaxYear_656" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_737" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_663" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_663" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_664" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_667" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_667" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryNet_665" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_734" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_StatementTable_734" use="optional" order="5" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_735" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_734" xlink:to="loc_us-gaap_StatementClassOfStockAxis_735" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_735" xlink:to="loc_us-gaap_ClassOfStockDomain_736" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_735" xlink:to="loc_us-gaap_ClassOfStockDomain_736_default" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_LaboratoryEquipmentMember" xlink:label="loc_plx_LaboratoryEquipmentMember_679" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_LaboratoryEquipmentMember_679" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="loc_plx_FurnitureAndComputerEquipmentMember_680" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_FurnitureAndComputerEquipmentMember_680" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_681" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_681" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="loc_plx_EquipmentUnderConstructionMember_682" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_EquipmentUnderConstructionMember_682" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_684" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_684" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_685" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_685" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_852" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_852" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_700" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_700" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" xlink:to="loc_us-gaap_RelatedPartyDomain_697" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" xlink:to="loc_us-gaap_RelatedPartyDomain_697_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="loc_plx_CompensationToTheNon-executiveDirectorsMember_699" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_697" xlink:to="loc_plx_CompensationToTheNon-executiveDirectorsMember_699" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_701" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_700" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_701" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_802" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_803" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_803" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_804" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_804" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_799" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_StatementTable_799" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_800" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_799" xlink:to="loc_us-gaap_StatementClassOfStockAxis_800" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_801" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800" xlink:to="loc_us-gaap_ClassOfStockDomain_801" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_801_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800" xlink:to="loc_us-gaap_ClassOfStockDomain_801_default" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_710" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesIssued_710" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_711" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_711" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_892" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_889" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_StatementTable_889" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_890" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_889" xlink:to="loc_us-gaap_StatementClassOfStockAxis_890" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_891" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_890" xlink:to="loc_us-gaap_ClassOfStockDomain_891" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_891_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_890" xlink:to="loc_us-gaap_ClassOfStockDomain_891_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_893" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_893" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement_900" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement_900" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_894" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_894" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_895" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_895" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_901" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_901" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable_902" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable_902" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet_903" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet_903" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_896" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_896" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_897" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_897" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_898" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_898" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_899" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_899" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1177" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_921" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_us-gaap_StatementTable_921" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_922" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_StatementClassOfStockAxis_922" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_923" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_922" xlink:to="loc_us-gaap_ClassOfStockDomain_923" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_923_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_922" xlink:to="loc_us-gaap_ClassOfStockDomain_923_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_924" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_TypeOfArrangementAxis_924" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_930" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_930" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_936" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_PfizerMember_936" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ChiesiAgreementMember" xlink:label="loc_plx_ChiesiAgreementMember_1176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_ChiesiAgreementMember_1176" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_928" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_RangeAxis_928" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_928" xlink:to="loc_us-gaap_RangeMember_1178" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1178_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_928" xlink:to="loc_us-gaap_RangeMember_1178_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1178" xlink:to="loc_us-gaap_MaximumMember_1179" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1178" xlink:to="loc_us-gaap_MinimumMember_1180" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="loc_plx_CollaborativeArrangementProfitSharePercentage_926" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_CollaborativeArrangementProfitSharePercentage_926" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_938" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_938" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_939" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_939" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1171" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1172" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1173" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1174" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_1175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_PaymentOnNetSalesPercentage_1175" use="optional" order="23" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1064" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1061" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_StatementTable_1061" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1062" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1061" xlink:to="loc_us-gaap_DebtInstrumentAxis_1062" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1063" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1063" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1063_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1063_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1067" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1063" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1067" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1063" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1243" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1068" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_SharePrice_1068" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1069" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1069" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1070" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1070" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1071" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1071" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1072" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1072" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1078" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1075" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_StatementTable_1075" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1076" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1075" xlink:to="loc_us-gaap_DebtInstrumentAxis_1076" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1077" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1076" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1077" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1077_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1076" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1077_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2016Member" xlink:label="loc_plx_Notes2016Member_1111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1077" xlink:to="loc_plx_Notes2016Member_1111" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2017Member" xlink:label="loc_plx_Notes2017Member_1246" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1077" xlink:to="loc_plx_Notes2017Member_1246" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1081" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1081" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_1247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_1247" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1083" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1083" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1084" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1084" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestExpenseDebt_1244" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnConversionOfDebt" xlink:label="loc_plx_GainLossOnConversionOfDebt_1245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_plx_GainLossOnConversionOfDebt_1245" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1085" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_1085" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1284" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1284" xlink:to="loc_us-gaap_StatementTable_1193" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_1280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1193" xlink:to="loc_us-gaap_StatementGeographicalAxis_1280" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_1280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1283" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1283_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_1280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1283_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_1286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1283" xlink:to="loc_country_BR_1286" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1193" xlink:to="loc_dei_LegalEntityAxis_1282" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1282" xlink:to="loc_dei_EntityDomain_1285" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1285_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1282" xlink:to="loc_dei_EntityDomain_1285_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_1287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1285" xlink:to="loc_plx_PfizerMember_1287" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1284" xlink:to="loc_us-gaap_Revenues_1202" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1302" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1207" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_StatementTable_1298" use="optional" order="2" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1299" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300_default" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_DebtInstrumentAxis_1301" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1301" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1303" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1303_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1301" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1303_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwentyThirteenAndTwentySixteenNotesMember" xlink:label="loc_plx_TwentyThirteenAndTwentySixteenNotesMember_1304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1303" xlink:to="loc_plx_TwentyThirteenAndTwentySixteenNotesMember_1304" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1232" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_StatementTable_1219" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1220" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1220" xlink:to="loc_us-gaap_ClassOfStockDomain_1221" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1221_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1220" xlink:to="loc_us-gaap_ClassOfStockDomain_1221_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_DebtInstrumentAxis_1222" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1222" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1227" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1227_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1222" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1227_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1227" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1228" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1227" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1229" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1234" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_SharePrice_1231" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1237" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1238" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1239" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1240" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" xlink:to="loc_dei_LegalEntityAxis_1277" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1277" xlink:to="loc_dei_EntityDomain_1278" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1278_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1277" xlink:to="loc_dei_EntityDomain_1278_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" xlink:to="loc_us-gaap_Depreciation_1261" use="optional" order="5" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>plx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DocumentAndEntityInformationAbstract" xlink:to="lab_plx_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">COMMITMENTS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="loc_plx_CommitmentsAndContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments And Contingencies [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments And Contingencies Table</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesTable" xlink:to="lab_plx_CommitmentsAndContingenciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US">Commitments And Contingencies [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesAxis" xml:lang="en-US">Commitments And Contingencies Axis</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesAxis" xlink:to="lab_plx_CommitmentsAndContingenciesAxis" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US">Commitments And Contingencies [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesDomain" xml:lang="en-US">Commitments And Contingencies [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesDomain" xlink:to="lab_plx_CommitmentsAndContingenciesDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OCSMember" xlink:label="loc_plx_OCSMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OCSMember" xml:lang="en-US">OCS [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OCSMember" xml:lang="en-US">OCS Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OCSMember" xlink:to="lab_plx_OCSMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="loc_plx_ProductsManufacturedOutsideOfIsraelMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProductsManufacturedOutsideOfIsraelMember" xml:lang="en-US">Products Manufactured Outside Of Israel [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProductsManufacturedOutsideOfIsraelMember" xml:lang="en-US">Products Manufactured Outside Of Israel Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProductsManufacturedOutsideOfIsraelMember" xlink:to="lab_plx_ProductsManufacturedOutsideOfIsraelMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="loc_plx_ResearchAndLicenseAgreementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ResearchAndLicenseAgreementsMember" xml:lang="en-US">Research And License Agreements [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ResearchAndLicenseAgreementsMember" xml:lang="en-US">Research And License Agreements Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ResearchAndLicenseAgreementsMember" xlink:to="lab_plx_ResearchAndLicenseAgreementsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember" xml:lang="en-US">Lease Agreements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US">Vehicle Lease And Maintenance Agreements [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" xml:lang="en-US">Vehicle Lease and Maintenance Agreements Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="lab_plx_VehicleLeaseAndMaintenanceAgreementsMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="loc_plx_CommitmentsAndContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems" xlink:to="lab_plx_CommitmentsAndContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="loc_plx_RoyaltiesOnSaleOfProducts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RoyaltiesOnSaleOfProducts" xml:lang="en-US">Royalties On Sale Of Products</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_RoyaltiesOnSaleOfProducts" xml:lang="en-US">Royalties based on sale of products developed from funded projects, percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RoyaltiesOnSaleOfProducts" xml:lang="en-US">Percentage of royalties based on sale of products developed from projects funded.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RoyaltiesOnSaleOfProducts" xlink:to="lab_plx_RoyaltiesOnSaleOfProducts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense included in cost of revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Royalties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued royalties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentAmount" xlink:label="loc_plx_CommitmentAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommitmentAmount" xml:lang="en-US">Commitment Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_CommitmentAmount" xml:lang="en-US">Subcontracting commitment amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CommitmentAmount" xml:lang="en-US">Commitment amount.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommitmentAmount" xlink:to="lab_plx_CommitmentAmount" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="loc_plx_MonthlyRentLeaseExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MonthlyRentLeaseExpense" xml:lang="en-US">Monthly Rent Lease Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_MonthlyRentLeaseExpense" xml:lang="en-US">Monthly rent/lease expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MonthlyRentLeaseExpense" xml:lang="en-US">Monthly rent/lease expense.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MonthlyRentLeaseExpense" xlink:to="lab_plx_MonthlyRentLeaseExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Future minimum lease payments, 2018</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Future minimum lease payments, 2019</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Future minimum lease payments, 2020</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Cash deposited as bank guarantee</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Lease/rent expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Share-based compensation related to restricted stock award, forfeitures, (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">SHARE CAPITAL [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Option to purchase shares of common stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Vest on the first anniversary of the grant date [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued for cash (net of issuance costs) (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Common stock available for issuance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="loc_plx_PresidentAndChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US">President and Chief Executive Officer [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US">President and Chief Executive Officer [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US">First or second ranking officer of the entity that may be appointed by the board of directors and Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="lab_plx_PresidentAndChiefExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="loc_plx_OfficersAndCertainEmployeesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OfficersAndCertainEmployeesMember" xml:lang="en-US">Officers And Certain Employees [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OfficersAndCertainEmployeesMember" xml:lang="en-US">Officers And Certain Employees Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OfficersAndCertainEmployeesMember" xlink:to="lab_plx_OfficersAndCertainEmployeesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember" xlink:to="lab_us-gaap_ExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding at beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Outstanding at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Restricted stock awards forfeited, share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeesMember" xlink:label="loc_plx_EmployeesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_EmployeesMember" xml:lang="en-US">Employees [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_EmployeesMember" xml:lang="en-US">Employees [Member].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_EmployeesMember" xlink:to="lab_plx_EmployeesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OnePointSevenTwoZeroMember" xlink:label="loc_plx_OnePointSevenTwoZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OnePointSevenTwoZeroMember" xml:lang="en-US">One Point Seven Two Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_OnePointSevenTwoZeroMember" xml:lang="en-US">1.720 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OnePointSevenTwoZeroMember" xlink:to="lab_plx_OnePointSevenTwoZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="loc_plx_TwoPointThreeFiveZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TwoPointThreeFiveZeroMember" xml:lang="en-US">Two Point Three Five Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TwoPointThreeFiveZeroMember" xml:lang="en-US">2.350 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_TwoPointThreeFiveZeroMember" xml:lang="en-US">Two Point Three Five Zero [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TwoPointThreeFiveZeroMember" xlink:to="lab_plx_TwoPointThreeFiveZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="loc_plx_TwoPointThreeSevenZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TwoPointThreeSevenZeroMember" xml:lang="en-US">Two Point Three Seven Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TwoPointThreeSevenZeroMember" xml:lang="en-US">2.370 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_TwoPointThreeSevenZeroMember" xml:lang="en-US">Two Point Three Seven Zero [Member].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TwoPointThreeSevenZeroMember" xlink:to="lab_plx_TwoPointThreeSevenZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointSixFiveMember" xlink:label="loc_plx_TwoPointSixFiveMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TwoPointSixFiveMember" xml:lang="en-US">Two Point Six Five [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TwoPointSixFiveMember" xml:lang="en-US">2.650 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_TwoPointSixFiveMember" xml:lang="en-US">Two Point Six Five [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TwoPointSixFiveMember" xlink:to="lab_plx_TwoPointSixFiveMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="loc_plx_ThreePointZeroTwoZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ThreePointZeroTwoZeroMember" xml:lang="en-US">Three Point Zero Two Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ThreePointZeroTwoZeroMember" xml:lang="en-US">3.020 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ThreePointZeroTwoZeroMember" xml:lang="en-US">Three Point Zero Two Zero Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ThreePointZeroTwoZeroMember" xlink:to="lab_plx_ThreePointZeroTwoZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="loc_plx_ThreePointThreeSevenZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ThreePointThreeSevenZeroMember" xml:lang="en-US">Three Point Three Seven Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ThreePointThreeSevenZeroMember" xml:lang="en-US">3.370 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ThreePointThreeSevenZeroMember" xml:lang="en-US">Three Point Three Seven Zero [Member].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ThreePointThreeSevenZeroMember" xlink:to="lab_plx_ThreePointThreeSevenZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FivePointZeroMember" xlink:label="loc_plx_FivePointZeroMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FivePointZeroMember" xml:lang="en-US">Five Point Zero [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_FivePointZeroMember" xml:lang="en-US">5.000 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FivePointZeroMember" xml:lang="en-US">Five Point Zero Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FivePointZeroMember" xlink:to="lab_plx_FivePointZeroMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SixPointNineMember" xlink:label="loc_plx_SixPointNineMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SixPointNineMember" xml:lang="en-US">Six Point Nine [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SixPointNineMember" xml:lang="en-US">6.900 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SixPointNineMember" xml:lang="en-US">Six Point Nine Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SixPointNineMember" xlink:to="lab_plx_SixPointNineMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFiveFiveMember" xlink:label="loc_plx_SevenPointFiveFiveMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFiveFiveMember" xml:lang="en-US">Seven Point Five Five [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SevenPointFiveFiveMember" xml:lang="en-US">7.550 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SevenPointFiveFiveMember" xml:lang="en-US">Seven Point Five Five Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFiveFiveMember" xlink:to="lab_plx_SevenPointFiveFiveMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_NinePointSixSixMember" xlink:label="loc_plx_NinePointSixSixMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_NinePointSixSixMember" xml:lang="en-US">Nine Point Six Six [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_NinePointSixSixMember" xml:lang="en-US">9.660 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_NinePointSixSixMember" xml:lang="en-US">Nine Point Six Six [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_NinePointSixSixMember" xlink:to="lab_plx_NinePointSixSixMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Exercise price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Number of options and restricted stock outstanding at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Number of options exercisable at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted average remaining contractual life, exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="loc_plx_OptionsAndRestrictedStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OptionsAndRestrictedStockMember" xml:lang="en-US">Options And Restricted Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_OptionsAndRestrictedStockMember" xml:lang="en-US">Options and Restricted Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OptionsAndRestrictedStockMember" xml:lang="en-US">Options And Restricted Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OptionsAndRestrictedStockMember" xlink:to="lab_plx_OptionsAndRestrictedStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesTable" xlink:to="lab_plx_SignificantAccountingPoliciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PfizerAgreementMember" xml:lang="en-US">Pfizer Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PfizerAgreementMember" xml:lang="en-US">Pfizer Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PfizerAgreementMember" xlink:to="lab_plx_PfizerAgreementMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AmendedPfizerAgreementMember" xlink:to="lab_plx_AmendedPfizerAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Inc. [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="lab_plx_ProtalixBioTherapeuticsIncorporationMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis" xlink:to="lab_us-gaap_CounterpartyNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis" xlink:to="lab_us-gaap_StatementGeographicalAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain" xlink:to="lab_us-gaap_SegmentGeographicalDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BR" xml:lang="en-US">BRAZIL</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xml:lang="en-US">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xml:lang="en-US">Represents the percentage of adult Gaucher patients treated with Uplyso.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:to="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">TAXES ON INCOME [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="loc_plx_IncomeTaxDisclosureTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure Table</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncomeTaxDisclosureTable" xlink:to="lab_plx_IncomeTaxDisclosureTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis" xlink:to="lab_us-gaap_ConsolidatedEntitiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory income tax rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry forwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain" xlink:to="lab_us-gaap_ConsolidatedEntitiesDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiariesMember" xml:lang="en-US">Protalix Ltd. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiariesMember" xlink:to="lab_us-gaap_SubsidiariesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="loc_plx_TaxYearTwoThousandNineMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TaxYearTwoThousandNineMember" xml:lang="en-US">Tax Year Two Thousand Nine [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TaxYearTwoThousandNineMember" xml:lang="en-US">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TaxYearTwoThousandNineMember" xlink:to="lab_plx_TaxYearTwoThousandNineMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearThereafterMember" xlink:label="loc_plx_TaxYearThereafterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TaxYearThereafterMember" xml:lang="en-US">Tax Year Thereafter [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TaxYearThereafterMember" xml:lang="en-US">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TaxYearThereafterMember" xlink:to="lab_plx_TaxYearThereafterMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RestrictedAmountMember" xlink:label="loc_plx_RestrictedAmountMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RestrictedAmountMember" xml:lang="en-US">Restricted Amount [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RestrictedAmountMember" xml:lang="en-US">Restricted Amount Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RestrictedAmountMember" xlink:to="lab_plx_RestrictedAmountMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplementalInformationAbstract" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplementalInformationAbstract" xlink:to="lab_plx_SupplementalInformationAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="loc_plx_SupplementaryBalanceSheetsInformationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xml:lang="en-US">Supplemental Information, Balance Sheets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="lab_plx_SupplementaryBalanceSheetsInformationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Supplemental Information, Statements of Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts payable and accruals - other:</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts payable and accruals:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Payroll and related expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedVacationCurrent" xml:lang="en-US">Accrued Vacation, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedVacationCurrent" xml:lang="en-US">Provision for vacation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent" xlink:to="lab_us-gaap_AccruedVacationCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Accrued Royalties, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xml:lang="en-US">Royalties payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xml:lang="en-US">Property and equipment suppliers</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="lab_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Other assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="loc_plx_OtherAssetsInstitutionsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OtherAssetsInstitutionsCurrent" xml:lang="en-US">Other Assets, Institutions, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_OtherAssetsInstitutionsCurrent" xml:lang="en-US">Institutions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OtherAssetsInstitutionsCurrent" xml:lang="en-US">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OtherAssetsInstitutionsCurrent" xlink:to="lab_plx_OtherAssetsInstitutionsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="loc_us-gaap_PrepaidRoyalties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidRoyalties" xml:lang="en-US">Prepaid Royalties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidRoyalties" xml:lang="en-US">State of Israel (see note 6a)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets of discontinued operation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets of discontinued operation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total current assets of discontinued operation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">General</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations Policy</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_NatureOfOperationsPolicyTextBlock" xlink:to="lab_plx_NatureOfOperationsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Functional currency</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventories</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment in value of long-lived assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and development costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of credit risks and trade receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net earnings (loss) per share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Recently Adopted standards [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Recently adopted standards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity&#39;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:to="lab_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="loc_plx_ScheduleOfUsefulLifeTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ScheduleOfUsefulLifeTableTextBlock" xml:lang="en-US">Schedule Of Useful Life [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ScheduleOfUsefulLifeTableTextBlock" xml:lang="en-US">Schedule of Useful Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ScheduleOfUsefulLifeTableTextBlock" xml:lang="en-US">Schedule Of Useful Life Table Text Block</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="lab_plx_ScheduleOfUsefulLifeTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_LaboratoryEquipmentMember" xlink:label="loc_plx_LaboratoryEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_LaboratoryEquipmentMember" xlink:to="lab_plx_LaboratoryEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property and equipment, useful life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable - Trade</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventory</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible Debt, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">LONG TERM LIABILITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible Debt, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred revenues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Liability for employee rights upon retirement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long term liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS (Note 6)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, $0.001 par value: Authorized - as of December 31, 2016 and 2017, 250,000,000 shares; issued and outstanding, respectively - as of December 31, 2016 and 2017, 124,134,085 shares and 143,728,797 shares, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total capital deficiency</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities net of capital deficiency</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">CAPITAL DEFICIENCY:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">NET (LOSS) INCOME FOR THE YEAR</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">(Loss) income from discontinued operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">(LOSS) INCOME FROM DISCONTINUED OPERATIONS</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net income loss from discontinued operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">NET (LOSS) INCOME</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Financial (income) expenses, net (mainly exchange differences)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Pension and Other Postretirement Benefit Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">(Gain) loss on amounts funded in respect of employee rights upon retirement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (decrease) in deferred revenues (including non-current potion)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Increase) decrease in accounts receivable and other assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Decrease (increase) in inventories</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss (gain) on sale of fixed assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from continuing operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net loss from continuing operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">(Increase) decrease in restricted deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in continuing operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Net payment for conversion of convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Net proceeds from issuance of convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xml:lang="en-US">Issuance of shares, net of issuance cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xml:lang="en-US">Proceeds from issuance of common stock net of expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="lab_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Exercise of options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">COMMITMENTS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">CONVERTIBLE NOTES [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Contractual interest expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="loc_plx_AmortizationOfDebtIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AmortizationOfDebtIssuanceCosts" xml:lang="en-US">Amortization Of Debt Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_AmortizationOfDebtIssuanceCosts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AmortizationOfDebtIssuanceCosts" xml:lang="en-US">Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AmortizationOfDebtIssuanceCosts" xlink:to="lab_plx_AmortizationOfDebtIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_DebtInstrumentConvertibleConversionShareNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_DebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US">Number of shares for basis conversion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="lab_plx_DebtInstrumentConvertibleConversionShareNumber" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xlink:label="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xml:lang="en-US">Debt Instrument, Principal Amount Related To Initial Purchaser Over-Allotment Option</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xml:lang="en-US">Principal amount, related to the initial purchaser&#39;s over-allotment option</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xml:lang="en-US">Aggregate principal amount of Notes related to the initial purchaser&#39;s over-allotment option.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xlink:to="lab_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price per share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xml:lang="en-US">Base value for conversion rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="lab_plx_DebtInstrumentConvertibleBaseValueForConversionRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">CONVERTIBLE NOTES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US">Schedule of Interest Expense Recognized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lab_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="loc_plx_EmployeeSeveranceObligationPayment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_EmployeeSeveranceObligationPayment" xml:lang="en-US">Employee Severance Obligation Payment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_EmployeeSeveranceObligationPayment" xml:lang="en-US">Employee severance obligation payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_EmployeeSeveranceObligationPayment" xml:lang="en-US">Employee severance obligation payment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_EmployeeSeveranceObligationPayment" xlink:to="lab_plx_EmployeeSeveranceObligationPayment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Contributions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="loc_us-gaap_PostemploymentBenefitsPeriodExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsPeriodExpense" xml:lang="en-US">Postemployment Benefits, Period Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PostemploymentBenefitsPeriodExpense" xml:lang="en-US">Severance expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="lab_us-gaap_PostemploymentBenefitsPeriodExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xml:lang="en-US">Net gain (loss) for the period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="loc_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xml:lang="en-US">Schedule Of Options And Restricted Stocks Granted [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xml:lang="en-US">Schedule of Options and Restricted Stocks Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xml:lang="en-US">Tabular disclosure of options and restricted stocks granted during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="lab_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity - Options Granted to Employees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Activity - Options Granted to Employees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xml:lang="en-US">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xml:lang="en-US">Schedule of Options Granted to Service Providers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Information about Share Options Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Stock-Based Compensation Expense in Statement of Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Marketing, General and administrative expenses [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">General and Administrative Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options or restricted stock granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US">Fair value at grant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US">Shares of common stock issued, lock up period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US">Expiration period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award granted contractual term.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Number of options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Forfeited and Expired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of options granted to employee (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted average exercise price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited and Expired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable at end of year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xml:lang="en-US">Options And Restricted Stock Granted To Employees [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xml:lang="en-US">Options And Restricted Stock Granted To Employees Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:to="lab_plx_OptionsAndRestrictedStockGrantedToEmployeesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of options/ restricted stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="loc_plx_StockIssuedDuringPeriodSharesStockExpired" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_StockIssuedDuringPeriodSharesStockExpired" xml:lang="en-US">Stock Issued During Period Shares Stock Expired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_StockIssuedDuringPeriodSharesStockExpired" xml:lang="en-US">Expired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_StockIssuedDuringPeriodSharesStockExpired" xml:lang="en-US">Number of share options (or share units) expired during the current period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_StockIssuedDuringPeriodSharesStockExpired" xlink:to="lab_plx_StockIssuedDuringPeriodSharesStockExpired" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xml:lang="en-US">Vested restricted stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xml:lang="en-US">Number of share options (or share units) vested during the current period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Expired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US">Options and Restricted Stocks Granted to Consultants Directors and Other Service Providers [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xml:lang="en-US">Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member].</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="lab_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">REVENUES</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">COST OF REVENUES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">GROSS PROFIT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants And Reimbursements Received Or Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Less - grants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research Development And Engineering Expense Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research and development expenses, net.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">OPERATING LOSS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">FINANCIAL EXPENSES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">FINANCIAL INCOME</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair value of convertible notes embedded derivative</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair value of convertible note embedded derivative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">(LOSS) GAIN ON EXTINGUISHMENT OF CONVERTIBLE NOTES</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss (gain) on extinguishment of convertible notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on extinguishment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">FINANCIAL (EXPENSES) INCOME - NET</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Common stock issued for cash (net of issuance costs)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Equity component of convertible notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation related to stock options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share-based compensation related to restricted stock award, net of forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Reclassification of embedded derivative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Convertible note conversions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Convertible note conversions (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of options granted to employee</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">FAIR VALUE MEASUREMENT [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="loc_plx_ScheduleOfOpenTaxYearsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ScheduleOfOpenTaxYearsTableTextBlock" xml:lang="en-US">Schedule Of Open Tax Years [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_ScheduleOfOpenTaxYearsTableTextBlock" xml:lang="en-US">Schedule of Open Tax Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ScheduleOfOpenTaxYearsTableTextBlock" xml:lang="en-US">Schedule Of Open Tax Years Table Text Block</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="lab_plx_ScheduleOfOpenTaxYearsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Timing Differences</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry forwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">TAXES ON INCOME</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US">Income Tax Contingency [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UsIsraelMember" xlink:label="loc_plx_UsIsraelMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_UsIsraelMember" xml:lang="en-US">Us Israel [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_UsIsraelMember" xml:lang="en-US">ISRAEL [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_UsIsraelMember" xlink:to="lab_plx_UsIsraelMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open tax year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US">Income Tax Contingency [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">INVENTORIES [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Work in progress</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished goods</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">INVENTORIES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">PROPERTY AND EQUIPMENT [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="loc_plx_FurnitureAndComputerEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FurnitureAndComputerEquipmentMember" xml:lang="en-US">Furniture And Computer Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FurnitureAndComputerEquipmentMember" xml:lang="en-US">Furniture And Computer Equipment Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FurnitureAndComputerEquipmentMember" xlink:to="lab_plx_FurnitureAndComputerEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="loc_plx_EquipmentUnderConstructionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_EquipmentUnderConstructionMember" xml:lang="en-US">Equipment Under Construction [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_EquipmentUnderConstructionMember" xml:lang="en-US">Equipment Under Construction [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_EquipmentUnderConstructionMember" xlink:to="lab_plx_EquipmentUnderConstructionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less - accumulated depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property Plant And Equipment Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">RELATED PARTY TRANSACTIONS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="loc_plx_CompensationToTheNon-executiveDirectorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CompensationToTheNon-executiveDirectorsMember" xml:lang="en-US">Compensation To The Non -executiveDirectors [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_CompensationToTheNon-executiveDirectorsMember" xml:lang="en-US">Compensation To The non-executive Directors [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CompensationToTheNon-executiveDirectorsMember" xml:lang="en-US">Compensation To The Non-executive Directors Member</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CompensationToTheNon-executiveDirectorsMember" xlink:to="lab_plx_CompensationToTheNon-executiveDirectorsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2015 and the Chairman of the Board for part of 2015)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#39; EQUITY (NET OF CAPITAL DEFICIENCY)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="loc_plx_OtherAssetsSundryCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_OtherAssetsSundryCurrent" xml:lang="en-US">Other Assets, Sundry, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_OtherAssetsSundryCurrent" xml:lang="en-US">Sundry</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_OtherAssetsSundryCurrent" xml:lang="en-US">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_OtherAssetsSundryCurrent" xlink:to="lab_plx_OtherAssetsSundryCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">SHARE CAPITAL</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantYearTwoThousandFifteenMember" xlink:label="loc_plx_GrantYearTwoThousandFifteenMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GrantYearTwoThousandFifteenMember" xml:lang="en-US">Grant Year Two Thousand Fifteen [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_GrantYearTwoThousandFifteenMember" xml:lang="en-US">2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GrantYearTwoThousandFifteenMember" xlink:to="lab_plx_GrantYearTwoThousandFifteenMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Loss from continuing operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income from discontinued operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net (loss) income per share of common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">NET (LOSS) INCOME PER SHARE OF COMMON STOCK - BASIC AND DILUTED</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments required to reconcile net (loss) income to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in continuing operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by (used in) discontinued operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by discontinued operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used in) provided by investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently issued accounting pronouncements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">DISCONTINUED OPERATIONS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Schedule of Discontinued Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">REVENUES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xml:lang="en-US">Disposal Group Including Discontinued Operation Share In Collaboration Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xml:lang="en-US">COMPANY&#8217;S SHARE IN COLLABORATION AGREEMENT</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xml:lang="en-US">Amount of share of company in Collaboration Agreement attributable to disposal group, including, but not limited to, discontinued operation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xlink:to="lab_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xml:lang="en-US">COST OF REVENUES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xml:lang="en-US">GROSS PROFIT (LOSS)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Disposal Group Including Discontinued Operation Research And Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Amount of Research And Development Gross expense attributable to disposal group, including, but not limited to, discontinued operation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Disposal Group Including Discontinued Operation Grants And Reimbursements Received Or Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Less -reimbursements</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Amount of Grants And Reimbursements Received Or Receivable attributable to disposal group, including, but not limited to, discontinued operation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xlink:to="lab_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xml:lang="en-US">Disposal Group Including Discontinued Operation Research Development Expense Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xml:lang="en-US">Amount of Research Development Expense Net attributable to disposal group, including, but not limited to, discontinued operation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:to="lab_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xml:lang="en-US">GAIN ON THE DISPOSAL</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeOnConversionOfConvertibleNotes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncomeOnConversionOfConvertibleNotes" xml:lang="en-US">Income on conversion of convertible notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_IncomeOnConversionOfConvertibleNotes" xml:lang="en-US">Net income in connection with conversions of convertible notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncomeOnConversionOfConvertibleNotes" xml:lang="en-US">The amount of Income from conversions of convertible notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncomeOnConversionOfConvertibleNotes" xlink:to="lab_plx_IncomeOnConversionOfConvertibleNotes" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="loc_plx_CommercializationAgreementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CommercializationAgreementsAbstract" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_CommercializationAgreementsAbstract" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CommercializationAgreementsAbstract" xlink:to="lab_plx_CommercializationAgreementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AgreementsWithPfizerAbstract" xlink:label="loc_plx_AgreementsWithPfizerAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AgreementsWithPfizerAbstract" xml:lang="en-US">AGREEMENTS WITH PFIZER [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AgreementsWithPfizerAbstract" xlink:to="lab_plx_AgreementsWithPfizerAbstract" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="loc_plx_CollaborativeArrangementProfitSharePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CollaborativeArrangementProfitSharePercentage" xml:lang="en-US">Collaborative Arrangement Profit Share Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CollaborativeArrangementProfitSharePercentage" xml:lang="en-US">Collaborative arrangement profit sharing percentage.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CollaborativeArrangementProfitSharePercentage" xlink:to="lab_plx_CollaborativeArrangementProfitSharePercentage" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PfizerMember" xml:lang="en-US">Pfizer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PfizerMember" xlink:to="lab_plx_PfizerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized share-based compensation expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation cost, recognition period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net, Classification [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xml:lang="en-US">In respect of:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Notes Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Issuance of promissory note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePotentialPayable" xlink:label="loc_plx_MilestonePotentialPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MilestonePotentialPayable" xml:lang="en-US">Milestone Potential Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MilestonePotentialPayable" xml:lang="en-US">Milestone payments to be paid.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MilestonePotentialPayable" xlink:to="lab_plx_MilestonePotentialPayable" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePaymentAmountPaid" xlink:label="loc_plx_MilestonePaymentAmountPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MilestonePaymentAmountPaid" xml:lang="en-US">Milestone Payment, Amount Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MilestonePaymentAmountPaid" xml:lang="en-US">It represents milestone payments made during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MilestonePaymentAmountPaid" xlink:to="lab_plx_MilestonePaymentAmountPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Financial expenses in respect to convertible notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xml:lang="en-US">Tax Rate Assumption Related To Deferred Tax Difference Reversal</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xml:lang="en-US">Tax rates expected to be in effect when deferred tax asset differences reverse</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xml:lang="en-US">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="lab_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FourPointFivePercentageConvertibleNotesMember" xml:lang="en-US">Four Point Five Percentage Convertible Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FourPointFivePercentageConvertibleNotesMember" xlink:to="lab_plx_FourPointFivePercentageConvertibleNotesMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotesMember" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNotesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price (USD)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price (USD)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Yield</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Yield</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Debt discount (premium) amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible note conversions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xml:lang="en-US">Convertible Notes Due Two Thousand Twenty One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:to="lab_plx_ConvertibleNotesDueTwoThousandTwentyOneMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Future minimum lease payments, 2021</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US">Maximum Debt Instrument Convertible Conversion Share Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xml:lang="en-US">The maximum price per share of the conversion feature embedded in the debt instrument.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:to="lab_plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument, Redemption, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2016Member" xlink:label="loc_plx_Notes2016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_Notes2016Member" xml:lang="en-US">Notes 2016 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_Notes2016Member" xml:lang="en-US">2016 Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_Notes2016Member" xlink:to="lab_plx_Notes2016Member" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2013Member" xlink:label="loc_plx_Notes2013Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_Notes2013Member" xml:lang="en-US">Notes 2013 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_Notes2013Member" xml:lang="en-US">2013 Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_Notes2013Member" xlink:to="lab_plx_Notes2013Member" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotes2013Member" xlink:label="loc_plx_ConvertibleNotes2013Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ConvertibleNotes2013Member" xml:lang="en-US">Convertible Notes 2013 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ConvertibleNotes2013Member" xlink:to="lab_plx_ConvertibleNotes2013Member" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfExcessSharesOutstanding" xlink:label="loc_plx_PercentageOfExcessSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PercentageOfExcessSharesOutstanding" xml:lang="en-US">Percentage Of Excess Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PercentageOfExcessSharesOutstanding" xml:lang="en-US">It represents the percentage of excess shares outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PercentageOfExcessSharesOutstanding" xlink:to="lab_plx_PercentageOfExcessSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="loc_plx_BenefitsPayableDuringNextFiveYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_BenefitsPayableDuringNextFiveYears" xml:lang="en-US">Benefits Payable During Next Five Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_BenefitsPayableDuringNextFiveYears" xml:lang="en-US">Amount of benefits payable during next five years.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_BenefitsPayableDuringNextFiveYears" xlink:to="lab_plx_BenefitsPayableDuringNextFiveYears" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProceedsFromExchangeForRightsToRoyalties" xml:lang="en-US">Proceeds From Exchange For Rights To Royalties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProceedsFromExchangeForRightsToRoyalties" xml:lang="en-US">Amount received in exchange for rights to royalties.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProceedsFromExchangeForRightsToRoyalties" xlink:to="lab_plx_ProceedsFromExchangeForRightsToRoyalties" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment in connection with conversions of convertible notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment regarding conversion of convertible notes,</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:to="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase in other long term liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FutureResearchAndDevelopmentReimbursement" xlink:label="loc_plx_FutureResearchAndDevelopmentReimbursement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FutureResearchAndDevelopmentReimbursement" xml:lang="en-US">Future research and development reimbursement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FutureResearchAndDevelopmentReimbursement" xml:lang="en-US">Amount of research and development reimbursement payment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FutureResearchAndDevelopmentReimbursement" xlink:to="lab_plx_FutureResearchAndDevelopmentReimbursement" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ChiesiAgreementMember" xlink:label="loc_plx_ChiesiAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChiesiAgreementMember" xml:lang="en-US">Chiesi Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChiesiAgreementMember" xlink:to="lab_plx_ChiesiAgreementMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems" xlink:to="lab_plx_SignificantAccountingPoliciesLineItems" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">Upfront Nonrefundable Noncreditable Payment Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">The definition should be: &#34;The maximum amount payable to the entity to cover development costs under agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Payment On Net Sales Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PaymentOnNetSalesPercentage" xlink:to="lab_plx_PaymentOnNetSalesPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long term liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="loc_plx_IncomeTaxDisclosureLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure Line Items</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncomeTaxDisclosureLineItems" xlink:to="lab_plx_IncomeTaxDisclosureLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2017Member" xlink:label="loc_plx_Notes2017Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_Notes2017Member" xml:lang="en-US">Notes 2017 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_Notes2017Member" xlink:to="lab_plx_Notes2017Member" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FourPointFivePercentageConvertibleNotesOneMember" xml:lang="en-US">Four Point Five Percentage Convertible Notes One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:to="lab_plx_FourPointFivePercentageConvertibleNotesOneMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentMaturityYear" xlink:label="loc_plx_DebtInstrumentMaturityYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DebtInstrumentMaturityYear" xml:lang="en-US">Year when the debt instrument is scheduled to be fully repaid.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DebtInstrumentMaturityYear" xlink:to="lab_plx_DebtInstrumentMaturityYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest payment in connection with conversions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnConversionOfDebt" xlink:label="loc_plx_GainLossOnConversionOfDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GainLossOnConversionOfDebt" xml:lang="en-US">Gain Loss On Conversion Of Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_GainLossOnConversionOfDebt" xml:lang="en-US">Income in connection with conversions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GainLossOnConversionOfDebt" xml:lang="en-US">The aggregate gain (loss) recognized on the converion of debt.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GainLossOnConversionOfDebt" xlink:to="lab_plx_GainLossOnConversionOfDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotes2013Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FourPointFivePercentageConvertibleNotes2013Member" xml:lang="en-US">Four Point Five Percentage Convertible Notes 2013 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:to="lab_plx_FourPointFivePercentageConvertibleNotes2013Member" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotes2016Member" xml:lang="en-US">Seven Point Five Percentage Convertible Notes 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNotes2016Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Debt Instrument Carrying Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockholdersApprovalDescriptionForCommonStockIssuance" xlink:label="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_StockholdersApprovalDescriptionForCommonStockIssuance" xml:lang="en-US">Stockholders Approval Description For Common Stock Issuance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_StockholdersApprovalDescriptionForCommonStockIssuance" xml:lang="en-US">The description for stockholders approval description for issuing common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance" xlink:to="lab_plx_StockholdersApprovalDescriptionForCommonStockIssuance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xml:lang="en-US">Retirement Plan Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="loc_plx_PercentageOfRoyaltiesToGrantReceived" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PercentageOfRoyaltiesToGrantReceived" xml:lang="en-US">Percentage of Royalties to Grant Received</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PercentageOfRoyaltiesToGrantReceived" xml:lang="en-US">Required royalty payments represented as a percentage to grants received.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PercentageOfRoyaltiesToGrantReceived" xlink:to="lab_plx_PercentageOfRoyaltiesToGrantReceived" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwentyThirteenAndTwentySixteenNotesMember" xlink:label="loc_plx_TwentyThirteenAndTwentySixteenNotesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_TwentyThirteenAndTwentySixteenNotesMember" xml:lang="en-US">Twenty Thirteen and Twenty Sixteen Notes [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_TwentyThirteenAndTwentySixteenNotesMember" xml:lang="en-US">2013 Notes and 2016 Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_TwentyThirteenAndTwentySixteenNotesMember" xlink:to="lab_plx_TwentyThirteenAndTwentySixteenNotesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xml:lang="en-US">Retirement Plan Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xml:lang="en-US">Postretirement Life Insurance [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xml:lang="en-US">Contribution to Insurance Companies [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:to="lab_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ContributionPlansMember" xlink:label="loc_plx_ContributionPlansMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ContributionPlansMember" xml:lang="en-US">Contribution Plans [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_ContributionPlansMember" xml:lang="en-US">Contribution to Defined Contribution Plans [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ContributionPlansMember" xlink:to="lab_plx_ContributionPlansMember" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>plx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Mar-2018 [08:02:19] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#CommercializationAgreements" roleURI="http://www.protalix.com/role/CommercializationAgreements" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipment" roleURI="http://www.protalix.com/role/PropertyAndEquipment" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#Inventories" roleURI="http://www.protalix.com/role/Inventories" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#LiabilityForEmployeeRightsUponRetirement" roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#Commitments" roleURI="http://www.protalix.com/role/Commitments" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapital" roleURI="http://www.protalix.com/role/ShareCapital" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotes" roleURI="http://www.protalix.com/role/ConvertibleNotes" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurement" roleURI="http://www.protalix.com/role/FairValueMeasurement" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncome" roleURI="http://www.protalix.com/role/TaxesOnIncome" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperations" roleURI="http://www.protalix.com/role/DiscontinuedOperations" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#RelatedPartyTransactions" roleURI="http://www.protalix.com/role/RelatedPartyTransactions" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipmentTables" roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#InventoriesTables" roleURI="http://www.protalix.com/role/InventoriesTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalTables" roleURI="http://www.protalix.com/role/ShareCapitalTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesTables" roleURI="http://www.protalix.com/role/ConvertibleNotesTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeTables" roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperationsTables" roleURI="http://www.protalix.com/role/DiscontinuedOperationsTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#RelatedPartyTransactionsTables" roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#CommercializationAgreementsNarrativeDetails" roleURI="http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#PropertyAndEquipmentNarrativeDetails" roleURI="http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#LiabilityForEmployeeRightsUponRetirementNarrativeDetails" roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#CommitmentsNarrativeDetails" roleURI="http://www.protalix.com/role/CommitmentsNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalOptionsGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalRestrictedStockGrantedToEmployeesDetails" roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" roleURI="http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalShareBasedCompensationExpenseAllocationDetails" roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesFairValueIncomeApproachDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesScheduleOfDebtInterestExpensesDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConvertibleNotesNarrativeDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeDeferredIncomeTaxesDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#TaxesOnIncomeNarrativeDetails" roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SupplementaryFinancialStatementInformationStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#DiscontinuedOperationsOperationsDetails" roleURI="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#RelatedPartyTransactionsCompensationDetails" roleURI="http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="plx-20171231.xsd#SignificantAccountingPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" />

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract_1133" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_1133" xlink:to="loc_dei_DocumentInformationTable_1134" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1134" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1201" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1201" xlink:to="loc_us-gaap_ClassOfStockDomain_1203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1134" xlink:to="loc_dei_DocumentInformationLineItems_1135" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentType_1136" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_AmendmentFlag_1137" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentPeriodEndDate_1138" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentFiscalYearFocus_1139" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1140" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityRegistrantName_1141" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCentralIndexKey_1142" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_CurrentFiscalYearEndDate_1143" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1144" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_1145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityVoluntaryFilers_1145" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCurrentReportingStatus_1146" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityFilerCategory_1147" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityPublicFloat_1148" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_TradingSymbol_1149" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1135" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1150" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CommercializationAgreements">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="loc_plx_CommercializationAgreementsAbstract_918" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommercializationAgreementsAbstract_918" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_691" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_692" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_691" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_692" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Inventories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_669" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_669" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_670" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_486" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_486" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_487" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Commitments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_454" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_454" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_828" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_829" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_828" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_829" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_472" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_472" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_628" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_629" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_628" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_629" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_645" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_646" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_645" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_646" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformation">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract_332" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_332" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_333" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_381" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_722" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_381" xlink:to="loc_us-gaap_StatementTable_722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_723" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementClassOfStockAxis_723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_724" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_724" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_725" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementLineItems_725" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_725" xlink:to="loc_us-gaap_AssetsAbstract_382" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_AssetsCurrentAbstract_383" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_384" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_385" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_OtherAssetsCurrent_388" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_InventoryNet_386" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_383" xlink:to="loc_us-gaap_AssetsCurrent_387" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_391" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_389" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_382" xlink:to="loc_us-gaap_Assets_390" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_725" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_394" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_396" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_395" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_397" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_1039" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_1039" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_DeferredRevenueCurrent_398" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_394" xlink:to="loc_us-gaap_LiabilitiesCurrent_399" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_403" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_404" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_402" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_400" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1186" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_405" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_Liabilities_406" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_CommitmentsAndContingencies_407" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_393" xlink:to="loc_us-gaap_StockholdersEquityAbstract_409" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_CommonStockValue_410" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_411" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_412" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_StockholdersEquity_413" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_409" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_408" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DiscontinuedOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_860" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_861" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_860" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_861" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_703" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_704" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_703" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_343" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_plx_NatureOfOperationsPolicyTextBlock_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_345" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_UseOfEstimates_349" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_350" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_351" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_352" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_353" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_354" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_355" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_356" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_357" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_358" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_359" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_346" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_DebtPolicyTextBlock_347" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_847" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_847" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_348" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_361" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="loc_plx_ScheduleOfUsefulLifeTableTextBlock_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_361" xlink:to="loc_plx_ScheduleOfUsefulLifeTableTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_688" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_689" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_688" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_689" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_672" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_672" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_673" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="loc_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_497" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_503" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_499" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_499" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_500" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_500" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_501" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_496" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_502" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_475" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_475" xlink:to="loc_us-gaap_StatementTable_1208" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1209" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1209" xlink:to="loc_us-gaap_ClassOfStockDomain_1210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_1211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_StatementGeographicalAxis_1211" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_1211" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1213" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2013Member" xlink:label="loc_plx_Notes2013Member_1214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2013Member_1214" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2016Member" xlink:label="loc_plx_Notes2016Member_1215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2016Member_1215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2017Member" xlink:label="loc_plx_Notes2017Member_1216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1213" xlink:to="loc_plx_Notes2017Member_1216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_DebtInstrumentAxis_1212" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1212" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1224" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1224" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1225" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1224" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1230" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1208" xlink:to="loc_us-gaap_StatementLineItems_1223" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_476" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1223" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_476" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1057" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1223" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1057" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1206" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1206" xlink:to="loc_us-gaap_StatementTable_1298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_DebtInstrumentAxis_1301" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1301" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1303" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwentyThirteenAndTwentySixteenNotesMember" xlink:label="loc_plx_TwentyThirteenAndTwentySixteenNotesMember_1304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1303" xlink:to="loc_plx_TwentyThirteenAndTwentySixteenNotesMember_1304" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementLineItems_1302" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_631" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_631" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_632" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="loc_plx_ScheduleOfOpenTaxYearsTableTextBlock_633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_631" xlink:to="loc_plx_ScheduleOfOpenTaxYearsTableTextBlock_633" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_709" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_799" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_709" xlink:to="loc_us-gaap_StatementTable_799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_800" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_799" xlink:to="loc_us-gaap_StatementClassOfStockAxis_800" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_801" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800" xlink:to="loc_us-gaap_ClassOfStockDomain_801" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_802" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_799" xlink:to="loc_us-gaap_StatementLineItems_802" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_803" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_803" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_804" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_804" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_710" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesIssued_710" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_802" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_711" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract_318" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="loc_plx_SupplementaryBalanceSheetsInformationTableTextBlock_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_318" xlink:to="loc_plx_SupplementaryBalanceSheetsInformationTableTextBlock_320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_318" xlink:to="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_319" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DiscontinuedOperationsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_863" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_864" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_863" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_864" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_706" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_707" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_706" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_707" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_367" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_367" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_369" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_LaboratoryEquipmentMember" xlink:label="loc_plx_LaboratoryEquipmentMember_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_plx_LaboratoryEquipmentMember_371" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_ComputerEquipmentMember_372" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_RangeAxis_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_374" xlink:to="loc_us-gaap_RangeMember_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_375" xlink:to="loc_us-gaap_MinimumMember_376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_375" xlink:to="loc_us-gaap_MaximumMember_377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_379" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_197" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_plx_SignificantAccountingPoliciesTable_198" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_199" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_202" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_PfizerAgreementMember_205" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_AmendedPfizerAgreementMember_206" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ChiesiAgreementMember" xlink:label="loc_plx_ChiesiAgreementMember_1164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_plx_ChiesiAgreementMember_1164" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_dei_LegalEntityAxis_207" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_207" xlink:to="loc_dei_EntityDomain_208" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_208" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_210" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_CounterpartyNameAxis_211" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_211" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_212" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_StatementGeographicalAxis_215" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_215" xlink:to="loc_us-gaap_SegmentGeographicalDomain_216" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_216" xlink:to="loc_country_BR_217" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_StatementScenarioAxis_219" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_219" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_220" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_225" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_850" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_849" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_us-gaap_RangeAxis_849" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_849" xlink:to="loc_us-gaap_RangeMember_1168" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1168" xlink:to="loc_us-gaap_MinimumMember_1169" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1168" xlink:to="loc_us-gaap_MaximumMember_1170" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_1167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_198" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_1167" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_237" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_239" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_242" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1046" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_1046" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties_1121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_ProceedsFromExchangeForRightsToRoyalties_1121" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FutureResearchAndDevelopmentReimbursement" xlink:label="loc_plx_FutureResearchAndDevelopmentReimbursement_1163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_FutureResearchAndDevelopmentReimbursement_1163" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1181" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1182" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1183" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1184" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_1185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_1167" xlink:to="loc_plx_PaymentOnNetSalesPercentage_1185" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AgreementsWithPfizerAbstract" xlink:label="loc_plx_AgreementsWithPfizerAbstract_920" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_921" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_AgreementsWithPfizerAbstract_920" xlink:to="loc_us-gaap_StatementTable_921" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_922" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_StatementClassOfStockAxis_922" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_923" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_922" xlink:to="loc_us-gaap_ClassOfStockDomain_923" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_924" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_TypeOfArrangementAxis_924" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_930" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_930" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_936" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_PfizerMember_936" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ChiesiAgreementMember" xlink:label="loc_plx_ChiesiAgreementMember_1176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929" xlink:to="loc_plx_ChiesiAgreementMember_1176" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_928" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_RangeAxis_928" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_928" xlink:to="loc_us-gaap_RangeMember_1178" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1178" xlink:to="loc_us-gaap_MaximumMember_1179" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1178" xlink:to="loc_us-gaap_MinimumMember_1180" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_921" xlink:to="loc_us-gaap_StatementLineItems_1177" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="loc_plx_CollaborativeArrangementProfitSharePercentage_926" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_CollaborativeArrangementProfitSharePercentage_926" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_938" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_938" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_939" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_939" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_1171" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_1172" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_1173" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_1174" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_1175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1177" xlink:to="loc_plx_PaymentOnNetSalesPercentage_1175" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_675" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_675" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_677" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_LaboratoryEquipmentMember" xlink:label="loc_plx_LaboratoryEquipmentMember_679" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_LaboratoryEquipmentMember_679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="loc_plx_FurnitureAndComputerEquipmentMember_680" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_FurnitureAndComputerEquipmentMember_680" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_681" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_681" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EquipmentUnderConstructionMember" xlink:label="loc_plx_EquipmentUnderConstructionMember_682" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_678" xlink:to="loc_plx_EquipmentUnderConstructionMember_682" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_676" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_684" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_684" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_685" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_685" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_852" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_852" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1258" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1258" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" xlink:to="loc_dei_LegalEntityAxis_1277" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1277" xlink:to="loc_dei_EntityDomain_1278" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1260" xlink:to="loc_us-gaap_Depreciation_1261" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_662" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_734" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_662" xlink:to="loc_us-gaap_StatementTable_734" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_735" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_734" xlink:to="loc_us-gaap_StatementClassOfStockAxis_735" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_735" xlink:to="loc_us-gaap_ClassOfStockDomain_736" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_737" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_734" xlink:to="loc_us-gaap_StatementLineItems_737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_663" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_664" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_667" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_667" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_737" xlink:to="loc_us-gaap_InventoryNet_665" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_576" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_726" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_576" xlink:to="loc_us-gaap_StatementTable_726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_727" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_726" xlink:to="loc_us-gaap_StatementClassOfStockAxis_727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_728" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_727" xlink:to="loc_us-gaap_ClassOfStockDomain_728" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_729" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_726" xlink:to="loc_us-gaap_StatementLineItems_729" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_Revenues_577" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_CostOfRevenue_579" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_580" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_GrossProfit_580" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_581" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_583" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_584" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OperatingIncomeLoss_585" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OtherNonoperatingExpense_586" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_OtherNonoperatingIncome_587" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1151" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1041" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1041" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_588" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_588" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_831" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_832" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_832" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_NetIncomeLoss_589" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_833" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_833" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_834" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_834" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_835" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_591" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_729" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_593" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_478" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_855" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_478" xlink:to="loc_us-gaap_StatementTable_855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_858" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementScenarioAxis_858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_858" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1263" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_1262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_1262" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1262" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1307" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_1308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1307" xlink:to="loc_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_1308" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ContributionPlansMember" xlink:label="loc_plx_ContributionPlansMember_1309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1307" xlink:to="loc_plx_ContributionPlansMember_1309" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementLineItems_1306" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="loc_plx_EmployeeSeveranceObligationPayment_479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_plx_EmployeeSeveranceObligationPayment_479" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_480" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="loc_us-gaap_PostemploymentBenefitsPeriodExpense_483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_PostemploymentBenefitsPeriodExpense_483" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_484" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="loc_plx_BenefitsPayableDuringNextFiveYears_1119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_plx_BenefitsPayableDuringNextFiveYears_1119" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1293" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1306" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_1293" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CommitmentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesTable" xlink:label="loc_plx_CommitmentsAndContingenciesTable_25" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24" xlink:to="loc_plx_CommitmentsAndContingenciesTable_25" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesTable_25" xlink:to="loc_us-gaap_RangeAxis_26" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_26" xlink:to="loc_us-gaap_RangeMember_27" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_27" xlink:to="loc_us-gaap_MinimumMember_28" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_27" xlink:to="loc_us-gaap_MaximumMember_29" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="loc_plx_CommitmentsAndContingenciesAxis_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesTable_25" xlink:to="loc_plx_CommitmentsAndContingenciesAxis_30" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="loc_plx_CommitmentsAndContingenciesDomain_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesAxis_30" xlink:to="loc_plx_CommitmentsAndContingenciesDomain_31" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OCSMember" xlink:label="loc_plx_OCSMember_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_OCSMember_32" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:label="loc_plx_ProductsManufacturedOutsideOfIsraelMember_33" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_ProductsManufacturedOutsideOfIsraelMember_33" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:label="loc_plx_ResearchAndLicenseAgreementsMember_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_ResearchAndLicenseAgreementsMember_35" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_us-gaap_LeaseAgreementsMember_38" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesDomain_31" xlink:to="loc_plx_VehicleLeaseAndMaintenanceAgreementsMember_39" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="loc_plx_CommitmentsAndContingenciesLineItems_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesTable_25" xlink:to="loc_plx_CommitmentsAndContingenciesLineItems_41" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="loc_plx_RoyaltiesOnSaleOfProducts_42" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_RoyaltiesOnSaleOfProducts_42" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_RoyaltyExpense_44" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_45" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_45" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CommitmentAmount" xlink:label="loc_plx_CommitmentAmount_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_CommitmentAmount_46" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MonthlyRentLeaseExpense" xlink:label="loc_plx_MonthlyRentLeaseExpense_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MonthlyRentLeaseExpense_47" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_48" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_49" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_49" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_50" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_SecurityDeposit_55" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_56" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePotentialPayable" xlink:label="loc_plx_MilestonePotentialPayable_1007" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MilestonePotentialPayable_1007" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MilestonePaymentAmountPaid" xlink:label="loc_plx_MilestonePaymentAmountPaid_1008" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_MilestonePaymentAmountPaid_1008" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1092" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1092" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="loc_plx_PercentageOfRoyaltiesToGrantReceived_1294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_plx_PercentageOfRoyaltiesToGrantReceived_1294" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_514" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_514" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_516" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" xlink:to="loc_us-gaap_PlanNameAxis_516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_516" xlink:to="loc_us-gaap_PlanNameDomain_517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GrantYearTwoThousandFifteenMember" xlink:label="loc_plx_GrantYearTwoThousandFifteenMember_830" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_517" xlink:to="loc_plx_GrantYearTwoThousandFifteenMember_830" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" xlink:to="loc_us-gaap_TitleOfIndividualAxis_521" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_521" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeesMember" xlink:label="loc_plx_EmployeesMember_530" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_529" xlink:to="loc_plx_EmployeesMember_530" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_522" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_525" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_525" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_526" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_526" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_527" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_528" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_527" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_532" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_532" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" xlink:to="loc_us-gaap_TitleOfIndividualAxis_534" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_534" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:label="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_552" xlink:to="loc_plx_OptionsAndRestrictedStockGrantedToEmployeesMember_553" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_533" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_539" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_541" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_542" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_543" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_545" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_546" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_547" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_548" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_544" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_550" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_105" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_105" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" xlink:to="loc_us-gaap_AwardTypeAxis_107" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_107" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" xlink:to="loc_us-gaap_TitleOfIndividualAxis_110" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_EmployeesMember" xlink:label="loc_plx_EmployeesMember_118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_117" xlink:to="loc_plx_EmployeesMember_118" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_106" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_111" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_115" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_113" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_555" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" xlink:to="loc_us-gaap_TitleOfIndividualAxis_557" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_557" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_572" xlink:to="loc_plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_574" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="loc_plx_StockIssuedDuringPeriodSharesStockExpired_927" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_plx_StockIssuedDuringPeriodSharesStockExpired_927" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_931" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_931" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_562" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_559" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_563" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_566" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_937" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_937" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_568" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_565" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_120" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_120" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_122" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OnePointSevenTwoZeroMember" xlink:label="loc_plx_OnePointSevenTwoZeroMember_947" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_OnePointSevenTwoZeroMember_947" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:label="loc_plx_TwoPointThreeFiveZeroMember_128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointThreeFiveZeroMember_128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointThreeSevenZeroMember" xlink:label="loc_plx_TwoPointThreeSevenZeroMember_137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointThreeSevenZeroMember_137" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TwoPointSixFiveMember" xlink:label="loc_plx_TwoPointSixFiveMember_129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_TwoPointSixFiveMember_129" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:label="loc_plx_ThreePointZeroTwoZeroMember_130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_ThreePointZeroTwoZeroMember_130" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ThreePointThreeSevenZeroMember" xlink:label="loc_plx_ThreePointThreeSevenZeroMember_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_ThreePointThreeSevenZeroMember_138" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FivePointZeroMember" xlink:label="loc_plx_FivePointZeroMember_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_FivePointZeroMember_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SixPointNineMember" xlink:label="loc_plx_SixPointNineMember_133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_SixPointNineMember_133" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFiveFiveMember" xlink:label="loc_plx_SevenPointFiveFiveMember_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_SevenPointFiveFiveMember_134" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_NinePointSixSixMember" xlink:label="loc_plx_NinePointSixSixMember_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_123" xlink:to="loc_plx_NinePointSixSixMember_135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" xlink:to="loc_us-gaap_AwardTypeAxis_139" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OptionsAndRestrictedStockMember" xlink:label="loc_plx_OptionsAndRestrictedStockMember_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_148" xlink:to="loc_plx_OptionsAndRestrictedStockMember_150" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_121" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_140" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_141" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_142" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_143" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_147" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_144" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_505" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_505" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_507" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_507" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_509" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_509" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_511" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_509" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_512" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_506" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_508" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_948" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_AwardTypeAxis_72" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_VestingAxis_76" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_76" xlink:to="loc_us-gaap_VestingDomain_77" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_77" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_78" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_TitleOfIndividualAxis_80" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_80" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="loc_plx_PresidentAndChiefExecutiveOfficerMember_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_plx_PresidentAndChiefExecutiveOfficerMember_100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:label="loc_plx_OfficersAndCertainEmployeesMember_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_plx_OfficersAndCertainEmployeesMember_102" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_97" xlink:to="loc_us-gaap_ExecutiveOfficerMember_103" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_96" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_96" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_965" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_964" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_964" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_999" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_964" xlink:to="loc_us-gaap_EquityComponentDomain_999" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1000" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_999" xlink:to="loc_us-gaap_CommonStockMember_1000" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_998" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_DebtInstrumentAxis_998" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_998" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1101" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1102" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1103" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1235" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1101" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1241" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_85" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_949" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_949" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_950" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_950" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_952" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_952" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_953" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_953" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_954" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_954" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_955" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_955" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_956" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_958" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_959" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_959" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_992" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_992" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1104" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1105" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1236" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentMaturityYear" xlink:label="loc_plx_DebtInstrumentMaturityYear_1242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_plx_DebtInstrumentMaturityYear_1242" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1100" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1269" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_457" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_819" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_457" xlink:to="loc_us-gaap_StatementTable_819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_820" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_820" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_821" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820" xlink:to="loc_us-gaap_ClassOfStockDomain_821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_1112" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1112" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1113" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2013Member" xlink:label="loc_plx_Notes2013Member_1114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1113" xlink:to="loc_plx_Notes2013Member_1114" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_819" xlink:to="loc_us-gaap_StatementLineItems_822" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_460" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AmortizationOfDebtIssuanceCosts" xlink:label="loc_plx_AmortizationOfDebtIssuanceCosts_459" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_plx_AmortizationOfDebtIssuanceCosts_459" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_822" xlink:to="loc_us-gaap_InterestExpense_458" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1060" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1061" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1060" xlink:to="loc_us-gaap_StatementTable_1061" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1062" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1061" xlink:to="loc_us-gaap_DebtInstrumentAxis_1062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1063" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1067" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1063" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1067" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1063" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1243" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1064" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1061" xlink:to="loc_us-gaap_StatementLineItems_1064" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1068" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_SharePrice_1068" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1069" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1069" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1070" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1070" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1071" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1071" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1072" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1072" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1074" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1075" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1074" xlink:to="loc_us-gaap_StatementTable_1075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1076" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1075" xlink:to="loc_us-gaap_DebtInstrumentAxis_1076" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1077" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1076" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1077" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2016Member" xlink:label="loc_plx_Notes2016Member_1111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1077" xlink:to="loc_plx_Notes2016Member_1111" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_Notes2017Member" xlink:label="loc_plx_Notes2017Member_1246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1077" xlink:to="loc_plx_Notes2017Member_1246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1078" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1075" xlink:to="loc_us-gaap_StatementLineItems_1078" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1081" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1081" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_1247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_1247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1083" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1083" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1084" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1084" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestExpenseDebt_1244" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnConversionOfDebt" xlink:label="loc_plx_GainLossOnConversionOfDebt_1245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_plx_GainLossOnConversionOfDebt_1245" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1085" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1078" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_1085" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_462" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_823" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_462" xlink:to="loc_us-gaap_StatementTable_823" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_824" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_823" xlink:to="loc_us-gaap_DebtInstrumentAxis_824" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_825" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_824" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_825" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1088" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1088" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1090" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1091" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_1091" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ConvertibleNotes2013Member" xlink:label="loc_plx_ConvertibleNotes2013Member_1115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_ConvertibleNotes2013Member_1115" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesOneMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_825" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesOneMember_1255" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_826" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_823" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_826" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1005" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_826" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1005" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1006" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1005" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1006" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1004" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_823" xlink:to="loc_us-gaap_StatementLineItems_1004" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_463" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_DebtInstrumentConvertibleConversionShareNumber_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentConvertibleConversionShareNumber_464" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_465" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption" xlink:label="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption_466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption_466" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_467" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_468" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_468" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_469" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate_470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentConvertibleBaseValueForConversionRate_470" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1089" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1089" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1093" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1093" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber_1094" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_MaximumDebtInstrumentConvertibleConversionShareNumber_1094" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_1095" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PercentageOfExcessSharesOutstanding" xlink:label="loc_plx_PercentageOfExcessSharesOutstanding_1116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_PercentageOfExcessSharesOutstanding_1116" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1120" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1250" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1251" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_StockholdersApprovalDescriptionForCommonStockIssuance" xlink:label="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance_1252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_StockholdersApprovalDescriptionForCommonStockIssuance_1252" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1253" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1253" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DebtInstrumentMaturityYear" xlink:label="loc_plx_DebtInstrumentMaturityYear_1256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_plx_DebtInstrumentMaturityYear_1256" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1004" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1295" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1218" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1218" xlink:to="loc_us-gaap_StatementTable_1219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1220" xlink:to="loc_us-gaap_ClassOfStockDomain_1221" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_DebtInstrumentAxis_1222" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1222" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1227" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1227" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1228" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1227" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1229" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1226" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1233" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1234" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1219" xlink:to="loc_us-gaap_StatementLineItems_1232" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_SharePrice_1231" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1237" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1238" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1239" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1232" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1240" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_625" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_625" xlink:to="loc_us-gaap_StatementTable_745" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1052" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_747" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1052" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_748" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_DebtInstrumentAxis_748" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1054" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_748" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1054" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotesMember_1055" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotesMember_1055" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1056" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_1056" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_FourPointFivePercentageConvertibleNotes2013Member" xlink:label="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_FourPointFivePercentageConvertibleNotes2013Member_1296" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SevenPointFivePercentageConvertibleNotes2016Member" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1054" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotes2016Member_1297" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_1053" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1097" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1096" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_745" xlink:to="loc_us-gaap_StatementLineItems_1096" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1096" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_626" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1096" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1310" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_635" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_813" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_635" xlink:to="loc_us-gaap_StatementTable_813" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_814" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_813" xlink:to="loc_us-gaap_StatementClassOfStockAxis_814" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_815" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_814" xlink:to="loc_us-gaap_ClassOfStockDomain_815" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_816" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_813" xlink:to="loc_us-gaap_StatementLineItems_816" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_816" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_641" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_641" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_642" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_643" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_643" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_648" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_648" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_649" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_649" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_650" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_650" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_651" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_UsIsraelMember" xlink:label="loc_plx_UsIsraelMember_990" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_651" xlink:to="loc_plx_UsIsraelMember_990" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_651" xlink:to="loc_country_US_653" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_649" xlink:to="loc_us-gaap_RangeAxis_655" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_655" xlink:to="loc_us-gaap_RangeMember_658" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MinimumMember_659" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_658" xlink:to="loc_us-gaap_MaximumMember_660" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_649" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_657" xlink:to="loc_us-gaap_OpenTaxYear_656" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_285" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="loc_plx_IncomeTaxDisclosureTable_286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_285" xlink:to="loc_plx_IncomeTaxDisclosureTable_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_RangeAxis_287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_287" xlink:to="loc_us-gaap_RangeMember_288" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_288" xlink:to="loc_us-gaap_MinimumMember_289" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_288" xlink:to="loc_us-gaap_MaximumMember_290" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_291" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_291" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_303" xlink:to="loc_us-gaap_SubsidiariesMember_304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_302" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_302" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_306" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearTwoThousandNineMember" xlink:label="loc_plx_TaxYearTwoThousandNineMember_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_TaxYearTwoThousandNineMember_307" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_TaxYearThereafterMember" xlink:label="loc_plx_TaxYearThereafterMember_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_TaxYearThereafterMember_309" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_RestrictedAmountMember" xlink:label="loc_plx_RestrictedAmountMember_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_306" xlink:to="loc_plx_RestrictedAmountMember_310" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_us-gaap_StatementScenarioAxis_1108" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_1108" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1188" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_1189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1188" xlink:to="loc_us-gaap_ScenarioPlanMember_1189" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="loc_plx_IncomeTaxDisclosureLineItems_1187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureTable_286" xlink:to="loc_plx_IncomeTaxDisclosureLineItems_1187" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureLineItems_1187" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_292" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_IncomeTaxDisclosureLineItems_1187" xlink:to="loc_us-gaap_OperatingLossCarryforwards_299" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract_335" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_805" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_335" xlink:to="loc_us-gaap_StatementTable_805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_806" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_806" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_807" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_806" xlink:to="loc_us-gaap_ClassOfStockDomain_807" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_805" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1270" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1270" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1271" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_805" xlink:to="loc_us-gaap_StatementLineItems_808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_808" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="loc_plx_OtherAssetsInstitutionsCurrent_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_plx_OtherAssetsInstitutionsCurrent_337" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidRoyalties" xlink:label="loc_us-gaap_PrepaidRoyalties_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_PrepaidRoyalties_338" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_339" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_340" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1268" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1268" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="loc_plx_OtherAssetsSundryCurrent_341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_plx_OtherAssetsSundryCurrent_341" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_818" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_336" xlink:to="loc_us-gaap_OtherAssetsCurrent_818" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract_322" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_322" xlink:to="loc_us-gaap_StatementTable_809" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_810" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_809" xlink:to="loc_us-gaap_StatementClassOfStockAxis_810" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_811" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_810" xlink:to="loc_us-gaap_ClassOfStockDomain_811" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_812" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_809" xlink:to="loc_us-gaap_StatementLineItems_812" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_812" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_InterestPayableCurrent_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedVacationCurrent_326" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_327" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_328" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_330" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1009" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_323" xlink:to="loc_us-gaap_AccountsPayableCurrent_1009" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_604" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_604" xlink:to="loc_us-gaap_StatementTable_605" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_606" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_606" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_606" xlink:to="loc_us-gaap_EquityComponentDomain_607" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_CommonStockMember_608" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_607" xlink:to="loc_us-gaap_RetainedEarningsMember_610" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_611" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_605" xlink:to="loc_us-gaap_StatementLineItems_611" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_613" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockholdersEquity_613" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_615" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_SharesOutstanding_615" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_838" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_838" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_839" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_839" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1040" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1040" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_612" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_612" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_614" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_614" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_616" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_616" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1152" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1153" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1154" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_617" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_618" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_618" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_836" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_836" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_837" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_837" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_621" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_StockholdersEquity_621" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_611" xlink:to="loc_us-gaap_SharesOutstanding_620" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails">
    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_SupplementalInformationAbstract" xlink:label="loc_plx_SupplementalInformationAbstract_1192" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SupplementalInformationAbstract_1192" xlink:to="loc_us-gaap_StatementTable_1193" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_1280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1193" xlink:to="loc_us-gaap_StatementGeographicalAxis_1280" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_1280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1283" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_1286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1283" xlink:to="loc_country_BR_1286" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1193" xlink:to="loc_dei_LegalEntityAxis_1282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1282" xlink:to="loc_dei_EntityDomain_1285" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_1287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1285" xlink:to="loc_plx_PfizerMember_1287" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1193" xlink:to="loc_us-gaap_StatementLineItems_1284" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1284" xlink:to="loc_us-gaap_Revenues_1202" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_888" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_888" xlink:to="loc_us-gaap_StatementTable_889" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_890" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_889" xlink:to="loc_us-gaap_StatementClassOfStockAxis_890" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_891" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_890" xlink:to="loc_us-gaap_ClassOfStockDomain_891" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_889" xlink:to="loc_us-gaap_StatementLineItems_892" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_893" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement_900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement_900" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_894" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_895" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_901" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_901" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable_902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable_902" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet" xlink:label="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet_903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet_903" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_896" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_896" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_897" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_898" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_892" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_899" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_694" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_694" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_697" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_696" xlink:to="loc_us-gaap_RelatedPartyDomain_697" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:label="loc_plx_CompensationToTheNon-executiveDirectorsMember_699" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_697" xlink:to="loc_plx_CompensationToTheNon-executiveDirectorsMember_699" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_700" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_695" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_700" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_701" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_700" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_701" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_58" xlink:to="loc_us-gaap_StatementTable_59" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_59" xlink:to="loc_us-gaap_AwardTypeAxis_60" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61" xlink:to="loc_us-gaap_RestrictedStockMember_62" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_59" xlink:to="loc_us-gaap_StatementLineItems_63" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_64" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_415" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_730" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_415" xlink:to="loc_us-gaap_StatementTable_730" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_731" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_730" xlink:to="loc_us-gaap_StatementClassOfStockAxis_731" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_732" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731" xlink:to="loc_us-gaap_ClassOfStockDomain_732" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_733" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_730" xlink:to="loc_us-gaap_StatementLineItems_733" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetIncomeLoss_417" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_840" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_840" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_841" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_841" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_ShareBasedCompensation_419" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_Depreciation_420" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_421" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_429" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_422" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_842" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_842" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1042" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1042" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncomeOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeOnConversionOfConvertibleNotes_1155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_IncomeOnConversionOfConvertibleNotes_1155" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1043" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1043" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_430" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_1156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_1156" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_418" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_424" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_425" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_426" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_427" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_423" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1157" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_431" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_843" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_843" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_844" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_844" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_433" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_435" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_436" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_437" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_434" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_845" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_845" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_846" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_1158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_1158" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_439" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_440" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_441" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_443" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_444" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_445" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_446" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="plx-20171231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_450" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_1002" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_NotesIssued1_1002" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1044" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_StockIssued1_1044" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_449" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1159" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_733" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_447" xlink:to="loc_us-gaap_InterestPaidNet_448" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_364" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778404304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,569,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778713168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,163<span></span>
</td>
<td class="nump">$ 63,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,833<span></span>
</td>
<td class="nump">5,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">62,651<span></span>
</td>
<td class="nump">71,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">7,676<span></span>
</td>
<td class="nump">8,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">72,214<span></span>
</td>
<td class="nump">82,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">7,521<span></span>
</td>
<td class="nump">4,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">9,310<span></span>
</td>
<td class="nump">7,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">5,921<span></span>
</td>
<td class="nump">53,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,752<span></span>
</td>
<td class="nump">66,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">46,267<span></span>
</td>
<td class="nump">19,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">26,851<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">2,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">80,755<span></span>
</td>
<td class="nump">25,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">103,507<span></span>
</td>
<td class="nump">92,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>CAPITAL DEFICIENCY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2016 and 2017, 250,000,000 shares; issued and outstanding, respectively - as of December 31, 2016 and 2017, 124,134,085 shares and 143,728,797 shares, respectively</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">266,495<span></span>
</td>
<td class="nump">202,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(297,932)<span></span>
</td>
<td class="num">(212,656)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(31,293)<span></span>
</td>
<td class="num">(9,957)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 72,214<span></span>
</td>
<td class="nump">$ 82,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764705520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
<td class="nump">143,728,797<span></span>
</td>
<td class="nump">124,134,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
<td class="nump">143,728,797<span></span>
</td>
<td class="nump">124,134,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778559280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 19,242<span></span>
</td>
<td class="nump">$ 9,199<span></span>
</td>
<td class="nump">$ 4,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="num">(15,231)<span></span>
</td>
<td class="num">(8,398)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(32,170)<span></span>
</td>
<td class="num">(30,412)<span></span>
</td>
<td class="num">(24,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants</a></td>
<td class="nump">3,336<span></span>
</td>
<td class="nump">5,804<span></span>
</td>
<td class="nump">4,864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="num">(28,834)<span></span>
</td>
<td class="num">(24,608)<span></span>
</td>
<td class="num">(20,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(11,530)<span></span>
</td>
<td class="num">(9,356)<span></span>
</td>
<td class="num">(7,279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(36,353)<span></span>
</td>
<td class="num">(33,163)<span></span>
</td>
<td class="num">(23,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(9,725)<span></span>
</td>
<td class="num">(4,192)<span></span>
</td>
<td class="num">(3,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</a></td>
<td class="num">(38,061)<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(LOSS) GAIN ON EXTINGUISHMENT OF CONVERTIBLE NOTES</a></td>
<td class="num">(1,325)<span></span>
</td>
<td class="nump">14,063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL (EXPENSES) INCOME - NET</a></td>
<td class="num">(48,923)<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
<td class="num">(3,612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(85,276)<span></span>
</td>
<td class="num">(29,176)<span></span>
</td>
<td class="num">(27,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">(LOSS) INCOME FROM DISCONTINUED OPERATIONS</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">85,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME FOR THE YEAR</a></td>
<td class="num">$ (85,276)<span></span>
</td>
<td class="num">$ (29,365)<span></span>
</td>
<td class="nump">$ 58,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>NET (LOSS) INCOME PER SHARE OF COMMON STOCK - BASIC AND DILUTED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Loss from continuing operations</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Income from discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">(0.00)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net (loss) income per share of common stock</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED</a></td>
<td class="nump">131,085,958<span></span>
</td>
<td class="nump">101,387,704<span></span>
</td>
<td class="nump">94,922,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ResearchDevelopmentAndEngineeringExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779391424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="num">$ (55,601)<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 185,633<span></span>
</td>
<td class="num">$ (241,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,603,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">6,101<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,079<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,501)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employee</a></td>
<td class="nump">534<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(27,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income loss from discontinued operations</a></td>
<td class="nump">85,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,319<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">194,064<span></span>
</td>
<td class="num">(183,291)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,800,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,846,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible notes</a></td>
<td class="nump">685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employee</a></td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(29,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income loss from discontinued operations</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="num">(9,957)<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">202,575<span></span>
</td>
<td class="num">(212,656)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,134,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible notes</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Reclassification of embedded derivative</a></td>
<td class="nump">43,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note conversions</a></td>
<td class="nump">18,654<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible note conversions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,594,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(85,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income loss from discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">$ (31,293)<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 266,495<span></span>
</td>
<td class="num">$ (297,932)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,728,797<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount of less than $1 thousand.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769474480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY [Parenthetical]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Share-based compensation related to restricted stock award, forfeitures, (in shares)</a></td>
<td class="nump">2,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778325040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (85,276)<span></span>
</td>
<td class="num">$ (29,365)<span></span>
</td>
<td class="nump">$ 58,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">(Loss) income from discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">85,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(85,276)<span></span>
</td>
<td class="num">(29,176)<span></span>
</td>
<td class="num">(27,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial (income) expenses, net (mainly exchange differences)</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">(Gain) loss on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on sale of fixed assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on extinguishment of convertible notes</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="num">(14,063)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeOnConversionOfConvertibleNotes', window );">Net income in connection with conversions of convertible notes</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of convertible notes embedded derivative</a></td>
<td class="nump">38,061<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes', window );">Issuance of shares for interest payment in connection with conversions of convertible notes</a></td>
<td class="nump">2,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues (including non-current potion)</a></td>
<td class="nump">26,014<span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable and other assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(2,588)<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="num">(2,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">4,902<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
<td class="num">(1,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase in other long term liabilities</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operations</a></td>
<td class="num">(9,994)<span></span>
</td>
<td class="num">(32,087)<span></span>
</td>
<td class="num">(25,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,994)<span></span>
</td>
<td class="num">(32,098)<span></span>
</td>
<td class="num">(24,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(971)<span></span>
</td>
<td class="num">(849)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">(Increase) decrease in restricted deposit</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in continuing operations</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(967)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(967)<span></span>
</td>
<td class="nump">39,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for conversion of convertible notes</a></td>
<td class="num">(10,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="nump">9,542<span></span>
</td>
<td class="nump">19,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">19,695<span></span>
</td>
<td class="nump">6,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(12,118)<span></span>
</td>
<td class="num">(13,093)<span></span>
</td>
<td class="nump">21,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
<td class="nump">63,281<span></span>
</td>
<td class="nump">76,374<span></span>
</td>
<td class="nump">54,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
<td class="nump">51,163<span></span>
</td>
<td class="nump">63,281<span></span>
</td>
<td class="nump">76,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible note conversions</a></td>
<td class="nump">16,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 4,854<span></span>
</td>
<td class="nump">$ 3,659<span></span>
</td>
<td class="nump">$ 3,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Income from conversions of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for interest payment regarding conversion of convertible notes,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769298832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">a.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">General</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-style:normal">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-style:normal">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s current strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s product pipeline currently includes, among other candidates:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;), as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#8220;Amended Pfizer Agreement&#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36.0</font> million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues. For further details see note 2.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In 2017, the Company received a purchase order from the Brazilian Ministry of Health (the &#8220;Brazilian Ministry&#8221;) for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3 million. The purchase order consists of a number of shipments in increasing volumes. Shipments started in June 2017. The Company has recorded revenues of $7.1 million for sales of alfataliglicerase to Fiocruz in 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Ex-US license (the &#8220;Chiesi Agreement&#8221;) pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase alfa. Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase in the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25.0</font> million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million in development costs, capped at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million per year. Protalix Ltd. is also eligible to receive&#160;additional paymentS of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">320</font> million, in the aggregate, in regulatory and commercial milestone payments.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Under the terms of the agreement, Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi will make tiered payments of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements <font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> as of December 31, 2017</font>, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">b.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Basis of presentation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">c.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Use of estimates in the preparation of financial statements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">d.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Functional currency</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &#150; historical exchange rates. Currency transaction gains and losses are recorded as financial income or expenses, as appropriate.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">e.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Cash equivalents</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">f.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Inventories</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">g.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Property and equipment</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt">Years</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Laboratory equipment</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Furniture</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Computer equipment&#160;&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></font></div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="center"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">h.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Impairment in value of long-lived assets</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">i.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Income taxes</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Deferred income taxes</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used tax rates of 39%, 24% and 23%. See note 10.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Uncertainty in income taxes</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">j.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Revenue Recognition</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Revenues from supply agreements and from selling products</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company recognizes revenues from supply agreements and from selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Revenues from Chiesi Agreement</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Since there is only one unit of account, all payments received by Chiesi prior to the satisfaction of Protalix's obligation will be deferred. Therefore,&#160;the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million upfront payment and future research and development reimbursement payments (up to $25 million) and any potential additional development milestone payments will be deferred until the commencement of commercial manufacturing.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">k.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Research and development costs</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#8220;NATI&#8221;), which has replaced many of the functions of the Office of the Chief Scientist of Israel&#8217;s Ministry of Industry, Trade and Labor (the &#8220;OCS&#8221;), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">l.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Concentration of credit risks and trade receivable</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">m.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Share-based compensation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company accounts for employee&#8217;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted are measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">n.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Net (loss) earnings per share</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share (the &#8220;Common Stock&#8221;) outstanding for each period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19,778,424</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,532,492</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 76,848,199</font> shares of Common Stock underlying outstanding options, restricted shares of Common Stock and shares issuable upon conversion of the convertible notes for the fiscal years ended December 31, 2015, 2016 and 2017, respectively, because the effect would be anti-dilutive.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">o.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Convertible notes</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">All outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The Company accounts for the 2013 Notes (as defined in note 8a) as a liability, on an aggregated basis, in their entirety. The 2016 Notes (as defined in note 8b) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December 31, 2017, the embedded derivative was reclassified to additional paid in capital, see note 8.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Issuance costs regarding the issuance of the 2016 Notes and the 2017 Notes (as defined in note 8c) were allocated to the liability, equity component, derivative and shares based on their relative fair values. Issuance costs that were allocated to the liability are amortized using the effective interest rate, other than issuance costs that were allocated to the derivative which were expensed immediately.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The debt discount and debt issuance costs regarding the issuance of the 2013 Notes are deferred and amortized over the 2013 Notes period (5 years).</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">p.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Recently adopted standards</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Compensation - Stock Compensation (Topic 718)&#8221; (&#8220;ASU 2016-09&#8221;) which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted this standard in the fourth quarter of 2016. The Company elected to account for forfeitures as they occur. The implementation of this ASU did not have a material impact on the consolidated financial statements.</font><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">q.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Recently issued accounting pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> In May 2014, the FASB issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017. The implementation of this ASU did not have a material impact on the consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In January&#160;2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in annual reporting periods beginning after December 15, 2017. The implementation of this ASU&#160;is expected to have&#160;no material impact on the consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934759568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommercializationAgreementsAbstract', window );"><strong>COMMERCIALIZATION AGREEMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COMMERCIALIZATION AGREEMENTS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 2 - COMMERCIALIZATION AGREEMENTS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">On November&#160;30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June 2013) pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and Brazil. Under the Pfizer Agreement Protalix was entitled to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% of the results (profits or losses) earned on Pfizer&#8217;s sales of taliglucerase alfa.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">In October 2015, the Company entered into the following agreements with Pfizer:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Amended Pfizer Agreement - Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Protalix also agreed to provide Pfizer with:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">Stock Purchase Agreement - the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,649,079</font> shares of Common Stock to Pfizer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Promissory note &#150; as of the date of the amendment, the Company owed Pfizer $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.3</font> million as a result of the accumulated losses incurred by the Collaboration Operation. Following the new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a) November 12, 2020 and (b) the date upon which it becomes due pursuant to any event of default, as defined. The promissory note is presented in "other long term liabilities".</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">The Amended Pfizer Agreement resulted in a discontinued operation as defined under ASU 2014-08 because it represented a strategic shift for the Company that has a major effect on the entity&#8217;s operations and financial results.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Revenues from the Pfizer Agreements as well as revenues from sales of Elelyso in Israel were presented as discontinued operations. See&#160;note 12.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">In October 2017, Protalix Ltd. entered into the Chiesi Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter &#150; the drug) for treatment of the Fabry disease. Under the terms of the Chiesi Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. Protalix Ltd. maintains the exclusive commercialization rights to the drug in the United States.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Protalix Ltd. will be mainly responsible for (i) continuing the development of the drug until a regulatory approval is granted and (ii) manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">The consideration consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">a. Upfront, non-refundable payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">b. Additional payments of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million in development costs, capped at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million per year.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">c. Milestone payments of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">320</font> million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">d. Additional payments as consideration for the supply of the drug. The payment will vary from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">e. Protalix will be the sole manufacturer of the drug.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Chiesi does not have sublicensing rights (except for certain territories).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">The Company analyzed the agreement terms and concluded that the Chiesi Agreement qualifies as a contract with customer under ASC 605. Chiesi is a customer of the Company as it contracted with the entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Therefore, all payments received prior to the fulfillment of the one unit of account will be deferred until the commencement of commercial manufacturing. The Company will recognize revenues after the commencement of the drug supply over the period of the product&#8217;s sales according to the Company&#8217;s best estimate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">3.</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">On June 18, 2013, the Company entered into the Brazil Agreement with Fiocruz for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommercializationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommercializationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769437664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 3 - PROPERTY AND EQUIPMENT</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">a.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Composition of property and equipment grouped by major classifications is as follows:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Laboratory equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Furniture and computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,438</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,123</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Equipment under construction</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35,141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Less &#150; accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(25,601)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(27,465)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,676</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.3pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">b.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Depreciation in respect of property and equipment totaled approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.4</font> million, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.0</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.9</font> million for the years ended December 31, 2015, 2016 and 2017, respectively.</font></div> </div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934709840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 4 - INVENTORIES</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Inventories at December&#160;31, 2016 and 2017 consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,838</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>485</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,259</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Total inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769342672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2015, 2016 and 2017, the Company deposited approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">168,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">164,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">166,000</font>, respectively, with insurance companies in connection with its severance payment obligations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">The amounts of severance pay expenses were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">800,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">842,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">906,000</font> for each of the years ended December 31, 2015, 2016 and 2017, respectively, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">746,000</font> in the years ended December 31, 2015, 2016 and 2017, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately ($18,000), ($7,000) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,000</font> for the years ended December 31, 2015, 2016 and 2017, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">The Company expects to contribute approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">830,000</font> in the year ending December 31, 2018 to insurance companies in connection with its severance liabilities for its operations for that year, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">664,000</font> of which will be contributed to one or more Contribution Plans.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"><font style="FONT-SIZE: 10pt">During the five-year period following December 31, 2017, the Company expects to pay future benefits to three employees upon each such employee&#8217;s normal retirement age. The Company anticipates that the benefits payable will be approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769259184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 6 - COMMITMENTS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">a.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Royalty Commitments</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#8220;NATI&#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Chief Scientist of the Israeli Department of Labor&#160;&#160;(&#8220;OCS&#8221;). At the time the grants were received, successful development of the related projects was not assured.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the OCS.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Under the terms of the applicable funding arrangements, royalties of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font>% are payable on the sale of products developed from projects funded by NATI or the OCS, which payments shall not exceed, in the aggregate, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font></font>% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300</font></font></font>% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Royalty expenses to NATI or the OCS are included in the statement of operations as a component of the cost of revenues both in continuing and discontinued operations and were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.2</font>&#160;million, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">288,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,384,000</font> during the years ended December&#160;31, 2015, 2016 and 2017, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">At December 31, 2016 and 2017, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42.2</font> million, respectively (without interest, assuming <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the funds are payable).</font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">The Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues both in continuing and discontinued operations and were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">286,000</font> and&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> during the years ended December&#160;31, 2015, 2016 and 2017, respectively.</font>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments total payable would be approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.3</font> million and would be payable, if at all, as the Company&#8217;s projects progress over the course of a number of years. Milestone payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> and <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font> were made during the years ended December&#160;31, 2015, 2016 and 2017, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">b.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Subcontracting Agreements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December 31, 2017, total commitments under said agreements were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19.2</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">c.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Lease Agreements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each, for a total of 10 additional years. Under the leases, the aggregate monthly rental payments are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,000</font>. As of December 31, 2017, the Company provided bank guarantees of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">306,000</font> in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required under the operating leases for such premises are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">783,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">717,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">717,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">580,000</font>, for fiscal years 2018 through 2021, respectively. Lease expenses totaled approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font></font> million for each of the years ended December 31, 2015, 2016 and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">775,000</font> for the year ended December 31,2017, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">d.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Vehicle Lease and Maintenance Agreements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">52,000</font>. The expected lease payments for the years ending December 31, 2018, 2019 and 2020 are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">565,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">385,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">186,000</font>, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769316208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 7 - SHARE CAPITAL</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">a.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Rights of the Company&#8217;s Common Stock</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s Common Stock is listed on the NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">b.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Stock based compensation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of common stock available under the Plan to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,841,655</font> shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">As of December 31, 2017, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,554,075</font> shares of Common Stock remain available for grant under the Plan.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">From January 1, 2015 through December 31, 2017, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Options and restricted stock granted to employees:</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Below is a table summarizing all of the options grants to employees during the year ended December 31, 2015:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div> <div>Year&#160;of<br/> grant</div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>No.&#160;of&#160;options<br/> granted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Vesting&#160;period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Fair&#160;value<br/> at&#160;grant<br/> (U.S.&#160;<br/> dollars&#160;in<br/> thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Expiration<br/> period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,909,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1.72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>4 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2017 (such grants appear in the table above):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">On March 23, 2015, the Company&#8217;s compensation committee approved the grant of a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>-year option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,909,000</font> shares of Common Stock to its officers and other employees with an exercise price equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.72</font> per share under the Plan. The options vest over a four-year period; the first <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% shares vest on the first anniversary of the grant date and the remaining shares vest in 12 equal quarterly increments over the subsequent three-year period. Vesting of the options granted to certain executive officers is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.9</font> million based on the following weighted average assumptions: dividend yield of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% for all years; expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 61.7</font>%; risk-free interest rates of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.6</font>%; and expected life of six years.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">b)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">The total unrecognized compensation cost of employee stock options at December 31, 2017 is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,000</font>. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.54</font> years.</font></div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2015, 2016 and 2017 was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">534,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively. The Company did not realize any tax benefit in connection with these exercises.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Options granted to consultants, directors, and other service providers:</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">During the three years ended December 31, 2017 there were no option grants by the Company to its consultants, directors, and other service providers. In addition, during the three years ended December 31, 2017, there were no option exercises by any of the Company&#8217;s consultants, directors, and other service providers and, consequently, no shares of Common Stock were issued in connection with exercises of options by, nor was any cash received from, the Company&#8217;s consultants, directors, and other service providers during such period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">3.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the years ended December&#160;31, 2015, 2016 and 2017 is as follows:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Options granted to employees:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,870,309</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,952,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,884,211</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,909,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Forfeited and Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>277,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,514,957</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.748</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>154,594</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercised (*)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.972</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>553,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,952,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,884,211</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,729,617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.604</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercisable at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,477,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,498,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.296</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,457,461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt">(*) The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">213,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Restricted stock granted to employees:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Number&#160;of&#160;restricted&#160;stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>386,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>255,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">c.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Options and restricted stocks granted to consultants, directors, and other service providers:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at beginning of Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,208,592</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.136</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>637,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11.638</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>466,883</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>429,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.748</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Vested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>104,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>637,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11.638</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercisable at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>549,709</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>12.954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>170,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">d.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2017:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%" colspan="14"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="50%" colspan="8"> <div>Options&#160;outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%" colspan="5"> <div>Options&#160;exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercise<br/> prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of<br/> options<br/> outstanding<br/> at&#160;end&#160;of<br/> year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of<br/> options<br/> exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a&#160;(Restricted&#160;Stock)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,720,685</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,617,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>900,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>731,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>211,682</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>211,682</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5.000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>949,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>949,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>680,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>680,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>9.660</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>68,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>68,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>4,929,617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>4,657,461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">e.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table illustrates the effect of share-based compensation on the statement of operations:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>904</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>571</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Selling, general and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>898</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>988</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">c.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Private and 144A Offerings</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">On October 12, 2015, the Company completed a private offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,649,079</font> shares of the Company&#8217;s common stock to Pfizer. See also note 2.</font></div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">On December 7, 2016, the Company exchanged with certain existing note holders $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">54.052</font> million aggregate principal amount of the Company&#8217;s outstanding <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% Convertible Senior Notes due 2018 for, among other consideration, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40.186</font> million aggregate principal amount of convertible notes due 2021 (as described in note 8b) and for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,846,735</font> shares of common stock. See also note 8b.</font></div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -21.3pt; MARGIN: 0in 0in 0pt 78pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">3.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">On July 24, 2017, the Company entered into a Note Purchase Agreement with certain institutional investors relating to the private issuance and sale by the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million in aggregate principal amount of its <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.5</font>% secured convertible promissory notes due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2021</font>. The 7.5% convertible notes were issued pursuant to the base indenture dated December 7, 2016 (the existing 2016 Notes). Concurrently, the Company exchanged with certain existing note holders $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0</font> million aggregate principal amount of the Company&#8217;s outstanding <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% Convertible Senior Notes due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2018</font> for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.55</font> million aggregate principal amount of newly issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% Senior Convertible Notes due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2022</font>. See also note 8c.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769314608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 8 - CONVERTIBLE NOTES</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">a.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">4.5% Convertible Notes (&#8220;2013 Notes&#8221;)</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">On September 18, 2013, the Company completed a private placement of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">69.0</font> million in aggregate principal amount of Senior Convertible Notes (the &#8220;2013 Notes&#8221;), including $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0</font> million aggregate principal amount of 2013 Notes related to the initial purchaser&#8217;s over-allotment option, which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 2013 Notes. The 2013 Notes accrue interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. In December 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">54.1</font> million aggregate principal amount of 2013 Notes were exchanged for 2016 Notes and shares of common stock (see also note 8b) and in July 2017, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0</font> million aggregate principal amount of 2013 Notes were exchanged for 2017 Notes as defined in note 8c (see also note 8c). Accordingly, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.9</font> million aggregate principal amount of 2013 Notes remain outstanding as of December 31, 2017. The 2013 Notes mature on September 15, 2018.</font></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Holders may convert their 2013 Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the 2013 Notes is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 173.6593</font> shares of the Common Stock for each $1,000 principal amount of 2013 Notes (equivalent to an initial conversion price of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.76</font> per share of the Common Stock). Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of 2013 Notes, equal to the conversion rate. The conversion rate is subject to adjustment for certain events but will not be adjusted for any accrued and unpaid interest.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 56.7pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth total interest expense recognized for the years ended December 31, 2015, 2016 and 2017 related to the 2013 Notes:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,943</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Amortization of debt issuance costs and debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,549</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>572</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -99.55pt; MARGIN: 0in 0in 0pt 127.6pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">b.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">7.5% Convertible Notes (&#8220;2016 Notes&#8221;)</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">On December 1, 2016, the Company entered into a note purchase agreement with institutional investors, which held part of the 2013 Notes (the &#8220;2016 Purchasers&#8221;), relating to the sale by the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.5</font> million aggregate principal amount of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.50</font>% Senior Secured Convertible Notes due 2021 in a private placement pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Concurrently with the consummation of the private placement of the 2016 Notes, the Company entered into a privately negotiated exchange agreement (the &#8220;2016 Exchange Agreement&#8221;) with certain existing note holders identified therein to exchange $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">54.1</font> million aggregate principal amount of the Company&#8217;s outstanding 2013 Notes for (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40.186</font> million aggregate principal amount of 2016 Notes, (ii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,846,735</font> shares of Common Stock and (iii) cash, equal to the accrued and unpaid interest on the 2013 Notes and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December 7, 2016. The issuance of the 2016 Notes and shares in the exchange and the private placement were made in reliance on the exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof. The net proceeds from the private placement were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19.7</font> million, after deducting the placement agent&#8217;s fees and the Company&#8217;s estimated offering expenses.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">In connection with the completion of the exchange and the private placement, the Company entered into an indenture (the &#8220;2016 Indenture&#8221;) with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 2016 Notes. The 2016 Notes accrue interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.50</font>% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2017. A portion of the interest payable may be made in shares of Common Stock at the Company&#8217;s election. The Notes will mature on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">November 15, 2021</font>; provided that all of the then-outstanding 2013 Notes, or any Permitted Refinancing Indebtedness (as defined in the 2016 Indenture) have been redeemed, repurchased, otherwise retired, discharged in accordance with their terms or converted into common stock of the Company, or have been effectively discharged, in each case on or prior to June 16, 2018 or the scheduled maturity date of the 2013 Notes (or any Permitted Refinancing Indebtedness incurred in respect thereof) is extended to a date that is after February 15, 2022, otherwise the 2016 Notes will mature on June 15, 2018.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">On July 24, 2017, the Company entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million in aggregate principal amount of its 2016 Notes. The 2016 Notes were issued pursuant to the 2016 Indenture dated (December 7, 2016). The net proceeds from this purchase agreement were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.5</font> million, after deducting the Company&#8217;s offering expenses.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Holders may convert their 2016 Notes at any time. The initial conversion rate for the 2016 Notes is 1,176.4706 shares of the Common Stock for each $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> principal amount of 2016 Notes (equivalent to an initial conversion price of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.85</font> per share of the Common Stock). Upon conversion, the Company may settle the 2016 Notes by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#8217;s election.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">During 2017, approximately $13.6 million aggregate principal amount of the Company&#8217;s 2016 Notes were&#160;converted. Settlement of the conversions resulted in the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,827,624</font> shares of Common Stock and cash payments of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font> million, in the aggregate. A total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">59.1</font> million aggregate principal amount of the 2016 Notes remains outstanding as of December 31, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">Prior to the maturity date, the Company may redeem in cash:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 53.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 35.45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="47"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">any or all of the 2016 Notes if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days exceeds 150% of the conversion price on each applicable trading day, or</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 53.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 35.45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="47"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">b)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">all of the 2016 Notes then outstanding if the aggregate principal amount of the 2016 Notes then outstanding is less than 15% of the aggregate principal amount of the notes issued.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">No redemption was made during the years 2016 and 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">The 2016 Notes are guaranteed by the Restricted Subsidiaries (as defined in the 2016 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#8220;Collateral&#8221;), including, but not limited to, (i) 100% of the capital stock of the Guarantors (as defined in the 2016 Indenture) and each Restricted Subsidiary of the Company that is held by the Company or any Restricted Subsidiary, (ii) intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii) all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv) all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2016 Indenture, and (v) all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United States, and with Altshuler Shaham Trusts Ltd., as security trustee in Israel. The 2016 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#8217;s assets that constitute collateral securing the 2016 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">Upon (i) the occurrence of a fundamental change (as defined in the 2016 Indenture) or (ii) if the Company calls the 2016 Notes for redemption as described below (either event, a &#8220;make-whole fundamental change&#8221;) and a holder elects to convert its 2016 Notes in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#8220;Additional Shares&#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is 1,787.3100 shares per $1,000 principal amount of 2016 Notes, which amount is inclusive of repayment of the principal of the 2016 Notes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2016 Notes, or any portion of the principal amount thereof, that is equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> or an integral multiple of $1,000 in excess thereof, on a date of the Company&#8217;s choosing that is not less than 20 calendar days nor more than 35 calendar days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2016 Note is equal to 100% of the principal amount of such 2016 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">For accounting purposes, since the terms of the 2013 Notes and the 2016 Notes are substantially different, the 2016 Exchange Agreement was considered as an extinguishment, which in essence means recording a gain due to the 2013 Notes that were exchanged for the 2016 Notes recorded at fair value as of the closing date. The gain on extinguishment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.1</font> million was recognized.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">As the settlement upon conversion was subject to compliance with the listing standards of the NYSE American, until the Company&#8217;s stockholders&#8217; approval was obtained, the Company was prohibited by these rules from issuing shares in excess of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% of its outstanding shares (calculated as of December 1, 2016). The accounting guidance assumed that the conversion will be settled in cash and, as such, is precluded from equity classification for any part of the 2016 Notes that may have cash settlement. As such, that part of the conversion feature was accounted for as a derivative which is bifurcated from the debt host contract and was measured at fair value through the statement of operations until the Company&#8217;s stockholders approved, in April 2017, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">the issuance of shares in excess of 20% of its outstanding shares. On April 12, 2017, the Company&#8217;s stockholders approved the issuance of shares of the Company&#8217;s Common Stock in excess of 20% of the Company&#8217;s outstanding shares of Common Stock to settle conversion requests and pay interest on the Company&#8217;s issued 7.5% convertible notes.</font> As a result, the Company reclassified the embedded derivative to additional paid in capital. During 2017, the measurement of the derivative resulted in a non-cash charge to the Company&#8217;s statement of operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,061</font> thousand. The conversion feature of the 7.5% convertible notes issued in July 2017 is accounted for as equity, which is bifurcated from the debt host contract. With respect to the remainder of the 2016 Notes, for which the conversion feature qualifies for equity classification (since upon conversion the Company at its election may settle the 2016 Notes by paying cash, shares of Common Stock or a combination of cash and shares of Common Stock) separate liability (debt) and equity (conversion option) components of such 2016 Notes were recorded. The Company measures the liability according to amortized cost using the effective interest method.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Company prepared a valuation of the fair value of the 2016 Notes (a Level 3 valuation) for the issuance dates. The value of the 2016 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;7,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;24,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54.12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth total interest expense recognized related to the 2016 Notes:<br/> <br/> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Debt discount amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,309</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Gain on extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,063)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Change in fair value of convertible note embedded derivative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Interest payment in connection with conversions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Income in connection with conversions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,643)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(7,130)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 35.45pt; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt"></font><strong><font style="FONT-SIZE: 10pt"></font></strong>&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">c.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">4.5% Convertible Notes Due 2022 (&#8220;2017 Notes&#8221;)</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">On July 24, 2017, the Company entered into a privately negotiated exchange agreement (the &#8220;2017 Exchange Agreement&#8221;) with certain existing note holders identified therein to exchange $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0</font> million aggregate principal amount of the Company&#8217;s outstanding 2013 Notes for (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.55</font> million aggregate principal amount of the Company&#8217;s <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.5</font>% convertible promissory notes due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2022</font>, (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">275,000</font> in cash consideration and (iii) cash, equal to the accrued and unpaid interest on the exchanged 2013 Notes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">As the terms of the 2013 Notes and the 2017 Notes are substantially different, the 2017 Exchange Agreement was considered an extinguishment of debt, which in essence means recording a loss due to the 2013 Notes that were exchanged for the 2017 Notes recorded at fair value as of the closing date. The Company recognized a loss of $1.3 million due to the extinguishment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company prepared a valuation of the fair value of the 2017 Notes (a Level 3 valuation) for the issuance date. The value of the 2017 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;24,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>62.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely. The debt discount and debt issuance costs are deferred and amortized over the applicable convertible period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">All of the 2017 Notes were converted during the year ended December 31, 2017 into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,239,641</font> shares of Common Stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth total interest expense recognized related to the 2017 Notes:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Year&#160;Ended&#160;December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Debt premium amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(46)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Loss on extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934746512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 9 - FAIR VALUE MEASUREMENT</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The fair value of the convertible notes derivative is based on level 3 measurement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The fair value of the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.9</font> million 2013 Notes and the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">59.1</font> million 2016 Notes as of December 31, 2017 is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.7</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76.6</font> million, respectively, based on a level 3 measurement.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The Company prepared a valuation of the fair value of the 2013 Notes and the 2016 Notes (a Level 3 valuation) as of December 31, 2017. The value of these notes were estimated by implementing the binomial model. The liability component was valued based on the Income Approach. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following parameters were used:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013&#160;Notes</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016&#160;Notes</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.6612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.6612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>79.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>68.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769304560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 10 - TAXES ON INCOME</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">a.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">The Company</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at the rate of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 39</font>%.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act, which among other changes reduces the federal corporate tax rate to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">b.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Protalix Ltd.</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Israeli Subsidiary is taxed according to Israeli tax laws:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Tax rates</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates which were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26.5</font>% for fiscal year 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26.5</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>%.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23</font>%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24</font>% in 2017 and will be <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23</font>% in 2018 and thereafter.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Capital gain is subject to capital gain tax according to the corporate tax rate for the year during which the assets are sold.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.1pt; MARGIN: 0in 0in 0pt 1.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Reduced tax rates</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to&#160;tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable had such income not been exempted.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Accelerated depreciation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">c.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Conditions for entitlement to the benefits</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">d.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Amendment of the Law for the Encouragement of Capital Investments, 1959</font></strong></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In recent years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The amendment&#160;sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.On December 29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">The Company elected not to have the Capital Investments Law Amendment apply to the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">c.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Tax losses carried forward to future years</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">As of December 31, 2017, the Company had aggregate net operating loss (&#8220;NOL&#8221;) carry-forwards equal to approximately $207 million that are available to reduce future taxable income as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">The Company</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s carry-forward NOLs, equal to approximately $23 million (as of December 31, 2016, approximately $20 million), may be restricted under Section 382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Protalix Ltd.</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">At December 31, 2017, the Israeli Subsidiary had approximately $184 million (as of December 31, 2016, approximately $133 million) of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">d.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Deferred income taxes:</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The components of the Company&#8217;s net deferred tax assets at December 31, 2016 and 2017 were as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">In respect of:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Timing Differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Net operating loss carry forwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">38,515</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">47,033</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(42,035)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(58,368)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">e.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Reconciliation of the theoretical tax expense to actual tax expense</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">f.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Tax assessments</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In accordance with the Income Tax Ordinance, as of December 31, 2017, all of Protalix Ltd.&#8217;s tax assessments through tax year 2012 are considered final.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of open tax years by major jurisdiction is presented below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="MARGIN: auto auto auto 1in; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="65%"> <tr> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 52%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="52%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Jurisdiction:</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 1pt; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="9%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 39%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="39%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><strong> <font style="FONT-SIZE: 10pt">Years:</font></strong></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Israel</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"><font style="FONT-SIZE: 10pt">2013-2017</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">United States (*)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"><font style="FONT-SIZE: 10pt">2013-2017</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934722176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 4.5pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 11 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Balance sheets:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&#160;assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Institutions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">394</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">State of Israel (see note 6a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">195</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Restricted deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">477</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Assets of discontinued operation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">327</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Sundry</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts&#160;payable&#160;and&#160;accruals&#160;&#150;&#160;other:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Payroll and related expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,386</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Interest payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">645</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Provision for vacation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Royalties payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">301</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Property and equipment suppliers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">595</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">526</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,496</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,310</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Statements of operations:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 28.4pt"> &#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 15px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">Revenues:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">Pfizer</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12,181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">Brazil</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,973</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,242</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657481792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 12 - DISCONTINUED OPERATIONS</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">As mentioned in note 2, the Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No.&#160;2014-08.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The following summarizes financial information related to the Company&#8217;s discontinued operations, in the Company&#8217;s consolidated statements of operations:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>REVENUES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>COMPANY&#8217;S SHARE IN COLLABORATION AGREEMENT</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>COST OF REVENUES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,697)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(373)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>GROSS PROFIT (LOSS)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>46,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(164)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>RESEARCH AND DEVELOPMENT EXPENSES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(586)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less &#150;reimbursements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>545</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>RESEARCH AND DEVELOPMENT EXPENSES, NET</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(41)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(25)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>45,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>GAIN ON THE DISPOSAL</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>39,899</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>NET (LOSS) INCOME</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934752992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 13 - RELATED PARTY TRANSACTIONS</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;TEXT-INDENT: -13px; MARGIN-LEFT: 13px"> Compensation (including share based compensation)<br/> to the non-executive directors (includes the<br/> interim Chairman of the Board through 2015 and<br/> the Chairman of the Board for part of 2015)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>560</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779395616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">a.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">General</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-style:normal">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-style:normal">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s current strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s product pipeline currently includes, among other candidates:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;), as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement (the &#8220;Amended Pfizer Agreement&#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36.0</font> million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues. For further details see note 2.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In 2017, the Company received a purchase order from the Brazilian Ministry of Health (the &#8220;Brazilian Ministry&#8221;) for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3 million. The purchase order consists of a number of shipments in increasing volumes. Shipments started in June 2017. The Company has recorded revenues of $7.1 million for sales of alfataliglicerase to Fiocruz in 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Ex-US license (the &#8220;Chiesi Agreement&#8221;) pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to commercialize pegunigalsidase alfa. Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase in the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25.0</font> million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million in development costs, capped at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million per year. Protalix Ltd. is also eligible to receive&#160;additional paymentS of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">320</font> million, in the aggregate, in regulatory and commercial milestone payments.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Under the terms of the agreement, Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Chiesi will make tiered payments of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months from the date of approval of the financial statements <font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> as of December 31, 2017</font>, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">b.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Basis of presentation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">c.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Use of estimates in the preparation of financial statements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">d.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Functional currency</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &#150; exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) &#150; historical exchange rates. Currency transaction gains and losses are recorded as financial income or expenses, as appropriate.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">e.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Cash equivalents</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">f.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Inventories</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">g.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Property and equipment</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt">Years</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Laboratory equipment</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Furniture</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Computer equipment&#160;&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></font></div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in" align="center"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">h.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Impairment in value of long-lived assets</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">i.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Income taxes</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Deferred income taxes</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used tax rates of 39%, 24% and 23%. See note 10.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Uncertainty in income taxes</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">j.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Revenue Recognition</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Revenues from supply agreements and from selling products</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company recognizes revenues from supply agreements and from selling products upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Revenues from Chiesi Agreement</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">As Chiesi is obligated to acquire pegunigalsidase alfa from the Company and the development services are not considered to have a stand-alone value, development and manufacturing of a product to be commercialized by Chiesi is viewed as one unit of account. Since there is only one unit of account, all payments received by Chiesi prior to the satisfaction of Protalix's obligation will be deferred. Therefore,&#160;the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> million upfront payment and future research and development reimbursement payments (up to $25 million) and any potential additional development milestone payments will be deferred until the commencement of commercial manufacturing.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">k.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Research and development costs</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#8220;NATI&#8221;), which has replaced many of the functions of the Office of the Chief Scientist of Israel&#8217;s Ministry of Industry, Trade and Labor (the &#8220;OCS&#8221;), are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">l.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Concentration of credit risks and trade receivable</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">m.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Share-based compensation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company accounts for employee&#8217;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted are measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">n.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Net (loss) earnings per share</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share (the &#8220;Common Stock&#8221;) outstanding for each period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19,778,424</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,532,492</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 76,848,199</font> shares of Common Stock underlying outstanding options, restricted shares of Common Stock and shares issuable upon conversion of the convertible notes for the fiscal years ended December 31, 2015, 2016 and 2017, respectively, because the effect would be anti-dilutive.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">o.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Convertible notes</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">All outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The Company accounts for the 2013 Notes (as defined in note 8a) as a liability, on an aggregated basis, in their entirety. The 2016 Notes (as defined in note 8b) were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December 31, 2017, the embedded derivative was reclassified to additional paid in capital, see note 8.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Issuance costs regarding the issuance of the 2016 Notes and the 2017 Notes (as defined in note 8c) were allocated to the liability, equity component, derivative and shares based on their relative fair values. Issuance costs that were allocated to the liability are amortized using the effective interest rate, other than issuance costs that were allocated to the derivative which were expensed immediately.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The debt discount and debt issuance costs regarding the issuance of the 2013 Notes are deferred and amortized over the 2013 Notes period (5 years).</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock', window );">Recently adopted standards</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">p.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Recently adopted standards</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Compensation - Stock Compensation (Topic 718)&#8221; (&#8220;ASU 2016-09&#8221;) which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted this standard in the fourth quarter of 2016. The Company elected to account for forfeitures as they occur. The implementation of this ASU did not have a material impact on the consolidated financial statements.</font><font style="FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">q.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Recently issued accounting pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> In May 2014, the FASB issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017. The implementation of this ASU did not have a material impact on the consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In January&#160;2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in annual reporting periods beginning after December 15, 2017. The implementation of this ASU&#160;is expected to have&#160;no material impact on the consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769340784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 81.1pt; WIDTH: 64%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="64%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 36%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="36%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><b><font style="FONT-SIZE: 10pt">Years</font></b></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Laboratory equipment</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Furniture</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Computer equipment&#160;&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Useful Life Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934712912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Composition of property and equipment grouped by major classifications is as follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Laboratory equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Furniture and computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,438</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,123</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Equipment under construction</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>35,141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Less &#150; accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(25,601)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(27,465)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,676</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6610048016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Inventories at December&#160;31, 2016 and 2017 consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.9in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,838</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>485</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,259</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Total inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780076368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock', window );">Schedule of Options and Restricted Stocks Granted</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Below is a table summarizing all of the options grants to employees during the year ended December 31, 2015: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 89.85pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div> <div>Year&#160;of<br/> grant</div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>No.&#160;of&#160;options<br/> granted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Vesting&#160;period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Fair&#160;value<br/> at&#160;grant<br/> (U.S.&#160;<br/> dollars&#160;in<br/> thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Expiration<br/> period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,909,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1.72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>4 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>1,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity - Options Granted to Employees</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">a.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Options granted to employees:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,870,309</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,952,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,884,211</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,909,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Forfeited and Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>277,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.395</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,514,957</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.748</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>154,594</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercised (*)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.972</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>553,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,952,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,884,211</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,729,617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.604</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercisable at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,477,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,498,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.296</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,457,461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt">(*) The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">213,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity - Options Granted to Employees</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.3in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="96"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Restricted stock granted to employees:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Number&#160;of&#160;restricted&#160;stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>386,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>255,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>127,874</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock', window );">Schedule of Options Granted to Service Providers</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Options and restricted stocks granted to consultants, directors, and other service providers: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="71%" colspan="17"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>options/</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>restricted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at beginning of Year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,208,592</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.136</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>637,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11.638</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Changes during the year:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>466,883</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>429,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.748</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Vested restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>104,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>637,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11.638</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.156</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="27%"> <div>Exercisable at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>549,709</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>12.954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>170,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about Share Options Outstanding</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2017: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="84%" colspan="14"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="50%" colspan="8"> <div>Options&#160;outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%" colspan="5"> <div>Options&#160;exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercise<br/> prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of<br/> options<br/> outstanding<br/> at&#160;end&#160;of<br/> year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of<br/> options<br/> exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted<br/> average<br/> remaining<br/> contractual<br/> life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a&#160;(Restricted&#160;Stock)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,720,685</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,617,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>900,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>731,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>211,682</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>211,682</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5.000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>949,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>949,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6.900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>680,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>680,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>9.660</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>68,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>68,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>4,929,617</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>4,657,461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table illustrates the effect of share-based compensation on the statement of operations: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 1.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>904</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>571</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>Selling, general and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>898</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>988</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of options and restricted stocks granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5444-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764795728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company prepared a valuation of the fair value of the 2016 Notes (a Level 3 valuation) for the issuance dates. The value of the 2016 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;7,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;24,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54.12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember', window );">Four Point Five Percentage Convertible Notes One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company prepared a valuation of the fair value of the 2017 Notes (a Level 3 valuation) for the issuance date. The value of the 2017 Notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;24,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>62.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=plx_Notes2013Member', window );">Notes 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table sets forth total interest expense recognized for the years ended December 31, 2015, 2016 and 2017 related to the 2013 Notes: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,943</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Amortization of debt issuance costs and debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,549</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>572</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=plx_Notes2016Member', window );">Notes 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table sets forth total interest expense recognized related to the 2016 Notes:<br/> <br/> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Year&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="68%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Debt discount amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,309</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Gain on extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,063)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Change in fair value of convertible note embedded derivative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Interest payment in connection with conversions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Income in connection with conversions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,643)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(7,130)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=plx_Notes2017Member', window );">Notes 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table sets forth total interest expense recognized related to the 2017 Notes: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Year&#160;Ended&#160;December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>(U.S.&#160;Dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Contractual interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Debt premium amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(46)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Loss on extinguishment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,325</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=plx_Notes2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=plx_Notes2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=plx_Notes2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=plx_Notes2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=plx_Notes2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=plx_Notes2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934705904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_TwentyThirteenAndTwentySixteenNotesMember', window );">2013 Notes and 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35.45pt"> <font style="FONT-SIZE: 10pt">The following parameters were used:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013&#160;Notes</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016&#160;Notes</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Stock price (USD)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.6612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.6612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>79.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>68.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_TwentyThirteenAndTwentySixteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_TwentyThirteenAndTwentySixteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769358096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The components of the Company&#8217;s net deferred tax assets at December 31, 2016 and 2017 were as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">In respect of:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Timing Differences</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Net operating loss carry forwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">38,515</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">47,033</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(42,035)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(58,368)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of open tax years by major jurisdiction is presented below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="MARGIN: auto auto auto 1in; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="65%"> <tr> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 52%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="52%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Jurisdiction:</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 1pt; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="9%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 39%; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="39%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="center"><strong> <font style="FONT-SIZE: 10pt">Years:</font></strong></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">Israel</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"><font style="FONT-SIZE: 10pt">2013-2017</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">United States (*)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BACKGROUND: white; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="right"><font style="FONT-SIZE: 10pt">2013-2017</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Open Tax Years Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOpenTaxYearsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6933014432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Balance sheets:</font></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0in 0in 0pt 71.3pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other&#160;assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Institutions</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">394</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">State of Israel (see note 6a)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">195</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Restricted deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">477</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">623</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Assets of discontinued operation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">327</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Sundry</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,648</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts&#160;payable&#160;and&#160;accruals&#160;&#150;&#160;other:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Payroll and related expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,386</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Interest payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">645</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Provision for vacation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Royalties payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">301</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Property and equipment suppliers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">595</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">526</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,496</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,310</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Supplemental Information, Statements of Operations</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Statements of operations:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 28.4pt"> &#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 15px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both"> (U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="56%"> <div style="CLEAR:both;CLEAR: both">Revenues:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">Pfizer</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12,181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">Brazil</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,973</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="56%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,364</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,199</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,242</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767042784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The following summarizes financial information related to the Company&#8217;s discontinued operations, in the Company&#8217;s consolidated statements of operations:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>REVENUES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>COMPANY&#8217;S SHARE IN COLLABORATION AGREEMENT</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>COST OF REVENUES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,697)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(373)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>GROSS PROFIT (LOSS)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>46,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(164)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>RESEARCH AND DEVELOPMENT EXPENSES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(586)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less &#150;reimbursements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>545</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>RESEARCH AND DEVELOPMENT EXPENSES, NET</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(41)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(25)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>45,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>GAIN ON THE DISPOSAL</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>39,899</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>NET (LOSS) INCOME</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85,319</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(189)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769467056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div>(U.S.&#160;dollars&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;TEXT-INDENT: -13px; MARGIN-LEFT: 13px"> Compensation (including share based compensation)<br/> to the non-executive directors (includes the<br/> interim Chairman of the Board through 2015 and<br/> the Chairman of the Board for part of 2015)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>631</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>560</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764945008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780536752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,848,199<span></span>
</td>
<td class="nump">23,532,492<span></span>
</td>
<td class="nump">19,778,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal', window );">Tax Rate Assumption Related To Deferred Tax Difference Reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company used tax rates of 39%, 24% and 23%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase', window );">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromExchangeForRightsToRoyalties', window );">Proceeds From Exchange For Rights To Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FutureResearchAndDevelopmentReimbursement', window );">Future research and development reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The definition should be: "The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FutureResearchAndDevelopmentReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development reimbursement payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FutureResearchAndDevelopmentReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of adult Gaucher patients treated with Uplyso.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExchangeForRightsToRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received in exchange for rights to royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExchangeForRightsToRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767082336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2009</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember', window );">Protalix Bio Therapeutics Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Collaborative Arrangement Profit Share Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember', window );">Chiesi Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The definition should be: "The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement profit sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementProfitSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779704816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 35,141<span></span>
</td>
<td class="nump">$ 34,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
<td class="num">(27,465)<span></span>
</td>
<td class="num">(25,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">7,676<span></span>
</td>
<td class="nump">8,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">16,561<span></span>
</td>
<td class="nump">16,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember', window );">Furniture And Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">16,123<span></span>
</td>
<td class="nump">15,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember', window );">Equipment Under Construction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_EquipmentUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771175328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,920<span></span>
</td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="nump">$ 2,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6932815184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,838<span></span>
</td>
<td class="nump">$ 2,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,510<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 7,833<span></span>
</td>
<td class="nump">$ 5,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766695648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
<td class="nump">746,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expense</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="nump">842,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Net gain (loss) for the period</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="num">$ (7,000)<span></span>
</td>
<td class="num">$ (18,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_BenefitsPayableDuringNextFiveYears', window );">Benefits Payable During Next Five Years</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember', window );">Contribution to Insurance Companies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</a></td>
<td class="nump">830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember', window );">Contribution to Defined Contribution Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</a></td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_BenefitsPayableDuringNextFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits payable during next five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_BenefitsPayableDuringNextFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee severance obligation payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EmployeeSeveranceObligationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions expected to be received by defined benefit plan from employer in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82843861&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779572784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePotentialPayable', window );">Milestone Potential Payable</a></td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePaymentAmountPaid', window );">Milestone Payment, Amount Paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_OCSMember', window );">OCS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
<td class="nump">1,384,000<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember', window );">Research And License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2018</a></td>
<td class="nump">783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2019</a></td>
<td class="nump">717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2020</a></td>
<td class="nump">717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposited as bank guarantee</a></td>
<td class="nump">306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Lease/rent expense</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Future minimum lease payments, 2021</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember', window );">Vehicle Lease And Maintenance Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2018</a></td>
<td class="nump">565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2019</a></td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2020</a></td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | OCS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | OCS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="nump">$ 42,200,000<span></span>
</td>
<td class="nump">$ 38,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Products Manufactured Outside Of Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents milestone payments made during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePotentialPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePotentialPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MonthlyRentLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly rent/lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MonthlyRentLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfRoyaltiesToGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required royalty payments represented as a percentage to grants received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfRoyaltiesToGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties based on sale of products developed from projects funded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RoyaltiesOnSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_OCSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_OCSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_ResearchAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_ProductsManufacturedOutsideOfIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_ProductsManufacturedOutsideOfIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766888416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=plx_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="nump">1,909,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFifteenMember', window );">2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award granted contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_GrantYearTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778639904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Options Granted to Employees) (Details) - Options And Restricted Stock Granted To Employees [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,884,211<span></span>
</td>
<td class="nump">6,952,293<span></span>
</td>
<td class="nump">5,870,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,909,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154,594<span></span>
</td>
<td class="nump">1,514,957<span></span>
</td>
<td class="nump">277,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">553,125<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,729,617<span></span>
</td>
<td class="nump">4,884,211<span></span>
</td>
<td class="nump">6,952,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,457,461<span></span>
</td>
<td class="nump">3,498,492<span></span>
</td>
<td class="nump">4,477,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.617<span></span>
</td>
<td class="nump">$ 3.363<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.004<span></span>
</td>
<td class="nump">3.748<span></span>
</td>
<td class="nump">5.395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.067<span></span>
</td>
<td class="nump">0.972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.604<span></span>
</td>
<td class="nump">3.617<span></span>
</td>
<td class="nump">3.363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.696<span></span>
</td>
<td class="nump">$ 4.296<span></span>
</td>
<td class="nump">$ 4.182<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $675,000, $213,000 and $0, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStockGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656181536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details) - Employees [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">127,874<span></span>
</td>
<td class="nump">386,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">127,874<span></span>
</td>
<td class="nump">255,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">127,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767278624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details) - Options and Restricted Stocks Granted To Consultants Directors And Other Service Providers [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options/ restricted stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">208,000<span></span>
</td>
<td class="nump">637,209<span></span>
</td>
<td class="nump">1,208,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesStockExpired', window );">Expired</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">429,209<span></span>
</td>
<td class="nump">466,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested', window );">Vested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="nump">637,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">170,500<span></span>
</td>
<td class="nump">549,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
<td class="nump">$ 3.156<span></span>
</td>
<td class="nump">$ 11.638<span></span>
</td>
<td class="nump">$ 6.136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">15.748<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
<td class="nump">3.282<span></span>
</td>
<td class="nump">3.156<span></span>
</td>
<td class="nump">11.638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 3.282<span></span>
</td>
<td class="nump">$ 3.109<span></span>
</td>
<td class="nump">$ 12.954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) vested during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesStockExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) expired during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesStockExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_OptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780364192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details) - Options and Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">4,929,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">4,657,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OnePointSevenTwoZeroMember', window );">1.720 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">1,720,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">1,617,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember', window );">2.350 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 months 22 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">9 months 22 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember', window );">2.370 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">731,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember', window );">2.650 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">211,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 year 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">211,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">1 year 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember', window );">3.020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember', window );">3.370 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 6 months 22 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">6 years 6 months 22 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember', window );">5.000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">949,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">949,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember', window );">6.900 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 6.900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">680,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">680,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember', window );">7.550 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember', window );">9.660 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 9.660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options and restricted stock outstanding at end of year</a></td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">2 years 9 months 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OnePointSevenTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_OnePointSevenTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeFiveZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointThreeSevenZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_TwoPointSixFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ThreePointThreeSevenZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_FivePointZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SixPointNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_SevenPointFiveFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NinePointSixSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767834976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 1,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Marketing, General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781749408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2016</div></th>
<th class="th"><div>Oct. 12, 2015</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Jun. 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 23, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 02, 2016</div></th>
<th class="th"><div>Dec. 14, 2006</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">13,841,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">23,846,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,239,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember', window );">Four Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 54,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember', window );">Convertible Notes Due Two Thousand Twenty One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">40,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 40,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176.4706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember', window );">Four Point Five Percentage Convertible Notes One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,550,000<span></span>
</td>
<td class="nump">$ 8,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022 years<span></span>
</td>
<td class="text">2022 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,846,735<span></span>
</td>
<td class="nump">5,649,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock [Member] | Vest on the first anniversary of the grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The total intrinsic value of options exercised during the years ended December 31, 2015, 2016 and 2017, was approximately $675,000, $213,000 and $0, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year when the debt instrument is scheduled to be fully repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661422672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details) - 2013 Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 501<span></span>
</td>
<td class="nump">$ 2,943<span></span>
</td>
<td class="nump">$ 3,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AmortizationOfDebtIssuanceCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
<td class="nump">$ 572<span></span>
</td>
<td class="nump">$ 3,364<span></span>
</td>
<td class="nump">$ 3,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767492192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Fair Value Income Approach) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2016</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">54.12%<span></span>
</td>
<td class="nump">63.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Yield</a></td>
<td class="nump">13.98%<span></span>
</td>
<td class="nump">11.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember', window );">Four Point Five Percentage Convertible Notes One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767485392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule Of Debt Interest Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="num">$ (14,063)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of convertible note embedded derivative</a></td>
<td class="num">(38,061)<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2016Member', window );">2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount (premium) amortization</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of convertible note embedded derivative</a></td>
<td class="nump">38,061<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest payment in connection with conversions</a></td>
<td class="nump">3,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnConversionOfDebt', window );">Income in connection with conversions</a></td>
<td class="num">(1,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total</a></td>
<td class="nump">47,079<span></span>
</td>
<td class="num">$ (7,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2017Member', window );">Notes 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount (premium) amortization</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total</a></td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate gain (loss) recognized on the converion of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782643776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2016</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Jun. 24, 2017</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 02, 2016</div></th>
<th class="th"><div>Sep. 18, 2013</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173.6593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,542,000<span></span>
</td>
<td class="nump">$ 19,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption', window );">Principal amount, related to the initial purchaser's over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,325,000)<span></span>
</td>
<td class="nump">14,063,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfExcessSharesOutstanding', window );">Percentage Of Excess Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">23,846,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,239,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,961,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockholdersApprovalDescriptionForCommonStockIssuance', window );">Stockholders Approval Description For Common Stock Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the issuance of shares in excess of 20% of its outstanding shares. On April 12, 2017, the Companys stockholders approved the issuance of shares of the Companys Common Stock in excess of 20% of the Companys outstanding shares of Common Stock to settle conversion requests and pay interest on the Companys issued 7.5% convertible notes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,061,000)<span></span>
</td>
<td class="num">$ (6,473,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber', window );">Maximum Debt Instrument Convertible Conversion Share Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,787.3100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, Redemption, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prior to the maturity date, the Company may redeem in cash: a) any or all of the 2016 Notes if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days exceeds 150% of the conversion price on each applicable trading day, or b) all of the 2016 Notes then outstanding if the aggregate principal amount of the 2016 Notes then outstanding is less than 15% of the aggregate principal amount of the notes issued.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176.4706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember', window );">Four Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 54,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember', window );">Convertible Notes Due Two Thousand Twenty One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">40,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="nump">$ 40,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotes2013Member', window );">Convertible Notes 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotes2013Member', window );">Four Point Five Percentage Convertible Notes 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member', window );">Seven Point Five Percentage Convertible Notes 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,827,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember', window );">Four Point Five Percentage Convertible Notes One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,550,000<span></span>
</td>
<td class="nump">$ 8,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMaturityYear', window );">Debt Instrument Maturity Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022 years<span></span>
</td>
<td class="text">2022 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year when the debt instrument is scheduled to be fully repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount of Notes related to the initial purchaser's over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumDebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfExcessSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage of excess shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfExcessSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockholdersApprovalDescriptionForCommonStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description for stockholders approval description for issuing common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockholdersApprovalDescriptionForCommonStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotes2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotes2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotes2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotes2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779726336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2016</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember', window );">Four Point Five Percentage Convertible Notes [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 16 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">54.12%<span></span>
</td>
<td class="nump">63.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Yield</a></td>
<td class="nump">13.98%<span></span>
</td>
<td class="nump">11.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.89%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768453440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 24, 2017</div></th>
<th class="th"><div>Jun. 24, 2017</div></th>
<th class="th"><div>Dec. 02, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember', window );">Four Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member', window );">Seven Point Five Percentage Convertible Notes 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Four Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">76.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Four Point Five Percentage Convertible Notes 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Seven Point Five Percentage Convertible Notes 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotes2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotes2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotes2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934753136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME (Deferred Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Timing Differences</a></td>
<td class="nump">$ 11,335<span></span>
</td>
<td class="nump">$ 3,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">47,033<span></span>
</td>
<td class="nump">38,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(58,368)<span></span>
</td>
<td class="num">(42,035)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934979440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Open Tax Years) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">ISRAEL [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2013<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">ISRAEL [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2013<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767699152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearTwoThousandNineMember', window );">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember', window );">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember', window );">Restricted Amount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">Protalix Ltd. [Member] | Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure Line Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearTwoThousandNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearTwoThousandNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_RestrictedAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661698192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsInstitutionsCurrent', window );">Institutions</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">State of Israel (see note 6a)</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted deposit</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of discontinued operation</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsSundryCurrent', window );">Sundry</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">$ 1,934<span></span>
</td>
<td class="nump">$ 2,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsInstitutionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsInstitutionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsSundryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsSundryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779505488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">$ 9,310<span></span>
</td>
<td class="nump">$ 7,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934925024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Statements Of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 19,242<span></span>
</td>
<td class="nump">$ 9,199<span></span>
</td>
<td class="nump">$ 4,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">12,181<span></span>
</td>
<td class="nump">5,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_BR', window );">BRAZIL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,061<span></span>
</td>
<td class="nump">$ 3,973<span></span>
</td>
<td class="nump">$ 4,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767161600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 48,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement', window );">COMPANY&#8217;S SHARE IN COLLABORATION AGREEMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">COST OF REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(7,697)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">GROSS PROFIT (LOSS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="nump">46,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable', window );">Less -reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">45,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">GAIN ON THE DISPOSAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">NET (LOSS) INCOME</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (189)<span></span>
</td>
<td class="nump">$ 85,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Grants And Reimbursements Received Or Receivable attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Research And Development Gross expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Research Development Expense Net attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of share of company in Collaboration Agreement attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657633888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember', window );">Compensation To The non-executive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Compensation (including share based compensation) to the non-executive directors (includes the interim Chairman of the Board through 2015 and the Chairman of the Board for part of 2015)</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToTheNon-executiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)NQ[ZP[N'QM?!54#O^Y"?0%02P,$%     @ -(%F3)E<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MU.$P3J<NGO?7KP[7B[$[+U]4\MMGG>U_4$L#!!0    ( #2!9DRJ@Y+<[P$
M $T%   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC93=CILP$(5?!?$
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MR,./AJ_GXZGK&Z+-ZI(?W5^N^_ORTOBKZ-;+_ERZJCW75="XPSI\YD^9D'W
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MU%*2(J<Z,*P+L5"AC2TM3LB)@,X.3;?< 9!W@,M%U!N7GMN;-SBCAK"+<@_
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MS/WL*9F;_P87D @/2K!&::2+7U(.SALULZ 4)5ZGL]/Q'&?^:]IV I\3^)+
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MR"> ?-;()TMJL\:!9EA4>NVM@<R?[68O+6/J$Z"^3LPE(>I[O2M9 9DG\P2
MZN(<, C#GP#\1<.?++4E%>:AQ:K(W+0U4 TY7>;&&H< @1 0'0)D\5[ZS%:)
M,+<)<%LTMPEP.Z5DU@Z0,1511R32D2]SFSS"04 @",18 MM]NYJMR$G,S3*,
M> *(%XUXLER&XPADPS@FC7FD(Z&8V7L2)CU%"V#)=1XSG, 3@GZB7)+=V%^E
M4D<R4D4Q2PRH)&3ZS3@U&*2&Z-1@ 'KE&$CT@\_ZI]5<FL5IP2 M]*@L&26!
MZ$TL5!7Z,1FH<CL(QFG!("V\3@L&A-<!AS3FL B)4F86<^:\" 6%1B$CN#N7
MM&<@2T&#$*F\R^PC& <%@Z#PFG!L@X)33)F'/L91P2 JO(XDAEM\.SXH4>SX
M6!4GCKE30)P3'"S??&[U8;@S@+O7SQP,:.R*%#+;8<8T9K#O]CI'&)S[>+T[
M6 &52R'F_&"T,T"[-["P. ZNR#0D&,<"<.QUA@"1.;D4<!RC[M4::#QGXD,P
MD040V>OX$$ADLQJ ;+A3R9P.6UD(G*&R8"H+HK(.$K$P%?.D!$14ZA4,1%?G
M1R^7EC&7!7 YZ" 1Q&5RYGP,ZKA(^G$)Z&AH-8,>R;Q  &S6AQ!+L6P.3%%O
MC("L#%R:F6UE7LK<BQ/!I!= ^J!)+Q;.WCE]M+0",M"]-9!==N_2-T:] -2'
M#.H%HU[0/MY@"!S"Z//[%1+9)0U.:F(FE@4GAH#$"&9:V"P0SA(:1X'8*$BF
MTR )HF1.:SU. @^2P.G9YP'E ^5NML<,]P[,EPQ//>:I!SP-^ISL*"HO[K+>
M0*R BH-F\QJI7*%-+\Y>!N_J]FEZT=[-[IO7?3^^4SV[>GJ9_W%ZEZ^N+]WU
M^O!*_D<UA_\0^*-JGS;[;O:EZ?MF-[U0?FR:OAY,%A^&^_)<5P^G+]OZL1\_
MEL/G]O!F_O"E;UZ._W6P./WKP]W_4$L#!!0    ( #2!9DP.)"H(M0$  -(#
M   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;;MLP#/T501]0)8[7
M9H%MH.DPK$ +!!VV/2LV;0O5Q9/DN/W[4;+K>:VQ%TFD> X/*2H;C'UV+8 G
M+TIJE]/6^^[ F"M;4-Q=F0XTWM3&*N[1M USG05>19"2+-ELKIGB0M,BB[Z3
M+3+3>RDTG"QQO5+<OAY!FB&G6_KF>!)-ZX.#%5G'&_@._D=WLFBQF:42"K03
M1A,+=4YOMX=C&N)CP$\!@UN<2:CD;,QS,.ZKG&Z"()!0^L# <;O '4@9B%#&
M[XF3SBD#<'E^8_\::\=:SMS!G9&_1.7;G.XIJ:#FO?1/9O@&4SV?*)F*?X +
M2 P/2C!'::2+*RE[YXV:6%"*XB_C+G3<A_$FW4VP=4 R 9(9L(]YV)@H*O_"
M/2\R:P9BQ]YW/#SQ]I!@;\K@C*V(=RC>H?=2;*]O,G8)1%/,<8Q)EC%S!$/V
M.46REN*8?( GZ_#=JL)=A._^4;A?)TA7"=)(D/ZWQ+68S^^2L$5/%=@F3I,C
MI>EUG.2%=Q[8VR2^R=_P<=H?N6V$=N1L/+YL[']MC >4LKG"$6KQ@\V&A-J'
MXPV>[3AFH^%--_T@-G_CX@]02P,$%     @ -(%F3+9N#E.R 0  T@,  !@
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M0>=?-O:_1G3@I>QN_ BU_H,MAH+:A>-'?S;3F$V&PW[^06SYQL5O4$L#!!0
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M^E\C>@A2-G=AA-KPP69#0>WC\2&<[3AFH^&QFWX0F[]Q\0M02P,$%     @
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M#[#4\XJ2I?A/< 7IPX,2GZ-&:>-*ZM$Z5 N+EZ+X\[P+'?=IOLGR!;8/2!=
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M/]AL**A<.%[[LQG';#0<=M,/8O,WSO\!4$L#!!0    ( #2!9DQHG#?DM0$
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MI@B&[%.*9"G%,?D 3Y;AFT6%FPC?_*-POTRP72381H+MIR4NQ=S^EX3->JK
MUG&:'"E,I^,DS[S3P-XE\4W>PX=I_\EM+;0C9^/Q96/_*V,\H)35%8Y0@Q]L
M,B14/AQW>+;#F V&-^WX@]CTC?._4$L#!!0    ( #2!9DQ(YL$>M $  -(#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;'U3VV[;, S]%4$?4"5*
MLA6!;:#I,&S !@0=MCXK-FT+U<63Y+C[^U&RZWJ;UQ=)I'@.#RDJ&ZQ[\BU
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MOL>S&\=L-(+MIA_$YF]<_ 902P,$%     @ -(%F3#W':_NT 0  T@,  !D
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MN%J_W;J]'N;+8%C5C:.33O.[^ -02P,$%     @ -(%F3,DWEZ,- @  <P8
M !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC57MCILP$'P5Q .<P?F
M1 0IN5/52JT47=7VMT,V@,[&U';"]>UK&X[C<ALI?V)[/3LSZ]A+UDGUHBL
M$[P*WNA-6!G3K@G1106"Z0?90F-W3E()9NQ2E42W"MC1)PE.:!0MB6!U$^:9
MC^U5GLFSX74#>Q7HLQ!,_=L!E]TFC,.WP'-=5L8%2)ZUK(2?8'ZU>V579&0Y
MU@(:7<LF4'#:A-MXO8NI2_"(WS5T>C(/7"D'*5_<XMMQ$T;.$7 HC*-@=KC
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M<]6WP7YA9#NT>#)^9_+_4$L#!!0    ( #2!9DP*AH(VM@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;&U386_;(!#]*X@?4!+B)%5D6VHZ
M39NT25&G;9^)?;91P><!CKM_/\"NZ[7^ MQQ[]V[XT@'-,^V 7#D1:O69K1Q
MKCLQ9HL&M+!WV$'K;RHT6CAOFIK9SH H(T@KQC>; ]-"MC1/H^]B\A1[IV0+
M%T-LK[4P?\^@<,CHEKXZGF3=N.!@>=J)&GZ ^]E=C+?8S%)*#:V5V!(#548?
MMJ=S$N)CP"\)@UV<2:CDBO@<C*]E1C=!$"@H7& 0?KO!(R@5B+R,/Q,GG5,&
MX/+\ROXYUNYKN0H+CZA^R](U&;VGI(1*],H]X? %IGKVE$S%?X,;*!\>E/@<
M!2H;5U+TUJ&>6+P4+5[&7;9Q'\:;/9]@ZP ^ ?@,N(]YV)@H*O\DG,A3@P,Q
M8^\[$9YX>^*^-T5PQE;$.R_>>N\MY\<D9;= -,6<QQB^B-G.$<RSSRGX6HHS
M_P#GZ_#=JL)=A"?_*=RO$R2K!,E'@L/N78DK,<?#NR1LT5,-IH[39$F!?1LG
M>>&=!_8A/B)["Q^G_;LPM6PMN:+S+QO[7R$Z\%(V=WZ$&O_!9D-!Y<+QZ,]F
M'+/1<-A-/XC-WSC_!U!+ P04    "  T@69,7VK6OL8!   W!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6QM5&%OVR 0_2N('U <$B]I9%MJ6E6;
MM$E1IVV?B7VV4<%X@./NWP^PZWDI7PQWO'OO[N"<C4J_FA; HC<I.I/CUMK^
M2(@I6Y#,W*D>.G=2*RV9=:9NB.DUL"H$24%HDGPBDO$.%UGPG761J<$*WL%9
M(S-(R?2?$P@UYGB#WQTOO&FM=Y BZUD#W\'^Z,_:661AJ;B$SG#5(0UUCA\V
MQU/J\0'PD\-H5GOD*[DH]>J-+U6.$Y\0""BM9V!NN<(C".&)7!J_9TZ\2/K
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M,1Y?-O:_,<8#2DEN<(0Z_&"KH:#QX?@!SW8>L]GP9EA^$%N_<?D'4$L#!!0
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MQ'U.7FS.P1#(XC",//*P]@!J#X!V8XB6"$,X20B3A(" 8X(($D37KY<8$L1
M@6GB%A.>#2@G%R=A+OY4N""-/T(Q\K5AUY?*X)?BCA%0$9A?(P0:\3##)F8<
M4(Q)Q39FWB>JQ>9CR'V&J18=Z&)N@Y$TV"<,F&!T=6 7L/ 3Q6(?L BH8&:Q
M"#3B5X;MPH!?:,2QA+U [O75$O8",:#",_<S-IA:&K$<8;\0L (9N_>\ _G7
MI,%V(6 7"LPT_/HTV%($MD8*S33>8-#8R&(F;#L"MJ.QZ<66HN 3*P1;BL#.
M0K%9+ #QL6JQ[PA8BH\=W["E*+Z^6HXMQ<'V,J@6@;CI?N?L\)N+<MM<72IK
M)0^%JC6>]?;7HSNJ#\]&_YS=+ACH7^KK5'OY>:=O[V+?DW*;%I7U+)4^LC<'
MZXV42FCM[HU>5#M]_>L;F=BH^C74[V5[!VH;2NZ[^YW37S)G_P!02P,$%
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MFM4$+YP.!-IQBS @$TYE\/_+P&9#@-MP-)7Q9FY!"V9!L"41X$D/+5# AD.
MXW \S12R)5[0@7V) -/A!<\@V'4(L-T\5<B;TZHZHQ9147XU[5=8&;O54G]D
M1ZM#B]]BW6(FZSNTWG>-^IVFNS?\(/Q:U,(Z,:D:F&DS%\8D53FZ3ZJ<N;JJ
M#).27J0>1FK,NW[=321K^KN(,UR(TG]02P,$%     @ -(%F3!_:G;-^ @
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M-MP& %7?ZQ8'W@H0!G#HA 6\&2#RCJ+ 2QA!:WA4E/'J1!1A,JP*($LIRR:
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MZ+F8/N)IH?@POT]H>23S/U!+ P04    "  T@69,O?/OIWH"  """   &0
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MIS-J:.0)?!,:&B?_*3&9+2I_^?^16)D3"W,V8TY,YGAY;U)KGM3, Q<"9-8
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MR=JV[Q%TU15/74,".!(C&Q^!? )X73PV%$I \<(NGK@2%A-4V'@H,!X^\Z3
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MVDXS,Y>^E_F%%MW0I\GX9U'^!5!+ P04    "  T@69,C5$<;&T#  #K#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R-EVUOFS 0Q[\*X@,$V]B
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M"7I 2 ^<N7H!0>[B]0%H> P0],*,T(L+X^M%$H9@D1@!'$8EZ(I!&XW$C0J
M8NM&]#YH&(V@4(:\/E)APV>DXY;YQ(E-4 P#%,,]BYT;_X041C95L7/LN %
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M@)@#@AP0<T"0 VH&'G) S %!#H@Y(,@!,0<$.2#F@" 'Q!P0Y("8 X(<$'-
MD /#'!C(@6$.#.3 , <&S_YF^D,.#'-@( >&.3"0 \,<&,B!80X,Y, P!P9R
M8)@# SFPS(&%'-CF0A)R8)D#"SFPS('%&M"( .3 ,@<6<?#%,@<6<<#*MKLL
M#=XTJ[MJ763EXW)337X5=5VLVXN=AZ*H<Q9$=<3"_)1G]_N'5?Y0-S]C_EUV
M5YS=0UUL^^O;8'^'?/H_4$L#!!0    ( #2!9DS1A(HC'P(  /4%   9
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M#"Z&J,-D+29ZP&"<]#%K $-0'[-Q,>]*@<[RGFH$IAK9<-Q+=0H33$&"J4.
MDW"08XM!+:BVH' 2QV@D4PP*84!HN!DNAF ,BQ!0A  B>"#B8@@FL$@,BL2
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M?5"RHS*O,_TNVN:K'2C>=(UE<.]NTW]02P,$%     @ -(%F3"A&.[1D @
MGP@  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULC5;MSIHP&+T5P@4
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M:?O*;"><U/ISP.V^2=)_4$L#!!0    ( #2!9DS%68W$_@$  '0%   9
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M+JS6<.-$:^QX+>TUV)VEXLT015MIZ%M_KUI[O_9O\F2@P81D("0C 9%/">E
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MSCBHV4&9QUP_BW[#[P>*=\-A)AI/5*O_4$L#!!0    ( #2!9DS$[[8Y]P$
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M;) H$@;2-N>A <<;$?R0 6#B;9$N\1./%3_%Q<HL%L37NR3=[AJX_]]W]'V
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M &J</J[9.5(G!YJ@?0H7H?HPG5YI@A0J4 ,^,?-!N^R&'I<Q>#V&BS2N_N;
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MN+=E#AB[Q"@K<>"09<<1B5SA!Q:\VZJ['6DEJV1#R(FTF;1#3]R_#U%): A
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M?4 -=Q"O#L9V3Y=8+3\GJP8!^AM0ZCI^<BI. #R"P23",PS&@!P_Y\6O^"K
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M1,1N7?BGCZ!K!,Q]^D5R6!Y _R0A0UO/88NR9H%(*)^[;]6EA9;LPRS4H):
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MQZ!"W^^R]!Z$(_@6><SZ+J9PY:OK/Y]$G2YFZS9LQXYCN1NH0Z:]W%E\6U!
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MM.W'P]!D%!(QD$FH=@?0=P[1<IS-(F$E7W42MA$1J5LS&=EM$M@M:Q#:]-)
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M]_'Z;?'A@>+[M%O2HQW2S:GN.,7Q_D!_,_1%UIO7@K>C6^$C_]##WG_:;?G
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MR(31!%5YP%)(\JSU3*G,M0%+"%98*C+?M/R6*)WB0E7E5"3',O<ND/G4Y[S
M'$M$-Z%U[9_S*?]GXO[HWY'M5Z4-?$)&TP]< .3@$B"'EP!Y$34Y/G_(_LWY
M,YI.\_PA1R?XLK\]9/#&D%[9KFWTA%L=86T%LYQ017B)NR1QC!V/:<E#^,/<
M".A67]8TAEI>H9F^M&[IZ]@8)RBGZL%LT3I#V(R_&?!@6*^:UA(A;,;?<4QR
M9N\V7G,SCOX 4$L#!!0    ( #2!9DS&SU$$I@0  $XG   /    >&PO=V]R
M:V)O;VLN>&ULQ9I;;^HX$(#_BL53S\O2W.A%;24WI*VED&23@+;[LG+!+%%S
M04GH.>??KP.'W0F%T;Y,>0*",9\<VY]G)G??J_K]K:K>V8\B+YO[P:IMU[?#
M83-?J4(VOU5K5>IOEE5=R%9_K/\>-NM:R46S4JHM\J%Y>3D:%C(K!P]W^[ZB
M>OAPU[V99>I[\]_U[B.3\S;[4*E\NQ]<#G2[(6BX[73_NB.ZK?\/4[5<9G,U
MKN:;0I7M#JI6N6RSJFQ6V;H9L%(6ZGZP;\)XN6!>V6;M3R;*75>Z[8!M_UHL
M[@>&?M_*5O_F(VNRMUP-6'V;Z2]JL3 Z<#I(-PR2T!=CGGIC]LA]'K@>2UX\
M+TT H(D FF<#9']%$D!:"*3UA9!)JE\F7J !PR<61EX,(&T$TCX;I/O" P#I
M()#..2%' '*$0([.!\F3%P!YA4!>T4(FXCD03\+E0<JXZX;3(!7!,XLTN"L\
MN+JO$<AKZI&<3+S8%=P7?_)4A 'CS[&W&TY >(,0WM 21G&W@M-7QH,Q\WZ?
MBJB#@YOW);9[7]+2B6"F:<*X?T,-5"C$1O$%?Q2^T"/V%,;,FT1^^.IY+!;/
M+WJ)3"$FIA6#W"N3B4@/)YJ!2<0@MDCRPF-/[R"12+D/H3!I&/36F.GY+QY]
MCP5AVI]GF"@,8E,\<1&S&?>G'IMX/)G&WN'"Q QA$"LBY7]X6@@!$X&>:1[$
MPIQ@4$MA&D7^=J!XK!>H"/1Q2F^^>XE!3,P*!K$6QB+1\T[[:JH%V^V_6S?T
MIAZF!(/8";'G;]4?\4X,:<R#A+N'A";F!9/8"ZC\30-B8JXPB5V!8YH0$PU!
MB%UQ_ S +G1DF:OF&\3$_&$2^P,<!HZR81HQB372<]M1.LPE)GW4T9?<44+,
M)R:Q3X[;[B@FYA>3V"\'VCO*AXG%)!8+ZC_S!F)B@C&)!7/"?_OAA$D/S#(6
ML65.>W!+"C$QRUCGM(P%+6-AEK&(+8-C6A 33761Y[I.A^SL J:1+$PX%K%P
M3CE[K%J9Y;TEA)G'(C;/*<Q UK5N#3$Q_5C$^ND=+7X-(=S4+4PZ%K%TT(R#
M=0TQ,?=87Y#K^I5Q^/?^?JAO^_&$F)A[+&+W')S4DDU1R/HGJY8L7.O&,)>-
MN<>FCG#ZF%NVLF'/M2Q;M6 0$W./3>V>/F:LFK;.YAUATE;S=XB)N<>F=L_Q
MT93E@G7($!-SC_V5&;+^W-RT?4RTT/*UP4ZRDK5BC[+1=]VMBC7$Q-QC$[OG
M /-P2X*8F'ML^FK+87"6Z&X7FUQU=QYB8A:RB2UT!/-)9C6;R7RCF("8F(5L
M<@N='LW0AA&0C5G()K;0$4PX/V&Q$K.00VRADV'Y2K$\@TO(P2SD$%OH%.;G
M4Z:#6<@AMM"G[,%8+55=ZVU3E/.J@)B8A1QB"WW"#'5G+)4_V*N2-0PM',Q"
M#K&%/F'V-WB(B1;\J2V$I60<6/%W, LYQ!;",:\@)F8AYYP%'@?&0@YF(><\
M!9[M4M)S%&)B%G+.5NAA%VYO0QIA%AKMGC[;/W*V4,NL5(M _T6CK\]E/H]J
MUKWLJN*VTU6WEIL\=_6UL/0KN7U(K.MC_WS;PS]02P,$%     @ -(%F3)08
MY'(4 @  620  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\7:2V[B
M0!2%X:T@+R!%W8>3M$)&F63:Z0U84#P4L"U7M3K9?3M,VI$2GQZ@PP2$C.[]
M1Q]6F8>?Z=B40]?F_:'/B[?3L<VK:E]*_R.$O-ZG4Y-ONCZUXY5M-YR:,GX<
M=J%OUJ_-+@59+NLP3&=4CP_3F8OGS:H:GC>Q6OQJAETJJRJ\'<.?;GC-^Y1*
M#N>W>#,N&+_RWJ?_6=]MMX=U>NK6OT^I+5]4_%M0A:^#9#Y(Z$$Z'Z3T()L/
M,GJ0SP<Y/:B>#ZKI0;?S0;?TH+OYH#MZT/U\T#T]*"Z!C$M^$L*:KW4$7$>^
MUQ& '?EB1T!VY)L= =J1KW8$;$>^VQ' '?ER1T!WY-L= =Z1K[< O86OMP"]
MY0KWVNAFFZ^W +V%K[< O86OMP"]A:^W +V%K[< O86OMP"]A:^W +V%K[<"
MO96OMP*]E:^W KWU"F<EZ+"$K[<"O96OMP*]E:^W KV5K[<"O96OMP*]E:^W
M KV5K[<!O8VOMP&]C:^W ;V-K[<!O>T*9]WHL)NOMP&]C:^W ;V-K[<!O8VO
MMP&]C:^W ;V-K[<#O9VOMP.]G:^W [V=K[<#O9VOMP.]_0K/*M'#2K[>#O1V
MOMX.]':^W@[T=K[>#O1VOMXUT+OFZUU/],[[9DB;ES(<VEV^=,FGX=_63.#.
MY?V8+I]QGOKM_HG29=R2POGUXK]@YZD?$>'3/XD>_P)02P,$%     @ -(%F
M3&3'G-'E 0  XB,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=I=3\(P% ;@
MOT)V:UCI%WY$O%%OE43_0-T.;&%;F[8B_'N[H28:3#!"\MXPMM.=\VXTSQ77
MSUM'8;1IFR[,LBI&=\58*"IJ3<BMHRY5%M:W)J93OV3.%"NS)"8FDRDK;!>I
MB^/8]\ANKN]H85Z;.+K=7>];SS+C7%,7)M:V8^NN_-%T_-$P]]0,:T)5NW"6
M%F2C^TWJ$M*U69:J(6,'3/AY8W^>[GM<D_=U27^*9A>+NJ#2%J]MNB4/SI,I
M0T44VR8/E?%4/D5?=\N/O'/CXX-I4V.V:=BW!?GI<L1M0_L##)5C3HYI6]"^
M44-A]\G_-?!S-Q36T]CY5/6QWO-X*=(\50/K%Q[S$:G?.B65!PU/K4_WP[Y9
MOQJ^[WOA7\7 AL/_WOKQ<@B0'!(DAP+)H4%R3$%RG(/DN #)<0F2@T]0@J"(
MRE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM D56@
MR"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K0I%5
MH<BJ4&15*+(J%%D5BJP*15:%(JM&D56CR*I19-4HLFH4636*K!I%5HTBJT:1
M5:/(.CVAK,,Q;TW=_9;DQ=K5YWPV_+7GYAU02P$"% ,4    "  T@69,'R//
M \     3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M    "  T@69,9O,+8((   "Q    $               @ 'I    9&]C4')O
M<',O87!P+GAM;%!+ 0(4 Q0    ( #2!9DP&N-F([P   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  T@69,JH.2W.\!  !-!0  &
M    @ 'J#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M-(%F3"1?\T(4!   4!(  !@              ( !#Q(  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #2!9DSY&<WV_ 0  (@8   8
M          "  5D6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  T@69,>6RT&KD!  #5 P  &               @ &+&P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ -(%F3)^^4O@4!@  !B$
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #2!9DSZ5CC6M0$  -(#   9
M      "  6TK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ -(%F3'EJ'62S 0  T@,  !D              ( !62T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  T@69,IYL(0;0!  #2 P
M&0              @ %#+P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( #2!9DS33)%:M0$  -(#   9              "  2XQ  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ -(%F3+.2$.^S
M 0  T@,  !D              ( !&C,  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  T@69,&0IY,+4!  #2 P  &0
M@ $$-0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #2!
M9DQHG#?DM0$  -(#   9              "  ? V  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ -(%F3$CFP1ZT 0  T@,  !D
M         ( !W#@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  T@69,/<=K^[0!  #2 P  &0              @ ''.@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #2!9DQ#415!D0(  $(*
M   9              "  ;(\  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ -(%F3)7R@VNV 0  T@,  !D              ( !>C\
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  T@69,#G<<
M]+4!  #2 P  &0              @ %G00  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( #2!9DSY:;/,M@$  -(#   9
M  "  5-#  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M-(%F3(&,5F;[ 0  RP4  !D              ( !0$4  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  T@69,R3>7HPT"  !S!@  &0
M            @ %R1P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( #2!9DP*AH(VM@$  -(#   9              "  ;9)  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ -(%F3%]JUK[& 0
M-P0  !D              ( !HTL  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  T@69,;A^X \8!   W!   &0              @ &@
M30  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #2!9DR8
MSC3<N $  -(#   9              "  9U/  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ -(%F3,E@GGRV 0  T@,  !D
M     ( !C%$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #2!9DQ^GB4\\ $  -T$   9              "
M ;M>  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ -(%F
M3'0HI"ON 0  , 4  !D              ( !XF   'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  T@69,O?/OIWH"  """   &0
M        @ $'8P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( #2!9DP2L_5-P ,  '42   9              "  ;AE  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ -(%F3#3I5A(; @  . 8
M !D              ( !KVD  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  T@69,C5$<;&T#  #K#0  &0              @ $!;
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #2!9DRW-\WO
M(0(   H&   9              "  :5O  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ -(%F3,56RL_> @  N@H  !D
M ( !_7$  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  T
M@69,7-8)+A$%   "'@  &0              @ $2=0  >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #2!9DP?7WT12 (  #\'   9
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M970T.2YX;6Q02P$"% ,4    "  T@69,8#'RHR,%  !.&P  &0
M    @ '-B@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M #2!9DSK0,JFK0(  .D*   9              "  2>0  !X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ -(%F3"A&.[1D @  GP@  !D
M             ( !"Y,  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    "  T@69,Q5F-Q/X!  !T!0  &0              @ &FE0  >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( #2!9DP%X:%!8 (
M #T(   9              "  =N7  !X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ -(%F3!2RX7XP P  \ X  !D              ( !
M<IH  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  T@69,
M-"/?Q#$"   &!P  &0              @ '9G0  >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( #2!9DP![U=9.P(   X'   9
M      "  4&@  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ -(%F3%+7!30K @  6P8  !D              ( !LZ(  'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  T@69,^D-_.ZL"  !="0
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  T@69,QL]1!*8$  !.)P  #P
M            @ 'T(@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -(%F
M3)08Y'(4 @  620  !H              ( !QR<! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ -(%F3&3'G-'E 0  XB,  !,
M         ( !$RH! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $4 10#5
)$@  *2P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>204</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - COMMERCIALIZATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CommercializationAgreements</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DiscontinuedOperations</Role>
      <ShortName>DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/PropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Inventories</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapital</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/TaxesOnIncome</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SupplementaryFinancialStatementInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DiscontinuedOperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RelatedPartyTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - COMMERCIALIZATION AGREEMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CommercializationAgreementsNarrativeDetails</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/CommercializationAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/InventoriesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementNarrativeDetails</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - COMMITMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CommitmentsNarrativeDetails</Role>
      <ShortName>COMMITMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Commitments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Options Granted to Employees) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalOptionsAndRestrictedStocksGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails</Role>
      <ShortName>SHARE CAPITAL (Options and Restricted Stocks Granted to Consultants, Directors and Other Service Providers) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ShareCapitalTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>147 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesScheduleOfInterestExpenseRecognizedDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>148 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesFairValueIncomeApproachDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>149 - Disclosure - CONVERTIBLE NOTES (Schedule Of Debt Interest Expenses) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesScheduleOfDebtInterestExpensesDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule Of Debt Interest Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>150 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesNarrativeDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>151 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>152 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>153 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails</Role>
      <ShortName>TAXES ON INCOME (Deferred Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>154 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails</Role>
      <ShortName>TAXES ON INCOME (Open Tax Years) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>155 - Disclosure - TAXES ON INCOME (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>156 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationOtherAssetsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>157 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>158 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Statements Of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationStatementsOfOperationsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Statements Of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>159 - Disclosure - DISCONTINUED OPERATIONS (Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DiscontinuedOperationsOperationsDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS (Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="plx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>160 - Disclosure - RELATED PARTY TRANSACTIONS (Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactionsCompensationDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20171231.xml</File>
    <File>plx-20171231.xsd</File>
    <File>plx-20171231_cal.xml</File>
    <File>plx-20171231_def.xml</File>
    <File>plx-20171231_lab.xml</File>
    <File>plx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001144204-18-013053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-013053-xbrl.zip
M4$L#!!0    ( #2!9DS\987*>EX! +J\%@ 0    <&QX+3(P,3<Q,C,Q+GAM
M;.R]_7/B2+(H^ON)./^#KL_9.ST1V(T^ ??.W*!MW,,];N.PZ=F=^^)%AXP*
MHS-"8B7A-G/C_>\OJR2!)(1*$A)(4!L[,QBDJLRL_*ZJS+__K_>YP;TAV]$M
M\Y<+_JI]P2%S8FFZ^?K+Q;?QW67W@OM?O_[[O_W]?UQ><E^0B6S511KWLN)N
M55<=V^KD3R=XGQ.NVAS\IRU=?E7M2Z'-=[G_I]V];@O7?.__Y?[OX]?_CQL\
MC[E+[L>/'U<:O.^2]Z\FUIR[O QF^:PZ, .,\\_/3_<P)N__]OYB&_HU_C<'
M0)O.]<)X_^5BYKJ+ZX\?\8@+VW)50W_'XWV$V3N\(/(7_L.&;OX9>1H/=&79
MK_!D6_R(?WZ!B8/'\:^:OGXA_+#RT?MQ_>C6T#]$\BS?Z_4^DE_7CSIZTH,P
M*/_QGU_OGR<S-%<O==-Q57,2@45/@3W^O.Y8DL!WTM[PG@A>T-#"1A.\L#O?
MZ7U4[8EM&>CCYN'@]8FU-%U[%266@R97K];;1_]'LAZ7;?YRLR*3I6T#K^UZ
MS_\UX44-Z<GOP _X<2GZ.'J?S)*?Q[\DC*^;;\AQDU_Q?L,OB=&73%6?.,GO
MD)\2YG'T2?(+\ -^G(\][B[L'<_#+PDO+)W+5U5=K-^9JLX+64__AP20WHT4
MKOGG?8B5EZZ=PBSPZP7(+,?]';/_M4,8^PE-.2(.U^YJ@7ZY</3YPL!<2[Z;
MV6CZRP7(]&4@NE?O#O#81QC'TPPWENFB=Y=[1A,7U W1"C"#IQ<F_H\Z\/!C
MF_\._X=QY+'%"]]%[[,'T?H-9+JZN_*_6W^K:_C[J8YLCD"-(E@&%+\9_M?%
MKVT06U '0I?_^\?XR\%4'V-S12!8(%NWM#@$(,RV"]H5_8J!QNO37D^P^2T8
M*H2.MGF)%V!1-Y-K_BMAD$*3!U_Y-/3'3B6L$B*LTD3"*D4(JU1/V$Z(L)TF
M$K93A+"=Z@@K;E0!?!;$)JL"L8 J@)<$L0+"]IV1N29NMR$$]5PE%U.F&R5G
M\$L9+"=M9!D^B^TFR[)40);A);%=%<LI#2-HB.6 ,DJ(,F6R7"?$<IWO@M0D
M"L59KE.$Y3J7@E05R_6^\UU,4+$A! VQ'*BXWB7?K8#EP$L)NX*8ZQKK"H+S
M4<@5;'<J8CD@*(]EN-T4@FY8KDTHPTL5L)Q/F69%'2%AC(4/55&F*7H_8AD/
M0AFI>921#D.9ID1$(<K()5 &IY5N]3DR2?Z:GE@B-&L'-/O>AS<UI#U.];^0
MW7^U$9#$=+^B^0NREP[.L8U7"S2:]FU;-5_)C_UWW?G^^<G[]=D%FX&__8*L
M5UM=S/2):I G'OU<]F?=&L\0_(26KCYQAN;$LA>6K6(XO7DTI-^C5]48$"KB
MEP^\E''3BEXQ1NOY_!\T .1]8>@3W:</IP5T_^7"3TA>)U+KXM>%\7Z=1NJ_
M?TR<(01;%B" D-=;E,139U^+<@ )J+&3.RY^];/JUY^?=D_I3_<Q:5GV%[UV
M-4H)A&N3N=T(6EX).TD1R,G[9:]_+!D%'% @+]T^9/J4KF>;RR<U4PYU3@''
MC+8G1N>L0@ZM.0YB.:+!X?=[]06;9LM>#?ZUU!=QJP$V'69Q5X\&3-\WM?5#
MGU>8?,UF@$S(87;82:2C\,:APF/&&\WCC0,E")3O=TO;U-VEC8 V-]9\L721
MS;AD)Y=D(-=IZQ+&+R?!+P?3+_=(==#,,K3A?&%;;\0_<QB?A)$+'DXAU6GK
M%,8CC>61@^F1-56^F1JR;RR8R%Y.-JE(QB@;HT.CU6EK$\8I#>>4ZG3*CK3I
M5]W4Y\MYF#V><"Z)[$R-;IZ]'X!>X,'-=9?H7.+/ 7[PF#G1D=-,AL$\0$4*
M/[2F0KE;/FLR;RQ<9#%80C>-;=5WQK:U8=OP8C"VW7TKA7%F5LZLE%<:<=&&
M\4HM>*41=X<8K]2"5VIF@V*Q(7.9F,MTC.S5^?+=_NM_*FKR(+FP'3[W$W*0
M:D]F0)![?0+40NMC=<[I\EYF;J"3AWGI*5XZXZYF<E<S_'JRY<48RDG8"*P)
M']7;YV?\4T/^.>9VS^]HID\,Y%' U+ZJ.KQCXHI2C$M"9BL[F9C:25 [C,L:
MRV5'N*C[?;3 N^Z84. NNK8^<9'V[%J3/[_8,"'2QM9@OC"L%4*1DU%CW370
M:#HT-?U-UY9-O^6S QT2L><ET%'XY5#7EQF_G :_E'&I.U,&DO'+2?#+P3.'
MC&^:RS<-3"4R=CL1=FM&;I&QVXFP6[US 8S-FLMFQT@&G#DWU&&M#Q;(L[4^
M^EI7%X3O"*K8FM? 96A&0,18I0:L4K-@)GXUEK'(L2W(@2ZWIFP3.6M/&=_B
M7!IX?N=6M]'$M6S\_,B=(?L9V6_Z!#W:%E 1V6?*,940\;2]5,9WC.]JM6W%
M^.X<^>X VU\9]R,8_YT-_]4Y%,B[K\'8]CS9MJ'[(XQ=SX9=#WLB?.?UN%OT
MA@R+U$0:O"_P99TP-^$>"'.TKD5^;TU(-X1F\U0J4NO[FW02L3QN"HL](\/0
MS5>OI;@!5.QK<]W405"!V&_()Z3#F(T4^\]#+,9VV:YF,LW6-,U6UU@CRF),
MLYV89JLKVT5#7*;9&JS9:A:.[F QIME.3+/5C.UBS=^ \TBH@.]-6B8)W<.L
MM:8_+MKKKG W <M$^')EHYF+@E;PV!91CN;V%VT$QPM5L%!B5^KO=];2?K1T
MT[T#T7M$]@3P55_1C66^(=O57PST8+E1S76+7MPAJ?^,R=5LGDK"A73CR$.6
MHWE?=>S.S1BKB8P5WSG=<$B9+4R355 <]]LE&O^PQC-KZ:BF-OX!>*Q&)CHW
M3LE%%J:" A74[GWGNYBQQ"W&PE^>.Q=M:' 4Y2)>MGN7?+>BXT I:_^HKE3X
M''&39Y;MCI$]Q[1K?BN/'>ALW.(4@IP8+\0,S;J#(7-)&N22E&1H#KEU=[96
MYFBFI8$;;8Q)V)X%-:',F(2E?[=3*T*PC_J&3.;(;/%./KH<,;FRSN^6?QV"
M)56:F%0Y2/HM=I26:9'&:I&#%T)FO-(L7JFS,[-C%X"Q6(-9K&;[ ,!3:RV&
M^4MB6JSQ+ 9:K%- B\%+@E355A-CK::R5L29BO!(=2$9XY'&\LC!@K([5;=_
M5XTE&IJ+I>O<X\.XD1S@^H'/J_7'WV"I\.G=%7F<= H\\ZVN;%3:;(ZFD'TW
MOY4I S7=@SM\2<OR1.#<U6WC9* !=N#@]XWQ(6>@'SE%/[;&,Z" >8G>T62)
MC\JOKV:'>?@)&>#C:H_@'Z_&M@HO3\AU[\^K\"_-YNT\./H-AK*3D>U>I^Q>
M,X8\&X9LQDXY8\BS8<B:);)C!3?99:QZ7<8Z?/%+Z7M?TW0L0:KQJ.K:T+Q1
M%[JK&HP?@L=2"73:O/&$7%4WD390;5,W7QW&%!M;E4294^8&=G6WQM;B0"5K
M968MFF<M#L8;S%HTP%H<K+@ULQ:UM18':NB@,(W0!(UP,&Y@OD/C?(<#\4:'
M:8HF:(J#[:<S3=$X37$PWF!^96W]RF,<-6"\4"->:,3A@"@+,5/3#%/3"-;:
M.G?"M%-=M5-=3XI$68AIIP9JI[JR5O00$F.M!K)6S8X3[>PXQ)(Y]4SF--"+
M8LS4"&9JAM%C+GF-7?*F&+=(_\$P&_5_J+;6_*JL,31"#5>V$6>F*X55[I'J
MH/ZKC8@0^OIY8;QC@=-=\EW?U&Y@)%#?R)SHJ*$*QS^-GXY4P$>)5&%\E.("
M,3ZJ.Q\UP_OYJIOZ?#F/W"M2@;CD[O$W9^C8*HHD +S>2&/UO;]T9Y:M-_V&
MT2Y\,-]%\=_-1T7F75-YP[V1M6 .5QK7JN^,:^O"M>&U8%Q;6-<^GQ>G3JRE
MZ=JKZV_/3*_6AD/OU1?+5EW+7N'T .F>&>;61]N"V=S5HZ&:+GABZX<^KYH?
MXF9"#NO7G41BK)7"6G=+V]3=I8V M'?Z._[DY.2M5 7:7,8KKK$J8_-U,9V=
MB\9XO6I>3W%Q3XO7L_F/C-?KR>MX!V'I(ILY#*G<M8-,C+4*1_DL7F(1_>$Y
M-+J;\\4&T?\#J7:H^\:=/G41,B-J$#3$@SIONKZ+8($C(2KZ; LGX4X\8YJZ
M,,U![L#O\IMF.G+T]5Y5>.6Q]S":]FT;JV;\8[-98 <Z9&,OB0C,XJ18G-&"
MU+\#=S-V]L(A<H6TL74#OR\-S+[.NN =/#]R9\A^1O:;/D'@NK[!<D?K"8YU
MUX"%&IJ:#C\N5:/A;)>,#F:[2HC(;%T*VSXO7QQ=TU5;CV9",)DM0]=@=FV
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M%XW,Y$I>!1:$'JI&G<$\X%2 2LJBT.JM"+$22?M@DOR45[PSK@WS+PJM,HO
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M48:F\>5@EU9@$+#K='=TP\L$?D'DA^;XAT6-3$K"/ST9T.$[1?#?8%"<!#-
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MCS-T]87<#P\B]& >B,F]D)Y,9B#SU9WA>1ROMP:.MLGS6/H=EYL#26;&B@.
M,:J7G&4B[TMOY;H"W_GD!#_C"!RIDQFW0JH=3*G][%%H@C6=QF$4<0AOS1>J
MN8J,\@*C8 2<&4*NPRU-T(Q<\(30_G2_1HI,%%".F'G'0VBC:*[6+_*?"($V
M) F#HSH<R+[N<C^034A'M++J>GA$(.(T?&<>)H%E ]A @>'[G# &$%1WKAK
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M"*Z^AUR6D/R3QP*I7WLC44'"KA.VS:]+<"<VZC3R:A)78&E7_?(*)(JP+</
MAGGEF7$02U JQ+*O-00,14(OK%8<!+"CB)\4T7$[-";1[ 'LQ-P8(/4VN(?
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M*A^X?8?#H@6,ZVVBFI:+."&:1O?/0"%MO5$9.TV.OWJ<ZG\AF^NO3_ $YV5
M;E#PD*%/2+MEU>%43@N)SV;KJ(6AB)\#ZS]_XQZL4&TE'"9?MKO'VJ@Y:9;
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MP<OVE:R;G[@$S#A>-PM@%]OCS("3MW69O-W=WNPA^[]X]<Y"W_]C>#O^#0.
MMSBWMFW#&]/;@_F'1M8_7(1W4"D[HYLM[/ >=OBLU\X]?$W2VI-N#*7UM\&)
MEC4-],@F]>7-Z'[T=,VYMFH">#;(7;P:''G#IXN_P+%C,MZ8X4W[&$S^<UM
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MX6AU+POX)$/3<75W24YY'8M]*KL;T CAJ:PF1P;LZ]4+NKK:'!E((8IB[3F
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MO;&OP]DH5G*7\3[C?<;[Y\+[-;ZZ<-33?X_JRK8,@P-?@[.1H>*B3L<NP-"
M,Q!UP+X"5<K*[X9. ?&]=NUY@$D DX#J)$#L'JWV2 ,DH,8NQ5%O0PYQ9@PY
M+A<D-)A76F?L&Q21-?D>ELSSM6<%)@A,$*HO#BFQFM.-="J.FZ>P+7RFW3*Y
MJ65S;^J$56\ZR_BLIAKUV(%:[V@5$Y@H,%&HDR@H,LO:-=*].&K.HH]/5]1@
MZZ,!'FH=L#\?;7K44$ULR1T6K-4;>R8*ARE)UNJVA=HS W,LZI:W>+)6JN'J
M -Z1=T,:X)S6 ?OS4:='C=,$@>TLUQM[)@B'<;';1]L6;( @U-BK.'*K+-S
MPEV18YOH7TM],4>X&-)RL3!T9+/T!2N?R\KGEG-L@W5(9L+$A*DD83J>U]\
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M%1DZA_Q#%DX<4' 2G>7+?\-"X<?QURZRY_"EJR^6Y$ &=M.>X7<\Y(9)^;9
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MI\^GPR.6^ ITZ**55M+"5F[/)?E8!>5?$,)%'?$ZA3>S/?"OE1NLWWN3?AF
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M&WL(N 7)-KCUEO<"JW'JPN.AQ(,=L$"[%&%\@1E9_/J)R@K7@ *$I,8BK!(
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MPP7\(B+C+49VWQG""CP0)2&J,F7>[[<?^.1[9A1'11;X 8P<6T7EI4N=/)'
M&5D+&6Z77PM98\4.H&#.P9HD:AC#$^H(($FY4YTWT=8"D\@:"<.+)P-U2$&C
MI!EP\T+X\-D$S+)K-.9,S'C21MY*2TF:C6:S5:12;@]*V7/Y&14VQ(\CJ@+"
M/2#W&SR0G?12:XOWCQKE &6TUFW+Q>RY2.7381:K]&*JS9IJYT6?+24/ZJ-
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MD5K%JTL!@^Q2P'2<HLVKVG$>HO^"KD+ZE++1<LF-NHV,2ZTL"W66R6#PH2/
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M?S^+@^+,7&QT#>8_Z#$R7G3HKAP#U$J  JO+AT./58> %\=!57OQV5 HM=L
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M0 Y\+[95%+9%[_KXA2BL='9>4\S%Q3E8%$#_SW(0^%21JPXJ+6="]U!2I'"
MXF!LJ6Y)U$.H%IM=-VQTWAE7BLF/S(56IH\7C6!_H9LOGV>-!QVYEVC'J'+X
MQ+Y3/;CQVV">.R#M;X6J4XODH?2&KC696& Q/>30H<HC,PR&JB::CH_1WK:F
M(79V3F"ES53,VE8BB57Y&J9[-4#3&@F3V:7*7)US 0T:G+,8T3G7RA G<]"1
M(%XB\@>F6(SN18\Y.DDQ+2:*)(>'RCD0:(DJ0W*$S=403Y@%DF9IT/&A3TM
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MC>QTX5F.26_'65L":S#;RA:O$6!02<P"W/Q[AL$L"0WU-*9!>T%^.CY[9'[
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M4N<NO<?^X7$;AWW8FKD1OMQG+'=Z*]X:G[:&!8>SJR!\Q&?/F5-@>!2.Y20
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M=&II>*X1PJNFJ+O@DQD:3U[DV,8],WQF,? [;&/D>Q.Z*C =9G@C>+)X1\V
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M$Q:BQ4+;*X);/^P%AVR/G[<$!=WO:BCH=2#^6AKRJ>Q#=O668 ET)[J#Z9J
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M5G(L( JS8QE=Z75 6<#.)51-]KVR_X4H=+UCFM8^*D'[\ZA&IZ, ]<R?8(H
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M-32*702@3DT#,+1@#X0,W-?@2A7\;FP7D#[J2J\#R@*4!=1G >:P,>R1%EB
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MNI3%\?82IGZWN,>J+V/2JTF9.%5)C801*+__RS$T03[!OX*!_P=02P,$%
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MRL%9;X;_$VE3\4!0*J6:^5PD4,9\,R+4WD??H5/*.772S?.KO4F[;&(UD[D
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M7]#()U$1'K771C0I,!3DXWE\&960Z?\!4$L#!!0    ( #2!9DQ,./,0B T
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M2HD2NO1@,M<4 $SVP.3%AQQ+^'X0R_6  K]+KM LB%"8TL$44E@0UPHZ&X4
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MU@,-%O#S:)R @+6H#^2E2EF7,U@GV)F=974,T^])2HHRSZ3;(%?=,V7TF$+
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M2K)LFJ%&%JQVP^I D**<*T%/KK@!8,-0V-$MHRJHR(+>YCA_"R.^'NII%#<
M;!A*0;JE40456:R<%*>>2>%\@\"9X(=,&5ID<7=S:9?7>HW9W&X!Z'I,7^*7
M2S%69]%[XIM<FTCN:0XGHI)=([KZ5Y7P6V;\])$0JB"M94_!X2$"IX<C,COI
M %FXWQ8.HZ]5T" 8'&!P);K_6N58D07_+<]LLEM-X@>#4Z^\">\SM3MFBN26
M!NWMT16F):Z+-"R*NQ'/=67JL=QN PKT.<\:.2U5A&FH%</!%OBW+J4^OK;Q
M,(#RFDS"WD4I5KN8*QD>;.%^#DA"ZH[LSI;6$XG6ZLUMV^=%0<IBGRW<![UM
M$^XIF89)/,^/!AND-8V:6[8M>H%=+P+[BHP$\5=C#<^9)5MX<EM[^TU6E$E9
ML1=I#FGJ1B V D.)M9Z;YS 3F,CLSW/4J@QQLD<!#P*;2$?:U."069E7<8\7
M8<&2H+'_8T?\US!E>8?/2^Y+3K(7GI-6P:5E3Z -! =J1U2WPH[,4+VI"KVA
M1/A\<'B$P [F]@,6(<1FE.;0[D:723'-BS#]2O-J>I.Q#,$PYE@H2<XR_E0D
MGH>)&/F36G<:#(9^ZWOL=!ATUH-?N_<:J,<JB^G,>-^T\3B,ZQY30/K9,0D
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ME0R#SS@"M"_&+"B]N,DXEG&>LE0R=?F6?8S8/N[Q!F#+B.WC Y^[:-N(;:Y
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M<I\;]A"<(4UBJEC^K* A<YHW9+_)[FD>D:(0%S2U85C357",(33<BCQ#_HV
MH_.U;X%85OYC\<X7(:6S44[YE5>;,2#O)3C&4 '*!_TZS.@\^5ORLQ@1'LQ^
MGJ;YSS"+5&<6@]: &D$8C0^F95C1N?ZWY%;7Z1,]#K@0K,L^.%R"4WK[>['
MP$22P2_^"6M(GZ:7I0&HO@KU0K)H9F*%4;8+CC_W7&!M4S"=;4;:!@:/ST1:
M2C.-@8;%7X$&S7LPWBPAGE?E.*=).=-8;L0-0(L^C<U69AL-:QJJ!;"0F6^:
MHFH-!+(F@,_K[M+8E*-2OREAZY"067,<4X;+LN.6.P_&'6%0S(_BIJ AD6>G
M;CX$&R8$'C7UP-]4N R#%_-*0:)?7_+73Q%SV-%9_77,_[']8<Q_'?QX%&A^
M]4? A& _;:/Q;=F1V2\>6+D=S0J_? 80^#3T^U_4MY @LRAPZ?19UE=/ 0JO
M"4",5^LMO2J4ORXXLN-^*_7C6GG;\. A;M\-']]!AY-JHF5DXSE A" _<V.H
MBYD02(XMK?;W\,V,A/7G@N-C!/LB4Q*:DF-+@KUFT%)0L/84X$7@(VIM9FD@
M4<?#[\K(>).]D@PH3O8ZHNODL$<#8JW V4/X\SL(1I,PK3/_,(\??56F=]$W
MAH\7P>% IG+9R=<,%;+<+DNQ_Y'3WY=^6VLJY:T!-<[<EB9<ZF"ALQ_.Y;X&
M#1=C$G_-\]B>3'EK0(W@SD]+,G6PT%D6YW*KG97KCP$.!/=;6]*SE!]9Z%?K
M[%=>J]';1B\K&!#)+34C[I$#S&WT\LDA&HN9B# -M6(XR$R872-C3_S&TSF(
M7N9:%U,EPX/,M.F (UR6-H=DZ0QPI[L]Y<*V%2:5<G:>Q:P % ^][/&XNQ#G
M/@VS<ETFD^.OOG%P?-K;5NTQ@FUEE9*[D51.[>;!L(O@^,3G)*?<5IB2(%F+
MK!"^AP@<*<XOLR=XMV8K8M :5.7S.&:W*;&B5SQ$C"$C.W?+$<.;M:ND06M
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M8M8! X\VZ8YBTV*%#MLE3Y'5JFC"T"Z65OTP,P<.R[\5=QKZ+9!C*X3;WRC
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ME(=V+H\K"C,BBZ'E+7P'O_XG?N/*0F6L!F&HSK=!&I*!B(Y$9*@)\M# [:I
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M/,NKG_P=_<)&&+#^M9PM2P"'K0IEP'H5DX'S<>IEH#3/B@RPOYLD W6<K<A
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MS "GIJMH5]R=?G*M3IGO0WRT7">I$$7,S1KNIZ91A&.)"TXI+,H56([&JL-
MH=.::G0/I @0PZ#P(E-(;?M1RRBSZ&@#;O$ZB&=9%3O+9N?32.$#"S^*W?A$
MW2O^P:,-2.D9HY6">K%)%:((H_W8($U+<93&TX#TO*=/3R%^ K?>3H\ %DUG
MGW / 1/X4^JK,\7/;AB)1^\6OOTA,W7)."@W#-$X.QG\B FHY;F_D7\2-YXH
M>43H="HN_CORQV;G?F*.=R^FRD5'7D:/E6_S6?BE?2\O#-6U81=GV[0K9V,,
MV')Y\Z6I;J!IR?NO=Q$&\2>_^Y-E0&WN)OEHV$P;A$-E_^CTQ<[,BI[)I@[_
M@9/RB^5!TN0T3L,@M$@X1]RE,6GH)2U+*^=]%L!2%Y;^4,!B1$1\4%(=? PB
MUX *WQV%M=HZNX>DZCI1MM\G-8S7?$KD!9#/SH-&Z(WLW,VY0>5*"_\HISL,
M2GV\]?[&C8B=L;Q/87 Z+GRHK$]4$$(\@4]\VA-VLG<, I>K/9"J#XSVX4!9
M-%,DB&*!,V2"!Q41Y6]")N7PB^;D\2%YP9"!M^@4:0]22*U1X:^!4"C4I)30
M'7RQ?,J6)%MI(+RW<:M$Q >R;)VC<BLK/H5XO<]?E=T'GFN_M3U+%(!3&IL3
MH:-2'93"0#>_' K]PN#,>/G<A:I/V(?BN1IC=(.M!0/3&^L25I!BN$M2.]2Y
M9]=6Y!)SD]RK0]<3.J]VG9=%H-SM$J:L+'D4$':=''222)XYQF X*I.^G8;L
MJ'+R6-X]NPBC.EU[B(@%F$>Q>[!B;FRY/%"Y[E1F6I8>,H VC$N':% 0(3=<
ME!"<#D%)/M41SM!AUAEOGV6CY"_.]2M+O4"5E8(G3>J$_S8(L?N4.*M$&4/+
MCRR;;H53WZ'_]$3]S0%P*E>I/O27A3;!A5)DJ(B-AJV+^ Q5S4$9<O+M)&_,
M3O#IU\[>$E]6Y('$76$I]]H O+A^"\*K+_ N2%<UY[CQ5LE,'>U%*,XA]"NC
ME"A6*MK+RZ'*)]@O9#9!*'%F:P;1\ R[<?;5A*-DJ*G:TH&6QHP,M2^R^1)4
M?9,M(CXJKU+9*X![PN*X^!1 7"/$46BX<!6FKND1#U$8 &8]CU-P4[5H 'K/
M'^#H5S!9 :U>Z':13H5;T.%HN2%,:!VF%Q?K_3+PGY;N"W;8G8;$]M0)G?JM
MJQO5E:T@0P.YH-G];K!'@.J*XLHN<<U4V>$YX?K)N[R I;A>>90-[$90OT+W
M$?C*;MI;VC7TFY'Q-9M ]/6;$?'/TKX#QNJ<-#&Q]6J&M\F7H<9>.8;HP 83
M[_=$6Y0^^?3UFK@R",!JR)MMIZ>:/DIA4 '(5#T9B#S]>B,L=]6$6"FA4YJ=
MC@D3(+1R0^;H!=2G3=(6V1RYNB0 K2,+78"FFG1L"D4/+@6X/'O65.7J3:U3
MH-8.(A.\.PFYK$D^EQ-*I7U5;3(7=J>Y<:-?9R%VW!A^XH7@>5 Z.JMR:*AI
MK9J/1C!H@AA \@\SE:H/D?!&D5$8DN'L+I#\S8$'AS9V7\PHBB0@BC5-9<7D
M4&%7V6<KQ-=6A)U9<  %IW-;'VE?&]]9T F3(QQ$;:+6[:P3-O5]:3O17'GE
M!UBN'@$-*N*9((:)BFV&BP8O3;W%'IXA=@&/?E7M(>25MKE])5QA?7 K]%W_
M*;K'(9VU^ FO%5)];?!66BJ5P1,(1$ 0A3%UJY2G;85CA%/ZWGE!%+U'1T)F
M!.#ZU4U0\"KUP66D3IT:W>!'B3NXVM'*U:5^SI5G6&24J4HA1@%QJ%YP&+M0
MNPX>V!MP[N*(2UG@6V6E1_=4V(:\MZD3'&/L;&/BBUBA4X[ BSV*Z8I,<??5
MCA17S_4,$4HP0:XL0V5.WOPX!%ME@K6VHQV(ND*M/7*LM+*<>G1D:PE7TI;K
MTX[- 3U?UO,"Q<]6C [6&W(/1RNI>@FN7OSV;[___H>_1H7LZA#3,IC^TX?D
M92NDEC^>8N1&8*60YQY<5D1G@OYYL@B2O6MG1U^*.*VS$X1DSO$)>H71SVHN
MD=//KIRWX>UO5+IW,K2?L7/R\'K_$.']R5NZ>RS6ME  4&V/0A%**@>U! C>
MI3$P!' F=1_L159P1I;.?H)#KDYY<32W"A16H;.^@)+ZH_P)X7WA'1DYSF_=
M)Y\:9S\N/<=R<23QL+ C6EW/#;MRH?%Y7A$AC8L54!9>**(4J8JZN')O$X=B
MR7;Q:;6X7<RFJQV:SF;KA]5NL?J$[M?+Q6PQW^H_OPRA" TO&@?0 H6!\<Q4
M-28N4LO%BX8+HU ? A>GCK?-<G-S$W^B07^5QG\EU[(2].VTD ;DCE^_[<BW
MIZ\NOPBD +0Y&>-G-$DFBP,D^@5@#9!*B543SJ5N6C(#9!$F=A,<R&&[BRP6
MH<V1Q3.:.LDB@S99&JOK)BR-38O6^>!.G+4@A+%OV3?N\.$1AS4BU3)>Z3&=
M-^^RV.1CBULI&SZ6+RQRF!V9!E4'UU81*IY7!>5'80&"4^B[4(6'J-FM^PH_
M18T:( *DOH0 CX+JD_AD,#6>Z?"QM4'LY7\W.O0K@;@H59[N"\J1RG3 P_%$
MEJM]-VB%T) &V#3WZBTG&VF4+15<@FH*G #_#?!6EZZ/%S$^=#HX%8#-\56+
M%$FYJN@7 $44U@"!$U\R83^U8;T,$,,\3-Y%#HO0Y@CB&4V2AZ;Q[W7Z/>\6
MHNW\9?<$G1A17B-11JA7512%]:M)#A5&<]."9^M]UJ3M'CH&0"BZO>>9&+CZ
M**X8515_8KVZF:^V\QM$?MJNEXN;Z8[\XWJZG*YF<[3]:3[?;5L[G"D-X$HL
M7R5X*[UVJNO*B_?>,Z7+GFB'.3.[YHG.?O:PV4#;RNEV2Q3"@ YY4KWP!NIZ
M-V81-?'./:;VZ^G:NH931,V*4=;6F8*;5SM-@CY;J(A:;V*(W^$&D$46QF.1
ME&Z/ZULTFVY_0M/5#?MA_K\?%I^G2V(IMFBZ0]?S3XO5"B[UR<B?Y]/-J"3/
M?4<WP7/R>RZI^DOD"79=,KK74MHU?).]@5SA6*#+#!=,O>? IZ+B0"3#43Y^
M@@B$$9V8NM*2OV)%5U#DUC'@V"<B714/0UBTU&E)M>$O1S?J!BO7B-H9\WON
M&B#[$K/FU;OJ/UF1]CX#35:E/C;+<5D+VX180Q%78@8X6G<^3%^Q5C9+3H%6
M,L"(2JS\B8[8#U=$MUIFR9IAN>D@_8I5)Z2-M6$K$JKRV>G>];%SC7WR0PPA
M5:;CMT$(_TA^'ZT(U:W[7 =<&IZLRM-;?=!*<:!D,+U"2'L'HGT0TE^D?R7[
M:(Y,[U/7_I3?/JQNMFBQ0IOY]GX^V\&!;'YWOUS_/)^CS>+33^2H]G"_AK_O
M%IOY'3F[Z5?%SB)>?4C;2[X-N.?C[YA\,'-N]NJW@)8K/<V[K"PQF_7]?+/[
MF49#(!!R#[I$J)@;H% BXB5\::=Q[V/:VWH/HNWBH_&F0W\/TT87S)2#S?G:
MUE]:Z)4[X7LX[1=PK3=O1EVX\69+;]A,$4ZQFS7=5VI+UWIT/3<FYS_Q"V0>
MD'(AYE)022G/!YMVGRQ%1WJIO%Q,KQ?+Q6XQ-^%FN5V8RDH@*DGJ+TCNK3?Z
MI!P"Z^+W([50VJY'ZFEHO%%(AD_8;8(1 6(Y2@R[!>&(4-,E2*O\:%,$&B"6
M5H1S*-V*4**A71$H@(F*T$()_;-QBE G0BV*T"P_2JM%I^7AH-9:NPXT >BH
M$5T_<UX%/%;/;UR1%ZR:T6G^AE3PXTM-34WG5I%1>FN R02<I%U"N\0W >B(
M_]?/O";(3P>B9*011EY^]B$;:8"\\V6F)M;>*C!:#L%Y=%_N'%P'I_,H7$L'
M]S2<0YAW(!:C9KWZA';SS9VYI^)FZ>(<C-M$2YLG)'1KS('1[0]Q[T*K+I$9
M][Q=:3#3+6J_E164'VW.D6CJ1!.,;A>I+16BY"69H02=:##65Q)*31"1'X4I
M"-B/6/T]>D*_#\C&A&,WI$_DR&_A%_AP]((W6D\J3ZF(:C<V7M;"T%]2G^@P
M.*\JZ03L"S0G@B6@GG^$_N'\,ZB8W42\OP974&M.Q>A\2\>]T;0NA@MC%+I/
MSW&$3D?"TOR+^LW&2$I7R>484^,T'^ID#W.F'.+$#V\ZDT=$I\YR2:"9-2*6
MX("\'$Z_EDGIBJD2+R;G>J6;+].&R'&S]!HJLP*2JK'.UL&-#_0UI.^0@QV4
M:L:^S9=7+I2.>EL<&FIJ;J6CV3OMXGB]400I,M9W=XO='7VJ^VX5Q!C]Z;U^
MH1<0IYJZ86*RI%8I G\;!_:OK>4+*D.UB']IMG4R3QQG.L: T@-R$YZ@_^?;
M#]]^^Q$=K1"] ,"/:'J*GX/0_0T[Z I9M!/!#;9IP3GT_<<)(@O[)ZK=L,+D
MGW_\=O+MM_3_62N]Z*_(C:(3 8=!P2FF[8"(X$W(Z2*"%CWN"_;>A)!__.X/
MDX_?_V'R[5_^F""G?_SXA^\G?_[N+Y,___#GY-?GN,U0UCHQK]/09AE7F/WB
M.+2VC^7=6ZZS\&?6T27;?F%ZO"08 6#UN3 B%%528C(@!%!HX:,$#A751FMF
M3$^ZC@3JRO61S>#TJXJXZ%629R3E3ITZ;3#T1\-.VIUS:MNGP\FS8NS LRO;
MY9W,18"5JY,01=4N>0P(97UE"V H@=.I3)VH*M+@\&A0J47B$E?6(EEQ4UE_
MD*CP<^ Y9"GAA57,[:)>,UA#;<&:&5=ZP10&T3:(B U%TS@.W<=33(N<Q '9
M@G1'N(3H80&"9#])-((<,AJ\L-X3EZA:)33]:XO\TQ[+:Q<N.-5_KFIK2S:I
M9K62)%\OM<0+H9&6C'%I!]4966RBAA-NS-X3QV.IJ6SD492(2C@2^3B&<Z2H
M =(4J.2*'"=Z*2!O.G=DH3K S4 &[-"<%+OBX'23-B-94(J,V?1^L9LNT<W\
M%OHEKF8_&Y FV"Y*[3N)[@3!0I5D*']XZP5?1!Y"\\%T%L2NHT*P$/9V1_[#
M8N9I[<O;Y?IOQI;$;EPP3BGLEM52)W@K'"]\.SC@91#Q+I-*XY2+5GF>95DB
M?T=L 'H'0]XK/@.)F%H1&MYY=/(N':?3H6J=['Q'.+W>;M^CQ6JVOINCV_4&
M[7Z:CUET5_#YD[2PZ+<GM7I8-B <)5199C"=P2VAXL:-;'H;>,+.FAQ1:0N[
MB$QTO=]9KT4=W 4;? Q"N#B<$P#N*6G ;V@H<#@<?ZI%!XL6#J0(%3^ \B_0
MPDYPF"%?F338P@FB1Z"QXA6%=M.?3JX#X09-;$OXQ8PJ8YM39%N0?6&L!H_D
M:\2PGT*LG1-G%GNSOD,WBRUQOW:+U0/QO:"ZUG2W(.Z8WM*;XW$ U"(1!-AJ
M=4B#8&'/$7E0WKOU[W^#[RK5HJ*C;"D*CXB0GG!M1=B!)G[8CVJ[Q1:/* T
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M>NMIM,3#;3\M9O@"8@KS?Y[<^"UO%AC1<H^[9\M/XBDK:!,8$4HW@>?=!B$
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M3Y_+9W7",74<%[)>+._><IV%/[..+O$Z6@6E!4ZYT+3141:@?#P"@"MR=$A
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M_^JQ7)MP@PE)D1OCM+ 4M9$;; =//L5"S65/2]/OTT9:H9[<Y%FH7=5"+?+
M4_[A\Z*GV:?S&FNLV'[AZ\Q=,]U\#<S:8O57N\BQ$+- !MD1F%N45(2^##,W
MA#IW,8'#Z?+ )?1+Y?1H5=5HA8F1+K3)K3%DO3$:4"Q?E';A"OF5-E@,)638
MHO6^V#9;6]^.X1G18B3*1?*1Q6I()X>G_>@\Z5X^ORM;IH?@Q)S!D*GR;X1X
M3)V@.F852N:SP%9:%J&&;Y&19?2EC$A[[?P.%D2'562AM^%M8XKW4BQDQH<1
M[&32]$A/:NBH?!G,;"J(MX]L0K4)T 58S7,C,Y#MK+,P9AV[Z7NTGN?G!(>1
M!^&4OAXQ-XI"[\5!'TK)*<>SHLC=NS;3:6+5C'R5(RVN7<Z'-;)JQM4="]5%
M9,9G8;LMMLG(V.U\I2> UZBK/A$^=+@"S-&60^8Y9G,O![LP959^BF=G2 R(
M(0VB"C)7:I)ZH-TH,-=A!*L@C-@4LR#."1F[D&;_7*QAZ,X6GF4P+#MG$-T0
M-!.=%$.[G:#&C?XMZ]'%.G!QN\?+XS+%&G#I[> 8L"%I!Z$,F:E)-**49XT
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MM&Z(;.$=%4/[%EXS;_DMO!:)*5MX/8626WB]PINZA8N33#4Y=\6+.NUF)%_
MALX18\$-O56&5:KJEZEMP[LH,ATR3Y_\:+-"0O>!Y]IO[']%,M3E46E06VEJ
MJY+\!>4XT#F2"6((T"_)?PTI?3X W1MLD^'>6U)#@RAJQH/C&4(3]+:;3%>U
MMX] JZS'X</:L$U_XT:_7F/??CY8H4!)V590#74Y6JFI5K0H@"" 01F00<_?
M1->I6N%"9I$4OJNL=3KIY3Q+<?P4!J>CR+VV-";UKS"E::T\SA3)"658C.H?
MWG&5*V\Y^RRQ4IDNS&:1]NZJG[W<"[[^J'5(?5]NU*A!4=0G*,/:G UMY"O
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M_NDZFM]WMDI0\;6?H/@,(,[)G1>ML'-/N-0JSU4 30)=,W..1+/1$Y34@P8
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M*P;*$3;Y%6V[D>\J3Y$/%8$+',&@P9;%3'#UTN-Q\(9"JI6W)!\\J'CN[PH
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M  -[VI1XNWL]EIR-_\W_XO^ FR6AV/]02P,$%     @ -(%F3'5A<LF96@
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M+NR>W9^*Z13.%91@MAC%P2/)\C0<,_Z3\5]?85.$/S\G2SF::KRM7[.+NQQ
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M>J&+RU;A<@QZ4%\AU2<"81M87'%YL;1H5\"Q5:K<_>%O?:R]!I%=)/3]^0)
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MDO"0)D$QSK-O?EQ,X$8#EYN 9GB$ ;F?W&2I3R(I2=KM/;>IGVU(-,-H*1C
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MMW &)WWVB)]RX3;L"42((DM/PJ^F0NC@1)@-MKK 25?\RE?>$8[UO1$)]0V
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MLIX!0ZF?9&?Q]T" *"K V% #P<+5G=B&D%)W$\.*1)Z <.;4N%V 5[B0):U
M-,BLXM9YYRN:4B9#R% 3@%1ZAZ7M0#PH8A"4#!H1OXG-;1Z7'>H?@1.0Y]MY
M'%R2=Q(E,XIV<4@1>GP-6GM'.%YTUN"3KPC:&"UE>;EU;9$(^GS]2F(XL4<
M^3R8PI&=;LAY^$X6J,7O[C3J!\2'PB;86$4:H!W" R1VMF =5[_E7P(N440@
M[?PTTXD<+:6Y.57E!6822"_MLO!+K0Z\,QRA;YWH@2 0TT PEC+I(O>VGSL_
M+=?^7]:=VK7^!&TI)5Q/Y>)XULT"V2H3C@U!#<%JTRS4'\>+IG;9%&PE-=Q#
M,+X,(:+_!(5GNJX?)OYD"R(8@D%H=31<^_N4MWUA&^\$<4Z:!<(5MRRN. ;S
M+BY] HL6$)5O5AM?>2<HO%*[V*JJJ(=@[EE@4NXP6]]Y)RC\1E4^I*QMC'P(
MM@V!EC,U!DV'V7 OJ2'0H!?O!(61H\ZFT7% B Q!O1\[BE%[0UZQE'._]TYQ
M)([L8%$7X[=4"<CI,E%#]Z\P?V.W?!K*]1;.GI.K. _SN7(#,.S).T.Q18C9
MU=0&#926Z@793/=] &F' 9T"<7#Q%A(:&#LNJ.GR?C()QR25IOUJMO9&>RA6
MB2:<;;-O#!IM!:'%6&E^\@5)<X"[O+>(W;M:[0 W"I.4';(UX=JJ).3V[J\[
M]>4-0"(H[$'M%4 'IZV20F[O",4++&FAG\Z??':(HJ8+525]41OO[*>YY\ME
M8*L*D5O56 .CUJ_[";T49?Y8*T)0W1@$A<-&*&52P+XFNF%4'EK&15W]IX U
MD\ZD)&:^/L4R(6L'\L&1>K.+M4(M",?U@"R=(K;A*=<([O?>V1F*Z&$-T@1'
M!C$J6S5_G+(,R*9)+"\,)?R67HU07 @E+/%I%4$91&&;2_*2W\19GA9L49.O
MZ_6/06XH#+^[6,Q%Z&T5>T&D!UIA!:(FWFBTAR..24"8#KTU.+8*E]@TY%TG
M1;JJ>_M TC$5\BNY2.)WDN8AJ/-=DBML.T9]4%F@,/0HR*K;=)K M%4QPR;E
MU0%?%N3Y1_+\EA29'P?//P#67.;;,^Z#R@*%:<>8\B8P;96"L$GY=GGKAM/<
MK!-:?AG%%=V8]$8X;94A<+"VJ^:Z:3<@$1QUT+I:X:M(!=SWS&"G.O2*SKRW
MC8NNFG1..4-Q]]N)S<>6N 2:V3<3(ER;;[*L(,%ED8;Q:YE,5-:;N2,_V#_)
M;8DZ'7BG*!8M:]R+S(G:LA HC[%9L=T#E(Y7MV7AKT5UHW<_C.CDO4[2K]#6
MO/!N^Y_T3E$<J[K6TRZE)]#LOI9/KY7BJHOII2JFJX]9F+*/RP5 I<@V?L,[
M.\1AG=^!ZMJ3ET!9=V4CYM\GFTJ0S<%+/R?7?IC^Z4<%+RG2\B]X9SUY1:*9
MVG4B+8'2]<L@W5@J*V&<PVEH6E8EI"GG]"V.2QH51.+@$836Q>ZO^]O TT]Q
M7MV-' 7ZOBO3/&)]_S.AD6]1F,]=:/SVKP-7*%P'?=1YGB0%F:>[\DX@U/K'
M,/OK.B7D)H:S/<GR7>H\[[>!)Q2>DSYIO%B. GWO5[AU8UDMRBNS(U]VHWGO
ML_9#P ".F#VDFBP1FD!M>Q8KWMA:SI5,I4CX5EWQ-CIM;Q3 W2]#70<2%<R&
M'GK;FMB(V/];Y"@_4E%E:S]E%S8\V>\!'SA2-I#:\]2R$^ARO_QS6F4![Z@/
M/:,3FPHE>Z9E\#;_G58$NTOR?Y-\7310%OW=U6\"+SBB4;O5Z8[E)]#KGF4D
M="6C<J>[3M+%7]'O1BZ4G3L08/!G\-*X$*I@6O0KA6,[JFKSDLVR7@*M\XA^
M)][9\<]@YS85B$"5^I4Y\I F8T*"[!JDO5'V;/5*E.P$H&SKG9W]#,9B33D(
M]*5?#CTZ2<I@S(PMOBPLDP0;"1K3I(ASV5ZJVP65^<]@KS*4AT"-^N4G4V(N
M8X?**+E6RK35$17ASV 1:B0507W+?KFBMC?Q:W],RMFC?1!:-Z%I!3^#<46!
M7Z 63I-IMH?\S<^+-,SG_R:^*(%"W( F$ SYD**%7L#QP-P;"BOX\KBV,H2S
MNR;< ](PSL*Q*%1NES\/=!W_#):!'<I2H/IM?!F[?+NDFABUSHU97F 7#[6L
MK2,N7S:!A6C]+H7.BR7<!M[AT8FS56995T3YGLC6A][I",7$E0E4,!<Y.(;P
M:,<*UT7D9YEFY311&^]T'T> ,X<L!:U\*$-XH&,3F;(.1OUC$ 0.LZ><*3Z]
M(CA#>.FB;;6;T0C'LY7ZDU4(8@A/E]HM6C-"$:PI)$R'WQH>MX]0<&_@[+ )
M?WL@K5M0^8K"06'15<B[?H/F ['TR 2*[-S5X[DZM01J'\/FTK,E583!_E.6
M+IZ%W[KZ46V_^AA'14!?4IDF<%W\FQ$CH5BW"^_P&-?!MT(GGWPS=)8>B;!>
M"'YSI/<3MJ9E6>''8\(>=Q2LR8I6<!5$<5'5(U0;D*4''-RGFU=45W\*@QQP
MA-6UF:DEB*Z>9G!IN%NET92/V9_/H(D_?AN L6ZT5]DB>F"M@S&CN/M+1:IE
MKRN1#,%@U_K:OW>,\8Q:$J1_[V<HAF">LWKOWSM&>^]GA)G>^QD>M\8Z/&4L
M]XY1/#2F8*M^,FV$TZU)#UL52X2S6H/XADB'\-AL6T,2B!2%B=!@EQ:B&,PC
MM%HYO66"*"#'>LTL21%P6$4PF,=B915)GDDZE="J:DI%A=58)"-;$Q<"NU]W
M*F!89D6[RL=H[P2K0=A4)23X!F-.M%)WRJ#H$8@/A6'%XHK!18CA]=CN-42S
M$I]V(3B0'2X337OMX."S]>0L)O/U.NZTO"QM6>VS05BQ3PZ=WZF,K=@G*+*=
MI"+5M&*?B)_C[-5]JKT5^P1'4A*/( ,K]HDPM>AGMF*?(#1T;A!F;,4^$1HT
MG5JQE^%<QUK1:\?KH"\49U>%O.OF2#X02X;F=M%K4GI.M.@Y6=M04:R,C>G9
M!O++&,Q6'5S&1/5F)T0Q!&/P+@,+1WM(7@,2$<KGWQ#?8,S,]2@\>N*G>>0/
M*9F&A<S.K&Q+ET04)R-#9= %9LG2C"&0_"OL=-EMDF74O7GU00LO%F'V1F56
M2D"B!\JV=-*@\ @;ZH$NL+9FY;-2#V+RZI>N#,?*< 7GF2"@*<=I^ X<O1,J
M"2H($$/MW^Z(3#F,^Z(RQ>5*UE.6ID"'8W+F[*%F)PJZK/:1>C$46S;C#FYK
M:^U<EQP2+O7R!A0L"HNE)F]:: 34&9NY,.SN2P4M@]07:BI?MT5-Z*K5)ZXU
M\0C8-C9WU=EVZ=ZY\].4;3<#\.0<5L+ >^#(.=U'<>J5"53+C<-P_/+BT(PG
M7,>3#7JT?3@,PR\7SK:-]W0?Q9XFHLO0@</0(/3?N,E".$5ABY:353^?-H+9
MWR0$&QD(*U&<H0AE-&6\"4J$)4:JX[TLR/./Y/DM*3(_#IY_ *JY*N7$J \J
M"A0N!U/"FZ!TZX[2(EQ97D;<@+JX$6[$YE36(+FM3])F95;2:=P/-;#T<D]N
MBM22G\C%44P9;6/>$14*BO23KHYD-:B6T@Z&D1N*XVW'CJ9^%:@MYX[C7,(D
MS6F"%17:,_R:JMPJ[WL0+(HP+WW;B02&+;<.+EJ5YA-!"SB:8GF>0\B8)L5;
M@&QY@)RR7%VA'OPY57SAJJ[5C@H(QVR6$L@G70>9+7=0S\,XD3SDI+]DBT (
M^.QSQ=UVC^0<XBB\(R1,Q^)=A2,@V=@:9KWBX_:P-]:?=>@!*V1P5TB.VF:=
M@$1PS5TYP4T!"B@WMH>Y#Y[:?(UP [LBB$K2"@2$XU!F-L65B 24[S3V6F.6
M/Z1A/ YG?E2N4(\D8K&=R0U]U]:/'HIT_.9G)+T'A'X4)3F+*IT)PO"M]@]R
MQ'%X:[HVM,8NT*%>1F[S7PF[E*?VBQN!@/"&[.N>#.J !(SWL/3'KE^1/D1<
M&$I7']0 !0$Q/8S"UCA&L8)9JN=9M?H X:$PY;?2#B4^@7*TKOS1W<6"OK#'
M2IM<)^D:DZ#>2\.>O$/$):,,KQ@JE (-,#8%XE@>=O82^-YI7U<' WP"W>B7
MK;#K_+^S/IJ;=($)-,!IW-TW_R.<%E,KIJ=&?5'9],T$U0:H0 GZ5?EA&_DC
M"4A9%^V29.,T%%DG#%I38?71+*4/3: '3D/TUK>=^\G5QYAD&=/?[+[(L]R/
M:9$#P=37:$DCW/IF3]*'):"S7R^+*4\T)7KZ !,)6AW]MCH"$2)[7]?2 9"'
M4J HNXKRLZ,HCV16/LN>W4_TO1"25C0.JH\JH(8DX'M747V=&(O\-)V7!6],
MW,K;S:AX4(3CM[,)\3 )4JIV%<W'#^2E3T6_)1$,)6.OC[W[T<:AA-DSIE,X
ML-+OEB_LB6)YF_1%98.W^B]_^V\#5* $_8K]<USA9?^HC^: ID %&K.K.$(-
MR_'27_9OXNN%GVPVH"C[=OY7HA%PUB^CWO8Y]CX-7\.8+G0OQD9>3EL05&]O
M\CK !!K0QJBWRU(@J^+VWXA/RSZP^,DW<AOZ+^S1 ]C@9DD,?_DO/V/?!=0'
M$MS':!XR72%8UZ[(-,J'R)H!M:-35[.Q<3GX_1$*+XJ&8/DSCHMG".5$5L N
M(A\. 1-V7%0EQXC:@%R0&4LVZ5(P*P SA#(CF]"4&3+UCZDD<%V'!5SQ&18"
M<EM>!$<Y() $KINO>L8*4;@M'8*O(A!(!44<I) P'7YK>!#6"W%0(&9_'T5(
MHX*K^JVU"4R$!4.<E(':WT=QB#;FO!%.M]5&+%__OLQ7?_P?(4E!WF_S6Y!*
MI-BP]3J@$L-EO5)OXD;(W!8?L:P+&\:,K Y=N=L;]0/R.T!AIC:B6Z$Q!L#=
M5BVQK#@W\:S(,R8L<34CC594-BBBVIHPJM -(=IA5#%IFPV_?]"WRYX0Q4#J
MEQ@^<;]_@,L04V5%0&(5P9 *TW?ZROW^ 8H;O"'?FKBZ*UB/0PLZ>^A^_P#%
MY=^"5DCPV:IW@E4[.GWK?O\ A:G XKK!16BK7 IV';'^VOW^(2X_77O]X."S
M55G%[8,HO%L2AD=1NHAM.*Z\8="#T(83',]&J<6J%=AP(GDVJE<WJUV97D]P
MO/S,H[&5X?5$_!!TOV(?W-A=3W \&FM"M@VKZXGX2=E^A55T8'3=PY%BT(#0
M!C;7/7&:09_C,<SC:TYP/!.@OS^(,+@-NT 87+-WA,*)(N++-+:&P4$8:>'B
M\27D]?U+KEK'UNR)J_L[?=3%S1-K./)_C#EOA!/A8RXN7_(YZR?U3:$B?,K%
M[5,^9RCN:IU-_1K60<1"B*K9@!S")# ZJ/,:4ZFCB)QJ>G*7@!I$Z(0<K>&Y
MGM^<5D-"N#1(F&VB&%M8!_%>3/M'0W"<"/2GOA#$(!Z!J12OX;DZ) 1KM/:.
MD<5/5VGDLZZ-[-?3,=M-O-'!"*W_6T*X H^M: A'Z?[/_@<M4EHF[U\N!ES^
M%_LGA[[NU2C64TO#U2UIY1T?],[3?3I"<2!62E7+T<W #,'1;3>!_W2$PJC-
M(TM!*Q_*$#S8;;/W3W&\1ZY@2G#$$< 9@H^Y[37E%%G)6OVY6L$P##]Q.5+8
ME\ZSC.39LDI12+([DFN<%C1[\,[0UJ%G9(I.K@;@++F:,03UUG#?Q.QUN"Q[
M!-9HI,5Y'%S2T(ED1H5IHA^*KN PA&)],*)>4WNTH%MR9F-X[Z0"_WY&:/AO
M_$H+-[(RKY,D_>&G@=SFK=V+=WR((LVL"]51H;;D$$>H-=0V5#(81<D/00U=
M@]8@+Q01;5UHB0AM6\_Y6:D=,7FE+[CAT@]YB5S>YR 3%&>1+C1@!<^2NSRG
MYBY'*21;EC58 &/X"UHH=F FM4-G=3%7P[I(8KJWD'@\5UG7A&T "(KD/:6L
M^3-)@6L(-K<5Q/,B?TMHV66%P8W?P#O&\:Z$@C$%S1Q(0["ZU?$I;6^B)B 4
M%,=I&66Z)&\B<FN$XP:2?<]NLM0GD31(;/LC.!7@FH5<66_S(T)AR9)FSW*2
MD?$?K\G[YS%U4Z;S<OHM_J,Z\Q9_[7U_XO"V_D>0!XI#IPE?U=$/(9GBT8>=
M0K'OK;X!V"B<$(VVN@H*MTD2%LE3YK-M? 70420R5;B0$+8Y[B$4D_P6QO1A
M3R5I6]\!?!1WB1HC?.(X8Q]"[<?%FZQJZC:_\XZ/49Q+=*FKCWT(U1=Y&X:.
MOU;:#N2((JZXW<5/C&P0"08;=C()SQM? 784#C<-@OC,UK#82A2H.D.<V3XQ
MU,VQ;_C</VT02\B]/G-^163&E'T.(\(U$T1"J]^JY9"&8+PTN[?MGSK=J=24
MJ*YL#, 0#)+F5[;]4V17-L:%^LK&QCV$"+]F5[;]4W17-L:(SI6-C7T(\7S-
MKFS[.$S)NM35QSX$PR0<>[,D"@,:87$%)V :!:#8[T1-0"A./3=-MS\YGB$8
M,'D(U<'QPD;>P1X*IX*<.'VR-U$-P?CY5+QD81#Z:2BI^R+^& 2!(J]%116?
M8!$>2Z91]Z&*MN(I#O:<!B0V7:UE: 9E0[402G&PA\NRP*%,E^1-1(XMIEQC
MT,(4^/PC>7Y+BLR/@[LP%M] 54T *"ZC-Y>(ND5(C:DK,ZDU!M](2OP)=*]%
M7N5KP(CB/MJ4-RX<6W5.K%/V2+(\#6E!^S*U7\H8_V,/27$#4\)D: 91QV25
M,O<T)C&<YA+=-.W-[[W1:,^I6:_I*4>&9A %2I:XOL?9C(S#24C49:B$;4 P
M.*RW,MH$1"LP=5"FQ!W9#Y$?JR^DM8^I*%#LJBJRY!37 -EZ<L7F.9:S6-U*
M(CA432C27OG$- $)J.N7G>AJ,B%CZN!? :;O 3V2<1*/PR@L*<JO"6#S([JT
M%3"0^=;'DGELH7=O_PRCC:*J#/QI;PV_0-=Z:+IJE(HMR4'>/W.Z+;12#Q4L
M >OFJ90.PXF>BMDL8N<A/YU?A[$/FE_J.OO+FQ@@3]FOW>=P\RQS21M%&_$+
M):]_/MKX+4D D48K[Z"'Q<CVG.83:$M5<1?: #.$V"++Q<APV'IY9"EHY4,9
M0A12ZV)D.(S "J8$CE8!G"&$*GWQ(UKEXNF-D/R6_@SE0SYQ14V\T?X)"@.D
M_L150!E"0!,/HG("BQM1R:!(:E90I\_W%JXAQ$&UKB_HUL[<8ONM8!A"O--#
M2F9^&-#7CN.,G,?!QO7BHDBI(#6R" QZ@>,KKM-7A52^"A@#1%#NBWO1VQ@W
MK?@=Y@4=XA*#X)XG;P2 49R]C#FJFS-U@ XF.FHAK\=D[D<T8$P]OU>?@B10
MK.$M*9?#LU6@RSG1:P?XA9_1DI;T?Z[^4X3O?@02RLYS9E0+XU?VS(-$#PQ[
M CFB<$994I-&Z&U%8+E7HVTIBG<,Z??>P2&*.YS=E8.'$4/TEAWB%P5.)Y=A
M-DLR/_J:)L7L)AY'10"Z3JWY+"&X(,'"4I_$:NUHWBE<I8Z'M/NTEH2MH+-V
MY9E4Q\VG(@[2N?9!<^MSF%$HC )VCY@<B+;BT=PO&G7)R!R7M8^]T]&0YK@(
MH*T -9=58/5=E^=C5K L>_#GU.8"TH2_20L_RIA\T+LS]_>=V]R,W9G.W?Y:
M4M5T9PZDSJOMMY50G*AY9!F[,\4QV3^9.W.$XKRC8$K?G3ER7M85B>]CA.)I
M@P9SM8)A"*Y+P7$$AKXN\Z_O VG0&^Q]*++#120+[JM-@0[H_:6KZ2Q*YH0\
MDH@]N%%#+HOV5;4%::'(*F],-%]O-'$/YGFEFQC&0+)\(3ZU8O ;@%10E#BV
MK TRL B<I]9V&"JA/_VQKE64VP"D@L)G;ED%9& 'XV452DBM!=P5$H6KO1M%
M$.$=C"-V@7/E9];6A&H+D L*ZV@W>L!'B\&1RC4V5H3PD"8SDN9S$ ;U#;.'
M(YD-+(0?EKL_&O3D'1R@L/Y8TH164AB0QW5;!%KK!*>!-]K#46/#_CHA1FNM
M!(=#E\IF/:_5Y3R[GUR\T0J,V4W\] 9R?TLBP);169'/792<7@UM8>W;&I"&
MR42KO7=<J;'6 [?+L=LLL@;RU7+ ' \NGZP4Q44RG24Q"^'2=,+PVH%X4-S2
M>*0IZ!7#&8(SIH).Z8_A?@_B0''UTN!,8'X3HQJ"9P: 39.8+7/*NBFU;T$,
M*.Y3$HX$OC8^DD%X9X(@+ $\^&%P$U_XLQ".24IRI>U /"@.Q,9$:Z :0F[9
M(PT!BDEPY:=Q&+^J:_+R&WC'.&(BC&F6P1F,8Z2M$_T867"$_CFK@F$0%;1K
M%PLIF=6/01!87>",(A&A?!R6O!8SDH8)O?BGN=N)2JT,V7V19[D?TV!T&;75
M;T$BN"[!>LSR85AR0: AENKO3985)+@L4D#YP ;&TI;NR _V+_)%6:.]=XHC
M2;#!U-:#9LLC@2&@10"[G XM5*+2 0@.Q?G;BDYPL=ER0@1D$L;LR/^U" -:
M5<+=1>S_*;*<6:"?$\$]I'+0O9]<)#&H=1["R>B2O$A=%Q:Z]T9[.-(*S?3*
M(G0,A<=WIVYLYKWX&0FH8$B<,9X?"<@J"W/R1-+W<$S*64K+2+Z6,TF5WMSU
M3X,NX K_M::E[:6"(?.-GTM$H7VI0UOF@I<Q\:P<Y1V!^7F=I!,2YD7*W2Y;
M]@BR0A$:JJ=!5L!:2Y%#I!CER<&^>I3]@MQP.:*Z5))-R*TKP)^5JA*35Q:A
MC'T;9%F3+?<SUH<W&AT-=&?:Q&>KBCSB"QO;4<LC8@8PMXZ+3V0,7RI*_;3J
ME\JYK^:\EIAME;E'K%OE4MN!<FEV3"7=H]./5="V*MLC5B\VW=B_W3.<V=4'
M2<=AMHZ<,URNN'T!4[CB.%JO4!*8757&1Z,SY22RI#22SD"<P[%E*W$*@KYZ
M6+.L?'."OAMQ#;*\* LI@2!6E934K\'*&GNG:(N92M1"%Y= #7H83[^-F%M2
MJ[Q8TE<%<[ATOA0Y=>H_)X]DEJ3T[9$K^JRRS+=M[3= ^#W<H2S#%^A>#^W9
MK0,D]G%%NS0.D-@71KSL&UMY2T?Z5>S61M,R/F*_ARXK 0P!K\9&6AZO.&N9
M;:;EK%<X["7,1J/*,W$]2*:!,3NU*>G+5;06<N ,*HOF*TE>4W_V%H[]2#>#
MIMK&&^V?XEH/-^E2,"L ,X3DF2?R6D6H?GU8U(;*!9=]6,"<@&\%+CQY-!D9
M__&:O']F>;+IO*1[\1]5IA=_[7UYY%"Z_D>*$<=E5\'"-G<U 'AR8Y8D!22D
M!!W2/U!R#C?(@;_R;LFK'Y67(\'JROF*HL7ETA.OI^+AX\EIT26KA"!<(JN?
M4)Q.PZ3%LJ]SQ!FXVS>0N"?GATGX-TF%F4/53R@0I_86@63K41*<40\C@Z1=
M.A!( I=7T.#@6$5A*8'$<0[?.XGEP>++3P#U'JY-JDH(G[_*^"UEA]1]L[LT
M??!-MBU-&W8TBC^T\SC8>C(CTZ@X8MB3=WIZZGQ9-"WY?HHBPZ*1I+4,* S@
MH.PG=LK GV$TGS"R%+3RH0S!>-*Z#/P9+M\/GRD^O2(X>(PD#LO G^$Z]>C/
MU0H&/,:45J<+W7>W%N<^^0'#L#,0)"Z3:(5BOD(TQ8FB!CS7;&" B#E!;^*+
M) (-2,J_.W]-"1.?P.1@JWOO; _7/B]5%_O(+1F<,,3!FCSXEV34T?PU28+L
M*8EDP8TM>@4&<5E2;"]%?,!MC6B(LH8,9 &?9-E#FDS"G$9MV=&H2J<@7ZPU
M0.PH%!>OK=KUE0*TN]SA'H$F$#%]Y/@2MN\H8667%Z\@MM_AI-W#.H_KUF-S
MA]- WIDU<9<*]#7U:4W*.'@DX?2E2+,R5NJ1C$GX#M^EY9\$IJWN?@Q$C.OJ
M95.YC.6 HX*-K<6J/J'NB(7CN+1[D&./;F_VD5NKN=]BL]O]T8G$\*>(EK$/
MIF$<4A-V#C-,O#_:_Q&@%T<T3F='*QW\K<O>X#J[<Z3@AS$]6=['2]&QA^+K
M'RYS*TR=7\8_ (+'FIXB5SQKV*V5JL&PYM7!PG7F/:09R==)2J5#I;264%,]
MT^L5!(PUS])4N4P MZYQ@V@9ZUFNW1D*;[F9OEF&W[IL#H(7<Q:/BC[X:3Y_
MAFM0YH^9&#;K"3F,8!$-3R-D1=74.SYS]S[.^(T$143N)Z)1?IEO_8LJE*5)
M?R  %$9&/:($_M7FP(<0":,'6A$:H]\)" ['W:DYZWPU,A7!$&)L-I$I8VSJ
M'X,@4%QG3*E3*\ F/K=!-UP#W^;._)P\OY&[)/Z=?)!Q06_YEV%*QM"1^ 40
MXSY $BC.>B*.ZJ:Z!O L!>1@<(\+9L2M1LB5JJEW@B2(8D<;0 4XGJPJZ]IQ
M/F4O@\+59_UWYHK"ZP5$A\(MJ4>QD7J(X786;8/\-=4'1L4;R6EVZ7"?5CWJ
M77;#$8HM7%^Z@NM>'=00KG&L0O,S_(KBIK;UG7>,8RNN4\+GKC[X(=RB^!6X
MS].4+I%LO?PR7W_SX,_IWS%1K.41!P^1']_Y4Z*N$-'!SWG'*/;GNGX(UH"N
M1#"$!(M*Z7>-9R YWWO'.$)]NB):=,83B6((R1JMWX[$%:VCVFP$"(9P@9,7
MI^7.F<6S#RUJ^\J[]8ZQAK\?2TH)M,3;T;.R*"YX?O9V'24_G+C\-NX(JW&8
M7=QJS;S#RI.:/;BPG1S@.MX+Q:IU4V-HAG!5LYM[?G* XNC-(TM!*Q_*$&YT
M;7//3PYPG)[E3/'I%<$9PM6H[0GXY #C$5AGKE8P#.$Z<T=RNAVQ6$$X\WR9
M?X>SVDV\"..*7\_'>?C.WH'1.#J8=P8['XY " '%?(5HBM/2K<E]27D0P#H$
M4*X0Z^] !B@"'9JR)]2%*L2.+C2_(FD5H:0X7F"VJUZ6Q6.I7..F:%V_#M[Y
M"SN'**X67:J5&+>E3'),^K+U9B=]"CH>AQ'96L:?$WMGHBY^#IA%D:1B5R>[
MDY2EA';W&S+?G&KLY@2IH(ABZ(YQ$X]G*0U;F>CNE>22P(C'H4HU-C_S#G$\
M!;1KA:C+P%8Z.8;XU>LD)>%K?%' J./Q9KS=,N_T>YP2/PK_ECJT3+H!(:(X
M+>U:D<QE-*3$\0=82BF_<< >.W](0& D#U-F4?E"8C()):5[&O0"(OPI-S!C
M$5G+%&^QJW&3+]:9[XO8W^N"^EQO:,F/&1G#A?9J.HN2.2&/X>M;GGV?T6H@
M2ZB";(QVG8+$4#@<=J54MB0VI-SQM3R>?)H5 2(&H>9S&OR4T^C:F4#]S#J
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M'U!+ 0(4 Q0    ( #2!9DS\987*>EX! +J\%@ 0              "  0
M  !P;'@M,C Q-S$R,S$N>&UL4$L! A0#%     @ -(%F3""HH/:O%   6.<
M !               ( !J%X! '!L>"TR,#$W,3(S,2YX<V102P$"% ,4
M"  T@69,3#CS$(@-  !3T   %               @ &%<P$ <&QX+3(P,3<Q
M,C,Q7V-A;"YX;6Q02P$"% ,4    "  T@69,,1_750I3  !25P4 %
M        @ $_@0$ <&QX+3(P,3<Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  T
M@69, N?3*[!Y  !8;08 %               @ %[U $ <&QX+3(P,3<Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    "  T@69,=6%RR9E:  !G/@8 %
M    @ %=3@( <&QX+3(P,3<Q,C,Q7W!R92YX;6Q02P4&      8 !@"$ 0
&**D"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
